1	We	O
2	report	O
3	here	O
4	that	O
5	,	O
6	for	O
7	a	O
8	constant	O
9	amount	O
10	of	O
11	transfected	O
12	DNA	O
13	,	O
14	the	O
15	level	O
16	of	O
17	chloramphenicol	B
18	acetyltransferase	I
19	(	O
20	CAT	B
21	)	O
22	mRNA	O
23	is	O
24	increased	O
25	in	O
26	Vpr	B
27	-	O
28	expressing	O
29	cells	O
30	using	O
31	either	O
32	HIV	O
33	-	O
34	1	O
35	or	O
36	a	O
37	murine	O
38	leukemia	B
39	virus	I
40	(	I
41	MLV	I
42	)	I
43	SL3	I
44	-	I
45	3	I
46	LTR	I
47	-	O
48	CAT	B
49	reporter	O
50	construct	O
51	.	O

1	We	O
2	identified	O
3	telSMN	B
4	mutations	O
5	in	O
6	11	O
7	of	O
8	these	O
9	unrelated	O
10	SMA	O
11	-	O
12	like	O
13	individuals	O
14	who	O
15	carry	O
16	a	O
17	single	O
18	copy	O
19	of	O
20	telSMN	B
21	:	O
22	these	O
23	include	O
24	two	O
25	frameshift	O
26	mutations	O
27	(	O
28	800ins11	O
29	and	O
30	542delGT	O
31	)	O
32	and	O
33	three	O
34	missense	O
35	mutations	O
36	(	O
37	A2G	O
38	,	O
39	S262I	O
40	,	O
41	and	O
42	T274I	O
43	).	O

1	The	O
2	decrease	O
3	of	O
4	TNF	B
5	receptors	I
6	by	O
7	IL	B
8	-	I
9	4	I
10	was	O
11	accompanied	O
12	by	O
13	down	O
14	-	O
15	regulation	O
16	of	O
17	TNF	B
18	-	O
19	induced	O
20	activities	O
21	,	O
22	including	O
23	cytotoxicity	O
24	,	O
25	caspase	B
26	-	I
27	3	I
28	activation	O
29	,	O
30	NF	B
31	-	I
32	kappaB	I
33	and	O
34	AP	B
35	-	I
36	1	I
37	activation	O
38	,	O
39	and	O
40	c	B
41	-	I
42	Jun	I
43	N	I
44	-	I
45	terminal	I
46	kinase	I
47	induction	O
48	.	O

1	Type	B
2	2	I
3	deiodinase	I
4	(	O
5	D2	B
6	)	O
7	catalyzes	O
8	the	O
9	5	O
10	'-	O
11	deiodination	O
12	of	O
13	thyroxine	O
14	to	O
15	form	O
16	3	O
17	,	O
18	5	O
19	,	O
20	3	O
21	'-	O
22	triiodothyronine	O
23	.	O

1	We	O
2	have	O
3	identified	O
4	two	O
5	overlapping	O
6	expressed	O
7	sequence	O
8	tag	O
9	clones	O
10	,	O
11	which	O
12	contain	O
13	the	O
14	missing	O
15	4	O
16	.	O
17	4	O
18	-	O
19	kb	O
20	3	O
21	'-	O
22	UTR	O
23	of	O
24	the	O
25	human	B
26	D2	I
27	(	O
28	hD2	B
29	)	O
30	cDNA	O
31	.	O

1	Biol	O
2	.	O

1	Here	O
2	we	O
3	have	O
4	investigated	O
5	the	O
6	structural	O
7	requirements	O
8	and	O
9	consequences	O
10	of	O
11	regulatory	O
12	phosphorylation	O
13	for	O
14	the	O
15	interaction	O
16	between	O
17	c	B
18	-	I
19	Jun	I
20	and	O
21	JNK	B
22	in	O
23	vivo	O
24	.	O

1	P	B
2	-	I
3	CIP1	I
4	,	O
5	a	O
6	novel	O
7	protein	O
8	that	O
9	interacts	O
10	with	O
11	the	O
12	cytosolic	O
13	domain	O
14	of	O
15	peptidylglycine	B
16	alpha	I
17	-	I
18	amidating	I
19	monooxygenase	I
20	,	O
21	is	O
22	associated	O
23	with	O
24	endosomes	O
25	.	O

1	Immunolocalization	O
2	of	O
3	Sop1p	B
4	revealed	O
5	a	O
6	cytoplasmic	O
7	distribution	O
8	and	O
9	cell	O
10	fractionation	O
11	studies	O
12	showed	O
13	that	O
14	a	O
15	significant	O
16	fraction	O
17	of	O
18	Sop1p	B
19	was	O
20	recovered	O
21	in	O
22	a	O
23	sedimentable	O
24	fraction	O
25	of	O
26	the	O
27	cytosolic	O
28	material	O
29	.	O

1	Resultant	O
2	activation	O
3	of	O
4	c	B
5	-	I
6	Jun	I
7	N	I
8	-	I
9	terminal	I
10	kinase	I
11	/	O
12	stress	B
13	-	I
14	activated	I
15	protein	I
16	kinase	I
17	(	O
18	JNK	B
19	/	O
20	SAPK	B
21	).	O

1	Here	O
2	we	O
3	report	O
4	the	O
5	full	O
6	-	O
7	length	O
8	coding	O
9	cDNA	O
10	sequence	O
11	of	O
12	the	O
13	mouse	B
14	homologue	I
15	of	I
16	MPP3	I
17	.	O

1	The	O
2	method	O
3	also	O
4	eliminates	O
5	tagging	O
6	of	O
7	venous	O
8	spins	O
9	and	O
10	concern	O
11	about	O
12	asymmetric	O
13	magnetization	O
14	transfer	O
15	effects	O
16	.	O

1	Consistent	O
2	with	O
3	this	O
4	,	O
5	purified	O
6	Dlk	B
7	phosphorylated	O
8	core	O
9	histones	B
10	H3	I
11	,	O
12	H2A	B
13	and	O
14	H4	B
15	as	O
16	exogenous	O
17	substrates	O
18	and	O
19	endogenous	O
20	histone	B
21	H3	I
22	in	O
23	kinase	O
24	assays	O
25	with	O
26	nuclear	O
27	extracts	O
28	.	O

1	In	O
2	this	O
3	study	O
4	we	O
5	provide	O
6	evidence	O
7	that	O
8	B	B
9	-	I
10	Myb	I
11	is	O
12	a	O
13	direct	O
14	physiological	O
15	target	O
16	for	O
17	cyclin	B
18	A	I
19	/	O
20	Cdk2	B
21	.	O

1	Neither	O
2	Ha	B
3	-	I
4	Ras	I
5	(	O
6	G12V	O
7	,	O
8	T35S	O
9	)	O
10	(	O
11	Ha	B
12	-	I
13	RasV12S35	I
14	),	O
15	which	O
16	activates	O
17	the	O
18	Rafl	B
19	signaling	O
20	pathway	O
21	,	O
22	nor	O
23	Ha	B
24	-	I
25	Ras	I
26	(	I
27	G12V	I
28	,	I
29	E37G	I
30	)	I
31	(	O
32	Ha	B
33	-	I
34	RasV12G37	I
35	),	O
36	which	O
37	stimulates	O
38	the	O
39	RalGDS	B
40	pathway	O
41	,	O
42	did	O
43	not	O
44	have	O
45	significant	O
46	effects	O
47	on	O
48	factor	O
49	-	O
50	withdrawal	O
51	apoptosis	O
52	of	O
53	myeloid	O
54	cells	O
55	.	O

1	We	O
2	have	O
3	isolated	O
4	a	O
5	novel	O
6	human	B
7	cyclin	I
8	,	O
9	cyclin	B
10	E2	I
11	,	O
12	that	O
13	contains	O
14	significant	O
15	homology	O
16	to	O
17	cyclin	B
18	E	I
19	.	O

1	Initial	O
2	experience	O
3	with	O
4	the	O
5	new	O
6	technology	O
7	indicates	O
8	that	O
9	SieScape	O
10	is	O
11	an	O
12	alternative	O
13	to	O
14	other	O
15	methods	O
16	such	O
17	as	O
18	CT	O
19	and	O
20	MRI	O
21	.	O

1	The	O
2	dopamine	B
3	D4	I
4	receptor	I
5	as	O
6	well	O
7	as	O
8	many	O
9	other	O
10	catecholaminergic	B
11	receptors	I
12	contain	O
13	several	O
14	putative	O
15	SH3	B
16	binding	I
17	domains	I
18	.	O

1	The	O
2	highly	O
3	amyloidogenic	O
4	42	O
5	-	O
6	residue	O
7	form	O
8	of	O
9	Abeta	B
10	(	O
11	Abeta42	B
12	)	O
13	is	O
14	the	O
15	first	O
16	species	O
17	to	O
18	be	O
19	deposited	O
20	in	O
21	both	O
22	sporadic	O
23	and	O
24	familial	O
25	AD	O
26	.	O

1	This	O
2	model	O
3	is	O
4	supported	O
5	by	O
6	experiments	O
7	showing	O
8	that	O
9	Cdr2	B
10	associates	O
11	with	O
12	the	O
13	N	B
14	-	I
15	terminal	I
16	regulatory	I
17	domain	I
18	of	I
19	Wee1	I
20	in	O
21	cell	O
22	lysates	O
23	and	O
24	phosphorylates	O
25	Wee1	B
26	in	O
27	vitro	O
28	.	O

1	Schizosaccharomyces	O
2	pombe	O
3	cells	O
4	respond	O
5	to	O
6	nutrient	O
7	deprivation	O
8	by	O
9	altering	O
10	G2	O
11	/	O
12	M	O
13	cell	O
14	size	O
15	control	O
16	.	O

1	A	O
2	-	O
3	tracts	O
4	functioned	O
5	best	O
6	when	O
7	positioned	O
8	close	O
9	to	O
10	the	O
11	-	O
12	35	O
13	hexamer	O
14	rather	O
15	than	O
16	one	O
17	helical	O
18	turn	O
19	farther	O
20	upstream	O
21	,	O
22	similar	O
23	to	O
24	the	O
25	positioning	O
26	optimal	O
27	for	O
28	UP	O
29	element	O
30	function	O
31	.	O

1	Pyk2	B
2	phosphorylation	O
3	increased	O
4	upon	O
5	adherence	O
6	of	O
7	FLG	O
8	29	O
9	.	O
10	1	O
11	cells	O
12	to	O
13	fibronectin	B
14	and	O
15	to	O
16	ST2	O
17	stromal	O
18	cells	O
19	.	O

1	Raf	B
2	is	O
3	a	O
4	key	O
5	serine	B
6	-	I
7	threonine	I
8	protein	I
9	kinase	I
10	which	O
11	participates	O
12	in	O
13	the	O
14	transmission	O
15	of	O
16	growth	O
17	,	O
18	anti	O
19	-	O
20	apoptotic	O
21	and	O
22	differentiation	O
23	messages	O
24	.	O

1	The	O
2	US	O
3	National	O
4	Institute	O
5	on	O
6	Alcohol	O
7	Abuse	O
8	and	O
9	Alcoholism	O
10	(	O
11	NIAAA	O
12	)	O
13	recognizes	O
14	two	O
15	forms	O
16	of	O
17	problematic	O
18	drinking	O
19	:	O
20	'	O
21	willful	O
22	alcohol	O
23	abuse	O
24	',	O
25	a	O
26	behavioural	O
27	problem	O
28	,	O
29	and	O
30	'	O
31	alcohol	O
32	dependence	O
33	',	O
34	a	O
35	true	O
36	medical	O
37	disorder	O
38	,	O
39	which	O
40	includes	O
41	a	O
42	genetic	O
43	component	O
44	,	O
45	that	O
46	can	O
47	be	O
48	scientifically	O
49	understood	O
50	and	O
51	medically	O
52	treated	O
53	.	O

1	Collagen	B
2	was	O
3	extracted	O
4	from	O
5	the	O
6	skin	O
7	,	O
8	and	O
9	the	O
10	lack	O
11	of	O
12	type	B
13	III	I
14	collagen	I
15	was	O
16	determined	O
17	by	O
18	means	O
19	of	O
20	sodium	O
21	dodecyl	O
22	sulfate	O
23	-	O
24	polyacrylamide	O
25	gel	O
26	electrophoresis	O
27	(	O
28	SDS	O
29	-	O
30	PAGE	O
31	).	O

1	RESULTS	O
2	:	O
3	During	O
4	the	O
5	7	O
6	-	O
7	year	O
8	period	O
9	,	O
10	10	O
11	,	O
12	331	O
13	symptomatic	O
14	duodenal	O
15	ulcer	O
16	diseases	O
17	were	O
18	diagnosed	O
19	.	O

1	RESULTS	O
2	:	O
3	Significant	O
4	changes	O
5	from	O
6	pretreatment	O
7	to	O
8	posttreatment	O
9	were	O
10	observed	O
11	(	O
12	p	O
13	<	O
14	0	O
15	.	O
16	001	O
17	).	O

1	In	O
2	turn	O
3	,	O
4	assembly	O
5	of	O
6	this	O
7	complex	O
8	mediates	O
9	the	O
10	enzymatic	O
11	activation	O
12	of	O
13	the	O
14	p21	B
15	-	I
16	activated	I
17	protein	I
18	kinase	I
19	1	I
20	and	O
21	facilitates	O
22	actin	B
23	polymerization	O
24	.	O

1	The	O
2	tip	O
3	of	O
4	the	O
5	button	O
6	caused	O
7	a	O
8	perforation	O
9	of	O
10	the	O
11	posterior	O
12	stomach	O
13	wall	O
14	,	O
15	leading	O
16	to	O
17	death	O
18	.	O

1	Jembrana	O
2	disease	O
3	virus	O
4	(	O
5	JDV	O
6	)	O
7	is	O
8	a	O
9	newly	O
10	identified	O
11	bovine	O
12	lentivirus	O
13	that	O
14	is	O
15	closely	O
16	related	O
17	to	O
18	the	O
19	bovine	O
20	immunodeficiency	O
21	virus	O
22	(	O
23	BIV	O
24	).	O

1	Approximately	O
2	50	O
3	%	O
4	of	O
5	the	O
6	residues	O
7	are	O
8	conserved	O
9	among	O
10	all	O
11	three	O
12	sequences	O
13	,	O
14	yet	O
15	all	O
16	three	O
17	viruses	O
18	have	O
19	retained	O
20	response	O
21	elements	O
22	for	O
23	glucocorticoids	O
24	,	O
25	two	O
26	positionally	O
27	conserved	O
28	CCAAT	O
29	boxes	O
30	,	O
31	and	O
32	positionally	O
33	conserved	O
34	TATA	O
35	boxes	O
36	.	O

1	Nhp2p	B
2	is	O
3	a	O
4	highly	O
5	basic	O
6	protein	O
7	that	O
8	belongs	O
9	to	O
10	a	O
11	family	O
12	of	O
13	putative	O
14	RNA	O
15	-	O
16	binding	O
17	proteins	O
18	.	O

1	This	O
2	survey	O
3	included	O
4	3000	O
5	randomly	O
6	selected	O
7	Norwegians	O
8	above	O
9	18	O
10	years	O
11	of	O
12	age	O
13	who	O
14	received	O
15	the	O
16	European	O
17	Organization	O
18	for	O
19	Research	O
20	and	O
21	Treatment	O
22	of	O
23	Cancer	O
24	Core	O
25	Quality	O
26	of	O
27	Life	O
28	Questionnaire	O
29	(	O
30	EORTC	O
31	QLQ	O
32	-	O
33	C30	O
34	(+	O
35	3	O
36	)	O
37	by	O
38	mail	O
39	.	O

1	During	O
2	presentation	O
3	of	O
4	happy	O
5	facial	O
6	expressions	O
7	,	O
8	we	O
9	detected	O
10	a	O
11	signal	O
12	increase	O
13	predominantly	O
14	in	O
15	the	O
16	left	O
17	anterior	O
18	cingulate	O
19	gyrus	O
20	,	O
21	bilateral	O
22	posterior	O
23	cingulate	O
24	gyri	O
25	,	O
26	medial	O
27	frontal	O
28	cortex	O
29	and	O
30	right	O
31	supramarginal	O
32	gyrus	O
33	,	O
34	brain	O
35	regions	O
36	previously	O
37	implicated	O
38	in	O
39	visuospatial	O
40	and	O
41	emotion	O
42	processing	O
43	tasks	O
44	.	O

1	Down	O
2	-	O
3	regulation	O
4	of	O
5	IRS	B
6	-	I
7	1	I
8	is	O
9	linked	O
10	to	O
11	its	O
12	serine	O
13	phosphorylation	O
14	dependent	O
15	on	O
16	PI	B
17	3	I
18	-	I
19	kinase	I
20	activity	O
21	and	O
22	appears	O
23	required	O
24	for	O
25	differentiation	O
26	to	O
27	occur	O
28	,	O
29	as	O
30	IRS	B
31	-	I
32	1	I
33	is	O
34	not	O
35	modified	O
36	and	O
37	continues	O
38	to	O
39	accumulate	O
40	in	O
41	a	O
42	nondifferentiating	O
43	myoblast	O
44	cell	O
45	line	O
46	.	O

1	This	O
2	study	O
3	utilizes	O
4	the	O
5	mammalian	O
6	two	O
7	-	O
8	hybrid	O
9	system	O
10	to	O
11	examine	O
12	the	O
13	role	O
14	of	O
15	ligand	O
16	in	O
17	the	O
18	dimerization	O
19	of	O
20	human	B
21	progesterone	I
22	receptor	I
23	(	O
24	hPR	B
25	).	O

1	One	O
2	of	O
3	its	O
4	unique	O
5	features	O
6	appears	O
7	to	O
8	be	O
9	the	O
10	unusually	O
11	short	O
12	5	O
13	'-	O
14	untranslated	O
15	regions	O
16	(	O
17	UTR	O
18	)	O
19	(	O
20	1	O
21	-	O
22	6	O
23	nucleotides	O
24	(	O
25	nts	O
26	))	O
27	and	O
28	the	O
29	apparent	O
30	absence	O
31	of	O
32	5	O
33	'-	O
34	cap	O
35	structures	O
36	from	O
37	its	O
38	mRNAs	O
39	.	O

1	The	O
2	gene	B
3	encoding	I
4	human	I
5	tissue	I
6	-	I
7	type	I
8	plasminogen	I
9	activator	I
10	(	O
11	t	B
12	-	I
13	PA	I
14	)	O
15	is	O
16	regulated	O
17	in	O
18	a	O
19	cell	O
20	-	O
21	type	O
22	-	O
23	specific	O
24	manner	O
25	.	O

1	Both	O
2	the	O
3	presence	O
4	of	O
5	arginine	O
6	and	O
7	anaerobiosis	O
8	are	O
9	needed	O
10	to	O
11	trigger	O
12	induction	O
13	of	O
14	the	O
15	pathway	O
16	.	O

1	Competition	O
2	with	O
3	a	O
4	putative	O
5	MADS	B
6	box	I
7	consensus	O
8	binding	O
9	site	O
10	from	O
11	the	O
12	promoter	O
13	of	O
14	the	O
15	coordinately	O
16	regulated	O
17	opaque	B
18	-	I
19	phase	I
20	-	I
21	specific	I
22	gene	I
23	PEP1	I
24	(	O
25	SAP1	B
26	)	O
27	and	O
28	the	O
29	human	B
30	MADS	I
31	box	I
32	consensus	I
33	binding	I
34	site	I
35	for	O
36	serum	B
37	response	I
38	factor	I
39	demonstrated	O
40	that	O
41	one	O
42	of	O
43	the	O
44	three	O
45	complexes	O
46	formed	O
47	was	O
48	specific	O
49	to	O
50	the	O
51	OP4	B
52	sequence	I
53	.	O

1	The	O
2	human	B
3	SHBG	I
4	proximal	I
5	promoter	I
6	was	O
7	analyzed	O
8	by	O
9	DNase	B
10	I	I
11	footprinting	O
12	,	O
13	and	O
14	the	O
15	functional	O
16	significance	O
17	of	O
18	6	O
19	footprinted	O
20	regions	O
21	(	O
22	FP1	O
23	-	O
24	FP6	O
25	)	O
26	within	O
27	the	O
28	proximal	O
29	promoter	O
30	was	O
31	studied	O
32	in	O
33	human	O
34	HepG2	O
35	hepatoblastoma	O
36	cells	O
37	.	O

1	In	O
2	vitro	O
3	translation	O
4	and	O
5	in	O
6	vivo	O
7	polysome	O
8	profile	O
9	analysis	O
10	indicated	O
11	that	O
12	transcripts	B
13	C	I
14	and	I
15	E	I
16	were	O
17	translated	O
18	with	O
19	similar	O
20	translational	O
21	efficiencies	O
22	that	O
23	are	O
24	substantially	O
25	greater	O
26	than	O
27	that	O
28	of	O
29	transcript	B
30	D	I
31	,	O
32	suggesting	O
33	that	O
34	5	O
35	'-	O
36	untranslated	O
37	regions	O
38	play	O
39	a	O
40	role	O
41	in	O
42	translational	O
43	control	O
44	.	O

1	We	O
2	have	O
3	introduced	O
4	a	O
5	mutation	O
6	(	O
7	Ser36	O
8	-->	O
9	Asn	O
10	)	O
11	into	O
12	this	O
13	domain	O
14	of	O
15	p190	B
16	that	O
17	decreased	O
18	its	O
19	ability	O
20	to	O
21	bind	O
22	guanine	O
23	nucleotide	O
24	when	O
25	expressed	O
26	as	O
27	a	O
28	hemagglutinin	B
29	(	O
30	HA	B
31	)-	O
32	tagged	O
33	protein	O
34	in	O
35	COS	O
36	cells	O
37	.	O

1	Wild	O
2	type	O
3	HA	B
4	-	O
5	p190	B
6	induced	O
7	a	O
8	phenotype	O
9	of	O
10	rounded	O
11	cells	O
12	with	O
13	long	O
14	,	O
15	beaded	O
16	extensions	O
17	similar	O
18	to	O
19	that	O
20	seen	O
21	when	O
22	Rho	B
23	function	O
24	is	O
25	disrupted	O
26	by	O
27	ADP	O
28	-	O
29	ribosylation	O
30	.	O

1	We	O
2	emphasize	O
3	that	O
4	ANCA	B
5	-	O
6	associated	O
7	vasculitis	O
8	is	O
9	another	O
10	important	O
11	complication	O
12	of	O
13	RA	O
14	.	O

1	The	O
2	downstream	O
3	,	O
4	TATA	O
5	-	O
6	less	O
7	promoter	O
8	has	O
9	high	O
10	G	O
11	+	O
12	C	O
13	content	O
14	,	O
15	and	O
16	exon	O
17	1b	O
18	predominates	O
19	among	O
20	abundantly	O
21	expressed	O
22	mRNA	O
23	species	O
24	.	O

1	Although	O
2	we	O
3	predicted	O
4	that	O
5	overexpression	O
6	of	O
7	the	O
8	COOH	O
9	-	O
10	terminal	O
11	domains	O
12	,	O
13	which	O
14	were	O
15	thought	O
16	to	O
17	be	O
18	involved	O
19	in	O
20	the	O
21	regulation	O
22	of	O
23	SREBP	B
24	processing	O
25	,	O
26	would	O
27	result	O
28	in	O
29	disruption	O
30	of	O
31	the	O
32	SREBP	B
33	-	O
34	dependent	O
35	transcriptional	O
36	regulation	O
37	of	O
38	several	O
39	genes	O
40	,	O
41	the	O
42	mRNA	O
43	levels	O
44	for	O
45	3	B
46	-	I
47	hydroxy	I
48	-	I
49	3	I
50	-	I
51	methylglutaryl	I
52	coenzyme	I
53	A	I
54	(	I
55	HMG	I
56	CoA	I
57	)	I
58	synthase	I
59	in	O
60	these	O
61	two	O
62	cell	O
63	lines	O
64	were	O
65	regulated	O
66	in	O
67	a	O
68	sterol	O
69	-	O
70	dependent	O
71	manner	O
72	.	O

1	Dry	O
2	matter	O
3	intake	O
4	,	O
5	apparent	O
6	nutrient	O
7	digestibilities	O
8	,	O
9	serum	O
10	chemistry	O
11	profiles	O
12	,	O
13	sphingolipid	O
14	concentrations	O
15	,	O
16	and	O
17	persistency	O
18	of	O
19	FB1	O
20	in	O
21	tissues	O
22	were	O
23	evaluated	O
24	.	O

1	However	O
2	,	O
3	no	O
4	studies	O
5	have	O
6	been	O
7	conducted	O
8	to	O
9	further	O
10	investigate	O
11	this	O
12	potentially	O
13	hazardous	O
14	effect	O
15	of	O
16	lidocaine	O
17	.	O

1	E	O
2	.,	O
3	Scott	O
4	,	O
5	J	O
6	.	O

1	Yap1p	B
2	is	O
3	constitutively	O
4	nuclear	O
5	in	O
6	a	O
7	crm1	B
8	mutant	I
9	,	O
10	and	O
11	Crm1p	B
12	binds	O
13	to	O
14	a	O
15	nuclear	O
16	export	O
17	sequence	O
18	(	O
19	NES	O
20	)-	O
21	like	O
22	sequence	O
23	in	O
24	Yap1p	B
25	in	O
26	the	O
27	presence	O
28	of	O
29	RanGTP	B
30	.	O

1	Mean	O
2	intake	O
3	of	O
4	vitamin	O
5	A	O
6	amounted	O
7	to	O
8	1	O
9	.	O
10	1	O
11	and	O
12	0	O
13	.	O
14	9	O
15	mg	O
16	RE	O
17	/	O
18	day	O
19	for	O
20	men	O
21	and	O
22	women	O
23	,	O
24	respectively	O
25	;	O
26	the	O
27	contributions	O
28	of	O
29	meat	O
30	,	O
31	fats	O
32	and	O
33	oils	O
34	,	O
35	vegetables	O
36	and	O
37	dairy	O
38	products	O
39	to	O
40	total	O
41	intake	O
42	were	O
43	35	O
44	%,	O
45	24	O
46	%,	O
47	16	O
48	%,	O
49	and	O
50	16	O
51	%,	O
52	respectively	O
53	.	O

1	Also	O
2	,	O
3	the	O
4	amplitude	O
5	of	O
6	the	O
7	oscillatory	O
8	potentials	O
9	(	O
10	O1	O
11	+	O
12	O2	O
13	+	O
14	O3	O
15	+	O
16	O4	O
17	)	O
18	was	O
19	significantly	O
20	reduced	O
21	in	O
22	the	O
23	early	O
24	postoperative	O
25	period	O
26	.	O

1	Furthermore	O
2	,	O
3	RING1	B
4	overexpression	O
5	results	O
6	in	O
7	enhanced	O
8	expression	O
9	of	O
10	the	O
11	proto	O
12	-	O
13	oncogenes	O
14	c	B
15	-	I
16	jun	I
17	and	O
18	c	B
19	-	I
20	fos	I
21	.	O

1	The	O
2	yeast	B
3	RER2	I
4	gene	I
5	,	O
6	identified	O
7	by	O
8	endoplasmic	O
9	reticulum	O
10	protein	O
11	localization	O
12	mutations	O
13	,	O
14	encodes	O
15	cis	B
16	-	I
17	prenyltransferase	I
18	,	O
19	a	O
20	key	O
21	enzyme	O
22	in	O
23	dolichol	O
24	synthesis	O
25	.	O

1	The	O
2	yeast	O
3	retrotransposon	B
4	Ty5	I
5	preferentially	O
6	integrates	O
7	into	O
8	regions	O
9	of	O
10	silent	O
11	chromatin	O
12	.	O

1	The	O
2	loss	O
3	of	O
4	SKO1	B
5	completely	O
6	restored	O
7	ENA1	B
8	expression	O
9	in	O
10	a	O
11	hog1	B
12	mutant	I
13	and	O
14	partially	O
15	suppressed	O
16	the	O
17	osmotic	O
18	stress	O
19	sensitivity	O
20	,	O
21	qualifying	O
22	Sko1p	B
23	as	O
24	a	O
25	downstream	O
26	effector	O
27	of	O
28	the	O
29	HOG	B
30	pathway	O
31	.	O

1	Elevated	O
2	expression	O
3	of	O
4	a	O
5	previously	O
6	uncharacterized	O
7	gene	O
8	,	O
9	SPP381	B
10	,	O
11	efficiently	O
12	suppresses	O
13	the	O
14	growth	O
15	and	O
16	splicing	O
17	defects	O
18	of	O
19	a	O
20	temperature	O
21	-	O
22	sensitive	O
23	(	O
24	Ts	O
25	)	O
26	mutant	B
27	prp38	I
28	-	I
29	1	I
30	.	O

1	The	O
2	slower	O
3	-	O
4	electrophoretic	O
5	-	O
6	mobility	O
7	form	O
8	of	O
9	p68	B
10	was	O
11	absent	O
12	in	O
13	human	O
14	cells	O
15	in	O
16	G1	O
17	/	O
18	S	O
19	and	O
20	appeared	O
21	as	O
22	the	O
23	cells	O
24	entered	O
25	G2	O
26	/	O
27	M	O
28	.	O

1	We	O
2	have	O
3	identified	O
4	amino	O
5	acid	O
6	sequences	O
7	in	O
8	mammalian	O
9	and	O
10	Xenopus	O
11	NeuroD1	B
12	/	O
13	BETA2	B
14	that	O
15	are	O
16	necessary	O
17	for	O
18	insulin	B
19	gene	I
20	expression	O
21	and	O
22	ectopic	O
23	neurogenesis	O
24	.	O

1	Both	O
2	NUP98	B
3	-	O
4	HOXA9	B
5	chimeras	O
6	transformed	O
7	NIH	O
8	3T3	O
9	fibroblasts	O
10	,	O
11	and	O
12	this	O
13	transformation	O
14	required	O
15	the	O
16	HOXA9	B
17	domains	I
18	for	O
19	DNA	O
20	binding	O
21	and	O
22	PBX	B
23	interaction	O
24	.	O

1	Recent	O
2	studies	O
3	have	O
4	suggested	O
5	that	O
6	Y319	O
7	also	O
8	positively	O
9	regulate	O
10	ZAP	B
11	-	I
12	70	I
13	function	O
14	.	O

1	Genetic	O
2	and	O
3	molecular	O
4	data	O
5	indicate	O
6	that	O
7	wild	B
8	-	I
9	type	I
10	Pan	I
11	and	O
12	CiD	B
13	compete	O
14	for	O
15	binding	O
16	to	O
17	Arm	B
18	,	O
19	leading	O
20	to	O
21	a	O
22	compromised	O
23	transduction	O
24	of	O
25	the	O
26	Wg	B
27	signal	O
28	in	O
29	heterozygous	O
30	ciD	B
31	/+	I
32	animals	O
33	and	O
34	to	O
35	a	O
36	dramatic	O
37	enhancement	O
38	of	O
39	the	O
40	gain	O
41	-	O
42	of	O
43	-	O
44	function	O
45	activity	O
46	of	O
47	CiD	B
48	in	O
49	homozygous	O
50	mutants	O
51	.	O

1	Another	O
2	ORF	O
3	,	O
4	dda	B
5	.	I
6	2	I
7	located	O
8	between	O
9	modA	B
10	and	O
11	dda	B
12	,	O
13	shares	O
14	sequence	O
15	similarity	O
16	with	O
17	sigma70	B
18	,	O
19	and	O
20	we	O
21	call	O
22	it	O
23	srd	B
24	.	O

1	The	O
2	location	O
3	of	O
4	the	O
5	IBS	O
6	within	O
7	the	O
8	catB	B
9	structural	I
10	gene	I
11	,	O
12	the	O
13	cooperativity	O
14	observed	O
15	in	O
16	footprinting	O
17	studies	O
18	and	O
19	phasing	O
20	studies	O
21	suggest	O
22	that	O
23	the	O
24	IBS	O
25	participates	O
26	in	O
27	the	O
28	interaction	O
29	of	O
30	CatR	B
31	with	O
32	the	O
33	upstream	O
34	binding	O
35	sites	O
36	by	O
37	looping	O
38	out	O
39	the	O
40	intervening	O
41	DNA	O
42	.	O

1	In	O
2	vitro	O
3	transcription	O
4	assays	O
5	demonstrate	O
6	that	O
7	the	O
8	TCA	O
9	-	O
10	cycle	O
11	intermediate	O
12	,	O
13	fumarate	O
14	,	O
15	directly	O
16	and	O
17	specifically	O
18	inhibits	O
19	the	O
20	formation	O
21	of	O
22	the	O
23	clcA	B
24	transcript	I
25	.	O

1	BIAcore	O
2	analysis	O
3	gave	O
4	a	O
5	Kaff	O
6	of	O
7	4	O
8	.	O
9	4	O
10	x	O
11	10	O
12	(	O
13	10	O
14	)	O
15	M	O
16	-	O
17	1	O
18	for	O
19	the	O
20	binding	O
21	of	O
22	N	B
23	-	I
24	A3	I
25	to	O
26	T84	B
27	.	I
28	1	I
29	and	O
30	2	O
31	.	O
32	2	O
33	x	O
34	10	O
35	(	O
36	10	O
37	)	O
38	M	O
39	-	O
40	1	O
41	for	O
42	the	O
43	binding	O
44	of	O
45	N	B
46	-	I
47	A3	I
48	to	O
49	T84	B
50	.	I
51	66	I
52	.	O

1	Expression	O
2	of	O
3	p130	B
4	(	O
5	Cas	B
6	)	O
7	(	O
8	Cas	B
9	),	O
10	a	O
11	major	O
12	binding	O
13	protein	O
14	for	O
15	the	O
16	Crk	B
17	SH2	I
18	-	I
19	domain	I
20	,	O
21	also	O
22	induced	O
23	JNK	B
24	activation	O
25	,	O
26	which	O
27	was	O
28	blocked	O
29	by	O
30	the	O
31	SH2	B
32	-	I
33	mutant	I
34	of	O
35	Crk	B
36	.	O

1	Positive	O
2	correlations	O
3	were	O
4	seen	O
5	between	O
6	the	O
7	measurements	O
8	for	O
9	protein	O
10	intake	O
11	(	O
12	r	O
13	=.	O
14	58	O
15	,	O
16	P	O
17	=.	O
18	0026	O
19	)	O
20	energy	O
21	intake	O
22	(	O
23	r	O
24	=.	O
25	78	O
26	,	O
27	P	O
28	<.	O
29	00001	O
30	),	O
31	with	O
32	mean	O
33	differences	O
34	of	O
35	.	O
36	066	O
37	g	O
38	/	O
39	kg	O
40	/	O
41	d	O
42	(	O
43	SD	O
44	.	O
45	38	O
46	)	O
47	2	O
48	.	O
49	04	O
50	kcal	O
51	/	O
52	kg	O
53	/	O
54	day	O
55	(	O
56	SD	O
57	6	O
58	.	O
59	67	O
60	),	O
61	respectively	O
62	.	O

1	The	O
2	Og4C3	B
3	enzyme	O
4	-	O
5	linked	O
6	immunosorbent	O
7	assay	O
8	(	O
9	ELISA	O
10	)	O
11	to	O
12	detect	O
13	circulating	O
14	Wuchereria	B
15	bancrofti	I
16	antigen	I
17	uses	O
18	50	O
19	microL	O
20	of	O
21	serum	O
22	.	O

1	We	O
2	now	O
3	show	O
4	that	O
5	gp200	B
6	-	O
7	MR6	B
8	ligation	O
9	can	O
10	also	O
11	mimic	O
12	IL	B
13	-	I
14	4	I
15	and	O
16	have	O
17	an	O
18	anti	O
19	-	O
20	proliferative	O
21	pro	O
22	-	O
23	maturational	O
24	influence	O
25	within	O
26	the	O
27	immune	O
28	system	O
29	,	O
30	causing	O
31	up	O
32	-	O
33	regulation	O
34	of	O
35	co	O
36	-	O
37	stimulatory	O
38	molecules	O
39	on	O
40	B	O
41	lymphocytes	O
42	.	O

1	The	O
2	Mig1	B
3	repressor	I
4	is	O
5	a	O
6	zinc	B
7	finger	I
8	protein	I
9	that	O
10	mediates	O
11	glucose	O
12	repression	O
13	in	O
14	yeast	O
15	.	O

1	Ethylene	O
2	is	O
3	involved	O
4	in	O
5	endosperm	O
6	rupture	O
7	and	O
8	high	O
9	-	O
10	level	O
11	betaGLU	B
12	I	I
13	expression	O
14	;	O
15	but	O
16	,	O
17	it	O
18	does	O
19	not	O
20	affect	O
21	the	O
22	spatial	O
23	and	O
24	temporal	O
25	pattern	O
26	of	O
27	betaGLU	B
28	I	I
29	expression	O
30	.	O

1	The	O
2	divergence	O
3	in	O
4	primary	O
5	structure	O
6	between	O
7	the	O
8	sheep	O
9	CRF1	B
10	and	O
11	the	O
12	other	O
13	mammalian	B
14	CRF1s	I
15	is	O
16	primarily	O
17	localized	O
18	to	O
19	the	O
20	extracellular	O
21	amino	O
22	terminal	O
23	domain	O
24	of	O
25	the	O
26	receptor	O
27	(	O
28	18	O
29	of	O
30	22	O
31	divergent	O
32	residues	O
33	,	O
34	ovine	O
35	vs	O
36	human	B
37	CRF1	I
38	).	O

1	Agonist	O
2	-	O
3	induced	O
4	receptor	O
5	internalization	O
6	,	O
7	determined	O
8	as	O
9	the	O
10	percent	O
11	of	O
12	total	O
13	[	O
14	125I	O
15	]	O
16	Tyr0	B
17	-	I
18	oCRF	I
19	bound	O
20	located	O
21	in	O
22	the	O
23	acid	O
24	-	O
25	resistant	O
26	fraction	O
27	of	O
28	transfected	O
29	Cos	O
30	7	O
31	cells	O
32	,	O
33	increased	O
34	with	O
35	time	O
36	(	O
37	0	O
38	-	O
39	60	O
40	min	O
41	at	O
42	37	O
43	degrees	O
44	C	O
45	)	O
46	for	O
47	both	O
48	wild	O
49	-	O
50	type	O
51	and	O
52	variant	O
53	oCRF1	B
54	.	O

1	Recurrent	O
2	arterial	O
3	thrombotic	O
4	disease	O
5	on	O
6	young	O
7	onset	O
8	and	O
9	protein	B
10	S	I
11	deficiency	O
12	.	O

1	We	O
2	showed	O
3	that	O
4	Stat3	B
5	and	O
6	Stat3beta	B
7	were	O
8	affinity	O
9	purified	O
10	using	O
11	phosphopeptides	O
12	containing	O
13	Y704	O
14	and	O
15	Y744	O
16	but	O
17	not	O
18	by	O
19	nonphosphorylated	O
20	peptide	O
21	analogues	O
22	or	O
23	by	O
24	phosphopeptides	O
25	containing	O
26	Y729	O
27	and	O
28	Y764	O
29	.	O

1	Taken	O
2	together	O
3	,	O
4	our	O
5	results	O
6	indicate	O
7	that	O
8	the	O
9	FCR1	B
10	gene	I
11	behaves	O
12	as	O
13	a	O
14	negative	O
15	regulator	O
16	of	O
17	drug	O
18	resistance	O
19	in	O
20	C	O
21	.	O
22	albicans	O
23	and	O
24	constitute	O
25	the	O
26	first	O
27	evidence	O
28	that	O
29	FCZ	O
30	resistance	O
31	can	O
32	result	O
33	from	O
34	the	O
35	inactivation	O
36	of	O
37	a	O
38	regulatory	O
39	factor	O
40	such	O
41	as	O
42	Fcr1p	B
43	.	O

1	These	O
2	findings	O
3	suggest	O
4	that	O
5	late	O
6	MYO	O
7	/	O
8	M	O
9	is	O
10	more	O
11	useful	O
12	than	O
13	washout	O
14	rate	O
15	to	O
16	assess	O
17	the	O
18	effect	O
19	of	O
20	treatment	O
21	on	O
22	heart	O
23	failure	O
24	due	O
25	to	O
26	DCM	O
27	.	O

1	This	O
2	study	O
3	was	O
4	undertaken	O
5	to	O
6	evaluate	O
7	how	O
8	couplers	O
9	and	O
10	their	O
11	placement	O
12	affect	O
13	the	O
14	ALGO2	O
15	click	O
16	spectral	O
17	properties	O
18	.	O

1	CONCLUSIONS	O
2	:	O
3	Pretreatment	O
4	with	O
5	OCs	O
6	prior	O
7	to	O
8	pituitary	O
9	suppression	O
10	in	O
11	the	O
12	early	O
13	follicular	O
14	phase	O
15	decreases	O
16	ovarian	O
17	cyst	O
18	formation	O
19	,	O
20	without	O
21	an	O
22	apparent	O
23	effect	O
24	on	O
25	subsequent	O
26	follicular	O
27	recruitment	O
28	or	O
29	pregnancy	O
30	rates	O
31	.	O

1	With	O
2	regard	O
3	to	O
4	the	O
5	optimal	O
6	threshold	O
7	values	O
8	,	O
9	sensitivity	O
10	and	O
11	specificity	O
12	were	O
13	100	O
14	%/	O
15	97	O
16	%	O
17	and	O
18	95	O
19	%/	O
20	95	O
21	%	O
22	with	O
23	FDG	O
24	PET	O
25	,	O
26	compared	O
27	to	O
28	86	O
29	%/	O
30	92	O
31	%	O
32	and	O
33	77	O
34	%/	O
35	82	O
36	%	O
37	with	O
38	IS	O
39	,	O
40	respectively	O
41	.	O

1	This	O
2	c	B
3	-	I
4	Jun	I
5	activity	O
6	is	O
7	inhibited	O
8	by	O
9	c	B
10	-	I
11	Fos	I
12	,	O
13	another	O
14	protooncoprotein	O
15	that	O
16	can	O
17	dimerize	O
18	with	O
19	c	B
20	-	I
21	Jun	I
22	to	O
23	form	O
24	the	O
25	transcription	O
26	factor	O
27	AP	B
28	-	I
29	1	I
30	.	O

1	Dorsal	O
2	root	O
3	ganglia	O
4	neuron	O
5	-	O
6	specific	O
7	promoter	O
8	activity	O
9	of	O
10	the	O
11	rabbit	B
12	beta	I
13	-	I
14	galactoside	I
15	alpha1	I
16	,	I
17	2	I
18	-	I
19	fucosyltransferase	I
20	gene	I
21	.	O

1	CONCLUSION	O
2	:	O
3	Our	O
4	study	O
5	shows	O
6	that	O
7	(	O
8	1	O
9	)	O
10	total	O
11	body	O
12	BMD	O
13	and	O
14	femoral	O
15	neck	O
16	BMD	O
17	were	O
18	significantly	O
19	higher	O
20	in	O
21	the	O
22	study	O
23	group	O
24	that	O
25	performed	O
26	weight	O
27	-	O
28	bearing	O
29	exercises	O
30	than	O
31	in	O
32	control	O
33	subjects	O
34	,	O
35	(	O
36	2	O
37	)	O
38	swimming	O
39	exercise	O
40	had	O
41	no	O
42	effect	O
43	on	O
44	BMD	O
45	,	O
46	and	O
47	(	O
48	3	O
49	)	O
50	although	O
51	swimming	O
52	is	O
53	not	O
54	a	O
55	bone	O
56	-	O
57	building	O
58	exercise	O
59	,	O
60	it	O
61	can	O
62	significantly	O
63	improve	O
64	shoulder	O
65	,	O
66	back	O
67	,	O
68	and	O
69	grip	O
70	muscle	O
71	strength	O
72	.	O

1	This	O
2	suggests	O
3	roles	O
4	for	O
5	both	O
6	the	O
7	CE1	O
8	and	O
9	CE2	O
10	elements	O
11	in	O
12	regulating	O
13	Hoxb1	B
14	gene	I
15	expression	O
16	during	O
17	development	O
18	.	O

1	CAL	O
2	gain	O
3	amounted	O
4	to	O
5	4	O
6	.	O
7	2	O
8	+/-	O
9	1	O
10	.	O
11	3	O
12	mm	O
13	,	O
14	60	O
15	%	O
16	of	O
17	the	O
18	defects	O
19	showing	O
20	CAL	O
21	gain	O
22	>	O
23	or	O
24	=	O
25	4	O
26	mm	O
27	.	O

1	Comparisons	O
2	with	O
3	other	O
4	known	O
5	germins	B
6	and	O
7	germin	B
8	-	I
9	like	I
10	proteins	I
11	indicate	O
12	that	O
13	these	O
14	Arabidopsis	O
15	GLP	B
16	subfamilies	O
17	are	O
18	unique	O
19	from	O
20	wheat	O
21	germin	B
22	.	O

1	Lead	O
2	fixation	O
3	in	O
4	dogs	O
5	achieved	O
6	with	O
7	RF	O
8	energy	O
9	.	O

1	However	O
2	,	O
3	there	O
4	has	O
5	not	O
6	been	O
7	any	O
8	evidence	O
9	of	O
10	A	O
11	.	O
12	salmonicida	O
13	infections	O
14	,	O
15	specifically	O
16	furunculosis	O
17	,	O
18	associated	O
19	with	O
20	the	O
21	fish	O
22	in	O
23	this	O
24	loch	O
25	.	O

1	Further	O
2	,	O
3	we	O
4	show	O
5	that	O
6	this	O
7	EIA	B
8	-	O
9	inducible	O
10	CBF	O
11	/	O
12	cdc2	B
13	is	O
14	related	O
15	to	O
16	the	O
17	CBF	B
18	which	O
19	was	O
20	shown	O
21	to	O
22	activate	O
23	the	O
24	heat	B
25	shock	I
26	protein	I
27	70	I
28	promoter	I
29	.	O

1	The	O
2	percutaneous	O
3	absorption	O
4	of	O
5	clindamycin	O
6	was	O
7	studied	O
8	in	O
9	healthy	O
10	male	O
11	volunteers	O
12	,	O
13	comparing	O
14	two	O
15	investigative	O
16	clindamycin	O
17	(%	O
18	w	O
19	/	O
20	v	O
21	)/	O
22	tretinoin	O
23	(	O
24	0	O
25	.	O
26	025	O
27	%	O
28	w	O
29	/	O
30	v	O
31	)	O
32	gels	O
33	,	O
34	containing	O
35	clindamycin	O
36	phosphate	O
37	ester	O
38	and	O
39	clindamycin	O
40	HCl	O
41	,	O
42	respectively	O
43	,	O
44	relative	O
45	to	O
46	a	O
47	clindamycin	O
48	phosphate	O
49	lotion	O
50	(	O
51	1	O
52	%	O
53	clindamycin	O
54	;	O
55	Dalacin	O
56	T	O
57	).	O

1	The	O
2	BAL	O
3	concentrations	O
4	of	O
5	the	O
6	nine	O
7	cytokines	O
8	evaluated	O
9	for	O
10	the	O
11	more	O
12	and	O
13	less	O
14	affected	O
15	lungs	O
16	were	O
17	compared	O
18	:	O
19	interleukin	B
20	-	I
21	6	I
22	(	O
23	IL	B
24	-	I
25	6	I
26	),	O
27	IL	B
28	-	I
29	8	I
30	,	O
31	IL	B
32	-	I
33	12	I
34	,	O
35	tumor	B
36	necrosis	I
37	factor	I
38	-	I
39	alpha	I
40	(	O
41	TNF	B
42	-	I
43	alpha	I
44	),	O
45	and	O
46	interferon	B
47	gamma	I
48	(	O
49	IFN	B
50	-	I
51	gamma	I
52	)	O
53	showed	O
54	significant	O
55	differences	O
56	(	O
57	p	O
58	ranged	O
59	between	O
60	0	O
61	.	O

1	Phosphorylation	O
2	analyses	O
3	indicated	O
4	that	O
5	inhibition	O
6	of	O
7	ERK	B
8	-	I
9	1	I
10	/	I
11	2	I
12	decreased	O
13	okadaic	O
14	acid	O
15	-	O
16	elevated	O
17	phosphorylation	O
18	of	O
19	JunD	B
20	and	O
21	FosB	B
22	.	O

1	Two	O
2	-	O
3	way	O
4	analysis	O
5	of	O
6	variance	O
7	was	O
8	used	O
9	to	O
10	determine	O
11	whether	O
12	composite	O
13	knowledge	O
14	score	O
15	differed	O
16	among	O
17	patient	O
18	groups	O
19	.	O

1	The	O
2	human	O
3	pathogenic	O
4	bacterium	O
5	group	O
6	A	O
7	Streptococcus	O
8	produces	O
9	an	O
10	extracellular	O
11	cysteine	B
12	protease	I
13	[	O
14	streptococcal	B
15	pyrogenic	I
16	exotoxin	I
17	B	I
18	(	O
19	SpeB	B
20	)]	O
21	that	O
22	is	O
23	a	O
24	critical	O
25	virulence	O
26	factor	O
27	for	O
28	invasive	O
29	disease	O
30	episodes	O
31	.	O

1	The	O
2	orbitofrontal	O
3	,	O
4	cingulate	O
5	,	O
6	and	O
7	anteromedial	O
8	part	O
9	of	O
10	the	O
11	dorsal	O
12	premotor	O
13	areas	O
14	were	O
15	preferentially	O
16	activated	O
17	by	O
18	the	O
19	self	O
20	-	O
21	initiated	O
22	hand	O
23	movement	O
24	task	O
25	(	O
26	SELF	O
27	).	O

1	Improving	O
2	the	O
3	evidence	O
4	base	O
5	for	O
6	anaesthesia	O
7	.	O

1	Plasma	O
2	CCK	B
3	levels	O
4	were	O
5	determined	O
6	at	O
7	regular	O
8	intervals	O
9	.	O

1	The	O
2	peroxisome	O
3	biogenesis	O
4	disorders	O
5	(	O
6	PBDs	O
7	)	O
8	are	O
9	a	O
10	set	O
11	of	O
12	lethal	O
13	genetic	O
14	diseases	O
15	characterized	O
16	by	O
17	peroxisomal	O
18	metabolic	O
19	deficiencies	O
20	,	O
21	multisystem	O
22	abnormalities	O
23	,	O
24	mental	O
25	retardation	O
26	,	O
27	and	O
28	premature	O
29	death	O
30	.	O

1	The	O
2	active	O
3	site	O
4	includes	O
5	the	O
6	acidic	O
7	triad	O
8	Asp53	O
9	(	O
10	the	O
11	site	O
12	of	O
13	phosphorylation	O
14	),	O
15	Asp10	O
16	and	O
17	Glu9	O
18	.	O

1	Consistent	O
2	with	O
3	these	O
4	findings	O
5	,	O
6	relatively	O
7	weak	O
8	transcriptional	O
9	silencing	O
10	by	O
11	the	O
12	native	O
13	VDR	B
14	was	O
15	observed	O
16	using	O
17	the	O
18	osteopontin	B
19	VDRE	O
20	.	O

1	In	O
2	PAV	O
3	-	O
4	3	O
5	,	O
6	the	O
7	E1A	B
8	region	I
9	is	O
10	located	O
11	between	O
12	1	O
13	.	O
14	5	O
15	and	O
16	3	O
17	.	O
18	8	O
19	map	O
20	units	O
21	.	O

1	Six	O
2	putative	O
3	MDV	O
4	genome	O
5	products	O
6	,	O
7	including	O
8	one	O
9	Rep	B
10	and	O
11	five	O
12	non	O
13	-	O
14	Rep	B
15	proteins	O
16	,	O
17	show	O
18	high	O
19	(	O
20	70	O
21	.	O
22	4	O
23	-	O
24	90	O
25	.	O
26	9	O
27	%)	O
28	amino	O
29	acid	O
30	identity	O
31	to	O
32	the	O
33	corresponding	O
34	six	O
35	FBNYV	B
36	proteins	I
37	,	O
38	whereas	O
39	two	O
40	other	O
41	Rep	B
42	proteins	I
43	encoded	O
44	by	O
45	MDV	B
46	-	I
47	C2	I
48	and	O
49	C3	B
50	are	O
51	82	O
52	.	O
53	3	O
54	%	O
55	and	O
56	73	O
57	.	O
58	0	O
59	%	O
60	identical	O
61	to	O
62	those	O
63	encoded	O
64	by	O
65	SCSV	B
66	-	I
67	C2	I
68	and	O
69	C6	B
70	,	O
71	respectively	O
72	.	O

1	MPO	B
2	was	O
3	labeled	O
4	with	O
5	1	O
6	mCi	O
7	125I	O
8	by	O
9	a	O
10	technique	O
11	of	O
12	self	O
13	-	O
14	labeling	O
15	in	O
16	the	O
17	presence	O
18	of	O
19	10	O
20	(-	O
21	4	O
22	)	O
23	M	O
24	hydrogen	O
25	peroxide	O
26	.	O

1	It	O
2	is	O
3	related	O
4	to	O
5	a	O
6	variety	O
7	of	O
8	mammalian	O
9	Golgi	O
10	-	O
11	associated	O
12	proteins	O
13	and	O
14	to	O
15	the	O
16	yeast	O
17	Uso1p	B
18	,	O
19	an	O
20	essential	O
21	protein	O
22	involved	O
23	in	O
24	docking	O
25	of	O
26	endoplasmic	O
27	reticulum	O
28	-	O
29	derived	O
30	vesicles	O
31	to	O
32	the	O
33	cis	O
34	-	O
35	Golgi	O
36	.	O

1	The	O
2	data	O
3	indicate	O
4	that	O
5	Bmp2	B
6	is	O
7	directly	O
8	regulated	O
9	by	O
10	retinoic	O
11	acid	O
12	-	O
13	bound	O
14	receptors	O
15	and	O
16	Sp1	B
17	.	O

1	Both	O
2	proteins	O
3	were	O
4	shown	O
5	to	O
6	be	O
7	constitutively	O
8	associated	O
9	with	O
10	tubulin	B
11	.	O

1	HEED	B
2	was	O
3	found	O
4	to	O
5	bind	O
6	to	O
7	MA	B
8	protein	I
9	in	O
10	vitro	O
11	,	O
12	as	O
13	efficiently	O
14	as	O
15	in	O
16	vivo	O
17	in	O
18	yeast	O
19	cells	O
20	.	O

1	Fas	B
2	-	O
3	resistant	O
4	DT	O
5	-	O
6	40	O
7	lymphoma	O
8	B	O
9	-	O
10	cells	O
11	rendered	O
12	BTK	B
13	-	O
14	deficient	O
15	through	O
16	targeted	O
17	disruption	O
18	of	O
19	the	O
20	btk	B
21	gene	I
22	by	O
23	homologous	O
24	recombination	O
25	knockout	O
26	underwent	O
27	apoptosis	O
28	after	O
29	Fas	B
30	ligation	O
31	,	O
32	but	O
33	wild	O
34	-	O
35	type	O
36	DT	O
37	-	O
38	40	O
39	cells	O
40	or	O
41	BTK	B
42	-	O
43	deficient	O
44	DT	O
45	-	O
46	40	O
47	cells	O
48	reconstituted	O
49	with	O
50	wild	B
51	-	I
52	type	I
53	human	I
54	btk	I
55	gene	I
56	did	O
57	not	O
58	.	O

1	A	O
2	motif	O
3	(	O
4	TGATGTCA	O
5	)	O
6	which	O
7	matches	O
8	a	O
9	CREB	B
10	site	I
11	and	O
12	is	O
13	similar	O
14	to	O
15	an	O
16	AP	B
17	-	I
18	1	I
19	site	I
20	is	O
21	embedded	O
22	within	O
23	ER2	B
24	.	O

1	Conventionally	O
2	,	O
3	four	O
4	nominal	O
5	allotypic	O
6	variants	O
7	,	O
8	b4	O
9	,	O
10	b5	O
11	,	O
12	b6	O
13	and	O
14	b9	O
15	have	O
16	been	O
17	shown	O
18	to	O
19	be	O
20	co	O
21	-	O
22	dominantly	O
23	expressed	O
24	at	O
25	the	O
26	Ckappa1	B
27	gene	I
28	locus	I
29	.	O

1	Therefore	O
2	,	O
3	in	O
4	order	O
5	to	O
6	search	O
7	for	O
8	the	O
9	latent	O
10	genes	O
11	,	O
12	we	O
13	used	O
14	allotype	O
15	-	O
16	specific	O
17	oligonucleotides	O
18	for	O
19	b5	O
20	,	O
21	b6	O
22	and	O
23	b9	O
24	to	O
25	probe	O
26	DNAs	O
27	from	O
28	both	O
29	normal	O
30	and	O
31	T	O
32	.	O
33	brucei	O
34	-	O
35	infected	O
36	rabbits	O
37	by	O
38	Southern	O
39	blotting	O
40	.	O

1	TRAF2	B
2	is	O
3	known	O
4	to	O
5	associate	O
6	with	O
7	TRADD	B
8	,	O
9	and	O
10	expression	O
11	of	O
12	a	O
13	dominant	O
14	-	O
15	negative	O
16	N	O
17	-	O
18	terminal	O
19	deletion	O
20	TRAF2	B
21	mutant	I
22	was	O
23	found	O
24	to	O
25	partially	O
26	inhibit	O
27	LMP1	B
28	-	O
29	induced	O
30	JNK	B
31	activation	O
32	in	O
33	293	O
34	cells	O
35	.	O

1	These	O
2	data	O
3	further	O
4	define	O
5	a	O
6	role	O
7	for	O
8	TRADD	B
9	and	O
10	TRAF2	B
11	in	O
12	JNK	B
13	activation	O
14	and	O
15	confirm	O
16	that	O
17	LMP1	B
18	utilizes	O
19	signalling	O
20	mechanisms	O
21	used	O
22	by	O
23	the	O
24	TNF	B
25	receptor	I
26	/	O
27	CD40	B
28	family	O
29	to	O
30	elicit	O
31	its	O
32	pleiotropic	O
33	activities	O
34	.	O

1	Epstein	B
2	-	I
3	Barr	I
4	virus	I
5	-	I
6	encoded	I
7	latent	I
8	membrane	I
9	protein	I
10	1	I
11	activates	O
12	the	O
13	JNK	B
14	pathway	O
15	through	O
16	its	O
17	extreme	O
18	C	O
19	terminus	O
20	via	O
21	a	O
22	mechanism	O
23	involving	O
24	TRADD	B
25	and	O
26	TRAF2	B
27	.	O

1	In	O
2	contrast	O
3	,	O
4	transiently	O
5	transfected	O
6	cells	O
7	expressing	O
8	EBNA	B
9	-	I
10	3	I
11	revealed	O
12	a	O
13	sixfold	O
14	increase	O
15	in	O
16	EBNA	B
17	-	I
18	3	I
19	protein	I
20	expression	O
21	from	O
22	the	O
23	genomic	O
24	EBNA	B
25	-	I
26	3	I
27	gene	I
28	compared	O
29	to	O
30	EBNA	B
31	-	I
32	3	I
33	cDNA	I
34	.	O

1	However	O
2	,	O
3	serial	O
4	passages	O
5	of	O
6	fetal	O
7	lamb	O
8	kidney	O
9	(	O
10	FLK	O
11	)	O
12	cells	O
13	,	O
14	which	O
15	are	O
16	sensitive	O
17	to	O
18	infection	O
19	with	O
20	BLV	O
21	,	O
22	after	O
23	transient	O
24	transfection	O
25	revealed	O
26	that	O
27	mutation	O
28	of	O
29	a	O
30	second	O
31	tyrosine	O
32	residue	O
33	in	O
34	the	O
35	N	O
36	-	O
37	terminal	O
38	motif	O
39	completely	O
40	prevented	O
41	the	O
42	propagation	O
43	of	O
44	the	O
45	virus	O
46	.	O

1	Varicella	B
2	-	I
3	zoster	I
4	virus	I
5	(	I
6	VZV	I
7	)	I
8	glycoprotein	I
9	gI	I
10	is	O
11	a	O
12	type	B
13	1	I
14	transmembrane	I
15	glycoprotein	I
16	which	O
17	is	O
18	one	O
19	component	O
20	of	O
21	the	O
22	heterodimeric	O
23	gE	B
24	:	O
25	gI	B
26	Fc	I
27	receptor	I
28	complex	O
29	.	O

1	To	O
2	this	O
3	end	O
4	,	O
5	we	O
6	analyzed	O
7	the	O
8	phosphorylation	O
9	status	O
10	of	O
11	a	O
12	universal	O
13	tyrosine	B
14	kinase	I
15	substrate	O
16	,	O
17	the	O
18	transforming	O
19	Shc	B
20	adapter	I
21	protein	I
22	,	O
23	in	O
24	fibroblasts	O
25	expressing	O
26	the	O
27	viral	O
28	oncogene	O
29	.	O

1	These	O
2	genes	O
3	were	O
4	expressed	O
5	in	O
6	a	O
7	Saccharomyces	O
8	cerevisiae	O
9	mutant	O
10	in	O
11	which	O
12	the	O
13	endogenous	B
14	ferrochelatase	I
15	gene	I
16	(	O
17	HEM15	B
18	)	O
19	had	O
20	been	O
21	deleted	O
22	,	O
23	and	O
24	the	O
25	phenotypes	O
26	of	O
27	the	O
28	transformants	O
29	were	O
30	characterized	O
31	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	evidence	O
6	is	O
7	presented	O
8	that	O
9	temporally	O
10	and	O
11	spatially	O
12	specific	O
13	mef2	B
14	expression	O
15	is	O
16	controlled	O
17	by	O
18	a	O
19	complex	O
20	array	O
21	of	O
22	cis	O
23	-	O
24	acting	O
25	regulatory	O
26	modules	O
27	that	O
28	are	O
29	responsive	O
30	to	O
31	different	O
32	genetic	O
33	signals	O
34	.	O

1	Furthermore	O
2	,	O
3	using	O
4	transgenic	O
5	mouse	O
6	technology	O
7	we	O
8	localized	O
9	independent	O
10	cis	O
11	-	O
12	regulatory	O
13	elements	O
14	controlling	O
15	the	O
16	tissue	O
17	-	O
18	specific	O
19	expression	O
20	of	O
21	Pax6	B
22	.	O

1	In	O
2	the	O
3	second	O
4	experiment	O
5	,	O
6	a	O
7	stable	O
8	nickel	O
9	isotope	O
10	,	O
11	61Ni	O
12	,	O
13	was	O
14	given	O
15	in	O
16	drinking	O
17	water	O
18	to	O
19	20	O
20	nickel	O
21	-	O
22	sensitized	O
23	women	O
24	and	O
25	20	O
26	age	O
27	-	O
28	matched	O
29	controls	O
30	,	O
31	both	O
32	groups	O
33	having	O
34	vesicular	O
35	hand	O
36	eczema	O
37	of	O
38	the	O
39	pompholyx	O
40	type	O
41	.	O

1	Folded	O
2	tissue	O
3	and	O
4	crimped	O
5	collagen	B
6	fibers	O
7	in	O
8	the	O
9	tunica	O
10	albuginea	O
11	permit	O
12	its	O
13	expansion	O
14	during	O
15	erection	O
16	.	O

1	Number	O
2	of	O
3	patients	O
4	infected	O
5	with	O
6	nontuberculous	O
7	mycobacteria	O
8	(	O
9	NTM	O
10	)	O
11	is	O
12	increasing	O
13	world	O
14	-	O
15	wide	O
16	in	O
17	recent	O
18	years	O
19	.	O

1	Comparison	O
2	of	O
3	the	O
4	sequences	O
5	of	O
6	attP	B
7	,	O
8	attB	B
9	and	O
10	bacteria	O
11	-	O
12	prophage	O
13	junctions	O
14	attL	B
15	and	O
16	attR	B
17	showed	O
18	a	O
19	26	O
20	bp	O
21	common	O
22	core	O
23	sequence	O
24	,	O
25	where	O
26	recombination	O
27	takes	O
28	place	O
29	,	O
30	near	O
31	the	O
32	5	O
33	'	O
34	end	O
35	of	O
36	the	O
37	integrase	B
38	gene	I
39	.	O

1	Interferon	B
2	-	I
3	alpha	I
4	treatment	O
5	of	O
6	posttransplant	O
7	lymphoproliferative	O
8	disorder	O
9	in	O
10	recipients	O
11	of	O
12	solid	O
13	organ	O
14	transplants	O
15	.	O

1	Immunological	O
2	testing	O
3	was	O
4	performed	O
5	on	O
6	all	O
7	brewery	O
8	workers	O
9	and	O
10	some	O
11	control	O
12	volunteers	O
13	using	O
14	skin	O
15	prick	O
16	testing	O
17	with	O
18	hops	O
19	,	O
20	barley	O
21	,	O
22	and	O
23	yeast	O
24	antigens	O
25	as	O
26	well	O
27	as	O
28	other	O
29	nonoccupational	O
30	allergens	O
31	,	O
32	and	O
33	by	O
34	determining	O
35	total	O
36	serum	B
37	IgE	I
38	levels	O
39	.	O

1	OBJECTIVE	O
2	:	O
3	To	O
4	evaluate	O
5	the	O
6	accuracy	O
7	of	O
8	working	O
9	casts	O
10	for	O
11	crown	O
12	and	O
13	bridge	O
14	restorations	O
15	made	O
16	from	O
17	twin	O
18	mix	O
19	putty	O
20	/	O
21	wash	O
22	silicone	O
23	elastomeric	O
24	impression	O
25	materials	O
26	using	O
27	different	O
28	types	O
29	of	O
30	stock	O
31	tray	O
32	.	O

1	OBJECTIVES	O
2	:	O
3	To	O
4	assess	O
5	the	O
6	ability	O
7	of	O
8	pretreatment	O
9	and	O
10	post	O
11	-	O
12	treatment	O
13	prostate	B
14	-	I
15	specific	I
16	antigen	I
17	(	O
18	PSA	B
19	)	O
20	measurements	O
21	,	O
22	clinical	O
23	tumor	O
24	stage	O
25	,	O
26	tumor	O
27	grade	O
28	,	O
29	Gleason	O
30	sum	O
31	,	O
32	race	O
33	,	O
34	age	O
35	,	O
36	and	O
37	radiation	O
38	dose	O
39	to	O
40	predict	O
41	the	O
42	recurrence	O
43	of	O
44	prostate	O
45	cancer	O
46	following	O
47	external	O
48	beam	O
49	radiation	O
50	therapy	O
51	(	O
52	XRT	O
53	)	O
54	since	O
55	the	O
56	introduction	O
57	of	O
58	PSA	B
59	as	O
60	a	O
61	tumor	O
62	marker	O
63	at	O
64	one	O
65	tertiary	O
66	care	O
67	center	O
68	.	O

1	To	O
2	evaluate	O
3	whether	O
4	the	O
5	human	O
6	gene	O
7	is	O
8	also	O
9	a	O
10	target	O
11	of	O
12	thyroid	O
13	hormone	O
14	we	O
15	have	O
16	searched	O
17	for	O
18	T3	O
19	-	O
20	responsive	O
21	elements	O
22	in	O
23	NRGN	B
24	cloned	O
25	genomic	O
26	fragments	O
27	spanning	O
28	the	O
29	whole	O
30	gene	O
31	.	O

1	The	O
2	transcriptional	O
3	activity	O
4	of	O
5	PPARgamma	B
6	is	O
7	positively	O
8	modulated	O
9	by	O
10	ligand	O
11	binding	O
12	and	O
13	negatively	O
14	regulated	O
15	by	O
16	phosphorylation	O
17	mediated	O
18	by	O
19	the	O
20	MEK	B
21	/	O
22	ERK	B
23	signaling	O
24	pathway	O
25	.	O

1	BACKGROUND	O
2	:	O
3	Diazepam	O
4	,	O
5	one	O
6	of	O
7	the	O
8	benzodiazepine	O
9	group	O
10	of	O
11	tranquilizers	O
12	,	O
13	is	O
14	used	O
15	as	O
16	an	O
17	adjunctive	O
18	drug	O
19	for	O
20	sedation	O
21	and	O
22	for	O
23	relief	O
24	of	O
25	anxiety	O
26	in	O
27	the	O
28	treatment	O
29	of	O
30	epilepsy	O
31	.	O

1	Bioplastique	O
2	granuloma	O
3	presents	O
4	with	O
5	irregularly	O
6	shaped	O
7	cystic	O
8	spaces	O
9	of	O
10	varying	O
11	size	O
12	containing	O
13	jagged	O
14	,	O
15	translucent	O
16	,	O
17	nonbirefringent	O
18	foreign	O
19	bodies	O
20	whereas	O
21	Artecoll	O
22	granuloma	O
23	shows	O
24	numerous	O
25	round	O
26	vacuoles	O
27	nearly	O
28	identical	O
29	in	O
30	size	O
31	and	O
32	shape	O
33	enclosing	O
34	round	O
35	and	O
36	sharply	O
37	circumscribed	O
38	,	O
39	translucent	O
40	,	O
41	nonbirefringent	O
42	foreign	O
43	bodies	O
44	.	O

1	This	O
2	Tbx6	B
3	-	I
4	subfamily	I
5	gene	I
6	is	O
7	likely	O
8	to	O
9	participate	O
10	in	O
11	paraxial	O
12	mesoderm	O
13	formation	O
14	and	O
15	somitogenesis	O
16	in	O
17	human	O
18	embryo	O
19	.	O

1	Structure	O
2	-	O
3	function	O
4	analysis	O
5	of	O
6	the	O
7	Z	O
8	-	O
9	DNA	O
10	-	O
11	binding	O
12	domain	O
13	Zalpha	O
14	of	O
15	dsRNA	B
16	adenosine	I
17	deaminase	I
18	type	I
19	I	I
20	reveals	O
21	similarity	O
22	to	O
23	the	O
24	(	B
25	alpha	I
26	+	I
27	beta	I
28	)	I
29	family	I
30	of	O
31	helix	B
32	-	I
33	turn	I
34	-	I
35	helix	I
36	proteins	I
37	.	O

1	In	O
2	addition	O
3	,	O
4	the	O
5	regulation	O
6	of	O
7	Glvr	B
8	-	I
9	1	I
10	gene	I
11	expression	O
12	also	O
13	has	O
14	potential	O
15	applications	O
16	to	O
17	gene	O
18	therapy	O
19	,	O
20	since	O
21	retroviral	O
22	vectors	O
23	carrying	O
24	gibbon	B
25	ape	I
26	leukemia	I
27	virus	I
28	envelope	I
29	proteins	I
30	are	O
31	used	O
32	for	O
33	gene	O
34	delivery	O
35	into	O
36	different	O
37	cell	O
38	types	O
39	.	O

1	Carbohydrates	O
2	and	O
3	glycoconjugates	O
4	biophysical	O
5	methods	O
6	.	O

1	Molecular	O
2	cloning	O
3	of	O
4	mouse	B
5	glycolate	I
6	oxidase	I
7	.	O

1	In	O
2	such	O
3	a	O
4	manner	O
5	,	O
6	activated	O
7	PKR	B
8	inhibits	O
9	cell	O
10	growth	O
11	and	O
12	induces	O
13	apoptosis	O
14	,	O
15	whereas	O
16	disruption	O
17	of	O
18	normal	O
19	PKR	B
20	signaling	O
21	results	O
22	in	O
23	unregulated	O
24	cell	O
25	growth	O
26	.	O

1	We	O
2	isolated	O
3	a	O
4	ribosomal	B
5	protein	I
6	L18	I
7	by	O
8	interaction	O
9	with	O
10	PKR	B
11	.	O

1	Processing	O
2	of	O
3	the	O
4	polycistronic	O
5	precursor	O
6	requires	O
7	nucleases	O
8	also	O
9	involved	O
10	in	O
11	rRNA	O
12	processing	O
13	,	O
14	i	O
15	.	O
16	e	O
17	.,	O
18	Rnt1p	B
19	and	O
20	Rat1p	B
21	.	O

1	To	O
2	search	O
3	for	O
4	transcriptional	O
5	regulators	O
6	,	O
7	we	O
8	used	O
9	a	O
10	fragment	O
11	of	O
12	the	O
13	SpHE	B
14	promoter	I
15	containing	O
16	several	O
17	individual	O
18	elements	O
19	instead	O
20	of	O
21	the	O
22	conventional	O
23	bait	O
24	that	O
25	contains	O
26	a	O
27	multimerized	O
28	cis	O
29	element	O
30	.	O

1	As	O
2	expected	O
3	for	O
4	a	O
5	positive	O
6	SpHE	B
7	transcriptional	I
8	regulator	I
9	,	O
10	the	O
11	timing	O
12	of	O
13	SpEts4	B
14	gene	I
15	expression	O
16	precedes	O
17	the	O
18	transient	O
19	expression	O
20	of	O
21	SpHE	B
22	in	O
23	the	O
24	very	O
25	early	O
26	sea	O
27	urchin	O
28	blastula	O
29	.	O

1	Furthermore	O
2	,	O
3	rhoA	B
4	-	O
5	mediated	O
6	SRE	O
7	activation	O
8	was	O
9	blocked	O
10	by	O
11	dominant	O
12	negative	O
13	mutants	O
14	of	O
15	PKC	B
16	-	I
17	alpha	I
18	or	O
19	PKC	B
20	-	I
21	epsilon	I
22	.	O

1	Nip7p	B
2	-	O
3	depleted	O
4	cells	O
5	exhibited	O
6	the	O
7	same	O
8	defects	O
9	as	O
10	Nop8p	B
11	-	O
12	depleted	O
13	cells	O
14	,	O
15	except	O
16	that	O
17	they	O
18	accumulated	O
19	27S	B
20	precursors	I
21	.	O

1	We	O
2	show	O
3	that	O
4	the	O
5	Sm	B
6	-	I
7	binding	I
8	site	I
9	and	O
10	stem	O
11	-	O
12	loop	O
13	III	O
14	structures	O
15	are	O
16	necessary	O
17	for	O
18	correct	O
19	3	O
20	'-	O
21	end	O
22	formation	O
23	.	O

1	Five	O
2	different	O
3	subtypes	O
4	of	O
5	spondyloarthropathy	O
6	(	O
7	SpA	O
8	)	O
9	are	O
10	now	O
11	recognized	O
12	.	O

1	Further	O
2	experiments	O
3	will	O
4	be	O
5	required	O
6	to	O
7	highlight	O
8	the	O
9	in	O
10	vivo	O
11	role	O
12	of	O
13	ELE1	B
14	in	O
15	nuclear	O
16	receptor	O
17	functioning	O
18	.	O

1	Overexpression	O
2	of	O
3	PTTG	B
4	in	O
5	transfected	O
6	NIH	O
7	3T3	O
8	cells	O
9	also	O
10	stimulated	O
11	expression	O
12	and	O
13	secretion	O
14	of	O
15	basic	B
16	fibroblast	I
17	growth	I
18	factor	I
19	,	O
20	a	O
21	human	B
22	pituitary	I
23	tumor	I
24	growth	I
25	-	I
26	regulating	I
27	factor	I
28	.	O

1	The	O
2	perifascicular	O
3	connective	O
4	tissue	O
5	sheath	O
6	is	O
7	important	O
8	in	O
9	organising	O
10	the	O
11	contraction	O
12	of	O
13	the	O
14	myocardium	O
15	by	O
16	preventing	O
17	lateral	O
18	spread	O
19	of	O
20	conduction	O
21	and	O
22	by	O
23	permitting	O
24	transmission	O
25	of	O
26	the	O
27	impulse	O
28	only	O
29	at	O
30	the	O
31	termination	O
32	of	O
33	the	O
34	purkinje	O
35	fibre	O
36	.	O

1	E1	B
2	,	O
3	a	O
4	DNA	B
5	helicase	I
6	,	O
7	collaborates	O
8	with	O
9	the	O
10	HPV	B
11	E2	I
12	protein	I
13	in	O
14	ori	O
15	-	O
16	dependent	O
17	replication	O
18	.	O

1	Here	O
2	we	O
3	describe	O
4	a	O
5	mutant	O
6	alpha	O
7	subunit	O
8	designed	O
9	to	O
10	inhibit	O
11	receptor	O
12	-	O
13	mediated	O
14	hormonal	O
15	activation	O
16	of	O
17	Gs	B
18	,	O
19	the	O
20	stimulatory	O
21	regulator	O
22	of	O
23	adenylyl	B
24	cyclase	I
25	.	O

1	A	O
2	gapped	O
3	search	O
4	with	O
5	the	O
6	C	O
7	-	O
8	terminal	O
9	region	O
10	of	O
11	CDED	B
12	/	O
13	LIOR	B
14	revealed	O
15	a	O
16	36	O
17	-	O
18	41	O
19	%	O
20	similarity	O
21	to	O
22	several	O
23	proteins	O
24	related	O
25	to	O
26	signal	O
27	transduction	O
28	and	O
29	cell	O
30	replication	O
31	,	O
32	such	O
33	as	O
34	ORC1	B
35	and	O
36	KSR	B
37	.	O

1	Northern	O
2	blot	O
3	analysis	O
4	demonstrated	O
5	the	O
6	ubiquitous	O
7	expression	O
8	of	O
9	2	O
10	.	O
11	9	O
12	kb	O
13	and	O
14	3	O
15	.	O

1	Additionally	O
2	,	O
3	a	O
4	variety	O
5	of	O
6	regulatory	O
7	schemes	O
8	contribute	O
9	temporal	O
10	and	O
11	/	O
12	or	O
13	spatial	O
14	restriction	O
15	to	O
16	TGF	B
17	-	I
18	beta	I
19	responses	O
20	.	O

1	Induction	O
2	of	O
3	anaesthesia	O
4	was	O
5	standardised	O
6	:	O
7	fentanyl	O
8	(	O
9	3	O
10	micrograms	O
11	/	O
12	kg	O
13	),	O
14	thiopentone	O
15	(	O
16	5	O
17	mg	O
18	/	O
19	kg	O
20	),	O
21	atracurium	O
22	(	O
23	0	O
24	.	O
25	4	O
26	mg	O
27	/	O
28	kg	O
29	).	O

1	A	O
2	comparison	O
3	of	O
4	the	O
5	clinical	O
6	profile	O
7	of	O
8	cavernous	O
9	malformations	O
10	with	O
11	and	O
12	without	O
13	associated	O
14	venous	O
15	malformations	O
16	.	O

1	Conserved	O
2	and	O
3	distinct	O
4	roles	O
5	of	O
6	kreisler	B
7	in	O
8	regulation	O
9	of	O
10	the	O
11	paralogous	O
12	Hoxa3	B
13	and	O
14	Hoxb3	B
15	genes	I
16	.	O

1	Magnetically	O
2	induced	O
3	optical	O
4	self	O
5	-	O
6	pulsing	O
7	in	O
8	a	O
9	nonlinear	O
10	resonator	O
11	.	O

1	Wave	O
2	cybernetics	O
3	:	O
4	A	O
5	simple	O
6	model	O
7	of	O
8	wave	O
9	-	O
10	controlled	O
11	nonlinear	O
12	and	O
13	nonlocal	O
14	cooperative	O
15	phenomena	O
16	.	O

1	Autoionization	O
2	rates	O
3	and	O
4	energy	O
5	levels	O
6	of	O
7	triplet	O
8	nf	O
9	,	O
10	v	O
11	=	O
12	1	O
13	Rydberg	O
14	states	O
15	of	O
16	H2	O
17	.	O

1	Unitary	O
2	-	O
3	group	O
4	approach	O
5	to	O
6	spin	O
7	-	O
8	dependent	O
9	operators	O
10	.	O

1	Nonlocal	O
2	approach	O
3	to	O
4	scattering	O
5	in	O
6	a	O
7	one	O
8	-	O
9	dimensional	O
10	problem	O
11	.	O

1	Soft	O
2	-	O
3	x	O
4	-	O
5	ray	O
6	lasing	O
7	at	O
8	32	O
9	.	O
10	6	O
11	nm	O
12	in	O
13	Ne	O
14	-	O
15	like	O
16	Ti	O
17	ions	O
18	driven	O
19	by	O
20	40	O
21	J	O
22	of	O
23	energy	O
24	from	O
25	two	O
26	650	O
27	-	O
28	ps	O
29	laser	O
30	pulses	O
31	.	O

1	Next	O
2	,	O
3	to	O
4	identify	O
5	regions	O
6	of	O
7	the	O
8	promoter	O
9	involved	O
10	,	O
11	we	O
12	examined	O
13	a	O
14	series	O
15	of	O
16	tenascin	B
17	-	I
18	C	I
19	promoter	I
20	constructs	I
21	with	O
22	5	O
23	'	O
24	deletions	O
25	and	O
26	showed	O
27	that	O
28	denatured	O
29	collagen	B
30	-	I
31	dependent	I
32	promoter	I
33	activity	O
34	was	O
35	retained	O
36	by	O
37	a	O
38	122	O
39	-	O
40	base	O
41	pair	O
42	element	O
43	,	O
44	located	O
45	-	O
46	43	O
47	to	O
48	-	O
49	165	O
50	bp	O
51	upstream	O
52	of	O
53	the	O
54	RNA	O
55	start	O
56	site	O
57	.	O

1	Nuclear	B
2	factor	I
3	kappa	I
4	B	I
5	(	O
6	NF	B
7	-	I
8	kappaB	I
9	)	O
10	is	O
11	an	O
12	important	O
13	transcription	O
14	factor	O
15	for	O
16	the	O
17	genes	O
18	of	O
19	many	O
20	pro	O
21	-	O
22	inflammatory	O
23	proteins	O
24	and	O
25	is	O
26	strongly	O
27	activated	O
28	by	O
29	the	O
30	cytokines	O
31	interleukin	B
32	-	I
33	1	I
34	and	O
35	tumor	B
36	necrosis	I
37	factor	I
38	(	I
39	TNF	I
40	)	I
41	alpha	I
42	under	O
43	various	O
44	pathological	O
45	conditions	O
46	.	O

1	Moreover	O
2	,	O
3	this	O
4	enhancement	O
5	of	O
6	transcriptional	O
7	activation	O
8	by	O
9	COUP	B
10	-	I
11	TFI	I
12	requires	O
13	specifically	O
14	the	O
15	AF	O
16	-	O
17	1	O
18	transactivation	O
19	function	O
20	of	O
21	ER	B
22	and	O
23	can	O
24	be	O
25	observed	O
26	in	O
27	the	O
28	presence	O
29	of	O
30	E2	O
31	or	O
32	4	O
33	-	O
34	hydroxytamoxifen	O
35	but	O
36	not	O
37	ICI	O
38	164384	O
39	.	O

1	Recombinant	B
2	Ffh	I
3	has	O
4	a	O
5	melting	O
6	point	O
7	of	O
8	tm	O
9	=	O
10	89	O
11	degreesC	O
12	.	O

1	Unilateral	O
2	naris	O
3	occlusion	O
4	and	O
5	the	O
6	rat	O
7	accessory	O
8	olfactory	O
9	bulb	O
10	.	O

1	This	O
2	region	O
3	of	O
4	hsp90	B
5	mediates	O
6	ATP	O
7	-	O
8	independent	O
9	chaperone	O
10	activity	O
11	,	O
12	overlaps	O
13	the	O
14	hsp90	B
15	dimerization	I
16	domain	I
17	,	O
18	and	O
19	includes	O
20	structural	O
21	elements	O
22	important	O
23	for	O
24	steroid	B
25	receptor	I
26	interaction	O
27	.	O

1	The	O
2	promoter	O
3	of	O
4	the	O
5	rat	O
6	pgp2	B
7	/	O
8	mdr1b	B
9	gene	O
10	has	O
11	a	O
12	GC	O
13	-	O
14	rich	O
15	region	O
16	(	O
17	pgp2GC	B
18	)	O
19	that	O
20	is	O
21	highly	O
22	conserved	O
23	in	O
24	mdr	B
25	genes	I
26	and	O
27	contains	O
28	an	O
29	consensus	O
30	Sp1	B
31	site	I
32	.	O

1	Sp1	B
2	'	O
3	s	O
4	role	O
5	in	O
6	transactivation	O
7	of	O
8	the	O
9	pgp2	B
10	/	O
11	mdr1b	B
12	promoter	O
13	was	O
14	tested	O
15	in	O
16	Drosophila	O
17	Schneider	O
18	cells	O
19	.	O

1	Measurements	O
2	included	O
3	bone	O
4	mineral	O
5	density	O
6	of	O
7	the	O
8	lumbar	O
9	spine	O
10	and	O
11	proximal	O
12	femur	O
13	(	O
14	by	O
15	dual	O
16	-	O
17	energy	O
18	X	O
19	-	O
20	ray	O
21	absorptiometry	O
22	)	O
23	and	O
24	biochemical	O
25	markers	O
26	of	O
27	bone	O
28	remodeling	O
29	(	O
30	serum	O
31	bone	O
32	-	O
33	specific	O
34	alkaline	B
35	phosphatase	I
36	by	O
37	immunoassay	O
38	and	O
39	urine	O
40	deoxypyridinoline	O
41	by	O
42	high	O
43	-	O
44	pressure	O
45	liquid	O
46	chromatography	O
47	).	O

1	Human	B
2	MGP	I
3	is	O
4	a	O
5	10	B
6	-	I
7	kD	I
8	skeletal	I
9	extracellular	I
10	matrix	I
11	(	I
12	ECM	I
13	)	I
14	protein	I
15	that	O
16	consists	O
17	of	O
18	an	O
19	84	O
20	-	O
21	aa	O
22	mature	O
23	protein	O
24	and	O
25	a	O
26	19	O
27	-	O
28	aa	O
29	transmembrane	O
30	signal	O
31	peptide	O
32	.	O

1	Dual	O
2	roles	O
3	of	O
4	p82	B
5	,	O
6	the	O
7	clam	O
8	CPEB	B
9	homolog	I
10	,	O
11	in	O
12	cytoplasmic	O
13	polyadenylation	O
14	and	O
15	translational	O
16	masking	O
17	.	O

1	The	O
2	RNA	B
3	polymerase	I
4	III	I
5	-	I
6	recruiting	I
7	factor	I
8	TFIIIB	I
9	induces	O
10	a	O
11	DNA	O
12	bend	O
13	between	O
14	the	O
15	TATA	O
16	box	O
17	and	O
18	the	O
19	transcriptional	O
20	start	O
21	site	O
22	.	O

1	The	O
2	pattern	O
3	of	O
4	RNase	B
5	E	I
6	digestion	O
7	of	O
8	finP305	B
9	RNA	I
10	differed	O
11	from	O
12	FinP	B
13	,	O
14	and	O
15	GST	B
16	-	O
17	FinO	B
18	did	O
19	not	O
20	protect	O
21	finP305	B
22	RNA	I
23	from	O
24	cleavage	O
25	in	O
26	vitro	O
27	.	O

1	Transcription	O
2	readthrough	O
3	into	O
4	the	O
5	inverted	O
6	repeats	O
7	has	O
8	little	O
9	effect	O
10	on	O
11	this	O
12	event	O
13	.	O

1	Analysis	O
2	of	O
3	hematopoietic	B
4	growth	I
5	factor	I
6	prescriptions	O
7	in	O
8	19	O
9	french	O
10	cancer	O
11	centers	O

1	In	O
2	the	O
3	second	O
4	case	O
5	,	O
6	an	O
7	epidermal	O
8	cyst	O
9	was	O
10	diagnosed	O
11	.	O

1	MotA	B
2	also	O
3	binds	O
4	a	O
5	DNA	O
6	sequence	O
7	(	O
8	a	O
9	MotA	B
10	box	I
11	),	O
12	centered	O
13	at	O
14	position	O
15	-	O
16	30	O
17	.	O

1	We	O
2	suggest	O
3	that	O
4	MotA	B
5	and	O
6	AsiA	B
7	may	O
8	function	O
9	like	O
10	certain	O
11	eukaryotic	B
12	TAFs	I
13	(	O
14	TATA	B
15	binding	I
16	protein	I
17	(	I
18	TBP	I
19	)	I
20	associated	I
21	factors	I
22	)	O
23	whose	O
24	binding	O
25	to	O
26	TBP	B
27	results	O
28	in	O
29	transcription	O
30	from	O
31	new	O
32	core	O
33	promoter	O
34	sequences	O
35	.	O

1	The	O
2	S229A	O
3	variant	O
4	can	O
5	better	O
6	flip	O
7	modified	O
8	bases	O
9	but	O
10	does	O
11	not	O
12	tightly	O
13	lock	O
14	the	O
15	flipped	O
16	base	O
17	into	O
18	the	O
19	adenine	O
20	-	O
21	binding	O
22	pocket	O
23	,	O
24	suggesting	O
25	that	O
26	Ser229	O
27	could	O
28	form	O
29	a	O
30	contact	O
31	to	O
32	the	O
33	flipped	O
34	adenine	O
35	.	O

1	The	O
2	high	O
3	conservation	O
4	of	O
5	the	O
6	3	O
7	'	O
8	terminus	O
9	suggests	O
10	that	O
11	this	O
12	region	O
13	directs	O
14	the	O
15	assembly	O
16	of	O
17	proteins	O
18	required	O
19	for	O
20	the	O
21	initiation	O
22	of	O
23	RNA	O
24	replication	O
25	.	O

1	All	O
2	stimulations	O
3	were	O
4	down	O
5	-	O
6	regulated	O
7	with	O
8	GnRH	B
9	-	I
10	a	I
11	commenced	O
12	on	O
13	day	O
14	21	O
15	in	O
16	a	O
17	long	O
18	protocol	O
19	before	O
20	gonadotropin	B
21	stimulation	O
22	.	O

1	The	O
2	sequence	O
3	up	O
4	to	O
5	-	O
6	267	O
7	bp	O
8	relative	O
9	to	O
10	the	O
11	transcription	O
12	start	O
13	site	O
14	was	O
15	sufficient	O
16	to	O
17	enhance	O
18	reporter	O
19	gene	O
20	expression	O
21	depending	O
22	on	O
23	the	O
24	mesodermal	O
25	differentiation	O
26	of	O
27	P19	O
28	cells	O
29	.	O

1	Chem	O
2	.	O

1	No	O
2	significant	O
3	differences	O
4	between	O
5	the	O
6	substituted	O
7	and	O
8	wild	O
9	type	O
10	peptides	O
11	were	O
12	observed	O
13	,	O
14	suggesting	O
15	that	O
16	this	O
17	substitution	O
18	in	O
19	the	O
20	intact	O
21	protein	O
22	may	O
23	cause	O
24	disruption	O
25	of	O
26	global	O
27	rather	O
28	than	O
29	local	O
30	structures	O
31	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	the	O
6	c	B
7	-	I
8	met	I
9	gene	I
10	is	O
11	also	O
12	a	O
13	target	O
14	of	O
15	p53	B
16	gene	I
17	regulation	O
18	.	O

1	C3	B
2	toxin	I
3	completely	O
4	inhibited	O
5	RhoA	B
6	function	O
7	,	O
8	partially	O
9	inhibited	O
10	SRE	O
11	:	O
12	Luc	B
13	activity	O
14	,	O
15	but	O
16	had	O
17	no	O
18	effect	O
19	on	O
20	LPA	O
21	-	O
22	stimulated	O
23	c	B
24	-	I
25	Fos	I
26	expression	O
27	.	O

1	However	O
2	,	O
3	C3	B
4	toxin	I
5	alone	O
6	or	O
7	in	O
8	combination	O
9	with	O
10	growth	O
11	factors	O
12	did	O
13	not	O
14	stimulate	O
15	AP	B
16	-	I
17	1	I
18	:	O
19	Luc	B
20	activity	O
21	and	O
22	actually	O
23	antagonized	O
24	the	O
25	synergistic	O
26	activation	O
27	of	O
28	AP	B
29	-	I
30	1	I
31	:	O
32	Luc	B
33	observed	O
34	in	O
35	response	O
36	to	O
37	co	O
38	-	O
39	stimulation	O
40	with	O
41	growth	O
42	factors	O
43	and	O
44	Ro	O
45	-	O
46	31	O
47	-	O
48	8220	O
49	.	O

1	The	O
2	aim	O
3	of	O
4	the	O
5	present	O
6	study	O
7	was	O
8	to	O
9	examine	O
10	the	O
11	antimicrobial	O
12	susceptibility	O
13	to	O
14	10	O
15	currently	O
16	used	O
17	antimicrobial	O
18	agents	O
19	of	O
20	50	O
21	strains	O
22	of	O
23	P	O
24	.	O
25	acnes	O
26	isolated	O
27	from	O
28	acne	O
29	lesions	O
30	and	O
31	identified	O
32	using	O
33	a	O
34	Rap	O
35	ID	O
36	ANA	O
37	II	O
38	panel	O
39	.	O

1	The	O
2	role	O
3	of	O
4	intraoperative	O
5	echocardiography	O
6	in	O
7	surgery	O
8	of	O
9	the	O
10	heart	O
11	and	O
12	large	O
13	vessels	O

1	Taken	O
2	together	O
3	,	O
4	our	O
5	results	O
6	demonstrate	O
7	that	O
8	CAP1	B
9	is	O
10	involved	O
11	in	O
12	multidrug	O
13	resistance	O
14	and	O
15	oxidative	O
16	stress	O
17	response	O
18	in	O
19	C	O
20	.	O
21	albicans	O
22	.	O

1	Trinipatch	O
2	is	O
3	a	O
4	small	O
5	,	O
6	transparent	O
7	,	O
8	matricial	O
9	,	O
10	monolayer	O
11	patch	O
12	with	O
13	an	O
14	absorption	O
15	promoter	O
16	,	O
17	marketed	O
18	in	O
19	two	O
20	dose	O
21	-	O
22	strengths	O
23	(	O
24	5	O
25	mg	O
26	/	O
27	24	O
28	h	O
29	and	O
30	10	O
31	mg	O
32	/	O
33	24	O
34	h	O
35	)	O
36	by	O
37	Laboratoires	O
38	Synthelabo	O
39	.	O

1	The	O
2	RMRI	O
3	was	O
4	tested	O
5	for	O
6	interrater	O
7	reliability	O
8	using	O
9	three	O
10	simulated	O
11	and	O
12	10	O
13	actual	O
14	patients	O
15	.	O

1	The	O
2	starting	O
3	point	O
4	is	O
5	the	O
6	consideration	O
7	that	O
8	the	O
9	conceptions	O
10	underlying	O
11	the	O
12	ICIDH	O
13	are	O
14	not	O
15	suitable	O
16	to	O
17	serve	O
18	as	O
19	a	O
20	mainstay	O
21	of	O
22	a	O
23	model	O
24	for	O
25	diagnostics	O
26	in	O
27	rehabilitation	O
28	because	O
29	they	O
30	do	O
31	not	O
32	reflect	O
33	essential	O
34	characteristics	O
35	of	O
36	the	O
37	diagnostic	O
38	process	O
39	which	O
40	is	O
41	the	O
42	basis	O
43	for	O
44	intervention	O
45	.	O

1	Pokeweed	B
2	antiviral	I
3	protein	I
4	(	O
5	PAP	B
6	)	O
7	from	O
8	Phytolacca	O
9	americana	O
10	is	O
11	a	O
12	highly	O
13	specific	O
14	N	B
15	-	I
16	glycosidase	I
17	removing	O
18	adenine	O
19	residues	O
20	(	O
21	A4324	O
22	in	O
23	28S	B
24	rRNA	I
25	and	O
26	A2660	O
27	in	O
28	23S	B
29	rRNA	I
30	)	O
31	from	O
32	intact	O
33	ribosomes	O
34	of	O
35	both	O
36	eukaryotes	O
37	and	O
38	prokaryotes	O
39	.	O

1	OBJECTIVE	O
2	:	O
3	This	O
4	meta	O
5	-	O
6	analysis	O
7	of	O
8	67	O
9	controlled	O
10	trials	O
11	was	O
12	performed	O
13	to	O
14	quantify	O
15	the	O
16	cholesterol	O
17	-	O
18	lowering	O
19	effect	O
20	of	O
21	major	O
22	dietary	O
23	fibers	O
24	.	O

1	Among	O
2	these	O
3	360	O
4	ZFPs	B
5	,	O
6	a	O
7	novel	O
8	ZFP	B
9	cDNA	I
10	named	O
11	HFHZ	B
12	(	O
13	human	B
14	fetal	I
15	heart	I
16	ZFP	I
17	)	O
18	with	O
19	sequence	O
20	homology	O
21	to	O
22	a	O
23	Kruppel	B
24	-	I
25	associated	I
26	box	I
27	(	O
28	KRAB	B
29	)	O
30	was	O
31	identified	O
32	.	O

1	The	O
2	3	O
3	.	O
4	3	O
5	-	O
6	fold	O
7	higher	O
8	expression	O
9	in	O
10	the	O
11	fetal	O
12	heart	O
13	than	O
14	in	O
15	the	O
16	adult	O
17	heart	O
18	suggests	O
19	that	O
20	HFHZ	B
21	mRNA	I
22	is	O
23	downregulated	O
24	in	O
25	the	O
26	process	O
27	of	O
28	development	O
29	.	O

1	When	O
2	the	O
3	high	O
4	affinity	O
5	hnRNP	B
6	A1	I
7	binding	I
8	site	I
9	was	O
10	inserted	O
11	into	O
12	the	O
13	beta	B
14	-	I
15	globin	I
16	reporter	I
17	,	O
18	Rev	B
19	was	O
20	able	O
21	to	O
22	increase	O
23	the	O
24	cytoplasmic	O
25	levels	O
26	of	O
27	unspliced	O
28	mRNAs	O
29	to	O
30	14	O
31	%.	O

1	To	O
2	date	O
3	,	O
4	two	O
5	such	O
6	proteins	O
7	,	O
8	PLZF	B
9	and	O
10	LAZ	B
11	-	I
12	3	I
13	/	O
14	BCL	B
15	-	I
16	6	I
17	,	O
18	have	O
19	been	O
20	implicated	O
21	in	O
22	oncogenesis	O
23	.	O

1	Overexpression	O
2	of	O
3	POG1	B
4	inhibits	O
5	alpha	B
6	-	I
7	factor	I
8	-	O
9	induced	O
10	G1	O
11	arrest	O
12	and	O
13	transcriptional	O
14	repression	O
15	of	O
16	the	O
17	CLN1	B
18	and	O
19	CLN2	B
20	genes	I
21	.	O

1	We	O
2	now	O
3	show	O
4	that	O
5	RNU2	B
6	fragility	O
7	can	O
8	be	O
9	induced	O
10	by	O
11	transfection	O
12	with	O
13	an	O
14	expression	O
15	vector	O
16	encoding	O
17	Ad12	B
18	E1B	I
19	55	O
20	kDa	O
21	alone	O
22	but	O
23	not	O
24	by	O
25	an	O
26	E1	B
27	vector	O
28	encoding	O
29	all	O
30	E1	B
31	products	I
32	(	O
33	3	O
34	E1A	B
35	proteins	I
36	,	O
37	as	O
38	well	O
39	as	O
40	the	O
41	E1B	B
42	19	O
43	kDa	O
44	and	O
45	55	O
46	kDa	O
47	proteins	O
48	).	O

1	Competitionsupershift	O
2	EMSA	O
3	assays	O
4	revealed	O
5	that	O
6	multiple	O
7	proteins	O
8	were	O
9	involved	O
10	in	O
11	bandshift	O
12	complex	O
13	formation	O
14	with	O
15	KCS	B
16	,	O
17	one	O
18	of	O
19	which	O
20	was	O
21	identified	O
22	as	O
23	factor	O
24	Sp1	O
25	.	O

1	Similarity	O
2	of	O
3	DNA	O
4	binding	O
5	and	O
6	transcriptional	O
7	regulation	O
8	by	O
9	Caenorhabditis	B
10	elegans	I
11	MAB	I
12	-	I
13	3	I
14	and	O
15	Drosophila	B
16	melanogaster	I
17	DSX	I
18	suggests	O
19	conservation	O
20	of	O
21	sex	O
22	determining	O
23	mechanisms	O
24	.	O

1	CONTEXT	O
2	:	O
3	ThinPrep	O
4	,	O
5	AutoPap	O
6	,	O
7	and	O
8	Papnet	O
9	are	O
10	3	O
11	new	O
12	technologies	O
13	that	O
14	increase	O
15	the	O
16	sensitivity	O
17	and	O
18	cost	O
19	of	O
20	cervical	O
21	cancer	O
22	screening	O
23	.	O

1	Experiments	O
2	on	O
3	narcotized	O
4	cats	O
5	demonstrated	O
6	that	O
7	the	O
8	derivatives	O
9	of	O
10	2	O
11	-	O
12	mercaptobenzimidazole	O
13	possessing	O
14	the	O
15	properties	O
16	of	O
17	specific	O
18	bradycardic	O
19	agents	O
20	and	O
21	coded	O
22	as	O
23	CM	O
24	-	O
25	251	O
26	,	O
27	CM	O
28	-	O
29	266	O
30	,	O
31	and	O
32	CM	O
33	-	O
34	345	O
35	,	O
36	reduce	O
37	the	O
38	mean	O
39	rise	O
40	of	O
41	segment	O
42	ST	O
43	on	O
44	numerous	O
45	leads	O
46	of	O
47	the	O
48	epicardial	O
49	electrogram	O
50	during	O
51	5	O
52	-	O
53	min	O
54	occlusion	O
55	of	O
56	the	O
57	anterior	O
58	descending	O
59	branch	O
60	of	O
61	the	O
62	left	O
63	coronary	O
64	artery	O
65	.	O

1	Neither	O
2	the	O
3	p42	B
4	/	I
5	44	I
6	nor	O
7	the	O
8	JNK	B
9	pathway	O
10	was	O
11	involved	O
12	in	O
13	the	O
14	action	O
15	of	O
16	IL	B
17	-	I
18	1beta	I
19	.	O

1	In	O
2	protocol	O
3	2	O
4	,	O
5	eight	O
6	different	O
7	subjects	O
8	performed	O
9	Con	O
10	and	O
11	Ecc	O
12	arm	O
13	curls	O
14	to	O
15	fatigue	O
16	,	O
17	followed	O
18	by	O
19	postexercise	O
20	muscle	O
21	ischemia	O
22	,	O
23	by	O
24	using	O
25	the	O
26	same	O
27	resistance	O
28	as	O
29	in	O
30	protocol	O
31	1	O
32	.	O

1	Airflow	O
2	was	O
3	measured	O
4	with	O
5	a	O
6	custom	O
7	-	O
8	designed	O
9	turbine	O
10	and	O
11	a	O
12	45	O
13	-	O
14	ft	O
15	.-	O
16	long	O
17	cable	O
18	to	O
19	reach	O
20	the	O
21	volume	O
22	-	O
23	measuring	O
24	module	O
25	.	O

1	Both	O
2	mutations	O
3	confer	O
4	amino	O
5	acid	O
6	substitutions	O
7	in	O
8	the	O
9	viral	B
10	coat	I
11	protein	I
12	but	O
13	differ	O
14	in	O
15	their	O
16	relative	O
17	abilities	O
18	to	O
19	utilize	O
20	the	O
21	foreign	O
22	scaffolding	B
23	protein	I
24	.	O

1	Complete	O
2	recovery	O
3	of	O
4	liver	O
5	function	O
6	after	O
7	this	O
8	surgery	O
9	tended	O
10	to	O
11	be	O
12	slow	O
13	.	O

1	Although	O
2	both	O
3	transcripts	O
4	share	O
5	the	O
6	first	O
7	nine	O
8	exons	O
9	,	O
10	exon	O
11	10	O
12	of	O
13	ZIS	B
14	-	I
15	2	I
16	is	O
17	lacking	O
18	in	O
19	ZIS	B
20	-	I
21	1	I
22	,	O
23	and	O
24	instead	O
25	,	O
26	exon	O
27	11	O
28	(	O
29	10th	O
30	exon	O
31	)	O
32	of	O
33	ZIS	B
34	-	I
35	1	I
36	is	O
37	larger	O
38	in	O
39	size	O
40	,	O
41	leading	O
42	to	O
43	the	O
44	longer	O
45	3	O
46	'-	O
47	UTR	O
48	.	O

1	Expression	O
2	of	O
3	the	O
4	second	O
5	gene	O
6	(	O
7	XT3	B
8	)	O
9	was	O
10	found	O
11	to	O
12	be	O
13	conserved	O
14	in	O
15	human	O
16	kidney	O
17	,	O
18	and	O
19	partial	O
20	sequence	O
21	was	O
22	obtained	O
23	from	O
24	a	O
25	human	O
26	cDNA	O
27	library	O
28	.	O

1	IFN	B
2	-	I
3	gamma	I
4	was	O
5	elevated	O
6	during	O
7	active	O
8	TB	O
9	when	O
10	compared	O
11	with	O
12	healthy	O
13	controls	O
14	,	O
15	declining	O
16	during	O
17	and	O
18	after	O
19	treatment	O
20	.	O

1	The	O
2	missing	O
3	5	O
4	'	O
5	sequences	O
6	were	O
7	obtained	O
8	by	O
9	5	O
10	'-	O
11	rapid	O
12	amplification	O
13	of	O
14	cDNA	O
15	ends	O
16	and	O
17	by	O
18	analysis	O
19	of	O
20	an	O
21	NHE5	B
22	genomic	I
23	clone	I
24	,	O
25	and	O
26	the	O
27	missing	O
28	3	O
29	'	O
30	sequences	O
31	were	O
32	obtained	O
33	by	O
34	3	O
35	'-	O
36	rapid	O
37	amplification	O
38	of	O
39	cDNA	O
40	ends	O
41	.	O

1	If	O
2	no	O
3	alloantibodies	O
4	are	O
5	detected	O
6	,	O
7	further	O
8	analysis	O
9	to	O
10	define	O
11	a	O
12	role	O
13	of	O
14	drug	O
15	-	O
16	related	O
17	or	O
18	autoantibodies	O
19	is	O
20	required	O
21	.	O

1	This	O
2	dependence	O
3	,	O
4	however	O
5	,	O
6	can	O
7	be	O
8	overcome	O
9	to	O
10	a	O
11	large	O
12	extent	O
13	by	O
14	dividing	O
15	min	O
16	LVdP	O
17	/	O
18	dt	O
19	by	O
20	mean	O
21	aortic	O
22	pressure	O
23	.	O

1	Genoa	O
2	,	O
3	Italy	O
4	,	O
5	24	O
6	-	O
7	28	O
8	August	O
9	1997	O
10	.	O

1	Electronic	O
2	structure	O
3	of	O
4	delta	O
5	-	O
6	plutonium	O
7	and	O
8	of	O
9	single	O
10	Al	O
11	,	O
12	Ga	O
13	,	O
14	and	O
15	Sc	O
16	impurities	O
17	in	O
18	delta	O
19	-	O
20	plutonium	O
21	.	O

1	Bound	O
2	-	O
3	exciton	O
4	transfer	O
5	and	O
6	photoluminescence	O
7	undulation	O
8	spectra	O
9	for	O
10	acceptors	O
11	in	O
12	ZnTe	O
13	.	O

1	Unified	O
2	theory	O
3	of	O
4	segregated	O
5	-	O
6	stack	O
7	organic	O
8	charge	O
9	-	O
10	transfer	O
11	solids	O
12	:	O
13	Magnetic	O
14	properties	O
15	.	O

1	Internal	O
2	modes	O
3	of	O
4	a	O
5	soliton	O
6	.	O

1	II	O
2	.	O

1	Envelope	O
2	-	O
3	function	O
4	matching	O
5	conditions	O
6	for	O
7	GaAs	O
8	/(	O
9	Al	O
10	,	O
11	Ga	O
12	)	O
13	As	O
14	heterojunctions	O
15	.	O

1	Neutron	O
2	scattering	O
3	measurements	O
4	of	O
5	critical	O
6	exponents	O
7	in	O
8	CsMnBr3	O
9	:	O
10	A	O
11	Z2	O
12	&	O
13	gt	O
14	;=	O
15	1	O
16	antiferromagnet	O
17	.	O

1	(	O
2	2	O
3	)	O
4	Erythroid	O
5	32D	O
6	Epo1	B
7	cells	O
8	showed	O
9	a	O
10	lower	O
11	level	O
12	of	O
13	bulk	O
14	PKC	B
15	catalytic	O
16	activity	O
17	,	O
18	lacked	O
19	the	O
20	expression	O
21	of	O
22	epsilon	B
23	and	I
24	eta	I
25	PKC	I
26	isoforms	I
27	,	O
28	and	O
29	showed	O
30	a	O
31	weak	O
32	or	O
33	absent	O
34	upregulation	O
35	of	O
36	the	O
37	remaining	O
38	isoforms	O
39	,	O
40	except	O
41	betaI	B
42	,	O
43	upon	O
44	readdition	O
45	of	O
46	Epo	B
47	to	O
48	growth	O
49	factor	O
50	-	O
51	starved	O
52	cells	O
53	.	O

1	We	O
2	used	O
3	expression	O
4	cloning	O
5	to	O
6	identify	O
7	interleukin	B
8	-	I
9	6	I
10	(	O
11	IL	B
12	-	I
13	6	I
14	)	O
15	as	O
16	one	O
17	factor	O
18	that	O
19	suppressed	O
20	growth	O
21	of	O
22	a	O
23	pre	O
24	-	O
25	B	O
26	-	O
27	cell	O
28	variant	O
29	line	O
30	,	O
31	1A9	O
32	-	O
33	M	O
34	.	O

1	Airflow	O
2	through	O
3	the	O
4	dust	O
5	trap	O
6	was	O
7	controlled	O
8	with	O
9	a	O
10	vacuum	O
11	pump	O
12	.	O

1	Thus	O
2	,	O
3	in	O
4	normal	O
5	intestinal	O
6	epithelial	O
7	goblet	O
8	cells	O
9	,	O
10	TbetaRI	B
11	and	O
12	TbetaRII	B
13	can	O
14	respond	O
15	to	O
16	autocrine	O
17	but	O
18	not	O
19	exogenous	O
20	TGF	B
21	-	I
22	beta	I
23	without	O
24	the	O
25	participation	O
26	of	O
27	TbetaRIII	B
28	.	O

1	The	O
2	history	O
3	of	O
4	exposure	O
5	and	O
6	carboxyhemoglobin	B
7	levels	O
8	should	O
9	alert	O
10	the	O
11	physician	O
12	to	O
13	this	O
14	diagnosis	O
15	.	O

1	The	O
2	odds	O
3	ratio	O
4	for	O
5	CHD	O
6	was	O
7	1	O
8	.	O
9	21	O
10	(	O
11	95	O
12	%	O
13	confidence	O
14	interval	O
15	,	O
16	0	O
17	.	O
18	84	O
19	-	O
20	1	O
21	.	O
22	75	O
23	)	O
24	given	O
25	a	O
26	positive	O
27	serostatus	O
28	of	O
29	specific	O
30	IgG	B
31	antibodies	O
32	after	O
33	adjustment	O
34	for	O
35	covariates	O
36	.	O

1	Another	O
2	group	O
3	of	O
4	HIPP	O
5	-	O
6	and	O
7	HCX	O
8	-	O
9	lesioned	O
10	animals	O
11	trained	O
12	on	O
13	the	O
14	tasks	O
15	after	O
16	the	O
17	lesion	O
18	showed	O
19	reduced	O
20	impairments	O
21	of	O
22	the	O
23	type	O
24	described	O
25	above	O
26	,	O
27	suggesting	O
28	that	O
29	extrahippocampal	O
30	structures	O
31	trained	O
32	after	O
33	the	O
34	lesion	O
35	can	O
36	assume	O
37	the	O
38	role	O
39	of	O
40	the	O
41	hippocampus	O
42	to	O
43	some	O
44	degree	O
45	.	O

1	The	O
2	case	O
3	for	O
4	neutrinos	O
5	from	O
6	SN	O
7	1987A	O
8	.	O

1	Scaling	O
2	of	O
3	fluctuations	O
4	in	O
5	one	O
6	-	O
7	dimensional	O
8	interface	O
9	and	O
10	hopping	O
11	models	O
12	.	O

1	Model	O
2	of	O
3	spatiotemporal	O
4	dynamics	O
5	of	O
6	stick	O
7	-	O
8	slip	O
9	motion	O
10	.	O

1	NMR	O
2	of	O
3	diffusing	O
4	atoms	O
5	in	O
6	a	O
7	periodic	O
8	porous	O
9	medium	O
10	in	O
11	the	O
12	presence	O
13	of	O
14	a	O
15	nonuniform	O
16	magnetic	O
17	field	O
18	.	O

1	Microstructure	O
2	and	O
3	conductivity	O
4	of	O
5	hierarchical	O
6	laminate	O
7	composites	O
8	.	O

1	Anisotropic	O
2	heat	O
3	transport	O
4	in	O
5	the	O
6	octylcyanobiphenyl	O
7	(	O
8	8CB	O
9	)	O
10	liquid	O
11	crystal	O
12	.	O

1	Direct	O
2	approach	O
3	to	O
4	the	O
5	study	O
6	of	O
7	soliton	O
8	perturbations	O
9	.	O

1	Mutations	O
2	affecting	O
3	only	O
4	CD4	B
5	regulation	O
6	mapped	O
7	to	O
8	residues	O
9	previously	O
10	shown	O
11	to	O
12	mediate	O
13	the	O
14	binding	O
15	of	O
16	Nef	B
17	to	O
18	this	O
19	receptor	O
20	,	O
21	such	O
22	as	O
23	W57	O
24	and	O
25	L58	O
26	,	O
27	as	O
28	well	O
29	as	O
30	to	O
31	an	O
32	AP	B
33	-	I
34	recruiting	I
35	dileucine	I
36	motif	I
37	and	O
38	to	O
39	an	O
40	acidic	O
41	dipeptide	O
42	in	O
43	the	O
44	C	O
45	-	O
46	terminal	O
47	region	O
48	of	O
49	the	O
50	protein	O
51	.	O

1	Several	O
2	mutations	O
3	disrupted	O
4	the	O
5	endonuclease	O
6	and	O
7	helicase	B
8	activities	O
9	;	O
10	however	O
11	,	O
12	only	O
13	one	O
14	amino	B
15	-	I
16	terminal	I
17	-	I
18	charge	I
19	cluster	I
20	mutant	I
21	protein	I
22	(	O
23	D40A	O
24	-	O
25	D42A	O
26	-	O
27	D44A	O
28	)	O
29	completely	O
30	lost	O
31	AAV	O
32	hairpin	O
33	DNA	O
34	binding	O
35	activity	O
36	.	O

1	The	O
2	lytic	O
3	cycle	O
4	of	O
5	KSHV	O
6	,	O
7	probably	O
8	under	O
9	the	O
10	initial	O
11	control	O
12	of	O
13	the	O
14	KSHV	B
15	/	I
16	Rta	I
17	gene	I
18	,	O
19	may	O
20	directly	O
21	contribute	O
22	to	O
23	tumor	O
24	pathogenesis	O
25	.	O

1	We	O
2	conclude	O
3	that	O
4	(	O
5	i	O
6	)	O
7	we	O
8	have	O
9	identified	O
10	several	O
11	candidate	O
12	latency	O
13	genes	O
14	of	O
15	murine	O
16	gammaHV68	O
17	,	O
18	(	O
19	ii	O
20	)	O
21	expression	O
22	of	O
23	genes	O
24	during	O
25	latency	O
26	may	O
27	be	O
28	different	O
29	in	O
30	different	O
31	organs	O
32	,	O
33	consistent	O
34	with	O
35	multiple	O
36	latency	O
37	programs	O
38	and	O
39	/	O
40	or	O
41	multiple	O
42	cellular	O
43	sites	O
44	of	O
45	latency	O
46	,	O
47	and	O
48	(	O
49	iii	O
50	)	O
51	regions	O
52	of	O
53	the	O
54	viral	O
55	genome	O
56	(	O
57	v	B
58	-	I
59	bcl	I
60	-	I
61	2	I
62	gene	I
63	,	O
64	v	B
65	-	I
66	GCR	I
67	gene	I
68	,	O
69	and	O
70	gene	B
71	73	I
72	)	O
73	are	O
74	transcribed	O
75	during	O
76	latency	O
77	with	O
78	both	O
79	gammaHV68	O
80	and	O
81	primate	O
82	gammaherpesviruses	O
83	.	O

1	These	O
2	data	O
3	indicate	O
4	a	O
5	functional	O
6	role	O
7	for	O
8	U1	B
9	in	O
10	NRS	B
11	-	O
12	mediated	O
13	splicing	O
14	inhibition	O
15	.	O

1	This	O
2	suggests	O
3	that	O
4	the	O
5	DcuS	B
6	-	O
7	DcuR	B
8	system	O
9	responds	O
10	to	O
11	external	O
12	substrates	O
13	.	O

1	Here	O
2	we	O
3	describe	O
4	the	O
5	identification	O
6	and	O
7	characterization	O
8	of	O
9	several	O
10	Sp100	B
11	splice	I
12	variant	I
13	proteins	I
14	and	O
15	support	O
16	their	O
17	existence	O
18	by	O
19	elucidation	O
20	of	O
21	the	O
22	3	O
23	'-	O
24	end	O
25	of	O
26	the	O
27	Sp100	B
28	gene	I
29	.	O

1	Crossover	O
2	in	O
3	the	O
4	specific	O
5	heat	O
6	of	O
7	dilute	O
8	magnets	O
9	induced	O
10	by	O
11	critical	O
12	spin	O
13	-	O
14	wave	O
15	dynamics	O
16	.	O

1	Erratum	O
2	:	O
3	Absence	O
4	of	O
5	precursor	O
6	effects	O
7	above	O
8	the	O
9	martensitic	O
10	transformation	O
11	in	O
12	a	O
13	virgin	O
14	crystal	O
15	of	O
16	Li	O
17	metal	O

1	Interplane	O
2	coupling	O
3	in	O
4	the	O
5	superconductor	O
6	Y2Ba4Cu7O15	O
7	as	O
8	revealed	O
9	by	O
10	NQR	O
11	spin	O
12	-	O
13	echo	O
14	double	O
15	resonance	O
16	.	O

1	Electronic	O
2	structure	O
3	of	O
4	a	O
5	buried	O
6	NiSi2	O
7	or	O
8	CoSi2	O
9	layer	O
10	in	O
11	bulk	O
12	Si	O
13	.	O

1	Raman	O
2	investigation	O
3	of	O
4	YBa2	O
5	-	O
6	xLaxCu3O7	O
7	ceramics	O
8	.	O

1	Effects	O
2	of	O
3	point	O
4	defects	O
5	on	O
6	lattice	O
7	parameters	O
8	of	O
9	semiconductors	O
10	.	O

1	Chaotic	O
2	electron	O
3	dynamics	O
4	around	O
5	a	O
6	single	O
7	elliptically	O
8	shaped	O
9	antidot	O
10	.	O

1	However	O
2	,	O
3	deletions	O
4	of	O
5	the	O
6	C	O
7	terminal	O
8	11	O
9	or	O
10	14	O
11	amino	O
12	acids	O
13	had	O
14	more	O
15	substantial	O
16	effects	O
17	.	O

1	Sixty	O
2	months	O
3	after	O
4	the	O
5	initial	O
6	vaccination	O
7	,	O
8	all	O
9	vaccinees	O
10	who	O
11	received	O
12	annual	O
13	follow	O
14	-	O
15	up	O
16	still	O
17	had	O
18	protective	O
19	levels	O
20	of	O
21	anti	B
22	-	I
23	HAV	I
24	.	O

1	However	O
2	,	O
3	after	O
4	PRK	O
5	at	O
6	5	O
7	weeks	O
8	of	O
9	age	O
10	,	O
11	partial	O
12	retreatment	O
13	may	O
14	be	O
15	necessary	O
16	due	O
17	to	O
18	regression	O
19	of	O
20	the	O
21	PRK	O
22	effect	O
23	.	O

1	Its	O
2	early	O
3	lesions	O
4	were	O
5	characterized	O
6	by	O
7	angiomatosis	O
8	,	O
9	vasculopathy	O
10	,	O
11	and	O
12	proliferation	O
13	of	O
14	synoviocytes	O
15	and	O
16	fibroblasts	O
17	.	O

1	Molecular	O
2	cloning	O
3	of	O
4	human	O
5	cDNA	O
6	encoding	O
7	a	O
8	novel	O
9	beta1	B
10	,	I
11	6	I
12	-	I
13	N	I
14	-	I
15	acetylglucosaminyltransferase	I
16	forming	O
17	core	O
18	2	O
19	and	O
20	core	O
21	4	O
22	.	O

1	Interspecific	O
2	mouse	O
3	back	O
4	-	O
5	cross	O
6	analysis	O
7	identified	O
8	the	O
9	loci	O
10	for	O
11	mouse	B
12	3Ost	I
13	genes	I
14	and	O
15	syntenic	O
16	assignments	O
17	of	O
18	corresponding	O
19	human	O
20	isologs	O
21	were	O
22	confirmed	O
23	by	O
24	the	O
25	identification	O
26	of	O
27	mapped	O
28	sequence	O
29	-	O
30	tagged	O
31	site	O
32	markers	O
33	.	O

1	The	O
2	Scales	O
3	of	O
4	Cognitive	O
5	Impairment	O
6	Rated	O
7	From	O
8	Institutional	O
9	Records	O
10	(	O
11	SCIRFIR	O
12	),	O
13	a	O
14	battery	O
15	based	O
16	on	O
17	commonly	O
18	used	O
19	dementia	O
20	rating	O
21	instruments	O
22	,	O
23	was	O
24	tested	O
25	on	O
26	the	O
27	records	O
28	of	O
29	26	O
30	chronically	O
31	institutionalized	O
32	,	O
33	elderly	O
34	schizophrenia	O
35	patients	O
36	,	O
37	for	O
38	the	O
39	purpose	O
40	of	O
41	retrospectively	O
42	evaluating	O
43	the	O
44	long	O
45	-	O
46	term	O
47	course	O
48	of	O
49	cognitive	O
50	change	O
51	in	O
52	schizophrenia	O
53	and	O
54	relating	O
55	it	O
56	to	O
57	available	O
58	autopsy	O
59	materials	O
60	.	O

1	It	O
2	was	O
3	demonstrated	O
4	that	O
5	the	O
6	processing	O
7	signals	O
8	in	O
9	the	O
10	transcript	O
11	,	O
12	i	O
13	.	O
14	e	O
15	.	O
16	both	O
17	donor	O
18	splice	O
19	sites	O
20	and	O
21	the	O
22	polyadenylation	O
23	site	O
24	located	O
25	in	O
26	the	O
27	muscle	O
28	-	O
29	specific	O
30	intron	O
31	,	O
32	have	O
33	to	O
34	be	O
35	weak	O
36	.	O

1	Most	O
2	recently	O
3	,	O
4	the	O
5	use	O
6	of	O
7	the	O
8	product	O
9	of	O
10	brain	O
11	weight	O
12	and	O
13	clearance	O
14	has	O
15	been	O
16	proposed	O
17	.	O

1	Recombination	O
2	and	O
3	transcription	O
4	of	O
5	the	O
6	endogenous	B
7	Ig	I
8	heavy	I
9	chain	I
10	locus	I
11	is	O
12	effected	O
13	by	O
14	the	O
15	Ig	B
16	heavy	I
17	chain	I
18	intronic	I
19	enhancer	I
20	core	I
21	region	I
22	in	O
23	the	O
24	absence	O
25	of	O
26	the	O
27	matrix	O
28	attachment	O
29	regions	O
30	.	O

1	Two	O
2	of	O
3	these	O
4	motifs	O
5	are	O
6	part	O
7	of	O
8	a	O
9	highly	O
10	conserved	O
11	and	O
12	inducible	O
13	dyad	O
14	symmetry	O
15	element	O
16	shown	O
17	previously	O
18	to	O
19	control	O
20	a	O
21	remote	O
22	IL	B
23	-	I
24	2	I
25	enhancer	I
26	and	O
27	the	O
28	CD18	B
29	promoter	I
30	.	O

1	In	O
2	concert	O
3	with	O
4	the	O
5	coactivator	O
6	CREB	B
7	binding	I
8	protein	I
9	/	O
10	p300	B
11	,	O
12	which	O
13	interacts	O
14	with	O
15	GABPalpha	B
16	,	O
17	the	O
18	binding	O
19	of	O
20	GABPalpha	B
21	and	I
22	-	I
23	beta	I
24	to	O
25	the	O
26	dyad	O
27	symmetry	O
28	element	O
29	controls	O
30	the	O
31	induction	O
32	of	O
33	IL	B
34	-	I
35	16	I
36	promoter	I
37	in	O
38	T	O
39	cells	O
40	.	O

1	TPO	B
2	by	O
3	itself	O
4	did	O
5	not	O
6	activate	O
7	ERK1	B
8	,	O
9	ERK2	B
10	and	O
11	protein	B
12	kinase	I
13	C	I
14	(	O
15	PKC	B
16	),	O
17	whereas	O
18	TPO	B
19	directly	O
20	enhanced	O
21	the	O
22	PKC	B
23	-	O
24	dependent	O
25	activation	O
26	of	O
27	ERKs	B
28	induced	O
29	by	O
30	other	O
31	agonists	O
32	including	O
33	thrombin	B
34	and	O
35	phorbol	O
36	esters	O
37	,	O
38	without	O
39	affecting	O
40	the	O
41	PKC	B
42	activation	O
43	by	O
44	those	O
45	agonists	O
46	.	O

1	BACKGROUND	O
2	:	O
3	In	O
4	the	O
5	ubiquitin	B
6	-	O
7	dependent	O
8	proteolysis	O
9	pathway	O
10	,	O
11	a	O
12	ubiquitin	B
13	ligase	I
14	(	O
15	E3	B
16	)	O
17	is	O
18	responsible	O
19	for	O
20	substrate	O
21	selectivity	O
22	and	O
23	timing	O
24	of	O
25	degradation	O
26	.	O

1	CONCLUSIONS	O
2	:	O
3	Fission	B
4	yeast	I
5	SCF	I
6	is	O
7	composed	O
8	of	O
9	Pop1	B
10	and	O
11	Pop2	B
12	,	O
13	two	O
14	structurally	O
15	related	O
16	but	O
17	functionally	O
18	independent	O
19	F	B
20	-	I
21	box	I
22	/	I
23	WD	I
24	-	I
25	repeat	I
26	proteins	I
27	.	O

1	19F	O
2	NMR	O
3	studies	O
4	in	O
5	ABF4	O
6	-	O
7	type	O
8	layered	O
9	antiferromagnets	O
10	.	O

1	Optical	O
2	-	O
3	absorption	O
4	spectra	O
5	,	O
6	crystal	O
7	-	O
8	field	O
9	energy	O
10	levels	O
11	,	O
12	and	O
13	transition	O
14	line	O
15	strengths	O
16	of	O
17	holmium	O
18	in	O
19	trigonal	O
20	Na3	O

1	Observation	O
2	of	O
3	dipolar	O
4	interactions	O
5	between	O
6	Pb0	O
7	defects	O
8	at	O
9	the	O
10	(	O
11	111	O
12	)	O
13	Si	O
14	/	O
15	SiO2	O
16	interface	O
17	.	O

1	Quantum	O
2	-	O
3	statistical	O
4	theory	O
5	of	O
6	high	O
7	-	O
8	field	O
9	transport	O
10	phenomena	O
11	.	O

1	NH3	O
2	and	O
3	NO	O
4	interaction	O
5	with	O
6	Si	O
7	(	O
8	100	O
9	)-(	O
10	2	O
11	x	O
12	1	O
13	)	O
14	surfaces	O
15	.	O

1	Chirality	O
2	-	O
3	glass	O
4	and	O
5	spin	O
6	-	O
7	glass	O
8	correlations	O
9	in	O
10	the	O
11	two	O
12	-	O
13	dimensional	O
14	random	O
15	-	O
16	bond	O
17	XY	O
18	model	O
19	.	O

1	Echo	O
2	modulation	O
3	in	O
4	Pr3	O
5	+:	O
6	YAlO3	O
7	.	O

1	Mechanisms	O
2	of	O
3	visible	O
4	-	O
5	light	O
6	emission	O
7	from	O
8	electro	O
9	-	O
10	oxidized	O
11	porous	O
12	silicon	O
13	.	O

1	Far	O
2	-	O
3	infrared	O
4	hopping	O
5	conductivity	O
6	in	O
7	the	O
8	CuO	O
9	chains	O
10	of	O
11	a	O
12	single	O
13	-	O
14	domain	O
15	YBa2Cu3O7	O
16	-	O
17	delta	O
18	crystal	O
19	.	O

1	Surface	O
2	spin	O
3	waves	O
4	in	O
5	a	O
6	Heisenberg	O
7	ferrimagnet	O
8	with	O
9	a	O
10	single	O
11	-	O
12	ion	O
13	anisotropy	O
14	(	O
15	uniaxial	O
16	and	O
17	nonuniaxial	O
18	).	O

1	Optically	O
2	detected	O
3	librons	O
4	and	O
5	phonons	O
6	in	O
7	crystalline	O
8	C60	O
9	.	O

1	Multilayer	O
2	-	O
3	relaxation	O
4	geometry	O
5	and	O
6	electronic	O
7	structure	O
8	of	O
9	a	O
10	W	O
11	(	O
12	111	O
13	)	O
14	surface	O
15	.	O

1	Temperature	O
2	dependence	O
3	of	O
4	the	O
5	sublattice	O
6	spontaneous	O
7	magnetization	O
8	of	O
9	YBa2Cu3O6	O
10	.	O

1	GW	O
2	Gamma	O
3	approximation	O
4	for	O
5	electron	O
6	self	O
7	-	O
8	energies	O
9	in	O
10	semiconductors	O
11	and	O
12	insulators	O
13	.	O

1	Precision	O
2	measurement	O
3	of	O
4	the	O
5	pion	O
6	mass	O
7	difference	O
8	m	O
9	pi	O
10	--	O
11	m	O
12	pi	O
13	0	O
14	.	O

1	Testing	O
2	gravity	O
3	to	O
4	second	O
5	post	O
6	-	O
7	Newtonian	O
8	order	O
9	:	O
10	A	O
11	field	O
12	-	O
13	theory	O
14	approach	O
15	.	O

1	Genetic	O
2	experiments	O
3	using	O
4	mutants	O
5	defective	O
6	in	O
7	apontic	B
8	and	O
9	bruno	B
10	reveal	O
11	a	O
12	functional	O
13	interaction	O
14	between	O
15	these	O
16	genes	O
17	.	O

1	In	O
2	the	O
3	current	O
4	model	O
5	,	O
6	Wingless	B
7	/	O
8	Wnt	B
9	signal	O
10	stabilizes	O
11	Armadillo	B
12	/	O
13	beta	B
14	-	I
15	catenin	I
16	,	O
17	which	O
18	then	O
19	accumulates	O
20	in	O
21	nuclei	O
22	and	O
23	binds	O
24	TCF	B
25	/	O
26	LEF	B
27	family	O
28	proteins	O
29	,	O
30	forming	O
31	bipartite	O
32	transcription	O
33	factors	O
34	which	O
35	activate	O
36	transcription	O
37	of	O
38	Wingless	B
39	/	O
40	Wnt	B
41	responsive	O
42	genes	O
43	.	O

1	In	O
2	support	O
3	of	O
4	clinical	O
5	antianginal	O
6	studies	O
7	,	O
8	the	O
9	vasodilator	O
10	nicorandil	O
11	(	O
12	NIC	O
13	)	O
14	was	O
15	combined	O
16	with	O
17	the	O
18	beta	B
19	-	I
20	adrenergic	I
21	receptor	I
22	antagonists	O
23	propranolol	O
24	(	O
25	PRO	O
26	)	O
27	and	O
28	atenolol	O
29	(	O
30	ATN	O
31	)	O
32	and	O
33	with	O
34	the	O
35	calcium	O
36	channel	O
37	blocker	O
38	diltiazem	O
39	(	O
40	DTZ	O
41	)	O
42	to	O
43	determine	O
44	their	O
45	cardiovascular	O
46	and	O
47	pharmacokinetic	O
48	interactions	O
49	.	O

1	Factors	O
2	influencing	O
3	direct	O
4	-	O
5	immersion	O
6	(	O
7	DI	O
8	)-	O
9	SPME	O
10	process	O
11	were	O
12	also	O
13	checked	O
14	and	O
15	chosen	O
16	experimentally	O
17	.	O

1	In	O
2	contrast	O
3	,	O
4	an	O
5	amino	O
6	-	O
7	terminal	O
8	fragment	O
9	containing	O
10	the	O
11	C	O
12	/	O
13	H1	O
14	domain	O
15	was	O
16	sufficient	O
17	for	O
18	coactivation	O
19	of	O
20	Zta	B
21	transcription	O
22	and	O
23	viral	O
24	reactivation	O
25	function	O
26	.	O

1	In	O
2	addition	O
3	,	O
4	a	O
5	potent	O
6	splicing	O
7	enhancer	O
8	sequence	O
9	isolated	O
10	in	O
11	the	O
12	selection	O
13	specifically	O
14	binds	O
15	a	O
16	20	B
17	-	I
18	kDa	I
19	SR	I
20	protein	I
21	.	O

1	Elimination	O
2	of	O
3	ETH1	B
4	in	O
5	apn1	B
6	strains	O
7	also	O
8	increased	O
9	spontaneous	O
10	mutation	O
11	rates	O
12	9	O
13	-	O
14	or	O
15	31	O
16	-	O
17	fold	O
18	compared	O
19	to	O
20	the	O
21	wild	O
22	type	O
23	as	O
24	determined	O
25	by	O
26	reversion	O
27	to	O
28	adenine	O
29	or	O
30	lysine	O
31	prototrophy	O
32	,	O
33	respectively	O
34	.	O

1	Elimination	O
2	of	O
3	ETH1	B
4	in	O
5	apn1	B
6	strains	O
7	also	O
8	increased	O
9	spontaneous	O
10	mutation	O
11	rates	O
12	9	O
13	-	O
14	or	O
15	31	O
16	-	O
17	fold	O
18	compared	O
19	to	O
20	the	O
21	wild	O
22	type	O
23	as	O
24	determined	O
25	by	O
26	reversion	O
27	to	O
28	adenine	O
29	or	O
30	lysine	O
31	prototrophy	O
32	,	O
33	respectively	O
34	.	O

1	These	O
2	data	O
3	suggest	O
4	that	O
5	other	O
6	Ras	B
7	effectors	I
8	can	O
9	collaborate	O
10	with	O
11	PI	B
12	3	I
13	-	I
14	kinase	I
15	and	O
16	with	O
17	each	O
18	other	O
19	to	O
20	activate	O
21	Pak	B
22	.	O

1	Mammalian	O
2	Ras	B
3	GTPase	I
4	-	I
5	activating	I
6	protein	I
7	(	O
8	GAP	B
9	),	O
10	p120	B
11	Ras	I
12	-	O
13	GAP	B
14	,	O
15	has	O
16	been	O
17	implicated	O
18	as	O
19	both	O
20	a	O
21	downregulator	O
22	and	O
23	effector	O
24	of	O
25	Ras	B
26	proteins	I
27	,	O
28	but	O
29	its	O
30	precise	O
31	role	O
32	in	O
33	Ras	B
34	-	O
35	mediated	O
36	signal	O
37	transduction	O
38	pathways	O
39	is	O
40	unclear	O
41	.	O

1	Three	O
2	mog	B
3	-	I
4	1	I
5	alleles	I
6	possess	O
7	premature	O
8	stop	O
9	codons	O
10	and	O
11	are	O
12	likely	O
13	to	O
14	be	O
15	null	O
16	alleles	O
17	,	O
18	and	O
19	one	O
20	is	O
21	a	O
22	missense	O
23	mutation	O
24	and	O
25	is	O
26	likely	O
27	to	O
28	retain	O
29	residual	O
30	activity	O
31	.	O
32	mog	B
33	-	I
34	1	I
35	mRNA	I
36	is	O
37	expressed	O
38	in	O
39	both	O
40	germ	O
41	line	O
42	and	O
43	somatic	O
44	tissues	O
45	and	O
46	appears	O
47	to	O
48	be	O
49	ubiquitous	O
50	.	O

1	However	O
2	,	O
3	unlike	O
4	the	O
5	SIN3	B
6	gene	I
7	of	O
8	Saccharomyces	O
9	cerevisiae	O
10	,	O
11	pst1	B
12	(+)	I
13	is	O
14	essential	O
15	for	O
16	cell	O
17	viability	O
18	.	O

1	The	O
2	Nmd3	B
3	protein	I
4	sequence	I
5	does	O
6	not	O
7	contain	O
8	readily	O
9	recognizable	O
10	motifs	O
11	of	O
12	known	O
13	function	O
14	.	O

1	The	O
2	distribution	O
3	of	O
4	the	O
5	various	O
6	repeats	O
7	suggests	O
8	its	O
9	organization	O
10	is	O
11	similar	O
12	to	O
13	the	O
14	beta	O
15	-	O
16	heterochromatic	O
17	regions	O
18	near	O
19	the	O
20	base	O
21	of	O
22	the	O
23	major	O
24	chromosome	O
25	arms	O
26	.	O

1	Calcitonin	B
2	simultaneously	O
3	regulates	O
4	both	O
5	periosteal	O
6	hyperostosis	O
7	and	O
8	trabecular	O
9	osteopenia	O
10	in	O
11	the	O
12	spinal	O
13	hyperostotic	O
14	mouse	O
15	(	O
16	twy	B
17	/	O
18	twy	B
19	)	O
20	in	O
21	vivo	O
22	.	O

1	Electrophoretic	O
2	mobility	O
3	-	O
4	shift	O
5	assays	O
6	performed	O
7	with	O
8	the	O
9	HNF	B
10	-	I
11	3	I
12	X	O
13	and	O
14	Y	O
15	sites	O
16	demonstrated	O
17	that	O
18	both	O
19	sites	O
20	are	O
21	capable	O
22	of	O
23	binding	O
24	HNF	B
25	-	I
26	3alpha	I
27	and	O
28	HNF	B
29	-	I
30	3beta	I
31	.	O

1	In	O
2	addition	O
3	,	O
4	we	O
5	also	O
6	show	O
7	that	O
8	cdk7	B
9	may	O
10	phosphorylate	O
11	the	O
12	carboxy	O
13	-	O
14	terminal	O
15	domain	O
16	(	O
17	CTD	O
18	)	O
19	of	O
20	RNA	B
21	pol	I
22	II	I
23	in	O
24	the	O
25	absence	O
26	of	O
27	promoter	O
28	opening	O
29	.	O

1	The	O
2	therapy	O
3	with	O
4	a	O
5	H2	B
6	-	I
7	receptor	I
8	antagonist	O
9	is	O
10	less	O
11	effective	O
12	than	O
13	the	O
14	triple	O
15	therapies	O
16	with	O
17	omeprazole	O
18	or	O
19	lansoprazole	O
20	.	O

1	In	O
2	humans	O
3	,	O
4	three	O
5	tissue	B
6	-	I
7	specific	I
8	plastin	I
9	isoforms	I
10	have	O
11	been	O
12	identified	O
13	.	O

1	No	O
2	TATA	O
3	or	O
4	Inr	O
5	sequence	O
6	was	O
7	found	O
8	.	O

1	The	O
2	inhibition	O
3	by	O
4	the	O
5	RIalpha	B
6	subunit	I
7	is	O
8	reversed	O
9	by	O
10	addition	O
11	of	O
12	nanomolar	O
13	concentrations	O
14	of	O
15	cAMP	O
16	(	O
17	Ka	O
18	=	O
19	40	O
20	nM	O
21	),	O
22	thus	O
23	demonstrating	O
24	that	O
25	PrKX	B
26	is	O
27	a	O
28	novel	O
29	,	O
30	type	B
31	I	I
32	cAMP	I
33	-	I
34	dependent	I
35	protein	I
36	kinase	I
37	that	O
38	is	O
39	activated	O
40	at	O
41	lower	O
42	cAMP	O
43	concentrations	O
44	than	O
45	the	O
46	holoenzyme	O
47	with	O
48	the	O
49	Calpha	B
50	subunit	I
51	of	O
52	cAMP	B
53	-	I
54	dependent	I
55	protein	I
56	kinase	I
57	.	O

1	Proteins	O
2	known	O
3	to	O
4	bind	O
5	the	O
6	PEPCK	B
7	CRE	O
8	include	O
9	the	O
10	CRE	B
11	-	I
12	binding	I
13	protein	I
14	(	O
15	CREB	B
16	)	O
17	and	O
18	members	O
19	of	O
20	the	O
21	CCAAT	B
22	/	I
23	enhancer	I
24	-	I
25	binding	I
26	protein	I
27	(	O
28	C	B
29	/	I
30	EBP	I
31	)	O
32	family	O
33	.	O

1	This	O
2	construct	O
3	,	O
4	termed	O
5	pDeltaCREC	B
6	/	O
7	EBP	B
8	,	O
9	binds	O
10	C	B
11	/	I
12	EBPalpha	I
13	and	I
14	beta	I
15	but	O
16	not	O
17	CREB	B
18	,	O
19	yet	O
20	it	O
21	confers	O
22	a	O
23	nearly	O
24	complete	O
25	glucocorticoid	O
26	response	O
27	when	O
28	transiently	O
29	transfected	O
30	into	O
31	H4IIE	O
32	rat	O
33	hepatoma	O
34	cells	O
35	.	O

1	In	O
2	addition	O
3	,	O
4	in	O
5	vitro	O
6	mutagenesis	O
7	of	O
8	both	O
9	Engrailed	B
10	and	O
11	Pbx1	B
12	sites	I
13	indicated	O
14	that	O
15	other	O
16	unidentified	O
17	sites	O
18	are	O
19	responsible	O
20	for	O
21	the	O
22	transcriptional	O
23	enhancement	O
24	observed	O
25	with	O
26	the	O
27	intronic	O
28	fragment	O
29	.	O

1	Several	O
2	secondary	O
3	structure	O
4	elements	O
5	were	O
6	identified	O
7	.	O

1	Here	O
2	,	O
3	we	O
4	evidence	O
5	that	O
6	the	O
7	developmental	O
8	functions	O
9	of	O
10	the	O
11	family	O
12	of	O
13	transcription	O
14	factors	O
15	characterized	O
16	by	O
17	the	O
18	POU	B
19	DNA	I
20	binding	I
21	motif	I
22	exerts	O
23	roles	O
24	in	O
25	mammalian	O
26	development	O
27	.	O

1	High	O
2	-	O
3	affinity	O
4	site	O
5	-	O
6	specific	O
7	DNA	O
8	binding	O
9	by	O
10	POU	B
11	domain	I
12	transcription	I
13	factors	I
14	requires	O
15	both	O
16	the	O
17	POU	B
18	-	I
19	specific	I
20	and	O
21	the	O
22	POU	B
23	-	I
24	homeodomain	I
25	.	O

1	In	O
2	the	O
3	Oct	B
4	-	I
5	1	I
6	crystal	O
7	,	O
8	the	O
9	POU	B
10	-	I
11	specific	I
12	domain	I
13	recognizes	O
14	a	O
15	GCAT	O
16	half	O
17	-	O
18	site	O
19	,	O
20	while	O
21	the	O
22	corresponding	O
23	sequence	O
24	recognized	O
25	by	O
26	the	O
27	Pit	B
28	-	I
29	1	I
30	POU	I
31	-	O
32	specific	O
33	domain	O
34	,	O
35	GTAT	O
36	,	O
37	is	O
38	on	O
39	the	O
40	opposing	O
41	strand	O
42	.	O

1	Systematic	O
2	functional	O
3	analysis	O
4	of	O
5	V1a	B
6	/	I
7	V2	I
8	hybrid	I
9	receptors	I
10	showed	O
11	that	O
12	the	O
13	second	O
14	intracellular	O
15	loop	O
16	of	O
17	the	O
18	V1a	B
19	receptor	I
20	is	O
21	required	O
22	and	O
23	sufficient	O
24	for	O
25	efficient	O
26	coupling	O
27	to	O
28	Gq	B
29	/	I
30	11	I
31	,	O
32	whereas	O
33	the	O
34	third	O
35	intracellular	O
36	loop	O
37	of	O
38	the	O
39	V2	B
40	receptor	I
41	is	O
42	required	O
43	and	O
44	sufficient	O
45	for	O
46	coupling	O
47	to	O
48	Gs	B
49	.	O

1	Most	O
2	other	O
3	end	O
4	points	O
5	were	O
6	highly	O
7	significant	O
8	,	O
9	and	O
10	death	O
11	,	O
12	which	O
13	was	O
14	monitored	O
15	across	O
16	the	O
17	U	O
18	.	O
19	S	O
20	.	O
21	program	O
22	,	O
23	was	O
24	different	O
25	with	O
26	p	O
27	<	O
28	0	O
29	.	O
30	0001	O
31	.	O

1	The	O
2	other	O
3	is	O
4	located	O
5	at	O
6	-	O
7	1335	O
8	,	O
9	outside	O
10	this	O
11	highly	O
12	conserved	O
13	region	O
14	.	O

1	The	O
2	fatigue	O
3	exercise	O
4	showed	O
5	relatively	O
6	high	O
7	blood	O
8	lactate	O
9	concentration	O
10	[	O
11	12	O
12	.	O
13	5	O
14	(	O
15	SD	O
16	2	O
17	.	O
18	6	O
19	)	O
20	mmol	O
21	x	O
22	l	O
23	(-	O
24	1	O
25	)]	O
26	and	O
27	an	O
28	increase	O
29	of	O
30	serum	B
31	creatine	I
32	kinase	I
33	(	O
34	CK	B
35	)	O
36	activity	O
37	delayed	O
38	by	O
39	2	O
40	days	O
41	[	O
42	540	O
43	(	O
44	SD	O
45	407	O
46	)	O
47	U	O
48	x	O
49	l	O
50	(-	O
51	1	O
52	)].	O

1	Those	O
2	radiological	O
3	aspects	O
4	were	O
5	distributed	O
6	in	O
7	two	O
8	categories	O
9	:	O
10	1	O
11	)	O
12	type	O
13	I	O
14	-	O
15	presenting	O
16	variable	O
17	sinusoidal	O
18	filling	O
19	.	O

1	Results	O
2	demonstrated	O
3	that	O
4	the	O
5	presence	O
6	of	O
7	myofibroblasts	O
8	varied	O
9	considerably	O
10	from	O
11	case	O
12	to	O
13	case	O
14	and	O
15	was	O
16	always	O
17	related	O
18	to	O
19	smooth	O
20	muscle	O
21	cell	O
22	dispersion	O
23	,	O
24	which	O
25	occurred	O
26	around	O
27	medium	O
28	-	O
29	sized	O
30	damaged	O
31	portal	O
32	vein	O
33	branches	O
34	.	O

1	New	O
2	Langevin	O
3	equations	O
4	for	O
5	a	O
6	translating	O
7	and	O
8	simultaneously	O
9	rotating	O
10	asymmetric	O
11	top	O
12	.	O

1	Radiative	O
2	corrections	O
3	to	O
4	beta	O
5	decay	O
6	and	O
7	the	O
8	possibility	O
9	of	O
10	a	O
11	fourth	O
12	generation	O
13	.	O

1	Depth	O
2	-	O
3	controlled	O
4	grazing	O
5	-	O
6	incidence	O
7	diffraction	O
8	of	O
9	synchrotron	O
10	x	O
11	radiation	O
12	.	O

1	Oscillatory	O
2	exchange	O
3	of	O
4	atoms	O
5	between	O
6	traps	O
7	containing	O
8	Bose	O
9	condensates	O
10	.	O

1	Structure	O
2	determination	O
3	of	O
4	an	O
5	adsorbate	O
6	-	O
7	induced	O
8	multilayer	O
9	reconstruction	O
10	:	O
11	(	O
12	1	O
13	x	O
14	2	O
15	)-	O
16	H	O
17	/	O
18	Ni	O
19	(	O
20	110	O
21	).	O

1	Magnetic	O
2	trapping	O
3	of	O
4	spin	O
5	-	O
6	polarized	O
7	atomic	O
8	hydrogen	O
9	.	O

1	Northern	O
2	blot	O
3	and	O
4	in	O
5	situ	O
6	hybridization	O
7	analyses	O
8	revealed	O
9	GPR34	B
10	mRNA	I
11	transcripts	I
12	in	O
13	several	O
14	human	O
15	and	O
16	rat	O
17	brain	O
18	regions	O
19	.	O

1	The	O
2	microphthalmia	B
3	-	I
4	TFE	I
5	(	O
6	MiT	B
7	)	O
8	subfamily	O
9	of	O
10	basic	B
11	helix	I
12	-	I
13	loop	I
14	-	I
15	helix	I
16	leucine	I
17	zipper	I
18	(	I
19	bHLH	I
20	-	I
21	ZIP	I
22	)	I
23	transcription	I
24	factors	I
25	,	O
26	including	O
27	TFE3	B
28	,	O
29	TFEB	B
30	,	O
31	TFEC	B
32	,	O
33	and	O
34	Mitf	B
35	,	O
36	has	O
37	been	O
38	implicated	O
39	in	O
40	the	O
41	regulation	O
42	of	O
43	tissue	O
44	-	O
45	specific	O
46	gene	O
47	expression	O
48	in	O
49	several	O
50	cell	O
51	lineages	O
52	.	O

1	Fifty	O
2	-	O
3	seven	O
4	patients	O
5	aged	O
6	<	O
7	55	O
8	years	O
9	with	O
10	acute	O
11	lymphoblastic	O
12	leukemia	O
13	(	O
14	ALL	O
15	)	O
16	in	O
17	second	O
18	or	O
19	third	O
20	bone	O
21	marrow	O
22	(	O
23	BM	O
24	)	O
25	relapse	O
26	or	O
27	refractory	O
28	to	O
29	first	O
30	-	O
31	line	O
32	therapy	O
33	were	O
34	enrolled	O
35	in	O
36	an	O
37	Italian	O
38	cooperative	O
39	study	O
40	.	O

1	The	O
2	dorsal	O
3	nerves	O
4	of	O
5	the	O
6	penis	O
7	were	O
8	anesthetized	O
9	bilaterally	O
10	with	O
11	lidocaine	O
12	.	O

1	In	O
2	the	O
3	brain	O
4	,	O
5	muscarinic	B
6	receptors	I
7	mediate	O
8	motor	O
9	and	O
10	memory	O
11	function	O
12	by	O
13	interaction	O
14	with	O
15	their	O
16	ligand	O
17	acetylcholine	O
18	.	O

1	Early	O
2	-	O
3	onset	O
4	scleral	O
5	necrosis	O
6	after	O
7	iodine	O
8	I	O
9	125	O
10	plaque	O
11	radiotherapy	O
12	for	O
13	ciliochoroidal	O
14	melanoma	O
15	.	O

1	Successful	O
2	interaction	O
3	of	O
4	ARF	B
5	and	O
6	PKC	B
7	-	I
8	alpha	I
9	with	O
10	PLD1	B
11	was	O
12	not	O
13	achieved	O
14	,	O
15	but	O
16	a	O
17	C	O
18	-	O
19	terminal	O
20	fragment	O
21	of	O
22	human	B
23	PLD1	I
24	(	O
25	denoted	O
26	"	O
27	D4	O
28	")	O
29	interacted	O
30	with	O
31	the	O
32	active	O
33	mutant	O
34	of	O
35	RhoA	B
36	,	O
37	RhoAVal	B
38	-	I
39	14	I
40	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	investigated	O
7	the	O
8	signal	O
9	transduction	O
10	pathways	O
11	that	O
12	are	O
13	involved	O
14	in	O
15	OM	B
16	-	O
17	induced	O
18	LDLR	B
19	transcription	O
20	.	O

1	Vacuum	O
2	Rabi	O
3	splitting	O
4	as	O
5	a	O
6	feature	O
7	of	O
8	linear	O
9	-	O
10	dispersion	O
11	theory	O
12	:	O
13	Analysis	O
14	and	O
15	experimental	O
16	observations	O
17	.	O

1	High	O
2	-	O
3	pressure	O
4	effects	O
5	on	O
6	ultrafast	O
7	-	O
8	relaxation	O
9	kinetics	O
10	of	O
11	excitons	O
12	in	O
13	polydiacetylene	O
14	4BCMU	O
15	.	O

1	Drag	O
2	reduction	O
3	in	O
4	turbulent	O
5	flows	O
6	by	O
7	polymers	O
8	.	O

1	Large	O
2	scale	O
3	electronic	O
4	structure	O
5	calculations	O
6	.	O

1	Current	O
2	world	O
3	literature	O
4	.	O

1	These	O
2	results	O
3	show	O
4	that	O
5	Ski	B
6	is	O
7	a	O
8	component	O
9	of	O
10	the	O
11	HDAC	B
12	complex	I
13	and	O
14	that	O
15	Ski	B
16	is	O
17	required	O
18	for	O
19	the	O
20	transcriptional	O
21	repression	O
22	mediated	O
23	by	O
24	this	O
25	complex	O
26	.	O

1	Recombinant	O
2	unr	B
3	acts	O
4	synergistically	O
5	with	O
6	recombinant	O
7	PTB	B
8	to	O
9	stimulate	O
10	translation	O
11	dependent	O
12	on	O
13	the	O
14	rhinovirus	O
15	IRES	O
16	.	O

1	Analysis	O
2	of	O
3	the	O
4	consensus	O
5	binding	O
6	sequence	O
7	and	O
8	the	O
9	DNA	O
10	-	O
11	binding	O
12	domain	O
13	of	O
14	ZF5	B
15	.	O

1	Mapping	O
2	of	O
3	the	O
4	human	B
5	Voltage	I
6	-	I
7	Dependent	I
8	Anion	I
9	Channel	I
10	isoforms	I
11	1	I
12	and	I
13	2	I
14	reconsidered	O
15	.	O

1	Identification	O
2	of	O
3	RNase	B
4	T	I
5	as	O
6	a	O
7	high	O
8	-	O
9	copy	O
10	suppressor	O
11	of	O
12	the	O
13	UV	O
14	sensitivity	O
15	associated	O
16	with	O
17	single	B
18	-	I
19	strand	I
20	DNA	I
21	exonuclease	I
22	deficiency	O
23	in	O
24	Escherichia	O
25	coli	O
26	.	O

1	Inhibition	O
2	of	O
3	phosphatidylinositol	B
4	-	I
5	3	I
6	kinase	I
7	did	O
8	not	O
9	have	O
10	a	O
11	significant	O
12	effect	O
13	on	O
14	p53	B
15	conformation	O
16	but	O
17	did	O
18	have	O
19	a	O
20	weak	O
21	but	O
22	significant	O
23	effect	O
24	on	O
25	Tpo	B
26	-	O
27	enhanced	O
28	viability	O
29	.	O

1	No	O
2	difference	O
3	in	O
4	percentage	O
5	of	O
6	males	O
7	in	O
8	semen	O
9	production	O
10	was	O
11	noted	O
12	between	O
13	strains	O
14	,	O
15	CP	O
16	levels	O
17	,	O
18	or	O
19	feeding	O
20	regimens	O
21	.	O

1	The	O
2	Lp	B
3	mouse	I
4	mutant	I
5	provides	O
6	a	O
7	model	O
8	for	O
9	the	O
10	severe	O
11	human	O
12	neural	O
13	tube	O
14	defect	O
15	(	O
16	NTD	O
17	),	O
18	cranio	O
19	-	O
20	rachischisis	O
21	.	O

1	Further	O
2	analysis	O
3	of	O
4	AP	B
5	-	I
6	1	I
7	DNA	O
8	binding	O
9	activities	O
10	in	O
11	7	O
12	-	O
13	to	O
14	14	O
15	-	O
16	day	O
17	culture	O
18	activated	O
19	HSCs	O
20	led	O
21	to	O
22	the	O
23	discovery	O
24	of	O
25	high	B
26	mobility	I
27	AP	I
28	-	I
29	1	I
30	complexes	I
31	(	O
32	HMAP	B
33	-	I
34	1	I
35	).	O

1	Mutations	O
2	of	O
3	the	O
4	AP	B
5	-	I
6	1	I
7	site	I
8	of	O
9	the	O
10	TIMP	B
11	-	I
12	1	I
13	promoter	I
14	that	O
15	prevented	O
16	formation	O
17	of	O
18	HMAP	B
19	-	I
20	1	I
21	caused	O
22	a	O
23	70	O
24	%	O
25	loss	O
26	of	O
27	activity	O
28	in	O
29	transfected	O
30	activated	O
31	HSCs	O
32	.	O

1	STUDY	O
2	DESIGN	O
3	:	O
4	Salivary	B
5	immunoglobulin	I
6	A	I
7	levels	O
8	of	O
9	each	O
10	of	O
11	20	O
12	subjects	O
13	were	O
14	determined	O
15	on	O
16	3	O
17	occasions	O
18	:	O
19	first	O
20	,	O
21	while	O
22	the	O
23	subject	O
24	was	O
25	still	O
26	smoking	O
27	;	O
28	second	O
29	,	O
30	7	O
31	days	O
32	after	O
33	cessation	O
34	of	O
35	smoking	O
36	;	O
37	third	O
38	,	O
39	on	O
40	the	O
41	14th	O
42	day	O
43	after	O
44	cessation	O
45	.	O

1	Therefore	O
2	,	O
3	high	O
4	set	O
5	-	O
6	up	O
7	accuracy	O
8	and	O
9	reproducibility	O
10	are	O
11	mandatory	O
12	.	O

1	Role	O
2	of	O
3	g2	O
4	in	O
5	relating	O
6	the	O
7	Schwinger	O
8	and	O
9	Gerasimov	O
10	-	O
11	Drell	O
12	-	O
13	Hearn	O
14	sum	O
15	rules	O
16	.	O

1	Spectroscopy	O
2	of	O
3	negative	O
4	ions	O
5	utilizing	O
6	multiphoton	O
7	detachment	O
8	in	O
9	a	O
10	Raman	O
11	coupling	O
12	regime	O
13	.	O

1	Band	O
2	structure	O
3	effects	O
4	of	O
5	transport	O
6	properties	O
7	in	O
8	icosahedral	O
9	quasicrystals	O
10	.	O

1	Acoustic	O
2	transmission	O
3	spectra	O
4	in	O
5	the	O
6	Penrose	O
7	lattice	O
8	.	O

1	Two	O
2	-	O
3	Channel	O
4	Kondo	O
5	Lattice	O
6	:	O
7	An	O
8	Incoherent	O
9	Metal	O
10	.	O

1	Basal	O
2	midexpiratory	O
3	lower	O
4	esophageal	O
5	sphincter	O
6	pressure	O
7	was	O
8	similar	O
9	in	O
10	the	O
11	study	O
12	group	O
13	(	O
14	mean	O
15	[	O
16	SD	O
17	]	O
18	20	O
19	.	O
20	1	O
21	[	O
22	9	O
23	.	O
24	1	O
25	]	O
26	mmHg	O
27	)	O
28	and	O
29	controls	O
30	(	O
31	17	O
32	.	O
33	6	O
34	[	O
35	6	O
36	.	O
37	0	O
38	]	O
39	mmHg	O
40	);	O
41	the	O
42	pressure	O
43	did	O
44	not	O
45	change	O
46	following	O
47	EVS	O
48	or	O
49	EVL	O
50	.	O

1	CPDs	O
2	at	O
3	these	O
4	three	O
5	sites	O
6	may	O
7	partially	O
8	displace	O
9	TFIIIA	B
10	,	O
11	thereby	O
12	enabling	O
13	rapid	O
14	repair	O
15	.	O

1	There	O
2	was	O
3	no	O
4	difference	O
5	in	O
6	the	O
7	hormone	O
8	receptor	O
9	status	O
10	between	O
11	the	O
12	cases	O
13	without	O
14	lymph	O
15	node	O
16	metastases	O
17	and	O
18	with	O
19	lymph	O
20	node	O
21	metastases	O
22	,	O
23	'	O
24	clandestine	O
25	'	O
26	or	O
27	macrometastases	O
28	.	O

1	On	O
2	the	O
3	other	O
4	hand	O
5	,	O
6	subjects	O
7	with	O
8	air	O
9	trapping	O
10	(	O
11	residual	O
12	volume	O
13	(	O
14	RV	O
15	)/	O
16	total	O
17	lung	O
18	capacity	O
19	(	O
20	TLC	O
21	)	O
22	>	O
23	37	O
24	%)	O
25	disclosed	O
26	not	O
27	only	O
28	a	O
29	higher	O
30	n	O
31	(	O
32	mit	O
33	)	O
34	(	O
35	0	O
36	.	O
37	63	O
38	+/-	O
39	0	O
40	.	O
41	17	O
42	versus	O
43	0	O
44	.	O
45	43	O
46	+/-	O
47	0	O
48	.	O
49	07	O
50	mt	O
51	x	O
52	microm	O
53	(-	O
54	2	O
55	),	O
56	p	O
57	<	O
58	0	O
59	.	O
60	05	O
61	)	O
62	but	O
63	shorter	O
64	sarcomeres	O
65	(	O
66	L	O
67	(	O
68	sar	O
69	))	O
70	than	O
71	subjects	O
72	without	O
73	this	O
74	functional	O
75	abnormality	O
76	(	O
77	2	O
78	.	O
79	08	O
80	+/-	O
81	0	O
82	.	O
83	16	O
84	to	O
85	2	O
86	.	O
87	27	O
88	+/-	O
89	0	O
90	.	O
91	15	O
92	microm	O
93	,	O
94	p	O
95	<	O
96	0	O
97	.	O
98	05	O
99	).	O

1	Gel	O
2	filtration	O
3	,	O
4	sedimentation	O
5	velocity	O
6	,	O
7	and	O
8	immunoprecipitation	O
9	experiments	O
10	revealed	O
11	that	O
12	beta4	O
13	is	O
14	a	O
15	component	O
16	of	O
17	a	O
18	multisubunit	O
19	complex	O
20	(	O
21	AP	B
22	-	I
23	4	I
24	)	O
25	that	O
26	also	O
27	contains	O
28	the	O
29	sigma4	O
30	polypeptide	O
31	and	O
32	two	O
33	additional	O
34	adaptor	O
35	subunit	O
36	homologs	O
37	named	O
38	mu4	O
39	(	O
40	mu	O
41	-	O
42	ARP2	O
43	)	O
44	and	O
45	epsilon	O
46	.	O

1	Cyclin	B
2	D1	I
3	-	I
4	associated	I
5	kinase	I
6	activity	O
7	and	O
8	protein	O
9	levels	O
10	were	O
11	increased	O
12	in	O
13	mammary	O
14	tumors	O
15	from	O
16	murine	O
17	mammary	O
18	tumor	O
19	virus	O
20	-	O
21	pp60	B
22	(	O
23	c	B
24	-	I
25	src527F	I
26	)	O
27	transgenic	O
28	mice	O
29	.	O

1	The	O
2	SH2	B
3	domain	I
4	-	I
5	containing	I
6	inositol	I
7	5	I
8	'-	I
9	phosphatase	I
10	(	O
11	SHIP	B
12	)	O
13	recruits	O
14	the	O
15	p85	B
16	subunit	I
17	of	O
18	phosphoinositide	B
19	3	I
20	-	I
21	kinase	I
22	during	O
23	FcgammaRIIb1	B
24	-	O
25	mediated	O
26	inhibition	O
27	of	O
28	B	B
29	cell	I
30	receptor	I
31	signaling	O
32	.	O

1	We	O
2	show	O
3	that	O
4	the	O
5	mouse	O
6	genome	O
7	contains	O
8	four	O
9	copies	O
10	of	O
11	the	O
12	ubc	B
13	-	I
14	9	I
15	gene	I
16	.	O

1	An	O
2	increase	O
3	in	O
4	bone	O
5	mineral	O
6	density	O
7	at	O
8	the	O
9	spine	O
10	,	O
11	total	O
12	hip	O
13	,	O
14	and	O
15	total	O
16	body	O
17	has	O
18	been	O
19	reported	O
20	with	O
21	raloxifene	O
22	but	O
23	seems	O
24	to	O
25	be	O
26	less	O
27	than	O
28	that	O
29	seen	O
30	with	O
31	estrogen	O
32	or	O
33	alendronate	O
34	therapy	O
35	.	O

1	However	O
2	,	O
3	in	O
4	those	O
5	studies	O
6	due	O
7	to	O
8	the	O
9	presence	O
10	of	O
11	thiol	O
12	agents	O
13	in	O
14	the	O
15	PKC	B
16	preparations	O
17	,	O
18	the	O
19	sensitive	O
20	reaction	O
21	of	O
22	BPO	O
23	with	O
24	redox	O
25	-	O
26	active	O
27	cysteine	O
28	residues	O
29	in	O
30	PKC	B
31	was	O
32	not	O
33	observed	O
34	.	O

1	Interestingly	O
2	,	O
3	Csx	B
4	/	O
5	Nkx2	B
6	.	O

1	We	O
2	also	O
3	identified	O
4	an	O
5	alternative	O
6	spliced	O
7	form	O
8	of	O
9	Lyp	B
10	RNA	I
11	,	O
12	Lyp2	B
13	.	O

1	The	O
2	costs	O
3	were	O
4	DM	O
5	11	O
6	,	O
7	562	O
8	for	O
9	a	O
10	PE	O
11	,	O
12	DM	O
13	12	O
14	,	O
15	477	O
16	for	O
17	a	O
18	VR	O
19	and	O
20	DM	O
21	7	O
22	,	O
23	532	O
24	for	O
25	a	O
26	MR	O
27	.	O

1	We	O
2	now	O
3	provide	O
4	evidence	O
5	for	O
6	physical	O
7	and	O
8	functional	O
9	interaction	O
10	between	O
11	Doa4	B
12	and	O
13	the	O
14	proteasome	O
15	.	O

1	Independent	O
2	splicing	O
3	events	O
4	involve	O
5	three	O
6	previously	O
7	described	O
8	cassette	O
9	exons	O
10	,	O
11	which	O
12	are	O
13	predicted	O
14	to	O
15	encode	O
16	most	O
17	of	O
18	the	O
19	second	O
20	transmembrane	O
21	domain	O
22	.	O

1	Each	O
2	of	O
3	these	O
4	genes	O
5	contains	O
6	a	O
7	putative	O
8	upstream	O
9	ORF	O
10	,	O
11	while	O
12	STA2	B
13	has	O
14	two	O
15	additional	O
16	in	O
17	-	O
18	frame	O
19	AUG	O
20	codons	O
21	5	O
22	'	O
23	to	O
24	the	O
25	major	O
26	cistron	O
27	.	O

1	Nipponbare	O
2	as	O
3	well	O
4	as	O
5	O	O
6	.	O
7	australiensis	O
8	.	O

1	In	O
2	addition	O
3	,	O
4	mapping	O
5	of	O
6	the	O
7	promoter	O
8	region	O
9	and	O
10	the	O
11	identification	O
12	of	O
13	putative	O
14	promoter	O
15	regulatory	O
16	sequences	O
17	should	O
18	give	O
19	insight	O
20	into	O
21	the	O
22	transcriptional	O
23	regulation	O
24	of	O
25	UCP2	B
26	expression	O
27	--	O
28	in	O
29	particular	O
30	by	O
31	anyone	O
32	of	O
33	the	O
34	above	O
35	mentioned	O
36	factors	O
37	--	O
38	in	O
39	vitro	O
40	and	O
41	in	O
42	vivo	O
43	.	O

1	The	O
2	rate	O
3	of	O
4	resectability	O
5	is	O
6	low	O
7	and	O
8	5	O
9	-	O
10	year	O
11	survival	O
12	is	O
13	very	O
14	poor	O
15	.	O

1	In	O
2	order	O
3	to	O
4	better	O
5	characterize	O
6	the	O
7	distribution	O
8	of	O
9	ML	O
10	and	O
11	MAP	O
12	estimates	O
13	under	O
14	these	O
15	conditions	O
16	,	O
17	we	O
18	derive	O
19	a	O
20	point	O
21	approximation	O
22	to	O
23	density	O
24	values	O
25	of	O
26	the	O
27	conditional	O
28	distribution	O
29	of	O
30	such	O
31	estimates	O
32	.	O

1	RT	O
2	-	O
3	PCR	O
4	was	O
5	performed	O
6	using	O
7	previously	O
8	reported	O
9	degenerate	O
10	oligonucleotide	O
11	primers	O
12	to	O
13	the	O
14	ligand	O
15	binding	O
16	domain	O
17	(	O
18	LBD	O
19	)	O
20	of	O
21	known	O
22	beta	B
23	integrin	I
24	subunits	I
25	and	O
26	Bge	B
27	cDNA	I
28	.	O

1	The	O
2	lowest	O
3	culture	O
4	failure	O
5	rate	O
6	of	O
7	0	O
8	.	O
9	2	O
10	per	O
11	cent	O
12	was	O
13	found	O
14	after	O
15	EAF	O
16	compared	O
17	with	O
18	0	O
19	.	O
20	9	O
21	per	O
22	cent	O
23	among	O
24	CVS	O
25	.	O

1	Ectopic	O
2	expression	O
3	of	O
4	d	B
5	-	I
6	axin	I
7	inhibited	O
8	Wingless	B
9	signaling	O
10	.	O

1	The	O
2	corresponding	O
3	differences	O
4	in	O
5	FVIIa	B
6	and	O
7	PAI	B
8	-	I
9	1	I
10	were	O
11	not	O
12	statistically	O
13	significant	O
14	.	O

1	Primary	O
2	and	O
3	secondary	O
4	structural	O
5	elements	O
6	required	O
7	for	O
8	synthesis	O
9	of	O
10	barley	O
11	yellow	O
12	dwarf	O
13	virus	O
14	subgenomic	O
15	RNA1	O
16	.	O

1	On	O
2	the	O
3	other	O
4	side	O
5	,	O
6	when	O
7	the	O
8	aortic	O
9	ring	O
10	was	O
11	perfused	O
12	with	O
13	L	O
14	-	O
15	NNA	O
16	(	O
17	NO	O
18	-	O
19	synthesis	O
20	inhibitor	O
21	)	O
22	or	O
23	methylene	O
24	blue	O
25	(	O
26	soluble	O
27	cGMPase	B
28	inhibitor	O
29	),	O
30	the	O
31	changes	O
32	could	O
33	be	O
34	attenuated	O
35	.	O

1	Nevertheless	O
2	,	O
3	inactivation	O
4	of	O
5	the	O
6	cyclin	B
7	E	I
8	-	O
9	Cdk2	B
10	complex	O
11	in	O
12	response	O
13	to	O
14	mitogen	O
15	starvation	O
16	occurs	O
17	normally	O
18	in	O
19	MEFs	O
20	that	O
21	have	O
22	a	O
23	homozygous	O
24	deletion	O
25	of	O
26	the	O
27	p27	B
28	gene	I
29	.	O

1	Identification	O
2	and	O
3	characterization	O
4	of	O
5	IS2404	B
6	and	O
7	IS2606	B
8	:	O
9	two	O
10	distinct	O
11	repeated	O
12	sequences	O
13	for	O
14	detection	O
15	of	O
16	Mycobacterium	O
17	ulcerans	O
18	by	O
19	PCR	O
20	.	O

1	Taken	O
2	together	O
3	,	O
4	these	O
5	results	O
6	are	O
7	consistent	O
8	with	O
9	the	O
10	possibility	O
11	that	O
12	p202	B
13	protein	I
14	contributes	O
15	to	O
16	the	O
17	cell	O
18	growth	O
19	retardation	O
20	activity	O
21	of	O
22	the	O
23	IFNs	B
24	,	O
25	at	O
26	least	O
27	in	O
28	part	O
29	,	O
30	by	O
31	modulating	O
32	p21	B
33	protein	I
34	levels	O
35	.	O

1	Similar	O
2	results	O
3	were	O
4	also	O
5	obtained	O
6	with	O
7	a	O
8	HepG2	O
9	hepatoblastoma	O
10	cell	O
11	line	O
12	carrying	O
13	wt	B
14	p53	I
15	.	O

1	Partial	O
2	sequencing	O
3	of	O
4	the	O
5	region	O
6	downstream	O
7	of	O
8	ORF	B
9	-	I
10	Pto	I
11	revealed	O
12	homology	O
13	to	O
14	the	O
15	ru	B
16	/	I
17	AB	I
18	genes	I
19	,	O
20	involved	O
21	in	O
22	UV	O
23	resistance	O
24	,	O
25	from	O
26	plasmid	O
27	pPSR1	O
28	.	O

1	The	O
2	MSY2	B
3	associated	O
4	kinase	O
5	is	O
6	not	O
7	casein	B
8	kinase	I
9	2	I
10	,	O
11	the	O
12	kinase	O
13	believed	O
14	to	O
15	phosphorylate	O
16	mRNP3	B
17	+	I
18	4	I
19	in	O
20	oocytes	O
21	,	O
22	but	O
23	a	O
24	yet	O
25	unidentified	O
26	kinase	O
27	.	O

1	This	O
2	suggests	O
3	that	O
4	helicase	B
5	-	I
6	like	I
7	genes	I
8	may	O
9	be	O
10	involved	O
11	in	O
12	the	O
13	biosynthesis	O
14	of	O
15	nucleic	O
16	acids	O
17	and	O
18	proteins	O
19	,	O
20	and	O
21	that	O
22	the	O
23	genes	O
24	can	O
25	be	O
26	transcriptionally	O
27	activated	O
28	by	O
29	heat	O
30	shock	O
31	to	O
32	compensate	O
33	for	O
34	the	O
35	repressed	O
36	synthesis	O
37	of	O
38	mRNA	O
39	and	O
40	protein	O
41	.	O

1	These	O
2	data	O
3	provide	O
4	the	O
5	molecular	O
6	tools	O
7	for	O
8	the	O
9	final	O
10	identification	O
11	of	O
12	the	O
13	MKS	B
14	and	O
15	the	O
16	MUL	B
17	genes	I
18	.	O

1	The	O
2	H	O
3	-	O
4	reflex	O
5	recovery	O
6	curve	O
7	was	O
8	obtained	O
9	after	O
10	stimulation	O
11	of	O
12	the	O
13	median	O
14	nerve	O
15	at	O
16	the	O
17	elbow	O
18	and	O
19	recording	O
20	from	O
21	the	O
22	flexor	O
23	carpi	O
24	radialis	O
25	.	O

1	The	O
2	origins	O
3	of	O
4	reflected	O
5	light	O
6	changes	O
7	associated	O
8	with	O
9	neuronal	O
10	activity	O
11	(	O
12	optical	O
13	signals	O
14	)	O
15	were	O
16	investigated	O
17	in	O
18	rat	O
19	somatosensory	O
20	cortex	O
21	with	O
22	optical	O
23	imaging	O
24	,	O
25	microspectrophotometry	O
26	,	O
27	and	O
28	laser	O
29	-	O
30	Doppler	O
31	flowmetry	O
32	,	O
33	and	O
34	dynamic	O
35	changes	O
36	in	O
37	local	O
38	hemoglobin	B
39	concentration	O
40	and	O
41	oxygenation	O
42	were	O
43	focused	O
44	on	O
45	.	O

1	Human	B
2	neuronal	I
3	Elav	I
4	-	I
5	like	I
6	proteins	I
7	contain	O
8	three	O
9	RNP	O
10	-	O
11	type	O
12	RNA	O
13	recognition	O
14	motifs	O
15	(	O
16	RRMs	O
17	).	O

1	Comparison	O
2	of	O
3	frequencies	O
4	of	O
5	atrial	O
6	fibrillation	O
7	after	O
8	coronary	O
9	artery	O
10	bypass	O
11	grafting	O
12	with	O
13	and	O
14	without	O
15	the	O
16	use	O
17	of	O
18	cardiopulmonary	O
19	bypass	O
20	.	O

1	The	O
2	results	O
3	of	O
4	supershift	O
5	analysis	O
6	using	O
7	specific	O
8	antibodies	O
9	against	O
10	transcription	O
11	factors	O
12	suggested	O
13	that	O
14	both	O
15	binding	O
16	complexes	O
17	contained	O
18	the	O
19	NF	B
20	-	I
21	kappaB	I
22	components	O
23	p50	B
24	and	O
25	p65	B
26	,	O
27	and	O
28	did	O
29	not	O
30	contain	O
31	other	O
32	NF	B
33	-	I
34	kappaB	I
35	proteins	I
36	(	O
37	p52	B
38	,	O
39	c	B
40	-	I
41	Rel	I
42	,	O
43	Rel	B
44	B	I
45	),	O
46	AP	B
47	-	I
48	1	I
49	proteins	I
50	(	O
51	c	B
52	-	I
53	Fos	I
54	,	O
55	C	B
56	-	I
57	Jun	I
58	),	O
59	CREB	B
60	or	O
61	C	B
62	/	I
63	EBPbeta	I
64	(	O
65	NF	B
66	-	I
67	IL6	I
68	).	O

1	A	O
2	set	O
3	of	O
4	peptides	O
5	corresponding	O
6	to	O
7	the	O
8	individual	O
9	elements	O
10	of	O
11	secondary	O
12	structure	O
13	derived	O
14	from	O
15	the	O
16	N	O
17	-	O
18	terminal	O
19	domain	O
20	of	O
21	the	O
22	ribosomal	B
23	protein	I
24	L9	I
25	have	O
26	been	O
27	synthesized	O
28	.	O

1	The	O
2	results	O
3	showed	O
4	that	O
5	IFN	B
6	-	I
7	gamma	I
8	stimulated	O
9	the	O
10	rapid	O
11	accumulation	O
12	of	O
13	interferon	B
14	regulated	I
15	factor	I
16	(	I
17	IRF	I
18	)-	I
19	1	I
20	mRNA	I
21	,	O
22	followed	O
23	by	O
24	a	O
25	delayed	O
26	and	O
27	dose	O
28	-	O
29	dependent	O
30	inhibition	O
31	of	O
32	alpha1	B
33	(	I
34	I	I
35	)	I
36	procollagen	I
37	mRNA	I
38	expression	O
39	in	O
40	skin	O
41	fibroblasts	O
42	from	O
43	several	O
44	different	O
45	donors	O
46	.	O

1	Functional	O
2	domains	O
3	of	O
4	c	B
5	-	I
6	myc	I
7	promoter	I
8	binding	I
9	protein	I
10	1	I
11	involved	O
12	in	O
13	transcriptional	O
14	repression	O
15	and	O
16	cell	O
17	growth	O
18	regulation	O
19	.	O

1	Therefore	O
2	,	O
3	we	O
4	have	O
5	named	O
6	this	O
7	gene	O
8	UBP43	B
9	.	O

1	These	O
2	results	O
3	continue	O
4	to	O
5	support	O
6	the	O
7	hypothesis	O
8	that	O
9	HS2	O
10	,	O
11	HS3	O
12	,	O
13	and	O
14	HS4	O
15	act	O
16	as	O
17	a	O
18	single	O
19	,	O
20	integral	O
21	unit	O
22	to	O
23	regulate	O
24	human	B
25	globin	I
26	gene	I
27	transcription	O
28	as	O
29	a	O
30	holocomplex	O
31	,	O
32	but	O
33	they	O
34	can	O
35	also	O
36	be	O
37	interpreted	O
38	to	O
39	say	O
40	that	O
41	formation	O
42	of	O
43	a	O
44	DNase	B
45	I	I
46	hypersensitive	O
47	holocomplex	O
48	alone	O
49	is	O
50	not	O
51	sufficient	O
52	for	O
53	mediating	O
54	high	O
55	-	O
56	level	O
57	globin	B
58	gene	I
59	transcription	O
60	.	O

1	To	O
2	identify	O
3	additional	O
4	non	O
5	-	O
6	Sir	B
7	factors	I
8	that	O
9	affect	O
10	rDNA	O
11	silencing	O
12	,	O
13	we	O
14	performed	O
15	a	O
16	genetic	O
17	screen	O
18	designed	O
19	to	O
20	isolate	O
21	mutations	O
22	which	O
23	alter	O
24	the	O
25	expression	O
26	of	O
27	reporter	O
28	genes	O
29	integrated	O
30	within	O
31	the	O
32	rDNA	O
33	.	O

1	Because	O
2	there	O
3	is	O
4	great	O
5	need	O
6	for	O
7	iron	O
8	in	O
9	the	O
10	EPO	B
11	-	O
12	stimulated	O
13	erythroid	O
14	progenitors	O
15	,	O
16	it	O
17	is	O
18	essential	O
19	that	O
20	serum	B
21	ferritin	I
22	and	O
23	transferrin	B
24	saturation	O
25	levels	O
26	should	O
27	be	O
28	maintained	O
29	over	O
30	300	O
31	microg	O
32	/	O
33	liter	O
34	and	O
35	30	O
36	%,	O
37	respectively	O
38	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	the	O
6	p33	B
7	subunit	I
8	of	O
9	eIF3	B
10	plays	O
11	an	O
12	important	O
13	role	O
14	in	O
15	the	O
16	initiation	O
17	phase	O
18	of	O
19	protein	O
20	synthesis	O
21	and	O
22	that	O
23	its	O
24	RNA	O
25	-	O
26	binding	O
27	domain	O
28	is	O
29	required	O
30	for	O
31	optimal	O
32	activity	O
33	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	elucidate	O
7	signaling	O
8	pathways	O
9	induced	O
10	by	O
11	photodynamic	O
12	therapy	O
13	(	O
14	PDT	O
15	)	O
16	with	O
17	hypericin	O
18	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	ATF	B
6	-	I
7	2	I
8	plays	O
9	a	O
10	central	O
11	role	O
12	in	O
13	TGF	B
14	-	I
15	beta	I
16	signaling	O
17	by	O
18	acting	O
19	as	O
20	a	O
21	common	O
22	nuclear	O
23	target	O
24	of	O
25	both	O
26	Smad	B
27	and	O
28	TAK1	B
29	pathways	O
30	.	O

1	KEY	O
2	WORDS	O
3	:	O
4	Melaleuca	O
5	;	O
6	Lake	O
7	Okeechobee	O
8	;	O
9	Littoral	O
10	zone	O
11	;	O
12	Water	O
13	level	O
14	;	O
15	Regulation	O
16	schedule	O

1	The	O
2	systolic	O
3	peak	O
4	of	O
5	pulmonary	O
6	vein	O
7	was	O
8	higher	O
9	than	O
10	the	O
11	diastolic	O
12	peak	O
13	in	O
14	45	O
15	out	O
16	of	O
17	56	O
18	cases	O
19	.	O

1	Specimens	O
2	were	O
3	assayed	O
4	for	O
5	alpha	B
6	-	I
7	fetoprotein	I
8	,	O
9	unconjugated	O
10	estriol	O
11	,	O
12	free	O
13	alpha	B
14	hCG	I
15	,	O
16	and	O
17	total	O
18	hCG	B
19	.	O

1	FASEB	O
2	Federal	O
3	Funding	O
4	Consensus	O
5	Conference	O
6	FY	O
7	2000	O
8	.	O

1	The	O
2	following	O
3	data	O
4	were	O
5	recorded	O
6	at	O
7	arrival	O
8	in	O
9	the	O
10	intensive	O
11	care	O
12	unit	O
13	6	O
14	,	O
15	12	O
16	,	O
17	24	O
18	,	O
19	and	O
20	48	O
21	hours	O
22	after	O
23	termination	O
24	of	O
25	CPB	O
26	:	O
27	heart	O
28	rate	O
29	,	O
30	blood	O
31	pressure	O
32	,	O
33	left	O
34	atrial	O
35	pressure	O
36	,	O
37	central	O
38	-	O
39	peripheral	O
40	temperature	O
41	difference	O
42	,	O
43	arterial	O
44	-	O
45	central	O
46	venous	O
47	oxygen	O
48	saturation	O
49	difference	O
50	,	O
51	urine	O
52	output	O
53	,	O
54	serum	O
55	creatinine	O
56	,	O
57	lactate	O
58	and	O
59	neutrophil	B
60	elastase	I
61	levels	O
62	,	O
63	the	O
64	Doppler	O
65	echocardiographic	O
66	factors	O
67	shortening	O
68	fraction	O
69	and	O
70	preejection	O
71	period	O
72	/	O
73	left	O
74	-	O
75	ventricular	O
76	ejection	O
77	time	O
78	,	O
79	and	O
80	cumulative	O
81	doses	O
82	of	O
83	catecholamines	O
84	(	O
85	epinephrine	O
86	),	O
87	enoximone	O
88	,	O
89	and	O
90	furosemide	O
91	.	O

1	MDS1	B
2	/	O
3	EVI1	B
4	,	O
5	located	O
6	on	O
7	chromosome	O
8	3	O
9	band	O
10	q26	O
11	,	O
12	encodes	O
13	a	O
14	zinc	B
15	-	I
16	finger	I
17	DNA	I
18	-	I
19	binding	I
20	transcription	I
21	activator	I
22	not	O
23	detected	O
24	in	O
25	normal	O
26	hematopoietic	O
27	cells	O
28	but	O
29	expressed	O
30	in	O
31	several	O
32	normal	O
33	tissues	O
34	.	O

1	Analysis	O
2	of	O
3	the	O
4	protein	O
5	sequences	O
6	of	O
7	these	O
8	two	O
9	replicases	B
10	,	O
11	together	O
12	with	O
13	previously	O
14	characterized	O
15	H	B
16	.	I
17	pylori	I
18	plasmid	I
19	replication	I
20	proteins	I
21	,	O
22	supports	O
23	the	O
24	formation	O
25	of	O
26	a	O
27	distinct	O
28	class	O
29	of	O
30	H	B
31	.	I
32	pylori	I
33	plasmid	I
34	proteins	I
35	.	O

1	The	O
2	JTc	O
3	delta	O
4	among	O
5	the	O
6	three	O
7	groups	O
8	did	O
9	not	O
10	differ	O
11	as	O
12	well	O
13	:	O
14	JTc	O
15	delta	O
16	of	O
17	the	O
18	VT	O
19	group	O
20	was	O
21	70	O
22	ms	O
23	+/-	O
24	30	O
25	ms	O
26	,	O
27	the	O
28	JTc	O
29	delta	O
30	of	O
31	the	O
32	PVC	O
33	group	O
34	was	O
35	60	O
36	msec	O
37	+/-	O
38	25	O
39	msec	O
40	,	O
41	and	O
42	the	O
43	JTc	O
44	delta	O
45	of	O
46	the	O
47	control	O
48	group	O
49	was	O
50	70	O
51	ms	O
52	+/-	O
53	30	O
54	ms	O
55	.	O

1	In	O
2	contrast	O
3	,	O
4	deletion	O
5	of	O
6	the	O
7	upstream	O
8	portion	O
9	of	O
10	the	O
11	delta	O
12	promoter	O
13	led	O
14	to	O
15	a	O
16	10	O
17	fold	O
18	decrease	O
19	in	O
20	expression	O
21	.	O

1	Site	O
2	-	O
3	directed	O
4	mutagenesis	O
5	of	O
6	binding	O
7	sites	O
8	for	O
9	the	O
10	repressor	B
11	proteins	I
12	BP1	I
13	and	O
14	BP2	B
15	in	O
16	the	O
17	upstream	O
18	portion	O
19	of	O
20	the	O
21	beta	B
22	globin	I
23	gene	I
24	flanking	I
25	region	I
26	led	O
27	to	O
28	a	O
29	4	O
30	-	O
31	6	O
32	fold	O
33	increase	O
34	in	O
35	promoter	O
36	activity	O
37	.	O

1	However	O
2	,	O
3	with	O
4	the	O
5	alpha1	O
6	antagonist	O
7	prazosin	O
8	(	O
9	5	O
10	x	O
11	10	O
12	(-	O
13	8	O
14	)-	O
15	5	O
16	x	O
17	10	O
18	(-	O
19	7	O
20	)	O
21	M	O
22	),	O
23	no	O
24	relaxation	O
25	occurred	O
26	.	O

1	Differential	O
2	expression	O
3	of	O
4	AP	B
5	-	I
6	2alpha	I
7	and	O
8	AP	B
9	-	I
10	2beta	I
11	in	O
12	the	O
13	developing	O
14	chick	O
15	retina	O
16	:	O
17	repression	O
18	of	O
19	R	B
20	-	I
21	FABP	I
22	promoter	I
23	activity	O
24	by	O
25	AP	B
26	-	I
27	2	I
28	.	O

1	The	O
2	algorithm	O
3	also	O
4	limited	O
5	TG	O
6	to	O
7	20	O
8	and	O
9	64	O
10	%,	O
11	apoB	B
12	to	O
13	6	O
14	and	O
15	20	O
16	%,	O
17	and	O
18	Lp	B
19	(	I
20	a	I
21	)	I
22	to	O
23	15	O
24	and	O
25	56	O
26	%,	O
27	of	O
28	low	O
29	-	O
30	and	O
31	high	O
32	-	O
33	risk	O
34	groups	O
35	,	O
36	respectively	O
37	.	O

1	The	O
2	mean	O
3	value	O
4	of	O
5	the	O
6	CD79b	B
7	to	O
8	the	O
9	CD79b	B
10	internally	O
11	deleted	O
12	ratio	O
13	was	O
14	0	O
15	.	O
16	64	O
17	+/-	O
18	0	O
19	.	O
20	20	O
21	SD	O
22	in	O
23	normal	O
24	donors	O
25	and	O
26	0	O
27	.	O
28	44	O
29	+/-	O
30	0	O
31	.	O
32	27	O
33	SD	O
34	in	O
35	B	O
36	-	O
37	CLL	O
38	(	O
39	P	O
40	=.	O
41	01	O
42	).	O

1	As	O
2	normal	O
3	B	O
4	cells	O
5	also	O
6	present	O
7	this	O
8	variant	O
9	,	O
10	the	O
11	mechanism	O
12	of	O
13	CD79b	B
14	posttranscriptional	O
15	regulation	O
16	might	O
17	reflect	O
18	the	O
19	activation	O
20	stage	O
21	of	O
22	the	O
23	normal	O
24	B	O
25	cell	O
26	from	O
27	which	O
28	B	O
29	-	O
30	CLL	O
31	derives	O
32	.	O

1	Conformational	O
2	studies	O
3	combining	O
4	secondary	O
5	structure	O
6	predictions	O
7	,	O
8	CD	O
9	and	O
10	NMR	O
11	spectroscopy	O
12	together	O
13	with	O
14	ELISA	O
15	assays	O
16	,	O
17	showed	O
18	that	O
19	the	O
20	greater	O
21	is	O
22	the	O
23	propensity	O
24	of	O
25	the	O
26	epitope	O
27	for	O
28	helix	O
29	formation	O
30	the	O
31	higher	O
32	is	O
33	the	O
34	recognition	O
35	by	O
36	anti	B
37	-	I
38	K159	I
39	.	O

1	Schwab	O
2	and	O
3	England	O
4	ADL	O
5	scores	O
6	in	O
7	the	O
8	"	O
9	off	O
10	"	O
11	state	O
12	were	O
13	improved	O
14	by	O
15	18	O
16	%	O
17	and	O
18	in	O
19	the	O
20	"	O
21	on	O
22	"	O
23	state	O
24	the	O
25	scores	O
26	declined	O
27	by	O
28	2	O
29	%.	O

1	High	O
2	-	O
3	level	O
4	gains	O
5	(	O
6	HLGs	O
7	)	O
8	indicative	O
9	of	O
10	gene	O
11	amplifications	O
12	were	O
13	identified	O
14	at	O
15	11q13	O
16	in	O
17	two	O
18	cases	O
19	,	O
20	and	O
21	in	O
22	one	O
23	case	O
24	each	O
25	at	O
26	2q33	O
27	-	O
28	34	O
29	,	O
30	3q25	O
31	-	O
32	29	O
33	,	O
34	5p15	O
35	.	O
36	1	O
37	-	O
38	15	O
39	.	O
40	2	O
41	,	O
42	7q21	O
43	-	O
44	22	O
45	,	O
46	11p11	O
47	.	O
48	2	O
49	,	O
50	12p11	O
51	.	O
52	2	O
53	-	O
54	12	O
55	,	O
56	and	O
57	13q34	O
58	.	O

1	With	O
2	respect	O
3	to	O
4	the	O
5	distribution	O
6	of	O
7	active	O
8	MREs	O
9	over	O
10	the	O
11	promoter	O
12	region	O
13	,	O
14	the	O
15	hMT	B
16	-	I
17	IIA	I
18	gene	I
19	is	O
20	largely	O
21	different	O
22	from	O
23	the	O
24	mouse	O
25	metallothionein	B
26	-	I
27	I	I
28	gene	I
29	,	O
30	suggesting	O
31	that	O
32	MRE	O
33	arrangement	O
34	is	O
35	not	O
36	an	O
37	important	O
38	factor	O
39	for	O
40	metal	O
41	regulation	O
42	.	O

1	The	O
2	cDNA	O
3	was	O
4	expressed	O
5	in	O
6	Saccharomyces	O
7	cerevisiae	O
8	under	O
9	the	O
10	control	O
11	of	O
12	the	O
13	yeast	B
14	triose	I
15	phosphate	I
16	isomerase	I
17	promoter	I
18	.	O

1	Interestingly	O
2	,	O
3	the	O
4	RNA	O
5	sequences	O
6	selected	O
7	by	O
8	the	O
9	mutated	O
10	zinc	B
11	knuckle	I
12	9G8	I
13	variant	I
14	are	O
15	efficiently	O
16	recognized	O
17	by	O
18	SRp20	B
19	,	O
20	in	O
21	agreement	O
22	with	O
23	the	O
24	fact	O
25	that	O
26	the	O
27	RBD	O
28	of	O
29	9G8	B
30	and	O
31	SRp20	B
32	are	O
33	similar	O
34	.	O

1	Topoisomerase	B
2	II	I
3	is	O
4	a	O
5	major	O
6	target	O
7	of	O
8	the	O
9	protein	B
10	kinase	I
11	casein	I
12	kinase	I
13	2	I
14	(	O
15	PK	B
16	CK2	I
17	)	O
18	in	O
19	vivo	O
20	.	O

1	Recent	O
2	work	O
3	in	O
4	this	O
5	laboratory	O
6	has	O
7	shown	O
8	that	O
9	the	O
10	gene	O
11	coding	O
12	for	O
13	acetate	B
14	kinase	I
15	(	O
16	ackA	B
17	)	O
18	in	O
19	Sinorhizobium	O
20	meliloti	O
21	is	O
22	up	O
23	-	O
24	regulated	O
25	in	O
26	response	O
27	to	O
28	phosphate	O
29	limitation	O
30	.	O

1	All	O
2	numbers	O
3	refer	O
4	to	O
5	nucleotide	O
6	positions	O
7	on	O
8	the	O
9	wild	O
10	-	O
11	type	O
12	HIV	O
13	-	O
14	1	O
15	transcript	O
16	.	O

1	Sequence	O
2	analysis	O
3	revealed	O
4	that	O
5	the	O
6	MEMA	B
7	protein	I
8	is	O
9	identical	O
10	with	O
11	a	O
12	160	B
13	kDa	I
14	nuclear	I
15	'	I
16	domain	I
17	rich	I
18	in	I
19	serines	I
20	'	I
21	(	I
22	DRS	I
23	)	I
24	protein	I
25	occurring	O
26	free	O
27	in	O
28	the	O
29	nucleoplasm	O
30	and	O
31	in	O
32	U2	B
33	-	I
34	ribonucleoprotein	I
35	structures	I
36	.	O

1	Here	O
2	,	O
3	we	O
4	report	O
5	the	O
6	complete	O
7	structure	O
8	of	O
9	the	O
10	human	B
11	topoisomerase	I
12	IIalpha	I
13	gene	I
14	,	O
15	which	O
16	consists	O
17	of	O
18	35	O
19	exons	O
20	spanning	O
21	27	O
22	.	O
23	5	O
24	kb	O
25	.	O

1	Dopaminergic	O
2	modulation	O
3	of	O
4	transcallosal	O
5	activity	O
6	of	O
7	cat	O
8	motor	O
9	cortical	O
10	neurons	O
11	.	O

1	Previous	O
2	studies	O
3	characterized	O
4	a	O
5	cytokine	O
6	-	O
7	inducible	O
8	,	O
9	functional	O
10	nuclear	B
11	factor	I
12	(	I
13	NF	I
14	)-	I
15	kappaB	I
16	consensus	I
17	element	I
18	in	O
19	the	O
20	immediate	O
21	5	O
22	'	O
23	regulatory	O
24	region	O
25	of	O
26	the	O
27	MGSA	B
28	/	O
29	GRO	B
30	-	I
31	alpha	I
32	gene	O
33	at	O
34	-	O
35	78	O
36	bp	O
37	.	O

1	An	O
2	exon	O
3	that	O
4	prevents	O
5	transport	O
6	of	O
7	a	O
8	mature	O
9	mRNA	O
10	.	O

1	Four	O
2	CsA	O
3	-	O
4	treated	O
5	patients	O
6	developed	O
7	persistently	O
8	elevated	O
9	UAER	O
10	>	O
11	30	O
12	mg	O
13	/	O
14	24	O
15	h	O
16	(	O
17	n	O
18	=	O
19	3	O
20	with	O
21	microalbuminuria	O
22	),	O
23	whereas	O
24	all	O
25	the	O
26	17	O
27	placebo	O
28	-	O
29	treated	O
30	patients	O
31	had	O
32	normal	O
33	UAER	O
34	(<	O
35	30	O
36	mg	O
37	/	O
38	24	O
39	h	O
40	)	O
41	after	O
42	7	O
43	years	O
44	of	O
45	follow	O
46	-	O
47	up	O
48	.	O

1	Mutational	O
2	analysis	O
3	of	O
4	the	O
5	-	O
6	84	O
7	/-	O
8	55	O
9	DNA	O
10	showed	O
11	that	O
12	JEG	O
13	-	O
14	3	O
15	nuclear	O
16	proteins	O
17	bound	O
18	to	O
19	a	O
20	site	O
21	containing	O
22	,	O
23	but	O
24	not	O
25	identical	O
26	to	O
27	,	O
28	the	O
29	SF	B
30	-	I
31	1	I
32	sequence	I
33	.	O

1	In	O
2	contrast	O
3	,	O
4	no	O
5	change	O
6	was	O
7	detected	O
8	in	O
9	the	O
10	phenotype	O
11	of	O
12	'	O
13	unstressed	O
14	'	O
15	clones	O
16	,	O
17	with	O
18	respect	O
19	to	O
20	any	O
21	of	O
22	the	O
23	following	O
24	parameters	O
25	:	O
26	proliferation	O
27	rate	O
28	in	O
29	monolayer	O
30	,	O
31	serum	O
32	-	O
33	dependence	O
34	for	O
35	proliferation	O
36	or	O
37	survival	O
38	,	O
39	tumorigenicity	O
40	,	O
41	cellular	O
42	morphology	O
43	,	O
44	or	O
45	tissue	O
46	-	O
47	specific	O
48	differentiation	O
49	markers	O
50	.	O

1	A	O
2	high	O
3	reactor	O
4	pH	O
5	(+/-	O
6	8	O
7	),	O
8	a	O
9	short	O
10	solid	O
11	retention	O
12	time	O
13	(<	O
14	150	O
15	days	O
16	),	O
17	and	O
18	the	O
19	presence	O
20	of	O
21	a	O
22	substantial	O
23	SRB	O
24	population	O
25	in	O
26	the	O
27	inoculum	O
28	may	O
29	considerably	O
30	reduce	O
31	the	O
32	time	O
33	required	O
34	for	O
35	acetate	O
36	-	O
37	utilising	O
38	SRB	O
39	to	O
40	outcompete	O
41	MB	O
42	.	O

1	In	O
2	throttling	O
3	valves	O
4	,	O
5	the	O
6	aim	O
7	is	O
8	to	O
9	correlate	O
10	the	O
11	effect	O
12	of	O
13	shear	O
14	to	O
15	a	O
16	parameter	O
17	related	O
18	to	O
19	the	O
20	inner	O
21	geometry	O
22	of	O
23	the	O
24	valve	O
25	and	O
26	to	O
27	operating	O
28	conditions	O
29	.	O

1	The	O
2	induced	O
3	respiratory	O
4	burst	O
5	was	O
6	investigated	O
7	by	O
8	the	O
9	intracellular	O
10	oxidative	O
11	transformation	O
12	of	O
13	dihydrorhodamine	O
14	123	O
15	to	O
16	the	O
17	fluorescent	O
18	dye	O
19	rhodamine	O
20	123	O
21	via	O
22	flow	O
23	cytometry	O
24	.	O

1	A	O
2	mutation	O
3	linked	O
4	to	O
5	the	O
6	SOC1	B
7	gene	I
8	,	O
9	previously	O
10	defined	O
11	by	O
12	recessive	O
13	mutations	O
14	that	O
15	suppress	O
16	cbp1	B
17	ts	I
18	alleles	I
19	and	O
20	stabilize	O
21	many	O
22	mitochondrial	O
23	mRNAs	O
24	,	O
25	was	O
26	also	O
27	isolated	O
28	.	O

1	A	O
2	deletion	O
3	mutation	O
4	analysis	O
5	of	O
6	the	O
7	recombinant	O
8	protein	O
9	has	O
10	shown	O
11	that	O
12	the	O
13	N	O
14	-	O
15	terminal	O
16	region	O
17	and	O
18	the	O
19	two	O
20	leucine	O
21	zippers	O
22	are	O
23	necessary	O
24	for	O
25	the	O
26	binding	O
27	.	O

1	A	O
2	database	O
3	search	O
4	has	O
5	revealed	O
6	as	O
7	the	O
8	most	O
9	significative	O
10	homology	O
11	a	O
12	match	O
13	with	O
14	the	O
15	human	B
16	mitochondrial	I
17	transcription	I
18	termination	I
19	factor	I
20	(	O
21	mTERF	B
22	),	O
23	a	O
24	protein	O
25	that	O
26	also	O
27	binds	O
28	DNA	O
29	as	O
30	a	O
31	monomer	O
32	and	O
33	contains	O
34	three	O
35	leucine	O
36	zippers	O
37	forming	O
38	intramolecular	O
39	interactions	O
40	.	O

1	In	O
2	all	O
3	trials	O
4	,	O
5	antigen	O
6	challenge	O
7	followed	O
8	1	O
9	h	O
10	after	O
11	the	O
12	last	O
13	treatment	O
14	.	O

1	31	O
2	,	O
3	1997	O
4	,	O
5	40	O
6	patients	O
7	had	O
8	died	O
9	(	O
10	35	O
11	in	O
12	the	O
13	ERA	O
14	-	O
15	II	O
16	group	O
17	and	O
18	5	O
19	in	O
20	the	O
21	ERA	O
22	-	O
23	III	O
24	group	O
25	),	O
26	for	O
27	a	O
28	crude	O
29	mortality	O
30	rate	O
31	of	O
32	8	O
33	.	O
34	0	O
35	%.	O

1	We	O
2	found	O
3	that	O
4	total	O
5	PSA	B
6	can	O
7	be	O
8	detected	O
9	in	O
10	all	O
11	cyst	O
12	fluids	O
13	and	O
14	in	O
15	about	O
16	75	O
17	%	O
18	of	O
19	female	O
20	sera	O
21	.	O

1	Type	O
2	I	O
3	cysts	O
4	(	O
5	with	O
6	a	O
7	high	O
8	K	O
9	+/	O
10	Na	O
11	+	O
12	ratio	O
13	)	O
14	tend	O
15	to	O
16	have	O
17	higher	O
18	total	O
19	PSA	B
20	than	O
21	Type	O
22	II	O
23	cysts	O
24	.	O

1	Despite	O
2	this	O
3	DNA	O
4	binding	O
5	activity	O
6	,	O
7	AP	B
8	-	I
9	1	I
10	reporter	I
11	activity	O
12	was	O
13	suppressed	O
14	in	O
15	these	O
16	cells	O
17	.	O

1	A	O
2	single	O
3	N	O
4	-	O
5	glycosylation	O
6	site	O
7	present	O
8	in	O
9	chicken	B
10	gp42	I
11	is	O
12	conserved	O
13	among	O
14	all	O
15	five	O
16	of	O
17	these	O
18	proteins	O
19	:	O
20	carbohydrate	O
21	analysis	O
22	of	O
23	gp42	B
24	revealed	O
25	the	O
26	presence	O
27	of	O
28	a	O
29	complex	O
30	type	O
31	glycan	O
32	chain	O
33	at	O
34	this	O
35	site	O
36	.	O

1	Here	O
2	we	O
3	describe	O
4	the	O
5	optimization	O
6	and	O
7	characterization	O
8	of	O
9	a	O
10	140	O
11	-	O
12	residue	O
13	fragment	O
14	,	O
15	containing	O
16	the	O
17	Runt	B
18	domain	I
19	of	O
20	AML1	B
21	,	O
22	which	O
23	is	O
24	suitable	O
25	for	O
26	structural	O
27	studies	O
28	.	O

1	Judge	O
2	OKs	O
3	docs	O
4	'	O
5	bid	O
6	for	O
7	Chicago	O
8	hospital	O
9	.	O

1	HANYS	O
2	criticizes	O
3	laparoscopic	O
4	gall	O
5	bladder	O
6	guidelines	O
7	.	O

1	Groups	O
2	dicker	O
3	for	O
4	price	O
5	breaks	O
6	as	O
7	anesthetic	O
8	gas	O
9	goes	O
10	multi	O
11	-	O
12	source	O
13	.	O

1	Troubled	O
2	CareNetwork	O
3	gets	O
4	pact	O
5	from	O
6	largest	O
7	teacher	O
8	union	O
9	in	O
10	Wis	O
11	.	O

1	JCAHO	O
2	asks	O
3	for	O
4	hospitals	O
5	'	O
6	patience	O
7	.	O

1	Ultrasonography	O
2	provides	O
3	excellent	O
4	intraoperative	O
5	evaluation	O
6	of	O
7	spinal	O
8	cord	O
9	injury	O
10	.	O

1	UPMC	O
2	is	O
3	not	O
4	the	O
5	only	O
6	organization	O
7	pursuing	O
8	controlled	O
9	NHBC	O
10	organ	O
11	procurement	O
12	,	O
13	however	O
14	.	O

1	Because	O
2	of	O
3	concerns	O
4	regarding	O
5	blood	O
6	transfusion	O
7	-	O
8	related	O
9	communicable	O
10	disease	O
11	(	O
12	eg	O
13	,	O
14	acquired	O
15	immune	O
16	deficiency	O
17	syndrome	O
18	and	O
19	non	O
20	-	O
21	A	O
22	,	O
23	non	O
24	-	O
25	B	O
26	hepatitis	O
27	),	O
28	there	O
29	has	O
30	been	O
31	increasing	O
32	research	O
33	effort	O
34	into	O
35	postoperative	O
36	hemorrhage	O
37	related	O
38	to	O
39	cardiopulmonary	O
40	bypass	O
41	with	O
42	extracorporeal	O
43	circulation	O
44	.	O

1	They	O
2	contrast	O
3	trends	O
4	in	O
5	fertility	O
6	,	O
7	life	O
8	expectancy	O
9	ratios	O
10	,	O
11	and	O
12	gender	O
13	differences	O
14	in	O
15	these	O
16	countries	O
17	with	O
18	the	O
19	Hispanic	O
20	population	O
21	of	O
22	the	O
23	United	O
24	States	O
25	.	O

1	Holger	O
2	v	O
3	.	O

1	Hospital	O
2	hit	O
3	for	O
4	hiring	O
5	AHERF	O
6	physicians	O
7	.	O

1	Overexpression	O
2	of	O
3	either	O
4	DAP	B
5	-	I
6	1	I
7	or	O
8	sentrin	B
9	causes	O
10	apoptosis	O
11	of	O
12	TNF	B
13	-	O
14	sensitive	O
15	L929	O
16	fibroblast	O
17	cell	O
18	line	O
19	,	O
20	as	O
21	well	O
22	as	O
23	TNF	B
24	-	O
25	resistant	O
26	osteosarcoma	O
27	cell	O
28	line	O
29	,	O
30	U2OS	O
31	.	O

1	This	O
2	is	O
3	in	O
4	contrast	O
5	to	O
6	PPARgamma2	B
7	,	O
8	which	O
9	was	O
10	previously	O
11	shown	O
12	to	O
13	be	O
14	phosphorylated	O
15	at	O
16	a	O
17	single	O
18	site	O
19	in	O
20	a	O
21	motif	O
22	that	O
23	is	O
24	not	O
25	homologous	O
26	to	O
27	the	O
28	sites	O
29	now	O
30	described	O
31	in	O
32	PPARalpha	B
33	.	O

1	These	O
2	results	O
3	suggest	O
4	KCC3	B
5	is	O
6	a	O
7	new	O
8	member	O
9	of	O
10	the	O
11	KCC	B
12	family	I
13	that	O
14	is	O
15	under	O
16	distinct	O
17	regulation	O
18	from	O
19	KCC1	B
20	.	O

1	We	O
2	have	O
3	screened	O
4	the	O
5	elastin	B
6	gene	I
7	for	O
8	mutations	O
9	responsible	O
10	for	O
11	supravalvular	O
12	aortic	O
13	stenosis	O
14	(	O
15	SVAS	O
16	)	O
17	in	O
18	two	O
19	large	O
20	,	O
21	independently	O
22	collected	O
23	families	O
24	with	O
25	isolated	O
26	(	O
27	nonsyndromic	O
28	)	O
29	SVAS	O
30	.	O

1	Spatiotemporal	O
2	expression	O
3	of	O
4	the	O
5	PAX3	B
6	gene	I
7	is	O
8	tightly	O
9	regulated	O
10	during	O
11	development	O
12	.	O

1	25	O
2	-	O
3	OH	O
4	-	O
5	D3	O
6	did	O
7	not	O
8	adversely	O
9	affect	O
10	animal	O
11	health	O
12	at	O
13	the	O
14	proposed	O
15	use	O
16	level	O
17	of	O
18	99	O
19	micrograms	O
20	/	O
21	kg	O
22	feed	O
23	when	O
24	replacing	O
25	vitamin	O
26	D3	O
27	in	O
28	turkey	O
29	rations	O
30	.	O

1	A	O
2	list	O
3	of	O
4	12	O
5	names	O
6	for	O
7	the	O
8	disease	O
9	and	O
10	37	O
11	diagnostic	O
12	criteria	O
13	were	O
14	proposed	O
15	to	O
16	a	O
17	Consensus	O
18	Panel	O
19	of	O
20	12	O
21	Italian	O
22	experts	O
23	who	O
24	ranked	O
25	them	O
26	in	O
27	order	O
28	so	O
29	as	O
30	to	O
31	identify	O
32	a	O
33	core	O
34	set	O
35	of	O
36	criteria	O
37	.	O

1	Methanesulfonyl	O
2	fluoride	O
3	(	O
4	MSF	O
5	):	O
6	a	O
7	double	O
8	-	O
9	blind	O
10	,	O
11	placebo	O
12	-	O
13	controlled	O
14	study	O
15	of	O
16	safety	O
17	and	O
18	efficacy	O
19	in	O
20	the	O
21	treatment	O
22	of	O
23	senile	O
24	dementia	O
25	of	O
26	the	O
27	Alzheimer	O
28	type	O
29	.	O

1	METHODS	O
2	:	O
3	Between	O
4	August	O
5	1991	O
6	and	O
7	June	O
8	1994	O
9	,	O
10	198	O
11	men	O
12	with	O
13	clinical	O
14	T2	O
15	or	O
16	T3	O
17	classified	O
18	(	O
19	TNM	O
20	)	O
21	prostate	O
22	carcinoma	O
23	(	O
24	bone	O
25	scan	O
26	negative	O
27	)	O
28	who	O
29	were	O
30	at	O
31	high	O
32	risk	O
33	of	O
34	lymph	O
35	node	O
36	involvement	O
37	underwent	O
38	a	O
39	111In	O
40	-	O
41	capromab	O
42	pendetide	O
43	scan	O
44	prior	O
45	to	O
46	staging	O
47	lymphadenectomy	O
48	.	O

1	Voluntary	O
2	wheel	O
3	running	O
4	did	O
5	not	O
6	significantly	O
7	increase	O
8	estimated	O
9	alanine	O
10	or	O
11	pyruvate	O
12	Gneo	O
13	or	O
14	absolute	O
15	glycerol	O
16	Ra	O
17	.	O

1	Immediately	O
2	after	O
3	surgery	O
4	,	O
5	dialysate	O
6	PGE2	O
7	and	O
8	adenosine	O
9	concentrations	O
10	were	O
11	3	O
12	.	O
13	7	O
14	+/-	O
15	0	O
16	.	O
17	7	O
18	and	O
19	296	O
20	+/-	O
21	127	O
22	nM	O
23	,	O
24	respectively	O
25	.	O

1	Because	O
2	of	O
3	the	O
4	probable	O
5	causal	O
6	relationship	O
7	between	O
8	constitutive	O
9	p210	B
10	(	O
11	bcr	B
12	/	O
13	abl	B
14	)	O
15	protein	B
16	tyrosine	I
17	kinase	I
18	activity	O
19	and	O
20	manifestations	O
21	of	O
22	chronic	O
23	-	O
24	phase	O
25	chronic	O
26	myelogenous	O
27	leukemia	O
28	(	O
29	CML	O
30	;	O
31	myeloid	O
32	expansion	O
33	),	O
34	a	O
35	key	O
36	goal	O
37	is	O
38	to	O
39	identify	O
40	relevant	O
41	p210	B
42	substrates	O
43	in	O
44	primary	O
45	chronic	O
46	-	O
47	phase	O
48	CML	O
49	hematopoietic	O
50	progenitor	O
51	cells	O
52	.	O

1	In	O
2	vitro	O
3	precipitation	O
4	with	O
5	a	O
6	glutathione	B
7	-	I
8	S	I
9	-	I
10	transferase	I
11	-	I
12	fusion	I
13	protein	I
14	containing	O
15	the	O
16	C	O
17	-	O
18	terminal	O
19	transactivation	O
20	domain	O
21	of	O
22	STAT5a	B
23	showed	O
24	GH	B
25	-	O
26	regulated	O
27	association	O
28	of	O
29	ERK1	B
30	/	I
31	2	I
32	with	O
33	the	O
34	fusion	O
35	protein	O
36	,	O
37	while	O
38	this	O
39	was	O
40	not	O
41	seen	O
42	when	O
43	serine	O
44	780	O
45	in	O
46	STAT5a	B
47	was	O
48	changed	O
49	to	O
50	alanine	O
51	.	O

1	One	O
2	such	O
3	element	O
4	,	O
5	1P	O
6	,	O
7	was	O
8	employed	O
9	to	O
10	clone	O
11	from	O
12	a	O
13	rat	O
14	pituitary	O
15	cDNA	O
16	expression	O
17	library	O
18	a	O
19	novel	O
20	417	B
21	-	I
22	amino	I
23	acid	I
24	WD	I
25	protein	I
26	,	O
27	designated	O
28	PREB	B
29	(	I
30	PRL	I
31	regulatory	I
32	element	I
33	binding	I
34	)	I
35	protein	I
36	.	O

1	Characterization	O
2	of	O
3	the	O
4	transcription	B
5	factor	I
6	MTF	I
7	-	I
8	1	I
9	from	O
10	the	O
11	Japanese	O
12	pufferfish	O
13	(	O
14	Fugu	O
15	rubripes	O
16	)	O
17	reveals	O
18	evolutionary	O
19	conservation	O
20	of	O
21	heavy	O
22	metal	O
23	stress	O
24	response	O
25	.	O

1	The	O
2	peroxisome	B
3	proliferator	I
4	-	I
5	activated	I
6	receptors	I
7	(	O
8	PPARs	B
9	)	O
10	are	O
11	members	O
12	of	O
13	the	O
14	nuclear	B
15	hormone	I
16	receptor	I
17	superfamily	I
18	.	O

1	However	O
2	,	O
3	F	B
4	-	I
5	SRC	I
6	-	I
7	1	I
8	mutant	I
9	lacking	O
10	CBP	B
11	-	I
12	interacting	I
13	domain	I
14	still	O
15	preserved	O
16	enhancing	O
17	activity	O
18	.	O

1	The	O
2	catalytic	O
3	site	O
4	has	O
5	an	O
6	S1	O
7	pocket	O
8	lined	O
9	with	O
10	conserved	O
11	hydrophobic	O
12	residues	O
13	to	O
14	accommodate	O
15	the	O
16	pyroglutamyl	O
17	residue	O
18	.	O

1	The	O
2	complete	O
3	circular	O
4	TTV	O
5	genome	O
6	contained	O
7	a	O
8	novel	O
9	sequence	O
10	of	O
11	113	O
12	nt	O
13	(	O
14	nt	O
15	3740	O
16	to	O
17	3852	O
18	[=	O
19	0	O
20	])	O
21	in	O
22	between	O
23	the	O
24	known	O
25	3	O
26	'-	O
27	and	O
28	5	O
29	'-	O
30	end	O
31	arms	O
32	,	O
33	forming	O
34	a	O
35	117	O
36	-	O
37	nt	O
38	GC	O
39	-	O
40	rich	O
41	stretch	O
42	(	O
43	GC	O
44	content	O
45	,	O
46	90	O
47	.	O
48	6	O
49	%	O
50	at	O
51	nt	O
52	3736	O
53	to	O
54	3852	O
55	).	O

1	The	O
2	Asian	O
3	mouse	O
4	Mus	O
5	castaneus	O
6	is	O
7	resistant	O
8	to	O
9	infection	O
10	by	O
11	the	O
12	polytropic	O
13	mink	O
14	cell	O
15	focus	O
16	-	O
17	inducing	O
18	(	O
19	MCF	O
20	)	O
21	subgroup	O
22	of	O
23	murine	O
24	leukemia	O
25	viruses	O
26	(	O
27	MuLVs	O
28	).	O

1	To	O
2	determine	O
3	the	O
4	function	O
5	of	O
6	VZV	B
7	gK	I
8	in	O
9	virus	O
10	growth	O
11	,	O
12	a	O
13	series	O
14	of	O
15	gK	B
16	deletion	I
17	mutants	I
18	were	O
19	constructed	O
20	with	O
21	VZV	O
22	cosmid	O
23	DNA	O
24	derived	O
25	from	O
26	the	O
27	Oka	O
28	strain	O
29	.	O

1	CCAAT	B
2	displacement	I
3	protein	I
4	binds	O
5	to	O
6	and	O
7	negatively	O
8	regulates	O
9	human	O
10	papillomavirus	O
11	type	O
12	6	O
13	E6	B
14	,	O
15	E7	B
16	,	O
17	and	O
18	E1	B
19	promoters	O
20	.	O

1	As	O
2	such	O
3	the	O
4	findings	O
5	support	O
6	existing	O
7	studies	O
8	that	O
9	have	O
10	identified	O
11	given	O
12	social	O
13	characteristics	O
14	of	O
15	drink	O
16	drivers	O
17	.	O

1	Three	O
2	different	O
3	site	O
4	-	O
5	directed	O
6	mutations	O
7	of	O
8	the	O
9	cyclic	O
10	AMP	O
11	response	O
12	element	O
13	each	O
14	reduced	O
15	the	O
16	nerve	B
17	growth	I
18	factor	I
19	effect	O
20	by	O
21	>	O
22	90	O
23	%.	O

1	Using	O
2	an	O
3	RNase	B
4	H	I
5	protection	O
6	assay	O
7	and	O
8	specific	O
9	blocking	O
10	oligonucleotides	O
11	,	O
12	we	O
13	find	O
14	that	O
15	recognition	O
16	of	O
17	the	O
18	5	O
19	'	O
20	splice	O
21	-	O
22	site	O
23	(	O
24	5	O
25	'	O
26	ss	O
27	)	O
28	and	O
29	branchpoint	O
30	sequence	O
31	(	O
32	BPS	O
33	)	O
34	elements	O
35	by	O
36	U11	B
37	and	O
38	U12	B
39	snRNPs	I
40	,	O
41	respectively	O
42	,	O
43	displays	O
44	strong	O
45	cooperativity	O
46	,	O
47	requiring	O
48	both	O
49	sites	O
50	in	O
51	the	O
52	pre	O
53	-	O
54	mRNA	O
55	substrate	O
56	for	O
57	efficient	O
58	complex	O
59	formation	O
60	.	O

1	Analysis	O
2	of	O
3	lacZ	B
4	transcriptional	I
5	fusions	I
6	shows	O
7	that	O
8	the	O
9	KdgR	B
10	-	I
11	binding	I
12	sites	I
13	negatively	O
14	affect	O
15	the	O
16	expression	O
17	of	O
18	rsmB	B
19	.	O

1	Many	O
2	eukaryotic	O
3	cell	O
4	surface	O
5	proteins	O
6	are	O
7	anchored	O
8	in	O
9	the	O
10	lipid	O
11	bilayer	O
12	through	O
13	glycosylphosphatidylinositol	O
14	(	O
15	GPI	O
16	).	O

1	In	O
2	the	O
3	cell	O
4	-	O
5	free	O
6	import	O
7	assay	O
8	,	O
9	beta	B
10	-	I
11	catenin	I
12	rapidly	O
13	migrates	O
14	into	O
15	the	O
16	nucleus	O
17	without	O
18	the	O
19	exogenous	O
20	addition	O
21	of	O
22	cytosol	O
23	,	O
24	Ran	B
25	,	O
26	or	O
27	ATP	O
28	/	O
29	GTP	O
30	.	O

1	In	O
2	ischemic	O
3	and	O
4	hypoxic	O
5	hypoxia	O
6	,	O
7	a	O
8	strong	O
9	correlation	O
10	was	O
11	found	O
12	between	O
13	cyt	O
14	a	O
15	,	O
16	a3	O
17	oxidation	O
18	level	O
19	and	O
20	VO2	O
21	in	O
22	both	O
23	ischemic	O
24	and	O
25	hypoxic	O
26	hypoxia	O
27	(	O
28	r2	O
29	=.	O
30	90	O
31	and	O
32	.	O
33	87	O
34	,	O
35	respectively	O
36	).	O

1	An	O
2	endogenous	O
3	mammalian	O
4	regulator	O
5	of	O
6	this	O
7	process	O
8	,	O
9	named	O
10	Usurpin	B
11	,	O
12	has	O
13	been	O
14	identified	O
15	(	O
16	aliases	O
17	for	O
18	Usurpin	B
19	include	O
20	CASH	B
21	,	O
22	Casper	B
23	,	O
24	CLARP	B
25	,	O
26	FLAME	B
27	-	I
28	1	I
29	,	O
30	FLIP	B
31	,	O
32	I	B
33	-	I
34	FLICE	I
35	and	O
36	MRIT	B
37	).	O

1	Plasma	O
2	glucose	O
3	,	O
4	immunoreactive	B
5	insulin	I
6	(	O
7	IRI	B
8	),	O
9	C	B
10	-	I
11	peptide	I
12	,	O
13	glucagon	B
14	,	O
15	and	O
16	GLP	B
17	-	I
18	1	I
19	levels	O
20	at	O
21	each	O
22	time	O
23	point	O
24	during	O
25	OGTT	O
26	were	O
27	measured	O
28	.	O

1	Each	O
2	recombinant	O
3	product	O
4	was	O
5	a	O
6	fusion	O
7	protein	O
8	with	O
9	a	O
10	B	O
11	domain	O
12	of	O
13	Staphylococcal	B
14	protein	I
15	A	I
16	(	O
17	SPA	B
18	).	O

1	Polypyrimidine	O
2	and	O
3	ssDNA	O
4	binding	O
5	by	O
6	the	O
7	isolated	O
8	VH	B
9	domain	I
10	of	O
11	immunization	O
12	-	O
13	induced	O
14	anti	O
15	-	O
16	Z	O
17	-	O
18	DNA	O
19	Ab	O
20	resembles	O
21	the	O
22	activity	O
23	of	O
24	natural	O
25	autoantibodies	O
26	and	O
27	suggests	O
28	that	O
29	VH	B
30	-	O
31	dependent	O
32	binding	O
33	to	O
34	a	O
35	ligand	O
36	mimicked	O
37	by	O
38	polypyrimidines	O
39	may	O
40	play	O
41	a	O
42	role	O
43	in	O
44	B	O
45	cell	O
46	selection	O
47	before	O
48	immunization	O
49	with	O
50	Z	O
51	-	O
52	DNA	O
53	.	O

1	Technetium	O
2	-	O
3	99m	O
4	methylene	O
5	diphosphonate	O
6	scintimammography	O
7	for	O
8	evaluation	O
9	of	O
10	palpable	O
11	breast	O
12	masses	O
13	.	O

1	INTERVENTIONS	O
2	:	O
3	Study	O
4	patients	O
5	were	O
6	randomly	O
7	divided	O
8	into	O
9	four	O
10	parallel	O
11	groups	O
12	to	O
13	receive	O
14	either	O
15	terbinafine	O
16	250	O
17	mg	O
18	a	O
19	day	O
20	for	O
21	12	O
22	or	O
23	16	O
24	weeks	O
25	(	O
26	groups	O
27	T12	O
28	and	O
29	T16	O
30	)	O
31	or	O
32	itraconazole	O
33	400	O
34	mg	O
35	a	O
36	day	O
37	for	O
38	1	O
39	week	O
40	in	O
41	every	O
42	4	O
43	weeks	O
44	for	O
45	12	O
46	or	O
47	16	O
48	weeks	O
49	(	O
50	groups	O
51	I3	O
52	and	O
53	I4	O
54	).	O

1	Nuclear	O
2	receptors	O
3	(	O
4	NRs	O
5	)	O
6	can	O
7	function	O
8	as	O
9	ligandinducible	O
10	transregulators	O
11	in	O
12	both	O
13	mammalian	O
14	and	O
15	yeast	O
16	cells	O
17	,	O
18	indicating	O
19	that	O
20	important	O
21	features	O
22	of	O
23	transcriptional	O
24	control	O
25	have	O
26	been	O
27	conserved	O
28	throughout	O
29	evolution	O
30	.	O

1	When	O
2	tethered	O
3	to	O
4	a	O
5	heterologous	O
6	DNA	O
7	-	O
8	binding	O
9	domain	O
10	,	O
11	PSU1	B
12	can	O
13	activate	O
14	transcription	O
15	on	O
16	its	O
17	own	O
18	.	O

1	OBJECTIVE	O
2	:	O
3	To	O
4	follow	O
5	-	O
6	up	O
7	prospectively	O
8	patients	O
9	with	O
10	arthritis	O
11	after	O
12	infection	O
13	with	O
14	beta	O
15	-	O
16	haemolytic	O
17	streptococci	O
18	of	O
19	Lancefield	O
20	group	O
21	A	O
22	(	O
23	beta	O
24	HSA	O
25	),	O
26	with	O
27	emphasis	O
28	on	O
29	clinical	O
30	characteristics	O
31	and	O
32	serological	O
33	features	O
34	.	O

1	Bacteria	O
2	can	O
3	also	O
4	cause	O
5	a	O
6	labyrinthitis	O
7	acting	O
8	directly	O
9	on	O
10	the	O
11	inner	O
12	ear	O
13	:	O
14	among	O
15	these	O
16	,	O
17	Treponemas	O
18	Pallidum	O
19	,	O
20	a	O
21	spirochaete	O
22	which	O
23	causes	O
24	syphilis	O
25	and	O
26	Borrelia	O
27	Burgdorferi	O
28	,	O
29	a	O
30	spirochaete	O
31	that	O
32	causes	O
33	Lyme	O
34	Disease	O
35	,	O
36	must	O
37	be	O
38	mentioned	O
39	.	O

1	We	O
2	found	O
3	that	O
4	the	O
5	expression	O
6	of	O
7	the	O
8	protein	O
9	was	O
10	maximum	O
11	in	O
12	mitosis	O
13	and	O
14	minimum	O
15	in	O
16	G1	O
17	,	O
18	which	O
19	correlated	O
20	with	O
21	the	O
22	expression	O
23	of	O
24	its	O
25	messenger	O
26	RNA	O
27	.	O

1	These	O
2	findings	O
3	demonstrate	O
4	that	O
5	signature	O
6	-	O
7	tagged	O
8	mutagenesis	O
9	is	O
10	a	O
11	viable	O
12	approach	O
13	to	O
14	identify	O
15	bacterial	O
16	genes	O
17	associated	O
18	with	O
19	the	O
20	ability	O
21	to	O
22	infect	O
23	the	O
24	urinary	O
25	tract	O
26	.	O

1	Pathol	O
2	.	O

1	The	O
2	eukaryotic	O
3	cell	O
4	cycle	O
5	is	O
6	governed	O
7	in	O
8	part	O
9	by	O
10	the	O
11	periodic	O
12	transcription	O
13	of	O
14	cyclin	B
15	genes	I
16	,	O
17	whose	O
18	protein	O
19	products	O
20	associate	O
21	with	O
22	and	O
23	positively	O
24	regulate	O
25	the	O
26	cyclin	B
27	-	I
28	dependent	I
29	kinases	I
30	.	O

1	The	O
2	GAC1	B
3	gene	I
4	encodes	O
5	the	O
6	regulatory	O
7	subunit	O
8	for	O
9	a	O
10	type	B
11	1	I
12	serine	I
13	/	I
14	threonine	I
15	phosphoprotein	I
16	phosphatase	I
17	,	O
18	Glc7	B
19	.	O

1	The	O
2	results	O
3	demonstrate	O
4	that	O
5	the	O
6	Glc7	B
7	phosphatase	I
8	and	O
9	its	O
10	Gac1	B
11	regulatory	O
12	subunit	O
13	play	O
14	positive	O
15	roles	O
16	in	O
17	HSF	B
18	activation	O
19	of	O
20	CUP1	B
21	transcription	O
22	.	O

1	MEF	B
2	and	O
3	AML1B	B
4	synergistically	O
5	transactivated	O
6	an	O
7	interleukin	B
8	3	I
9	promoter	I
10	reporter	I
11	gene	I
12	construct	I
13	,	O
14	yet	O
15	the	O
16	activating	O
17	activity	O
18	of	O
19	MEF	B
20	was	O
21	abolished	O
22	when	O
23	MEF	B
24	was	O
25	coexpressed	O
26	with	O
27	AML1	B
28	/	O
29	ETO	B
30	.	O

1	Mechanistically	O
2	,	O
3	the	O
4	presence	O
5	of	O
6	the	O
7	GRR	O
8	appears	O
9	to	O
10	stop	O
11	further	O
12	degradation	O
13	of	O
14	p50	B
15	and	O
16	to	O
17	stabilize	O
18	the	O
19	molecule	O
20	.	O

1	This	O
2	phosphorylation	O
3	can	O
4	be	O
5	catalyzed	O
6	by	O
7	a	O
8	break	O
9	-	O
10	ended	O
11	double	O
12	-	O
13	stranded	O
14	DNA	O
15	-	O
16	activated	O
17	protein	O
18	kinase	O
19	activity	O
20	from	O
21	the	O
22	sea	O
23	urchin	O
24	nucleus	O
25	in	O
26	vitro	O
27	.	O

1	Concomitantly	O
2	,	O
3	the	O
4	total	O
5	cellular	O
6	level	O
7	of	O
8	p21	B
9	increased	O
10	severalfold	O
11	via	O
12	a	O
13	posttranscriptional	O
14	mechanism	O
15	.	O

1	Moreover	O
2	,	O
3	when	O
4	added	O
5	to	O
6	the	O
7	osteoclast	O
8	cultures	O
9	,	O
10	mrIhh	B
11	-	I
12	N	I
13	markedly	O
14	stimulated	O
15	the	O
16	formation	O
17	of	O
18	resorption	O
19	pits	O
20	on	O
21	dentine	O
22	slices	O
23	.	O

1	Overall	O
2	,	O
3	our	O
4	results	O
5	suggest	O
6	that	O
7	resistant	O
8	genotypes	O
9	exist	O
10	among	O
11	the	O
12	WAD	O
13	goat	O
14	population	O
15	.	O

1	The	O
2	molecular	O
3	mechanism	O
4	by	O
5	which	O
6	Gle2p	B
7	and	O
8	the	O
9	Gle2p	B
10	-	O
11	Nup116p	B
12	interaction	O
13	function	O
14	in	O
15	mRNA	O
16	export	O
17	is	O
18	unknown	O
19	.	O

1	The	O
2	Fyn	B
3	NH2	I
4	terminus	I
5	was	O
6	necessary	O
7	but	O
8	not	O
9	sufficient	O
10	for	O
11	interaction	O
12	with	O
13	zeta	O
14	and	O
15	both	O
16	Fyn	B
17	kinase	I
18	and	O
19	SH2	B
20	domains	I
21	were	O
22	required	O
23	,	O
24	directing	O
25	phosphorylation	O
26	of	O
27	zeta	B
28	ITAM	I
29	tyrosines	O
30	and	O
31	binding	O
32	to	O
33	zeta	B
34	ITAM	I
35	phosphotyrosines	O
36	.	O

1	In	O
2	budding	O
3	yeast	O
4	,	O
5	the	O
6	protein	O
7	Skp1p	B
8	,	O
9	the	O
10	cullin	B
11	-	I
12	family	I
13	member	I
14	Cdc53p	I
15	,	O
16	and	O
17	the	O
18	F	O
19	-	O
20	box	O
21	/	O
22	WD	O
23	-	O
24	repeat	O
25	protein	O
26	Cdc4p	B
27	form	O
28	the	O
29	SCFCdc4p	B
30	ubiquitin	I
31	ligase	I
32	complex	O
33	,	O
34	which	O
35	targets	O
36	the	O
37	cyclin	B
38	-	I
39	dependent	I
40	kinase	I
41	(	O
42	Cdk	B
43	)	O
44	inhibitor	O
45	Sic1p	B
46	for	O
47	proteolysis	O
48	[	O
49	3	O
50	]	O
51	[	O
52	4	O
53	]	O
54	[	O
55	5	O
56	]	O
57	[	O
58	6	O
59	]	O
60	[	O
61	7	O
62	]	O
63	[	O
64	8	O
65	].	O

1	We	O
2	show	O
3	here	O
4	that	O
5	,	O
6	despite	O
7	their	O
8	structural	O
9	and	O
10	functional	O
11	similarities	O
12	,	O
13	the	O
14	pop1	B
15	and	O
16	pop2	B
17	genes	I
18	fail	O
19	to	O
20	complement	O
21	each	O
22	other	O
23	'	O
24	s	O
25	deletion	O
26	phenotypes	O
27	,	O
28	indicating	O
29	that	O
30	they	O
31	perform	O
32	non	O
33	-	O
34	redundant	O
35	,	O
36	but	O
37	potentially	O
38	interdependent	O
39	,	O
40	functions	O
41	in	O
42	proteolysis	O
43	.	O

1	Antithrombin	B
2	III	I
3	prevents	O
4	60	O
5	min	O
6	warm	O
7	intestinal	O
8	ischemia	O
9	reperfusion	O
10	injury	O
11	in	O
12	rats	O
13	.	O

1	In	O
2	retrospect	O
3	,	O
4	the	O
5	diagnoses	O
6	were	O
7	reconsidered	O
8	applying	O
9	strict	O
10	criteria	O
11	.	O

1	These	O
2	observations	O
3	of	O
4	elevated	O
5	serum	B
6	lipase	I
7	and	O
8	serum	O
9	CA	B
10	19	I
11	-	I
12	9	I
13	in	O
14	Sjogren	O
15	'	O
16	s	O
17	syndrome	O
18	without	O
19	evidence	O
20	of	O
21	malignancy	O
22	may	O
23	reflect	O
24	pancreatic	O
25	involvement	O
26	in	O
27	this	O
28	disorder	O
29	.	O

1	Acute	O
2	pancreatitis	O
3	as	O
4	a	O
5	complication	O
6	of	O
7	polyarteritis	O
8	nodosa	O
9	.	O

1	Significantly	O
2	greater	O
3	improvement	O
4	(	O
5	p	O
6	<	O
7	0	O
8	.	O
9	05	O
10	)	O
11	in	O
12	the	O
13	sertraline	O
14	group	O
15	first	O
16	became	O
17	apparent	O
18	by	O
19	the	O
20	end	O
21	of	O
22	week	O
23	3	O
24	on	O
25	the	O
26	Y	O
27	-	O
28	BOCS	O
29	and	O
30	the	O
31	CGI	O
32	Improvement	O
33	scale	O
34	,	O
35	and	O
36	by	O
37	the	O
38	end	O
39	of	O
40	weeks	O
41	6	O
42	and	O
43	8	O
44	,	O
45	respectively	O
46	,	O
47	on	O
48	the	O
49	NIMH	O
50	and	O
51	CGI	O
52	Severity	O
53	scale	O
54	.	O

1	Stress	B
2	-	I
3	inducible	I
4	protein	I
5	kinases	I
6	capable	O
7	of	O
8	activating	O
9	c	B
10	-	I
11	jun	I
12	expression	O
13	include	O
14	stress	B
15	-	I
16	activated	I
17	protein	I
18	kinase	I
19	/	O
20	c	B
21	-	I
22	Jun	I
23	N	I
24	-	I
25	terminal	I
26	protein	I
27	kinase	I
28	(	O
29	SAPK	B
30	/	O
31	JNK	B
32	)	O
33	and	O
34	p38	B
35	members	O
36	of	O
37	the	O
38	mitogen	B
39	-	I
40	activated	I
41	protein	I
42	kinase	I
43	(	O
44	MAPK	B
45	)	O
46	superfamily	O
47	of	O
48	signaling	O
49	molecules	O
50	.	O

1	Transforming	B
2	growth	I
3	factor	I
4	(	I
5	TGF	I
6	)-	I
7	beta1	I
8	induces	O
9	extracellular	O
10	matrix	O
11	deposition	O
12	and	O
13	proliferation	O
14	of	O
15	mesenchymal	O
16	cells	O
17	.	O

1	Chronotherapeutics	O
2	in	O
3	cardiovascular	O
4	disease	O
5	.	O

1	Group	O
2	psychometric	O
3	functions	O
4	for	O
5	listeners	O
6	with	O
7	hearing	O
8	loss	O
9	do	O
10	not	O
11	show	O
12	a	O
13	decrease	O
14	in	O
15	performance	O
16	at	O
17	the	O
18	largest	O
19	values	O
20	of	O
21	delta	O
22	f	O
23	included	O
24	in	O
25	this	O
26	study	O
27	.	O

1	Uroflowmetry	O
2	can	O
3	detect	O
4	dysuria	O
5	,	O
6	which	O
7	may	O
8	be	O
9	poorly	O
10	perceived	O
11	or	O
12	even	O
13	unknown	O
14	to	O
15	the	O
16	subjects	O
17	themselves	O
18	.	O

1	Marked	O
2	racial	O
3	variation	O
4	in	O
5	birthweight	O
6	percentiles	O
7	by	O
8	gestational	O
9	age	O
10	was	O
11	evident	O
12	.	O

1	Significant	O
2	correlations	O
3	between	O
4	mental	O
5	status	O
6	as	O
7	measured	O
8	by	O
9	the	O
10	Mini	O
11	-	O
12	Mental	O
13	State	O
14	Examination	O
15	and	O
16	NA	O
17	/	O
18	mI	O
19	,	O
20	mI	O
21	/	O
22	Cr	O
23	and	O
24	NA	O
25	were	O
26	found	O
27	.	O

1	Glucagon	B
2	also	O
3	induced	O
4	LUC	B
5	activity	O
6	very	O
7	strongly	O
8	when	O
9	the	O
10	CRE1	O
11	and	O
12	CRE2	O
13	sites	O
14	were	O
15	combined	O
16	;	O
17	induction	O
18	of	O
19	the	O
20	(	O
21	CRE1	O
22	)	O
23	3	O
24	(	O
25	CRE2	O
26	)	O
27	2SV40	O
28	-	O
29	LUC	B
30	constructs	O
31	was	O
32	positively	O
33	modulated	O
34	by	O
35	the	O
36	pO2	O
37	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	report	O
7	the	O
8	isolation	O
9	and	O
10	characterization	O
11	of	O
12	the	O
13	entire	O
14	rat	B
15	GSTA3	I
16	(	O
17	rGST	B
18	Yc1	I
19	)	O
20	subunit	O
21	gene	O
22	.	O

1	Calcinosis	O
2	cutis	O
3	following	O
4	intravenous	O
5	infusion	O
6	of	O
7	calcium	O
8	gluconate	O
9	.	O

1	Initial	O
2	control	O
3	of	O
4	bleeding	O
5	is	O
6	similar	O
7	,	O
8	but	O
9	eradication	O
10	is	O
11	achieved	O
12	in	O
13	fewer	O
14	sessions	O
15	with	O
16	EVL	O
17	.	O

1	Finally	O
2	,	O
3	we	O
4	determined	O
5	the	O
6	genomic	O
7	organization	O
8	of	O
9	the	O
10	human	B
11	TrxR2	I
12	gene	I
13	,	O
14	which	O
15	consists	O
16	of	O
17	18	O
18	exons	O
19	spanning	O
20	about	O
21	67	O
22	kb	O
23	,	O
24	and	O
25	its	O
26	chromosomal	O
27	localization	O
28	at	O
29	position	O
30	22q11	O
31	.	O
32	2	O
33	.	O

1	The	O
2	aims	O
3	of	O
4	this	O
5	study	O
6	were	O
7	to	O
8	determine	O
9	and	O
10	rank	O
11	the	O
12	frequency	O
13	of	O
14	self	O
15	reported	O
16	visual	O
17	disability	O
18	in	O
19	daily	O
20	tasks	O
21	performed	O
22	by	O
23	glaucoma	O
24	patients	O
25	;	O
26	to	O
27	examine	O
28	the	O
29	interrelation	O
30	between	O
31	disabilities	O
32	using	O
33	factor	O
34	analysis	O
35	;	O
36	to	O
37	study	O
38	the	O
39	relation	O
40	between	O
41	perceived	O
42	visual	O
43	difficulty	O
44	and	O
45	a	O
46	measure	O
47	of	O
48	the	O
49	severity	O
50	of	O
51	visual	O
52	field	O
53	loss	O
54	;	O
55	to	O
56	develop	O
57	a	O
58	glaucoma	O
59	specific	O
60	subgroup	O
61	of	O
62	questions	O
63	;	O
64	and	O
65	examine	O
66	the	O
67	validity	O
68	and	O
69	reliability	O
70	of	O
71	this	O
72	subgroup	O
73	of	O
74	questions	O
75	.	O

1	Furthermore	O
2	,	O
3	the	O
4	validity	O
5	of	O
6	this	O
7	new	O
8	subset	O
9	of	O
10	questions	O
11	was	O
12	shown	O
13	to	O
14	be	O
15	significant	O
16	(	O
17	r	O
18	=	O
19	0	O
20	.	O
21	037	O
22	,	O
23	p	O
24	<	O
25	0	O
26	.	O
27	05	O
28	)	O
29	for	O
30	the	O
31	correlation	O
32	between	O
33	a	O
34	measure	O
35	of	O
36	the	O
37	severity	O
38	of	O
39	binocular	O
40	visual	O
41	field	O
42	loss	O
43	and	O
44	the	O
45	mean	O
46	score	O
47	of	O
48	the	O
49	variables	O
50	used	O
51	in	O
52	the	O
53	glaucoma	O
54	specific	O
55	subgroup	O
56	of	O
57	questions	O
58	.	O

1	Sequence	O
2	comparison	O
3	of	O
4	cytochromes	B
5	bd	I
6	and	O
7	their	O
8	homologs	O
9	from	O
10	various	O
11	organisms	O
12	demonstrates	O
13	that	O
14	the	O
15	proteins	O
16	can	O
17	be	O
18	classified	O
19	into	O
20	two	O
21	subfamilies	O
22	,	O
23	a	O
24	proteobacterial	O
25	type	O
26	including	O
27	E	B
28	.	I
29	coli	I
30	bd	I
31	and	O
32	a	O
33	more	O
34	widely	O
35	distributed	O
36	type	O
37	including	O
38	the	O
39	B	O
40	.	O
41	stearothermophilus	O
42	enzyme	O
43	,	O
44	suggesting	O
45	that	O
46	the	O
47	latter	O
48	type	O
49	is	O
50	evolutionarily	O
51	older	O
52	.	O

1	Canalith	O
2	repositioning	O
3	is	O
4	the	O
5	mainstay	O
6	of	O
7	treatment	O
8	.	O

1	Solution	O
2	structure	O
3	and	O
4	mechanism	O
5	of	O
6	the	O
7	MutT	B
8	pyrophosphohydrolase	I
9	.	O

1	In	O
2	11	O
3	eyes	O
4	that	O
5	had	O
6	been	O
7	selected	O
8	at	O
9	random	O
10	10	O
11	micrograms	O
12	of	O
13	recombinant	B
14	tissue	I
15	plasminogen	I
16	activator	I
17	were	O
18	injected	O
19	midvitreally	O
20	24	O
21	hrs	O
22	later	O
23	.	O

1	RESULTS	O
2	AND	O
3	CONCLUSIONS	O
4	:	O
5	Brandt	O
6	'	O
7	s	O
8	double	O
9	cuff	O
10	-	O
11	tubes	O
12	(	O
13	G2	O
14	)	O
15	succeed	O
16	in	O
17	avoiding	O
18	uncontrolled	O
19	increase	O
20	of	O
21	cuff	O
22	-	O
23	pressure	O
24	during	O
25	anaesthesia	O
26	with	O
27	N2O	O
28	.	O

1	Accordingly	O
2	,	O
3	we	O
4	designated	O
5	this	O
6	gene	B
7	CTL1	I
8	(	O
9	capping	B
10	enzyme	I
11	RNAtriphosphatase	I
12	-	I
13	like	I
14	1	I
15	).	O

1	The	O
2	binding	O
3	of	O
4	PH	B
5	domains	I
6	to	O
7	Gbetagamma	B
8	was	O
9	inhibited	O
10	by	O
11	preincubation	O
12	of	O
13	Gbetagamma	B
14	with	O
15	the	O
16	GDP	O
17	-	O
18	bound	O
19	but	O
20	not	O
21	the	O
22	GTP	O
23	-	O
24	bound	O
25	form	O
26	of	O
27	Gialpha	B
28	.	O

1	Their	O
2	afterglows	O
3	are	O
4	brighter	O
5	than	O
6	supernovae	O
7	and	O
8	therefore	O
9	are	O
10	called	O
11	hypernovae	O
12	.	O

1	Constrictive	O
2	pericarditis	O
3	and	O
4	pleuropulmonary	O
5	disease	O
6	linked	O
7	to	O
8	ergot	O
9	dopamine	O
10	agonist	O
11	therapy	O
12	(	O
13	cabergoline	O
14	)	O
15	for	O
16	Parkinson	O
17	'	O
18	s	O
19	disease	O
20	.	O

1	An	O
2	undilated	O
3	type	O
4	of	O
5	APBD	O
6	is	O
7	frequently	O
8	associated	O
9	with	O
10	AMT	O
11	and	O
12	we	O
13	believe	O
14	,	O
15	therefore	O
16	,	O
17	that	O
18	clinicians	O
19	should	O
20	be	O
21	aware	O
22	of	O
23	a	O
24	possible	O
25	coexistence	O
26	of	O
27	APBD	O
28	and	O
29	AMT	O
30	.	O

1	In	O
2	addition	O
3	,	O
4	we	O
5	also	O
6	constructed	O
7	and	O
8	expressed	O
9	chimeric	O
10	fusion	O
11	protein	O
12	that	O
13	contains	O
14	HIV	B
15	-	I
16	2	I
17	gag	I
18	with	O
19	V3	B
20	domains	O
21	of	O
22	HIV	O
23	-	O
24	1IIIB	O
25	,	O
26	HIV	O
27	-	O
28	1MN	O
29	,	O
30	HIV	O
31	-	O
32	1SF2	O
33	and	O
34	HIV	O
35	-	O
36	1RF	O
37	.	O

1	Our	O
2	results	O
3	indicate	O
4	that	O
5	V3	B
6	peptides	O
7	from	O
8	all	O
9	major	O
10	clades	O
11	of	O
12	HIV	O
13	-	O
14	1	O
15	carried	O
16	by	O
17	HIV	B
18	-	I
19	2	I
20	gag	I
21	can	O
22	be	O
23	used	O
24	as	O
25	a	O
26	potential	O
27	HIV	O
28	/	O
29	AIDS	O
30	vaccine	O
31	.	O

1	Efficacy	O
2	was	O
3	determined	O
4	by	O
5	responses	O
6	to	O
7	question	O
8	3	O
9	(	O
10	ability	O
11	to	O
12	achieve	O
13	an	O
14	erection	O
15	)	O
16	and	O
17	question	O
18	4	O
19	(	O
20	ability	O
21	to	O
22	maintain	O
23	an	O
24	erection	O
25	)	O
26	of	O
27	the	O
28	15	O
29	-	O
30	item	O
31	International	O
32	Index	O
33	of	O
34	Erectile	O
35	Function	O
36	(	O
37	IIEF	O
38	).	O

1	Evidence	O
2	for	O
3	the	O
4	involvement	O
5	of	O
6	the	O
7	Glc7	B
8	-	O
9	Reg1	B
10	phosphatase	O
11	and	O
12	the	O
13	Snf1	B
14	-	O
15	Snf4	B
16	kinase	O
17	in	O
18	the	O
19	regulation	O
20	of	O
21	INO1	B
22	transcription	O
23	in	O
24	Saccharomyces	O
25	cerevisiae	O
26	.	O

1	In	O
2	XO	O
3	males	O
4	,	O
5	two	O
6	her	B
7	-	I
8	1	I
9	mRNAs	I
10	,	O
11	her	B
12	-	I
13	1a	I
14	and	O
15	her	B
16	-	I
17	1b	I
18	,	O
19	are	O
20	transcribed	O
21	from	O
22	two	O
23	separate	O
24	promoters	O
25	:	O
26	P1	O
27	,	O
28	located	O
29	in	O
30	the	O
31	5	O
32	'-	O
33	flanking	O
34	region	O
35	,	O
36	and	O
37	P2	O
38	,	O
39	located	O
40	in	O
41	the	O
42	large	O
43	second	O
44	intron	O
45	.	O

1	Induction	O
2	of	O
3	Fas	B
4	ligand	I
5	expression	O
6	by	O
7	HIV	O
8	involves	O
9	the	O
10	interaction	O
11	of	O
12	Nef	B
13	with	O
14	the	O
15	T	B
16	cell	I
17	receptor	I
18	zeta	I
19	chain	I
20	.	O

1	Receptor	B
2	protein	I
3	tyrosine	I
4	phosphatases	I
5	(	O
6	RPTPs	B
7	)	O
8	comprise	O
9	a	O
10	family	O
11	of	O
12	proteins	O
13	that	O
14	feature	O
15	intracellular	O
16	phosphatase	O
17	domains	O
18	and	O
19	an	O
20	ectodomain	O
21	with	O
22	putative	O
23	ligand	O
24	-	O
25	binding	O
26	motifs	O
27	.	O

1	These	O
2	well	O
3	-	O
4	characterized	O
5	brain	O
6	regions	O
7	may	O
8	provide	O
9	a	O
10	basis	O
11	for	O
12	future	O
13	studies	O
14	of	O
15	RPTP	B
16	-	I
17	kappa	I
18	function	O
19	.	O

1	Commonly	O
2	used	O
3	stressors	O
4	are	O
5	mental	O
6	arithmetics	O
7	,	O
8	speech	O
9	tasks	O
10	,	O
11	the	O
12	Stroop	O
13	test	O
14	,	O
15	videogame	O
16	playing	O
17	,	O
18	films	O
19	or	O
20	videotapes	O
21	and	O
22	interviews	O
23	.	O

1	The	O
2	control	O
3	group	O
4	included	O
5	8	O
6	afterbirth	O
7	samples	O
8	from	O
9	physiological	O
10	full	O
11	-	O
12	term	O
13	pregnancies	O
14	.	O

1	However	O
2	,	O
3	we	O
4	identified	O
5	a	O
6	gene	O
7	between	O
8	the	O
9	MDV2	B
10	UL54	I
11	and	O
12	UL55	B
13	genes	I
14	with	O
15	homology	O
16	to	O
17	the	O
18	first	B
19	ORF	I
20	(	I
21	ORF	I
22	-	I
23	1	I
24	)	I
25	of	I
26	equine	I
27	herpesvirus	I
28	type	I
29	1	I
30	and	O
31	corresponding	O
32	gene	O
33	identified	O
34	in	O
35	pseudorabies	O
36	virus	O
37	.	O

1	In	O
2	contrast	O
3	,	O
4	the	O
5	loss	O
6	of	O
7	MAD2	B
8	staining	O
9	in	O
10	meiosis	O
11	was	O
12	not	O
13	correlated	O
14	with	O
15	initial	O
16	microtubule	O
17	attachment	O
18	but	O
19	was	O
20	correlated	O
21	with	O
22	a	O
23	measure	O
24	of	O
25	tension	O
26	:	O
27	the	O
28	distance	O
29	between	O
30	homologous	O
31	or	O
32	sister	O
33	kinetochores	O
34	(	O
35	in	O
36	meiosis	O
37	I	O
38	and	O
39	II	O
40	,	O
41	respectively	O
42	).	O

1	In	O
2	epithelial	O
3	cells	O
4	,	O
5	the	O
6	PH	B
7	domain	I
8	of	O
9	Akt	B
10	/	O
11	PKB	B
12	localised	O
13	to	O
14	sites	O
15	of	O
16	cell	O
17	-	O
18	cell	O
19	and	O
20	cell	O
21	-	O
22	matrix	O
23	contact	O
24	,	O
25	distinct	O
26	from	O
27	focal	O
28	contacts	O
29	,	O
30	even	O
31	in	O
32	the	O
33	absence	O
34	of	O
35	serum	O
36	.	O

1	The	O
2	5	O
3	'	O
4	untranslated	O
5	and	O
6	coding	O
7	regions	O
8	are	O
9	contained	O
10	within	O
11	12	O
12	exons	O
13	,	O
14	with	O
15	the	O
16	translation	O
17	start	O
18	site	O
19	located	O
20	within	O
21	the	O
22	first	O
23	exon	O
24	.	O

1	The	O
2	motility	O
3	of	O
4	sperm	O
5	,	O
6	except	O
7	for	O
8	those	O
9	adjacent	O
10	to	O
11	both	O
12	electrodes	O
13	,	O
14	did	O
15	not	O
16	change	O
17	after	O
18	stimulation	O
19	for	O
20	60s	O
21	,	O
22	despite	O
23	a	O
24	high	O
25	electrical	O
26	energy	O
27	.	O

1	Induction	O
2	of	O
3	the	O
4	CINC	B
5	promoter	I
6	by	O
7	IL	B
8	-	I
9	17	I
10	in	O
11	IEC	O
12	-	O
13	6	O
14	cells	O
15	was	O
16	TNF	B
17	receptor	I
18	-	I
19	associated	I
20	factor	I
21	-	I
22	6	I
23	(	O
24	TRAF6	B
25	),	O
26	but	O
27	not	O
28	TRAF2	B
29	,	O
30	dependent	O
31	.	O

1	SCFFWD1	B
2	may	O
3	be	O
4	critical	O
5	for	O
6	tumor	O
7	development	O
8	and	O
9	suppression	O
10	through	O
11	regulation	O
12	of	O
13	beta	B
14	-	I
15	catenin	I
16	protein	I
17	stability	O
18	.	O

1	A	O
2	Bub2p	B
3	-	O
4	dependent	O
5	spindle	O
6	checkpoint	O
7	pathway	O
8	regulates	O
9	the	O
10	Dbf2p	B
11	kinase	I
12	in	I
13	budding	I
14	yeast	I
15	.	O

1	We	O
2	analyzed	O
3	the	O
4	modular	O
5	organization	O
6	of	O
7	DNA	B
8	polymerase	I
9	beta	I
10	and	O
11	found	O
12	that	O
13	residues	O
14	making	O
15	contact	O
16	with	O
17	DNA	O
18	phosphates	O
19	were	O
20	localized	O
21	to	O
22	five	O
23	modules	O
24	.	O

1	RESULTS	O
2	:	O
3	Cholinergic	O
4	nerves	O
5	are	O
6	mainly	O
7	involved	O
8	in	O
9	the	O
10	regulation	O
11	of	O
12	enteric	O
13	nerve	O
14	responses	O
15	to	O
16	EFS	O
17	in	O
18	the	O
19	normal	O
20	IAS	O
21	.	O

1	Two	O
2	-	O
3	dimensional	O
4	gel	O
5	electrophoresis	O
6	of	O
7	anti	B
8	-	I
9	p59fyn	I
10	immunoprecipitates	O
11	obtained	O
12	from	O
13	non	O
14	-	O
15	transformed	O
16	resting	O
17	human	O
18	T	O
19	lymphocytes	O
20	resulted	O
21	in	O
22	the	O
23	identification	O
24	of	O
25	an	O
26	oligomeric	O
27	protein	O
28	complex	O
29	which	O
30	is	O
31	constitutively	O
32	formed	O
33	between	O
34	Fyn	B
35	and	O
36	several	O
37	additional	O
38	phosphoproteins	O
39	(	O
40	pp43	B
41	,	O
42	pp72	B
43	,	O
44	pp85	B
45	,	O
46	the	O
47	protein	B
48	tyrosine	I
49	kinase	I
50	Pyk2	I
51	,	O
52	as	O
53	well	O
54	as	O
55	the	O
56	two	O
57	recently	O
58	cloned	O
59	adaptor	O
60	proteins	O
61	,	O
62	SKAP55	B
63	and	O
64	SLAP	B
65	-	I
66	130	I
67	).	O

1	We	O
2	show	O
3	that	O
4	other	O
5	cdc33	B
6	mutants	I
7	also	O
8	arrest	O
9	in	O
10	G1	O
11	.	O

1	A	O
2	cdc33	B
3	-	I
4	1	I
5	strain	O
6	expressing	O
7	either	O
8	stable	O
9	Cln3p	B
10	(	O
11	Cln3	B
12	-	I
13	1p	I
14	)	O
15	or	O
16	a	O
17	hybrid	O
18	UBI4	B
19	5	I
20	'-	I
21	CLN3	I
22	mRNA	O
23	,	O
24	whose	O
25	translation	O
26	displays	O
27	decreased	O
28	dependence	O
29	on	O
30	eIF4E	B
31	,	O
32	arrested	O
33	randomly	O
34	in	O
35	the	O
36	cell	O
37	cycle	O
38	.	O

1	Regulatory	O
2	motifs	O
3	for	O
4	gene	O
5	expression	O
6	such	O
7	as	O
8	nuclear	B
9	-	I
10	factor	I
11	-	I
12	kappaB	I
13	-	I
14	binding	I
15	-	I
16	site	I
17	-	I
18	like	I
19	sequence	I
20	(	O
21	kappaB	B
22	site	I
23	)	O
24	and	O
25	nuclear	B
26	-	I
27	factor	I
28	-	I
29	interleukin	I
30	-	I
31	6	I
32	-	I
33	binding	I
34	-	I
35	site	I
36	-	I
37	like	I
38	sequence	I
39	(	O
40	NF	B
41	-	I
42	IL	I
43	-	I
44	6	I
45	site	I
46	)	O
47	were	O
48	found	O
49	in	O
50	the	O
51	5	O
52	'-	O
53	upstream	O
54	regulatory	O
55	region	O
56	.	O

1	The	O
2	gene	O
3	structure	O
4	of	O
5	Elk1	B
6	spans	O
7	15	O
8	.	O
9	2	O
10	kb	O
11	and	O
12	consists	O
13	of	O
14	seven	O
15	exons	O
16	and	O
17	six	O
18	introns	O
19	.	O

1	Total	O
2	serum	O
3	calcium	O
4	was	O
5	7	O
6	.	O
7	8	O
8	+/-	O
9	0	O
10	.	O
11	8	O
12	mg	O
13	/	O
14	dl	O
15	,	O
16	whereas	O
17	ionized	O
18	calcium	O
19	was	O
20	5	O
21	.	O
22	7	O
23	+/-	O
24	0	O
25	.	O
26	7	O
27	mg	O
28	/	O
29	dl	O
30	,	O
31	phosphorus	O
32	3	O
33	.	O
34	2	O
35	+/-	O
36	1	O
37	.	O
38	2	O
39	mg	O
40	/	O
41	dl	O
42	,	O
43	and	O
44	alkaline	B
45	phosphatase	I
46	149	O
47	+/-	O
48	48	O
49	.	O
50	6	O
51	U	O
52	/	O
53	liter	O
54	.	O

1	Sequence	O
2	analysis	O
3	suggests	O
4	that	O
5	TtrA	B
6	contains	O
7	a	O
8	molybdopterin	O
9	guanine	O
10	dinucleotide	O
11	cofactor	O
12	and	O
13	a	O
14	[	O
15	4Fe	O
16	-	O
17	4S	O
18	]	O
19	cluster	O
20	,	O
21	that	O
22	TtrB	B
23	binds	O
24	four	O
25	[	O
26	4Fe	O
27	-	O
28	4S	O
29	]	O
30	clusters	O
31	,	O
32	and	O
33	that	O
34	TtrC	B
35	is	O
36	an	O
37	integral	O
38	membrane	O
39	protein	O
40	containing	O
41	a	O
42	quinol	O
43	oxidation	O
44	site	O
45	.	O

1	Cranio	O
2	-	O
3	caudal	O
4	differences	O
5	in	O
6	granulation	O
7	tissue	O
8	formation	O
9	:	O
10	an	O
11	experimental	O
12	study	O
13	in	O
14	the	O
15	rat	O
16	.	O

1	Site	O
2	-	O
3	directed	O
4	mutagenesis	O
5	showed	O
6	that	O
7	two	O
8	adjacent	O
9	SP1	B
10	sites	I
11	proximal	O
12	to	O
13	exon	O
14	1	O
15	were	O
16	equally	O
17	important	O
18	in	O
19	sustaining	O
20	basal	O
21	promoter	O
22	activity	O
23	.	O

1	Breast	O
2	-	O
3	fed	O
4	newborn	O
5	infants	O
6	synthesize	O
7	n	O
8	-	O
9	6	O
10	long	O
11	-	O
12	chain	O
13	polyunsaturated	O
14	fatty	O
15	acids	O
16	already	O
17	during	O
18	the	O
19	first	O
20	week	O
21	of	O
22	life	O
23	,	O
24	but	O
25	the	O
26	contribution	O
27	of	O
28	endogenous	O
29	synthesis	O
30	to	O
31	the	O
32	total	O
33	plasma	O
34	long	O
35	-	O
36	chain	O
37	polyunsaturated	O
38	pool	O
39	is	O
40	small	O
41	.	O

1	Ischemia	O
2	and	O
3	reperfusion	O
4	markedly	O
5	increased	O
6	the	O
7	release	O
8	of	O
9	6	O
10	-	O
11	keto	O
12	-	O
13	PGF1	O
14	alpha	O
15	and	O
16	TXB2	O
17	.	O

1	Prostate	B
2	-	I
3	specific	I
4	antigen	I
5	(	O
6	PSA	B
7	)	O
8	promoter	O
9	-	O
10	driven	O
11	androgen	O
12	-	O
13	inducible	O
14	expression	O
15	of	O
16	sodium	B
17	iodide	I
18	symporter	I
19	in	O
20	prostate	O
21	cancer	O
22	cell	O
23	lines	O
24	.	O

1	It	O
2	is	O
3	clear	O
4	that	O
5	subclinical	O
6	and	O
7	silent	O
8	CD	O
9	exist	O
10	in	O
11	a	O
12	large	O
13	subgroup	O
14	of	O
15	the	O
16	celiac	O
17	population	O
18	.	O

1	Ras2p	B
2	activates	O
3	invasive	O
4	growth	O
5	using	O
6	either	O
7	of	O
8	two	O
9	downstream	O
10	signaling	O
11	pathways	O
12	,	O
13	the	O
14	filamentation	O
15	MAPK	B
16	(	O
17	Cdc42p	B
18	/	O
19	Ste20p	B
20	/	O
21	MAPK	B
22	)	O
23	cascade	O
24	or	O
25	the	O
26	cAMP	B
27	-	I
28	dependent	I
29	protein	I
30	kinase	I
31	(	O
32	Cyr1p	B
33	/	O
34	cAMP	O
35	/	O
36	PKA	B
37	)	O
38	pathway	O
39	.	O

1	Consistent	O
2	with	O
3	this	O
4	prediction	O
5	,	O
6	transfections	O
7	into	O
8	the	O
9	hematopoietic	O
10	cell	O
11	line	O
12	Jurkat	O
13	showed	O
14	a	O
15	9	O
16	.	O
17	0	O
18	-	O
19	and	O
20	2	O
21	.	O
22	5	O
23	-	O
24	fold	O
25	activation	O
26	of	O
27	the	O
28	mim	B
29	-	I
30	1	I
31	promoter	I
32	by	O
33	the	O
34	p32	B
35	and	O
36	p30	B
37	isoforms	I
38	,	O
39	respectively	O
40	.	O

1	Previous	O
2	work	O
3	has	O
4	shown	O
5	that	O
6	spleen	B
7	necrosis	I
8	virus	I
9	(	I
10	SNV	I
11	)	I
12	long	I
13	terminal	I
14	repeats	I
15	(	O
16	LTRs	O
17	)	O
18	are	O
19	associated	O
20	with	O
21	Rex	B
22	/	O
23	Rex	B
24	-	O
25	responsive	O
26	element	O
27	-	O
28	independent	O
29	expression	O
30	of	O
31	bovine	O
32	leukemia	O
33	virus	O
34	RNA	O
35	and	O
36	supports	O
37	the	O
38	hypothesis	O
39	that	O
40	SNV	O
41	RNA	O
42	contains	O
43	a	O
44	cis	O
45	-	O
46	acting	O
47	element	O
48	that	O
49	interacts	O
50	with	O
51	cellular	B
52	Rex	I
53	-	I
54	like	I
55	proteins	I
56	.	O

1	Despite	O
2	the	O
3	reported	O
4	detrimental	O
5	effects	O
6	on	O
7	CNS	O
8	development	O
9	,	O
10	a	O
11	number	O
12	of	O
13	animal	O
14	studies	O
15	have	O
16	shown	O
17	that	O
18	pretreatment	O
19	with	O
20	corticosteroids	O
21	nevertheless	O
22	protect	O
23	the	O
24	brain	O
25	from	O
26	hypoxia	O
27	-	O
28	ischemic	O
29	injury	O
30	;	O
31	however	O
32	,	O
33	clinically	O
34	such	O
35	treatment	O
36	is	O
37	no	O
38	longer	O
39	favored	O
40	.	O

1	In	O
2	one	O
3	mechanism	O
4	,	O
5	a	O
6	specialized	O
7	ubiquitin	B
8	-	O
9	dependent	O
10	proteolytic	O
11	system	O
12	(	O
13	called	O
14	the	O
15	APC	O
16	-	O
17	dependent	O
18	proteolysis	O
19	machinery	O
20	)	O
21	degrades	O
22	the	O
23	mitotic	O
24	(	O
25	Clb	B
26	)	O
27	cyclin	B
28	subunit	I
29	.	O

1	Predictors	O
2	of	O
3	success	O
4	in	O
5	pharmacy	O
6	school	O
7	:	O
8	PCAT	O
9	vs	O
10	.	O
11	other	O
12	admission	O
13	criteria	O
14	.	O

1	Canadian	O
2	survey	O
3	reveals	O
4	widespread	O
5	dissatisfaction	O
6	among	O
7	physicians	O
8	.	O

1	In	O
2	a	O
3	series	O
4	of	O
5	16	O
6	full	O
7	-	O
8	scale	O
9	fire	O
10	tests	O
11	,	O
12	investigators	O
13	at	O
14	the	O
15	IIT	O
16	Research	O
17	Institute	O
18	have	O
19	concluded	O
20	that	O
21	automatic	O
22	door	O
23	control	O
24	in	O
25	the	O
26	room	O
27	of	O
28	fire	O
29	origin	O
30	can	O
31	significantly	O
32	reduce	O
33	the	O
34	spread	O
35	of	O
36	toxic	O
37	smoke	O
38	and	O
39	gases	O
40	.	O

1	Online	O
2	LATCH	O
3	demonstrates	O
4	a	O
5	shift	O
6	in	O
7	identification	O
8	of	O
9	the	O
10	library	O
11	as	O
12	an	O
13	isolated	O
14	unit	O
15	to	O
16	an	O
17	interactive	O
18	resource	O
19	center	O
20	.	O

1	Reporting	O
2	of	O
3	adverse	O
4	events	O
5	occurring	O
6	during	O
7	clinical	O
8	trials	O
9	of	O
10	investigational	O
11	drugs	O
12	is	O
13	a	O
14	complex	O
15	and	O
16	controversial	O
17	issue	O
18	.	O

1	Medicare	O
2	SNF	O
3	benefits	O
4	revised	O
5	--	O
6	again	O
7	.	O

1	In	O
2	this	O
3	paper	O
4	,	O
5	the	O
6	current	O
7	status	O
8	of	O
9	the	O
10	understanding	O
11	of	O
12	the	O
13	interaction	O
14	mechanisms	O
15	of	O
16	ultrasound	O
17	with	O
18	biological	O
19	media	O
20	and	O
21	the	O
22	factors	O
23	that	O
24	govern	O
25	different	O
26	biological	O
27	effects	O
28	are	O
29	surveyed	O
30	.	O

1	Members	O
2	of	O
3	the	O
4	mitogen	B
5	activated	I
6	protein	I
7	(	I
8	MAP	I
9	)	I
10	kinase	I
11	family	I
12	,	O
13	extracellular	B
14	signal	I
15	-	I
16	regulated	I
17	kinase	I
18	,	O
19	stress	B
20	-	I
21	activated	I
22	protein	I
23	kinase	I
24	-	I
25	1	I
26	/	O
27	c	B
28	-	I
29	Jun	I
30	NH2	I
31	-	I
32	terminal	I
33	kinase	I
34	,	O
35	and	O
36	p38	B
37	,	O
38	are	O
39	central	O
40	elements	O
41	that	O
42	transduce	O
43	the	O
44	signal	O
45	generated	O
46	by	O
47	growth	O
48	factors	O
49	,	O
50	cytokines	O
51	,	O
52	and	O
53	stressing	O
54	agents	O
55	.	O

1	In	O
2	the	O
3	present	O
4	study	O
5	,	O
6	we	O
7	have	O
8	investigated	O
9	the	O
10	functional	O
11	role	O
12	of	O
13	the	O
14	other	O
15	MAP	B
16	kinases	I
17	in	O
18	PDGF	B
19	-	O
20	mediated	O
21	cellular	O
22	responses	O
23	.	O

1	Analyses	O
2	of	O
3	tyrosine	O
4	residue	O
5	-	O
6	mutated	O
7	PDGF	B
8	receptors	I
9	show	O
10	that	O
11	Src	B
12	homology	I
13	2	I
14	domain	I
15	-	I
16	containing	I
17	proteins	I
18	including	O
19	Src	B
20	family	I
21	kinases	I
22	,	O
23	phosphatidylinositol	B
24	3	I
25	-	I
26	kinase	I
27	,	O
28	the	O
29	GTPase	B
30	-	I
31	activating	I
32	protein	I
33	of	O
34	Ras	B
35	,	O
36	the	O
37	Src	B
38	homology	I
39	2	I
40	domain	I
41	-	I
42	containing	I
43	phosphatase	I
44	SHP	I
45	-	I
46	2	I
47	,	O
48	phospholipase	B
49	C	I
50	-	I
51	gamma	I
52	,	O
53	and	O
54	Crk	B
55	do	O
56	not	O
57	play	O
58	a	O
59	major	O
60	role	O
61	in	O
62	mediating	O
63	the	O
64	PDGF	B
65	-	O
66	induced	O
67	activation	O
68	of	O
69	p38	B
70	.	O

1	Here	O
2	we	O
3	show	O
4	that	O
5	calpeptin	B
6	inhibits	O
7	tyrosine	B
8	phosphatases	I
9	,	O
10	enhancing	O
11	tyrosine	O
12	phosphorylation	O
13	particularly	O
14	of	O
15	paxillin	B
16	.	O

1	Three	O
2	-	O
3	dimensional	O
4	structural	O
5	studies	O
6	using	O
7	electron	O
8	cryomicroscopy	O
9	showed	O
10	that	O
11	the	O
12	binding	O
13	of	O
14	one	O
15	Fab	B
16	(	O
17	8H2	O
18	/	O
19	G5	O
20	)	O
21	does	O
22	not	O
23	affect	O
24	the	O
25	conformation	O
26	of	O
27	the	O
28	capsid	O
29	,	O
30	and	O
31	the	O
32	efficiency	O
33	of	O
34	mRNA	O
35	production	O
36	is	O
37	similar	O
38	to	O
39	that	O
40	of	O
41	the	O
42	native	O
43	subviral	O
44	particle	O
45	.	O

1	Further	O
2	,	O
3	mutational	O
4	analysis	O
5	of	O
6	NS5A	B
7	assigned	O
8	the	O
9	SH3	B
10	-	I
11	binding	I
12	region	I
13	to	O
14	a	O
15	proline	O
16	-	O
17	rich	O
18	motif	O
19	that	O
20	is	O
21	highly	O
22	conserved	O
23	among	O
24	HCV	O
25	genotypes	O
26	.	O

1	Taken	O
2	together	O
3	,	O
4	these	O
5	findings	O
6	show	O
7	that	O
8	16K	B
9	hPRL	I
10	inhibits	O
11	the	O
12	VEGF	B
13	-	O
14	induced	O
15	Ras	B
16	activation	O
17	;	O
18	this	O
19	antagonism	O
20	represents	O
21	a	O
22	novel	O
23	and	O
24	potentially	O
25	important	O
26	mechanism	O
27	for	O
28	the	O
29	control	O
30	of	O
31	angiogenesis	O
32	.	O

1	Analysis	O
2	of	O
3	SRE	O
4	oligonucleotide	O
5	gel	O
6	mobility	O
7	shift	O
8	assays	O
9	with	O
10	nuclear	O
11	extracts	O
12	from	O
13	Sertoli	O
14	cells	O
15	demonstrated	O
16	the	O
17	presence	O
18	of	O
19	both	O
20	the	O
21	SRF	B
22	and	O
23	the	O
24	ubiquitously	O
25	expressed	O
26	bHLH	O
27	protein	O
28	E12	B
29	/	O
30	E47	B
31	.	O

1	We	O
2	calculated	O
3	differences	O
4	in	O
5	late	O
6	occlusion	O
7	rates	O
8	by	O
9	the	O
10	chi2	O
11	(	O
12	chi	O
13	-	O
14	square	O
15	)	O
16	test	O
17	,	O
18	and	O
19	found	O
20	these	O
21	differences	O
22	were	O
23	significant	O
24	(	O
25	P	O
26	=.	O
27	04	O
28	).	O

1	Baseline	O
2	electrocorticography	O
3	over	O
4	the	O
5	surface	O
6	of	O
7	the	O
8	temporal	O
9	lobe	O
10	and	O
11	depth	O
12	electrode	O
13	recordings	O
14	in	O
15	the	O
16	amygdala	O
17	and	O
18	hippocampus	O
19	were	O
20	obtained	O
21	,	O
22	followed	O
23	by	O
24	10	O
25	min	O
26	of	O
27	recording	O
28	before	O
29	and	O
30	after	O
31	the	O
32	i	O
33	.	O
34	v	O
35	.	O
36	administration	O
37	of	O
38	both	O
39	alfentanil	O
40	50	O
41	microg	O
42	/	O
43	kg	O
44	and	O
45	fentanyl	O
46	10	O
47	microg	O
48	/	O
49	kg	O
50	.	O

1	We	O
2	describe	O
3	a	O
4	genetic	O
5	system	O
6	for	O
7	further	O
8	characterizing	O
9	the	O
10	role	O
11	of	O
12	the	O
13	extreme	O
14	C	O
15	-	O
16	terminus	O
17	of	O
18	the	O
19	beta	O
20	subunit	O
21	of	O
22	E	B
23	.	I
24	coli	I
25	RNA	I
26	polymerase	I
27	.	O

1	We	O
2	suggest	O
3	that	O
4	FlgN	B
5	and	O
6	FliT	B
7	are	O
8	substrate	O
9	-	O
10	specific	O
11	flagellar	O
12	chaperones	O
13	that	O
14	prevent	O
15	oligomerization	O
16	of	O
17	the	O
18	HAPs	B
19	by	O
20	binding	O
21	to	O
22	their	O
23	helical	O
24	domains	O
25	before	O
26	export	O
27	.	O

1	Post	O
2	and	O
3	core	O
4	fabrication	O
5	for	O
6	divergent	O
7	canals	O
8	with	O
9	a	O
10	cast	O
11	post	O
12	and	O
13	core	O
14	and	O
15	a	O
16	prefabricated	O
17	dowel	O
18	.	O

1	Rep63A	O
2	(	O
3	513	O
4	amino	O
5	acids	O
6	[	O
7	aa	O
8	]),	O
9	encoded	O
10	by	O
11	the	O
12	largest	O
13	ORF	O
14	,	O
15	displayed	O
16	strong	O
17	similarity	O
18	(	O
19	40	O
20	%	O
21	identity	O
22	)	O
23	to	O
24	the	O
25	replication	O
26	proteins	O
27	from	O
28	plasmids	O
29	pAMbeta1	O
30	,	O
31	pIP501	O
32	,	O
33	and	O
34	pSM19035	O
35	,	O
36	indicating	O
37	that	O
38	the	O
39	pAW63	O
40	replicon	O
41	belongs	O
42	to	O
43	the	O
44	pAMbeta1	O
45	family	O
46	of	O
47	gram	O
48	-	O
49	positive	O
50	theta	O
51	-	O
52	replicating	O
53	plasmids	O
54	.	O

1	Here	O
2	we	O
3	report	O
4	the	O
5	cloning	O
6	and	O
7	characterization	O
8	of	O
9	Xenopus	B
10	Pax	I
11	-	I
12	5	I
13	and	O
14	Pax	B
15	-	I
16	8	I
17	,	O
18	two	O
19	orthologues	O
20	of	O
21	the	O
22	Pax	B
23	-	I
24	2	I
25	/	I
26	5	I
27	/	I
28	8	I
29	gene	I
30	family	I
31	.	O

1	Km	O
2	values	O
3	for	O
4	ammonium	O
5	,	O
6	2	O
7	-	O
8	oxoglutarate	O
9	,	O
10	NADH	O
11	,	O
12	glutamate	O
13	and	O
14	NAD	O
15	+	O
16	were	O
17	6	O
18	.	O
19	5	O
20	,	O
21	3	O
22	.	O
23	5	O
24	,	O
25	0	O
26	.	O
27	06	O
28	,	O
29	37	O
30	.	O
31	1	O
32	and	O
33	0	O
34	.	O
35	046	O
36	mM	O
37	,	O
38	respectively	O
39	.	O

1	Interferon	B
2	-	I
3	alpha	I
4	may	O
5	exacerbate	O
6	cryoblobulinemia	O
7	-	O
8	related	O
9	ischemic	O
10	manifestations	O
11	:	O
12	an	O
13	adverse	O
14	effect	O
15	potentially	O
16	related	O
17	to	O
18	its	O
19	anti	O
20	-	O
21	angiogenic	O
22	activity	O
23	.	O

1	Interferon	B
2	-	I
3	alpha	I
4	may	O
5	exacerbate	O
6	cryoblobulinemia	O
7	-	O
8	related	O
9	ischemic	O
10	manifestations	O
11	:	O
12	an	O
13	adverse	O
14	effect	O
15	potentially	O
16	related	O
17	to	O
18	its	O
19	anti	O
20	-	O
21	angiogenic	O
22	activity	O
23	.	O

1	In	O
2	addition	O
3	,	O
4	we	O
5	demonstrate	O
6	that	O
7	the	O
8	production	O
9	of	O
10	active	B
11	recombinant	I
12	telomerase	I
13	requires	O
14	a	O
15	factor	O
16	in	O
17	rabbit	O
18	reticulocyte	O
19	lysate	O
20	that	O
21	promotes	O
22	ribonucleoprotein	O
23	assembly	O
24	.	O

1	The	O
2	enhanced	O
3	binding	O
4	of	O
5	c	B
6	-	I
7	Abl	I
8	to	O
9	DNA	O
10	containing	O
11	5	O
12	-	O
13	methylcytosine	O
14	residues	O
15	may	O
16	result	O
17	from	O
18	an	O
19	increased	O
20	propensity	O
21	of	O
22	the	O
23	double	O
24	helix	O
25	to	O
26	denature	O
27	locally	O
28	coupled	O
29	with	O
30	a	O
31	protein	O
32	-	O
33	induced	O
34	reduction	O
35	in	O
36	the	O
37	base	O
38	stacking	O
39	interaction	O
40	.	O

1	Homozygous	O
2	mutation	O
3	in	O
4	two	O
5	children	O
6	led	O
7	to	O
8	amputation	O
9	of	O
10	legs	O
11	due	O
12	to	O
13	purpura	O
14	fulminans	O
15	.	O

1	According	O
2	to	O
3	pilot	O
4	experiments	O
5	which	O
6	considered	O
7	various	O
8	durations	O
9	of	O
10	global	O
11	no	O
12	-	O
13	flow	O
14	ischemia	O
15	ranging	O
16	from	O
17	10	O
18	to	O
19	20	O
20	minutes	O
21	,	O
22	two	O
23	durations	O
24	were	O
25	chosen	O
26	for	O
27	the	O
28	present	O
29	study	O
30	:	O
31	20	O
32	minutes	O
33	(	O
34	group	O
35	20	O
36	)	O
37	in	O
38	which	O
39	ventricular	O
40	fibrillation	O
41	(	O
42	VF	O
43	)	O
44	was	O
45	the	O
46	predominant	O
47	form	O
48	of	O
49	arrhythmias	O
50	,	O
51	and	O
52	18	O
53	minutes	O
54	(	O
55	group	O
56	18	O
57	)	O
58	in	O
59	which	O
60	the	O
61	prevalence	O
62	of	O
63	VF	O
64	was	O
65	markedly	O
66	lower	O
67	despite	O
68	the	O
69	small	O
70	difference	O
71	in	O
72	the	O
73	duration	O
74	of	O
75	ischemia	O
76	.	O

1	An	O
2	end	O
3	-	O
4	to	O
5	-	O
6	end	O
7	pancreaticojejunostomy	O
8	using	O
9	a	O
10	mechanical	O
11	purse	O
12	-	O
13	string	O
14	device	O
15	.	O

1	We	O
2	further	O
3	demonstrate	O
4	that	O
5	the	O
6	Stress	B
7	-	I
8	Activated	I
9	-	I
10	Protein	I
11	-	I
12	Kinase	I
13	(	O
14	SAPK	B
15	)	O
16	target	O
17	sites	O
18	of	O
19	ATF2	B
20	,	O
21	Thr69	O
22	and	O
23	Thr71	O
24	are	O
25	not	O
26	required	O
27	for	O
28	the	O
29	formation	O
30	of	O
31	the	O
32	p300	B
33	/	O
34	CBP	B
35	-	O
36	ATF2	B
37	multiprotein	O
38	complex	O
39	.	O

1	Blood	O
2	samples	O
3	were	O
4	obtained	O
5	daily	O
6	during	O
7	this	O
8	supplementation	O
9	period	O
10	and	O
11	5	O
12	d	O
13	thereafter	O
14	(	O
15	d	O
16	11	O
17	to	O
18	15	O
19	).	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	mitochondrial	O
6	presequences	O
7	interact	O
8	with	O
9	the	O
10	mt	B
11	-	I
12	hsp70	I
13	during	O
14	or	O
15	after	O
16	mitochondrial	O
17	protein	O
18	import	O
19	.	O

1	The	O
2	3	O
3	'	O
4	terminus	O
5	of	O
6	the	O
7	genome	O
8	can	O
9	be	O
10	folded	O
11	into	O
12	a	O
13	tRNA	O
14	-	O
15	like	O
16	secondary	O
17	structure	O
18	that	O
19	has	O
20	a	O
21	valine	O
22	anticodon	O
23	;	O
24	the	O
25	tRNA	O
26	-	O
27	like	O
28	structure	O
29	lacks	O
30	a	O
31	pseudoknot	O
32	in	O
33	the	O
34	aminoacyl	O
35	stem	O
36	,	O
37	a	O
38	feature	O
39	common	O
40	to	O
41	both	O
42	genera	O
43	of	O
44	tetraviruses	O
45	.	O

1	O	B
2	.	I
3	novo	I
4	-	I
5	ulmi	I
6	RNA	I
7	-	I
8	7	I
9	,	O
10	previously	O
11	believed	O
12	to	O
13	be	O
14	a	O
15	satellite	O
16	-	O
17	like	O
18	RNA	O
19	,	O
20	is	O
21	shown	O
22	to	O
23	be	O
24	a	O
25	defective	O
26	RNA	O
27	,	O
28	derived	O
29	from	O
30	OnuMV4	B
31	-	I
32	Ld	I
33	RNA	I
34	by	O
35	multiple	O
36	internal	O
37	deletions	O
38	.	O

1	Only	O
2	one	O
3	gene	O
4	,	O
5	fibronectin	B
6	(	O
7	FN	B
8	),	O
9	was	O
10	highly	O
11	overexpressed	O
12	(>	O
13	60	O
14	-	O
15	fold	O
16	)	O
17	in	O
18	LNCaP	O
19	-	O
20	r	O
21	cells	O
22	,	O
23	consistent	O
24	with	O
25	previously	O
26	reported	O
27	overexpression	O
28	of	O
29	FN	B
30	in	O
31	prostate	O
32	cancer	O
33	.	O

1	We	O
2	also	O
3	observed	O
4	that	O
5	cell	O
6	surface	O
7	CD4	B
8	(-)	O
9	CD8	B
10	(-)	O
11	CD3	B
12	(-)	O
13	cells	O
14	with	O
15	rearranged	B
16	TCR	I
17	genes	I
18	developed	O
19	from	O
20	Id3	B
21	-	O
22	transduced	O
23	but	O
24	not	O
25	from	O
26	control	O
27	-	O
28	transduced	O
29	pre	O
30	-	O
31	T	O
32	cells	O
33	in	O
34	an	O
35	FTOC	O
36	.	O

1	As	O
2	determined	O
3	in	O
4	a	O
5	modified	O
6	yeast	O
7	two	O
8	-	O
9	hybrid	O
10	system	O
11	,	O
12	mIRS3	B
13	bound	O
14	strongly	O
15	to	O
16	the	O
17	p85	B
18	subunit	I
19	of	O
20	phosphatidylinositol	B
21	3	I
22	-	I
23	kinase	I
24	.	O

1	Insulin	B
2	stimulation	O
3	promoted	O
4	the	O
5	association	O
6	of	O
7	mIRS3	B
8	with	O
9	p85	B
10	,	O
11	SHP2	B
12	,	O
13	Nck	B
14	,	O
15	and	O
16	Shc	B
17	.	O

1	The	O
2	mRNA	O
3	expression	O
4	of	O
5	RFX1	B
6	,	O
7	RFX2	B
8	,	O
9	and	O
10	RFX3	B
11	was	O
12	detected	O
13	ubiquitously	O
14	,	O
15	but	O
16	in	O
17	transient	O
18	-	O
19	transfection	O
20	assays	O
21	,	O
22	multimerized	B
23	RFX	I
24	binding	I
25	sites	I
26	in	O
27	front	O
28	of	O
29	a	O
30	basal	O
31	promoter	O
32	efficiently	O
33	functioned	O
34	in	O
35	a	O
36	tissue	O
37	-	O
38	and	O
39	lineage	O
40	-	O
41	specific	O
42	manner	O
43	.	O

1	In	O
2	the	O
3	case	O
4	of	O
5	the	O
6	unspliceable	O
7	intron	O
8	,	O
9	repression	O
10	of	O
11	luciferase	B
12	expression	O
13	likely	O
14	involved	O
15	two	O
16	AUF1	B
17	-	I
18	binding	I
19	sequences	I
20	,	O
21	since	O
22	luciferase	B
23	expression	O
24	was	O
25	increased	O
26	by	O
27	deletion	O
28	of	O
29	these	O
30	sites	O
31	.	O

1	Thus	O
2	,	O
3	VDR	B
4	acts	O
5	selectively	O
6	on	O
7	the	O
8	two	O
9	components	O
10	required	O
11	for	O
12	activation	O
13	of	O
14	this	O
15	promoter	O
16	/	O
17	enhancer	O
18	:	O
19	it	O
20	competes	O
21	with	O
22	NFAT1	B
23	for	O
24	binding	O
25	to	O
26	the	O
27	composite	O
28	site	O
29	,	O
30	positioning	O
31	itself	O
32	adjacent	O
33	to	O
34	Jun	B
35	-	O
36	Fos	B
37	on	O
38	the	O
39	DNA	O
40	.	O

1	Two	O
2	evolutionarily	O
3	conserved	O
4	kinases	O
5	,	O
6	the	O
7	cyclin	B
8	B	I
9	(	O
10	Clb	B
11	)/	O
12	cyclin	B
13	-	I
14	dependent	I
15	kinase	I
16	(	O
17	Cdk	B
18	/	O
19	Cdc28p	B
20	)	O
21	and	O
22	Cdc7p	B
23	along	O
24	with	O
25	its	O
26	interacting	O
27	factor	O
28	Dbf4p	B
29	,	O
30	are	O
31	required	O
32	late	O
33	in	O
34	G1	O
35	to	O
36	initiate	O
37	DNA	O
38	replication	O
39	.	O

1	The	O
2	RanQ69L	B
3	preincubation	O
4	leads	O
5	to	O
6	accumulation	O
7	of	O
8	CRM1	B
9	at	O
10	the	O
11	cytoplasmic	O
12	periphery	O
13	of	O
14	the	O
15	nuclear	O
16	pore	O
17	complex	O
18	(	O
19	NPC	O
20	)	O
21	in	O
22	association	O
23	with	O
24	the	O
25	p62	B
26	complex	I
27	and	O
28	Can	B
29	/	O
30	Nup214	B
31	.	O

1	All	O
2	of	O
3	the	O
4	elements	O
5	exhibited	O
6	a	O
7	uniform	O
8	structure	O
9	.	O

1	In	O
2	contrast	O
3	,	O
4	the	O
5	deduced	O
6	amino	O
7	acid	O
8	sequence	O
9	of	O
10	a	O
11	second	O
12	family	O
13	(	O
14	ART5	B
15	)	O
16	of	O
17	transferases	O
18	,	O
19	cloned	O
20	from	O
21	murine	O
22	lymphoma	O
23	cells	O
24	and	O
25	expressed	O
26	in	O
27	high	O
28	abundance	O
29	in	O
30	testis	O
31	,	O
32	displays	O
33	a	O
34	hydrophobic	O
35	amino	O
36	terminus	O
37	,	O
38	consistent	O
39	with	O
40	a	O
41	signal	O
42	sequence	O
43	,	O
44	but	O
45	lacks	O
46	a	O
47	hydrophobic	O
48	signal	O
49	sequence	O
50	at	O
51	its	O
52	carboxyl	O
53	terminus	O
54	,	O
55	suggesting	O
56	that	O
57	the	O
58	protein	O
59	is	O
60	destined	O
61	for	O
62	export	O
63	.	O

1	RESULTS	O
2	:	O
3	Each	O
4	year	O
5	,	O
6	on	O
7	average	O
8	39	O
9	%	O
10	of	O
11	cases	O
12	seen	O
13	in	O
14	Sardinia	O
15	are	O
16	notified	O
17	;	O
18	646	O
19	(	O
20	40	O
21	%)	O
22	of	O
23	the	O
24	1591	O
25	patients	O
26	notified	O
27	during	O
28	the	O
29	study	O
30	period	O
31	were	O
32	never	O
33	seen	O
34	by	O
35	regional	O
36	medical	O
37	centres	O
38	.	O

1	This	O
2	dimer	O
3	interface	O
4	is	O
5	likely	O
6	important	O
7	for	O
8	increasing	O
9	the	O
10	DNA	O
11	-	O
12	binding	O
13	specificity	O
14	and	O
15	affinity	O
16	of	O
17	the	O
18	trimeric	O
19	form	O
20	of	O
21	HSF	B
22	,	O
23	as	O
24	well	O
25	as	O
26	for	O
27	increasing	O
28	cooperativity	O
29	between	O
30	adjacent	O
31	trimers	O
32	.	O

1	The	O
2	paramyxovirus	B
3	fusion	I
4	(	I
5	F	I
6	)	I
7	protein	I
8	mediates	O
9	membrane	O
10	fusion	O
11	.	O

1	Additionally	O
2	,	O
3	deletion	O
4	analysis	O
5	of	O
6	the	O
7	UCP2	B
8	promoter	O
9	-	O
10	PLAP	B
11	constructs	O
12	indicated	O
13	that	O
14	the	O
15	minimal	O
16	region	O
17	exhibiting	O
18	the	O
19	promoter	O
20	activity	O
21	was	O
22	located	O
23	between	O
24	nt	O
25	-	O
26	33	O
27	and	O
28	+	O
29	100	O
30	,	O
31	and	O
32	that	O
33	a	O
34	strong	O
35	enhancer	O
36	was	O
37	present	O
38	within	O
39	601	O
40	bp	O
41	of	O
42	the	O
43	5	O
44	'-	O
45	promoter	O
46	region	O
47	.	O

1	The	O
2	hTERT	B
3	gene	I
4	encompasses	O
5	more	O
6	than	O
7	37kb	O
8	and	O
9	consists	O
10	of	O
11	16	O
12	exons	O
13	.	O

1	Both	O
2	betaAPP	B
3	mRNA	I
4	and	O
5	Abeta	B
6	levels	O
7	are	O
8	increased	O
9	in	O
10	trisomy	O
11	21	O
12	.	O

1	In	O
2	reperfusion	O
3	B	O
4	,	O
5	only	O
6	the	O
7	diabetic	O
8	group	O
9	demonstrated	O
10	a	O
11	significant	O
12	increase	O
13	in	O
14	IL	B
15	-	I
16	8	I
17	concentrations	O
18	at	O
19	1	O
20	and	O
21	15	O
22	min	O
23	compared	O
24	to	O
25	nondiabetics	O
26	.	O

1	This	O
2	repression	O
3	was	O
4	reversed	O
5	agonists	O
6	of	O
7	either	O
8	receptor	O
9	demonstrating	O
10	a	O
11	functional	O
12	interaction	O
13	between	O
14	NCoR	B
15	and	O
16	PPARalpha	B
17	.	O
18	RXRalpha	B
19	heterodimeric	O
20	complexes	O
21	in	O
22	mammalian	O
23	cells	O
24	.	O

1	In	O
2	the	O
3	present	O
4	study	O
5	,	O
6	we	O
7	show	O
8	that	O
9	SRm160	B
10	/	I
11	300	I
12	is	O
13	required	O
14	for	O
15	a	O
16	purine	O
17	-	O
18	rich	O
19	ESE	B
20	to	O
21	promote	O
22	the	O
23	splicing	O
24	of	O
25	a	O
26	pre	O
27	-	O
28	mRNA	O
29	derived	O
30	from	O
31	the	O
32	Drosophila	B
33	doublesex	I
34	gene	I
35	.	O

1	Spc42p	B
2	also	O
3	was	O
4	identified	O
5	as	O
6	a	O
7	component	O
8	of	O
9	a	O
10	cytoplasmic	O
11	SPB	O
12	subcomplex	O
13	containing	O
14	Spc94p	B
15	/	O
16	Nud1p	B
17	,	O
18	Cnm67p	B
19	,	O
20	and	O
21	Spc42p	B
22	.	O

1	The	O
2	average	O
3	coefficients	O
4	of	O
5	correlation	O
6	were	O
7	0	O
8	.	O
9	9998	O
10	and	O
11	0	O
12	.	O
13	9993	O
14	for	O
15	the	O
16	QMF	O
17	and	O
18	the	O
19	QIT	O
20	system	O
21	,	O
22	respectively	O
23	.	O

1	The	O
2	5	O
3	-	O
4	year	O
5	OS	O
6	for	O
7	stage	O
8	IIIB	O
9	was	O
10	30	O
11	.	O
12	9	O
13	%,	O
14	compared	O
15	to	O
16	7	O
17	.	O
18	8	O
19	%	O
20	for	O
21	stage	O
22	IV	O
23	.	O

1	Furthermore	O
2	,	O
3	heparin	B
4	lyase	I
5	treatment	O
6	of	O
7	extracts	O
8	of	O
9	cells	O
10	expressing	O
11	recombinant	B
12	YD	I
13	-	I
14	repeat	I
15	protein	I
16	releases	O
17	this	O
18	protein	O
19	from	O
20	high	O
21	molecular	O
22	mass	O
23	aggregates	O
24	.	O

1	The	O
2	coefficient	O
3	of	O
4	determination	O
5	,	O
6	r2	O
7	,	O
8	of	O
9	the	O
10	other	O
11	scores	O
12	ranged	O
13	from	O
14	0	O
15	.	O
16	56	O
17	to	O
18	0	O
19	.	O
20	61	O
21	.	O

1	While	O
2	determination	O
3	of	O
4	the	O
5	protein	O
6	content	O
7	of	O
8	the	O
9	formulae	O
10	gave	O
11	no	O
12	valid	O
13	information	O
14	,	O
15	RAST	O
16	/	O
17	EAST	O
18	inhibition	O
19	was	O
20	highest	O
21	for	O
22	cow	O
23	'	O
24	s	O
25	milk	O
26	,	O
27	followed	O
28	by	O
29	the	O
30	partially	O
31	hydrolysed	O
32	whey	O
33	formula	O
34	,	O
35	partially	O
36	hydrolysed	O
37	whey	O
38	/	O
39	casein	B
40	formula	O
41	,	O
42	soy	B
43	/	I
44	pork	I
45	collagen	I
46	formula	O
47	,	O
48	and	O
49	the	O
50	amino	O
51	acid	O
52	formula	O
53	.	O

1	In	O
2	light	O
3	of	O
4	the	O
5	importance	O
6	of	O
7	GnRHR	B
8	,	O
9	the	O
10	molecular	O
11	mechanisms	O
12	underlying	O
13	the	O
14	transcriptional	O
15	regulation	O
16	of	O
17	the	O
18	human	B
19	GnRHR	I
20	(	O
21	hGnRHR	B
22	)	O
23	gene	O
24	become	O
25	a	O
26	key	O
27	issue	O
28	in	O
29	understanding	O
30	human	O
31	reproduction	O
32	.	O

1	Competitive	O
2	mobility	O
3	shift	O
4	assays	O
5	using	O
6	either	O
7	alphaT3	O
8	-	O
9	1	O
10	nuclear	O
11	extract	O
12	or	O
13	recombinant	B
14	SF	I
15	-	I
16	1	I
17	protein	I
18	clearly	O
19	indicated	O
20	that	O
21	SF	B
22	-	I
23	1	I
24	is	O
25	able	O
26	to	O
27	interact	O
28	specifically	O
29	with	O
30	this	O
31	GSE	B
32	element	I
33	positioned	O
34	at	O
35	-	O
36	134	O
37	.	O

1	Grade	O
2	3	O
3	mucositis	O
4	was	O
5	reported	O
6	in	O
7	1	O
8	patient	O
9	.	O

1	CDK4	B
2	kinase	I
3	activities	O
4	were	O
5	unaffected	O
6	,	O
7	as	O
8	were	O
9	the	O
10	levels	O
11	of	O
12	the	O
13	CDK	B
14	inhibitor	O
15	p21Cip1	B
16	present	O
17	in	O
18	cyclin	B
19	E	I
20	immunocomplexes	I
21	.	O

1	The	O
2	recombinant	O
3	purified	O
4	protein	O
5	expressed	O
6	in	O
7	the	O
8	baculovirus	O
9	system	O
10	had	O
11	an	O
12	approximate	O
13	molecular	O
14	size	O
15	20	O
16	kDa	O
17	with	O
18	amino	O
19	-	O
20	terminal	O
21	sequence	O
22	of	O
23	AVQGP	O
24	.	O

1	Induction	O
2	of	O
3	the	O
4	urokinase	B
5	promoter	I
6	by	O
7	HGF	B
8	/	O
9	SF	B
10	via	O
11	the	O
12	Met	B
13	receptor	I
14	was	O
15	blocked	O
16	by	O
17	co	O
18	-	O
19	expression	O
20	of	O
21	a	O
22	dominant	O
23	-	O
24	negative	O
25	Grb2	B
26	and	O
27	Sos1	B
28	expression	O
29	construct	O
30	.	O

1	Serine	O
2	phosphorylation	O
3	of	O
4	STAT3	B
5	was	O
6	only	O
7	apparent	O
8	after	O
9	somatostatin	B
10	treatment	O
11	and	O
12	was	O
13	abolished	O
14	by	O
15	pertussis	B
16	toxin	I
17	or	O
18	PD	O
19	98059	O
20	,	O
21	together	O
22	with	O
23	the	O
24	associated	O
25	increases	O
26	in	O
27	proliferation	O
28	.	O

1	Nevertheless	O
2	,	O
3	we	O
4	demonstrate	O
5	that	O
6	the	O
7	entire	O
8	three	O
9	-	O
10	component	O
11	yeast	O
12	capping	O
13	apparatus	O
14	,	O
15	consisting	O
16	of	O
17	RNA	B
18	5	I
19	'-	I
20	triphosphatase	I
21	(	O
22	Cet1p	B
23	),	O
24	RNA	B
25	guanylyltransferase	I
26	(	O
27	Ceg1p	B
28	),	O
29	and	O
30	Abd1p	B
31	could	O
32	be	O
33	replaced	O
34	in	O
35	vivo	O
36	by	O
37	the	O
38	two	O
39	-	O
40	component	O
41	mammalian	O
42	apparatus	O
43	consisting	O
44	of	O
45	a	O
46	bifunctional	O
47	triphosphatase	B
48	-	I
49	guanylyltransferase	I
50	Mce1p	I
51	and	O
52	the	O
53	methyltransferase	B
54	Hcm1	I
55	(	I
56	121	I
57	-	I
58	476	I
59	)	I
60	p	I
61	.	O

1	The	O
2	IC50	O
3	values	O
4	for	O
5	rat	O
6	and	O
7	dog	O
8	urinary	O
9	bladder	O
10	were	O
11	3	O
12	.	O
13	9	O
14	x	O
15	10	O
16	(-	O
17	6	O
18	)	O
19	M	O
20	and	O
21	3	O
22	.	O
23	8	O
24	x	O
25	10	O
26	(-	O
27	6	O
28	)	O
29	M	O
30	,	O
31	respectively	O
32	.	O

1	Although	O
2	it	O
3	has	O
4	two	O
5	potential	O
6	binding	O
7	sites	O
8	,	O
9	the	O
10	purified	O
11	MerR	B
12	homodimer	I
13	binds	O
14	only	O
15	one	O
16	Hg	O
17	(	O
18	II	O
19	)	O
20	ion	O
21	,	O
22	employing	O
23	Cys82	O
24	from	O
25	one	O
26	monomer	O
27	and	O
28	Cys117	O
29	and	O
30	Cys126	O
31	from	O
32	the	O
33	other	O
34	.	O

1	The	O
2	influence	O
3	of	O
4	Epstein	O
5	-	O
6	Barr	O
7	virus	O
8	seropositivity	O
9	on	O
10	the	O
11	efficacy	O
12	of	O
13	intravenous	O
14	immune	B
15	globulin	I
16	in	O
17	children	O
18	with	O
19	immune	O
20	thrombocytopenic	O
21	purpura	O
22	.	O

1	The	O
2	results	O
3	of	O
4	the	O
5	lab	O
6	and	O
7	field	O
8	tests	O
9	yielded	O
10	high	O
11	levels	O
12	of	O
13	infestation	O
14	in	O
15	larvae	O
16	with	O
17	values	O
18	ranging	O
19	from	O
20	90	O
21	to	O
22	100	O
23	%	O
24	and	O
25	from	O
26	85	O
27	to	O
28	95	O
29	%,	O
30	respectively	O
31	.	O

1	Amisulpride	O
2	400	O
3	mg	O
4	had	O
5	several	O
6	adverse	O
7	effects	O
8	on	O
9	psychomotor	O
10	and	O
11	,	O
12	although	O
13	less	O
14	severe	O
15	,	O
16	on	O
17	cognitive	O
18	performance	O
19	on	O
20	the	O
21	fifth	O
22	day	O
23	only	O
24	.	O

1	MutY	B
2	is	O
3	an	O
4	adenine	B
5	-	I
6	DNA	I
7	glycosylase	I
8	with	O
9	specificity	O
10	for	O
11	mismatches	O
12	involving	O
13	8	O
14	-	O
15	oxoguanine	O
16	(	O
17	oG	O
18	.	O
19	A	O
20	)	O
21	or	O
22	guanine	O
23	(	O
24	G	O
25	.	O
26	A	O
27	).	O

1	The	O
2	kinetics	O
3	of	O
4	kinase	O
5	activity	O
6	within	O
7	these	O
8	complexes	O
9	compared	O
10	to	O
11	CheA	B
12	alone	O
13	indicate	O
14	approximately	O
15	a	O
16	50	O
17	%	O
18	decrease	O
19	in	O
20	the	O
21	KM	O
22	for	O
23	ATP	O
24	and	O
25	a	O
26	100	O
27	-	O
28	fold	O
29	increase	O
30	in	O
31	the	O
32	Vmax	O
33	.	O

1	Latexin	B
2	,	O
3	a	O
4	carboxypeptidase	B
5	A	I
6	inhibitor	O
7	,	O
8	is	O
9	expressed	O
10	in	O
11	a	O
12	cell	O
13	type	O
14	-	O
15	specific	O
16	manner	O
17	in	O
18	both	O
19	central	O
20	and	O
21	peripheral	O
22	nervous	O
23	systems	O
24	in	O
25	the	O
26	rat	O
27	.	O

1	Regression	O
2	analyses	O
3	identified	O
4	7	O
5	risk	O
6	and	O
7	7	O
8	protective	O
9	factors	O
10	with	O
11	minimal	O
12	overlap	O
13	.	O

1	During	O
2	1985	O
3	,	O
4	1990	O
5	,	O
6	and	O
7	1995	O
8	,	O
9	respectively	O
10	,	O
11	11	O
12	.	O
13	7	O
14	,	O
15	11	O
16	.	O
17	3	O
18	,	O
19	and	O
20	11	O
21	.	O
22	4	O
23	infants	O
24	per	O
25	100	O
26	,	O
27	000	O
28	live	O
29	births	O
30	had	O
31	a	O
32	diagnosis	O
33	of	O
34	HSV	O
35	(	O
36	P	O
37	=.	O
38	98	O
39	).	O

1	Subsets	O
2	of	O
3	patients	O
4	were	O
5	performed	O
6	according	O
7	to	O
8	the	O
9	severity	O
10	of	O
11	trauma	O
12	(	O
13	ISS	O
14	<	O
15	9	O
16	;	O
17	9	O
18	-	O
19	17	O
20	;	O
21	18	O
22	-	O
23	31	O
24	;	O
25	>	O
26	32	O
27	),	O
28	based	O
29	on	O
30	the	O
31	different	O
32	injury	O
33	pattern	O
34	,	O
35	and	O
36	survivors	O
37	versus	O
38	nonsurvivors	O
39	as	O
40	well	O
41	.	O

1	The	O
2	median	O
3	age	O
4	was	O
5	33	O
6	years	O
7	(	O
8	range	O
9	17	O
10	-	O
11	56	O
12	years	O
13	).	O

1	Developmental	O
2	follow	O
3	-	O
4	up	O
5	at	O
6	age	O
7	2	O
8	years	O
9	was	O
10	performed	O
11	.	O

1	In	O
2	the	O
3	whole	O
4	group	O
5	of	O
6	infected	O
7	children	O
8	,	O
9	an	O
10	age	O
11	-	O
12	specific	O
13	z	O
14	score	O
15	<	O
16	-	O
17	2	O
18	for	O
19	weight	O
20	and	O
21	for	O
22	FFM	O
23	was	O
24	significantly	O
25	associated	O
26	with	O
27	an	O
28	increased	O
29	risk	O
30	of	O
31	death	O
32	[	O
33	relative	O
34	risk	O
35	(	O
36	95	O
37	%	O
38	CI	O
39	)	O
40	=	O
41	11	O
42	.	O
43	4	O
44	(	O
45	3	O
46	.	O
47	1	O
48	,	O
49	41	O
50	.	O
51	0	O
52	)	O
53	and	O
54	5	O
55	.	O
56	1	O
57	(	O
58	1	O
59	.	O
60	5	O
61	,	O
62	18	O
63	.	O
64	2	O
65	),	O
66	respectively	O
67	];	O
68	when	O
69	only	O
70	children	O
71	with	O
72	more	O
73	severe	O
74	disease	O
75	were	O
76	considered	O
77	,	O
78	only	O
79	z	O
80	score	O
81	for	O
82	weight	O
83	was	O
84	significantly	O
85	associated	O
86	with	O
87	an	O
88	increased	O
89	risk	O
90	[	O
91	4	O
92	.	O
93	6	O
94	(	O
95	1	O
96	.	O
97	4	O
98	,	O
99	14	O
100	.	O
101	9	O
102	)].	O

1	In	O
2	addition	O
3	,	O
4	these	O
5	cells	O
6	contained	O
7	one	O
8	,	O
9	two	O
10	,	O
11	or	O
12	multiple	O
13	nuclei	O
14	indicative	O
15	of	O
16	a	O
17	G2	O
18	/	O
19	M	O
20	delay	O
21	in	O
22	nuclear	O
23	division	O
24	and	O
25	also	O
26	a	O
27	defect	O
28	in	O
29	cytokinesis	O
30	and	O
31	/	O
32	or	O
33	cell	O
34	separation	O
35	.	O

1	DAF16	B
2	is	O
3	known	O
4	to	O
5	be	O
6	a	O
7	component	O
8	of	O
9	a	O
10	signaling	O
11	pathway	O
12	that	O
13	has	O
14	been	O
15	partially	O
16	dissected	O
17	genetically	O
18	and	O
19	includes	O
20	homologues	O
21	of	O
22	the	O
23	insulin	B
24	/	O
25	IGF	B
26	-	I
27	1	I
28	receptor	I
29	,	O
30	PtdIns	B
31	3	I
32	-	I
33	kinase	I
34	and	O
35	PKB	B
36	.	O

1	However	O
2	,	O
3	neu	B
4	differentiation	O
5	factor	O
6	-	O
7	induced	O
8	heterodimers	O
9	of	O
10	ErbB2	B
11	and	O
12	ErbB4	B
13	activated	O
14	Stat5	B
15	.	O

1	Although	O
2	linker	O
3	regions	O
4	in	O
5	transcription	O
6	factors	O
7	are	O
8	known	O
9	to	O
10	modulate	O
11	DNA	O
12	binding	O
13	specificity	O
14	,	O
15	our	O
16	studies	O
17	suggest	O
18	that	O
19	the	O
20	human	B
21	HSF1	I
22	linker	O
23	plays	O
24	no	O
25	role	O
26	in	O
27	determining	O
28	HSF1	B
29	binding	O
30	preferences	O
31	in	O
32	vivo	O
33	but	O
34	is	O
35	a	O
36	critical	O
37	determinant	O
38	in	O
39	regulating	O
40	the	O
41	HSF1	B
42	monomer	I
43	-	I
44	trimer	I
45	equilibrium	O
46	.	O

1	Modulation	O
2	of	O
3	human	B
4	heat	I
5	shock	I
6	factor	I
7	trimerization	O
8	by	O
9	the	O
10	linker	O
11	domain	O
12	.	O

1	Both	O
2	functional	O
3	analyses	O
4	in	O
5	undifferentiated	O
6	and	O
7	differentiated	O
8	F9	O
9	cells	O
10	and	O
11	characterization	O
12	of	O
13	DNA	O
14	-	O
15	protein	O
16	complexes	O
17	in	O
18	vitro	O
19	have	O
20	identified	O
21	the	O
22	sequence	O
23	motifs	O
24	GTGACT	O
25	(	O
26	C	O
27	),	O
28	ATTGT	O
29	,	O
30	and	O
31	GATA	O
32	as	O
33	the	O
34	key	O
35	transcription	O
36	factor	O
37	binding	O
38	sites	O
39	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	the	O
6	phenotype	O
7	of	O
8	XLP	O
9	may	O
10	result	O
11	from	O
12	perturbed	O
13	signaling	O
14	not	O
15	only	O
16	through	O
17	SLAM	B
18	,	O
19	but	O
20	also	O
21	other	O
22	cell	O
23	surface	O
24	molecules	O
25	that	O
26	utilize	O
27	SAP	B
28	as	O
29	a	O
30	signaling	O
31	adaptor	O
32	protein	O
33	.	O

1	We	O
2	also	O
3	localized	O
4	the	O
5	Fra	B
6	-	I
7	2	I
8	phosphorylation	I
9	sites	I
10	by	O
11	MAPK	B
12	to	O
13	three	O
14	threonine	O
15	and	O
16	three	O
17	serine	O
18	residues	O
19	in	O
20	the	O
21	COOH	O
22	-	O
23	terminal	O
24	region	O
25	by	O
26	means	O
27	of	O
28	site	O
29	-	O
30	directed	O
31	mutagenesis	O
32	and	O
33	showed	O
34	that	O
35	the	O
36	threonine	O
37	residues	O
38	were	O
39	more	O
40	susceptible	O
41	to	O
42	MAPK	B
43	.	O

1	Nevertheless	O
2	,	O
3	they	O
4	are	O
5	functionally	O
6	distinct	O
7	in	O
8	that	O
9	FcalphaRI	B
10	binds	O
11	human	B
12	IgA	I
13	(	O
14	hIgA	B
15	)	O
16	but	O
17	not	O
18	bovine	B
19	IgG2	I
20	(	O
21	bIgG2	B
22	),	O
23	whereas	O
24	bFcgamma2R	B
25	binds	O
26	bIgG2	B
27	but	O
28	not	O
29	hIgA	B
30	.	O

1	Vac1p	B
2	was	O
3	found	O
4	to	O
5	bind	O
6	the	O
7	Sec1p	B
8	homologue	I
9	Vps45p	I
10	.	O

1	In	O
2	a	O
3	heterologous	O
4	transcriptional	O
5	system	O
6	in	O
7	which	O
8	the	O
9	upstream	O
10	regions	O
11	of	O
12	oIFNtau	B
13	were	O
14	inserted	O
15	in	O
16	front	O
17	of	O
18	simian	B
19	virus	I
20	40	I
21	(	I
22	SV40	I
23	)	I
24	promoter	I
25	,	O
26	the	O
27	regions	O
28	between	O
29	bases	O
30	-	O
31	654	O
32	and	O
33	-	O
34	555	O
35	were	O
36	determined	O
37	as	O
38	being	O
39	the	O
40	enhancer	O
41	region	O
42	required	O
43	for	O
44	oIFNtau	B
45	-	O
46	SV40	O
47	-	O
48	CAT	B
49	transactivation	O
50	.	O

1	In	O
2	co	O
3	-	O
4	transfection	O
5	studies	O
6	,	O
7	the	O
8	expression	O
9	of	O
10	c	B
11	-	I
12	Jun	I
13	plus	O
14	c	B
15	-	I
16	Fos	I
17	enhanced	O
18	the	O
19	transactivation	O
20	of	O
21	oIFNtau	B
22	-	O
23	CAT	B
24	but	O
25	the	O
26	expression	O
27	of	O
28	GATA	B
29	-	I
30	1	I
31	,	O
32	GATA	B
33	-	I
34	2	I
35	or	O
36	GATA	B
37	-	I
38	3	I
39	did	O
40	not	O
41	.	O

1	To	O
2	identify	O
3	these	O
4	sites	O
5	,	O
6	Cdk2	B
7	-	O
8	phosphorylated	O
9	MARCKS	B
10	was	O
11	digested	O
12	with	O
13	lysyl	B
14	endoprotease	I
15	and	O
16	analysed	O
17	by	O
18	electrospray	O
19	MS	O
20	.	O

1	The	O
2	yeast	B
3	LPD1	I
4	gene	I
5	encoding	O
6	lipoamide	B
7	dehydrogenase	I
8	is	O
9	subject	O
10	to	O
11	the	O
12	general	O
13	control	O
14	of	O
15	amino	O
16	acid	O
17	biosynthesis	O
18	mediated	O
19	by	O
20	the	O
21	GCN4	B
22	transcription	I
23	factor	I
24	.	O

1	The	O
2	relatively	O
3	mild	O
4	defects	O
5	observed	O
6	in	O
7	Rpd3	B
8	mutants	I
9	suggest	O
10	that	O
11	the	O
12	recently	O
13	identified	O
14	Groucho	B
15	and	O
16	dCtBP	B
17	corepressor	I
18	proteins	I
19	do	O
20	not	O
21	function	O
22	solely	O
23	through	O
24	the	O
25	recruitment	O
26	of	O
27	histone	B
28	deacetylases	I
29	.	O

1	However	O
2	,	O
3	the	O
4	serum	B
5	TNF	I
6	-	I
7	a	I
8	concentration	O
9	decreased	O
10	significantly	O
11	in	O
12	patients	O
13	receiving	O
14	pentoxifylline	O
15	(	O
16	basal	O
17	623	O
18	+/-	O
19	366	O
20	pg	O
21	/	O
22	ml	O
23	;	O
24	6th	O
25	month	O
26	562	O
27	+/-	O
28	358	O
29	pg	O
30	/	O
31	ml	O
32	,	O
33	p	O
34	<	O
35	0	O
36	.	O
37	01	O
38	),	O
39	but	O
40	not	O
41	in	O
42	the	O
43	control	O
44	group	O
45	.	O

1	In	O
2	addition	O
3	,	O
4	we	O
5	show	O
6	that	O
7	the	O
8	expression	O
9	of	O
10	individual	O
11	members	O
12	of	O
13	one	O
14	subfamily	O
15	of	O
16	KRAB	B
17	zinc	I
18	finger	I
19	genes	I
20	is	O
21	restricted	O
22	to	O
23	specific	O
24	hematopoietic	O
25	cell	O
26	lineages	O
27	.	O

1	Employing	O
2	fluorescence	O
3	spectroscopy	O
4	and	O
5	circular	O
6	dichroism	O
7	,	O
8	we	O
9	showed	O
10	that	O
11	the	O
12	binding	O
13	of	O
14	Ca2	O
15	+	O
16	to	O
17	ALG	B
18	-	I
19	2	I
20	induced	O
21	significant	O
22	conformational	O
23	changes	O
24	in	O
25	both	O
26	the	O
27	N	O
28	-	O
29	terminal	O
30	and	O
31	C	O
32	-	O
33	terminal	O
34	domains	O
35	of	O
36	the	O
37	protein	O
38	.	O

1	They	O
2	also	O
3	occur	O
4	in	O
5	similar	O
6	locations	O
7	in	O
8	the	O
9	promoters	O
10	of	O
11	several	O
12	other	O
13	ribosomal	B
14	protein	I
15	genes	I
16	.	O

1	Both	O
2	carbachol	O
3	(	O
4	100	O
5	microM	O
6	)	O
7	and	O
8	EGF	B
9	(	O
10	10	O
11	nM	O
12	)	O
13	induced	O
14	Ras	B
15	activation	O
16	.	O

1	Dominant	O
2	negative	O
3	Sos	B
4	did	O
5	not	O
6	affect	O
7	carbachol	O
8	stimulation	O
9	of	O
10	HA	B
11	-	O
12	ERK2	B
13	but	O
14	inhibited	O
15	the	O
16	stimulatory	O
17	effect	O
18	of	O
19	EGF	B
20	by	O
21	60	O
22	%.	O

1	RESULTS	O
2	:	O
3	Transpulmonary	O
4	passage	O
5	of	O
6	contrast	O
7	occurred	O
8	in	O
9	sufficient	O
10	amounts	O
11	to	O
12	enhance	O
13	the	O
14	intensity	O
15	of	O
16	the	O
17	Doppler	O
18	signal	O
19	significantly	O
20	,	O
21	but	O
22	the	O
23	duration	O
24	of	O
25	this	O
26	effect	O
27	was	O
28	short	O
29	.	O

1	In	O
2	this	O
3	paper	O
4	,	O
5	such	O
6	lesions	O
7	in	O
8	two	O
9	cases	O
10	were	O
11	evaluated	O
12	by	O
13	ultrasonography	O
14	.	O

1	These	O
2	regions	O
3	contain	O
4	inverted	O
5	E	O
6	-	O
7	box	O
8	palindromic	O
9	or	O
10	direct	O
11	repeat	O
12	motifs	O
13	and	O
14	bind	O
15	SREBP	B
16	-	I
17	1	I
18	with	O
19	different	O
20	affinities	O
21	.	O

1	To	O
2	address	O
3	these	O
4	questions	O
5	,	O
6	a	O
7	recombinant	O
8	FRAP	B
9	/	O
10	mTOR	B
11	protein	O
12	and	O
13	a	O
14	FRAP	B
15	/	O
16	mTOR	B
17	immunoprecipitate	O
18	were	O
19	utilized	O
20	in	O
21	in	O
22	vitro	O
23	kinase	O
24	assays	O
25	to	O
26	phosphorylate	O
27	4E	B
28	-	I
29	BP1	I
30	.	O

1	Hrs	B
2	has	O
3	a	O
4	FYVE	O
5	double	O
6	zinc	O
7	finger	O
8	domain	O
9	,	O
10	which	O
11	specifically	O
12	binds	O
13	phosphatidylinositol	O
14	(	O
15	3	O
16	)-	O
17	phosphate	O
18	and	O
19	is	O
20	conserved	O
21	in	O
22	several	O
23	proteins	O
24	involved	O
25	in	O
26	vesicular	O
27	traffic	O
28	.	O

1	The	O
2	coexpression	O
3	of	O
4	full	O
5	-	O
6	length	O
7	expression	O
8	constructs	O
9	for	O
10	both	O
11	DBP	B
12	and	O
13	hepatic	B
14	leukemia	I
15	factor	I
16	resulted	O
17	in	O
18	a	O
19	dramatic	O
20	increase	O
21	in	O
22	activation	O
23	mediated	O
24	by	O
25	the	O
26	GAL4	B
27	-	O
28	DBP	B
29	fusion	O
30	proteins	O
31	,	O
32	suggesting	O
33	the	O
34	involvement	O
35	of	O
36	a	O
37	regulated	O
38	coactivator	O
39	in	O
40	this	O
41	process	O
42	.	O

1	Three	O
2	subgenomes	O
3	also	O
4	comprised	O
5	15	O
6	to	O
7	75	O
8	nucleotides	O
9	derived	O
10	from	O
11	the	O
12	5	O
13	'	O
14	part	O
15	of	O
16	the	O
17	NS2	B
18	gene	I
19	.	O

1	Cp	B
2	is	O
3	normally	O
4	the	O
5	main	O
6	promoter	O
7	for	O
8	EBNA	B
9	mRNA	I
10	initiation	O
11	,	O
12	so	O
13	it	O
14	appears	O
15	that	O
16	EBNA3C	B
17	contributes	O
18	to	O
19	a	O
20	negative	O
21	autoregulatory	O
22	control	O
23	loop	O
24	.	O

1	These	O
2	indications	O
3	of	O
4	deregulated	O
5	signalling	O
6	in	O
7	the	O
8	absence	O
9	of	O
10	tyrosine	O
11	118	O
12	were	O
13	substantiated	O
14	by	O
15	sustained	O
16	activation	O
17	of	O
18	STAT3	B
19	.	O

1	With	O
2	exon	O
3	trapping	O
4	,	O
5	we	O
6	could	O
7	isolate	O
8	five	O
9	potential	O
10	exons	O
11	from	O
12	the	O
13	YAC	O
14	946E12	O
15	that	O
16	spans	O
17	the	O
18	region	O
19	,	O
20	four	O
21	of	O
22	which	O
23	could	O
24	be	O
25	placed	O
26	in	O
27	the	O
28	contig	O
29	in	O
30	the	O
31	vicinity	O
32	of	O
33	the	O
34	breakpoints	O
35	.	O

1	Campomelic	O
2	dysplasia	O
3	translocation	O
4	breakpoints	O
5	are	O
6	scattered	O
7	over	O
8	1	O
9	Mb	O
10	proximal	O
11	to	O
12	SOX9	B
13	:	O
14	evidence	O
15	for	O
16	an	O
17	extended	O
18	control	O
19	region	O
20	.	O

1	The	O
2	most	O
3	common	O
4	characteristics	O
5	of	O
6	VRE	O
7	patients	O
8	were	O
9	recent	O
10	prior	O
11	vancomycin	O
12	use	O
13	,	O
14	recent	O
15	prior	O
16	susceptible	O
17	enterococcal	O
18	infection	O
19	,	O
20	coinfection	O
21	with	O
22	other	O
23	microbial	O
24	pathogens	O
25	,	O
26	and	O
27	concurrent	O
28	fungal	O
29	infection	O
30	.	O

1	A	O
2	coiled	O
3	-	O
4	coil	O
5	domain	O
6	,	O
7	conserved	O
8	within	O
9	each	O
10	encoded	O
11	protein	O
12	,	O
13	serves	O
14	as	O
15	a	O
16	potential	O
17	interaction	O
18	motif	O
19	for	O
20	FLI	B
21	LRR	I
22	.	O

1	Binding	O
2	affinities	O
3	of	O
4	these	O
5	recombinant	O
6	phages	O
7	as	O
8	determined	O
9	by	O
10	the	O
11	retention	O
12	of	O
13	these	O
14	phages	O
15	by	O
16	a	O
17	His	O
18	-	O
19	tag	O
20	immobilized	O
21	gp17	B
22	column	O
23	,	O
24	and	O
25	by	O
26	co	O
27	-	O
28	immunoprecipitation	O
29	with	O
30	purified	O
31	terminase	B
32	supported	O
33	the	O
34	specific	O
35	nature	O
36	of	O
37	the	O
38	portal	B
39	protein	I
40	and	O
41	terminase	B
42	interaction	I
43	sites	I
44	.	O

1	Although	O
2	the	O
3	terminase	B
4	apparently	O
5	interacts	O
6	with	O
7	this	O
8	gp20	B
9	portal	I
10	peptide	I
11	,	O
12	polyclonal	O
13	antibody	O
14	against	O
15	the	O
16	portal	O
17	peptide	O
18	appears	O
19	unable	O
20	to	O
21	access	O
22	it	O
23	in	O
24	the	O
25	native	O
26	structure	O
27	,	O
28	suggesting	O
29	intimate	O
30	association	O
31	of	O
32	gp20	B
33	and	O
34	gp17	B
35	possibly	O
36	internalizes	O
37	terminase	B
38	regions	I
39	within	O
40	the	O
41	portal	O
42	in	O
43	the	O
44	packasome	O
45	complex	O
46	.	O

1	The	O
2	hybrid	O
3	viruses	O
4	were	O
5	found	O
6	to	O
7	accumulate	O
8	to	O
9	high	O
10	levels	O
11	in	O
12	infected	O
13	plants	O
14	,	O
15	to	O
16	form	O
17	stable	O
18	virions	O
19	,	O
20	and	O
21	to	O
22	be	O
23	mechanically	O
24	transmissible	O
25	.	O

1	cDNA	O
2	and	O
3	structural	O
4	organization	O
5	of	O
6	the	O
7	gene	B
8	Pole1	I
9	for	O
10	the	O
11	mouse	B
12	DNA	I
13	polymerase	I
14	epsilon	I
15	catalytic	I
16	subunit	I
17	.	O

1	Nevertheless	O
2	cryopreservation	O
3	of	O
4	spermatozoa	O
5	in	O
6	a	O
7	medium	O
8	containing	O
9	neither	O
10	SP	O
11	nor	O
12	biological	O
13	substances	O
14	could	O
15	offer	O
16	an	O
17	acceptable	O
18	cryoprotection	O
19	of	O
20	spermatozoa	O
21	to	O
22	be	O
23	used	O
24	in	O
25	assisted	O
26	fertilization	O
27	procedures	O
28	,	O
29	especially	O
30	for	O
31	intracytoplasmic	O
32	sperm	O
33	injection	O
34	.	O

1	A	O
2	liquid	O
3	chromatographic	O
4	method	O
5	is	O
6	described	O
7	for	O
8	analysis	O
9	of	O
10	beta	O
11	-	O
12	carotene	O
13	in	O
14	medical	O
15	food	O
16	.	O

1	The	O
2	FCMS	O
3	conditions	O
4	were	O
5	as	O
6	follows	O
7	:	O
8	2	O
9	kW	O
10	maximum	O
11	electrical	O
12	power	O
13	consumption	O
14	,	O
15	800	O
16	V	O
17	maximum	O
18	capacitor	O
19	voltage	O
20	,	O
21	720	O
22	microseconds	O
23	pulsewidth	O
24	(	O
25	180	O
26	microseconds	O
27	rise	O
28	time	O
29	),	O
30	and	O
31	5	O
32	-	O
33	30	O
34	Hz	O
35	frequency	O
36	.	O

1	Severe	O
2	hemolysis	O
3	resulted	O
4	in	O
5	statistically	O
6	significant	O
7	changes	O
8	in	O
9	the	O
10	mean	O
11	values	O
12	of	O
13	the	O
14	above	O
15	analytes	O
16	in	O
17	addition	O
18	to	O
19	the	O
20	following	O
21	increases	O
22	:	O
23	alanine	B
24	aminotransferase	I
25	,	O
26	calcium	O
27	,	O
28	and	O
29	serum	B
30	globulins	I
31	(	O
32	P	O
33	<	O
34	0	O
35	.	O
36	001	O
37	)	O
38	and	O
39	albumin	B
40	and	O
41	total	O
42	protein	O
43	(	O
44	P	O
45	<	O
46	0	O
47	.	O
48	01	O
49	).	O

1	EMSA	O
2	with	O
3	crude	O
4	nuclear	O
5	extracts	O
6	demonstrated	O
7	that	O
8	stimulation	O
9	with	O
10	CD40L	B
11	results	O
12	in	O
13	the	O
14	induction	O
15	of	O
16	NF	B
17	-	I
18	kappaB	I
19	complexes	I
20	that	O
21	bind	O
22	to	O
23	each	O
24	of	O
25	the	O
26	three	O
27	NF	B
28	-	I
29	kappaB	I
30	sites	I
31	and	O
32	are	O
33	composed	O
34	mainly	O
35	of	O
36	p50	B
37	and	O
38	RelB	B
39	,	O
40	but	O
41	also	O
42	include	O
43	c	B
44	-	I
45	Rel	I
46	and	O
47	p65	B
48	.	O

1	Optimal	O
2	monitoring	O
3	of	O
4	ODA	O
5	remains	O
6	undefined	O
7	.	O

1	The	O
2	major	O
3	transcription	O
4	factors	O
5	controlling	O
6	arginine	O
7	metabolism	O
8	in	O
9	Escherichia	O
10	coli	O
11	and	O
12	Bacillus	O
13	subtilis	O
14	,	O
15	ArgR	B
16	and	O
17	AhrC	B
18	,	O
19	respectively	O
20	,	O
21	are	O
22	homologous	O
23	multimeric	O
24	proteins	O
25	that	O
26	form	O
27	l	O
28	-	O
29	arginine	O
30	-	O
31	dependent	O
32	DNA	O
33	-	O
34	binding	O
35	complexes	O
36	capable	O
37	of	O
38	repressing	O
39	transcription	O
40	of	O
41	the	O
42	biosynthetic	O
43	genes	O
44	(	O
45	both	O
46	),	O
47	activating	O
48	transcription	O
49	of	O
50	catabolic	O
51	genes	O
52	(	O
53	AhrC	B
54	only	O
55	)	O
56	or	O
57	facilitating	O
58	plasmid	O
59	dimer	O
60	resolution	O
61	(	O
62	both	O
63	).	O

1	The	O
2	studied	O
3	protein	O
4	fragments	O
5	consist	O
6	of	O
7	residues	O
8	Arg183	O
9	-	O
10	His267	O
11	of	O
12	the	O
13	human	B
14	ER	I
15	and	O
16	residues	O
17	Lys438	O
18	-	O
19	Gln520	O
20	of	O
21	the	O
22	rat	O
23	GR	B
24	.	O

1	The	O
2	exon	O
3	:	O
4	intron	O
5	structure	O
6	of	O
7	chicken	B
8	IL8	I
9	corresponds	O
10	almost	O
11	exactly	O
12	to	O
13	that	O
14	of	O
15	human	B
16	IL8	I
17	and	O
18	differs	O
19	from	O
20	those	O
21	of	O
22	other	O
23	known	O
24	mammalian	B
25	CXC	I
26	chemokine	I
27	genes	I
28	.	O

1	The	O
2	Aa	B
3	-	I
4	Pri2	I
5	gene	I
6	,	O
7	specifically	O
8	expressed	O
9	during	O
10	basidiocarp	O
11	differentiation	O
12	of	O
13	the	O
14	mushroom	O
15	Agrocybe	O
16	aegerita	O
17	,	O
18	was	O
19	cloned	O
20	.	O

1	The	O
2	main	O
3	causes	O
4	of	O
5	liver	O
6	disease	O
7	in	O
8	the	O
9	patients	O
10	with	O
11	HCC	O
12	were	O
13	hepatitis	O
14	C	O
15	virus	O
16	(	O
17	HCV	O
18	)	O
19	(	O
20	77	O
21	%),	O
22	alcohol	O
23	abuse	O
24	(	O
25	73	O
26	%),	O
27	and	O
28	the	O
29	combination	O
30	of	O
31	HCV	O
32	and	O
33	alcohol	O
34	abuse	O
35	(	O
36	50	O
37	%).	O

1	Three	O
2	new	O
3	aromatase	B
4	inhibitors	O
5	have	O
6	recently	O
7	completed	O
8	phase	O
9	III	O
10	evaluation	O
11	as	O
12	treatment	O
13	of	O
14	metastatic	O
15	breast	O
16	cancer	O
17	in	O
18	post	O
19	-	O
20	menopausal	O
21	women	O
22	whose	O
23	disease	O
24	has	O
25	progressed	O
26	despite	O
27	tamoxifen	O
28	therapy	O
29	:	O
30	anastrozole	O
31	(	O
32	ARIMIDEX	O
33	,	O
34	Zeneca	O
35	),	O
36	letrozole	O
37	(	O
38	FEMARA	O
39	,	O
40	Novartis	O
41	)	O
42	and	O
43	vorozole	O
44	(	O
45	RIVIZOR	O
46	,	O
47	Janssen	O
48	).	O

1	CONCLUSIONS	O
2	:	O
3	Turbutest	O
4	is	O
5	a	O
6	valuable	O
7	tool	O
8	in	O
9	asthmatic	O
10	patients	O
11	'	O
12	training	O
13	,	O
14	allowing	O
15	identification	O
16	and	O
17	improvement	O
18	of	O
19	an	O
20	inadequate	O
21	inhalation	O
22	technique	O
23	with	O
24	Turbuhaler	O
25	.	O

1	Of	O
2	those	O
3	injuries	O
4	,	O
5	143	O
6	cases	O
7	were	O
8	snowboard	O
9	related	O
10	and	O
11	158	O
12	cases	O
13	were	O
14	ski	O
15	related	O
16	.	O

1	The	O
2	femoral	O
3	artery	O
4	/	O
5	vein	O
6	and	O
7	the	O
8	soleus	O
9	and	O
10	gastrocnemius	O
11	muscles	O
12	were	O
13	examined	O
14	in	O
15	healthy	O
16	human	O
17	male	O
18	volunteers	O
19	.	O

1	SRFDelta5	B
2	acts	O
3	as	O
4	a	O
5	naturally	O
6	occurring	O
7	dominant	O
8	negative	O
9	regulatory	O
10	mutant	O
11	that	O
12	blocks	O
13	SRF	B
14	-	O
15	dependent	O
16	skeletal	B
17	alpha	I
18	-	I
19	actin	I
20	,	O
21	cardiac	B
22	alpha	I
23	-	I
24	actin	I
25	,	O
26	smooth	B
27	alpha	I
28	-	I
29	actin	I
30	,	O
31	SM22alpha	B
32	,	O
33	and	O
34	SRF	B
35	promoter	O
36	-	O
37	luciferase	B
38	reporter	O
39	activities	O
40	.	O

1	In	O
2	serum	O
3	-	O
4	free	O
5	media	O
6	,	O
7	p50E4F	B
8	accelerated	O
9	E1A	B
10	-	O
11	induced	O
12	apoptosis	O
13	.	O

1	The	O
2	potency	O
3	of	O
4	the	O
5	effect	O
6	of	O
7	Nim	O
8	(	O
9	0	O
10	.	O
11	5	O
12	mg	O
13	.	O
14	kg	O
15	-	O
16	1	O
17	i	O
18	.	O
19	p	O
20	.)	O
21	was	O
22	similar	O
23	to	O
24	that	O
25	of	O
26	NBP	O
27	(	O
28	10	O
29	mg	O
30	.	O
31	kg	O
32	-	O
33	1	O
34	i	O
35	.	O
36	p	O
37	.).	O

1	CONCLUSION	O
2	:	O
3	NBP	O
4	pre	O
5	-	O
6	treatment	O
7	or	O
8	post	O
9	-	O
10	treatment	O
11	markedly	O
12	enhanced	O
13	the	O
14	rCBF	O
15	to	O
16	striatum	O
17	in	O
18	RMCAO	O
19	rats	O
20	.	O

1	Progression	O
2	after	O
3	first	O
4	-	O
5	line	O
6	chemotherapy	O
7	was	O
8	associated	O
9	with	O
10	significantly	O
11	worse	O
12	survival	O
13	for	O
14	patients	O
15	with	O
16	metastasis	O
17	.	O

1	Mutations	O
2	within	O
3	human	O
4	UTR1	O
5	modulate	O
6	NRF	B
7	-	I
8	1	I
9	expression	O
10	by	O
11	interfering	O
12	with	O
13	mRNA	O
14	translational	O
15	efficiency	O
16	in	O
17	transfected	O
18	cells	O
19	and	O
20	in	O
21	an	O
22	in	O
23	vitro	O
24	translation	O
25	system	O
26	.	O

1	As	O
2	is	O
3	deduced	O
4	from	O
5	the	O
6	nucleotide	O
7	sequence	O
8	of	O
9	the	O
10	cDNA	O
11	,	O
12	CBS	B
13	-	I
14	1	I
15	contains	O
16	an	O
17	open	O
18	reading	O
19	frame	O
20	consisting	O
21	of	O
22	182	O
23	amino	O
24	acids	O
25	,	O
26	with	O
27	a	O
28	molecular	O
29	weight	O
30	of	O
31	19	O
32	.	O
33	5kDa	O
34	.	O

1	Corticostriatal	O
2	and	O
3	corticosubthalamic	O
4	input	O
5	zones	O
6	from	O
7	the	O
8	presupplementary	O
9	motor	O
10	area	O
11	in	O
12	the	O
13	macaque	O
14	monkey	O
15	:	O
16	comparison	O
17	with	O
18	the	O
19	input	O
20	zones	O
21	from	O
22	the	O
23	supplementary	O
24	motor	O
25	area	O
26	.	O

1	Basic	B
2	fibroblast	I
3	growth	I
4	factor	I
5	(	O
6	bFGF	B
7	)	O
8	has	O
9	been	O
10	shown	O
11	to	O
12	induce	O
13	angiogenesis	O
14	in	O
15	various	O
16	animal	O
17	models	O
18	,	O
19	but	O
20	the	O
21	methods	O
22	of	O
23	administration	O
24	used	O
25	experimentally	O
26	are	O
27	not	O
28	clinically	O
29	feasible	O
30	.	O

1	Both	O
2	filters	O
3	equally	O
4	contributed	O
5	to	O
6	elevation	O
7	of	O
8	iliac	O
9	venous	O
10	pressure	O
11	(	O
12	median	O
13	,	O
14	9	O
15	.	O
16	3	O
17	and	O
18	7	O
19	.	O
20	2	O
21	mm	O
22	Hg	O
23	[	O
24	n	O
25	=	O
26	9	O
27	]	O
28	with	O
29	the	O
30	spring	O
31	filter	O
32	and	O
33	RF02	O
34	filter	O
35	,	O
36	respectively	O
37	).	O

1	12	O
2	healthy	O
3	women	O
4	(	O
5	age	O
6	18	O
7	-	O
8	38	O
9	years	O
10	)	O
11	were	O
12	examined	O
13	using	O
14	the	O
15	2	O
16	-	O
17	hour	O
18	'	O
19	s	O
20	method	O
21	of	O
22	passive	O
23	leg	O
24	rising	O
25	(	O
26	PLR	O
27	)	O
28	in	O
29	follicular	O
30	(	O
31	FP	O
32	)	O
33	and	O
34	luteal	O
35	(	O
36	LP	O
37	)	O
38	phases	O
39	of	O
40	normal	O
41	ovulatory	O
42	cycle	O
43	.	O

1	Thus	O
2	,	O
3	sgRNA2	B
4	has	O
5	the	O
6	3	O
7	'	O
8	TE	O
9	in	O
10	its	O
11	5	O
12	'	O
13	UTR	O
14	.	O

1	These	O
2	single	O
3	mutational	O
4	defects	O
5	in	O
6	the	O
7	eRF1	B
8	-	O
9	eRF3	B
10	interaction	O
11	became	O
12	evident	O
13	when	O
14	either	O
15	truncated	O
16	protein	O
17	eRF3C	B
18	or	O
19	C	O
20	-	O
21	terminally	O
22	altered	O
23	eRF1	B
24	proteins	O
25	were	O
26	used	O
27	for	O
28	the	O
29	authentic	O
30	protein	O
31	,	O
32	providing	O
33	further	O
34	support	O
35	for	O
36	the	O
37	presence	O
38	of	O
39	a	O
40	C	O
41	-	O
42	terminal	O
43	interaction	O
44	.	O

1	Removal	O
2	of	O
3	each	O
4	of	O
5	three	O
6	contiguous	O
7	segments	O
8	from	O
9	the	O
10	N	O
11	-	O
12	terminal	O
13	half	O
14	specifically	O
15	inhibits	O
16	the	O
17	formation	O
18	of	O
19	5	B
20	.	I
21	8Ss	I
22	rRNA	I
23	,	O
24	whereas	O
25	deleting	O
26	part	O
27	of	O
28	the	O
29	C	O
30	-	O
31	terminal	O
32	region	O
33	of	O
34	the	O
35	protein	O
36	only	O
37	blocks	O
38	the	O
39	production	O
40	of	O
41	18S	B
42	rRNA	I
43	.	O

1	Ras	B
2	is	O
3	not	O
4	associated	O
5	with	O
6	the	O
7	tegument	O
8	.	O

1	Green	O
2	fluorescent	O
3	protein	O
4	-	O
5	tagged	O
6	UNC	B
7	-	I
8	49B	I
9	and	O
10	UNC	B
11	-	I
12	49C	I
13	subunits	I
14	are	O
15	coexpressed	O
16	in	O
17	muscle	O
18	cells	O
19	and	O
20	are	O
21	colocalized	O
22	to	O
23	synaptic	O
24	regions	O
25	.	O

1	We	O
2	show	O
3	that	O
4	a	O
5	protein	O
6	,	O
7	UBC9	B
8	,	O
9	interacts	O
10	specifically	O
11	with	O
12	TEL	B
13	in	O
14	vitro	O
15	and	O
16	in	O
17	vivo	O
18	.	O

1	The	O
2	aim	O
3	of	O
4	this	O
5	study	O
6	was	O
7	to	O
8	investigate	O
9	the	O
10	spontaneous	O
11	reports	O
12	of	O
13	suspected	O
14	adverse	O
15	drug	O
16	reactions	O
17	,	O
18	observed	O
19	in	O
20	elderly	O
21	patients	O
22	(	O
23	over	O
24	65	O
25	years	O
26	of	O
27	age	O
28	)	O
29	in	O
30	Sicily	O
31	(	O
32	Italy	O
33	)	O
34	during	O
35	the	O
36	period	O
37	from	O
38	1	O
39	January	O
40	1995	O
41	to	O
42	31	O
43	December	O
44	1997	O
45	.	O

1	Molecules	O
2	of	O
3	NH3	O
4	are	O
5	capable	O
6	of	O
7	emitting	O
8	stimulated	O
9	radiation	O
10	(	O
11	MASER	O
12	).	O

1	The	O
2	major	O
3	findings	O
4	of	O
5	our	O
6	studies	O
7	are	O
8	as	O
9	follows	O
10	:	O
11	1	O
12	)	O
13	There	O
14	are	O
15	no	O
16	detectable	O
17	signals	O
18	around	O
19	GDF	B
20	-	I
21	9	I
22	-	O
23	deficient	O
24	follicles	O
25	for	O
26	several	O
27	theca	O
28	cell	O
29	layer	O
30	markers	O
31	[	O
32	i	O
33	.	O
34	e	O
35	.	O

1	Interestingly	O
2	,	O
3	highly	O
4	charged	O
5	residues	O
6	were	O
7	abundantly	O
8	possessed	O
9	in	O
10	the	O
11	carboxy	O
12	-	O
13	terminal	O
14	part	O
15	of	O
16	the	O
17	MDV2	B
18	UL10	I
19	protein	I
20	.	O

1	Identification	O
2	and	O
3	structure	O
4	of	O
5	the	O
6	Marek	B
7	'	I
8	s	I
9	disease	I
10	virus	I
11	serotype	I
12	2	I
13	glycoprotein	I
14	M	I
15	gene	I
16	:	O
17	comparison	O
18	with	O
19	glycoprotein	B
20	M	I
21	genes	I
22	of	O
23	Herpesviridae	O
24	family	O
25	.	O

1	OBJECTIVE	O
2	:	O
3	To	O
4	perform	O
5	a	O
6	cost	O
7	-	O
8	effectiveness	O
9	analysis	O
10	(	O
11	CEA	O
12	)	O
13	between	O
14	a	O
15	standard	O
16	antiemetic	O
17	regimen	O
18	-	O
19	chlorpromazine	O
20	+	O
21	dexamethasone	O
22	(	O
23	CPM	O
24	-	O
25	DEX	O
26	)-	O
27	and	O
28	a	O
29	5	B
30	-	I
31	HT3	I
32	receptor	I
33	antagonist	O
34	-	O
35	tropisetron	O
36	(	O
37	TROP	O
38	)--	O
39	in	O
40	the	O
41	control	O
42	of	O
43	acute	O
44	emesis	O
45	induced	O
46	by	O
47	highly	O
48	emetogenic	O
49	chemotherapy	O
50	in	O
51	children	O
52	,	O
53	considering	O
54	two	O
55	analytic	O
56	perspectives	O
57	:	O
58	hospital	O
59	and	O
60	patients	O
61	.	O

1	Baseline	O
2	data	O
3	were	O
4	obtained	O
5	from	O
6	10	O
7	adults	O
8	.	O

1	A	O
2	comparison	O
3	of	O
4	the	O
5	nucleotide	O
6	and	O
7	deduced	O
8	amino	O
9	acid	O
10	sequences	O
11	of	O
12	the	O
13	core	O
14	regions	O
15	of	O
16	the	O
17	RNA	B
18	-	I
19	dependent	I
20	RNA	I
21	polymerase	I
22	domains	I
23	found	O
24	in	O
25	these	O
26	three	O
27	dsRNAs	O
28	suggested	O
29	that	O
30	these	O
31	dsRNAs	O
32	probably	O
33	evolved	O
34	independently	O
35	within	O
36	each	O
37	host	O
38	plant	O
39	from	O
40	a	O
41	common	O
42	ancestor	O
43	.	O

1	Consistent	O
2	with	O
3	this	O
4	possibility	O
5	,	O
6	a	O
7	non	O
8	-	O
9	MBD	B
10	region	O
11	of	O
12	Bin1	B
13	was	O
14	sufficient	O
15	to	O
16	recruit	O
17	a	O
18	repression	O
19	function	O
20	to	O
21	DNA	O
22	that	O
23	was	O
24	unrelated	O
25	to	O
26	histone	B
27	deacetylase	I
28	.	O

1	Forty	O
2	-	O
3	eight	O
4	sequences	O
5	,	O
6	30	O
7	not	O
8	previously	O
9	identified	O
10	as	O
11	IR	O
12	-	O
13	responsive	O
14	,	O
15	were	O
16	significantly	O
17	regulated	O
18	by	O
19	IR	O
20	.	O

1	A	O
2	recently	O
3	described	O
4	protein	O
5	,	O
6	metaxin	B
7	1	I
8	,	O
9	serves	O
10	as	O
11	a	O
12	component	O
13	of	O
14	a	O
15	preprotein	O
16	import	O
17	complex	O
18	in	O
19	the	O
20	outer	O
21	membrane	O
22	of	O
23	the	O
24	mammalian	O
25	mitochondrion	O
26	.	O

1	Molecular	O
2	cloning	O
3	of	O
4	rat	B
5	SH2	I
6	-	I
7	containing	I
8	inositol	I
9	phosphatase	I
10	2	I
11	(	O
12	SHIP2	B
13	)	O
14	and	O
15	its	O
16	role	O
17	in	O
18	the	O
19	regulation	O
20	of	O
21	insulin	B
22	signaling	O
23	.	O

1	Slp1	B
2	represses	O
3	transcription	O
4	via	O
5	this	O
6	binding	O
7	site	O
8	in	O
9	yeast	O
10	cells	O
11	,	O
12	consistent	O
13	with	O
14	its	O
15	role	O
16	as	O
17	a	O
18	direct	O
19	repressor	O
20	of	O
21	ftz	B
22	stripes	O
23	in	O
24	interstripe	O
25	regions	O
26	during	O
27	late	O
28	stages	O
29	of	O
30	embryogenesis	O
31	.	O

1	The	O
2	results	O
3	of	O
4	these	O
5	studies	O
6	support	O
7	a	O
8	model	O
9	in	O
10	which	O
11	VirB4	B
12	dimers	I
13	or	O
14	homomultimers	O
15	contribute	O
16	structural	O
17	information	O
18	for	O
19	the	O
20	assembly	O
21	of	O
22	a	O
23	transenvelope	O
24	channel	O
25	competent	O
26	for	O
27	bidirectional	O
28	DNA	O
29	transfer	O
30	,	O
31	whereas	O
32	an	O
33	ATP	O
34	-	O
35	dependent	O
36	activity	O
37	is	O
38	required	O
39	for	O
40	configuring	O
41	this	O
42	channel	O
43	as	O
44	a	O
45	dedicated	O
46	export	O
47	machine	O
48	.	O

1	The	O
2	penicillin	B
3	binding	I
4	proteins	I
5	(	O
6	PBPs	B
7	)	O
8	synthesize	O
9	and	O
10	remodel	O
11	peptidoglycan	O
12	,	O
13	the	O
14	structural	O
15	component	O
16	of	O
17	the	O
18	bacterial	O
19	cell	O
20	wall	O
21	.	O

1	TCR	B
2	alpha	I
3	(	O
4	TCRA	B
5	)	O
6	expression	O
7	was	O
8	examined	O
9	in	O
10	RNA	O
11	samples	O
12	from	O
13	PBMC	O
14	and	O
15	isolated	O
16	populations	O
17	of	O
18	CD4	O
19	+,	O
20	CD8	O
21	+,	O
22	and	O
23	DN	O
24	T	O
25	cells	O
26	from	O
27	15	O
28	healthy	O
29	individuals	O
30	.	O

1	Similar	O
2	results	O
3	were	O
4	obtained	O
5	with	O
6	xylitol	O
7	,	O
8	an	O
9	activator	O
10	of	O
11	the	O
12	pentose	O
13	phosphate	O
14	pathway	O
15	.	O

1	The	O
2	high	B
3	density	I
4	lipoprotein	I
5	(	I
6	HDL	I
7	)	I
8	receptor	I
9	mediates	O
10	the	O
11	uptake	O
12	of	O
13	cholesterol	O
14	and	O
15	cholesteryl	O
16	esters	O
17	,	O
18	substrates	O
19	for	O
20	steroidogenesis	O
21	,	O
22	from	O
23	an	O
24	HDL	B
25	particle	O
26	in	O
27	the	O
28	adrenal	O
29	gland	O
30	and	O
31	gonads	O
32	.	O

1	D3S1261	B
2	is	O
3	physically	O
4	located	O
5	at	O
6	or	O
7	near	O
8	the	O
9	MITF	B
10	locus	I
11	,	O
12	while	O
13	D3S2465	B
14	and	O
15	D3S1766	B
16	are	O
17	flanking	O
18	the	O
19	locus	O
20	at	O
21	about	O
22	17	O
23	.	O
24	5	O
25	cM	O
26	genetic	O
27	distance	O
28	each	O
29	side	O
30	.	O

1	The	O
2	percentages	O
3	of	O
4	recovery	O
5	decreased	O
6	with	O
7	storage	O
8	time	O
9	,	O
10	although	O
11	the	O
12	addition	O
13	of	O
14	dispersant	O
15	(	O
16	Tris	O
17	-	O
18	Tween	O
19	80	O
20	)	O
21	before	O
22	storage	O
23	appeared	O
24	to	O
25	partially	O
26	prevent	O
27	adhesion	O
28	.	O

1	Point	O
2	mutations	O
3	of	O
4	the	O
5	site	O
6	that	O
7	suppressed	O
8	Pit	B
9	-	I
10	1	I
11	binding	O
12	in	O
13	vitro	O
14	restored	O
15	full	O
16	tiGH	B
17	promoter	I
18	activity	O
19	.	O

1	A	O
2	human	B
3	Raf	I
4	-	I
5	responsive	I
6	zinc	I
7	-	I
8	finger	I
9	protein	I
10	that	O
11	binds	O
12	to	O
13	divergent	O
14	sequences	O
15	.	O

1	We	O
2	are	O
3	reporting	O
4	an	O
5	autopsy	O
6	case	O
7	of	O
8	so	O
9	-	O
10	called	O
11	"	O
12	acute	O
13	multiple	O
14	sclerosis	O
15	"	O
16	that	O
17	was	O
18	difficult	O
19	to	O
20	differentiate	O
21	from	O
22	a	O
23	brain	O
24	tumor	O
25	on	O
26	MRI	O
27	findings	O
28	.	O

1	Furthermore	O
2	,	O
3	MOM	B
4	-	I
5	4	I
6	and	O
7	TAK1	B
8	bind	O
9	related	O
10	proteins	O
11	that	O
12	promote	O
13	their	O
14	kinase	O
15	activities	O
16	.	O

1	BACKGROUND	O
2	:	O
3	The	O
4	MAZE	O
5	-	O
6	III	O
7	is	O
8	the	O
9	surgical	O
10	treatment	O
11	of	O
12	choice	O
13	for	O
14	medically	O
15	refractory	O
16	atrial	O
17	fibrillation	O
18	.	O

1	Gab2	B
2	,	O
3	a	O
4	new	O
5	pleckstrin	B
6	homology	O
7	domain	O
8	-	O
9	containing	O
10	adapter	O
11	protein	O
12	,	O
13	acts	O
14	to	O
15	uncouple	O
16	signaling	O
17	from	O
18	ERK	B
19	kinase	I
20	to	O
21	Elk	B
22	-	I
23	1	I
24	.	O

1	The	O
2	presence	O
3	of	O
4	cutaneous	O
5	xanthomas	O
6	with	O
7	normal	O
8	serum	O
9	lipid	O
10	levels	O
11	is	O
12	due	O
13	to	O
14	the	O
15	antibetalipoproteic	O
16	activity	O
17	of	O
18	the	O
19	monoclonal	B
20	immunoglobulin	I
21	.	O

1	In	O
2	an	O
3	attempt	O
4	to	O
5	reduce	O
6	the	O
7	incidence	O
8	of	O
9	NSAID	O
10	-	O
11	induced	O
12	gastrointestinal	O
13	lesions	O
14	,	O
15	the	O
16	following	O
17	approaches	O
18	have	O
19	been	O
20	proposed	O
21	:	O
22	(	O
23	i	O
24	)	O
25	use	O
26	of	O
27	the	O
28	prostaglandin	O
29	analogue	O
30	misoprostol	O
31	,	O
32	which	O
33	is	O
34	an	O
35	antiulcer	O
36	drug	O
37	which	O
38	has	O
39	been	O
40	proven	O
41	to	O
42	be	O
43	as	O
44	effective	O
45	in	O
46	the	O
47	prevention	O
48	of	O
49	NSAID	O
50	-	O
51	induced	O
52	gastric	O
53	and	O
54	duodenal	O
55	ulcers	O
56	as	O
57	in	O
58	the	O
59	reduction	O
60	of	O
61	serious	O
62	upper	O
63	gastrointestinal	O
64	complications	O
65	;	O
66	(	O
67	ii	O
68	)	O
69	histamine	B
70	H2	I
71	receptor	I
72	antagonists	O
73	(	O
74	H2	O
75	antagonists	O
76	),	O
77	e	O
78	.	O
79	g	O
80	.	O
81	ranitidine	O
82	,	O
83	cimetidine	O
84	and	O
85	famotidine	O
86	,	O
87	which	O
88	are	O
89	useful	O
90	in	O
91	the	O
92	prevention	O
93	of	O
94	NSAID	O
95	-	O
96	induced	O
97	duodenal	O
98	ulcers	O
99	during	O
100	long	O
101	term	O
102	treatment	O
103	,	O
104	but	O
105	not	O
106	in	O
107	the	O
108	prevention	O
109	of	O
110	NSAID	O
111	-	O
112	induced	O
113	gastric	O
114	ulcers	O
115	;	O
116	(	O
117	iii	O
118	)	O
119	proton	O
120	pump	O
121	inhibitors	O
122	,	O
123	e	O
124	.	O
125	g	O
126	omeprazole	O
127	,	O
128	and	O
129	pantoprazole	O
130	,	O
131	whose	O
132	efficacy	O
133	in	O
134	preventing	O
135	NSAID	O
136	-	O
137	associated	O
138	ulcers	O
139	has	O
140	been	O
141	recently	O
142	demonstrated	O
143	;	O
144	and	O
145	(	O
146	iv	O
147	)	O
148	barrier	O
149	agents	O
150	,	O
151	e	O
152	.	O
153	g	O
154	.	O
155	sucralfate	O
156	,	O
157	which	O
158	cannot	O
159	be	O
160	recommended	O
161	as	O
162	prophylactic	O
163	agents	O
164	to	O
165	prevent	O
166	NSAID	O
167	-	O
168	induced	O
169	gastropathy	O
170	.	O

1	Lung	O
2	mesenchyme	O
3	serves	O
4	as	O
5	a	O
6	'	O
7	compleat	O
8	'	O
9	inducer	O
10	of	O
11	lung	O
12	morphogenesis	O
13	by	O
14	secreting	O
15	soluble	O
16	peptide	O
17	growth	O
18	factors	O
19	.	O

1	The	O
2	activation	O
3	of	O
4	the	O
5	HIV	O
6	promoter	O
7	required	O
8	the	O
9	nuclear	O
10	localization	O
11	of	O
12	c	B
13	-	I
14	Abl	I
15	and	O
16	could	O
17	be	O
18	correlated	O
19	with	O
20	increased	O
21	tyrosine	O
22	phosphorylation	O
23	of	O
24	RNA	B
25	polymerase	I
26	II	I
27	.	O

1	The	O
2	bovine	B
3	papillomavirus	I
4	E2	I
5	protein	I
6	can	O
7	inhibit	O
8	the	O
9	proliferation	O
10	of	O
11	HT	O
12	-	O
13	3	O
14	cells	O
15	,	O
16	a	O
17	p53	B
18	-	O
19	negative	O
20	cervical	O
21	carcinoma	O
22	cell	O
23	line	O
24	containing	O
25	integrated	O
26	human	O
27	papillomavirus	O
28	type	O
29	30	O
30	DNA	O
31	.	O

1	E2	B
2	point	O
3	mutants	O
4	unable	O
5	to	O
6	inhibit	O
7	cell	O
8	growth	O
9	did	O
10	not	O
11	repress	O
12	cdc25A	B
13	and	O
14	cdc25B	B
15	expression	O
16	,	O
17	nor	O
18	did	O
19	the	O
20	cell	O
21	cycle	O
22	inhibitors	O
23	hydroxyurea	O
24	and	O
25	mimosine	O
26	.	O

1	BACKGROUND	O
2	/	O
3	PURPOSE	O
4	:	O
5	Anomalous	O
6	arrangement	O
7	of	O
8	the	O
9	pancreaticobiliary	O
10	duct	O
11	(	O
12	AAPBD	O
13	)	O
14	is	O
15	closely	O
16	related	O
17	to	O
18	congenital	O
19	biliary	O
20	dilatation	O
21	and	O
22	frequently	O
23	associated	O
24	with	O
25	biliary	O
26	tract	O
27	malignancy	O
28	.	O

1	Neurospora	O
2	crassa	O
3	CYT	B
4	-	I
5	18	I
6	,	O
7	can	O
8	rescue	O
9	the	O
10	exonic	O
11	trap	O
12	and	O
13	intron	O
14	mutants	O
15	which	O
16	cause	O
17	a	O
18	structural	O
19	defect	O
20	.	O

1	DDP1	B
2	also	O
3	localizes	O
4	to	O
5	heterochromatin	O
6	in	O
7	interphase	O
8	nuclei	O
9	of	O
10	larval	O
11	neuroblasts	O
12	.	O

1	In	O
2	a	O
3	reconstituted	O
4	human	O
5	DNA	O
6	repair	O
7	system	O
8	containing	O
9	DNA	B
10	polymerase	I
11	beta	I
12	and	O
13	DNA	B
14	ligase	I
15	III	I
16	-	O
17	XRCC1	B
18	,	O
19	accurate	O
20	rejoining	O
21	of	O
22	a	O
23	3	O
24	'	O
25	mismatched	O
26	base	O
27	residue	O
28	at	O
29	a	O
30	single	O
31	-	O
32	strand	O
33	break	O
34	is	O
35	dependent	O
36	on	O
37	addition	O
38	of	O
39	the	O
40	exonuclease	O
41	.	O

1	The	O
2	PAC	O
3	clone	O
4	with	O
5	an	O
6	insert	O
7	size	O
8	of	O
9	120kb	O
10	was	O
11	isolated	O
12	and	O
13	mapped	O
14	by	O
15	restriction	O
16	analysis	O
17	.	O

1	Sequence	O
2	of	O
3	10q24	B
4	locus	I
5	surrounding	O
6	the	O
7	HOX11	B
8	oncogene	I
9	reveals	O
10	a	O
11	new	O
12	gene	O
13	HUG1	B
14	expressed	O
15	in	O
16	a	O
17	T	O
18	-	O
19	ALL	O
20	cell	O
21	line	O
22	.	O

1	About	O
2	20	O
3	kb	O
4	upstream	O
5	of	O
6	LAMB2	B
7	we	O
8	found	O
9	a	O
10	gene	O
11	encoding	O
12	a	O
13	transcribed	O
14	,	O
15	non	O
16	-	O
17	processed	O
18	LAMB2	B
19	-	I
20	like	I
21	pseudogene	I
22	(	O
23	LAMB2L	B
24	).	O

1	Site	O
2	-	O
3	directed	O
4	mutagenesis	O
5	of	O
6	the	O
7	R2	B
8	protein	I
9	was	O
10	used	O
11	to	O
12	provide	O
13	evidence	O
14	that	O
15	this	O
16	motif	O
17	is	O
18	also	O
19	part	O
20	of	O
21	the	O
22	active	O
23	site	O
24	of	O
25	the	O
26	endonuclease	O
27	encoded	O
28	by	O
29	this	O
30	element	O
31	.	O

1	The	O
2	infected	B
3	cell	I
4	protein	I
5	no	I
6	.	I
7	0	I
8	(	O
9	ICP0	B
10	)	O
11	of	O
12	herpes	O
13	simplex	O
14	virus	O
15	1	O
16	is	O
17	a	O
18	promiscuous	O
19	transactivator	O
20	shown	O
21	to	O
22	enhance	O
23	the	O
24	expression	O
25	of	O
26	genes	O
27	introducted	O
28	into	O
29	cells	O
30	by	O
31	infection	O
32	or	O
33	transfection	O
34	.	O

1	Wrist	O
2	measurement	O
3	of	O
4	blood	O
5	pressure	O
6	:	O
7	some	O
8	critical	O
9	remarks	O
10	to	O
11	oscillometry	O
12	.	O

1	G	O
2	-	O
3	box	O
4	-	O
5	directed	O
6	expression	O
7	in	O
8	leaves	O
9	required	O
10	the	O
11	presence	O
12	of	O
13	an	O
14	enhancer	O
15	region	O
16	from	O
17	the	O
18	cauliflower	O
19	mosaic	O
20	virus	O
21	(	O
22	CaMV	O
23	)	O
24	35S	B
25	promoter	I
26	.	O

1	Another	O
2	element	O
3	necessary	O
4	for	O
5	augmenting	O
6	the	O
7	amplitude	O
8	of	O
9	the	O
10	oscillation	O
11	lies	O
12	between	O
13	-	O
14	178	O
15	and	O
16	-	O
17	264	O
18	.	O

1	This	O
2	scFv	O
3	was	O
4	therefore	O
5	used	O
6	as	O
7	control	O
8	in	O
9	experiments	O
10	where	O
11	another	O
12	anti	B
13	-	I
14	Ras	I
15	scFv	I
16	(	O
17	Y259	B
18	scFv	I
19	,	O
20	derived	O
21	from	O
22	the	O
23	neutralizing	O
24	anti	B
25	-	I
26	Ras	I
27	mAb	I
28	Y13	I
29	-	I
30	259	I
31	)	O
32	blocked	O
33	the	O
34	Ras	B
35	pathway	O
36	in	O
37	vitro	O
38	and	O
39	led	O
40	to	O
41	tumor	O
42	regression	O
43	in	O
44	a	O
45	nude	O
46	mouse	O
47	model	O
48	[	O
49	Cochet	O
50	,	O
51	O	O
52	.,	O
53	Kenigsberg	O
54	,	O
55	M	O
56	.,	O
57	Delumeau	O
58	,	O
59	I	O
60	.,	O
61	Virone	O
62	-	O
63	Oddos	O
64	,	O
65	A	O
66	.,	O
67	Multon	O
68	,	O
69	M	O
70	.	O
71	C	O
72	.,	O
73	Fridman	O
74	,	O
75	W	O
76	.	O
77	H	O
78	.,	O
79	Schweighoffer	O
80	,	O
81	F	O
82	.,	O
83	Teillaud	O
84	,	O
85	J	O
86	.	O
87	L	O
88	.,	O
89	Tocque	O
90	,	O
91	B	O
92	.,	O
93	1998	O
94	.	O

1	There	O
2	was	O
3	no	O
4	competition	O
5	between	O
6	activin	B
7	A	I
8	and	O
9	OP	B
10	-	I
11	1	I
12	for	O
13	availability	O
14	of	O
15	Smad4	B
16	,	O
17	indicating	O
18	that	O
19	the	O
20	concentration	O
21	of	O
22	this	O
23	common	O
24	signal	O
25	transducer	O
26	is	O
27	not	O
28	limiting	O
29	for	O
30	generating	O
31	the	O
32	observed	O
33	biological	O
34	responses	O
35	.	O

1	Our	O
2	data	O
3	therefore	O
4	indicate	O
5	that	O
6	it	O
7	is	O
8	possible	O
9	to	O
10	engineer	O
11	the	O
12	HA	B
13	envelope	I
14	glycoprotein	I
15	by	O
16	fusing	O
17	ligands	O
18	to	O
19	its	O
20	amino	O
21	-	O
22	terminal	O
23	end	O
24	without	O
25	affecting	O
26	its	O
27	fusion	O
28	activity	O
29	.	O

1	However	O
2	,	O
3	the	O
4	favored	O
5	,	O
6	parallel	O
7	beta	O
8	helix	O
9	model	O
10	is	O
11	a	O
12	compact	O
13	coil	O
14	of	O
15	ten	O
16	helically	O
17	arranged	O
18	beta	O
19	strands	O
20	forming	O
21	two	O
22	parallel	O
23	beta	O
24	sheet	O
25	faces	O
26	.	O

1	This	O
2	is	O
3	predicted	O
4	to	O
5	encode	O
6	a	O
7	315	O
8	-	O
9	residue	O
10	protein	O
11	containing	O
12	seven	O
13	hydrophobic	O
14	helical	O
15	regions	O
16	and	O
17	a	O
18	17	O
19	amino	O
20	acid	O
21	motif	O
22	characteristic	O
23	of	O
24	the	O
25	R7G	B
26	family	I
27	of	O
28	G	B
29	-	I
30	protein	I
31	coupled	I
32	membrane	I
33	-	I
34	bound	I
35	receptors	I
36	.	O

1	Characterisation	O
2	of	O
3	the	O
4	chicken	B
5	apolipoprotein	I
6	A	I
7	-	I
8	I	I
9	gene	I
10	5	O
11	'-	O
12	flanking	O
13	region	O
14	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	members	O
6	of	O
7	the	O
8	ATF	B
9	family	I
10	are	O
11	involved	O
12	in	O
13	mediating	O
14	the	O
15	transcriptional	O
16	regulation	O
17	of	O
18	the	O
19	KGF	B
20	gene	I
21	in	O
22	response	O
23	to	O
24	extracellular	O
25	stimuli	O
26	via	O
27	a	O
28	novel	O
29	CRE	O
30	regulatory	O
31	element	O
32	.	O

1	Moreover	O
2	,	O
3	a	O
4	high	O
5	proportion	O
6	of	O
7	blood	O
8	samples	O
9	from	O
10	a	O
11	random	O
12	sample	O
13	of	O
14	the	O
15	rest	O
16	of	O
17	the	O
18	suspects	O
19	tested	O
20	positive	O
21	for	O
22	trypanosome	O
23	-	O
24	specific	O
25	DNA	O
26	by	O
27	PCR	O
28	(	O
29	79	O
30	.	O
31	9	O
32	%	O
33	for	O
34	T	O
35	.	O
36	b	O
37	.	O
38	gambiense	O
39	and	O
40	13	O
41	.	O
42	9	O
43	%	O
44	for	O
45	T	O
46	.	O
47	b	O
48	.	O
49	rhodesiense	O
50	).	O

1	A	O
2	multi	O
3	-	O
4	centre	O
5	evaluation	O
6	of	O
7	the	O
8	card	O
9	indirect	O
10	agglutination	O
11	test	O
12	for	O
13	trypanosomiasis	O
14	(	O
15	TrypTect	O
16	CIATT	O
17	).	O

1	Results	O
2	for	O
3	men	O
4	who	O
5	drank	O
6	up	O
7	to	O
8	two	O
9	drinks	O
10	per	O
11	day	O
12	suggest	O
13	that	O
14	if	O
15	the	O
16	dependence	O
17	criteria	O
18	were	O
19	invalid	O
20	,	O
21	reductions	O
22	in	O
23	the	O
24	prevalence	O
25	of	O
26	specific	O
27	indicators	O
28	of	O
29	alcohol	O
30	dependence	O
31	would	O
32	range	O
33	from	O
34	0	O
35	.	O
36	3	O
37	%	O
38	to	O
39	5	O
40	.	O
41	2	O
42	%.	O

1	Mutagenesis	O
2	of	O
3	the	O
4	CDE	O
5	/	O
6	CHR	O
7	elements	O
8	and	O
9	Sp1	B
10	sites	I
11	in	O
12	this	O
13	region	O
14	,	O
15	alone	O
16	or	O
17	in	O
18	combination	O
19	,	O
20	reduced	O
21	transcriptional	O
22	activity	O
23	by	O
24	40	O
25	-	O
26	60	O
27	%	O
28	in	O
29	asynchronously	O
30	growing	O
31	cells	O
32	and	O
33	abolished	O
34	cell	O
35	cycle	O
36	periodicity	O
37	in	O
38	G2	O
39	-	O
40	M	O
41	-	O
42	synchronized	O
43	cells	O
44	.	O

1	Using	O
2	Scheffe	O
3	'	O
4	s	O
5	procedure	O
6	as	O
7	an	O
8	illustration	O
9	,	O
10	comparisons	O
11	are	O
12	made	O
13	to	O
14	usual	O
15	sample	O
16	size	O
17	methods	O
18	that	O
19	incorrectly	O
20	ignore	O
21	the	O
22	stochastic	O
23	nature	O
24	of	O
25	S2p	O
26	.	O

1	The	O
2	crystal	O
3	structure	O
4	of	O
5	the	O
6	VP16	B
7	core	I
8	has	O
9	been	O
10	determined	O
11	at	O
12	2	O
13	.	O
14	1	O
15	A	O
16	resolution	O
17	.	O

1	Ozagrel	O
2	,	O
3	ifenprodil	O
4	,	O
5	cinnarizine	O
6	and	O
7	dilazep	O
8	were	O
9	more	O
10	effective	O
11	than	O
12	pentoxifylline	O
13	in	O
14	increasing	O
15	rCBF	O
16	at	O
17	the	O
18	HPC	O
19	.	O

1	The	O
2	latter	O
3	method	O
4	adds	O
5	clamping	O
6	of	O
7	the	O
8	inferior	O
9	vena	O
10	cava	O
11	,	O
12	which	O
13	results	O
14	in	O
15	hypotension	O
16	,	O
17	requiring	O
18	invasive	O
19	anesthetic	O
20	management	O
21	.	O

1	By	O
2	contrast	O
3	,	O
4	PvirE	B
5	or	O
6	Plac	B
7	promoter	I
8	constructs	I
9	yielded	O
10	functional	O
11	VirE2	B
12	only	O
13	if	O
14	virE1	B
15	was	O
16	coexpressed	O
17	with	O
18	virE2	B
19	.	O

1	Simian	O
2	parainfluenza	O
3	virus	O
4	5	O
5	(	O
6	SV5	O
7	)	O
8	is	O
9	a	O
10	prototype	O
11	of	O
12	the	O
13	Paramyxoviridae	O
14	family	O
15	of	O
16	nonsegmented	O
17	negative	O
18	-	O
19	sense	O
20	RNA	O
21	viruses	O
22	.	O

1	To	O
2	investigate	O
3	the	O
4	functions	O
5	of	O
6	GE	O
7	,	O
8	IG	O
9	,	O
10	and	O
11	GS	O
12	sequences	O
13	in	O
14	transcription	O
15	,	O
16	we	O
17	constructed	O
18	plasmids	O
19	containing	O
20	cDNAs	O
21	of	O
22	the	O
23	full	O
24	-	O
25	length	O
26	SV5	O
27	genome	O
28	in	O
29	which	O
30	the	O
31	gene	O
32	junction	O
33	sequences	O
34	(	O
35	GE	O
36	,	O
37	IG	O
38	,	O
39	and	O
40	GS	O
41	sequences	O
42	)	O
43	located	O
44	between	O
45	the	O
46	hemagglutinin	B
47	-	I
48	neuraminidase	I
49	(	O
50	HN	B
51	)	O
52	and	O
53	the	O
54	polymerase	B
55	(	I
56	L	I
57	)	I
58	genes	I
59	were	O
60	replaced	O
61	with	O
62	the	O
63	counterpart	O
64	sequences	O
65	from	O
66	other	O
67	gene	O
68	junctions	O
69	.	O

1	CXCR4	B
2	is	O
3	a	O
4	chemokine	O
5	receptor	O
6	and	O
7	a	O
8	coreceptor	O
9	for	O
10	T	O
11	-	O
12	cell	O
13	-	O
14	line	O
15	-	O
16	tropic	O
17	(	O
18	X4	O
19	)	O
20	and	O
21	dual	O
22	-	O
23	tropic	O
24	(	O
25	R5X4	O
26	)	O
27	human	O
28	immunodeficiency	O
29	virus	O
30	type	O
31	1	O
32	(	O
33	HIV	O
34	-	O
35	1	O
36	)	O
37	isolates	O
38	.	O

1	These	O
2	data	O
3	will	O
4	help	O
5	us	O
6	to	O
7	better	O
8	detail	O
9	the	O
10	CXCR4	B
11	structural	O
12	requirements	O
13	exhibited	O
14	by	O
15	different	O
16	HIV	O
17	-	O
18	1	O
19	strains	O
20	and	O
21	will	O
22	direct	O
23	further	O
24	mutagenesis	O
25	efforts	O
26	aimed	O
27	at	O
28	better	O
29	defining	O
30	the	O
31	domains	O
32	in	O
33	CXCR4	B
34	involved	O
35	in	O
36	the	O
37	HIV	O
38	-	O
39	1	O
40	Env	B
41	-	O
42	mediated	O
43	fusion	O
44	process	O
45	.	O

1	The	O
2	results	O
3	of	O
4	these	O
5	analyses	O
6	indicate	O
7	that	O
8	the	O
9	proteinase	O
10	cleaves	O
11	at	O
12	amino	O
13	acid	O
14	residues	O
15	E960	O
16	-	O
17	A961	O
18	,	O
19	E1071	O
20	-	O
21	S1072	O
22	,	O
23	E1345	O
24	-	O
25	T1346	O
26	,	O
27	and	O
28	E1419	O
29	-	O
30	G1420	O
31	;	O
32	however	O
33	,	O
34	the	O
35	cleavage	O
36	efficiency	O
37	is	O
38	varied	O
39	.	O

1	y	O
2	.	O

1	SM	B
2	is	O
3	also	O
4	shown	O
5	to	O
6	be	O
7	associated	O
8	in	O
9	vivo	O
10	with	O
11	other	O
12	components	O
13	of	O
14	the	O
15	CRM	B
16	1	I
17	export	O
18	pathway	O
19	,	O
20	including	O
21	the	O
22	small	B
23	GTPase	I
24	Ran	I
25	and	O
26	the	O
27	nucleoporin	O
28	CAN	B
29	/	O
30	Nup214	B
31	.	O

1	Identification	O
2	of	O
3	a	O
4	spliced	O
5	gene	O
6	from	O
7	Kaposi	O
8	'	O
9	s	O
10	sarcoma	O
11	-	O
12	associated	O
13	herpesvirus	O
14	encoding	O
15	a	O
16	protein	O
17	with	O
18	similarities	O
19	to	O
20	latent	B
21	membrane	I
22	proteins	I
23	1	I
24	and	I
25	2A	I
26	of	I
27	Epstein	I
28	-	I
29	Barr	I
30	virus	I
31	.	O

1	Auditory	O
2	clicks	O
3	were	O
4	given	O
5	at	O
6	a	O
7	rate	O
8	of	O
9	20	O
10	s	O
11	(-	O
12	1	O
13	).	O

1	Myosin	B
2	light	I
3	chain	I
4	kinase	I
5	functions	O
6	downstream	O
7	of	O
8	Ras	B
9	/	O
10	ERK	B
11	to	O
12	promote	O
13	migration	O
14	of	O
15	urokinase	B
16	-	I
17	type	I
18	plasminogen	I
19	activator	I
20	-	O
21	stimulated	O
22	cells	O
23	in	O
24	an	O
25	integrin	B
26	-	O
27	selective	O
28	manner	O
29	.	O

1	The	O
2	inhibition	O
3	of	O
4	StAR	B
5	gene	I
6	transcription	O
7	by	O
8	DAX	B
9	-	I
10	1	I
11	was	O
12	dose	O
13	-	O
14	dependent	O
15	reducing	O
16	transcription	O
17	to	O
18	6	O
19	%	O
20	of	O
21	control	O
22	levels	O
23	.	O

1	In	O
2	a	O
3	prospective	O
4	randomized	O
5	study	O
6	,	O
7	287	O
8	patients	O
9	with	O
10	advanced	O
11	non	O
12	-	O
13	small	O
14	cell	O
15	lung	O
16	cancer	O
17	(	O
18	NSCLC	O
19	)	O
20	stage	O
21	IIIb	O
22	or	O
23	IV	O
24	with	O
25	ECOG	O
26	performance	O
27	status	O
28	(	O
29	PS	O
30	)	O
31	0	O
32	-	O
33	1	O
34	or	O
35	2	O
36	were	O
37	randomly	O
38	assigned	O
39	to	O
40	receive	O
41	either	O
42	best	O
43	supportive	O
44	care	O
45	(	O
46	BSC	O
47	)	O
48	or	O
49	supportive	O
50	care	O
51	plus	O
52	combination	O
53	chemotherapy	O
54	(	O
55	IEP	O
56	regimen	O
57	:	O
58	ifosfamide	O
59	3	O
60	gm	O
61	/	O
62	m2	O
63	IV	O
64	with	O
65	mesna	O
66	uroprotection	O
67	,	O
68	epirubicin	O
69	60	O
70	mg	O
71	/	O
72	m2	O
73	IV	O
74	on	O
75	day	O
76	1	O
77	and	O
78	cisplatin	O
79	60	O
80	mg	O
81	/	O
82	m2	O
83	IV	O
84	on	O
85	day	O
86	2	O
87	;	O
88	or	O
89	MVP	O
90	regimen	O
91	:	O
92	mitomycin	O
93	-	O
94	C	O
95	8	O
96	mg	O
97	/	O
98	m2	O
99	,	O
100	cisplatin	O
101	100	O
102	mg	O
103	/	O
104	m2	O
105	IV	O
106	on	O
107	day	O
108	1	O
109	,	O
110	vinblastine	O
111	4	O
112	mg	O
113	/	O
114	m2	O
115	IV	O
116	on	O
117	days	O
118	1	O
119	and	O
120	15	O
121	).	O

1	Using	O
2	sequence	O
3	information	O
4	from	O
5	human	B
6	BMAL1	I
7	(	O
8	hBMAL1	B
9	)	O
10	cDNAs	O
11	previously	O
12	reported	O
13	by	O
14	our	O
15	laboratory	O
16	,	O
17	we	O
18	have	O
19	isolated	O
20	and	O
21	characterized	O
22	cDNAs	O
23	encoding	O
24	three	O
25	splice	O
26	variants	O
27	of	O
28	the	O
29	mouse	B
30	BMAL1	I
31	(	O
32	mBMAL1	B
33	)	O
34	gene	O
35	.	O

1	Comparison	O
2	with	O
3	the	O
4	bHLH	B
5	/	O
6	PAS	B
7	family	O
8	genes	O
9	revealed	O
10	that	O
11	the	O
12	intron	O
13	/	O
14	exon	O
15	splice	O
16	pattern	O
17	of	O
18	mBMAL1	B
19	most	O
20	closely	O
21	matches	O
22	that	O
23	of	O
24	the	O
25	mAhr	B
26	,	O
27	which	O
28	suggests	O
29	that	O
30	BMAL1	B
31	and	O
32	Ahr	B
33	belong	O
34	to	O
35	the	O
36	same	O
37	subclass	O
38	and	O
39	may	O
40	be	O
41	derived	O
42	from	O
43	a	O
44	common	O
45	primordial	O
46	gene	O
47	.	O

1	The	O
2	transcriptional	O
3	activities	O
4	of	O
5	the	O
6	full	O
7	-	O
8	length	O
9	promoter	O
10	(-	O
11	295	O
12	to	O
13	+	O
14	85	O
15	)	O
16	and	O
17	of	O
18	three	O
19	deletion	O
20	constructs	O
21	(-	O
22	197	O
23	,	O
24	-	O
25	154	O
26	and	O
27	-	O
28	74	O
29	to	O
30	+	O
31	85	O
32	)	O
33	were	O
34	significantly	O
35	down	O
36	-	O
37	regulated	O
38	in	O
39	resistant	O
40	cells	O
41	.	O

1	We	O
2	were	O
3	able	O
4	to	O
5	detect	O
6	significant	O
7	differences	O
8	in	O
9	functional	O
10	residual	O
11	capacity	O
12	adjusted	O
13	for	O
14	weight	O
15	or	O
16	height	O
17	,	O
18	and	O
19	compliance	O
20	of	O
21	the	O
22	respiratory	O
23	system	O
24	adjusted	O
25	for	O
26	weight	O
27	or	O
28	lung	O
29	volume	O
30	in	O
31	the	O
32	ILD	O
33	infants	O
34	compared	O
35	to	O
36	the	O
37	healthy	O
38	controls	O
39	or	O
40	infants	O
41	who	O
42	had	O
43	PPHN	O
44	,	O
45	indicating	O
46	that	O
47	these	O
48	PFTs	O
49	were	O
50	sensitive	O
51	enough	O
52	to	O
53	determine	O
54	abnormal	O
55	lung	O
56	function	O
57	in	O
58	this	O
59	age	O
60	group	O
61	.	O

1	A	O
2	13	O
3	-	O
4	bp	O
5	cis	O
6	-	O
7	regulatory	O
8	element	O
9	in	O
10	the	O
11	LTR	O
12	promoter	O
13	of	O
14	the	O
15	tobacco	B
16	retrotransposon	I
17	Tto1	I
18	is	O
19	involved	O
20	in	O
21	responsiveness	O
22	to	O
23	tissue	O
24	culture	O
25	,	O
26	wounding	O
27	,	O
28	methyl	O
29	jasmonate	O
30	and	O
31	fungal	O
32	elicitors	O
33	.	O

1	In	O
2	this	O
3	study	O
4	we	O
5	describe	O
6	that	O
7	platelet	B
8	-	I
9	derived	I
10	growth	I
11	factor	I
12	(	O
13	PDGF	B
14	),	O
15	12	O
16	-	O
17	O	O
18	-	O
19	tetradecanoyl	O
20	-	O
21	phorbol	O
22	-	O
23	acetate	O
24	(	O
25	TPA	O
26	),	O
27	and	O
28	forskolin	O
29	induced	O
30	CREB	B
31	(	O
32	cAMP	B
33	-	I
34	responsive	I
35	element	I
36	-	I
37	binding	I
38	protein	I
39	)	O
40	Ser	O
41	-	O
42	133	O
43	phosphorylation	O
44	with	O
45	comparable	O
46	magnitude	O
47	and	O
48	kinetics	O
49	in	O
50	NIH	O
51	3T3	O
52	cells	O
53	.	O

1	This	O
2	constitutes	O
3	evidence	O
4	for	O
5	an	O
6	in	O
7	vivo	O
8	role	O
9	of	O
10	SRC	B
11	-	I
12	1	I
13	in	O
14	dimerization	O
15	-	O
16	induced	O
17	activation	O
18	by	O
19	OR1	B
20	/	O
21	RXRalpha	B
22	.	O

1	By	O
2	contrast	O
3	,	O
4	mTRAP100	B
5	coprecipitates	O
6	in	O
7	vivo	O
8	with	O
9	another	O
10	component	O
11	of	O
12	the	O
13	TRAP	B
14	complex	I
15	(	O
16	TRAP220	B
17	),	O
18	which	O
19	directly	O
20	contacts	O
21	TR	B
22	and	O
23	the	O
24	vitamin	B
25	D	I
26	receptor	I
27	in	O
28	a	O
29	ligand	O
30	-	O
31	dependent	O
32	manner	O
33	.	O

1	This	O
2	sequence	O
3	also	O
4	confers	O
5	VDR	B
6	and	O
7	vitamin	O
8	D	O
9	responsiveness	O
10	to	O
11	a	O
12	heterologous	O
13	promoter	O
14	.	O

1	Classical	O
2	ligand	O
3	-	O
4	activated	O
5	nuclear	O
6	receptors	O
7	(	O
8	e	O
9	.	O
10	g	O
11	.	O
12	thyroid	B
13	hormone	I
14	receptor	I
15	,	O
16	retinoic	B
17	acid	I
18	receptor	I
19	),	O
20	orphan	B
21	nuclear	I
22	receptors	I
23	(	O
24	e	O
25	.	O
26	g	O
27	.	O

1	Expression	O
2	of	O
3	GlcNAc	B
4	-	I
5	TI	I
6	mRNA	I
7	in	O
8	tobacco	O
9	leaves	O
10	was	O
11	detected	O
12	using	O
13	RT	O
14	-	O
15	PCR	O
16	.	O

1	Chemical	O
2	stability	O
3	tests	O
4	and	O
5	site	O
6	-	O
7	specific	O
8	mutagenesis	O
9	identified	O
10	amino	O
11	acids	O
12	H219	O
13	and	O
14	D63	O
15	of	O
16	RegS	B
17	and	O
18	RegR	B
19	,	O
20	respectively	O
21	,	O
22	as	O
23	the	O
24	phosphorylated	O
25	residues	O
26	.	O

1	An	O
2	overexpression	O
3	of	O
4	the	O
5	betaAPP	B
6	gene	I
7	in	O
8	certain	O
9	areas	O
10	of	O
11	the	O
12	AD	O
13	brain	O
14	has	O
15	been	O
16	suggested	O
17	to	O
18	be	O
19	an	O
20	important	O
21	factor	O
22	in	O
23	the	O
24	neuropathology	O
25	of	O
26	AD	O
27	.	O

1	For	O
2	functional	O
3	studies	O
4	,	O
5	two	O
6	promoter	O
7	regions	O
8	were	O
9	cloned	O
10	upstream	O
11	of	O
12	the	O
13	reporter	O
14	gene	O
15	,	O
16	chloramphenicol	B
17	acetyl	I
18	transferase	I
19	(	O
20	CAT	B
21	):	O
22	(	O
23	i	O
24	)	O
25	phbetaE	O
26	-	O
27	B	O
28	-	O
29	the	O
30	plasmid	O
31	that	O
32	contains	O
33	the	O
34	human	O
35	(	O
36	h	O
37	)	O
38	promoter	O
39	region	O
40	(-	O
41	2832	O
42	to	O
43	+	O
44	101	O
45	)	O
46	including	O
47	URE	O
48	,	O
49	and	O
50	(	O
51	ii	O
52	)	O
53	prhbetaE	O
54	-	O
55	B	O
56	-	O
57	the	O
58	plasmid	O
59	that	O
60	contains	O
61	the	O
62	rhesus	O
63	(	O
64	rh	O
65	)	O
66	promoter	O
67	region	O
68	excluding	O
69	URE	O
70	as	O
71	it	O
72	lacks	O
73	a	O
74	270	O
75	bp	O
76	region	O
77	of	O
78	the	O
79	hbetaAPP	B
80	promoter	I
81	(-	O
82	2435	O
83	to	O
84	-	O
85	2165	O
86	).	O

1	67	O
2	393	O
3	bp	O
4	of	O
5	contiguous	O
6	DNA	O
7	located	O
8	between	O
9	markers	O
10	cdc18	B
11	and	O
12	cdc14	B
13	on	O
14	the	O
15	right	O
16	arm	O
17	of	O
18	fission	O
19	yeast	O
20	chromosome	O
21	II	O
22	has	O
23	been	O
24	sequenced	O
25	as	O
26	part	O
27	of	O
28	the	O
29	European	O
30	Union	O
31	Schizosaccharomyces	O
32	pombe	O
33	genome	O
34	sequencing	O
35	project	O
36	.	O

1	67	O
2	393	O
3	bp	O
4	of	O
5	contiguous	O
6	DNA	O
7	located	O
8	between	O
9	markers	O
10	cdc18	B
11	and	O
12	cdc14	B
13	on	O
14	the	O
15	right	O
16	arm	O
17	of	O
18	fission	O
19	yeast	O
20	chromosome	O
21	II	O
22	has	O
23	been	O
24	sequenced	O
25	as	O
26	part	O
27	of	O
28	the	O
29	European	O
30	Union	O
31	Schizosaccharomyces	O
32	pombe	O
33	genome	O
34	sequencing	O
35	project	O
36	.	O

1	G	B
2	-	I
3	CSF	I
4	(	O
5	480	O
6	micrograms	O
7	subcutaneously	O
8	(	O
9	s	O
10	.	O
11	c	O
12	.))	O
13	were	O
14	used	O
15	in	O
16	55	O
17	and	O
18	GM	B
19	-	I
20	CSF	I
21	(	O
22	400	O
23	micrograms	O
24	s	O
25	.	O
26	c	O
27	.)	O
28	in	O
29	28	O
30	chemotherapeutic	O
31	cycles	O
32	.	O

1	Overexpression	O
2	of	O
3	H411	B
4	cDNA	I
5	in	O
6	the	O
7	RAW	O
8	264	O
9	.	O
10	7	O
11	macrophage	O
12	cell	O
13	line	O
14	promoted	O
15	an	O
16	increased	O
17	growth	O
18	rate	O
19	,	O
20	suggesting	O
21	that	O
22	expression	O
23	of	O
24	H411	B
25	is	O
26	part	O
27	of	O
28	the	O
29	proliferative	O
30	cell	O
31	response	O
32	to	O
33	LPS	O
34	.	O

1	Human	O
2	expressed	O
3	sequence	O
4	tag	O
5	clones	O
6	were	O
7	identified	O
8	by	O
9	sequence	O
10	similarity	O
11	to	O
12	mammalian	B
13	and	I
14	yeast	I
15	oligosaccharide	I
16	-	I
17	processing	I
18	mannosidases	I
19	,	O
20	and	O
21	the	O
22	full	O
23	-	O
24	length	O
25	coding	O
26	region	O
27	of	O
28	the	O
29	putative	O
30	mannosidase	B
31	homolog	I
32	was	O
33	isolated	O
34	by	O
35	a	O
36	combination	O
37	of	O
38	5	O
39	'-	O
40	rapid	O
41	amplification	O
42	of	O
43	cDNA	O
44	ends	O
45	and	O
46	direct	O
47	polymerase	O
48	chain	O
49	reaction	O
50	from	O
51	human	O
52	placental	O
53	cDNA	O
54	.	O

1	Activation	O
2	of	O
3	ERK1	B
4	/	I
5	2	I
6	is	O
7	correlated	O
8	with	O
9	induction	O
10	of	O
11	the	O
12	immediate	B
13	-	I
14	early	I
15	response	I
16	genes	I
17	.	O

1	The	O
2	transcription	O
3	of	O
4	most	O
5	RP	B
6	genes	I
7	is	O
8	activated	O
9	by	O
10	two	O
11	Rap1p	B
12	binding	I
13	sites	I
14	,	O
15	250	O
16	to	O
17	400	O
18	bp	O
19	upstream	O
20	from	O
21	the	O
22	initiation	O
23	of	O
24	transcription	O
25	.	O

1	We	O
2	have	O
3	isolated	O
4	three	O
5	mutant	O
6	alleles	O
7	of	O
8	CDC4	B
9	(	O
10	cdc4	B
11	-	I
12	10	I
13	,	O
14	cdc4	B
15	-	I
16	11	I
17	,	O
18	and	O
19	cdc4	B
20	-	I
21	16	I
22	)	O
23	which	O
24	suppress	O
25	the	O
26	nuclear	O
27	division	O
28	defect	O
29	of	O
30	cdc20	B
31	-	I
32	1	I
33	cells	O
34	.	O

1	Role	O
2	of	O
3	secondary	O
4	structure	O
5	in	O
6	discrimination	O
7	between	O
8	constitutive	O
9	and	O
10	inducible	O
11	activators	O
12	.	O

1	In	O
2	summary	O
3	,	O
4	Ca	O
5	(	O
6	2	O
7	+)-	O
8	dependent	O
9	activation	O
10	of	O
11	NO	O
12	production	O
13	mediates	O
14	apoptosis	O
15	after	O
16	TG	B
17	exposure	O
18	in	O
19	JT	O
20	/	O
21	Neo	O
22	cells	O
23	.	O

1	Accumulation	O
2	of	O
3	the	O
4	U4	B
5	/	O
6	U6	B
7	duplex	O
8	was	O
9	relieved	O
10	by	O
11	overexpression	O
12	of	O
13	wild	B
14	-	I
15	type	I
16	Prp44p	I
17	.	O

1	Our	O
2	results	O
3	,	O
4	when	O
5	combined	O
6	with	O
7	previously	O
8	published	O
9	in	O
10	vitro	O
11	results	O
12	,	O
13	support	O
14	a	O
15	direct	O
16	role	O
17	for	O
18	Prp44p	B
19	in	O
20	unwinding	O
21	of	O
22	the	O
23	U4	B
24	/	O
25	U6	B
26	helix	O
27	.	O

1	This	O
2	approximately	O
3	125	O
4	-	O
5	nt	O
6	RNA	O
7	proved	O
8	to	O
9	arise	O
10	via	O
11	RNase	B
12	E	I
13	cleavage	O
14	from	O
15	the	O
16	3	O
17	'-	O
18	terminal	O
19	region	O
20	of	O
21	the	O
22	mRNAs	O
23	bearing	O
24	the	O
25	terminator	O
26	.	O

1	The	O
2	mysteries	O
3	of	O
4	geographic	O
5	variability	O
6	in	O
7	nonmelanoma	O
8	skin	O
9	cancer	O
10	incidence	O
11	.	O

1	In	O
2	Saccharomyces	O
3	cerevisiae	O
4	the	O
5	cAMP	B
6	-	I
7	dependent	I
8	kinases	I
9	(	O
10	PKAs	B
11	)	O
12	promote	O
13	cytoplasmic	O
14	growth	O
15	and	O
16	modulate	O
17	the	O
18	growth	O
19	-	O
20	regulated	O
21	mechanism	O
22	triggering	O
23	the	O
24	begin	O
25	of	O
26	DNA	O
27	synthesis	O
28	.	O

1	We	O
2	have	O
3	shown	O
4	previously	O
5	that	O
6	in	O
7	contrast	O
8	to	O
9	other	O
10	extracellular	O
11	matrix	O
12	molecules	O
13	pepsin	B
14	-	O
15	solubilized	O
16	collagen	B
17	VI	I
18	(	O
19	CVI	B
20	)	O
21	can	O
22	stimulate	O
23	DNA	O
24	synthesis	O
25	of	O
26	various	O
27	mesenchymal	O
28	cell	O
29	types	O
30	,	O
31	apparently	O
32	independent	O
33	of	O
34	integrin	B
35	-	O
36	mediated	O
37	signal	O
38	transduction	O
39	.	O

1	A	O
2	recombinant	O
3	derivative	O
4	harboring	O
5	the	O
6	pMJ101	O
7	replication	O
8	region	O
9	proved	O
10	to	O
11	be	O
12	compatible	O
13	with	O
14	pJM1	O
15	,	O
16	a	O
17	plasmid	O
18	containing	O
19	the	O
20	iron	O
21	acquisition	O
22	system	O
23	required	O
24	for	O
25	the	O
26	virulence	O
27	of	O
28	V	O
29	.	O
30	anguillarum	O
31	775	O
32	,	O
33	another	O
34	important	O
35	pathogen	O
36	that	O
37	causes	O
38	vibriosis	O
39	.	O

1	FAK	B
2	localizes	O
3	to	O
4	sites	O
5	of	O
6	transmembrane	B
7	integrin	I
8	receptor	I
9	clustering	O
10	and	O
11	facilitates	O
12	intracellular	O
13	signaling	O
14	events	O
15	.	O

1	Expression	O
2	of	O
3	various	O
4	FAK	B
5	mutants	I
6	in	O
7	the	O
8	FAK	B
9	-	O
10	cells	O
11	showed	O
12	that	O
13	FAK	B
14	kinase	I
15	activity	O
16	,	O
17	the	O
18	Tyr	B
19	-	I
20	397	I
21	/	I
22	SH2	I
23	domain	I
24	binding	I
25	site	I
26	,	O
27	and	O
28	the	O
29	first	O
30	proline	O
31	-	O
32	rich	O
33	SH3	B
34	binding	I
35	region	I
36	in	O
37	the	O
38	FAK	B
39	C	I
40	-	I
41	terminal	I
42	domain	I
43	were	O
44	individually	O
45	needed	O
46	to	O
47	promote	O
48	full	O
49	FAK	B
50	-	O
51	mediated	O
52	FAK	B
53	-	O
54	cell	O
55	migration	O
56	to	O
57	FN	B
58	whereas	O
59	direct	O
60	paxillin	B
61	binding	O
62	to	O
63	FAK	B
64	was	O
65	not	O
66	required	O
67	.	O

1	This	O
2	dominant	O
3	-	O
4	negative	O
5	effect	O
6	of	O
7	FRNK	B
8	was	O
9	reversed	O
10	by	O
11	a	O
12	point	O
13	mutation	O
14	(	O
15	Leu	O
16	-	O
17	1034	O
18	to	O
19	Ser	O
20	)	O
21	which	O
22	prevented	O
23	FRNK	B
24	localization	O
25	to	O
26	focal	O
27	contact	O
28	sites	O
29	.	O

1	Fifty	O
2	six	O
3	young	O
4	patients	O
5	(	O
6	age	O
7	<	O
8	45	O
9	yr	O
10	)	O
11	with	O
12	doppler	O
13	-	O
14	proven	O
15	DVT	O
16	were	O
17	investigated	O
18	for	O
19	the	O
20	presence	O
21	of	O
22	resistance	O
23	to	O
24	activated	B
25	protein	I
26	C	I
27	(	O
28	APC	B
29	-	I
30	R	I
31	),	O
32	lupus	O
33	anticoagulant	O
34	(	O
35	LA	O
36	),	O
37	anticardiolipin	B
38	antibodies	I
39	and	O
40	deficiencies	O
41	of	O
42	protein	B
43	C	I
44	,	O
45	protein	B
46	S	I
47	,	O
48	ATIII	B
49	activities	O
50	.	O

1	DESIGN	O
2	:	O
3	Comparison	O
4	of	O
5	number	O
6	of	O
7	women	O
8	with	O
9	PKU	O
10	aged	O
11	15	O
12	-	O
13	44	O
14	years	O
15	on	O
16	the	O
17	NSW	O
18	PKU	O
19	database	O
20	(	O
21	observed	O
22	number	O
23	)	O
24	with	O
25	expected	O
26	number	O
27	derived	O
28	from	O
29	population	O
30	data	O
31	.	O

1	PURPOSE	O
2	:	O
3	The	O
4	purposes	O
5	of	O
6	the	O
7	present	O
8	study	O
9	were	O
10	to	O
11	assess	O
12	the	O
13	effects	O
14	of	O
15	a	O
16	12	O
17	-	O
18	wk	O
19	laboratory	O
20	based	O
21	aerobic	O
22	exercise	O
23	program	O
24	on	O
25	cardiopulmonary	O
26	function	O
27	,	O
28	CD4	B
29	cell	O
30	count	O
31	,	O
32	and	O
33	physician	O
34	-	O
35	assessed	O
36	health	O
37	status	O
38	among	O
39	symptomatic	O
40	pre	O
41	-	O
42	AIDS	O
43	HIV	O
44	-	O
45	infected	O
46	individuals	O
47	(	O
48	N	O
49	=	O
50	28	O
51	)	O
52	and	O
53	to	O
54	assess	O
55	the	O
56	degree	O
57	to	O
58	which	O
59	ill	O
60	health	O
61	was	O
62	associated	O
63	with	O
64	exercise	O
65	relapse	O
66	.	O

1	The	O
2	enzyme	O
3	displays	O
4	optimal	O
5	activity	O
6	at	O
7	about	O
8	0	O
9	.	O
10	5	O
11	mM	O
12	pantoate	O
13	(	O
14	k	O
15	(	O
16	cat	O
17	)	O
18	0	O
19	.	O
20	63	O
21	s	O
22	(-	O
23	1	O
24	))	O
25	and	O
26	at	O
27	pH	O
28	7	O
29	.	O
30	8	O
31	.	O

1	Taken	O
2	together	O
3	,	O
4	these	O
5	results	O
6	demonstrate	O
7	that	O
8	the	O
9	RP	B
10	,	O
11	like	O
12	the	O
13	20S	B
14	proteasome	I
15	,	O
16	is	O
17	functionally	O
18	and	O
19	structurally	O
20	conserved	O
21	among	O
22	eukaryotes	O
23	and	O
24	indicate	O
25	that	O
26	the	O
27	plant	B
28	RPT	I
29	subunits	I
30	,	O
31	like	O
32	their	O
33	yeast	O
34	counterparts	O
35	,	O
36	have	O
37	non	O
38	-	O
39	redundant	O
40	functions	O
41	.	O

1	Epidemiologic	O
2	evidence	O
3	indicates	O
4	that	O
5	estrogen	O
6	replacement	O
7	therapy	O
8	after	O
9	menopause	O
10	increases	O
11	breast	O
12	cancer	O
13	risk	O
14	.	O

1	In	O
2	addition	O
3	to	O
4	its	O
5	elongation	O
6	activity	O
7	,	O
8	ELL	B
9	contains	O
10	a	O
11	novel	O
12	type	O
13	of	O
14	RNA	B
15	polymerase	I
16	II	I
17	interaction	I
18	domain	I
19	that	O
20	is	O
21	capable	O
22	of	O
23	repressing	O
24	polymerase	O
25	activity	O
26	in	O
27	promoter	O
28	-	O
29	specific	O
30	transcription	O
31	.	O

1	A	O
2	diagnosis	O
3	of	O
4	IgA	B
5	lambda	I
6	multiple	O
7	myeloma	O
8	with	O
9	peritoneal	O
10	involvement	O
11	was	O
12	made	O
13	.	O

1	The	O
2	radiation	O
3	burden	O
4	associated	O
5	with	O
6	the	O
7	majority	O
8	of	O
9	examinations	O
10	in	O
11	nuclear	O
12	medicine	O
13	expressed	O
14	as	O
15	the	O
16	effective	O
17	dose	O
18	is	O
19	comparable	O
20	with	O
21	the	O
22	radiation	O
23	burden	O
24	of	O
25	radiodiagnostic	O
26	examinations	O
27	,	O
28	only	O
29	after	O
30	administration	O
31	of	O
32	preparations	O
33	with	O
34	131I	O
35	,	O
36	201Tl	O
37	,	O
38	67Ga	O
39	and	O
40	111In	O
41	it	O
42	is	O
43	markedly	O
44	higher	O
45	.	O

1	Although	O
2	the	O
3	risk	O
4	of	O
5	malformation	O
6	in	O
7	children	O
8	born	O
9	after	O
10	ICSI	O
11	is	O
12	not	O
13	increased	O
14	there	O
15	is	O
16	an	O
17	increased	O
18	risk	O
19	to	O
20	transmit	O
21	genetic	O
22	abnormalities	O
23	in	O
24	case	O
25	of	O
26	NOA	O
27	(	O
28	such	O
29	as	O
30	the	O
31	rate	O
32	of	O
33	sex	O
34	chromosome	O
35	,	O
36	or	O
37	microdeletions	O
38	of	O
39	the	O
40	Y	O
41	chromosome	O
42	)	O
43	and	O
44	in	O
45	case	O
46	of	O
47	congenital	O
48	OA	O
49	(	O
50	mutations	O
51	of	O
52	the	O
53	cystic	B
54	fibrosis	I
55	gene	I
56	).	O

1	TaV	O
2	particles	O
3	have	O
4	a	O
5	buoyant	O
6	density	O
7	of	O
8	1	O
9	.	O
10	296	O
11	g	O
12	/	O
13	cm3	O
14	in	O
15	CsCl	O
16	and	O
17	consist	O
18	of	O
19	two	O
20	capsid	B
21	proteins	I
22	of	O
23	56	O
24	and	O
25	6	O
26	kDa	O
27	.	O

1	CONCLUSION	O
2	:	O
3	These	O
4	results	O
5	suggest	O
6	that	O
7	vibration	O
8	-	O
9	induced	O
10	neural	O
11	involvement	O
12	can	O
13	be	O
14	considered	O
15	neither	O
16	pure	O
17	digital	O
18	neuropathy	O
19	,	O
20	nor	O
21	definite	O
22	CTS	O
23	,	O
24	as	O
25	previously	O
26	described	O
27	.	O

1	In	O
2	about	O
3	770	O
4	bp	O
5	upstream	O
6	region	O
7	of	O
8	Spam1	B
9	that	O
10	has	O
11	been	O
12	cloned	O
13	and	O
14	sequenced	O
15	,	O
16	multiple	O
17	transcription	O
18	factor	O
19	binding	O
20	sites	O
21	including	O
22	a	O
23	CRE	O
24	(	O
25	cAMP	O
26	-	O
27	responsive	O
28	element	O
29	)	O
30	were	O
31	found	O
32	.	O

1	The	O
2	in	O
3	vitro	O
4	relaxivity	O
5	of	O
6	the	O
7	complex	O
8	is	O
9	16	O
10	.	O
11	24	O
12	s	O
13	(-	O
14	1	O
15	)	O
16	mM	O
17	(-	O
18	1	O
19	).	O

1	Structure	O
2	and	O
3	expression	O
4	of	O
5	the	O
6	mouse	B
7	growth	I
8	hormone	I
9	receptor	I
10	/	O
11	growth	B
12	hormone	I
13	binding	I
14	protein	I
15	gene	I
16	.	O

1	Bacterial	O
2	recovery	O
3	of	O
4	SA	O
5	from	O
6	the	O
7	liver	O
8	/	O
9	spleen	O
10	and	O
11	the	O
12	cecal	O
13	tonsil	O
14	in	O
15	contact	O
16	poults	O
17	and	O
18	SG	O
19	from	O
20	contact	O
21	chicks	O
22	treated	O
23	with	O
24	ILK	B
25	was	O
26	dramatically	O
27	reduced	O
28	when	O
29	compared	O
30	to	O
31	non	O
32	-	O
33	treated	O
34	contact	O
35	poults	O
36	and	O
37	chicks	O
38	.	O

1	The	O
2	results	O
3	of	O
4	the	O
5	ISIS	O
6	-	O
7	2	O
8	trial	O
9	and	O
10	the	O
11	data	O
12	from	O
13	the	O
14	Antiplatelet	O
15	Trialists	O
16	'	O
17	Collaboration	O
18	indicated	O
19	that	O
20	aspirin	O
21	is	O
22	mandatory	O
23	in	O
24	patients	O
25	with	O
26	acute	O
27	myocardial	O
28	infarction	O
29	and	O
30	for	O
31	secondary	O
32	prevention	O
33	.	O

1	This	O
2	study	O
3	was	O
4	performed	O
5	to	O
6	assess	O
7	the	O
8	role	O
9	of	O
10	additional	O
11	diagnostic	O
12	laparoscopy	O
13	in	O
14	the	O
15	preoperative	O
16	staging	O
17	of	O
18	patients	O
19	with	O
20	adenocarcinoma	O
21	of	O
22	the	O
23	esophagus	O
24	,	O
25	gastric	O
26	cancer	O
27	and	O
28	pancreatic	O
29	cancer	O
30	prior	O
31	to	O
32	intended	O
33	curative	O
34	surgery	O
35	.	O

1	This	O
2	report	O
3	presents	O
4	state	O
5	-	O
6	specific	O
7	MMRs	O
8	for	O
9	1987	O
10	-	O
11	1996	O
12	,	O
13	focusing	O
14	on	O
15	persistent	O
16	disparities	O
17	in	O
18	maternal	O
19	mortality	O
20	between	O
21	black	O
22	and	O
23	white	O
24	women	O
25	.	O

1	Preheparin	O
2	LPL	B
3	mass	O
4	level	O
5	did	O
6	not	O
7	significantly	O
8	differ	O
9	in	O
10	individuals	O
11	from	O
12	19	O
13	to	O
14	70	O
15	years	O
16	old	O
17	,	O
18	for	O
19	both	O
20	men	O
21	and	O
22	women	O
23	.	O

1	A	O
2	decrease	O
3	in	O
4	insulin	B
5	-	O
6	induced	O
7	receptor	O
8	kinase	O
9	activity	O
10	was	O
11	observed	O
12	for	O
13	solubilized	O
14	chimeric	O
15	receptors	O
16	.	O

1	Cat	B
2	-	I
3	1	I
4	is	O
5	identical	O
6	to	O
7	the	O
8	recently	O
9	identified	O
10	binding	O
11	partner	O
12	for	O
13	the	O
14	beta	B
15	-	I
16	adrenergic	I
17	receptor	I
18	kinase	I
19	(	O
20	betaARK	B
21	or	O
22	GRK	B
23	-	I
24	2	I
25	),	O
26	which	O
27	was	O
28	shown	O
29	to	O
30	have	O
31	Arf	B
32	-	O
33	GAP	B
34	activity	O
35	.	O

1	Cat	B
2	proteins	I
3	are	O
4	tyrosine	O
5	-	O
6	phosphorylated	O
7	when	O
8	co	O
9	-	O
10	expressed	O
11	in	O
12	cells	O
13	with	O
14	the	O
15	focal	B
16	adhesion	I
17	kinase	I
18	Fak	I
19	and	O
20	Src	B
21	.	O

1	Immunoprecipitation	O
2	experiments	O
3	using	O
4	DokR	B
5	-	I
6	specific	I
7	antibodies	I
8	revealed	O
9	an	O
10	interaction	O
11	between	O
12	endogenous	B
13	DokR	I
14	and	O
15	a	O
16	150	O
17	-	O
18	kDa	O
19	protein	O
20	that	O
21	is	O
22	tyrosine	O
23	-	O
24	phosphorylated	O
25	in	O
26	EGF	B
27	-	O
28	stimulated	O
29	BaF	O
30	/	O
31	3	O
32	cells	O
33	.	O

1	Expansins	B
2	are	O
3	a	O
4	family	O
5	of	O
6	proteins	O
7	that	O
8	catalyse	O
9	long	O
10	-	O
11	term	O
12	extension	O
13	of	O
14	isolated	O
15	plant	O
16	cell	O
17	walls	O
18	due	O
19	to	O
20	an	O
21	as	O
22	yet	O
23	unknown	O
24	biochemical	O
25	mechanism	O
26	.	O

1	This	O
2	review	O
3	summarizes	O
4	the	O
5	clinical	O
6	evidence	O
7	to	O
8	support	O
9	current	O
10	therapies	O
11	in	O
12	irritable	O
13	bowel	O
14	syndrome	O
15	(	O
16	IBS	O
17	).	O

1	The	O
2	responsive	O
3	region	O
4	of	O
5	the	O
6	alpha	B
7	2	I
8	(	I
9	V	I
10	)	I
11	collagen	I
12	gene	I
13	was	O
14	localized	O
15	to	O
16	a	O
17	fragment	O
18	including	O
19	100	O
20	bp	O
21	of	O
22	basal	O
23	promoter	O
24	and	O
25	150	O
26	bp	O
27	of	O
28	exon	O
29	1	O
30	sequences	O
31	,	O
32	which	O
33	contained	O
34	two	O
35	CRE	O
36	-	O
37	like	O
38	elements	O
39	.	O

1	Furthermore	O
2	,	O
3	addition	O
4	of	O
5	B	B
6	-	I
7	Myb	I
8	-	O
9	glutathionine	B
10	S	I
11	-	I
12	transferase	I
13	fusion	O
14	protein	O
15	inhibited	O
16	complex	O
17	formation	O
18	.	O

1	APOE	B
2	-	O
3	epsilon4	O
4	count	O
5	predicts	O
6	age	O
7	when	O
8	prevalence	O
9	of	O
10	AD	O
11	increases	O
12	,	O
13	then	O
14	declines	O
15	:	O
16	the	O
17	Cache	O
18	County	O
19	Study	O
20	.	O

1	Repair	O
2	of	O
3	double	O
4	-	O
5	strand	O
6	breaks	O
7	(	O
8	DSBs	O
9	)	O
10	in	O
11	chromosomal	O
12	DNA	O
13	by	O
14	nonhomologous	O
15	end	O
16	-	O
17	joining	O
18	(	O
19	NHEJ	O
20	)	O
21	is	O
22	not	O
23	well	O
24	characterized	O
25	in	O
26	the	O
27	yeast	O
28	Saccharomyces	O
29	cerevisiae	O
30	.	O

1	A	O
2	new	O
3	DNA	B
4	repair	I
5	gene	I
6	from	O
7	Schizosaccharomyces	O
8	pombe	O
9	with	O
10	homology	O
11	to	O
12	RecA	B
13	was	O
14	identified	O
15	and	O
16	characterized	O
17	.	O

1	Among	O
2	mucus	O
3	-	O
4	secreting	O
5	cells	O
6	,	O
7	the	O
8	gastric	O
9	gland	O
10	mucous	O
11	cells	O
12	,	O
13	Brunner	O
14	'	O
15	s	O
16	glands	O
17	,	O
18	accessory	O
19	glands	O
20	of	O
21	pancreaticobiliary	O
22	tract	O
23	,	O
24	and	O
25	pancreatic	O
26	ducts	O
27	exhibiting	O
28	gastric	O
29	metaplasia	O
30	are	O
31	unique	O
32	in	O
33	that	O
34	they	O
35	express	O
36	class	B
37	III	I
38	mucin	I
39	identified	O
40	by	O
41	paradoxical	O
42	Con	B
43	A	I
44	staining	O
45	composed	O
46	of	O
47	periodate	O
48	oxidation	O
49	,	O
50	sodium	O
51	borohydride	O
52	reduction	O
53	,	O
54	Con	B
55	A	I
56	,	O
57	and	O
58	horseradish	B
59	peroxidase	I
60	reaction	O
61	.	O

1	The	O
2	C	O
3	-	O
4	terminal	O
5	mutants	O
6	were	O
7	strongly	O
8	dominant	O
9	over	O
10	TraR	B
11	,	O
12	suggesting	O
13	that	O
14	they	O
15	can	O
16	form	O
17	heteromultimers	O
18	with	O
19	the	O
20	wild	O
21	-	O
22	type	O
23	activator	O
24	.	O

1	Thus	O
2	,	O
3	elongin	B
4	C	I
5	is	O
6	found	O
7	to	O
8	oligomerize	O
9	in	O
10	solution	O
11	and	O
12	to	O
13	undergo	O
14	significant	O
15	structural	O
16	rearrangements	O
17	upon	O
18	binding	O
19	of	O
20	two	O
21	different	O
22	partner	O
23	proteins	O
24	.	O

1	The	O
2	data	O
3	imply	O
4	that	O
5	JAK	B
6	/	O
7	STAT	B
8	signaling	O
9	has	O
10	a	O
11	role	O
12	in	O
13	EBV	O
14	-	O
15	associated	O
16	malignancies	O
17	.	O

1	There	O
2	were	O
3	27	O
4	men	O
5	and	O
6	156	O
7	women	O
8	.	O

1	A	O
2	.,	O
3	Bowers	O
4	,	O
5	K	O
6	.	O
7	E	O
8	,	O
9	and	O
10	Matthews	O
11	,	O
12	C	O
13	.	O

1	Spfkh1	B
2	is	O
3	transcribed	O
4	in	O
5	one	O
6	open	O
7	reading	O
8	frame	O
9	that	O
10	contains	O
11	the	O
12	DNA	O
13	binding	O
14	domain	O
15	,	O
16	nuclear	O
17	localization	O
18	signal	O
19	and	O
20	transactivation	O
21	domain	O
22	.	O

1	The	O
2	molecular	O
3	mechanism	O
4	of	O
5	Tax	B
6	-	O
7	mediated	O
8	trans	O
9	-	O
10	activation	O
11	has	O
12	been	O
13	well	O
14	investigated	O
15	.	O

1	Gel	O
2	filtration	O
3	and	O
4	co	O
5	-	O
6	immunoprecipitation	O
7	analyses	O
8	reveal	O
9	that	O
10	Mad2p	B
11	tightly	O
12	associates	O
13	with	O
14	another	O
15	spindle	O
16	checkpoint	O
17	component	O
18	,	O
19	Mad1p	B
20	.	O

1	METHODS	O
2	:	O
3	109	O
4	suspected	O
5	cases	O
6	with	O
7	SS	O
8	underwent	O
9	the	O
10	biopsies	O
11	.	O

1	We	O
2	also	O
3	identify	O
4	several	O
5	regulatory	O
6	domain	O
7	mutants	O
8	in	O
9	which	O
10	Cd	O
11	(	O
12	2	O
13	+)	O
14	tolerance	O
15	of	O
16	the	O
17	mutant	O
18	strain	O
19	and	O
20	transport	O
21	activity	O
22	of	O
23	the	O
24	protein	O
25	are	O
26	dissociated	O
27	.	O

1	The	O
2	human	B
3	immunodeficiency	I
4	virus	I
5	type	I
6	-	I
7	1	I
8	(	I
9	HIV	I
10	-	I
11	1	I
12	)	I
13	Tat	I
14	protein	I
15	regulates	O
16	transcription	O
17	by	O
18	stimulating	O
19	RNA	B
20	polymerase	I
21	processivity	O
22	.	O

1	One	O
2	of	O
3	these	O
4	SEBPs	B
5	,	O
6	SEBP2	B
7	,	O
8	was	O
9	shown	O
10	to	O
11	be	O
12	the	O
13	product	O
14	of	O
15	the	O
16	homeotic	B
17	gene	I
18	fork	I
19	head	I
20	.	O

1	Identity	O
2	elements	O
3	in	O
4	tRNA	O
5	for	O
6	mono	O
7	-	O
8	and	O
9	dimethylation	O
10	reactions	O
11	by	O
12	the	O
13	recombinant	B
14	pfTrm1p	I
15	were	O
16	identified	O
17	using	O
18	in	O
19	vitro	O
20	T7	O
21	transcripts	O
22	of	O
23	33	O
24	variants	O
25	of	O
26	tRNA	B
27	(	I
28	Asp	I
29	)	I
30	and	O
31	tRNA	B
32	(	I
33	Phe	I
34	)	I
35	from	O
36	yeast	O
37	.	O

1	In	O
2	insulin	B
3	-	O
4	responsive	O
5	cells	O
6	,	O
7	Akt	B
8	phosphorylates	O
9	and	O
10	inactivates	O
11	the	O
12	serine	B
13	/	I
14	threonine	I
15	kinase	I
16	glycogen	I
17	synthase	I
18	kinase	I
19	-	I
20	3	I
21	(	O
22	GSK	B
23	-	I
24	3	I
25	).	O

1	The	O
2	B	B
3	cell	I
4	antigen	I
5	receptor	I
6	activates	O
7	the	O
8	Akt	B
9	(	O
10	protein	B
11	kinase	I
12	B	I
13	)/	O
14	glycogen	B
15	synthase	I
16	kinase	I
17	-	I
18	3	I
19	signaling	O
20	pathway	O
21	via	O
22	phosphatidylinositol	B
23	3	I
24	-	I
25	kinase	I
26	.	O

1	Fewer	O
2	recombination	O
3	events	O
4	are	O
5	detected	O
6	in	O
7	four	O
8	different	O
9	B	O
10	and	O
11	T	O
12	cell	O
13	lines	O
14	that	O
15	do	O
16	not	O
17	undergo	O
18	switch	O
19	recombination	O
20	of	O
21	their	O
22	endogenous	O
23	genes	O
24	.	O

1	IL	B
2	-	I
3	1	I
4	and	O
5	TNF	B
6	increase	O
7	AND	B
8	-	I
9	34	I
10	transcript	I
11	levels	O
12	in	O
13	thymic	O
14	cortical	O
15	reticular	O
16	,	O
17	thymic	O
18	nurse	O
19	,	O
20	and	O
21	fibroblast	O
22	cell	O
23	lines	O
24	.	O

1	To	O
2	determine	O
3	what	O
4	role	O
5	eIF4E	B
6	might	O
7	play	O
8	in	O
9	c	B
10	-	I
11	myc	I
12	expression	O
13	,	O
14	the	O
15	c	B
16	-	I
17	myc	I
18	5	I
19	'	I
20	untranslated	I
21	region	I
22	(	I
23	UTR	I
24	)	I
25	was	O
26	fused	O
27	in	O
28	-	O
29	frame	O
30	to	O
31	CAT	B
32	reporters	I
33	,	O
34	and	O
35	several	O
36	more	O
37	derivative	O
38	constructs	O
39	were	O
40	made	O
41	.	O

1	Analysis	O
2	of	O
3	cell	O
4	cycle	O
5	proteins	O
6	showed	O
7	that	O
8	24	O
9	h	O
10	of	O
11	lovastatin	O
12	treatment	O
13	in	O
14	the	O
15	control	O
16	cells	O
17	caused	O
18	an	O
19	elevation	O
20	in	O
21	the	O
22	levels	O
23	of	O
24	the	O
25	cyclin	B
26	-	I
27	dependent	I
28	kinase	I
29	inhibitor	O
30	p27	B
31	(	O
32	kip1	B
33	),	O
34	inhibition	O
35	of	O
36	both	O
37	cyclin	B
38	E	I
39	-	I
40	and	I
41	cyclin	I
42	A	I
43	-	I
44	dependent	I
45	kinase	I
46	activity	O
47	,	O
48	and	O
49	decreased	O
50	levels	O
51	of	O
52	hyperphosphorylated	O
53	retinoblastoma	B
54	protein	I
55	(	O
56	pRb	B
57	).	O

1	RESULTS	O
2	:	O
3	Circulating	O
4	leptin	B
5	concentrations	O
6	in	O
7	AN	O
8	were	O
9	3	O
10	.	O
11	5	O
12	+/-	O
13	0	O
14	.	O
15	5	O
16	versus	O
17	7	O
18	.	O
19	6	O
20	+/-	O
21	1	O
22	.	O
23	2	O
24	ng	O
25	/	O
26	ml	O
27	in	O
28	control	O
29	subjects	O
30	.	O

1	Copyright	O
2	1999	O
3	Academic	O
4	Press	O
5	.	O

1	Oligonucleotide	O
2	probes	O
3	corresponding	O
4	to	O
5	wild	O
6	-	O
7	type	O
8	and	O
9	mutant	O
10	EpRE	O
11	sequences	O
12	were	O
13	used	O
14	in	O
15	gel	O
16	-	O
17	shift	O
18	and	O
19	super	O
20	-	O
21	shift	O
22	analyses	O
23	to	O
24	identify	O
25	proteins	O
26	binding	O
27	.	O

1	PKNbeta	B
2	had	O
3	high	O
4	sequence	O
5	homology	O
6	with	O
7	PKNalpha	B
8	,	O
9	originally	O
10	isolated	O
11	PKN	B
12	,	O
13	especially	O
14	in	O
15	the	O
16	repeats	O
17	of	O
18	charged	O
19	amino	O
20	acid	O
21	-	O
22	rich	O
23	region	O
24	with	O
25	leucine	O
26	-	O
27	zipper	O
28	like	O
29	sequences	O
30	(	O
31	CZ	O
32	region	O
33	/	O
34	HR1	O
35	),	O
36	in	O
37	the	O
38	carboxyl	O
39	-	O
40	terminal	O
41	catalytic	O
42	domain	O
43	,	O
44	and	O
45	in	O
46	approximately	O
47	130	O
48	amino	O
49	acid	O
50	stretch	O
51	(	O
52	D	O
53	region	O
54	/	O
55	HR2	O
56	),	O
57	located	O
58	between	O
59	CZ	O
60	region	O
61	/	O
62	HR1	O
63	and	O
64	the	O
65	catalytic	O
66	domain	O
67	.	O

1	At	O
2	baseline	O
3	,	O
4	serum	O
5	levels	O
6	of	O
7	lycopene	O
8	and	O
9	FLOP	O
10	were	O
11	abnormally	O
12	high	O
13	and	O
14	serum	O
15	FLOP	O
16	was	O
17	correlated	O
18	significantly	O
19	with	O
20	plasma	O
21	cyclosporine	O
22	levels	O
23	(	O
24	r	O
25	=	O
26	0	O
27	.	O
28	646	O
29	,	O
30	p	O
31	=	O
32	0	O
33	.	O
34	016	O
35	).	O

1	BACKGROUND	O
2	:	O
3	Chronic	O
4	alcohol	O
5	consumption	O
6	has	O
7	been	O
8	demonstrated	O
9	to	O
10	be	O
11	deleterious	O
12	to	O
13	bone	O
14	health	O
15	.	O

1	Interestingly	O
2	,	O
3	following	O
4	induction	O
5	of	O
6	stress	O
7	by	O
8	heat	O
9	shock	O
10	,	O
11	high	O
12	salt	O
13	,	O
14	or	O
15	ethanol	O
16	,	O
17	conditions	O
18	under	O
19	which	O
20	most	O
21	mRNA	O
22	export	O
23	is	O
24	blocked	O
25	,	O
26	Npl3p	B
27	is	O
28	still	O
29	exported	O
30	from	O
31	the	O
32	nucleus	O
33	.	O

1	For	O
2	symptomatic	O
3	relief	O
4	and	O
5	inhibition	O
6	of	O
7	the	O
8	growth	O
9	of	O
10	the	O
11	metastases	O
12	interferon	B
13	-	I
14	a	I
15	and	O
16	somatostatin	B
17	analogues	O
18	can	O
19	be	O
20	employed	O
21	.	O

1	In	O
2	summary	O
3	,	O
4	the	O
5	no	O
6	-	O
7	adverse	O
8	-	O
9	effect	O
10	-	O
11	level	O
12	for	O
13	this	O
14	study	O
15	was	O
16	determined	O
17	to	O
18	be	O
19	1000	O
20	ppm	O
21	,	O
22	based	O
23	on	O
24	decreased	O
25	weight	O
26	gain	O
27	in	O
28	female	O
29	rats	O
30	,	O
31	and	O
32	on	O
33	slight	O
34	organ	O
35	weight	O
36	changes	O
37	in	O
38	both	O
39	sexes	O
40	at	O
41	3000	O
42	ppm	O
43	.	O

1	Some	O
2	of	O
3	them	O
4	produce	O
5	gigantic	O
6	sperm	O
7	several	O
8	times	O
9	the	O
10	total	O
11	male	O
12	body	O
13	length	O
14	.	O

1	John	O
2	leonard	O
3	dawson	O

1	PDGF	B
2	A	I
3	-	I
4	chain	I
5	levels	O
6	increase	O
7	in	O
8	cultured	O
9	vascular	O
10	smooth	O
11	muscle	O
12	cells	O
13	(	O
14	SMCs	O
15	)	O
16	exposed	O
17	to	O
18	ATII	B
19	.	O

1	M	B
2	-	I
3	Ras	I
4	interacted	O
5	poorly	O
6	in	O
7	a	O
8	yeast	O
9	two	O
10	-	O
11	hybrid	O
12	assay	O
13	with	O
14	multiple	O
15	Ras	B
16	effectors	O
17	,	O
18	including	O
19	c	B
20	-	I
21	Raf	I
22	-	I
23	1	I
24	,	O
25	A	B
26	-	I
27	Raf	I
28	,	O
29	B	B
30	-	I
31	Raf	I
32	,	O
33	phosphoinositol	B
34	-	I
35	3	I
36	kinase	I
37	delta	I
38	,	O
39	RalGDS	B
40	,	O
41	and	O
42	Rin1	B
43	.	O

1	Deletion	O
2	mapping	O
3	of	O
4	the	O
5	human	B
6	presenilin	I
7	-	I
8	1	I
9	(	O
10	PS1	B
11	)	O
12	promoter	O
13	delineated	O
14	the	O
15	most	O
16	active	O
17	fragment	O
18	from	O
19	-	O
20	118	O
21	to	O
22	+	O
23	178	O
24	in	O
25	relation	O
26	to	O
27	the	O
28	transcription	O
29	start	O
30	site	O
31	mapped	O
32	in	O
33	this	O
34	study	O
35	,	O
36	in	O
37	both	O
38	human	O
39	neuroblastoma	O
40	SK	O
41	-	O
42	N	O
43	-	O
44	SH	O
45	and	O
46	hepatoma	O
47	HepG2	O
48	cells	O
49	.	O

1	Microcirculatory	O
2	oxygenation	O
3	and	O
4	shunting	O
5	in	O
6	sepsis	O
7	and	O
8	shock	O
9	.	O

1	Analysis	O
2	of	O
3	the	O
4	E2F1	B
5	gene	I
6	promoter	I
7	showed	O
8	that	O
9	the	O
10	-	O
11	146	O
12	to	O
13	-	O
14	54	O
15	region	O
16	was	O
17	required	O
18	for	O
19	E2	B
20	-	O
21	responsiveness	O
22	in	O
23	transient	O
24	transfection	O
25	assays	O
26	,	O
27	and	O
28	subsequent	O
29	deletion	O
30	/	O
31	mutation	O
32	analysis	O
33	showed	O
34	that	O
35	a	O
36	single	O
37	upstream	O
38	GC	O
39	-	O
40	rich	O
41	and	O
42	two	O
43	downstream	O
44	CCAAT	O
45	-	O
46	binding	O
47	sites	O
48	were	O
49	required	O
50	for	O
51	transactivation	O
52	by	O
53	E2	B
54	.	O

1	In	O
2	the	O
3	course	O
4	of	O
5	investigating	O
6	the	O
7	mechanisms	O
8	by	O
9	which	O
10	OF5	B
11	and	O
12	OF3	B
13	regulated	O
14	CYP11A1	B
15	transcription	O
16	,	O
17	we	O
18	found	O
19	that	O
20	OF5	B
21	and	O
22	OF3	B
23	bound	O
24	Sp1	B
25	and	O
26	Sp3	B
27	in	O
28	JEG	O
29	-	O
30	3	O
31	cells	O
32	.	O

1	In	O
2	contrast	O
3	,	O
4	the	O
5	differentiation	O
6	of	O
7	neoplastically	O
8	transformed	O
9	cells	O
10	does	O
11	not	O
12	repress	O
13	mitogenic	O
14	responsiveness	O
15	or	O
16	junB	B
17	or	O
18	c	B
19	-	I
20	fos	I
21	inducibility	O
22	.	O

1	Adipocyte	O
2	differentiation	O
3	of	O
4	nontransformed	O
5	cells	O
6	also	O
7	markedly	O
8	represses	O
9	the	O
10	ability	O
11	of	O
12	SRF	B
13	to	O
14	bind	O
15	to	O
16	the	O
17	junB	B
18	SRE	O
19	,	O
20	the	O
21	c	B
22	-	I
23	fos	I
24	SRE	O
25	,	O
26	and	O
27	other	O
28	SREs	O
29	,	O
30	as	O
31	determined	O
32	by	O
33	mobility	O
34	shift	O
35	and	O
36	gel	O
37	supershift	O
38	assays	O
39	,	O
40	without	O
41	affecting	O
42	the	O
43	DNA	O
44	binding	O
45	characteristics	O
46	of	O
47	the	O
48	nuclear	O
49	protein	O
50	SP	O
51	-	O
52	1	O
53	.	O

1	Transformation	O
2	blocks	O
3	differentiation	O
4	-	O
5	induced	O
6	inhibition	O
7	of	O
8	serum	B
9	response	I
10	factor	I
11	interactions	O
12	with	O
13	serum	O
14	response	O
15	elements	O
16	.	O

1	The	O
2	core	B
3	enzyme	I
4	is	O
5	homologous	O
6	to	O
7	those	O
8	of	O
9	bacteriophages	O
10	T3	O
11	,	O
12	T7	O
13	and	O
14	SP6	O
15	whereas	O
16	the	O
17	specificity	O
18	factor	O
19	shows	O
20	similarities	O
21	with	O
22	bacterial	B
23	sigma	I
24	factors	I
25	.	O

1	The	O
2	Cr	B
3	.	I
4	psbA	I
5	-	I
6	4	I
7	ORF	I
8	contains	O
9	an	O
10	H	O
11	-	O
12	N	O
13	-	O
14	H	O
15	motif	O
16	,	O
17	and	O
18	possibly	O
19	a	O
20	GIY	O
21	-	O
22	YIG	O
23	motif	O
24	.	O

1	The	O
2	interaction	O
3	of	O
4	zf4	B
5	-	I
6	6	I
7	with	O
8	full	B
9	-	I
10	length	I
11	5	I
12	S	I
13	RNA	I
14	was	O
15	far	O
16	more	O
17	sensitive	O
18	to	O
19	non	O
20	-	O
21	specific	O
22	competitor	O
23	concentration	O
24	than	O
25	was	O
26	the	O
27	zf4	B
28	-	I
29	7	I
30	:	O
31	5	B
32	S	I
33	RNA	I
34	interaction	O
35	,	O
36	suggesting	O
37	that	O
38	finger	O
39	seven	O
40	contributes	O
41	to	O
42	both	O
43	affinity	O
44	and	O
45	specificity	O
46	in	O
47	this	O
48	protein	O
49	:	O
50	RNA	O
51	interaction	O
52	.	O

1	The	O
2	STAT	B
3	protein	I
4	accumulation	O
5	resulting	O
6	from	O
7	C	B
8	/	I
9	EBP	I
10	expression	O
11	was	O
12	tightly	O
13	coupled	O
14	to	O
15	the	O
16	morphological	O
17	conversion	O
18	of	O
19	fibroblasts	O
20	to	O
21	adipocytes	O
22	and	O
23	represents	O
24	an	O
25	expression	O
26	profile	O
27	identical	O
28	to	O
29	that	O
30	reported	O
31	for	O
32	mature	O
33	adipocytes	O
34	in	O
35	vivo	O
36	.	O

1	The	O
2	median	O
3	durations	O
4	for	O
5	response	O
6	and	O
7	survival	O
8	time	O
9	in	O
10	the	O
11	late	O
12	phase	O
13	II	O
14	trial	O
15	were	O
16	2	O
17	.	O
18	3	O
19	months	O
20	and	O
21	5	O
22	.	O
23	8	O
24	months	O
25	,	O
26	respectively	O
27	.	O

1	The	O
2	role	O
3	of	O
4	'	O
5	scientific	O
6	psychiatry	O
7	'	O
8	in	O
9	understanding	O
10	patients	O
11	with	O
12	chronic	O
13	schizophrenia	O
14	or	O
15	severe	O
16	personality	O
17	disorder	O
18	.	O

1	Myocardial	O
2	antioxidant	O
3	enzymes	O
4	,	O
5	catalase	B
6	,	O
7	glutathione	B
8	peroxidase	I
9	and	O
10	superoxide	B
11	dismutase	I
12	,	O
13	in	O
14	the	O
15	MCT	O
16	-	O
17	treated	O
18	rats	O
19	were	O
20	not	O
21	different	O
22	compared	O
23	to	O
24	control	O
25	rats	O
26	.	O

1	The	O
2	second	O
3	goal	O
4	was	O
5	to	O
6	ascertain	O
7	the	O
8	somatotopic	O
9	arrangement	O
10	of	O
11	the	O
12	GPi	O
13	in	O
14	PD	O
15	.	O

1	These	O
2	overall	O
3	results	O
4	indicate	O
5	that	O
6	there	O
7	is	O
8	generally	O
9	one	O
10	PERV	O
11	copy	O
12	per	O
13	integration	O
14	site	O
15	.	O

1	The	O
2	present	O
3	investigation	O
4	conducted	O
5	in	O
6	a	O
7	population	O
8	of	O
9	258	O
10	dentally	O
11	aware	O
12	individuals	O
13	in	O
14	the	O
15	age	O
16	range	O
17	20	O
18	-	O
19	69	O
20	years	O
21	,	O
22	was	O
23	initiated	O
24	to	O
25	elucidate	O
26	the	O
27	relationship	O
28	between	O
29	tobacco	O
30	smoking	O
31	and	O
32	supragingival	O
33	calculus	O
34	,	O
35	taking	O
36	into	O
37	account	O
38	possible	O
39	confounding	O
40	factors	O
41	such	O
42	as	O
43	age	O
44	,	O
45	gender	O
46	,	O
47	oral	O
48	hygiene	O
49	and	O
50	gingival	O
51	inflammation	O
52	.	O

1	OBJECTIVE	O
2	:	O
3	To	O
4	determine	O
5	whether	O
6	administration	O
7	of	O
8	misoprostol	O
9	prevents	O
10	gastric	O
11	hemorrhage	O
12	in	O
13	healthy	O
14	dogs	O
15	treated	O
16	with	O
17	high	O
18	doses	O
19	of	O
20	methylprednisolone	O
21	sodium	O
22	succinate	O
23	(	O
24	MPSS	O
25	).	O

1	Patients	O
2	were	O
3	assessed	O
4	for	O
5	cardiac	O
6	MIBG	O
7	uptake	O
8	,	O
9	circulating	O
10	norepinephrine	O
11	concentration	O
12	,	O
13	LVEF	O
14	,	O
15	peak	O
16	Vo2	O
17	,	O
18	x	O
19	-	O
20	ray	O
21	cardiothoracic	O
22	ratio	O
23	,	O
24	M	O
25	-	O
26	mode	O
27	echographic	O
28	end	O
29	-	O
30	diastolic	O
31	diameter	O
32	and	O
33	right	O
34	-	O
35	sided	O
36	heart	O
37	catheterization	O
38	parameters	O
39	.	O

1	Nuclear	O
2	hormone	O
3	receptors	O
4	(	O
5	NRs	O
6	)	O
7	are	O
8	ligand	O
9	-	O
10	inducible	O
11	transcription	O
12	factors	O
13	that	O
14	mediate	O
15	critical	O
16	functions	O
17	in	O
18	many	O
19	species	O
20	.	O

1	These	O
2	cells	O
3	were	O
4	able	O
5	to	O
6	present	O
7	influenza	O
8	virus	O
9	particles	O
10	to	O
11	HLA	B
12	-	I
13	DR1	I
14	-	O
15	restricted	O
16	T	O
17	cell	O
18	clones	O
19	.	O

1	Sequencing	O
2	of	O
3	zebrafish	O
4	(	O
5	Danio	O
6	rerio	O
7	)	O
8	bacterial	O
9	artificial	O
10	chromosome	O
11	and	O
12	P1	O
13	artificial	O
14	chromosome	O
15	genomic	O
16	clone	O
17	fragments	O
18	and	O
19	of	O
20	cDNA	O
21	clones	O
22	has	O
23	led	O
24	to	O
25	the	O
26	identification	O
27	of	O
28	five	O
29	new	O
30	loci	O
31	coding	O
32	for	O
33	beta	O
34	subunits	O
35	of	O
36	proteasomes	O
37	(	O
38	PSMB	B
39	).	O

1	In	O
2	addition	O
3	to	O
4	homologues	O
5	of	O
6	the	O
7	human	B
8	genes	I
9	PSMB5	I
10	through	O
11	PSMB9	B
12	,	O
13	two	O
14	new	O
15	genes	O
16	,	O
17	PSMB11	B
18	and	O
19	PSMB12	B
20	,	O
21	have	O
22	been	O
23	found	O
24	for	O
25	which	O
26	there	O
27	are	O
28	no	O
29	known	O
30	corresponding	O
31	genes	O
32	in	O
33	humans	O
34	.	O

1	It	O
2	applies	O
3	Udry	O
4	'	O
5	s	O
6	biosocial	O
7	perspective	O
8	,	O
9	which	O
10	attempts	O
11	to	O
12	reconcile	O
13	the	O
14	biological	O
15	and	O
16	sociological	O
17	models	O
18	of	O
19	premarital	O
20	sexual	O
21	and	O
22	reproductive	O
23	behaviour	O
24	.	O

1	Weight	O
2	and	O
3	height	O
4	z	O
5	-	O
6	scores	O
7	were	O
8	significantly	O
9	associated	O
10	with	O
11	BMD	O
12	z	O
13	-	O
14	scores	O
15	.	O

1	A	O
2	limited	O
3	sampling	O
4	strategy	O
5	was	O
6	used	O
7	based	O
8	on	O
9	a	O
10	bayesian	O
11	parameter	O
12	estimation	O
13	algorithm	O
14	that	O
15	is	O
16	part	O
17	of	O
18	the	O
19	ADAPT	O
20	II	O
21	software	O
22	package	O
23	.	O

1	Interaction	O
2	of	O
3	HRI	B
4	with	O
5	Hsc70	B
6	was	O
7	required	O
8	for	O
9	the	O
10	transformation	O
11	of	O
12	HRI	B
13	,	O
14	as	O
15	the	O
16	Hsc70	B
17	antagonist	O
18	clofibric	O
19	acid	O
20	inhibited	O
21	the	O
22	folding	O
23	of	O
24	HRI	B
25	into	O
26	a	O
27	mature	O
28	-	O
29	competent	O
30	conformation	O
31	.	O

1	The	O
2	amino	O
3	acid	O
4	changes	O
5	D206A	O
6	and	O
7	D208A	O
8	abolish	O
9	singly	O
10	or	O
11	in	O
12	combination	O
13	the	O
14	exonuclease	O
15	activity	O
16	in	O
17	vivo	O
18	.	O

1	Previous	O
2	experimental	O
3	evidence	O
4	had	O
5	indicated	O
6	that	O
7	Reg1	B
8	might	O
9	target	O
10	Glc7	B
11	to	O
12	nuclear	O
13	substrates	O
14	such	O
15	as	O
16	the	O
17	Snf1	B
18	kinase	I
19	complex	I
20	.	O

1	In	O
2	the	O
3	budding	O
4	yeast	O
5	,	O
6	Saccharomyces	O
7	cerevisiae	O
8	,	O
9	replicators	O
10	can	O
11	function	O
12	outside	O
13	the	O
14	chromosome	O
15	as	O
16	autonomously	O
17	replicating	O
18	sequence	O
19	(	O
20	ARS	O
21	)	O
22	elements	O
23	;	O
24	however	O
25	,	O
26	within	O
27	chromosome	O
28	III	O
29	,	O
30	certain	O
31	ARSs	O
32	near	O
33	the	O
34	transcriptionally	O
35	silent	O
36	HML	B
37	locus	I
38	show	O
39	no	O
40	replication	O
41	origin	O
42	activity	O
43	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	,	O
6	for	O
7	the	O
8	HML	B
9	ARS	O
10	cluster	O
11	(	O
12	ARS303	B
13	,	O
14	ARS320	B
15	,	O
16	and	O
17	ARS302	B
18	),	O
19	inactivity	O
20	of	O
21	origins	O
22	is	O
23	independent	O
24	of	O
25	local	O
26	transcriptional	O
27	silencing	O
28	,	O
29	even	O
30	though	O
31	origins	O
32	and	O
33	silencers	O
34	share	O
35	key	O
36	cis	O
37	-	O
38	and	O
39	trans	O
40	-	O
41	acting	O
42	components	O
43	.	O

1	In	O
2	the	O
3	present	O
4	study	O
5	,	O
6	we	O
7	demonstrate	O
8	that	O
9	expression	O
10	of	O
11	TD	B
12	-	I
13	IkappaBalpha	I
14	blocked	O
15	phorbol	O
16	myristate	O
17	acetate	B
18	-	I
19	phytohemagglutinin	I
20	or	O
21	tumor	B
22	necrosis	I
23	factor	I
24	alpha	I
25	-	O
26	induced	O
27	IkappaBalpha	B
28	gene	I
29	transcription	O
30	and	O
31	abolished	O
32	NF	B
33	-	I
34	kappaB	I
35	DNA	O
36	binding	O
37	activity	O
38	,	O
39	due	O
40	to	O
41	the	O
42	continued	O
43	cytoplasmic	O
44	sequestration	O
45	of	O
46	RelA	B
47	(	O
48	p65	B
49	)	O
50	by	O
51	TD	B
52	-	I
53	IkappaBalpha	I
54	.	O

1	(	O
2	i	O
3	)	O
4	Complete	O
5	Grb10	B
6	expression	O
7	from	O
8	cDNA	O
9	with	O
10	an	O
11	ecdysone	O
12	-	O
13	regulated	O
14	transient	O
15	expression	O
16	system	O
17	stimulated	O
18	PDGF	B
19	-	I
20	BB	I
21	-,	O
22	IGF	B
23	-	I
24	I	I
25	,	O
26	and	O
27	insulin	B
28	-	O
29	but	O
30	not	O
31	epidermal	B
32	growth	I
33	factor	I
34	(	O
35	EGF	B
36	)-	O
37	induced	O
38	DNA	O
39	synthesis	O
40	in	O
41	an	O
42	ecdysone	O
43	dose	O
44	-	O
45	responsive	O
46	fashion	O
47	.	O

1	The	O
2	analysis	O
3	of	O
4	two	O
5	distinct	O
6	mitogen	B
7	-	I
8	activated	I
9	protein	I
10	kinase	I
11	pathways	O
12	shows	O
13	that	O
14	stress	B
15	-	I
16	activated	I
17	protein	I
18	kinase	I
19	-	O
20	Jun	B
21	N	I
22	-	I
23	terminal	I
24	kinase	I
25	activation	O
26	,	O
27	resulting	O
28	in	O
29	the	O
30	phosphorylation	O
31	of	O
32	ATF	B
33	-	I
34	2	I
35	,	O
36	c	B
37	-	I
38	Jun	I
39	,	O
40	and	O
41	JunD	B
42	,	O
43	is	O
44	required	O
45	not	O
46	only	O
47	for	O
48	the	O
49	IL	B
50	-	I
51	1	I
52	-	O
53	but	O
54	also	O
55	for	O
56	the	O
57	TPA	O
58	-	O
59	dependent	O
60	induction	O
61	,	O
62	while	O
63	the	O
64	extracellular	B
65	signal	I
66	-	I
67	related	I
68	kinase	I
69	1	I
70	(	O
71	ERK	B
72	-	I
73	1	I
74	)	O
75	and	O
76	ERK	B
77	-	I
78	2	I
79	activation	O
80	is	O
81	involved	O
82	in	O
83	the	O
84	TPA	O
85	-	O
86	but	O
87	not	O
88	in	O
89	the	O
90	IL	B
91	-	I
92	1	I
93	-	O
94	dependent	O
95	stimulation	O
96	of	O
97	the	O
98	uPA	B
99	enhancer	I
100	.	O

1	CONCLUSIONS	O
2	:	O
3	In	O
4	healthy	O
5	individuals	O
6	,	O
7	whole	O
8	body	O
9	insulin	B
10	sensitivity	O
11	is	O
12	related	O
13	,	O
14	or	O
15	"	O
16	coupled	O
17	,	O
18	"	O
19	to	O
20	the	O
21	anaerobic	O
22	threshold	O
23	.	O

1	Interdomain	O
2	signaling	O
3	in	O
4	a	O
5	two	O
6	-	O
7	domain	O
8	fragment	O
9	of	O
10	the	O
11	human	B
12	glucocorticoid	I
13	receptor	I
14	.	O

1	In	O
2	contrast	O
3	,	O
4	the	O
5	xtRNA	B
6	(	O
7	Sec	B
8	)	O
9	gene	O
10	needs	O
11	the	O
12	binding	O
13	of	O
14	the	O
15	seven	O
16	Staf	B
17	zinc	I
18	fingers	I
19	,	O
20	but	O
21	not	O
22	Oct	B
23	-	I
24	1	I
25	,	O
26	for	O
27	optimal	O
28	transcriptional	O
29	capacity	O
30	.	O

1	Collectively	O
2	,	O
3	these	O
4	results	O
5	show	O
6	that	O
7	the	O
8	differential	O
9	utilization	O
10	of	O
11	Staf	B
12	zinc	I
13	finger	I
14	1	I
15	represents	O
16	a	O
17	new	O
18	,	O
19	critical	O
20	determinant	O
21	of	O
22	the	O
23	transcriptional	O
24	activation	O
25	mechanism	O
26	for	O
27	the	O
28	Xenopus	B
29	tRNA	I
30	(	O
31	Sec	B
32	)	O
33	and	O
34	human	B
35	U6	I
36	snRNA	I
37	genes	I
38	.	O

1	In	O
2	B	O
3	cells	O
4	,	O
5	HEF1	B
6	is	O
7	phosphorylated	O
8	by	O
9	a	O
10	cytoskeleton	O
11	-	O
12	dependent	O
13	mechanism	O
14	that	O
15	is	O
16	triggered	O
17	by	O
18	integrin	B
19	ligation	O
20	.	O

1	The	O
2	calcitonin	B
3	-	O
4	induced	O
5	tyrosine	O
6	phosphorylation	O
7	of	O
8	HEF1	B
9	increased	O
10	in	O
11	a	O
12	time	O
13	-	O
14	and	O
15	dose	O
16	-	O
17	dependent	O
18	manner	O
19	.	O

1	Independent	O
2	protrudor	O
3	muscle	O
4	stimulation	O
5	increased	O
6	VI	O
7	,	O
8	max	O
9	(	O
10	peak	O
11	increase	O
12	61	O
13	%,	O
14	P	O
15	<	O
16	0	O
17	.	O
18	05	O
19	),	O
20	did	O
21	not	O
22	change	O
23	Pcrit	O
24	,	O
25	and	O
26	decreased	O
27	Rn	O
28	(	O
29	peak	O
30	decrease	O
31	of	O
32	41	O
33	%,	O
34	P	O
35	<	O
36	0	O
37	.	O
38	05	O
39	).	O

1	We	O
2	report	O
3	the	O
4	construction	O
5	of	O
6	an	O
7	approximately	O
8	1	O
9	.	O
10	7	O
11	-	O
12	Mb	O
13	sequence	O
14	-	O
15	ready	O
16	YAC	O
17	/	O
18	BAC	O
19	clone	O
20	contig	O
21	of	O
22	8p22	O
23	-	O
24	p23	O
25	.	O

1	The	O
2	human	B
3	RAD30B	I
4	and	O
5	mouse	B
6	Rad30b	I
7	mRNA	I
8	transcripts	I
9	,	O
10	like	O
11	many	O
12	repair	O
13	proteins	O
14	,	O
15	are	O
16	highly	O
17	expressed	O
18	in	O
19	the	O
20	testis	O
21	.	O

1	Analysis	O
2	of	O
3	the	O
4	mouse	B
5	STAP	I
6	gene	I
7	isolated	O
8	from	O
9	the	O
10	genomic	O
11	library	O
12	revealed	O
13	that	O
14	the	O
15	STAP	B
16	gene	I
17	spans	O
18	a	O
19	region	O
20	of	O
21	over	O
22	11	O
23	kb	O
24	and	O
25	comprises	O
26	eight	O
27	exons	O
28	.	O

1	A	O
2	reduced	O
3	matrix	O
4	distribution	O
5	and	O
6	enhanced	O
7	cell	O
8	density	O
9	were	O
10	observed	O
11	as	O
12	the	O
13	biofilm	O
14	aged	O
15	.	O

1	After	O
2	10	O
3	months	O
4	of	O
5	treatment	O
6	with	O
7	the	O
8	conjugated	O
9	estrogen	O
10	,	O
11	both	O
12	his	O
13	height	O
14	and	O
15	weight	O
16	showed	O
17	improvement	O
18	,	O
19	while	O
20	his	O
21	bone	O
22	mineral	O
23	density	O
24	and	O
25	bone	O
26	age	O
27	were	O
28	increased	O
29	.	O

1	Viscosity	O
2	experiments	O
3	on	O
4	the	O
5	catalytic	O
6	fragment	O
7	kinase	O
8	reaction	O
9	demonstrated	O
10	that	O
11	the	O
12	chemical	O
13	(	O
14	phosphoryl	O
15	transfer	O
16	)	O
17	step	O
18	had	O
19	a	O
20	reduced	O
21	rate	O
22	.	O

1	Velocity	O
2	sedimentation	O
3	,	O
4	cross	O
5	-	O
6	linking	O
7	,	O
8	and	O
9	immunoprecipitation	O
10	analyses	O
11	of	O
12	detergent	O
13	-	O
14	solubilized	O
15	rat	O
16	brain	O
17	revealed	O
18	that	O
19	the	O
20	32	O
21	and	O
22	34	O
23	kDa	O
24	polypeptides	O
25	reside	O
26	within	O
27	heterotetramers	O
28	.	O

1	In	O
2	vitro	O
3	expression	O
4	levels	O
5	of	O
6	the	O
7	different	O
8	plasmids	O
9	differed	O
10	by	O
11	as	O
12	much	O
13	as	O
14	tenfold	O
15	.	O

1	In	O
2	EEG	O
3	only	O
4	single	O
5	slow	O
6	waves	O
7	above	O
8	left	O
9	temporal	O
10	region	O
11	were	O
12	revealed	O
13	.	O

1	Molecular	O
2	characterization	O
3	of	O
4	type	O
5	-	O
6	specific	O
7	capsular	O
8	polysaccharide	O
9	biosynthesis	O
10	genes	O
11	of	O
12	Streptococcus	O
13	agalactiae	O
14	type	O
15	Ia	O
16	.	O

1	(	O
2	1998	O
3	)	O
4	FASEB	O
5	J	O
6	.	O

1	IL	B
2	-	I
3	1beta	I
4	(	O
5	10	O
6	ng	O
7	/	O
8	ml	O
9	)	O
10	drastically	O
11	increased	O
12	both	O
13	PDGFalphaR	B
14	and	O
15	CCAAT	B
16	/	I
17	enhancer	I
18	-	I
19	binding	I
20	protein	I
21	delta	I
22	(	O
23	C	B
24	/	I
25	EBPdelta	I
26	)	O
27	mRNA	O
28	levels	O
29	in	O
30	a	O
31	time	O
32	dependent	O
33	manner	O
34	.	O

1	The	O
2	recruitment	O
3	of	O
4	constitutively	O
5	phosphorylated	O
6	p185	B
7	(	O
8	neu	B
9	)	O
10	and	O
11	the	O
12	activated	O
13	mitogenic	O
14	pathway	O
15	proteins	O
16	to	O
17	this	O
18	membrane	O
19	-	O
20	microfilament	O
21	interaction	O
22	site	O
23	provides	O
24	a	O
25	physical	O
26	model	O
27	for	O
28	integrating	O
29	the	O
30	assembly	O
31	of	O
32	the	O
33	mitogenic	O
34	pathway	O
35	with	O
36	the	O
37	transmission	O
38	of	O
39	growth	O
40	factor	O
41	signal	O
42	to	O
43	the	O
44	cytoskeleton	O
45	.	O

1	Transient	O
2	tyrosine	O
3	phosphorylation	O
4	of	O
5	Crk	B
6	in	O
7	fibroblast	B
8	growth	I
9	factor	I
10	-	I
11	2	I
12	-	O
13	stimulated	O
14	endothelial	O
15	cells	O
16	was	O
17	dependent	O
18	on	O
19	the	O
20	juxtamembrane	O
21	tyrosine	O
22	residue	O
23	463	O
24	in	O
25	FGFR	B
26	-	I
27	1	I
28	,	O
29	and	O
30	a	O
31	Crk	B
32	SH2	I
33	domain	I
34	precipitated	O
35	FGFR	B
36	-	I
37	1	I
38	via	O
39	phosphorylated	O
40	Tyr	O
41	-	O
42	463	O
43	,	O
44	indicating	O
45	direct	O
46	complex	O
47	formation	O
48	between	O
49	Crk	B
50	and	O
51	FGFR	B
52	-	I
53	1	I
54	.	O

1	ECG	O
2	-	O
3	gated	O
4	myocardial	O
5	Technetium	O
6	-	O
7	99m	O
8	sestamibi	O
9	SPECT	O
10	is	O
11	a	O
12	useful	O
13	technique	O
14	to	O
15	measure	O
16	myocardial	O
17	perfusion	O
18	and	O
19	function	O
20	simultaneously	O
21	.	O

1	Role	O
2	of	O
3	the	O
4	3	O
5	'	O
6	untranslated	O
7	region	O
8	of	O
9	baculovirus	B
10	p10	I
11	mRNA	I
12	in	O
13	high	O
14	-	O
15	level	O
16	expression	O
17	of	O
18	foreign	O
19	genes	O
20	.	O

1	The	O
2	intron	O
3	RNA	O
4	consists	O
5	of	O
6	2492	O
7	nucleotides	O
8	which	O
9	can	O
10	be	O
11	folded	O
12	into	O
13	a	O
14	secondary	O
15	structure	O
16	with	O
17	all	O
18	the	O
19	expected	O
20	sequence	O
21	motifs	O
22	of	O
23	subgroup	O
24	-	O
25	IIA1	O
26	introns	O
27	(	O
28	Michel	O
29	et	O
30	al	O
31	.	O

1	The	O
2	intron	O
3	is	O
4	capable	O
5	of	O
6	splicing	O
7	despite	O
8	the	O
9	fact	O
10	that	O
11	both	O
12	the	O
13	EBS1	B
14	/	O
15	IBS1	B
16	and	O
17	the	O
18	EBS2	B
19	/	O
20	IBS2	B
21	sequence	O
22	motifs	O
23	,	O
24	thought	O
25	to	O
26	be	O
27	necessary	O
28	for	O
29	correct	O
30	splicing	O
31	,	O
32	extend	O
33	over	O
34	5	O
35	instead	O
36	of	O
37	6	O
38	bp	O
39	.	O

1	The	O
2	Trk	B
3	/	I
4	Nerve	I
5	Growth	I
6	Factor	I
7	receptor	I
8	mediates	O
9	the	O
10	rapid	O
11	activation	O
12	of	O
13	a	O
14	number	O
15	of	O
16	intracellular	O
17	signaling	O
18	proteins	O
19	,	O
20	including	O
21	phosphatidylinositol	B
22	3	I
23	-	I
24	kinase	I
25	(	O
26	PI	B
27	3	I
28	-	I
29	kinase	I
30	).	O

1	The	O
2	controversy	O
3	of	O
4	significance	O
5	testing	O
6	:	O
7	misconceptions	O
8	and	O
9	alternatives	O
10	.	O

1	Chemical	O
2	uptake	O
3	into	O
4	human	O
5	stratum	O
6	corneum	O
7	in	O
8	vivo	O
9	from	O
10	volatile	O
11	and	O
12	non	O
13	-	O
14	volatile	O
15	solvents	O
16	.	O

1	Like	O
2	DNA	O
3	binding	O
4	,	O
5	transcriptional	O
6	enhancement	O
7	required	O
8	amino	O
9	-	O
10	terminally	O
11	located	O
12	basic	O
13	amino	O
14	acid	O
15	residues	O
16	but	O
17	not	O
18	the	O
19	carboxyl	O
20	-	O
21	terminal	O
22	portion	O
23	of	O
24	Hap46	B
25	known	O
26	to	O
27	participate	O
28	in	O
29	hsp70	B
30	interaction	O
31	.	O

1	We	O
2	have	O
3	tested	O
4	the	O
5	function	O
6	of	O
7	two	O
8	potential	O
9	NF	B
10	-	I
11	kappaB	I
12	-	I
13	like	I
14	sites	I
15	present	O
16	in	O
17	the	O
18	PAI	B
19	-	I
20	2	I
21	proximal	I
22	promoter	I
23	for	O
24	responsiveness	O
25	to	O
26	TNFalpha	B
27	using	O
28	chloramphenicol	B
29	acetyl	I
30	transferase	I
31	reporter	I
32	gene	I
33	deletion	O
34	and	O
35	mutation	O
36	analyses	O
37	.	O

1	N	O
2	-	O
3	terminal	O
4	sequence	O
5	analysis	O
6	and	O
7	NMR	O
8	measurements	O
9	revealed	O
10	that	O
11	this	O
12	fragment	O
13	originates	O
14	from	O
15	the	O
16	C	O
17	-	O
18	terminal	O
19	80	O
20	residues	O
21	of	O
22	MBF1	B
23	and	O
24	form	O
25	a	O
26	well	O
27	structured	O
28	C	O
29	-	O
30	terminal	O
31	domain	O
32	of	O
33	MBF1	B
34	,	O
35	MBF1CTD	B
36	.	O

1	The	O
2	nucleosomal	O
3	response	O
4	associated	O
5	with	O
6	immediate	B
7	-	I
8	early	I
9	gene	I
10	induction	O
11	is	O
12	mediated	O
13	via	O
14	alternative	O
15	MAP	B
16	kinase	I
17	cascades	I
18	:	O
19	MSK1	B
20	as	O
21	a	O
22	potential	O
23	histone	B
24	H3	I
25	/	O
26	HMG	B
27	-	I
28	14	I
29	kinase	O
30	.	O

1	The	O
2	arrangement	O
3	of	O
4	these	O
5	cutoff	O
6	-	O
7	levels	O
8	leads	O
9	to	O
10	a	O
11	sensitivity	O
12	of	O
13	85	O
14	%	O
15	at	O
16	a	O
17	specificity	O
18	of	O
19	55	O
20	%	O
21	for	O
22	Protein	B
23	S100	I
24	when	O
25	measured	O
26	by	O
27	RIA	O
28	,	O
29	and	O
30	to	O
31	a	O
32	sensitivity	O
33	of	O
34	77	O
35	%	O
36	at	O
37	a	O
38	specificity	O
39	of	O
40	61	O
41	%	O
42	when	O
43	measured	O
44	by	O
45	LIA	O
46	.	O

1	272	O
2	,	O
3	1904	O
4	].	O

1	Using	O
2	16	O
3	strains	O
4	of	O
5	C	O
6	.	O
7	trachomatis	O
8	in	O
9	triplicate	O
10	assays	O
11	,	O
12	we	O
13	found	O
14	the	O
15	RT	O
16	-	O
17	PCR	O
18	method	O
19	consistently	O
20	more	O
21	sensitive	O
22	than	O
23	the	O
24	conventional	O
25	technique	O
26	for	O
27	all	O
28	eight	O
29	antimicrobials	O
30	tested	O
31	,	O
32	with	O
33	resultant	O
34	MICs	O
35	determined	O
36	by	O
37	RT	O
38	-	O
39	PCR	O
40	ranging	O
41	from	O
42	1	O
43	.	O
44	6	O
45	-	O
46	fold	O
47	higher	O
48	(	O
49	erythromycin	O
50	)	O
51	to	O
52	>/=	O
53	195	O
54	-	O
55	fold	O
56	higher	O
57	(	O
58	amoxicillin	O
59	).	O

1	Null	O
2	alleles	O
3	of	O
4	SAS4	B
5	and	O
6	SAS5	B
7	bypassed	O
8	the	O
9	role	O
10	of	O
11	the	O
12	Abf1p	B
13	binding	I
14	site	I
15	of	O
16	the	O
17	HMR	B
18	-	I
19	E	I
20	silencer	I
21	but	O
22	not	O
23	the	O
24	role	O
25	of	O
26	the	O
27	ACS	B
28	or	O
29	Rap1p	B
30	binding	I
31	site	I
32	.	O

1	Recent	O
2	molecular	O
3	analysis	O
4	has	O
5	revealed	O
6	that	O
7	the	O
8	S	B
9	locus	I
10	is	O
11	highly	O
12	polymorphic	O
13	and	O
14	contains	O
15	several	O
16	genes	O
17	,	O
18	i	O
19	.	O
20	e	O
21	.,	O
22	SLG	B
23	,	O
24	SRK	B
25	,	O
26	the	O
27	as	O
28	-	O
29	yet	O
30	-	O
31	unidentified	O
32	pollen	O
33	S	O
34	gene	O
35	(	O
36	s	O
37	),	O
38	and	O
39	other	O
40	linked	O
41	genes	O
42	.	O

1	A	O
2	cDNA	O
3	encoding	O
4	a	O
5	putative	O
6	RNA	B
7	and	I
8	/	I
9	or	I
10	DNA	I
11	helicase	I
12	has	O
13	been	O
14	isolated	O
15	from	O
16	Arabidopsis	O
17	thaliana	O
18	cDNA	O
19	libraries	O
20	.	O

1	In	O
2	vivo	O
3	,	O
4	MyoD	B
5	requires	O
6	this	O
7	tryptophan	O
8	motif	O
9	to	O
10	evoke	O
11	chromatin	O
12	remodeling	O
13	in	O
14	the	O
15	Myogenin	B
16	promoter	I
17	and	O
18	to	O
19	activate	O
20	Myogenin	B
21	transcription	O
22	.	O

1	RESULTS	O
2	:	O
3	256	O
4	Periods	O
5	of	O
6	TTP	O
7	or	O
8	PUNP	O
9	were	O
10	reported	O
11	by	O
12	men	O
13	and	O
14	174	O
15	by	O
16	women	O
17	.	O

1	Feed	O
2	intake	O
3	and	O
4	BW	O
5	gains	O
6	were	O
7	decreased	O
8	(	O
9	P	O
10	<	O
11	0	O
12	.	O
13	05	O
14	)	O
15	by	O
16	dietary	O
17	treatments	O
18	containing	O
19	M	O
20	.	O

1	The	O
2	N	O
3	terminus	O
4	of	O
5	beta	O
6	(	O
7	95	O
8	kDa	O
9	)	O
10	corresponds	O
11	to	O
12	alpha	O
13	with	O
14	the	O
15	integrase	B
16	domain	I
17	attached	O
18	to	O
19	the	O
20	C	O
21	terminus	O
22	(	O
23	32	O
24	kDa	O
25	).	O

1	Skn	B
2	-	I
3	1a	I
4	lacking	O
5	the	O
6	C	O
7	-	O
8	terminal	O
9	region	O
10	completely	O
11	lost	O
12	transactivation	O
13	ability	O
14	,	O
15	irrespective	O
16	of	O
17	the	O
18	promoter	O
19	tested	O
20	,	O
21	and	O
22	was	O
23	able	O
24	to	O
25	block	O
26	transactivation	O
27	by	O
28	normal	O
29	Skn	B
30	-	I
31	1a	I
32	in	O
33	competition	O
34	assays	O
35	.	O

1	In	O
2	early	O
3	Xenopus	O
4	embryos	O
5	,	O
6	the	O
7	transforming	B
8	growth	I
9	factor	I
10	-	I
11	beta	I
12	member	O
13	activin	B
14	induces	O
15	the	O
16	gene	B
17	Mix	I
18	.	I
19	2	I
20	by	O
21	stimulating	O
22	the	O
23	formation	O
24	of	O
25	a	O
26	multiprotein	O
27	complex	O
28	,	O
29	activin	B
30	-	I
31	responsive	I
32	factor	I
33	(	O
34	ARF	B
35	).	O

1	To	O
2	further	O
3	characterize	O
4	the	O
5	structure	O
6	and	O
7	evolutionary	O
8	synthesis	O
9	of	O
10	the	O
11	CMT1A	O
12	-	O
13	REP	O
14	repeat	O
15	,	O
16	fluorescent	O
17	in	O
18	situ	O
19	hybridization	O
20	(	O
21	FISH	O
22	)	O
23	analysis	O
24	and	O
25	heterologous	O
26	PCR	O
27	-	O
28	based	O
29	assays	O
30	were	O
31	carried	O
32	out	O
33	for	O
34	a	O
35	series	O
36	of	O
37	primates	O
38	.	O

1	Natl	O
2	.	O

1	In	O
2	the	O
3	face	O
4	of	O
5	the	O
6	outbreak	O
7	,	O
8	there	O
9	was	O
10	a	O
11	delay	O
12	before	O
13	vaccination	O
14	was	O
15	able	O
16	to	O
17	stop	O
18	deaths	O
19	.	O

1	Here	O
2	we	O
3	show	O
4	that	O
5	a	O
6	novel	O
7	isoform	O
8	of	O
9	Rapl	B
10	GTPase	I
11	-	I
12	activating	I
13	protein	I
14	,	O
15	called	O
16	rap1GAPII	B
17	,	O
18	binds	O
19	specifically	O
20	to	O
21	the	O
22	alpha	O
23	-	O
24	subunits	O
25	of	O
26	the	O
27	G	B
28	(	I
29	i	I
30	)	I
31	family	I
32	of	O
33	heterotrimeric	B
34	G	I
35	-	I
36	proteins	I
37	.	O

1	The	O
2	B	O
3	-	O
4	oligomer	O
5	of	O
6	pertussis	B
7	toxin	I
8	deactivates	O
9	CC	B
10	chemokine	I
11	receptor	I
12	5	I
13	and	O
14	blocks	O
15	entry	O
16	of	O
17	M	O
18	-	O
19	tropic	O
20	HIV	O
21	-	O
22	1	O
23	strains	O
24	.	O

1	Cross	O
2	-	O
3	linking	O
4	the	O
5	B	B
6	cell	I
7	Ag	I
8	receptor	I
9	(	O
10	BCR	B
11	)	O
12	to	O
13	surface	B
14	Fc	I
15	receptors	I
16	for	O
17	IgG	B
18	(	O
19	Fc	B
20	gamma	I
21	R	I
22	)	O
23	inhibits	O
24	G1	O
25	-	O
26	to	O
27	-	O
28	S	O
29	progression	O
30	;	O
31	the	O
32	mechanism	O
33	by	O
34	which	O
35	this	O
36	occurs	O
37	is	O
38	not	O
39	completely	O
40	known	O
41	.	O

1	Cross	O
2	-	O
3	linking	O
4	the	O
5	B	B
6	cell	I
7	Ag	I
8	receptor	I
9	(	O
10	BCR	B
11	)	O
12	to	O
13	surface	B
14	Fc	I
15	receptors	I
16	for	O
17	IgG	B
18	(	O
19	Fc	B
20	gamma	I
21	R	I
22	)	O
23	inhibits	O
24	G1	O
25	-	O
26	to	O
27	-	O
28	S	O
29	progression	O
30	;	O
31	the	O
32	mechanism	O
33	by	O
34	which	O
35	this	O
36	occurs	O
37	is	O
38	not	O
39	completely	O
40	known	O
41	.	O

1	TRAF2	B
2	is	O
3	a	O
4	potent	O
5	activator	O
6	of	O
7	a	O
8	95	B
9	-	I
10	kDa	I
11	serine	I
12	/	I
13	threonine	I
14	kinase	I
15	termed	O
16	germinal	B
17	center	I
18	kinase	I
19	related	I
20	(	O
21	GCKR	B
22	,	O
23	also	O
24	referred	O
25	to	O
26	as	O
27	KHS1	B
28	),	O
29	which	O
30	signals	O
31	activation	O
32	of	O
33	the	O
34	SAPK	B
35	pathway	O
36	.	O

1	An	O
2	activation	O
3	-	O
4	responsive	O
5	element	O
6	in	O
7	single	B
8	C	I
9	motif	I
10	-	I
11	1	I
12	/	O
13	lymphotactin	B
14	promoter	O
15	is	O
16	a	O
17	site	O
18	of	O
19	constitutive	O
20	and	O
21	inducible	O
22	DNA	O
23	-	O
24	protein	O
25	interactions	O
26	involving	O
27	nuclear	O
28	factor	O
29	of	O
30	activated	O
31	T	O
32	cell	O
33	.	O

1	Cytokine	O
2	-	O
3	induced	O
4	NF	B
5	-	I
6	kappa	I
7	B	I
8	DNA	O
9	binding	O
10	activity	O
11	,	O
12	RelA	B
13	nuclear	O
14	translocation	O
15	,	O
16	I	B
17	kappa	I
18	B	I
19	alpha	I
20	degradation	O
21	,	O
22	I	B
23	kappa	I
24	B	I
25	serine	O
26	32	O
27	phosphorylation	O
28	,	O
29	and	O
30	I	B
31	kappa	I
32	B	I
33	kinase	I
34	(	O
35	IKK	B
36	)	O
37	activity	O
38	were	O
39	blocked	O
40	by	O
41	curcumin	O
42	treatment	O
43	.	O

1	A	O
2	portion	O
3	of	O
4	p193	B
5	is	O
6	nuclear	O
7	and	O
8	localizes	O
9	to	O
10	the	O
11	mitotic	O
12	spindle	O
13	.	O

1	The	O
2	main	O
3	issues	O
4	are	O
5	the	O
6	need	O
7	to	O
8	explain	O
9	a	O
10	number	O
11	of	O
12	still	O
13	unknown	O
14	mechanisms	O
15	,	O
16	to	O
17	determine	O
18	which	O
19	"	O
20	natural	O
21	diet	O
22	"	O
23	carries	O
24	the	O
25	minimum	O
26	coronary	O
27	risk	O
28	and	O
29	whether	O
30	"	O
31	new	O
32	"	O
33	foods	O
34	produced	O
35	by	O
36	modern	O
37	technology	O
38	are	O
39	really	O
40	needed	O
41	to	O
42	contrast	O
43	this	O
44	epidemic	O
45	.	O

1	Cotransfection	O
2	of	O
3	the	O
4	coactivator	O
5	CREB	B
6	-	I
7	binding	I
8	protein	I
9	relieved	O
10	the	O
11	transcriptional	O
12	repression	O
13	of	O
14	PPARalphawt	B
15	by	O
16	PPARalphatr	B
17	,	O
18	suggesting	O
19	that	O
20	the	O
21	dominant	O
22	negative	O
23	effect	O
24	of	O
25	PPARalphatr	B
26	might	O
27	occur	O
28	through	O
29	competition	O
30	for	O
31	essential	O
32	coactivators	O
33	.	O

1	SF	B
2	-	I
3	1	I
4	does	O
5	not	O
6	have	O
7	an	O
8	N	O
9	-	O
10	terminal	O
11	AF1	O
12	domain	O
13	.	O

1	To	O
2	estimate	O
3	the	O
4	locations	O
5	of	O
6	sources	O
7	with	O
8	the	O
9	TF	O
10	-	O
11	MUSIC	O
12	algorithm	O
13	,	O
14	we	O
15	first	O
16	set	O
17	the	O
18	target	O
19	region	O
20	on	O
21	the	O
22	spectrogram	O
23	of	O
24	the	O
25	somatosensory	O
26	responses	O
27	.	O

1	We	O
2	discuss	O
3	these	O
4	results	O
5	in	O
6	terms	O
7	of	O
8	the	O
9	influence	O
10	that	O
11	time	O
12	and	O
13	nutritional	O
14	constraints	O
15	have	O
16	on	O
17	odonate	O
18	development	O
19	patterns	O
20	and	O
21	fitness	O
22	.	O

1	OBJECTIVE	O
2	:	O
3	1998	O
4	Surveillance	O
5	,	O
6	Epidemiology	O
7	,	O
8	and	O
9	End	O
10	Results	O
11	(	O
12	SEER	O
13	)	O
14	data	O
15	estimate	O
16	an	O
17	83	O
18	.	O
19	1	O
20	%	O
21	5	O
22	-	O
23	year	O
24	survival	O
25	rate	O
26	for	O
27	corpus	O
28	uteri	O
29	adenocarcinoma	O
30	FIGO	O
31	stage	O
32	II	O
33	.	O

1	A	O
2	novel	O
3	Drosophila	B
4	A	I
5	kinase	I
6	anchor	I
7	protein	I
8	,	O
9	Drosophila	B
10	A	I
11	kinase	I
12	anchor	I
13	protein	I
14	200	I
15	(	O
16	DAKAP200	B
17	),	O
18	is	O
19	predicted	O
20	to	O
21	be	O
22	involved	O
23	in	O
24	routing	O
25	,	O
26	mediating	O
27	,	O
28	and	O
29	integrating	O
30	signals	O
31	carried	O
32	by	O
33	cAMP	O
34	,	O
35	Ca	O
36	(	O
37	2	O
38	+),	O
39	and	O
40	diacylglycerol	O
41	(	O
42	Li	O
43	,	O
44	Z	O
45	.,	O
46	Rossi	O
47	,	O
48	E	O
49	.	O

1	In	O
2	vitro	O
3	transcription	O
4	results	O
5	indicate	O
6	that	O
7	this	O
8	5	O
9	'	O
10	structure	O
11	functions	O
12	in	O
13	the	O
14	attenuation	O
15	mechanism	O
16	,	O
17	since	O
18	deletion	O
19	of	O
20	the	O
21	stem	O
22	-	O
23	loop	O
24	caused	O
25	an	O
26	increase	O
27	in	O
28	transcription	O
29	readthrough	O
30	.	O

1	A	O
2	5	O
3	'	O
4	RNA	O
5	stem	O
6	-	O
7	loop	O
8	participates	O
9	in	O
10	the	O
11	transcription	O
12	attenuation	O
13	mechanism	O
14	that	O
15	controls	O
16	expression	O
17	of	O
18	the	O
19	Bacillus	B
20	subtilis	I
21	trpEDCFBA	I
22	operon	I
23	.	O

1	Single	O
2	-	O
3	alanine	O
4	-	O
5	substitution	O
6	mutations	O
7	had	O
8	minimal	O
9	,	O
10	if	O
11	any	O
12	,	O
13	effects	O
14	on	O
15	S	O
16	-	O
17	induced	O
18	cell	O
19	-	O
20	to	O
21	-	O
22	cell	O
23	fusion	O
24	.	O

1	Furthermore	O
2	,	O
3	we	O
4	demonstrate	O
5	that	O
6	transcription	O
7	from	O
8	the	O
9	MMTV	B
10	5	I
11	'	I
12	LTR	I
13	is	O
14	highly	O
15	active	O
16	in	O
17	the	O
18	absence	O
19	of	O
20	Stat5a	B
21	,	O
22	a	O
23	transcription	O
24	factor	O
25	that	O
26	had	O
27	been	O
28	shown	O
29	previously	O
30	to	O
31	be	O
32	required	O
33	for	O
34	transcription	O
35	from	O
36	the	O
37	MMTV	B
38	LTR	I
39	.	O

1	Regional	O
2	insertional	O
3	mutagenesis	O
4	of	O
5	specific	O
6	genes	O
7	on	O
8	the	O
9	CIC5F11	B
10	/	O
11	CIC2B9	B
12	locus	O
13	of	O
14	Arabidopsis	O
15	thaliana	O
16	chromosome	O
17	5	O
18	using	O
19	the	O
20	Ac	B
21	/	O
22	Ds	B
23	transposon	O
24	in	O
25	combination	O
26	with	O
27	the	O
28	cDNA	O
29	scanning	O
30	method	O
31	.	O

1	RESULTS	O
2	:	O
3	CK	B
4	-	O
5	MB	B
6	elevation	O
7	was	O
8	detected	O
9	in	O
10	313	O
11	patients	O
12	(	O
13	18	O
14	.	O
15	7	O
16	%),	O
17	with	O
18	1	O
19	-	O
20	3x	O
21	in	O
22	12	O
23	.	O
24	8	O
25	%,	O
26	3	O
27	-	O
28	5x	O
29	in	O
30	3	O
31	.	O
32	5	O
33	%	O
34	and	O
35	>	O
36	5x	O
37	normal	O
38	in	O
39	2	O
40	.	O
41	4	O
42	%	O
43	of	O
44	patients	O
45	.	O

1	Thus	O
2	,	O
3	NART	O
4	-	O
5	R	O
6	performance	O
7	may	O
8	not	O
9	be	O
10	a	O
11	valid	O
12	estimate	O
13	of	O
14	baseline	O
15	IQ	O
16	for	O
17	patients	O
18	with	O
19	neurologic	O
20	disorders	O
21	with	O
22	suspected	O
23	language	O
24	impairment	O
25	.	O

1	Activated	O
2	areas	O
3	have	O
4	been	O
5	identified	O
6	by	O
7	means	O
8	of	O
9	cross	O
10	-	O
11	correlation	O
12	analysis	O
13	.	O

1	Natural	O
2	Haemophilus	O
3	influenzae	O
4	type	O
5	b	O
6	capsular	O
7	polysaccharide	O
8	antibodies	O
9	in	O
10	412	O
11	infants	O
12	and	O
13	children	O
14	from	O
15	West	O
16	Africa	O
17	(	O
18	Burkina	O
19	-	O
20	Faso	O
21	)	O
22	and	O
23	France	O
24	:	O
25	a	O
26	cross	O
27	-	O
28	sectional	O
29	serosurvey	O
30	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	identified	O
7	Sp1	B
8	and	O
9	Sp3	B
10	as	O
11	major	O
12	factors	O
13	binding	O
14	to	O
15	the	O
16	Sp1	B
17	sites	I
18	of	O
19	the	O
20	p21	B
21	/	O
22	WAF1	B
23	/	O
24	Cip1	B
25	promoter	O
26	in	O
27	MG63	O
28	cells	O
29	through	O
30	electrophoretic	O
31	mobility	O
32	shift	O
33	assays	O
34	and	O
35	showed	O
36	that	O
37	TSA	O
38	treatment	O
39	did	O
40	not	O
41	change	O
42	their	O
43	binding	O
44	activities	O
45	.	O

1	Galoyan	O
2	has	O
3	summarized	O
4	the	O
5	results	O
6	of	O
7	his	O
8	discovery	O
9	of	O
10	cardioactive	O
11	neurohormones	O
12	.	O

1	To	O
2	study	O
3	the	O
4	regulation	O
5	of	O
6	its	O
7	expression	O
8	,	O
9	the	O
10	human	B
11	aldehyde	I
12	reductase	I
13	gene	I
14	and	O
15	promoter	O
16	were	O
17	cloned	O
18	and	O
19	characterized	O
20	.	O

1	Immunohistochemical	O
2	staining	O
3	with	O
4	MIB	B
5	-	I
6	1	I
7	and	O
8	p53	B
9	antibodies	I
10	showed	O
11	low	O
12	(<	O
13	1	O
14	%)	O
15	and	O
16	negative	O
17	reaction	O
18	.	O

1	The	O
2	C2C	B
3	-	O
4	Prx	B
5	is	O
6	encoded	O
7	as	O
8	a	O
9	preprotein	O
10	of	O
11	273	O
12	amino	O
13	acids	O
14	containing	O
15	a	O
16	putative	O
17	chloroplast	O
18	-	O
19	targeting	O
20	signal	O
21	of	O
22	65	O
23	amino	O
24	acids	O
25	at	O
26	its	O
27	N	O
28	-	O
29	terminus	O
30	.	O

1	Immediately	O
2	before	O
3	surgery	O
4	patients	O
5	received	O
6	either	O
7	intravenous	O
8	hydrocortisone	O
9	100	O
10	mg	O
11	or	O
12	placebo	O
13	in	O
14	random	O
15	,	O
16	double	O
17	-	O
18	blind	O
19	order	O
20	.	O

1	A	O
2	tyrosine	O
3	-	O
4	based	O
5	sorting	O
6	signal	O
7	in	O
8	the	O
9	beta2	B
10	integrin	I
11	cytoplasmic	I
12	domain	I
13	mediates	O
14	its	O
15	recycling	O
16	to	O
17	the	O
18	plasma	O
19	membrane	O
20	and	O
21	is	O
22	required	O
23	for	O
24	ligand	O
25	-	O
26	supported	O
27	migration	O
28	.	O

1	The	O
2	injection	O
3	of	O
4	XDRP1	B
5	protein	I
6	into	O
7	fertilized	O
8	Xenopus	O
9	eggs	O
10	blocked	O
11	embryonic	O
12	cell	O
13	division	O
14	.	O

1	Using	O
2	transgenic	O
3	Xenopus	O
4	embryos	O
5	,	O
6	we	O
7	demonstrate	O
8	that	O
9	the	O
10	integrity	O
11	of	O
12	these	O
13	two	O
14	sequences	O
15	is	O
16	necessary	O
17	for	O
18	correct	O
19	spatial	O
20	expression	O
21	of	O
22	a	O
23	Xbra2	B
24	promoter	I
25	-	I
26	driven	I
27	reporter	I
28	gene	I
29	.	O

1	In	O
2	order	O
3	to	O
4	screen	O
5	for	O
6	such	O
7	cofactors	O
8	,	O
9	we	O
10	have	O
11	used	O
12	a	O
13	transcriptionally	O
14	inactive	O
15	mutant	O
16	of	O
17	Xenopus	B
18	MEF2D	I
19	in	O
20	a	O
21	yeast	O
22	two	O
23	-	O
24	hybrid	O
25	screen	O
26	.	O

1	NuA4	B
2	has	O
3	an	O
4	apparent	O
5	molecular	O
6	mass	O
7	of	O
8	1	O
9	.	O
10	3	O
11	MDa	O
12	.	O

1	ATF1	B
2	transcription	O
3	is	O
4	negatively	O
5	regulated	O
6	by	O
7	unsaturated	O
8	fatty	O
9	acids	O
10	and	O
11	oxygen	O
12	.	O

1	Two	O
2	patients	O
3	with	O
4	recurrent	O
5	tumors	O
6	had	O
7	high	O
8	S	O
9	-	O
10	phase	O
11	fractions	O
12	both	O
13	on	O
14	the	O
15	first	O
16	resected	O
17	specimens	O
18	and	O
19	at	O
20	the	O
21	time	O
22	of	O
23	the	O
24	second	O
25	operation	O
26	.	O

1	Mutation	O
2	of	O
3	TTF	B
4	-	I
5	1	I
6	-	I
7	binding	I
8	sites	I
9	(	I
10	TBE	I
11	)	I
12	1	I
13	,	I
14	3	I
15	,	I
16	and	I
17	4	I
18	in	O
19	combination	O
20	markedly	O
21	decreased	O
22	transcriptional	O
23	activity	O
24	of	O
25	SP	B
26	-	I
27	A	I
28	promoter	O
29	-	O
30	chloramphenicol	B
31	acetyltransferase	I
32	constructs	O
33	containing	O
34	SP	B
35	-	I
36	A	I
37	gene	I
38	sequences	O
39	from	O
40	-	O
41	256	O
42	to	O
43	+	O
44	45	O
45	.	O

1	Insulin	B
2	-	I
3	like	I
4	growth	I
5	factor	I
6	-	I
7	I	I
8	induces	O
9	bcl	B
10	-	I
11	2	I
12	promoter	I
13	through	O
14	the	O
15	transcription	O
16	factor	O
17	cAMP	B
18	-	I
19	response	I
20	element	I
21	-	I
22	binding	I
23	protein	I
24	.	O

1	Synthesis	O
2	of	O
3	antisense	O
4	RNA	O
5	and	O
6	S	O
7	phase	O
8	-	O
9	dependent	O
10	binding	O
11	of	O
12	E2F	B
13	complexes	I
14	in	O
15	intron	O
16	1	O
17	.	O

1	Identification	O
2	of	O
3	eotaxin	B
4	-	I
5	3	I
6	will	O
7	further	O
8	promote	O
9	our	O
10	understanding	O
11	of	O
12	the	O
13	control	O
14	of	O
15	eosinophil	O
16	trafficking	O
17	and	O
18	other	O
19	CCR3	B
20	-	O
21	mediated	O
22	biological	O
23	phenomena	O
24	.	O

1	NF	B
2	-	I
3	kappaB	I
4	plays	O
5	a	O
6	critical	O
7	role	O
8	in	O
9	activation	O
10	of	O
11	HIV	O
12	-	O
13	1	O
14	gene	O
15	expression	O
16	by	O
17	cytokines	O
18	and	O
19	other	O
20	stimuli	O
21	,	O
22	but	O
23	the	O
24	signal	O
25	transduction	O
26	pathways	O
27	that	O
28	regulate	O
29	the	O
30	switch	O
31	from	O
32	latent	O
33	to	O
34	productive	O
35	infection	O
36	have	O
37	not	O
38	been	O
39	defined	O
40	.	O

1	These	O
2	studies	O
3	suggest	O
4	that	O
5	MAPK	B
6	acts	O
7	by	O
8	stimulating	O
9	AP	B
10	-	I
11	1	I
12	and	O
13	a	O
14	subsequent	O
15	physical	O
16	and	O
17	functional	O
18	interaction	O
19	of	O
20	AP	B
21	-	I
22	1	I
23	with	O
24	NF	B
25	-	I
26	kappaB	I
27	,	O
28	resulting	O
29	in	O
30	a	O
31	complex	O
32	that	O
33	synergistically	O
34	transactivates	O
35	the	O
36	HIV	B
37	-	I
38	1	I
39	LTR	I
40	.	O

1	ERK	B
2	MAP	I
3	kinase	I
4	links	O
5	cytokine	O
6	signals	O
7	to	O
8	activation	O
9	of	O
10	latent	O
11	HIV	O
12	-	O
13	1	O
14	infection	O
15	by	O
16	stimulating	O
17	a	O
18	cooperative	O
19	interaction	O
20	of	O
21	AP	B
22	-	I
23	1	I
24	and	O
25	NF	B
26	-	I
27	kappaB	I
28	.	O

1	A	O
2	human	O
3	nuclear	O
4	-	O
5	localized	O
6	chaperone	O
7	that	O
8	regulates	O
9	dimerization	O
10	,	O
11	DNA	O
12	binding	O
13	,	O
14	and	O
15	transcriptional	O
16	activity	O
17	of	O
18	bZIP	B
19	proteins	I
20	.	O

1	Clinical	O
2	differentiation	O
3	of	O
4	patients	O
5	with	O
6	mild	O
7	diplegic	O
8	cerebral	O
9	palsy	O
10	(	O
11	CP	O
12	)	O
13	and	O
14	idiopathic	O
15	toe	O
16	walking	O
17	(	O
18	ITW	O
19	)	O
20	can	O
21	be	O
22	difficult	O
23	.	O

1	Sputum	B
2	IL	I
3	-	I
4	8	I
5	and	O
6	MPO	B
7	were	O
8	significantly	O
9	increased	O
10	after	O
11	BPT	O
12	in	O
13	both	O
14	TDI	O
15	-	O
16	and	O
17	grain	O
18	dust	O
19	-	O
20	asthma	O
21	(	O
22	P	O
23	<	O
24	0	O
25	.	O
26	05	O
27	).	O

1	Montelukast	O
2	reduces	O
3	airway	O
4	eosinophilic	O
5	inflammation	O
6	in	O
7	asthma	O
8	:	O
9	a	O
10	randomized	O
11	,	O
12	controlled	O
13	trial	O
14	.	O

1	Treatment	O
2	of	O
3	unstable	O
4	angina	O
5	:	O
6	role	O
7	of	O
8	antithrombotic	O
9	therapy	O
10	.	O

1	Here	O
2	,	O
3	we	O
4	demonstrate	O
5	that	O
6	kinase	O
7	-	O
8	dead	O
9	but	O
10	not	O
11	wild	O
12	-	O
13	type	O
14	forms	O
15	of	O
16	Fyn	B
17	,	O
18	Lck	B
19	,	O
20	and	O
21	ZAP	B
22	-	I
23	70	I
24	block	O
25	70Z	O
26	Cbl	B
27	-	O
28	mediated	O
29	NFAT	B
30	activation	O
31	.	O

1	Substitutions	O
2	of	O
3	region	O
4	I	O
5	with	O
6	synthetic	O
7	sequences	O
8	showed	O
9	that	O
10	no	O
11	specific	O
12	sequence	O
13	but	O
14	rather	O
15	repeats	O
16	of	O
17	three	O
18	or	O
19	more	O
20	consecutive	O
21	adenines	O
22	or	O
23	thymines	O
24	,	O
25	without	O
26	interruption	O
27	by	O
28	guanine	O
29	or	O
30	cytosine	O
31	,	O
32	are	O
33	required	O
34	for	O
35	the	O
36	ARS	O
37	activity	O
38	.	O

1	In	O
2	Saccharomyces	O
3	cerevisiae	O
4	,	O
5	PHO85	B
6	encodes	O
7	a	O
8	cyclin	B
9	-	I
10	dependent	I
11	protein	I
12	kinase	I
13	(	O
14	Cdk	B
15	)	O
16	catalytic	O
17	subunit	O
18	with	O
19	multiple	O
20	regulatory	O
21	roles	O
22	thought	O
23	to	O
24	be	O
25	specified	O
26	by	O
27	association	O
28	with	O
29	different	O
30	cyclin	B
31	partners	O
32	(	O
33	Pcls	B
34	).	O

1	Mutants	O
2	with	O
3	mild	O
4	lace	B
5	alleles	I
6	grow	O
7	to	O
8	become	O
9	adults	O
10	with	O
11	multiple	O
12	aberrant	O
13	morphologies	O
14	in	O
15	the	O
16	appendages	O
17	,	O
18	compound	O
19	eye	O
20	,	O
21	and	O
22	bristles	O
23	.	O

1	In	O
2	fact	O
3	,	O
4	SPT	B
5	activity	O
6	in	O
7	the	O
8	fly	O
9	expressing	O
10	epitope	O
11	-	O
12	tagged	O
13	Lace	B
14	was	O
15	absorbed	O
16	by	O
17	epitope	O
18	-	O
19	specific	O
20	antibody	O
21	.	O

1	Mutations	O
2	of	O
3	the	O
4	RET	B
5	gene	I
6	,	O
7	encoding	O
8	a	O
9	receptor	B
10	tyrosine	I
11	kinase	I
12	,	O
13	have	O
14	been	O
15	associated	O
16	with	O
17	the	O
18	inherited	O
19	cancer	O
20	syndromes	O
21	MEN	O
22	2A	O
23	and	O
24	MEN	O
25	2B	O
26	.	O

1	These	O
2	results	O
3	show	O
4	that	O
5	targeting	O
6	of	O
7	Ras	B
8	-	O
9	GAP	B
10	could	O
11	represent	O
12	a	O
13	novel	O
14	anticancer	O
15	approach	O
16	.	O

1	EB	B
2	-	I
3	1	I
4	,	O
5	a	O
6	tyrosine	B
7	kinase	I
8	signal	I
9	transduction	I
10	gene	I
11	,	O
12	is	O
13	transcriptionally	O
14	activated	O
15	in	O
16	the	O
17	t	O
18	(	O
19	1	O
20	;	O
21	19	O
22	)	O
23	subset	O
24	of	O
25	pre	O
26	-	O
27	B	O
28	ALL	O
29	,	O
30	which	O
31	express	O
32	oncoprotein	O
33	E2a	B
34	-	O
35	Pbx1	B
36	.	O

1	Protein	B
2	kinase	I
3	A	I
4	-	I
5	Ialpha	I
6	subunit	O
7	-	O
8	directed	O
9	antisense	O
10	inhibition	O
11	of	O
12	ovarian	O
13	cancer	O
14	cell	O
15	growth	O
16	:	O
17	crosstalk	O
18	with	O
19	tyrosine	B
20	kinase	I
21	signaling	O
22	pathway	O
23	.	O

1	BCL6	B
2	encodes	O
3	a	O
4	POZ	B
5	/	I
6	Zn	I
7	finger	I
8	protein	I
9	,	O
10	a	O
11	structure	O
12	similar	O
13	to	O
14	that	O
15	of	O
16	many	O
17	Drosophila	O
18	developmental	O
19	regulators	O
20	and	O
21	to	O
22	another	O
23	protein	O
24	involved	O
25	in	O
26	a	O
27	human	O
28	hematopoietic	O
29	malignancy	O
30	,	O
31	PLZF	B
32	.	O

1	Beta	B
2	1	I
3	integrin	I
4	-	O
5	and	O
6	proteoglycan	O
7	-	O
8	mediated	O
9	stimulation	O
10	of	O
11	T	O
12	lymphoma	O
13	cell	O
14	adhesion	O
15	and	O
16	mitogen	B
17	-	I
18	activated	I
19	protein	I
20	kinase	I
21	signaling	O
22	by	O
23	thrombospondin	B
24	-	I
25	1	I
26	and	O
27	thrombospondin	B
28	-	I
29	1	I
30	peptides	I
31	.	O

1	Optical	O
2	CD	O
3	,	O
4	and	O
5	spectral	O
6	and	O
7	activity	O
8	analyses	O
9	were	O
10	used	O
11	to	O
12	examine	O
13	reactivity	O
14	of	O
15	HO	B
16	isozymes	I
17	with	O
18	NO	O
19	species	O
20	produced	O
21	by	O
22	NO	O
23	donors	O
24	.	O

1	The	O
2	phosphotransferase	O
3	system	O
4	(	O
5	PTS	O
6	)	O
7	of	O
8	Streptomyces	O
9	coelicolor	O
10	identification	O
11	and	O
12	biochemical	O
13	analysis	O
14	of	O
15	a	O
16	histidine	B
17	phosphocarrier	I
18	protein	I
19	HPr	I
20	encoded	O
21	by	O
22	the	O
23	gene	O
24	ptsH	B
25	.	O

1	Serum	O
2	concentrations	O
3	of	O
4	bone	B
5	specific	I
6	alkaline	I
7	phosphatase	I
8	(	O
9	BALP	B
10	)	O
11	and	O
12	osteocalcin	B
13	(	O
14	bone	B
15	Gla	I
16	protein	I
17	,	O
18	BGP	B
19	),	O
20	urinary	O
21	levels	O
22	of	O
23	pyridinoline	O
24	(	O
25	Pyr	O
26	)	O
27	and	O
28	deoxypyridinoline	O
29	(	O
30	Dpyr	O
31	)	O
32	and	O
33	computed	O
34	tomography	O
35	(	O
36	CT	O
37	)	O
38	measurements	O
39	of	O
40	the	O
41	cross	O
42	-	O
43	sectional	O
44	areas	O
45	of	O
46	the	O
47	vertebrae	O
48	and	O
49	the	O
50	femurs	O
51	,	O
52	the	O
53	apparent	O
54	density	O
55	of	O
56	cancellous	O
57	bone	O
58	in	O
59	the	O
60	vertebrae	O
61	,	O
62	and	O
63	the	O
64	volume	O
65	and	O
66	the	O
67	material	O
68	density	O
69	of	O
70	cortical	O
71	bone	O
72	in	O
73	the	O
74	femurs	O
75	were	O
76	determined	O
77	in	O
78	126	O
79	boys	O
80	and	O
81	143	O
82	girls	O
83	,	O
84	ages	O
85	7	O
86	-	O
87	18	O
88	years	O
89	.	O

1	In	O
2	another	O
3	study	O
4	,	O
5	intravenous	O
6	administration	O
7	of	O
8	devazepide	O
9	,	O
10	a	O
11	specific	O
12	cholecystokinin	B
13	-	I
14	A	I
15	receptor	I
16	antagonist	O
17	,	O
18	at	O
19	a	O
20	dose	O
21	of	O
22	0	O
23	.	O
24	1	O
25	mg	O
26	/	O
27	kg	O
28	/	O
29	hr	O
30	was	O
31	begun	O
32	15	O
33	min	O
34	before	O
35	postprandial	O
36	saline	O
37	intake	O
38	and	O
39	continued	O
40	for	O
41	1	O
42	hr	O
43	.	O

1	This	O
2	cluster	O
3	consisted	O
4	of	O
5	four	O
6	apparently	O
7	unrelated	O
8	ESTs	O
9	and	O
10	two	O
11	genes	O
12	,	O
13	pregnancy	B
14	-	I
15	associated	I
16	plasma	I
17	protein	I
18	-	I
19	A	I
20	(	O
21	PAPP	B
22	-	I
23	A	I
24	)	O
25	and	O
26	a	O
27	novel	O
28	gene	O
29	(	O
30	tentatively	O
31	named	O
32	EST	B
33	-	I
34	YD1	I
35	).	O

1	Prognostic	O
2	value	O
3	of	O
4	a	O
5	treadmill	O
6	exercise	O
7	score	O
8	in	O
9	symptomatic	O
10	patients	O
11	with	O
12	nonspecific	O
13	ST	O
14	-	O
15	T	O
16	abnormalities	O
17	on	O
18	resting	O
19	ECG	O
20	.	O

1	Structural	O
2	changes	O
3	in	O
4	the	O
5	C	O
6	-	O
7	terminus	O
8	of	O
9	Ca2	O
10	+-	O
11	bound	O
12	rat	B
13	S100B	I
14	(	O
15	beta	B
16	beta	I
17	)	O
18	upon	O
19	binding	O
20	to	O
21	a	O
22	peptide	O
23	derived	O
24	from	O
25	the	O
26	C	O
27	-	O
28	terminal	O
29	regulatory	O
30	domain	O
31	of	O
32	p53	B
33	.	O

1	We	O
2	propose	O
3	that	O
4	Gly84	O
5	is	O
6	part	O
7	of	O
8	a	O
9	putative	O
10	"	O
11	oxyanion	O
12	hole	O
13	"	O
14	involved	O
15	in	O
16	the	O
17	stabilization	O
18	of	O
19	the	O
20	transition	O
21	state	O
22	similar	O
23	to	O
24	the	O
25	C	B
26	group	I
27	of	O
28	the	O
29	esterase	B
30	/	O
31	lipase	B
32	family	O
33	.	O

1	The	O
2	solution	O
3	structure	O
4	of	O
5	the	O
6	adduct	O
7	derived	O
8	from	O
9	the	O
10	covalent	O
11	bonding	O
12	of	O
13	the	O
14	fjord	O
15	region	O
16	(+)-(	O
17	11S	O
18	,	O
19	12R	O
20	,	O
21	13R	O
22	,	O
23	14S	O
24	)	O
25	stereoisomer	O
26	of	O
27	anti	O
28	-	O
29	11	O
30	,	O
31	12	O
32	-	O
33	dihydroxy	O
34	-	O
35	13	O
36	,	O
37	14	O
38	-	O
39	epoxy	O
40	-	O
41	11	O
42	,	O
43	12	O
44	,	O
45	13	O
46	,	O
47	14	O
48	-	O
49	tetrahydrobenzo	O
50	[	O
51	g	O
52	]	O
53	chrysene	O
54	,	O
55	(+)-	O
56	anti	O
57	-	O
58	B	O
59	[	O
60	g	O
61	]	O
62	CDE	O
63	,	O
64	to	O
65	the	O
66	exocyclic	O
67	N	O
68	(	O
69	6	O
70	)	O
71	amino	O
72	group	O
73	of	O
74	the	O
75	adenine	O
76	residue	O
77	dA6	O
78	,	O
79	(	O
80	designated	O
81	(+)-	O
82	trans	O
83	-	O
84	anti	O
85	-(	O
86	B	O
87	[	O
88	g	O
89	]	O
90	C	O
91	)	O
92	dA6	O
93	),	O
94	positioned	O
95	opposite	O
96	a	O
97	thymine	O
98	residue	O
99	dT17	O
100	in	O
101	the	O
102	DNA	O
103	sequence	O
104	context	O
105	d	O
106	(	O
107	C1	O
108	-	O
109	T2	O
110	-	O
111	C3	O
112	-	O
113	T4	O
114	-	O
115	C5	O
116	-(	O
117	B	O
118	[	O
119	g	O
120	]	O
121	C	O
122	)	O
123	A6	O
124	-	O
125	C7	O
126	-	O
127	T8	O
128	-	O
129	T9	O
130	-	O
131	C10	O
132	-	O
133	C11	O
134	).	O
135	d	O
136	(	O
137	G12	O
138	-	O
139	G13	O
140	-	O
141	A14	O
142	-	O
143	A15	O
144	-	O
145	G16	O
146	-	O
147	T17	O
148	-	O
149	G18	O
150	-	O
151	A19	O
152	-	O
153	G20	O
154	++	O
155	+-	O
156	A21	O
157	-	O
158	G22	O
159	)	O
160	(	O
161	designated	O
162	(	O
163	B	O
164	[	O
165	g	O
166	]	O
167	C	O
168	)	O
169	dA	O
170	.	O
171	dT	O
172	11	O
173	-	O
174	mer	O
175	duplex	O
176	),	O
177	has	O
178	been	O
179	studied	O
180	using	O
181	structural	O
182	information	O
183	derived	O
184	from	O
185	NMR	O
186	data	O
187	in	O
188	combination	O
189	with	O
190	molecular	O
191	dynamics	O
192	(	O
193	MD	O
194	)	O
195	calculations	O
196	.	O

1	Since	O
2	sildenafil	O
3	came	O
4	on	O
5	the	O
6	market	O
7	,	O
8	it	O
9	seems	O
10	that	O
11	the	O
12	place	O
13	of	O
14	MUSE	O
15	is	O
16	reduced	O
17	because	O
18	comparative	O
19	studies	O
20	give	O
21	better	O
22	results	O
23	for	O
24	sildenafil	O
25	than	O
26	MUSE	O
27	(	O
28	70	O
29	%	O
30	vs	O
31	40	O
32	%)	O
33	and	O
34	of	O
35	course	O
36	with	O
37	a	O
38	better	O
39	acceptance	O
40	.	O

1	Serum	O
2	antibodies	O
3	were	O
4	detected	O
5	in	O
6	at	O
7	least	O
8	95	O
9	%	O
10	of	O
11	the	O
12	infected	O
13	guinea	O
14	pigs	O
15	between	O
16	4	O
17	-	O
18	30	O
19	WPI	O
20	and	O
21	rats	O
22	between	O
23	3	O
24	-	O
25	16	O
26	WPI	O
27	.	O

1	During	O
2	both	O
3	encephalopathy	O
4	episodes	O
5	,	O
6	CSF	O
7	protein	O
8	and	O
9	immunoglobulin	B
10	G	I
11	(	O
12	IgG	B
13	)	O
14	levels	O
15	were	O
16	elevated	O
17	without	O
18	an	O
19	increased	O
20	IgG	B
21	index	O
22	or	O
23	IgG	B
24	synthesis	O
25	rate	O
26	.	O

1	CONCLUSIONS	O
2	:	O
3	These	O
4	results	O
5	show	O
6	that	O
7	once	O
8	daily	O
9	oral	O
10	valganciclovir	O
11	can	O
12	produce	O
13	exposures	O
14	of	O
15	ganciclovir	O
16	(	O
17	AUC24	O
18	)	O
19	exceeding	O
20	those	O
21	attained	O
22	using	O
23	intravenous	O
24	ganciclovir	O
25	10	O
26	mg	O
27	/	O
28	kg	O
29	.	O

1	Except	O
2	for	O
3	nonperfusion	O
4	of	O
5	neurosensory	O
6	retinal	O
7	vessels	O
8	at	O
9	a	O
10	light	O
11	dose	O
12	of	O
13	150	O
14	J	O
15	/	O
16	cm2	O
17	,	O
18	no	O
19	other	O
20	adverse	O
21	events	O
22	were	O
23	of	O
24	concern	O
25	.	O

1	Except	O
2	for	O
3	nonperfusion	O
4	of	O
5	neurosensory	O
6	retinal	O
7	vessels	O
8	at	O
9	a	O
10	light	O
11	dose	O
12	of	O
13	150	O
14	J	O
15	/	O
16	cm2	O
17	,	O
18	no	O
19	other	O
20	adverse	O
21	events	O
22	were	O
23	of	O
24	concern	O
25	.	O

1	The	O
2	healing	O
3	rate	O
4	in	O
5	HIV	O
6	-	O
7	positive	O
8	patients	O
9	was	O
10	66	O
11	percent	O
12	after	O
13	14	O
14	weeks	O
15	and	O
16	100	O
17	percent	O
18	after	O
19	32	O
20	weeks	O
21	;	O
22	the	O
23	corresponding	O
24	figures	O
25	for	O
26	patients	O
27	with	O
28	acquired	O
29	immunodeficiency	O
30	syndrome	O
31	were	O
32	0	O
33	and	O
34	50	O
35	percent	O
36	.	O

1	The	O
2	P	B
3	mRNA	I
4	also	O
5	contains	O
6	a	O
7	third	O
8	ORF	O
9	for	O
10	the	O
11	V	B
12	protein	I
13	,	O
14	although	O
15	it	O
16	is	O
17	unclear	O
18	how	O
19	or	O
20	whether	O
21	this	O
22	ORF	O
23	is	O
24	accessed	O
25	.	O

1	A	O
2	genetic	O
3	screen	O
4	in	O
5	yeast	O
6	has	O
7	allowed	O
8	us	O
9	to	O
10	identify	O
11	a	O
12	novel	O
13	transcriptional	O
14	factor	O
15	binding	O
16	to	O
17	the	O
18	GlRE	O
19	,	O
20	i	O
21	.	O
22	e	O
23	.	O
24	the	O
25	chicken	B
26	ovalbumin	I
27	upstream	I
28	promoter	I
29	-	I
30	transcription	I
31	factor	I
32	II	I
33	(	O
34	COUP	B
35	-	I
36	TFII	I
37	).	O

1	We	O
2	have	O
3	cloned	O
4	the	O
5	single	O
6	-	O
7	copy	O
8	gene	O
9	for	O
10	the	O
11	trans	B
12	-	I
13	spliceosomal	I
14	U5	I
15	snRNA	I
16	from	O
17	the	O
18	trypanosomatid	O
19	species	O
20	Leptomonas	O
21	seymouri	O
22	,	O
23	using	O
24	U5	B
25	RNA	I
26	affinity	O
27	selection	O
28	and	O
29	cDNA	O
30	cloning	O
31	.	O

1	The	O
2	MMPI	O
3	-	O
4	A	O
5	(	O
6	Butcher	O
7	et	O
8	al	O
9	.,	O
10	1992	O
11	),	O
12	like	O
13	the	O
14	older	O
15	MMPI	O
16	(	O
17	Hathaway	O
18	&	O
19	McKinley	O
20	,	O
21	1983	O
22	),	O
23	distinguishes	O
24	between	O
25	anorexia	O
26	and	O
27	bulimia	O
28	.	O

1	On	O
2	the	O
3	other	O
4	hand	O
5	,	O
6	phosphatidyl	O
7	inositol	O
8	4	O
9	,	O
10	5	O
11	bisphosphate	O
12	(	O
13	PIP2	O
14	)	O
15	hydrolysis	O
16	requires	O
17	direct	O
18	phosphorylation	O
19	at	O
20	tyrosine	O
21	residue	O
22	of	O
23	the	O
24	PLC	B
25	-	I
26	gamma1	I
27	isozyme	I
28	.	O

1	A	O
2	G22V	B
3	mutant	I
4	of	O
5	M	B
6	-	I
7	Ras	I
8	was	O
9	constitutively	O
10	active	O
11	and	O
12	its	O
13	expression	O
14	in	O
15	an	O
16	interleukin	B
17	-	I
18	3	I
19	(	O
20	IL	B
21	-	I
22	3	I
23	)-	O
24	dependent	O
25	mast	O
26	cell	O
27	/	O
28	megakaryocyte	O
29	cell	O
30	line	O
31	resulted	O
32	in	O
33	increased	O
34	survival	O
35	in	O
36	the	O
37	absence	O
38	of	O
39	IL	B
40	-	I
41	3	I
42	,	O
43	increased	O
44	growth	O
45	in	O
46	IL	B
47	-	I
48	4	I
49	,	O
50	and	O
51	,	O
52	at	O
53	high	O
54	expression	O
55	levels	O
56	,	O
57	in	O
58	factor	O
59	-	O
60	independent	O
61	growth	O
62	.	O

1	Mammalian	B
2	M	I
3	-	I
4	Ras	I
5	and	O
6	a	O
7	Caenorhabditis	O
8	elegans	O
9	orthologue	O
10	exhibit	O
11	conserved	O
12	structural	O
13	features	O
14	,	O
15	and	O
16	these	O
17	are	O
18	likely	O
19	to	O
20	mediate	O
21	activation	O
22	of	O
23	distinctive	O
24	signaling	O
25	paths	O
26	that	O
27	function	O
28	in	O
29	parallel	O
30	to	O
31	those	O
32	downstream	O
33	of	O
34	p21	B
35	Ras	I
36	.	O

1	Taken	O
2	together	O
3	,	O
4	our	O
5	data	O
6	suggest	O
7	that	O
8	PecS	B
9	attenuates	O
10	pelD	B
11	and	O
12	pelE	B
13	expression	O
14	rather	O
15	than	O
16	acting	O
17	as	O
18	a	O
19	true	O
20	repressor	O
21	like	O
22	KdgR	B
23	.	O

1	These	O
2	observations	O
3	establish	O
4	that	O
5	RsmC	B
6	negatively	O
7	regulates	O
8	rsmB	B
9	transcription	O
10	but	O
11	positively	O
12	affects	O
13	RsmA	B
14	production	O
15	.	O

1	All	O
2	were	O
3	experienced	O
4	hearing	O
5	aid	O
6	users	O
7	who	O
8	wore	O
9	linear	O
10	Class	O
11	D	O
12	instruments	O
13	with	O
14	input	O
15	compression	O
16	limiting	O
17	at	O
18	the	O
19	time	O
20	of	O
21	their	O
22	enrollment	O
23	in	O
24	this	O
25	study	O
26	.	O

1	SCOB	O
2	testing	O
3	of	O
4	food	O
5	-	O
6	restricted	O
7	animals	O
8	,	O
9	using	O
10	a	O
11	multiple	O
12	fixed	O
13	ratio	O
14	(	O
15	FR	O
16	)/	O
17	fixed	O
18	interval	O
19	(	O
20	FI	O
21	)	O
22	schedule	O
23	(	O
24	FR20	O
25	:	O
26	FI120	O
27	),	O
28	was	O
29	conducted	O
30	prior	O
31	to	O
32	each	O
33	exposure	O
34	to	O
35	maintain	O
36	the	O
37	operant	O
38	behavior	O
39	;	O
40	the	O
41	data	O
42	from	O
43	Weeks	O
44	-	O
45	1	O
46	,	O
47	4	O
48	,	O
49	8	O
50	,	O
51	and	O
52	13	O
53	were	O
54	evaluated	O
55	for	O
56	evidence	O
57	of	O
58	neurotoxicity	O
59	.	O

1	Ribonuclease	O
2	protection	O
3	assays	O
4	revealed	O
5	that	O
6	hmg1	B
7	and	O
8	hmg2	B
9	are	O
10	differentially	O
11	expressed	O
12	in	O
13	a	O
14	developmentally	O
15	-	O
16	and	O
17	spatially	O
18	-	O
19	modulated	O
20	manner	O
21	during	O
22	morphogenesis	O
23	of	O
24	specialized	O
25	terpenoid	O
26	-	O
27	containing	O
28	pigment	O
29	glands	O
30	in	O
31	embryos	O
32	.	O

1	Differential	O
2	expression	O
3	was	O
4	confirmed	O
5	by	O
6	Northern	O
7	blot	O
8	analysis	O
9	employing	O
10	multiple	O
11	normal	O
12	and	O
13	tumor	O
14	cell	O
15	lines	O
16	.	O

1	Inactivation	O
2	of	O
3	the	O
4	Neurospora	B
5	crassa	I
6	mitochondrial	I
7	outer	I
8	membrane	I
9	protein	I
10	TOM70	I
11	by	O
12	repeat	O
13	-	O
14	induced	O
15	point	O
16	mutation	O
17	(	O
18	RIP	O
19	)	O
20	causes	O
21	defects	O
22	in	O
23	mitochondrial	O
24	protein	O
25	import	O
26	and	O
27	morphology	O
28	.	O

1	Several	O
2	genes	O
3	or	O
4	transcriptional	O
5	units	O
6	were	O
7	identified	O
8	,	O
9	including	O
10	the	O
11	3	O
12	'	O
13	end	O
14	of	O
15	ribosomal	B
16	s6	I
17	kinase	I
18	(	O
19	Rsk3	B
20	);	O
21	two	O
22	apparently	O
23	intronless	O
24	and	O
25	ORF	O
26	-	O
27	less	O
28	genes	O
29	;	O
30	and	O
31	Gpr31	B
32	,	O
33	an	O
34	intronless	O
35	,	O
36	putative	O
37	G	B
38	-	I
39	protein	I
40	coupled	I
41	receptor	I
42	.	O

1	The	O
2	results	O
3	suggest	O
4	that	O
5	GATA	B
6	-	I
7	5	I
8	may	O
9	have	O
10	specific	O
11	downstream	O
12	targets	O
13	and	O
14	that	O
15	GATA	B
16	-	I
17	4	I
18	,	I
19	-	I
20	5	I
21	,	I
22	and	I
23	-	I
24	6	I
25	can	O
26	only	O
27	partially	O
28	substitute	O
29	for	O
30	each	O
31	other	O
32	in	O
33	cardiogenesis	O
34	.	O

1	This	O
2	study	O
3	was	O
4	designed	O
5	to	O
6	compare	O
7	the	O
8	efficacy	O
9	of	O
10	efegatran	O
11	plus	O
12	streptokinase	B
13	versus	O
14	heparin	O
15	plus	O
16	accelerated	O
17	tissue	B
18	plasminogen	I
19	activator	I
20	(	O
21	TPA	B
22	)	O
23	in	O
24	coronary	O
25	reperfusion	O
26	in	O
27	acute	O
28	MI	O
29	.	O

1	Recently	O
2	,	O
3	cell	O
4	-	O
5	surface	O
6	TRAIL	B
7	has	O
8	been	O
9	shown	O
10	to	O
11	be	O
12	expressed	O
13	by	O
14	activated	O
15	human	O
16	and	O
17	mouse	O
18	T	O
19	lymphocytes	O
20	,	O
21	raising	O
22	the	O
23	possibility	O
24	that	O
25	TRAIL	B
26	might	O
27	be	O
28	involved	O
29	in	O
30	T	O
31	cell	O
32	-	O
33	mediated	O
34	cytotoxicity	O
35	and	O
36	/	O
37	or	O
38	immune	O
39	regulation	O
40	.	O

1	A	O
2	panel	O
3	of	O
4	pharmacologic	O
5	inhibitors	O
6	was	O
7	used	O
8	to	O
9	investigate	O
10	the	O
11	signal	O
12	transduction	O
13	pathways	O
14	involved	O
15	in	O
16	TRAIL	B
17	gene	I
18	induction	O
19	following	O
20	T	O
21	lymphocyte	O
22	activation	O
23	.	O

1	From	O
2	February	O
3	1991	O
4	to	O
5	August	O
6	1997	O
7	,	O
8	124	O
9	patients	O
10	with	O
11	endometrial	O
12	carcinoma	O
13	were	O
14	treated	O
15	postoperatively	O
16	with	O
17	high	O
18	-	O
19	dose	O
20	-	O
21	rate	O
22	vaginal	O
23	vault	O
24	brachytherapy	O
25	as	O
26	the	O
27	only	O
28	adjuvant	O
29	treatment	O
30	.	O

1	Twelve	O
2	patients	O
3	had	O
4	stage	O
5	IBG3	O
6	,	O
7	14	O
8	had	O
9	ICG1	O
10	,	O
11	9	O
12	had	O
13	ICG2	O
14	,	O
15	and	O
16	3	O
17	had	O
18	ICG3	O
19	disease	O
20	.	O

1	Defective	O
2	provirus	O
3	genomes	O
4	of	O
5	human	O
6	T	O
7	-	O
8	cell	O
9	leukemia	O
10	virus	O
11	type	O
12	I	O
13	are	O
14	frequently	O
15	detected	O
16	in	O
17	lymphocytes	O
18	from	O
19	infected	O
20	individuals	O
21	and	O
22	in	O
23	infected	O
24	cell	O
25	lines	O
26	.	O

1	A	O
2	total	O
3	of	O
4	174	O
5	primer	O
6	pairs	O
7	gave	O
8	interpretable	O
9	banding	O
10	patterns	O
11	,	O
12	137	O
13	(	O
14	79	O
15	%)	O
16	of	O
17	which	O
18	revealed	O
19	at	O
20	least	O
21	two	O
22	alleles	O
23	on	O
24	native	O
25	polyacrylamide	O
26	gels	O
27	.	O

1	A	O
2	population	O
3	pharmacokinetic	O
4	study	O
5	of	O
6	cyclosporin	O
7	in	O
8	organ	O
9	transplant	O
10	patients	O
11	,	O
12	including	O
13	elderly	O
14	allograft	O
15	recipients	O
16	up	O
17	to	O
18	75	O
19	years	O
20	of	O
21	age	O
22	,	O
23	did	O
24	not	O
25	identify	O
26	age	O
27	as	O
28	a	O
29	covariable	O
30	influencing	O
31	cyclosporin	O
32	pharmacokinetics	O
33	.	O

1	Immunofluoresence	O
2	data	O
3	indicated	O
4	that	O
5	once	O
6	bound	O
7	to	O
8	the	O
9	mutant	O
10	receptor	O
11	,	O
12	fluorescent	O
13	-	O
14	labeled	O
15	RAP	B
16	co	O
17	-	O
18	localized	O
19	with	O
20	markers	O
21	of	O
22	the	O
23	endosomal	O
24	pathway	O
25	,	O
26	whereas	O
27	,	O
28	in	O
29	cells	O
30	expressing	O
31	the	O
32	wild	O
33	-	O
34	type	O
35	receptor	O
36	,	O
37	RAP	B
38	fluorescence	O
39	co	O
40	-	O
41	localized	O
42	with	O
43	lysosomal	O
44	markers	O
45	.	O

1	Interleukin	B
2	-	I
3	12	I
4	(	O
5	IL	B
6	-	I
7	12	I
8	)	O
9	is	O
10	a	O
11	cytokine	O
12	produced	O
13	by	O
14	peripheral	O
15	blood	O
16	mononuclear	O
17	cells	O
18	(	O
19	PBMC	O
20	)	O
21	that	O
22	causes	O
23	interferon	B
24	-	I
25	gamma	I
26	(	O
27	IFN	B
28	-	I
29	gamma	I
30	)	O
31	production	O
32	and	O
33	enhancement	O
34	of	O
35	cell	O
36	-	O
37	mediated	O
38	cytotoxicity	O
39	.	O

1	IL	B
2	-	I
3	12	I
4	production	O
5	was	O
6	correlated	O
7	with	O
8	C3a	O
9	concentration	O
10	measured	O
11	at	O
12	the	O
13	outlet	O
14	of	O
15	hemodialyzer	O
16	after	O
17	15	O
18	min	O
19	of	O
20	dialysis	O
21	(	O
22	r	O
23	=	O
24	0	O
25	.	O
26	69	O
27	,	O
28	P	O
29	<	O
30	0	O
31	.	O
32	01	O
33	).	O

1	In	O
2	HeLa	O
3	cells	O
4	,	O
5	the	O
6	JNKK2	B
7	-	O
8	JNK1	B
9	fusion	O
10	protein	O
11	showed	O
12	significant	O
13	JNK	B
14	activity	O
15	,	O
16	which	O
17	was	O
18	comparable	O
19	with	O
20	that	O
21	of	O
22	JNK1	B
23	activated	O
24	by	O
25	many	O
26	stimuli	O
27	and	O
28	activators	O
29	,	O
30	including	O
31	EGF	B
32	,	O
33	TNF	B
34	-	I
35	alpha	I
36	,	O
37	anisomycin	O
38	,	O
39	UV	O
40	irradiation	O
41	,	O
42	MEKK1	B
43	,	O
44	and	O
45	small	B
46	GTP	I
47	binding	I
48	proteins	I
49	Rac1	I
50	and	O
51	Cdc42Hs	B
52	.	O

1	J	O
2	.	O

1	Our	O
2	results	O
3	implicate	O
4	TGF	B
5	-	I
6	beta	I
7	RII	I
8	as	O
9	a	O
10	direct	O
11	target	O
12	of	O
13	EWS	B
14	-	O
15	FLI1	B
16	.	O

1	The	O
2	reduction	O
3	in	O
4	saturated	O
5	fatty	O
6	acids	O
7	intake	O
8	led	O
9	to	O
10	modest	O
11	(	O
12	but	O
13	in	O
14	group	O
15	1	O
16	significant	O
17	)	O
18	0	O
19	.	O
20	15	O
21	mmol	O
22	/	O
23	l	O
24	(	O
25	2	O
26	.	O
27	5	O
28	%)	O
29	reduction	O
30	in	O
31	total	O
32	serum	O
33	cholesterol	O
34	level	O
35	.	O

1	Secondly	O
2	,	O
3	an	O
4	ethanol	O
5	repression	O
6	autoregulation	O
7	(	O
8	ERA	O
9	)/	O
10	twelve	O
11	-	O
12	fold	O
13	TA	O
14	repeat	O
15	(	O
16	TAB	O
17	)	O
18	repressor	O
19	element	O
20	was	O
21	identified	O
22	within	O
23	the	O
24	promoter	O
25	region	O
26	of	O
27	the	O
28	GLK1	B
29	gene	I
30	.	O

1	A	O
2	crucial	O
3	transcription	O
4	factor	O
5	in	O
6	this	O
7	process	O
8	is	O
9	STAT6	B
10	,	O
11	which	O
12	binds	O
13	to	O
14	a	O
15	specific	O
16	DNA	O
17	element	O
18	upon	O
19	cytokine	O
20	activation	O
21	.	O

1	CONCLUSIONS	O
2	:	O
3	Congenital	O
4	horizontal	O
5	tarsal	O
6	kink	O
7	is	O
8	rare	O
9	and	O
10	its	O
11	cause	O
12	is	O
13	unknown	O
14	.	O

1	A	O
2	local	O
3	,	O
4	high	O
5	-	O
6	density	O
7	,	O
8	single	O
9	-	O
10	nucleotide	O
11	polymorphism	O
12	map	O
13	used	O
14	to	O
15	clone	O
16	Caenorhabditis	B
17	elegans	I
18	cdf	I
19	-	I
20	1	I
21	.	O

1	This	O
2	machinery	O
3	involves	O
4	a	O
5	secondary	O
6	structure	O
7	,	O
8	SECIS	O
9	element	O
10	,	O
11	in	O
12	the	O
13	selenoprotein	B
14	-	O
15	encoding	O
16	mRNA	O
17	,	O
18	directing	O
19	selenocysteine	O
20	insertion	O
21	at	O
22	the	O
23	position	O
24	of	O
25	an	O
26	opal	O
27	(	O
28	UGA	O
29	)	O
30	codon	O
31	,	O
32	normally	O
33	conferring	O
34	termination	O
35	of	O
36	translation	O
37	.	O

1	High	O
2	-	O
3	level	O
4	expression	O
5	in	O
6	Escherichia	O
7	coli	O
8	of	O
9	selenocysteine	O
10	-	O
11	containing	O
12	rat	B
13	thioredoxin	I
14	reductase	I
15	utilizing	O
16	gene	O
17	fusions	O
18	with	O
19	engineered	O
20	bacterial	O
21	-	O
22	type	O
23	SECIS	O
24	elements	O
25	and	O
26	co	O
27	-	O
28	expression	O
29	with	O
30	the	O
31	selA	B
32	,	O
33	selB	B
34	and	O
35	selC	B
36	genes	I
37	.	O

1	In	O
2	Wnt	B
3	signaling	O
4	,	O
5	beta	B
6	-	I
7	catenin	I
8	and	O
9	plakoglobin	B
10	transduce	O
11	signals	O
12	to	O
13	the	O
14	nucleus	O
15	through	O
16	interactions	O
17	with	O
18	TCF	B
19	-	I
20	type	I
21	transcription	I
22	factors	I
23	.	O

1	Assembly	O
2	of	O
3	a	O
4	complex	O
5	between	O
6	FAK	B
7	and	O
8	Src	B
9	kinases	I
10	may	O
11	serve	O
12	to	O
13	regulate	O
14	the	O
15	subcellular	O
16	localization	O
17	and	O
18	the	O
19	enzymatic	O
20	activity	O
21	of	O
22	members	O
23	of	O
24	the	O
25	Src	B
26	family	I
27	of	O
28	kinases	O
29	.	O

1	For	O
2	EPV	O
3	3	O
4	,	O
5	10	O
6	,	O
7	or	O
8	40	O
9	,	O
10	the	O
11	bias	O
12	exceeded	O
13	25	O
14	%	O
15	for	O
16	7	O
17	,	O
18	3	O
19	,	O
20	and	O
21	1	O
22	in	O
23	the	O
24	8	O
25	-	O
26	predictor	O
27	model	O
28	respectively	O
29	,	O
30	when	O
31	a	O
32	conventional	O
33	selection	O
34	criterion	O
35	was	O
36	used	O
37	(	O
38	alpha	O
39	=	O
40	0	O
41	.	O
42	05	O
43	).	O

1	Our	O
2	study	O
3	also	O
4	demonstrated	O
5	significant	O
6	increases	O
7	in	O
8	the	O
9	number	O
10	of	O
11	larger	O
12	myelinated	O
13	fibers	O
14	crossing	O
15	the	O
16	repair	O
17	site	O
18	in	O
19	comparison	O
20	with	O
21	the	O
22	neonatal	O
23	and	O
24	adult	O
25	groups	O
26	(	O
27	p	O
28	<	O
29	0	O
30	.	O
31	04	O
32	).	O

1	Me	O
2	(	O
3	2	O
4	)	O
5	SO	O
6	-	O
7	induced	O
8	neuronal	O
9	differentiation	O
10	of	O
11	N1E	O
12	-	O
13	115	O
14	neuroblastoma	O
15	cells	O
16	increased	O
17	both	O
18	the	O
19	expression	O
20	of	O
21	the	O
22	endogenous	B
23	Ntr	I
24	-	I
25	1	I
26	gene	I
27	and	O
28	reporter	O
29	genes	O
30	driven	O
31	by	O
32	NTR	B
33	-	I
34	1	I
35	promoter	I
36	sequences	I
37	by	O
38	3	O
39	-	O
40	4	O
41	-	O
42	fold	O
43	.	O

1	Cortical	O
2	dysplasias	O
3	,	O
4	genetics	O
5	,	O
6	and	O
7	epileptogenesis	O
8	.	O

1	In	O
2	the	O
3	work	O
4	reported	O
5	here	O
6	,	O
7	we	O
8	used	O
9	peptide	O
10	mapping	O
11	,	O
12	mass	O
13	spectrometry	O
14	,	O
15	and	O
16	site	O
17	-	O
18	directed	O
19	mutagenesis	O
20	to	O
21	identify	O
22	two	O
23	sets	O
24	of	O
25	pAP	B
26	phosphorylation	O
27	sites	O
28	.	O

1	Both	O
2	HERV	O
3	-	O
4	K	O
5	type	O
6	1	O
7	and	O
8	2	O
9	clones	O
10	were	O
11	isolated	O
12	.	O

1	Duch	O
2	,	O
3	and	O
4	F	O
5	.	O

1	At	O
2	all	O
3	time	O
4	-	O
5	points	O
6	,	O
7	most	O
8	patients	O
9	(>/=	O
10	87	O
11	%)	O
12	were	O
13	receiving	O
14	irbesartan	O
15	/	O
16	HCTZ	O
17	alone	O
18	.	O

1	Modification	O
2	of	O
3	dopamine	B
4	D2	I
5	receptor	I
6	activity	O
7	by	O
8	pergolide	O
9	in	O
10	Parkinson	O
11	'	O
12	s	O
13	disease	O
14	:	O
15	an	O
16	in	O
17	vivo	O
18	study	O
19	by	O
20	PET	O
21	.	O

1	High	O
2	-	O
3	affinity	O
4	binding	O
5	sites	O
6	for	O
7	both	O
8	GR	B
9	and	O
10	AP	B
11	-	I
12	1	I
13	nucleoproteins	I
14	were	O
15	identified	O
16	at	O
17	adjacent	O
18	elements	O
19	within	O
20	the	O
21	nGRE	O
22	.	O

1	When	O
2	the	O
3	73	O
4	-	O
5	bp	O
6	fragment	O
7	was	O
8	fused	O
9	to	O
10	an	O
11	alpha1	B
12	-	I
13	globin	I
14	promoter	O
15	-	O
16	CAT	B
17	construct	O
18	and	O
19	cotransfected	O
20	with	O
21	CCAAT	B
22	transcription	I
23	factor	I
24	1	I
25	(	O
26	CTF1	B
27	)/	O
28	NF1	B
29	into	O
30	Drosophila	O
31	Schneider	O
32	SL2	O
33	insect	O
34	cells	O
35	(	O
36	which	O
37	lack	O
38	NF1	B
39	-	I
40	like	I
41	proteins	I
42	)	O
43	trans	O
44	-	O
45	activation	O
46	of	O
47	CAT	B
48	activity	O
49	was	O
50	observed	O
51	.	O

1	Western	O
2	blot	O
3	analysis	O
4	showed	O
5	a	O
6	rapid	O
7	corresponding	O
8	increase	O
9	in	O
10	p21WAF1	B
11	/	O
12	CIP1	B
13	protein	O
14	,	O
15	whereas	O
16	protein	O
17	levels	O
18	of	O
19	another	O
20	member	O
21	of	O
22	the	O
23	cyclin	B
24	-	I
25	dependent	I
26	kinase	I
27	inhibitor	I
28	family	I
29	,	O
30	p27kip1	B
31	,	O
32	were	O
33	unchanged	O
34	.	O

1	Aggregation	O
2	of	O
3	vHnf1	B
4	-	O
5	deficient	O
6	embryonic	O
7	stem	O
8	cells	O
9	with	O
10	wild	O
11	-	O
12	type	O
13	tetraploid	O
14	embryos	O
15	,	O
16	which	O
17	contribute	O
18	exclusively	O
19	to	O
20	extraembryonic	O
21	tissues	O
22	,	O
23	rescues	O
24	periimplantation	O
25	lethality	O
26	and	O
27	allows	O
28	development	O
29	to	O
30	progress	O
31	to	O
32	early	O
33	organogenesis	O
34	.	O

1	nos	B
2	-	I
3	1	I
4	and	O
5	nos	B
6	-	I
7	2	I
8	,	O
9	two	O
10	genes	O
11	related	O
12	to	O
13	Drosophila	B
14	nanos	I
15	,	O
16	regulate	O
17	primordial	O
18	germ	O
19	cell	O
20	development	O
21	and	O
22	survival	O
23	in	O
24	Caenorhabditis	O
25	elegans	O
26	.	O

1	Although	O
2	upstream	O
3	regulators	O
4	of	O
5	Tec	B
6	family	I
7	kinases	I
8	are	O
9	relatively	O
10	well	O
11	characterized	O
12	,	O
13	little	O
14	is	O
15	known	O
16	of	O
17	the	O
18	downstream	O
19	effectors	O
20	of	O
21	these	O
22	enzymes	O
23	.	O

1	Efficient	O
2	phosphorylation	O
3	of	O
4	BRDG1	B
5	by	O
6	Tec	B
7	required	O
8	the	O
9	PH	B
10	and	O
11	SH2	B
12	domains	I
13	as	O
14	well	O
15	as	O
16	the	O
17	kinase	O
18	domain	O
19	of	O
20	the	O
21	latter	O
22	.	O

1	CONCLUSION	O
2	:	O
3	These	O
4	findings	O
5	imply	O
6	that	O
7	eotaxin	O
8	either	O
9	is	O
10	mechanistically	O
11	involved	O
12	in	O
13	acute	O
14	asthma	O
15	or	O
16	serves	O
17	as	O
18	a	O
19	biomarker	O
20	for	O
21	activity	O
22	of	O
23	the	O
24	CCR3	B
25	receptor	I
26	ligand	I
27	system	O
28	,	O
29	which	O
30	is	O
31	functionally	O
32	linked	O
33	to	O
34	asthma	O
35	.	O

1	The	O
2	expression	O
3	analysis	O
4	of	O
5	the	O
6	KlHIS4	B
7	gene	I
8	under	O
9	phosphate	O
10	starvation	O
11	or	O
12	high	O
13	adenine	O
14	supply	O
15	shows	O
16	that	O
17	factors	O
18	,	O
19	such	O
20	as	O
21	Bas1	B
22	or	O
23	Bas2	B
24	,	O
25	involved	O
26	in	O
27	the	O
28	basal	O
29	control	O
30	may	O
31	also	O
32	operate	O
33	in	O
34	a	O
35	different	O
36	way	O
37	in	O
38	K	O
39	.	O
40	lactis	O
41	.	O

1	These	O
2	thyroid	O
3	hormone	O
4	changes	O
5	may	O
6	be	O
7	mediated	O
8	in	O
9	part	O
10	by	O
11	cytokines	O
12	or	O
13	other	O
14	inflammatory	O
15	mediators	O
16	,	O
17	acting	O
18	at	O
19	the	O
20	level	O
21	of	O
22	the	O
23	hypothalamus	O
24	and	O
25	pituitary	O
26	gland	O
27	,	O
28	the	O
29	thyroid	O
30	gland	O
31	,	O
32	and	O
33	the	O
34	hepatic	B
35	deiodinase	I
36	system	O
37	.	O

1	ESS	O
2	type	O
3	1	O
4	,	O
5	with	O
6	FT3	O
7	low	O
8	and	O
9	FT4	O
10	and	O
11	TSH	B
12	normal	O
13	,	O
14	is	O
15	the	O
16	most	O
17	frequent	O
18	form	O
19	.	O

1	METHODS	O
2	:	O
3	We	O
4	studied	O
5	20	O
6	symptomatic	O
7	patients	O
8	with	O
9	HOCM	O
10	(	O
11	12	O
12	men	O
13	),	O
14	mean	O
15	age	O
16	52	O
17	+/-	O
18	17	O
19	years	O
20	,	O
21	before	O
22	and	O
23	after	O
24	septal	O
25	reduction	O
26	using	O
27	echocardiography	O
28	and	O
29	electrocardiogram	O
30	(	O
31	ECG	O
32	).	O

1	Paleoceanographic	O
2	data	O
3	from	O
4	the	O
5	Laurentian	O
6	Fan	O
7	,	O
8	used	O
9	as	O
10	a	O
11	proxy	O
12	for	O
13	sea	O
14	surface	O
15	temperature	O
16	,	O
17	reveal	O
18	that	O
19	surface	O
20	slope	O
21	waters	O
22	north	O
23	of	O
24	the	O
25	Gulf	O
26	Stream	O
27	experienced	O
28	warming	O
29	during	O
30	the	O
31	Little	O
32	Ice	O
33	Age	O
34	of	O
35	the	O
36	16th	O
37	to	O
38	19th	O
39	centuries	O
40	and	O
41	support	O
42	the	O
43	notion	O
44	of	O
45	an	O
46	NAO	O
47	-	O
48	driven	O
49	coupled	O
50	system	O
51	.	O

1	This	O
2	effect	O
3	required	O
4	(	O
5	i	O
6	)	O
7	IR	B
8	activation	O
9	since	O
10	it	O
11	was	O
12	abrogated	O
13	by	O
14	IR	B
15	mutation	O
16	at	O
17	tyrosines	O
18	1162	O
19	and	O
20	1163	O
21	and	O
22	(	O
23	ii	O
24	)	O
25	NF	B
26	-	I
27	kappaB	I
28	activation	O
29	since	O
30	it	O
31	was	O
32	abolished	O
33	by	O
34	overexpression	O
35	of	O
36	dominant	B
37	-	I
38	negative	I
39	IkappaB	I
40	-	I
41	alpha	I
42	(	I
43	A32	I
44	/	I
45	36	I
46	)	I
47	and	O
48	mimicked	O
49	by	O
50	overexpression	O
51	of	O
52	the	O
53	NF	B
54	-	I
55	kappaB	I
56	c	I
57	-	I
58	Rel	I
59	subunit	I
60	.	O

1	The	O
2	factor	O
3	designated	O
4	B	O
5	formed	O
6	a	O
7	complex	O
8	centered	O
9	on	O
10	the	O
11	sequence	O
12	TGTGGT	O
13	,	O
14	a	O
15	core	O
16	motif	O
17	recognized	O
18	by	O
19	members	O
20	of	O
21	the	O
22	AML	B
23	/	I
24	CBFalpha	I
25	transcription	I
26	factor	I
27	family	I
28	.	O

1	Furthermore	O
2	,	O
3	overexpression	O
4	of	O
5	AML3	B
6	/	O
7	CBFalpha1	B
8	could	O
9	rescue	O
10	the	O
11	AML1	B
12	-	O
13	ETO	B
14	repression	O
15	.	O

1	We	O
2	examined	O
3	Akt	B
4	activation	O
5	in	O
6	Lyn	B
7	-,	O
8	Syk	B
9	-	O
10	and	O
11	Btk	B
12	-	O
13	deficient	O
14	DT40	O
15	cells	O
16	and	O
17	B	O
18	cells	O
19	from	O
20	Lyn	B
21	(-/-)	I
22	mice	O
23	.	O

1	Regulators	O
2	of	O
3	G	B
4	protein	I
5	signaling	I
6	(	I
7	RGS	I
8	)	I
9	proteins	I
10	that	O
11	contain	O
12	DEP	B
13	(	O
14	disheveled	B
15	,	O
16	EGL	B
17	-	I
18	10	I
19	,	O
20	pleckstrin	B
21	)	O
22	and	O
23	GGL	B
24	(	O
25	G	B
26	protein	I
27	gamma	I
28	subunit	I
29	-	I
30	like	I
31	)	O
32	domains	O
33	form	O
34	a	O
35	subfamily	O
36	that	O
37	includes	O
38	the	O
39	mammalian	B
40	RGS	I
41	proteins	I
42	RGS6	I
43	,	O
44	RGS7	B
45	,	O
46	RGS9	B
47	,	O
48	and	O
49	RGS11	B
50	.	O

1	Cloning	O
2	and	O
3	expression	O
4	of	O
5	a	O
6	specific	O
7	human	B
8	alpha	I
9	1	I
10	,	I
11	2	I
12	-	I
13	mannosidase	I
14	that	O
15	trims	O
16	Man9GlcNAc2	O
17	to	O
18	Man8GlcNAc2	O
19	isomer	O
20	B	O
21	during	O
22	N	O
23	-	O
24	glycan	O
25	biosynthesis	O
26	.	O

1	The	O
2	ORs	O
3	of	O
4	GC	O
5	,	O
6	adjusted	O
7	for	O
8	age	O
9	and	O
10	sex	O
11	,	O
12	varied	O
13	from	O
14	17	O
15	.	O
16	1	O
17	,	O
18	for	O
19	those	O
20	with	O
21	baseline	O
22	diagnoses	O
23	of	O
24	superficial	O
25	intestinal	O
26	metaplasia	O
27	(	O
28	IM	O
29	),	O
30	to	O
31	29	O
32	.	O
33	3	O
34	,	O
35	for	O
36	those	O
37	with	O
38	deep	O
39	IM	O
40	or	O
41	mild	O
42	dysplasia	O
43	(	O
44	DYS	O
45	)	O
46	or	O
47	IM	O
48	with	O
49	glandular	O
50	atrophy	O
51	and	O
52	neck	O
53	hyperplasia	O
54	,	O
55	to	O
56	104	O
57	.	O
58	2	O
59	,	O
60	for	O
61	those	O
62	with	O
63	moderate	O
64	or	O
65	severe	O
66	DYS	O
67	,	O
68	as	O
69	compared	O
70	with	O
71	subjects	O
72	with	O
73	superficial	O
74	gastritis	O
75	(	O
76	SG	O
77	)	O
78	or	O
79	chronic	O
80	atrophic	O
81	gastritis	O
82	(	O
83	CAG	O
84	)	O
85	at	O
86	baseline	O
87	.	O

1	Here	O
2	we	O
3	report	O
4	that	O
5	Dbp5p	B
6	and	O
7	Rat7p	B
8	interact	O
9	through	O
10	their	O
11	Nterminal	O
12	domains	O
13	.	O

1	Thus	O
2	,	O
3	the	O
4	nematode	O
5	genes	O
6	could	O
7	be	O
8	the	O
9	homologs	B
10	of	I
11	Hh	I
12	molecules	I
13	in	O
14	other	O
15	phyla	O
16	.	O

1	A	O
2	subset	O
3	of	O
4	mutations	O
5	in	O
6	the	O
7	Psi	B
8	synthase	I
9	domain	I
10	impairs	O
11	association	O
12	of	O
13	the	O
14	altered	O
15	Cbf5p	B
16	proteins	I
17	with	O
18	selected	O
19	box	O
20	H	B
21	/	I
22	ACA	I
23	snoRNAs	I
24	,	O
25	suggesting	O
26	that	O
27	the	O
28	functional	O
29	catalytic	O
30	domain	O
31	is	O
32	essential	O
33	for	O
34	that	O
35	interaction	O
36	.	O

1	Although	O
2	the	O
3	Src	B
4	tyrosine	I
5	kinase	I
6	induces	O
7	constitutive	O
8	Stat3	B
9	phosphorylation	O
10	on	O
11	tyrosine	O
12	,	O
13	activation	O
14	of	O
15	Stat3	B
16	-	O
17	mediated	O
18	gene	O
19	regulation	O
20	requires	O
21	both	O
22	tyrosine	O
23	and	O
24	serine	O
25	phosphorylation	O
26	of	O
27	Stat3	B
28	.	O

1	The	O
2	transcription	B
3	factor	I
4	CHOP	I
5	(	O
6	C	B
7	/	I
8	EBP	I
9	homologous	I
10	protein	I
11	10	I
12	)	O
13	is	O
14	a	O
15	bZIP	B
16	protein	I
17	induced	O
18	by	O
19	a	O
20	variety	O
21	of	O
22	stimuli	O
23	that	O
24	evoke	O
25	cellular	O
26	stress	O
27	responses	O
28	and	O
29	has	O
30	been	O
31	shown	O
32	to	O
33	arrest	O
34	cell	O
35	growth	O
36	and	O
37	to	O
38	promote	O
39	programmed	O
40	cell	O
41	death	O
42	.	O

1	Thus	O
2	,	O
3	CHOP	B
4	not	O
5	only	O
6	is	O
7	a	O
8	negative	O
9	or	O
10	a	O
11	positive	O
12	regulator	O
13	of	O
14	C	B
15	/	I
16	EBP	I
17	target	O
18	genes	O
19	but	O
20	also	O
21	,	O
22	when	O
23	tethered	O
24	to	O
25	AP	B
26	-	I
27	1	I
28	factors	I
29	,	O
30	can	O
31	activate	O
32	AP	B
33	-	I
34	1	I
35	target	O
36	genes	O
37	.	O

1	This	O
2	motif	O
3	,	O
4	first	O
5	described	O
6	for	O
7	the	O
8	Drosophila	B
9	homeobox	I
10	activator	I
11	DEAF	I
12	-	I
13	1	I
14	,	O
15	identifies	O
16	an	O
17	emerging	O
18	group	O
19	of	O
20	metazoan	O
21	transcriptional	O
22	modulators	O
23	.	O

1	RNase	B
2	MRP	I
3	is	O
4	a	O
5	ribonucleoprotein	O
6	endoribonuclease	O
7	that	O
8	has	O
9	been	O
10	shown	O
11	to	O
12	have	O
13	roles	O
14	in	O
15	both	O
16	mitochondrial	O
17	DNA	O
18	replication	O
19	and	O
20	nuclear	B
21	5	I
22	.	I
23	8S	I
24	rRNA	I
25	processing	O
26	.	O

1	We	O
2	have	O
3	examined	O
4	the	O
5	regulation	O
6	of	O
7	the	O
8	FGFR	B
9	-	I
10	1	I
11	gene	I
12	(	O
13	cek	B
14	-	I
15	1	I
16	)	O
17	in	O
18	avian	O
19	myogenic	O
20	cultures	O
21	by	O
22	immunocytochemistry	O
23	and	O
24	Northern	O
25	blot	O
26	analysis	O
27	.	O

1	Regulation	O
2	of	O
3	avian	B
4	fibroblast	I
5	growth	I
6	factor	I
7	receptor	I
8	1	I
9	(	O
10	FGFR	B
11	-	I
12	1	I
13	)	O
14	gene	O
15	expression	O
16	during	O
17	skeletal	O
18	muscle	O
19	differentiation	O
20	.	O

1	The	O
2	backbone	O
3	dynamics	O
4	of	O
5	residues	O
6	located	O
7	in	O
8	the	O
9	folded	O
10	part	O
11	of	O
12	CRP2	B
13	(	O
14	LIM2	B
15	)	O
16	R122A	B
17	have	O
18	been	O
19	characterized	O
20	by	O
21	proton	O
22	-	O
23	detected	O
24	(	O
25	15	O
26	)	O
27	N	O
28	NMR	O
29	spectroscopy	O
30	.	O

1	Rac	B
2	causes	O
3	uncapping	O
4	of	O
5	actin	B
6	filaments	I
7	(	O
8	F	B
9	-	I
10	actin	I
11	)	O
12	at	O
13	the	O
14	plus	O
15	-	O
16	ends	O
17	,	O
18	through	O
19	phosphatidylinositol	O
20	4	O
21	,	O
22	5	O
23	bisphosphate	O
24	(	O
25	PIP2	O
26	),	O
27	and	O
28	eventually	O
29	induces	O
30	membrane	O
31	ruffling	O
32	.	O

1	However	O
2	,	O
3	a	O
4	specific	O
5	ICE	B
6	/	O
7	caspase	B
8	-	I
9	1	I
10	inhibitor	O
11	called	O
12	N1445	O
13	completely	O
14	abolished	O
15	the	O
16	CK	B
17	-	O
18	induced	O
19	apoptosis	O
20	by	O
21	reactivating	O
22	PKB	B
23	,	O
24	but	O
25	without	O
26	affecting	O
27	the	O
28	CK	B
29	-	O
30	induced	O
31	suppression	O
32	of	O
33	Ras	B
34	transformation	O
35	.	O

1	OBJECTIVE	O
2	:	O
3	Although	O
4	the	O
5	preponderance	O
6	of	O
7	findings	O
8	offer	O
9	support	O
10	for	O
11	transient	O
12	(	O
13	where	O
14	is	O
15	it	O
16	?)	O
17	as	O
18	opposed	O
19	to	O
20	sustained	O
21	(	O
22	what	O
23	is	O
24	it	O
25	?)	O
26	deficit	O
27	,	O
28	a	O
29	need	O
30	remains	O
31	for	O
32	specific	O
33	depiction	O
34	of	O
35	the	O
36	deficit	O
37	.	O

1	The	O
2	AL	O
3	-	O
4	R8	O
5	SI	O
6	:	O
7	the	O
8	next	O
9	generation	O
10	staging	O
11	container	O
12	for	O
13	plutonium	O
14	pits	O
15	at	O
16	the	O
17	USDOE	O
18	Pantex	O
19	Plant	O
20	.	O

1	RESULTS	O
2	:	O
3	Factors	O
4	associated	O
5	with	O
6	significantly	O
7	(	O
8	P	O
9	<.	O
10	05	O
11	)	O
12	increased	O
13	risk	O
14	of	O
15	treatment	O
16	failure	O
17	in	O
18	a	O
19	Cox	O
20	multivariate	O
21	analysis	O
22	included	O
23	age	O
24	older	O
25	than	O
26	45	O
27	years	O
28	(	O
29	relative	O
30	hazard	O
31	,	O
32	1	O
33	.	O
34	17	O
35	;	O
36	95	O
37	%	O
38	confidence	O
39	interval	O
40	[	O
41	CI	O
42	],	O
43	1	O
44	.	O
45	02	O
46	-	O
47	1	O
48	.	O
49	33	O
50	),	O
51	Karnofsky	O
52	performance	O
53	score	O
54	less	O
55	than	O
56	90	O
57	%	O
58	(	O
59	1	O
60	.	O
61	27	O
62	;	O
63	95	O
64	%	O
65	CI	O
66	,	O
67	1	O
68	.	O
69	07	O
70	-	O
71	1	O
72	.	O
73	51	O
74	),	O
75	absence	O
76	of	O
77	hormone	O
78	receptors	O
79	(	O
80	1	O
81	.	O
82	31	O
83	;	O
84	95	O
85	%	O
86	CI	O
87	,	O
88	1	O
89	.	O
90	15	O
91	-	O
92	1	O
93	.	O
94	51	O
95	),	O
96	prior	O
97	use	O
98	of	O
99	adjuvant	O
100	chemotherapy	O
101	(	O
102	1	O
103	.	O
104	31	O
105	;	O
106	95	O
107	%	O
108	CI	O
109	,	O
110	1	O
111	.	O
112	10	O
113	-	O
114	1	O
115	.	O
116	56	O
117	),	O
118	initial	O
119	disease	O
120	-	O
121	free	O
122	survival	O
123	interval	O
124	after	O
125	adjuvant	O
126	treatment	O
127	of	O
128	no	O
129	more	O
130	than	O
131	18	O
132	months	O
133	(	O
134	1	O
135	.	O
136	99	O
137	;	O
138	95	O
139	%	O
140	CI	O
141	,	O
142	1	O
143	.	O
144	62	O
145	-	O
146	2	O
147	.	O
148	43	O
149	),	O
150	metastases	O
151	in	O
152	the	O
153	liver	O
154	(	O
155	1	O
156	.	O
157	47	O
158	;	O
159	95	O
160	%	O
161	CI	O
162	,	O
163	1	O
164	.	O
165	20	O
166	-	O
167	1	O
168	.	O
169	80	O
170	)	O
171	or	O
172	central	O
173	nervous	O
174	system	O
175	(	O
176	1	O
177	.	O
178	56	O
179	;	O
180	95	O
181	%	O
182	CI	O
183	,	O
184	0	O
185	.	O
186	99	O
187	-	O
188	2	O
189	.	O
190	46	O
191	[	O
192	approaches	O
193	significance	O
194	])	O
195	vs	O
196	soft	O
197	tissue	O
198	,	O
199	bone	O
200	,	O
201	or	O
202	lung	O
203	,	O
204	3	O
205	or	O
206	more	O
207	sites	O
208	of	O
209	metastatic	O
210	disease	O
211	(	O
212	1	O
213	.	O
214	32	O
215	;	O
216	95	O
217	%	O
218	CI	O
219	,	O
220	1	O
221	.	O
222	13	O
223	-	O
224	1	O
225	.	O
226	54	O
227	),	O
228	and	O
229	incomplete	O
230	response	O
231	vs	O
232	complete	O
233	response	O
234	to	O
235	standard	O
236	-	O
237	dose	O
238	chemotherapy	O
239	(	O
240	1	O
241	.	O
242	65	O
243	;	O
244	95	O
245	%	O
246	CI	O
247	,	O
248	1	O
249	.	O
250	36	O
251	-	O
252	1	O
253	.	O
254	99	O
255	).	O

1	One	O
2	form	O
3	of	O
4	the	O
5	SBEI	B
6	gene	I
7	transcript	I
8	in	O
9	12	O
10	-	O
11	day	O
12	old	O
13	kernels	O
14	contained	O
15	the	O
16	exon	O
17	I	O
18	+	O
19	II	O
20	+	O
21	III	O
22	combination	O
23	at	O
24	the	O
25	5	O
26	'	O
27	end	O
28	,	O
29	whereas	O
30	other	O
31	forms	O
32	differed	O
33	by	O
34	inclusion	O
35	of	O
36	intron	O
37	1	O
38	or	O
39	exclusion	O
40	of	O
41	exon	O
42	II	O
43	sequences	O
44	.	O

1	In	O
2	PC	O
3	,	O
4	rare	O
5	MNGCs	O
6	had	O
7	intranuclear	O
8	inclusions	O
9	and	O
10	grooves	O
11	.	O

1	16	O
2	percent	O
3	,	O
4	P	O
5	<	O
6	0	O
7	.	O
8	001	O
9	),	O
10	and	O
11	sustained	O
12	normalization	O
13	of	O
14	serum	B
15	alanine	I
16	aminotransferase	I
17	levels	O
18	(	O
19	41	O
20	percent	O
21	vs	O
22	.	O

1	Its	O
2	C	O
3	-	O
4	terminal	O
5	catalytic	O
6	domain	O
7	was	O
8	found	O
9	to	O
10	be	O
11	highly	O
12	conserved	O
13	in	O
14	the	O
15	homologues	O
16	p140	B
17	(	O
18	ras	B
19	-	O
20	GRF	B
21	)	O
22	and	O
23	Sos	B
24	.	O

1	356	O
2	,	O
3	93	O
4	-	O
5	98	O
6	].	O

1	The	O
2	proteasome	O
3	is	O
4	a	O
5	large	O
6	complex	O
7	consisting	O
8	of	O
9	two	O
10	multisubunit	O
11	structures	O
12	,	O
13	the	O
14	20S	B
15	and	O
16	19S	B
17	(	O
18	PA700	B
19	)	O
20	or	O
21	P28	B
22	complexes	I
23	,	O
24	that	O
25	combine	O
26	to	O
27	form	O
28	the	O
29	26S	B
30	particles	I
31	.	O

1	In	O
2	assays	O
3	with	O
4	purified	O
5	enzymes	O
6	,	O
7	wild	O
8	-	O
9	type	O
10	but	O
11	not	O
12	PTPS	B
13	-	O
14	S19A	B
15	was	O
16	a	O
17	specific	O
18	substrate	O
19	for	O
20	the	O
21	cGMP	B
22	-	I
23	dependent	I
24	protein	I
25	kinase	I
26	(	I
27	cGK	I
28	)	I
29	type	I
30	I	I
31	and	I
32	II	I
33	.	O

1	R	O
2	.,	O
3	Fleischmann	O
4	,	O
5	R	O
6	.,	O
7	Venter	O
8	,	O
9	J	O
10	.	O

1	The	O
2	N	O
3	-	O
4	terminal	O
5	domain	O
6	of	O
7	approximately	O
8	70	O
9	kDa	O
10	exhibits	O
11	11	O
12	imperfect	O
13	amino	O
14	acid	O
15	repeats	O
16	that	O
17	show	O
18	some	O
19	homology	O
20	to	O
21	promastigote	O
22	surface	O
23	glycoproteins	O
24	of	O
25	the	O
26	psa2	B
27	/	O
28	gp46	B
29	complex	O
30	.	O

1	In	O
2	contrast	O
3	to	O
4	previously	O
5	characterized	O
6	proteophosphoglycans	O
7	,	O
8	the	O
9	ppg1	B
10	gene	O
11	product	O
12	is	O
13	predominantly	O
14	membrane	O
15	-	O
16	associated	O
17	and	O
18	it	O
19	is	O
20	expressed	O
21	on	O
22	the	O
23	promastigote	O
24	cell	O
25	surface	O
26	.	O

1	Most	O
2	important	O
3	,	O
4	infection	O
5	of	O
6	the	O
7	cells	O
8	with	O
9	an	O
10	adenoviral	O
11	construct	O
12	expressing	O
13	this	O
14	mutant	O
15	inhibited	O
16	the	O
17	induction	O
18	of	O
19	VEGF	B
20	mRNA	I
21	under	O
22	conditions	O
23	that	O
24	mimic	O
25	hypoxia	O
26	.	O

1	Neuregulin	B
2	stimulates	O
3	ErbB2	B
4	,	O
5	ErbB3	B
6	,	O
7	and	O
8	ErbB4	B
9	,	O
10	members	O
11	of	O
12	the	O
13	ErbB	B
14	family	I
15	of	O
16	receptor	B
17	tyrosine	I
18	kinases	I
19	.	O

1	Our	O
2	results	O
3	suggest	O
4	that	O
5	Anu2p	B
6	is	O
7	the	O
8	yeast	B
9	homologue	I
10	of	I
11	mammalian	I
12	epsilon	I
13	-	I
14	COP	I
15	and	O
16	the	O
17	abrupt	O
18	accumulation	O
19	of	O
20	the	O
21	ER	O
22	membrane	O
23	caused	O
24	by	O
25	a	O
26	blockage	O
27	of	O
28	the	O
29	early	O
30	protein	O
31	transport	O
32	pathway	O
33	leads	O
34	to	O
35	alteration	O
36	of	O
37	nuclear	O
38	morphology	O
39	of	O
40	the	O
41	budding	O
42	yeast	O
43	cells	O
44	.	O

1	In	O
2	PC12	O
3	cells	O
4	,	O
5	nerve	B
6	growth	I
7	factor	I
8	induces	O
9	neuronal	O
10	differentiation	O
11	and	O
12	repressed	O
13	expression	O
14	of	O
15	nrg	B
16	-	I
17	1	I
18	.	O

1	In	O
2	a	O
3	PC12	O
4	cell	O
5	mutant	O
6	that	O
7	is	O
8	deficient	O
9	in	O
10	protein	B
11	kinase	I
12	A	I
13	activity	O
14	(	O
15	AB	O
16	.	O
17	11	O
18	),	O
19	all	O
20	three	O
21	differentiating	O
22	agents	O
23	were	O
24	unable	O
25	to	O
26	down	O
27	-	O
28	regulate	O
29	nrg	B
30	-	I
31	1	I
32	mRNA	I
33	.	O

1	TSC1	B
2	mutations	I
3	include	O
4	two	O
5	nonsense	O
6	mutations	O
7	,	O
8	four	O
9	insertions	O
10	,	O
11	and	O
12	three	O
13	splice	O
14	mutations	O
15	.	O

1	Twelve	O
2	patients	O
3	without	O
4	abnormalities	O
5	in	O
6	the	O
7	PTT	O
8	are	O
9	assumed	O
10	to	O
11	harbor	O
12	missense	O
13	mutations	O
14	,	O
15	probably	O
16	in	O
17	TSC2	B
18	.	O

1	The	O
2	first	O
3	algorithm	O
4	,	O
5	FOREPROJ	O
6	,	O
7	is	O
8	a	O
9	fast	O
10	-	O
11	forward	O
12	projection	O
13	algorithm	O
14	that	O
15	allows	O
16	calculation	O
17	of	O
18	the	O
19	3	O
20	-	O
21	D	O
22	attenuation	O
23	correction	O
24	factors	O
25	(	O
26	ACF	O
27	'	O
28	s	O
29	)	O
30	directly	O
31	from	O
32	a	O
33	two	O
34	-	O
35	dimensional	O
36	(	O
37	2	O
38	-	O
39	D	O
40	)	O
41	transmission	O
42	scan	O
43	,	O
44	without	O
45	first	O
46	reconstructing	O
47	the	O
48	attenuation	O
49	map	O
50	and	O
51	then	O
52	performing	O
53	a	O
54	3	O
55	-	O
56	D	O
57	forward	O
58	projection	O
59	.	O

1	We	O
2	have	O
3	cloned	O
4	cDNA	O
5	and	O
6	genomic	O
7	DNA	O
8	for	O
9	a	O
10	mouse	O
11	gene	O
12	encoding	O
13	a	O
14	protein	O
15	with	O
16	significant	O
17	sequence	O
18	similarity	O
19	to	O
20	conserved	O
21	domains	O
22	found	O
23	in	O
24	proteins	O
25	of	O
26	the	O
27	Spo11p	B
28	family	I
29	.	O

1	RT	O
2	-	O
3	PCR	O
4	and	O
5	in	O
6	situ	O
7	hybridization	O
8	analyses	O
9	of	O
10	a	O
11	time	O
12	course	O
13	of	O
14	juvenile	O
15	testis	O
16	development	O
17	indicate	O
18	that	O
19	Spo11	B
20	expression	O
21	begins	O
22	in	O
23	early	O
24	meiotic	O
25	Prophase	O
26	I	O
27	,	O
28	prior	O
29	to	O
30	the	O
31	pachytene	O
32	stage	O
33	,	O
34	with	O
35	increasing	O
36	accumulation	O
37	of	O
38	mRNA	O
39	through	O
40	the	O
41	pachytene	O
42	stage	O
43	.	O

1	Animals	O
2	were	O
3	put	O
4	to	O
5	death	O
6	8	O
7	weeks	O
8	later	O
9	and	O
10	the	O
11	grafts	O
12	were	O
13	sterilely	O
14	explanted	O
15	and	O
16	analyzed	O
17	via	O
18	microbiologic	O
19	culture	O
20	and	O
21	standard	O
22	histologic	O
23	procedures	O
24	for	O
25	evidence	O
26	of	O
27	infection	O
28	.	O

1	The	O
2	RMR	O
3	was	O
4	measured	O
5	twice	O
6	in	O
7	each	O
8	phase	O
9	and	O
10	found	O
11	to	O
12	be	O
13	similar	O
14	(	O
15	F	O
16	(	O
17	1	O
18	,	O
19	18	O
20	)	O
21	=	O
22	0	O
23	.	O
24	863	O
25	)	O
26	across	O
27	the	O
28	follicular	O
29	(	O
30	5018	O
31	kJ	O
32	/	O
33	24	O
34	h	O
35	)	O
36	and	O
37	the	O
38	luteal	O
39	(	O
40	5098	O
41	kJ	O
42	/	O
43	24	O
44	h	O
45	)	O
46	phases	O
47	.	O

1	Oseltamivir	O
2	(	O
3	GS4104	O
4	),	O
5	which	O
6	can	O
7	be	O
8	administered	O
9	orally	O
10	,	O
11	is	O
12	the	O
13	prodrug	O
14	of	O
15	GS4071	O
16	,	O
17	a	O
18	potent	O
19	and	O
20	selective	O
21	inhibitor	O
22	of	O
23	influenzavirus	B
24	neuraminidases	I
25	.	O

1	In	O
2	gel	O
3	mobility	O
4	shift	O
5	assays	O
6	,	O
7	we	O
8	found	O
9	no	O
10	evidence	O
11	for	O
12	VDR	B
13	-	O
14	TR	B
15	heterodimer	O
16	interaction	O
17	with	O
18	any	O
19	tested	O
20	element	O
21	.	O

1	The	O
2	relative	O
3	importance	O
4	of	O
5	these	O
6	two	O
7	mechanisms	O
8	differed	O
9	in	O
10	a	O
11	response	O
12	element	O
13	-	O
14	specific	O
15	manner	O
16	.	O

1	After	O
2	14	O
3	d	O
4	of	O
5	overfeeding	O
6	,	O
7	hepatic	O
8	PL	O
9	profiles	O
10	were	O
11	identical	O
12	in	O
13	the	O
14	two	O
15	breeds	O
16	and	O
17	similar	O
18	to	O
19	that	O
20	in	O
21	control	O
22	livers	O
23	;	O
24	choline	O
25	-	O
26	containing	O
27	PL	O
28	accounted	O
29	for	O
30	95	O
31	%	O
32	of	O
33	total	O
34	PL	O
35	.	O

1	C	O
2	-	O
3	SP	O
4	duration	O
5	was	O
6	significantly	O
7	reduced	O
8	in	O
9	ALS	O
10	patients	O
11	compared	O
12	to	O
13	controls	O
14	at	O
15	low	O
16	stimulation	O
17	intensity	O
18	corresponding	O
19	to	O
20	an	O
21	MEP	O
22	threshold	O
23	increased	O
24	by	O
25	15	O
26	%.	O

1	These	O
2	data	O
3	show	O
4	that	O
5	the	O
6	spv	B
7	virulence	I
8	genes	I
9	belong	O
10	simultaneously	O
11	to	O
12	several	O
13	regulons	O
14	in	O
15	the	O
16	cell	O
17	,	O
18	raising	O
19	the	O
20	possibility	O
21	that	O
22	spv	B
23	expression	O
24	can	O
25	be	O
26	fine	O
27	-	O
28	tuned	O
29	in	O
30	response	O
31	to	O
32	multiple	O
33	environmental	O
34	inputs	O
35	.	O

1	Intensive	O
2	synthesis	O
3	of	O
4	PNA	B
5	in	O
6	the	O
7	cells	O
8	of	O
9	microvascular	O
10	wall	O
11	evidenced	O
12	of	O
13	their	O
14	high	O
15	functional	O
16	activity	O
17	,	O
18	and	O
19	the	O
20	synthesis	O
21	of	O
22	DNA	O
23	in	O
24	them	O
25	showed	O
26	their	O
27	ability	O
28	for	O
29	proliferation	O
30	,	O
31	i	O
32	.	O
33	g	O
34	.--	O
35	for	O
36	growth	O
37	.	O

1	Tracheal	O
2	transsection	O
3	combined	O
4	with	O
5	hilar	O
6	ligation	O
7	(	O
8	TL	O
9	&	O
10	PL	O
11	)	O
12	effected	O
13	a	O
14	reduction	O
15	of	O
16	19	O
17	.	O
18	9	O
19	%	O
20	(	O
21	n	O
22	.	O
23	s	O
24	.).	O

1	Kinase	O
2	-	O
3	deficient	O
4	erbB	B
5	proteins	I
6	reduced	O
7	epidermal	B
8	growth	I
9	factor	I
10	(	O
11	EGF	B
12	)-	O
13	induced	O
14	tyrosine	O
15	phosphorylation	O
16	of	O
17	endogenous	O
18	Shc	B
19	proteins	I
20	and	O
21	also	O
22	reduced	O
23	immediate	O
24	and	O
25	sustained	O
26	EGF	B
27	-	I
28	induced	I
29	ERK	I
30	MAPK	I
31	activities	O
32	in	O
33	human	O
34	glioblastoma	O
35	cells	O
36	,	O
37	although	O
38	basal	O
39	ERK	B
40	MAPK	I
41	activities	O
42	were	O
43	unaffected	O
44	.	O

1	Using	O
2	immunolocalization	O
3	,	O
4	we	O
5	observe	O
6	that	O
7	ACE3	B
8	,	O
9	a	O
10	440	O
11	-	O
12	bp	O
13	chorion	O
14	element	O
15	that	O
16	contains	O
17	information	O
18	sufficient	O
19	to	O
20	drive	O
21	amplification	O
22	,	O
23	directs	O
24	DmORC	B
25	localization	O
26	in	O
27	follicle	O
28	cells	O
29	.	O

1	Therefore	O
2	,	O
3	homozygous	O
4	co	O
5	-	O
6	deletions	O
7	of	O
8	CDKN2A	B
9	and	O
10	CDKN2B	B
11	rather	O
12	than	O
13	mutations	O
14	targeting	O
15	individual	O
16	transcripts	O
17	are	O
18	frequently	O
19	selected	O
20	for	O
21	in	O
22	these	O
23	tumors	O
24	.	O

1	Here	O
2	,	O
3	we	O
4	show	O
5	that	O
6	aortic	O
7	explants	O
8	isolated	O
9	from	O
10	PPARalpha	B
11	-	O
12	null	O
13	mice	O
14	display	O
15	an	O
16	exacerbated	O
17	response	O
18	to	O
19	inflammatory	O
20	stimuli	O
21	,	O
22	such	O
23	as	O
24	lipopolysaccharide	O
25	(	O
26	LPS	O
27	),	O
28	as	O
29	demonstrated	O
30	by	O
31	increased	O
32	IL	B
33	-	I
34	6	I
35	secretion	O
36	.	O

1	Albumin	O
2	expression	O
3	is	O
4	maintained	O
5	in	O
6	the	O
7	liver	O
8	by	O
9	a	O
10	combination	O
11	of	O
12	liver	O
13	-	O
14	enriched	O
15	transcription	O
16	factors	O
17	such	O
18	as	O
19	CAAT	B
20	enhancer	I
21	-	I
22	binding	I
23	protein	I
24	(	I
25	C	I
26	/	I
27	EBP	I
28	)	I
29	alpha	I
30	and	O
31	C	B
32	/	I
33	EBPbeta	I
34	.	O

1	The	O
2	requirement	O
3	for	O
4	proteolytic	O
5	activity	O
6	of	O
7	both	O
8	FVIIa	B
9	and	O
10	FXa	B
11	suggests	O
12	that	O
13	protease	O
14	-	O
15	activated	O
16	receptors	O
17	may	O
18	be	O
19	involved	O
20	.	O

1	Amyloid	B
2	beta	I
3	-	I
4	protein	I
5	(	O
6	Abeta	B
7	)	O
8	is	O
9	the	O
10	main	O
11	constituent	O
12	of	O
13	amyloid	O
14	fibrils	O
15	found	O
16	in	O
17	senile	O
18	plaques	O
19	and	O
20	cerebral	O
21	vessels	O
22	in	O
23	Alzheimer	O
24	'	O
25	s	O
26	disease	O
27	(	O
28	AD	O
29	)	O
30	and	O
31	is	O
32	derived	O
33	by	O
34	proteolysis	O
35	from	O
36	the	O
37	beta	B
38	-	I
39	amyloid	I
40	precursor	I
41	protein	I
42	(	O
43	APP	B
44	).	O

1	We	O
2	also	O
3	show	O
4	that	O
5	activation	O
6	of	O
7	protein	B
8	kinase	I
9	A	I
10	(	O
11	PKA	B
12	)	O
13	signaling	O
14	is	O
15	sufficient	O
16	to	O
17	down	O
18	-	O
19	regulate	O
20	caveolin	B
21	-	I
22	1	I
23	protein	I
24	expression	O
25	and	O
26	promoter	O
27	activity	O
28	.	O

1	The	O
2	importin	B
3	alpha	I
4	.	I
5	beta	I
6	heterodimer	I
7	mediates	O
8	nuclear	O
9	import	O
10	of	O
11	proteins	O
12	containing	O
13	classical	O
14	nuclear	O
15	localization	O
16	signals	O
17	.	O

1	The	O
2	expressed	O
3	G1	B
4	-	O
5	G2	B
6	bound	O
7	to	O
8	both	O
9	hyaluronan	O
10	and	O
11	link	B
12	protein	I
13	indicating	O
14	that	O
15	the	O
16	immunoglobulin	B
17	-	I
18	fold	I
19	motif	I
20	and	O
21	proteoglycan	O
22	tandem	O
23	repeat	O
24	loops	O
25	of	O
26	the	O
27	G1	B
28	domain	I
29	were	O
30	correctly	O
31	folded	O
32	.	O

1	The	O
2	results	O
3	suggest	O
4	that	O
5	the	O
6	presence	O
7	or	O
8	absence	O
9	per	O
10	se	O
11	of	O
12	keratan	O
13	sulfate	O
14	on	O
15	native	O
16	G1	O
17	-	O
18	G2	O
19	does	O
20	not	O
21	affect	O
22	the	O
23	activity	O
24	of	O
25	atrolysin	O
26	C	O
27	toward	O
28	the	O
29	two	O
30	sites	O
31	.	O

1	Despite	O
2	i	O
3	.	O
4	v	O
5	.	O
6	steroid	O
7	therapy	O
8	,	O
9	[	O
10	NOexh	O
11	]	O
12	remained	O
13	elevated	O
14	throughout	O
15	recovery	O
16	(	O
17	37	O
18	.	O
19	9	O
20	+/-	O
21	4	O
22	.	O
23	8	O
24	ppb	O
25	,	O
26	p	O
27	<	O
28	0	O
29	.	O
30	001	O
31	)	O
32	until	O
33	discharge	O
34	(	O
35	40	O
36	.	O
37	9	O
38	+/-	O
39	4	O
40	.	O
41	3	O
42	ppb	O
43	,	O
44	p	O
45	<	O
46	0	O
47	.	O
48	001	O
49	).	O

1	It	O
2	contains	O
3	binding	O
4	sites	O
5	for	O
6	several	O
7	transcription	O
8	factors	O
9	,	O
10	for	O
11	example	O
12	:	O
13	(	O
14	i	O
15	)	O
16	a	O
17	well	O
18	-	O
19	characterized	O
20	binding	O
21	site	O
22	for	O
23	rel	B
24	/	O
25	NF	B
26	-	I
27	kappaB	I
28	transcription	O
29	factors	O
30	in	O
31	its	O
32	3	O
33	'-	O
34	end	O
35	(	O
36	the	O
37	H2TF1	B
38	or	O
39	kappaB1	B
40	element	I
41	),	O
42	(	O
43	ii	O
44	)	O
45	a	O
46	second	O
47	kappaB	B
48	site	I
49	(	O
50	the	O
51	kappaB2	B
52	element	I
53	),	O
54	which	O
55	is	O
56	located	O
57	immediately	O
58	adjacent	O
59	5	O
60	'	O
61	to	O
62	the	O
63	H2TF1	B
64	element	I
65	and	O
66	which	O
67	is	O
68	recognized	O
69	by	O
70	p65	B
71	/	O
72	relA	B
73	in	O
74	the	O
75	human	B
76	HLA	I
77	system	O
78	,	O
79	and	O
80	(	O
81	iii	O
82	)	O
83	an	O
84	AP	B
85	-	I
86	1	I
87	/	O
88	ATF	B
89	recognition	O
90	sequence	O
91	in	O
92	the	O
93	5	O
94	'	O
95	end	O
96	(	O
97	EnA	B
98	-	I
99	TRE	I
100	).	O

1	The	O
2	tumorigenic	O
3	E1A	B
4	+	O
5	cHa	B
6	-	I
7	ras	I
8	cells	O
9	are	O
10	characterized	O
11	by	O
12	high	O
13	and	O
14	constitutive	O
15	DNA	O
16	binding	O
17	activities	O
18	of	O
19	AP	B
20	-	I
21	1	I
22	,	O
23	in	O
24	contrast	O
25	to	O
26	nontransformed	O
27	cells	O
28	and	O
29	the	O
30	E1A	B
31	cells	O
32	.	O

1	The	O
2	yeast	O
3	C	B
4	-	I
5	type	I
6	cyclin	I
7	Ume3p	I
8	/	O
9	Srb11p	B
10	and	O
11	its	O
12	cyclin	B
13	-	I
14	dependent	I
15	kinase	I
16	(	O
17	Cdk	B
18	)	O
19	Ume5p	B
20	are	O
21	required	O
22	for	O
23	the	O
24	full	O
25	repression	O
26	of	O
27	genes	O
28	involved	O
29	in	O
30	the	O
31	stress	O
32	response	O
33	or	O
34	meiosis	O
35	.	O

1	In	O
2	particular	O
3	,	O
4	the	O
5	S1	B
6	'	I
7	specificity	I
8	site	I
9	is	O
10	a	O
11	deep	O
12	and	O
13	highly	O
14	hydrophobic	O
15	cavity	O
16	.	O

1	FZD4	B
2	is	O
3	homologous	O
4	to	O
5	FZD9	B
6	and	O
7	FZD10	B
8	,	O
9	and	O
10	overall	O
11	amino	O
12	acid	O
13	identity	O
14	is	O
15	as	O
16	follows	O
17	:	O
18	FZD4	B
19	vs	O
20	FZD9	B
21	,	O
22	51	O
23	.	O
24	6	O
25	%;	O
26	FZD4	B
27	vs	O
28	FZD10	B
29	,	O
30	51	O
31	.	O
32	2	O
33	%;	O
34	FZD9	B
35	vs	O
36	FZD10	B
37	,	O
38	65	O
39	.	O
40	7	O
41	%.	O

1	The	O
2	NF	B
3	-	I
4	kappaB	I
5	responsive	O
6	reporter	O
7	construct	O
8	,	O
9	(	O
10	PRDII	O
11	)(	O
12	4	O
13	)-	O
14	CAT	B
15	,	O
16	was	O
17	used	O
18	to	O
19	explore	O
20	transcription	O
21	resulting	O
22	from	O
23	NF	B
24	-	I
25	kappaB	I
26	activated	O
27	by	O
28	Tat	B
29	.	O

1	The	O
2	RNA	O
3	transcripts	O
4	structurally	O
5	equivalent	O
6	to	O
7	I	B
8	(	I
9	2	I
10	)	I
11	sgRNAs	I
12	of	O
13	TMV	B
14	U1	I
15	and	O
16	crTMV	O
17	,	O
18	but	O
19	containing	O
20	a	O
21	hairpin	O
22	structure	O
23	(	O
24	H	O
25	)	O
26	immediately	O
27	upstream	O
28	of	O
29	IRES	B
30	(	I
31	MP	I
32	,	I
33	75	I
34	)	I
35	(	I
36	HIRES	I
37	(	I
38	MP	I
39	),	I
40	(	I
41	75	I
42	)(	I
43	CR	I
44	)-	I
45	MP	I
46	-	I
47	CP	I
48	-	I
49	3	I
50	'	I
51	UTR	I
52	;	O
53	HIRES	B
54	(	I
55	MP	I
56	,	I
57	75	I
58	)(	I
59	U1	I
60	)-	I
61	MP	I
62	-	I
63	CP	I
64	-	I
65	3	I
66	'	I
67	UTR	I
68	),	O
69	were	O
70	able	O
71	to	O
72	express	O
73	the	O
74	MP	B
75	gene	I
76	in	O
77	vitro	O
78	.	O

1	EIAV	B
2	LTR	I
3	sequence	I
4	variability	O
5	is	O
6	confined	O
7	mostly	O
8	to	O
9	a	O
10	small	O
11	portion	O
12	of	O
13	the	O
14	enhancer	O
15	within	O
16	the	O
17	U3	O
18	segment	O
19	of	O
20	the	O
21	LTR	O
22	.	O

1	Phosphatidylinositol	B
2	3	I
3	-	I
4	kinase	I
5	requirement	O
6	in	O
7	activation	O
8	of	O
9	the	O
10	ras	B
11	/	O
12	C	B
13	-	I
14	raf	I
15	-	I
16	1	I
17	/	O
18	MEK	B
19	/	O
20	ERK	B
21	and	O
22	p70	B
23	(	O
24	s6k	B
25	)	O
26	signaling	O
27	cascade	O
28	by	O
29	the	O
30	insulinomimetic	O
31	agent	O
32	vanadyl	O
33	sulfate	O
34	.	O

1	The	O
2	core	O
3	of	O
4	this	O
5	enhancer	O
6	contains	O
7	two	O
8	evolutionarily	O
9	conserved	O
10	binding	O
11	sites	O
12	for	O
13	the	O
14	homeodomain	B
15	protein	I
16	Tinman	I
17	(	O
18	Tin	B
19	),	O
20	expressed	O
21	in	O
22	developing	O
23	cardiac	O
24	,	O
25	somatic	O
26	,	O
27	and	O
28	visceral	O
29	muscle	O
30	lineages	O
31	.	O

1	For	O
2	example	O
3	,	O
4	introduction	O
5	of	O
6	immunogenic	O
7	and	O
8	purification	O
9	tag	O
10	sequences	O
11	into	O
12	the	O
13	C	O
14	-	O
15	terminal	O
16	coding	O
17	region	O
18	significantly	O
19	decreased	O
20	bop	B
21	gene	I
22	mRNA	I
23	and	O
24	protein	O
25	accumulation	O
26	.	O

1	Furthermore	O
2	,	O
3	the	O
4	striking	O
5	ability	O
6	of	O
7	polyoma	B
8	middle	I
9	T	I
10	antigens	I
11	to	O
12	promote	O
13	retinoic	O
14	acid	O
15	-	O
16	induced	O
17	differentiation	O
18	appears	O
19	to	O
20	utilize	O
21	ERK	B
22	,	O
23	but	O
24	not	O
25	JNK	B
26	/	O
27	SPK	B
28	or	O
29	p38	B
30	signaling	O
31	.	O

1	We	O
2	recommend	O
3	that	O
4	paracervical	O
5	block	O
6	with	O
7	lignocaine	O
8	should	O
9	be	O
10	used	O
11	in	O
12	conjunction	O
13	with	O
14	i	O
15	.	O
16	v	O
17	.	O
18	sedation	O
19	/	O
20	analgesia	O
21	during	O
22	egg	O
23	collection	O
24	performed	O
25	through	O
26	the	O
27	transvaginal	O
28	route	O
29	under	O
30	ultrasound	O
31	guidance	O
32	(	O
33	TUGOR	O
34	)	O
35	to	O
36	reduce	O
37	the	O
38	pain	O
39	of	O
40	the	O
41	procedure	O
42	.	O

1	All	O
2	loci	O
3	have	O
4	a	O
5	similar	O
6	organization	O
7	,	O
8	except	O
9	for	O
10	H1	B
11	.	I
12	8	I
13	that	O
14	harbors	O
15	two	O
16	TcP2beta	B
17	genes	I
18	arranged	O
19	in	O
20	tandem	O
21	and	O
22	separated	O
23	by	O
24	a	O
25	short	O
26	repetitive	O
27	sequence	O
28	,	O
29	named	O
30	SIRE	O
31	(	O
32	short	O
33	interspersed	O
34	repetitive	O
35	element	O
36	),	O
37	which	O
38	is	O
39	also	O
40	found	O
41	upstream	O
42	of	O
43	the	O
44	first	O
45	gene	O
46	of	O
47	the	O
48	tandem	O
49	and	O
50	downstream	O
51	of	O
52	the	O
53	second	O
54	.	O

1	A	O
2	proportion	O
3	of	O
4	APC	B
5	wild	O
6	-	O
7	type	O
8	colon	O
9	carcinomas	O
10	and	O
11	melanomas	O
12	also	O
13	contains	O
14	constitutive	O
15	nuclear	O
16	Tcf	B
17	-	I
18	4	I
19	/	O
20	beta	B
21	-	I
22	catenin	I
23	complexes	O
24	as	O
25	a	O
26	result	O
27	of	O
28	dominant	O
29	mutations	O
30	in	O
31	the	O
32	N	O
33	terminus	O
34	of	O
35	beta	B
36	-	I
37	catenin	I
38	that	O
39	render	O
40	it	O
41	insensitive	O
42	to	O
43	downregulation	O
44	by	O
45	APC	B
46	,	O
47	GSK3	B
48	beta	I
49	,	O
50	and	O
51	Axin	B
52	/	O
53	Conductin	B
54	.	O

1	Similar	O
2	mechanisms	O
3	leading	O
4	to	O
5	deregulation	O
6	of	O
7	Tcf	B
8	target	I
9	gene	I
10	activity	O
11	are	O
12	likely	O
13	to	O
14	be	O
15	involved	O
16	in	O
17	melanoma	O
18	and	O
19	other	O
20	forms	O
21	of	O
22	cancer	O
23	.	O

1	This	O
2	report	O
3	describes	O
4	a	O
5	patient	O
6	with	O
7	a	O
8	previous	O
9	inferior	O
10	acute	O
11	myocardial	O
12	infarction	O
13	who	O
14	developed	O
15	right	O
16	ventricular	O
17	infarction	O
18	with	O
19	significant	O
20	anterior	O
21	lead	O
22	ST	O
23	segment	O
24	elevation	O
25	(	O
26	V1	O
27	-	O
28	V4	O
29	)	O
30	caused	O
31	by	O
32	the	O
33	loss	O
34	of	O
35	two	O
36	large	O
37	right	O
38	ventricular	O
39	branches	O
40	during	O
41	a	O
42	coronary	O
43	angioplasty	O
44	of	O
45	the	O
46	right	O
47	coronary	O
48	artery	O
49	.	O

1	PATIENTS	O
2	AND	O
3	METHODS	O
4	:	O
5	Immediately	O
6	before	O
7	radical	O
8	prostatectomy	O
9	,	O
10	bone	O
11	marrow	O
12	aspirates	O
13	from	O
14	both	O
15	sides	O
16	of	O
17	the	O
18	iliac	O
19	crest	O
20	were	O
21	taken	O
22	from	O
23	287	O
24	patients	O
25	.	O

1	PURPOSE	O
2	:	O
3	Previous	O
4	WR	O
5	-	O
6	2721	O
7	human	O
8	pharmacokinetic	O
9	studies	O
10	were	O
11	limited	O
12	to	O
13	plasma	O
14	levels	O
15	in	O
16	patients	O
17	receiving	O
18	platinum	O
19	-	O
20	based	O
21	compounds	O
22	,	O
23	and	O
24	none	O
25	includes	O
26	the	O
27	effects	O
28	of	O
29	WR	O
30	-	O
31	2721	O
32	on	O
33	endogenous	O
34	thiols	O
35	.	O

1	With	O
2	regard	O
3	to	O
4	nonhematologic	O
5	toxicities	O
6	,	O
7	diarrhea	O
8	,	O
9	infection	O
10	and	O
11	elevated	O
12	serum	B
13	alkaline	I
14	phosphatase	I
15	of	O
16	grade	O
17	3	O
18	or	O
19	over	O
20	were	O
21	observed	O
22	in	O
23	2	O
24	%	O
25	of	O
26	cycles	O
27	,	O
28	but	O
29	were	O
30	tolerable	O
31	and	O
32	reversible	O
33	.	O

1	LHbeta	B
2	is	O
3	expressed	O
4	in	O
5	pituitary	O
6	gonadotrope	O
7	cells	O
8	and	O
9	CGbeta	B
10	is	O
11	expressed	O
12	in	O
13	placental	O
14	trophoblast	O
15	cells	O
16	.	O

1	Regulation	O
2	of	O
3	HIV	O
4	-	O
5	1	O
6	transcription	O
7	.	O

1	Human	B
2	LTBP	I
3	-	I
4	1	I
5	is	O
6	known	O
7	to	O
8	exist	O
9	in	O
10	different	O
11	forms	O
12	.	O

1	In	O
2	an	O
3	earlier	O
4	study	O
5	(	O
6	Kimura	O
7	,	O
8	Y	O
9	.,	O
10	Kurzydlowski	O
11	,	O
12	K	O
13	.,	O
14	Tada	O
15	,	O
16	M	O
17	.,	O
18	and	O
19	MacLennan	O
20	,	O
21	D	O
22	.	O

1	It	O
2	consists	O
3	of	O
4	2185	O
5	amino	O
6	acid	O
7	residues	O
8	encoded	O
9	by	O
10	a	O
11	9	O
12	-	O
13	kilobase	O
14	pair	O
15	mRNA	O
16	;	O
17	several	O
18	splice	O
19	variants	O
20	have	O
21	been	O
22	detected	O
23	in	O
24	human	O
25	and	O
26	rat	O
27	cDNA	O
28	libraries	O
29	.	O

1	Cyclic	B
2	AMP	I
3	-	I
4	dependent	I
5	protein	I
6	kinase	I
7	binding	O
8	to	O
9	A	B
10	-	I
11	kinase	I
12	anchoring	O
13	proteins	O
14	in	O
15	living	O
16	cells	O
17	by	O
18	fluorescence	O
19	resonance	O
20	energy	O
21	transfer	O
22	of	O
23	green	B
24	fluorescent	I
25	protein	I
26	fusion	O
27	proteins	O
28	.	O

1	CONCLUSIONS	O
2	:	O
3	In	O
4	addition	O
5	to	O
6	the	O
7	superiority	O
8	of	O
9	octafluoropropane	O
10	-	O
11	filled	O
12	microspheres	O
13	to	O
14	air	O
15	-	O
16	filled	O
17	microspheres	O
18	for	O
19	LV	O
20	opacification	O
21	,	O
22	the	O
23	efficacy	O
24	of	O
25	OCTA	O
26	is	O
27	relatively	O
28	unaffected	O
29	by	O
30	impaired	O
31	LV	O
32	function	O
33	and	O
34	is	O
35	less	O
36	susceptible	O
37	to	O
38	the	O
39	effects	O
40	of	O
41	poor	O
42	echogenicity	O
43	than	O
44	AIR	O
45	.	O

1	Factor	B
2	XI	I
3	deficiency	O
4	is	O
5	a	O
6	rare	O
7	hereditary	O
8	bleeding	O
9	disorder	O
10	affecting	O
11	the	O
12	intrinsic	O
13	pathway	O
14	.	O

1	The	O
2	Ishasha	O
3	samples	O
4	show	O
5	a	O
6	range	O
7	encompassing	O
8	three	O
9	trophic	O
10	levels	O
11	.	O

1	The	O
2	more	O
3	traditional	O
4	SERMS	O
5	,	O
6	clomiphene	O
7	citrate	O
8	and	O
9	tamoxifen	O
10	,	O
11	will	O
12	be	O
13	reviewed	O
14	along	O
15	with	O
16	such	O
17	modern	O
18	drugs	O
19	as	O
20	raloxifene	O
21	and	O
22	faslodex	O
23	,	O
24	with	O
25	emphasis	O
26	upon	O
27	their	O
28	actions	O
29	on	O
30	breast	O
31	,	O
32	uterus	O
33	,	O
34	bone	O
35	and	O
36	lipids	O
37	.	O

1	Ti	O
2	exhibited	O
3	a	O
4	feather	O
5	-	O
6	like	O
7	morphology	O
8	.	O

1	This	O
2	organization	O
3	suggests	O
4	that	O
5	duplication	O
6	events	O
7	that	O
8	have	O
9	generated	O
10	the	O
11	primate	O
12	FUT3	B
13	-	O
14	FUT5	B
15	-	O
16	FUT6	B
17	cluster	O
18	might	O
19	have	O
20	occurred	O
21	through	O
22	a	O
23	long	O
24	-	O
25	interspersed	O
26	-	O
27	nuclear	O
28	-	O
29	element	O
30	-	O
31	based	O
32	mechanism	O
33	of	O
34	unequal	O
35	crossing	O
36	over	O
37	,	O
38	as	O
39	described	O
40	for	O
41	the	O
42	globin	B
43	cluster	I
44	.	O

1	S	O
2	.,	O
3	Kim	O
4	,	O
5	S	O
6	.	O

1	The	O
2	cop	B
3	region	I
4	also	O
5	harbors	O
6	a	O
7	region	O
8	of	O
9	plasmid	O
10	incompatibility	O
11	,	O
12	inc	B
13	,	O
14	encompassing	O
15	a	O
16	stem	O
17	-	O
18	loop	O
19	structure	O
20	,	O
21	the	O
22	repA	B
23	promoter	I
24	,	O
25	Prep	B
26	,	O
27	as	O
28	well	O
29	as	O
30	two	O
31	distinct	O
32	RepA	B
33	binding	I
34	sites	I
35	,	O
36	BD	O
37	-	O
38	1	O
39	and	O
40	BD	O
41	-	O
42	2	O
43	.	O

1	WA	O
2	constructs	O
3	afforded	O
4	relaxed	O
5	and	O
6	positive	O
7	topoisomers	O
8	,	O
9	and	O
10	cyclization	O
11	kinetics	O
12	indicated	O
13	slow	O
14	interconversion	O
15	of	O
16	precursors	O
17	to	O
18	the	O
19	two	O
20	topoisomers	O
21	.	O

1	The	O
2	RFX	B
3	protein	I
4	family	I
5	includes	O
6	members	O
7	from	O
8	yeast	O
9	to	O
10	humans	O
11	,	O
12	which	O
13	function	O
14	in	O
15	various	O
16	biological	O
17	systems	O
18	,	O
19	and	O
20	share	O
21	a	O
22	DNA	O
23	-	O
24	binding	O
25	domain	O
26	and	O
27	a	O
28	conserved	O
29	C	O
30	-	O
31	terminal	O
32	region	O
33	.	O

1	Binding	O
2	to	O
3	sulphatides	O
4	and	O
5	the	O
6	alpha	B
7	-	I
8	dystroglycan	I
9	receptor	I
10	was	O
11	much	O
12	stronger	O
13	and	O
14	required	O
15	at	O
16	least	O
17	two	O
18	LG	B
19	modules	I
20	.	O

1	Here	O
2	,	O
3	we	O
4	propose	O
5	that	O
6	an	O
7	antagonistic	O
8	,	O
9	BMP	B
10	/	O
11	ALK2	B
12	/	O
13	Smad	B
14	-	O
15	mediated	O
16	signaling	O
17	pathway	O
18	is	O
19	active	O
20	on	O
21	the	O
22	right	O
23	side	O
24	of	O
25	the	O
26	Xenopus	O
27	embryo	O
28	.	O

1	These	O
2	kinases	O
3	belong	O
4	to	O
5	a	O
6	new	O
7	subfamily	O
8	related	O
9	to	O
10	the	O
11	Trk	B
12	subfamily	I
13	.	O

1	The	O
2	data	O
3	indicate	O
4	that	O
5	etr	B
6	-	I
7	1	I
8	is	O
9	essential	O
10	for	O
11	muscle	O
12	development	O
13	in	O
14	C	O
15	.	O
16	elegans	O
17	,	O
18	perhaps	O
19	by	O
20	playing	O
21	a	O
22	role	O
23	in	O
24	post	O
25	-	O
26	transcriptional	O
27	processing	O
28	of	O
29	some	O
30	muscle	O
31	component	O
32	,	O
33	and	O
34	thus	O
35	suggesting	O
36	a	O
37	possible	O
38	conservation	O
39	of	O
40	gene	O
41	function	O
42	with	O
43	human	B
44	CUG	I
45	-	I
46	bp	I
47	.	O

1	Gentamicin	O
2	given	O
3	by	O
4	DPI	O
5	and	O
6	SVN	O
7	significantly	O
8	decreased	O
9	the	O
10	sputum	O
11	Psa	O
12	density	O
13	(	O
14	p	O
15	<	O
16	0	O
17	.	O
18	05	O
19	),	O
20	by	O
21	almost	O
22	one	O
23	order	O
24	of	O
25	magnitude	O
26	.	O

1	CONCLUSIONS	O
2	:	O
3	The	O
4	largest	O
5	value	O
6	of	O
7	the	O
8	joint	O
9	space	O
10	may	O
11	be	O
12	used	O
13	when	O
14	evaluating	O
15	rheumatoid	O
16	AC	O
17	joint	O
18	space	O
19	.	O

1	An	O
2	analysis	O
3	of	O
4	sequence	O
5	of	O
6	the	O
7	mutant	B
8	recN	I
9	gene	I
10	revealed	O
11	a	O
12	G	O
13	:	O
14	C	O
15	to	O
16	T	O
17	:	O
18	A	O
19	transversion	O
20	near	O
21	the	O
22	3	O
23	'	O
24	end	O
25	of	O
26	the	O
27	coding	O
28	region	O
29	.	O

1	Nevertheless	O
2	,	O
3	in	O
4	view	O
5	of	O
6	the	O
7	potential	O
8	transmission	O
9	rates	O
10	of	O
11	HGV	O
12	and	O
13	the	O
14	lack	O
15	of	O
16	effective	O
17	immunization	O
18	,	O
19	HGV	O
20	should	O
21	be	O
22	regarded	O
23	as	O
24	a	O
25	potential	O
26	occupational	O
27	hazard	O
28	for	O
29	medical	O
30	and	O
31	dental	O
32	staff	O
33	.	O

1	Detection	O
2	of	O
3	poisoning	O
4	by	O
5	Impila	O
6	(	O
7	Callilepis	O
8	laureola	O
9	)	O
10	in	O
11	a	O
12	mother	O
13	and	O
14	child	O
15	.	O

1	We	O
2	have	O
3	previously	O
4	identified	O
5	mouse	B
6	and	I
7	human	I
8	cDNAs	I
9	encoding	I
10	UNC	I
11	-	I
12	51	I
13	-	I
14	like	I
15	kinase	I
16	(	O
17	ULK1	B
18	).	O

1	ULKs	B
2	and	O
3	UNC	B
4	-	I
5	51	I
6	share	O
7	a	O
8	typical	O
9	domain	O
10	structure	O
11	of	O
12	an	O
13	amino	O
14	-	O
15	terminal	O
16	kinase	O
17	domain	O
18	,	O
19	a	O
20	central	O
21	proline	O
22	/	O
23	serine	O
24	rich	O
25	(	O
26	PS	O
27	)	O
28	domain	O
29	,	O
30	and	O
31	a	O
32	carboxy	O
33	-	O
34	terminal	O
35	(	O
36	C	O
37	)	O
38	domain	O
39	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	ULK2	B
6	is	O
7	involved	O
8	in	O
9	a	O
10	previously	O
11	uncharacterized	O
12	signaling	O
13	pathway	O
14	in	O
15	mammalian	O
16	cells	O
17	.	O

1	Connector	B
2	enhancer	I
3	of	I
4	KSR	I
5	(	O
6	CNK	B
7	)	O
8	is	O
9	a	O
10	multidomain	O
11	protein	O
12	required	O
13	for	O
14	RAS	B
15	signaling	O
16	.	O

1	In	O
2	simpler	O
3	organisms	O
4	,	O
5	the	O
6	ATP	B
7	sulfurylase	I
8	and	O
9	APS	B
10	kinase	I
11	reactions	O
12	are	O
13	catalyzed	O
14	by	O
15	separate	O
16	enzymes	O
17	encoded	O
18	by	O
19	two	O
20	or	O
21	three	O
22	genes	O
23	,	O
24	suggesting	O
25	that	O
26	a	O
27	fusion	O
28	of	O
29	separate	O
30	genes	O
31	during	O
32	the	O
33	course	O
34	of	O
35	evolution	O
36	generated	O
37	the	O
38	bifunctional	O
39	enzyme	O
40	.	O

1	Epstein	B
2	-	I
3	Barr	I
4	virus	I
5	(	I
6	EBV	I
7	)	I
8	latent	I
9	membrane	I
10	protein	I
11	1	I
12	(	O
13	LMP1	B
14	)	O
15	is	O
16	essential	O
17	for	O
18	EBV	O
19	-	O
20	mediated	O
21	transformation	O
22	of	O
23	primary	O
24	B	O
25	lymphocytes	O
26	.	O

1	The	O
2	amino	O
3	-	O
4	terminal	O
5	half	O
6	of	O
7	1a	B
8	is	O
9	a	O
10	distant	O
11	homolog	B
12	of	I
13	alphavirus	I
14	nonstructural	I
15	protein	I
16	nsP1	I
17	,	O
18	which	O
19	has	O
20	been	O
21	implicated	O
22	in	O
23	capping	O
24	viral	O
25	RNAs	O
26	.	O

1	Moreover	O
2	,	O
3	a	O
4	recombinant	O
5	Ad	O
6	expressing	O
7	Ad5	B
8	E4orf6	I
9	/	I
10	7	I
11	induced	O
12	apoptosis	O
13	in	O
14	rat	O
15	cells	O
16	when	O
17	coinfected	O
18	with	O
19	wild	O
20	-	O
21	type	O
22	p53	B
23	-	O
24	expressing	O
25	Ad	O
26	.	O

1	In	O
2	HCMV	O
3	(	O
4	Towne	O
5	)-	O
6	infected	O
7	HF	O
8	cells	O
9	at	O
10	24	O
11	to	O
12	48	O
13	h	O
14	,	O
15	IE2	B
16	also	O
17	accumulated	O
18	in	O
19	newly	O
20	formed	O
21	viral	O
22	DNA	O
23	replication	O
24	compartments	O
25	containing	O
26	the	O
27	polymerase	B
28	processivity	I
29	factor	I
30	(	O
31	UL44	B
32	),	O
33	the	O
34	single	B
35	-	I
36	stranded	I
37	DNA	I
38	binding	I
39	protein	I
40	(	O
41	SSB	B
42	;	O
43	UL57	B
44	),	O
45	the	O
46	UL112	B
47	-	I
48	113	I
49	accessory	I
50	protein	I
51	,	O
52	and	O
53	newly	O
54	incorporated	O
55	bromodeoxyuridine	O
56	(	O
57	BrdU	O
58	).	O

1	Macroscopic	O
2	researches	O
3	on	O
4	heart	O
5	vascularization	O
6	have	O
7	indicated	O
8	that	O
9	the	O
10	angioarchitecture	O
11	of	O
12	the	O
13	conducting	O
14	system	O
15	differs	O
16	from	O
17	that	O
18	of	O
19	the	O
20	normal	O
21	myocardium	O
22	.	O

1	CONCLUSION	O
2	(	O
3	S	O
4	):	O
5	Measuring	O
6	urinary	O
7	LH	B
8	levels	O
9	is	O
10	an	O
11	excellent	O
12	method	O
13	for	O
14	determining	O
15	ovulation	O
16	.	O

1	However	O
2	,	O
3	reoperation	O
4	for	O
5	bulky	O
6	cervical	O
7	disease	O
8	(	O
9	group	O
10	3	O
11	)	O
12	rarely	O
13	results	O
14	in	O
15	normal	O
16	calcitonin	B
17	levels	O
18	and	O
19	is	O
20	associated	O
21	with	O
22	a	O
23	high	O
24	incidence	O
25	of	O
26	permanent	O
27	hypoparathyroidism	O
28	.	O

1	We	O
2	present	O
3	a	O
4	case	O
5	of	O
6	carcinoma	O
7	of	O
8	the	O
9	breast	O
10	presenting	O
11	concurrently	O
12	with	O
13	SSc	O
14	that	O
15	subsequently	O
16	progressed	O
17	to	O
18	dialysis	O
19	-	O
20	dependent	O
21	renal	O
22	failure	O
23	in	O
24	just	O
25	1	O
26	month	O
27	.	O

1	PURPOSE	O
2	:	O
3	To	O
4	evaluate	O
5	the	O
6	disease	O
7	-	O
8	free	O
9	survival	O
10	(	O
11	DFS	O
12	)	O
13	and	O
14	overall	O
15	survival	O
16	(	O
17	OS	O
18	),	O
19	prognostic	O
20	factors	O
21	,	O
22	and	O
23	treatment	O
24	-	O
25	related	O
26	mortality	O
27	of	O
28	women	O
29	with	O
30	stage	O
31	IIIB	O
32	inflammatory	O
33	breast	O
34	cancer	O
35	(	O
36	IBC	O
37	)	O
38	treated	O
39	with	O
40	combined	O
41	modality	O
42	therapy	O
43	(	O
44	CMT	O
45	)	O
46	and	O
47	high	O
48	-	O
49	dose	O
50	chemotherapy	O
51	(	O
52	HDCT	O
53	)	O
54	with	O
55	autologous	O
56	stem	O
57	-	O
58	cell	O
59	transplantation	O
60	.	O

1	The	O
2	GPI	O
3	anchor	O
4	moiety	O
5	is	O
6	either	O
7	absent	O
8	or	O
9	present	O
10	at	O
11	a	O
12	very	O
13	low	O
14	level	O
15	in	O
16	the	O
17	polypeptide	O
18	expressed	O
19	from	O
20	the	O
21	cDNA	O
22	that	O
23	contained	O
24	both	O
25	the	O
26	signal	O
27	peptide	O
28	and	O
29	GPI	O
30	signal	O
31	sequences	O
32	.	O

1	We	O
2	have	O
3	cloned	O
4	a	O
5	novel	O
6	100	O
7	-	O
8	kDa	O
9	mammalian	O
10	protein	O
11	,	O
12	which	O
13	was	O
14	recognized	O
15	by	O
16	an	O
17	anti	O
18	-	O
19	peptide	O
20	antibody	O
21	against	O
22	an	O
23	epitope	O
24	-	O
25	containing	O
26	nuclear	O
27	localization	O
28	signal	O
29	of	O
30	NF	B
31	-	I
32	kappaB	I
33	p65	I
34	subunit	I
35	.	O

1	Insulin	B
2	-	O
3	regulated	O
4	events	O
5	,	O
6	however	O
7	,	O
8	occur	O
9	in	O
10	all	O
11	cells	O
12	.	O

1	Regulatory	O
2	regions	O
3	in	O
4	the	O
5	promoter	O
6	and	O
7	third	O
8	intron	O
9	of	O
10	the	O
11	growth	B
12	hormone	I
13	gene	I
14	in	I
15	rainbow	I
16	trout	I
17	,	O
18	Oncorhynchus	O
19	mykiss	O
20	walbaum	O
21	.	O

1	Although	O
2	most	O
3	SFV	O
4	genes	O
5	have	O
6	homologs	O
7	encoded	O
8	by	O
9	other	O
10	Chordopoxvirinae	O
11	,	O
12	the	O
13	SFV	O
14	genome	O
15	lacks	O
16	a	O
17	key	O
18	gene	O
19	required	O
20	for	O
21	the	O
22	production	O
23	of	O
24	extracellular	O
25	enveloped	O
26	virus	O
27	.	O

1	They	O
2	self	O
3	-	O
4	completed	O
5	the	O
6	SF	O
7	-	O
8	36	O
9	questionnaire	O
10	and	O
11	their	O
12	QoL	O
13	was	O
14	described	O
15	and	O
16	retrospectively	O
17	compared	O
18	to	O
19	that	O
20	of	O
21	historical	O
22	controls	O
23	.	O

1	There	O
2	was	O
3	a	O
4	trend	O
5	toward	O
6	an	O
7	association	O
8	between	O
9	IENF	O
10	and	O
11	sural	O
12	nerve	O
13	unmyelinated	O
14	fiber	O
15	densities	O
16	(	O
17	r	O
18	=	O
19	0	O
20	.	O
21	32	O
22	,	O
23	p	O
24	=	O
25	0	O
26	.	O
27	054	O
28	).	O

1	In	O
2	addition	O
3	,	O
4	media	O
5	containing	O
6	F	B
7	beta	I
8	alpha	I
9	/	O
10	CG	B
11	beta	I
12	displayed	O
13	high	O
14	-	O
15	affinity	O
16	binding	O
17	to	O
18	both	O
19	CG	B
20	and	I
21	FSH	I
22	receptors	I
23	.	O

1	In	O
2	contrast	O
3	,	O
4	AP	B
5	-	I
6	2	I
7	binding	O
8	activity	O
9	was	O
10	significantly	O
11	greater	O
12	in	O
13	T47D	O
14	cells	O
15	,	O
16	and	O
17	Western	O
18	blots	O
19	confirmed	O
20	increased	O
21	AP	B
22	-	I
23	2	I
24	protein	I
25	levels	O
26	in	O
27	these	O
28	cells	O
29	.	O

1	N	O
2	.	O
3	van	O
4	Hoek	O
5	,	O
6	and	O
7	M	O
8	.	O

1	Here	O
2	,	O
3	we	O
4	describe	O
5	a	O
6	tyrosine	O
7	-	O
8	phosphorylated	O
9	nuclear	O
10	protein	O
11	,	O
12	YT521	B
13	-	I
14	B	I
15	,	O
16	and	O
17	show	O
18	that	O
19	it	O
20	interacts	O
21	with	O
22	the	O
23	nuclear	B
24	transcriptosomal	I
25	component	I
26	scaffold	I
27	attachment	I
28	factor	I
29	B	I
30	,	O
31	and	O
32	the	O
33	68	B
34	-	I
35	kDa	I
36	Src	I
37	substrate	O
38	associated	O
39	during	O
40	mitosis	O
41	,	O
42	Sam68	B
43	.	O

1	These	O
2	mutants	O
3	all	O
4	failed	O
5	to	O
6	interact	O
7	with	O
8	the	O
9	TraR	B
10	fusion	I
11	in	O
12	the	O
13	two	O
14	-	O
15	hybrid	O
16	system	O
17	.	O

1	PhoP	B
2	-	O
3	PhoQ	B
4	homologues	O
5	in	O
6	Pseudomonas	O
7	aeruginosa	O
8	regulate	O
9	expression	O
10	of	O
11	the	O
12	outer	B
13	-	I
14	membrane	I
15	protein	I
16	OprH	I
17	and	O
18	polymyxin	O
19	B	O
20	resistance	O
21	.	O

1	Deletion	O
2	of	O
3	fdsR	B
4	revealed	O
5	a	O
6	dual	O
7	regulatory	O
8	effect	O
9	of	O
10	FdsR	B
11	on	O
12	the	O
13	fds	B
14	operon	I
15	by	O
16	acting	O
17	as	O
18	transcriptional	O
19	activator	O
20	in	O
21	the	O
22	presence	O
23	of	O
24	formate	O
25	or	O
26	as	O
27	repressor	O
28	in	O
29	the	O
30	absence	O
31	of	O
32	formate	O
33	.	O

1	With	O
2	constructs	O
3	containing	O
4	the	O
5	binding	O
6	site	O
7	of	O
8	one	O
9	gene	O
10	fused	O
11	to	O
12	the	O
13	promoter	O
14	of	O
15	the	O
16	other	O
17	,	O
18	we	O
19	demonstrated	O
20	that	O
21	the	O
22	positional	O
23	requirements	O
24	are	O
25	a	O
26	function	O
27	of	O
28	the	O
29	specific	O
30	binding	O
31	site	O
32	,	O
33	not	O
34	the	O
35	promoter	O
36	.	O

1	In	O
2	addition	O
3	,	O
4	all	O
5	three	O
6	Opa	B
7	proteins	I
8	of	O
9	C751	O
10	bind	O
11	equally	O
12	well	O
13	to	O
14	HeLa	O
15	cells	O
16	transfected	O
17	with	O
18	cDNA	O
19	encoding	O
20	the	O
21	carcinoembryonic	B
22	antigen	I
23	[	O
24	CEA	B
25	(	O
26	CD66e	B
27	)]	O
28	subgroup	O
29	of	O
30	the	O
31	CD66	B
32	family	I
33	,	O
34	but	O
35	show	O
36	distinct	O
37	tropism	O
38	for	O
39	CGM1	B
40	-	O
41	(	O
42	CD66d	B
43	)	O
44	and	O
45	NCA	B
46	(	O
47	CD66c	B
48	)-	O
49	expressing	O
50	cells	O
51	.	O

1	FISH	O
2	using	O
3	a	O
4	whole	O
5	chromosome	O
6	4	O
7	paint	O
8	demonstrated	O
9	multiple	O
10	rearrangements	O
11	involving	O
12	chromosome	O
13	4	O
14	in	O
15	MCF	O
16	-	O
17	7	O
18	AdVp3000	O
19	and	O
20	MCF	O
21	-	O
22	7	O
23	MX	O
24	,	O
25	while	O
26	S1	O
27	-	O
28	M1	O
29	-	O
30	80	O
31	contained	O
32	only	O
33	a	O
34	simple	O
35	reciprocal	O
36	translocation	O
37	.	O

1	The	O
2	MXR	B
3	gene	I
4	encodes	O
5	a	O
6	half	O
7	-	O
8	transporter	O
9	and	O
10	the	O
11	absence	O
12	of	O
13	cytogenetic	O
14	evidence	O
15	of	O
16	coamplification	O
17	of	O
18	other	O
19	regions	O
20	suggests	O
21	that	O
22	a	O
23	partner	O
24	may	O
25	not	O
26	be	O
27	overexpressed	O
28	,	O
29	and	O
30	instead	O
31	the	O
32	MXR	B
33	half	I
34	-	I
35	transporter	I
36	homodimerizes	O
37	to	O
38	mediate	O
39	drug	O
40	transport	O
41	.	O

1	The	O
2	effect	O
3	of	O
4	smoking	O
5	was	O
6	not	O
7	examined	O
8	in	O
9	this	O
10	study	O
11	,	O
12	as	O
13	such	O
14	data	O
15	were	O
16	not	O
17	available	O
18	.	O

1	Serum	B
2	insulin	I
3	-	I
4	like	I
5	growth	I
6	factor	I
7	I	I
8	(	O
9	IGF	B
10	-	I
11	I	I
12	)	O
13	SD	O
14	score	O
15	increased	O
16	from	O
17	-	O
18	2	O
19	.	O
20	2	O
21	and	O
22	-	O
23	4	O
24	.	O
25	2	O
26	in	O
27	men	O
28	and	O
29	women	O
30	,	O
31	respectively	O
32	,	O
33	to	O
34	1	O
35	.	O
36	8	O
37	and	O
38	-	O
39	0	O
40	.	O
41	9	O
42	at	O
43	6	O
44	months	O
45	and	O
46	0	O
47	.	O
48	8	O
49	and	O
50	-	O
51	0	O
52	.	O
53	7	O
54	at	O
55	12	O
56	months	O
57	.	O

1	BACKGROUND	O
2	:	O
3	Measurement	O
4	of	O
5	stereoacuity	O
6	at	O
7	varying	O
8	distances	O
9	,	O
10	by	O
11	real	O
12	or	O
13	simulated	O
14	depth	O
15	stereoacuity	O
16	tests	O
17	,	O
18	is	O
19	helpful	O
20	in	O
21	the	O
22	evaluation	O
23	of	O
24	patients	O
25	with	O
26	binocular	O
27	imbalance	O
28	or	O
29	strabismus	O
30	.	O

1	Additional	O
2	studies	O
3	revealed	O
4	that	O
5	bovine	B
6	brain	I
7	Galpha	I
8	(	I
9	q	I
10	/	I
11	11	I
12	)	I
13	could	O
14	also	O
15	bind	O
16	to	O
17	an	O
18	N	O
19	-	O
20	terminal	O
21	construct	O
22	of	O
23	GRK2	B
24	,	O
25	while	O
26	no	O
27	binding	O
28	of	O
29	Galpha	O
30	(	O
31	q	O
32	/	O
33	11	O
34	),	O
35	Galpha	O
36	(	O
37	s	O
38	),	O
39	Galpha	O
40	(	O
41	i	O
42	),	O
43	or	O
44	Galpha	B
45	(	I
46	12	I
47	/	I
48	13	I
49	)	I
50	to	O
51	comparable	O
52	constructs	O
53	of	O
54	GRK5	B
55	or	O
56	GRK6	B
57	was	O
58	observed	O
59	.	O

1	The	O
2	elm1	B
3	kinase	I
4	functions	O
5	in	O
6	a	O
7	mitotic	O
8	signaling	O
9	network	O
10	in	O
11	budding	O
12	yeast	O
13	.	O

1	Reverse	O
2	transcription	O
3	(	O
4	RT	O
5	)-	O
6	PCR	O
7	products	O
8	were	O
9	synthesized	O
10	with	O
11	two	O
12	degenerate	O
13	primers	O
14	derived	O
15	from	O
16	the	O
17	conserved	O
18	motifs	O
19	of	O
20	various	O
21	tyrosine	B
22	kinases	I
23	.	O

1	In	O
2	addition	O
3	,	O
4	the	O
5	acetyltransferase	O
6	activity	O
7	of	O
8	p300	B
9	was	O
10	observed	O
11	to	O
12	be	O
13	distinct	O
14	from	O
15	the	O
16	broadly	O
17	essential	O
18	activation	O
19	function	O
20	of	O
21	the	O
22	CH3	B
23	domain	I
24	/	O
25	E1A	B
26	-	O
27	binding	O
28	region	O
29	.	O

1	The	O
2	proliferation	O
3	-	O
4	specific	O
5	HNF	B
6	-	I
7	3	I
8	/	O
9	fork	B
10	head	I
11	homolog	I
12	-	I
13	11B	I
14	protein	O
15	(	O
16	HFH	B
17	-	I
18	11B	I
19	;	O
20	also	O
21	known	O
22	as	O
23	Trident	B
24	and	O
25	Win	B
26	)	O
27	is	O
28	a	O
29	family	O
30	member	O
31	of	O
32	the	O
33	winged	B
34	helix	I
35	/	O
36	fork	B
37	head	I
38	transcription	O
39	factors	O
40	and	O
41	in	O
42	regenerating	O
43	liver	O
44	its	O
45	expression	O
46	is	O
47	reactivated	O
48	prior	O
49	to	O
50	hepatocyte	O
51	entry	O
52	into	O
53	DNA	O
54	replication	O
55	(	O
56	S	O
57	phase	O
58	).	O

1	In	O
2	the	O
3	mouse	O
4	,	O
5	CtBP1	B
6	is	O
7	expressed	O
8	from	O
9	embryo	O
10	to	O
11	adult	O
12	,	O
13	but	O
14	CtBP2	B
15	is	O
16	mainly	O
17	expressed	O
18	during	O
19	embryogenesis	O
20	.	O

1	The	O
2	multiple	O
3	functions	O
4	of	O
5	Pmt3p	B
6	described	O
7	here	O
8	suggest	O
9	that	O
10	several	O
11	nuclear	O
12	proteins	O
13	are	O
14	regulated	O
15	by	O
16	Pmt3p	B
17	conjugation	O
18	.	O

1	The	O
2	role	O
3	of	O
4	transport	O
5	by	O
6	sea	O
7	ice	O
8	from	O
9	the	O
10	Kara	O
11	Sea	O
12	into	O
13	the	O
14	Arctic	O
15	Ocean	O
16	was	O
17	assessed	O
18	by	O
19	a	O
20	small	O
21	subgroup	O
22	at	O
23	GEOMAR	O
24	.	O

1	We	O
2	determined	O
3	whether	O
4	a	O
5	single	O
6	injection	O
7	of	O
8	slow	O
9	-	O
10	release	O
11	estradiol	O
12	-	O
13	17beta	O
14	(	O
15	SRE2	O
16	)	O
17	would	O
18	induce	O
19	pseudopregnancy	O
20	in	O
21	gilts	O
22	and	O
23	whether	O
24	PGF2alpha	O
25	would	O
26	regress	O
27	the	O
28	corpora	O
29	lutea	O
30	(	O
31	CL	O
32	)	O
33	of	O
34	pseudopregnancy	O
35	.	O

1	The	O
2	level	O
3	of	O
4	serum	B
5	creatine	I
6	kinase	I
7	was	O
8	significantly	O
9	high	O
10	2	O
11	days	O
12	after	O
13	ESWIB	O
14	,	O
15	but	O
16	it	O
17	recovered	O
18	in	O
19	a	O
20	week	O
21	.	O

1	Among	O
2	the	O
3	remaining	O
4	22	O
5	sites	O
6	,	O
7	six	O
8	are	O
9	in	O
10	the	O
11	promoters	O
12	of	O
13	known	O
14	alpha	O
15	-	O
16	specific	O
17	genes	O
18	and	O
19	two	O
20	other	O
21	sites	O
22	have	O
23	an	O
24	alpha2	B
25	-	O
26	Mcm1	B
27	-	O
28	dependent	O
29	role	O
30	in	O
31	determining	O
32	the	O
33	direction	O
34	of	O
35	mating	O
36	type	O
37	switching	O
38	.	O

1	Activation	O
2	of	O
3	T	O
4	cells	O
5	via	O
6	the	O
7	TCR	B
8	and	O
9	other	O
10	costimulatory	O
11	receptors	O
12	triggers	O
13	a	O
14	number	O
15	of	O
16	signaling	O
17	cascades	O
18	.	O

1	A	O
2	phylogenetic	O
3	analysis	O
4	with	O
5	the	O
6	TK	B
7	domains	I
8	from	O
9	these	O
10	sequences	O
11	and	O
12	a	O
13	fourth	O
14	,	O
15	from	O
16	a	O
17	novel	O
18	scavenger	B
19	RTK	I
20	(	O
21	all	O
22	domains	O
23	comprise	O
24	the	O
25	signature	O
26	for	O
27	the	O
28	TK	B
29	class	I
30	II	I
31	receptors	I
32	),	O
33	showed	O
34	that	O
35	they	O
36	are	O
37	distantly	O
38	related	O
39	to	O
40	the	O
41	insulin	B
42	and	O
43	insulin	B
44	-	I
45	like	I
46	receptors	I
47	.	O

1	Several	O
2	7SL	B
3	RNA	I
4	-	I
5	encoding	I
6	sequences	I
7	and	O
8	various	O
9	intergenic	O
10	spacers	O
11	were	O
12	amplified	O
13	from	O
14	the	O
15	individual	O
16	HindIII	B
17	fragments	I
18	of	O
19	about	O
20	1	O
21	.	O
22	3	O
23	and	O
24	2	O
25	.	O
26	8	O
27	kb	O
28	.	O

1	Results	O
2	confirmed	O
3	that	O
4	stress	O
5	produced	O
6	CA3	O
7	dendritic	O
8	atrophy	O
9	and	O
10	tianeptine	O
11	prevented	O
12	it	O
13	.	O

1	We	O
2	have	O
3	isolated	O
4	a	O
5	binding	O
6	partner	O
7	for	O
8	the	O
9	Fanconi	B
10	anemia	I
11	group	I
12	C	I
13	protein	I
14	(	O
15	FANCC	B
16	)	O
17	by	O
18	yeast	O
19	two	O
20	-	O
21	hybrid	O
22	screening	O
23	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	both	O
6	transcription	O
7	activators	O
8	depend	O
9	on	O
10	or	O
11	interact	O
12	with	O
13	different	O
14	subunits	O
15	of	O
16	RNA	B
17	polymerase	I
18	,	O
19	although	O
20	their	O
21	role	O
22	in	O
23	formation	O
24	of	O
25	proper	O
26	DNA	O
27	geometry	O
28	may	O
29	also	O
30	be	O
31	crucial	O
32	.	O

1	Klebsiella	O
2	oxytoca	O
3	can	O
4	assimilate	O
5	nitrate	O
6	and	O
7	nitrite	O
8	by	O
9	using	O
10	enzymes	O
11	encoded	O
12	by	O
13	the	O
14	nasFEDCBA	B
15	operon	I
16	.	O

1	Marked	O
2	hemolysis	O
3	significantly	O
4	increased	O
5	plasma	O
6	values	O
7	of	O
8	potassium	O
9	,	O
10	phosphorus	O
11	,	O
12	total	O
13	protein	O
14	,	O
15	and	O
16	aspartate	B
17	aminotransferase	I
18	.	O

1	Studies	O
2	have	O
3	substantiated	O
4	the	O
5	involvement	O
6	of	O
7	numerous	O
8	loci	O
9	on	O
10	certain	O
11	chromosomes	O
12	;	O
13	in	O
14	excess	O
15	of	O
16	10	O
17	chromosomes	O
18	are	O
19	thought	O
20	to	O
21	be	O
22	involved	O
23	.	O

1	By	O
2	negatively	O
3	regulating	O
4	GRK	B
5	-	O
6	mediated	O
7	receptor	O
8	phosphorylation	O
9	,	O
10	beta	B
11	-	I
12	arrestin	I
13	-	O
14	mediated	O
15	processes	O
16	such	O
17	as	O
18	Src	B
19	recruitment	O
20	and	O
21	clathrin	B
22	-	O
23	mediated	O
24	internalization	O
25	,	O
26	which	O
27	are	O
28	required	O
29	for	O
30	GPCR	B
31	-	O
32	mediated	O
33	ERK	B
34	activation	O
35	,	O
36	are	O
37	inhibited	O
38	,	O
39	thus	O
40	dampening	O
41	further	O
42	ERK	B
43	activation	O
44	.	O

1	Based	O
2	on	O
3	subcellular	O
4	fractionation	O
5	,	O
6	the	O
7	47	B
8	-	I
9	kDa	I
10	P	I
11	-	I
12	CIP2	I
13	protein	I
14	is	O
15	mostly	O
16	cytosolic	O
17	.	O

1	Supershift	O
2	EMSAs	O
3	identified	O
4	that	O
5	upstream	B
6	stimulatory	I
7	factor	I
8	-	I
9	1	I
10	and	I
11	-	I
12	2	I
13	(	O
14	USF	B
15	-	I
16	1	I
17	and	I
18	-	I
19	2	I
20	)	O
21	were	O
22	part	O
23	of	O
24	these	O
25	complexes	O
26	.	O

1	Conversely	O
2	,	O
3	E1A	B
4	binding	O
5	to	O
6	only	O
7	p300	B
8	/	O
9	CBP	B
10	results	O
11	in	O
12	an	O
13	increase	O
14	in	O
15	PARP	B
16	enzyme	I
17	activity	O
18	and	O
19	consequently	O
20	in	O
21	cell	O
22	death	O
23	susceptibility	O
24	to	O
25	irradiation	O
26	,	O
27	which	O
28	is	O
29	effectively	O
30	counteracted	O
31	by	O
32	the	O
33	PARP	B
34	chemical	O
35	inhibitor	O
36	3	O
37	-	O
38	aminobenzamide	O
39	.	O

1	Analysis	O
2	of	O
3	its	O
4	genomic	O
5	region	O
6	revealed	O
7	that	O
8	the	O
9	13	O
10	-	O
11	kb	O
12	Cdc6	B
13	gene	I
14	is	O
15	divided	O
16	into	O
17	12	O
18	exons	O
19	by	O
20	11	O
21	introns	O
22	.	O

1	These	O
2	include	O
3	the	O
4	CACCC	O
5	and	O
6	CAAT	O
7	motifs	O
8	.	O

1	Skin	O
2	pH	O
3	changes	O
4	associated	O
5	with	O
6	iontophoresis	O
7	.	O

1	This	O
2	distinction	O
3	was	O
4	based	O
5	upon	O
6	whether	O
7	the	O
8	diagnosis	O
9	provided	O
10	a	O
11	straightforward	O
12	range	O
13	of	O
14	prognoses	O
15	or	O
16	an	O
17	ambiguous	O
18	clinical	O
19	implication	O
20	.	O

1	The	O
2	availability	O
3	of	O
4	potent	O
5	regulatory	O
6	DNA	O
7	cassettes	O
8	harboring	O
9	the	O
10	murine	B
11	D1A	I
12	gene	I
13	promoter	I
14	could	O
15	aid	O
16	testing	O
17	the	O
18	neuronal	O
19	-	O
20	specific	O
21	expression	O
22	of	O
23	transgenes	O
24	in	O
25	vivo	O
26	.	O

1	It	O
2	may	O
3	be	O
4	dependent	O
5	on	O
6	location	O
7	of	O
8	a	O
9	focus	O
10	(	O
11	according	O
12	to	O
13	EEG	O
14	)	O
15	as	O
16	well	O
17	as	O
18	on	O
19	the	O
20	character	O
21	and	O
22	manifestation	O
23	of	O
24	the	O
25	accompanying	O
26	neuropsychologic	O
27	symptomatology	O
28	.	O

1	The	O
2	results	O
3	of	O
4	these	O
5	studies	O
6	demonstrate	O
7	that	O
8	the	O
9	rat	O
10	HDL	O
11	receptor	O
12	SR	B
13	-	I
14	BI	I
15	promoter	O
16	contains	O
17	two	O
18	sterol	O
19	response	O
20	elements	O
21	(	O
22	pSRE	O
23	and	O
24	dSRE	O
25	)	O
26	through	O
27	which	O
28	SREBP	B
29	-	I
30	1a	I
31	can	O
32	bind	O
33	and	O
34	activate	O
35	transcription	O
36	of	O
37	this	O
38	gene	O
39	.	O

1	Phosphorylation	O
2	of	O
3	myosin	B
4	-	I
5	binding	I
6	subunit	I
7	(	O
8	MBS	B
9	)	O
10	of	O
11	myosin	B
12	phosphatase	I
13	by	O
14	Rho	B
15	-	I
16	kinase	I
17	in	O
18	vivo	O
19	.	O

1	Of	O
2	these	O
3	patients	O
4	,	O
5	46	O
6	,	O
7	164	O
8	were	O
9	placed	O
10	on	O
11	a	O
12	waiting	O
13	list	O
14	for	O
15	transplantation	O
16	,	O
17	23	O
18	,	O
19	275	O
20	of	O
21	whom	O
22	received	O
23	a	O
24	first	O
25	cadaveric	O
26	transplant	O
27	between	O
28	1991	O
29	and	O
30	1997	O
31	.	O

1	In	O
2	electrophoretic	O
3	mobility	O
4	shift	O
5	assay	O
6	(	O
7	EMSA	O
8	),	O
9	this	O
10	GLUT4	B
11	repressor	I
12	element	I
13	(	O
14	G4RE	B
15	)	O
16	generated	O
17	specific	O
18	bands	O
19	with	O
20	nuclear	O
21	extracts	O
22	from	O
23	preadipocytes	O
24	,	O
25	but	O
26	not	O
27	from	O
28	adipocytes	O
29	.	O

1	Syndromes	O
2	of	O
3	abnormal	O
4	fat	O
5	redistribution	O
6	and	O
7	metabolic	O
8	complications	O
9	in	O
10	HIV	O
11	-	O
12	infected	O
13	patients	O
14	.	O

1	Cytoprotection	O
2	with	O
3	amifostine	O
4	in	O
5	radiotherapy	O
6	or	O
7	radio	O
8	-	O
9	chemotherapy	O
10	of	O
11	head	O
12	and	O
13	neck	O
14	tumors	O

1	Immunohistochemical	O
2	staining	O
3	was	O
4	positive	O
5	for	O
6	S	B
7	-	I
8	100	I
9	in	O
10	all	O
11	9	O
12	cases	O
13	stained	O
14	,	O
15	positive	O
16	for	O
17	HMB	B
18	-	I
19	45	I
20	in	O
21	9	O
22	(	O
23	90	O
24	%)	O
25	of	O
26	10	O
27	,	O
28	and	O
29	negative	O
30	for	O
31	cytokeratin	B
32	in	O
33	all	O
34	9	O
35	cases	O
36	in	O
37	which	O
38	myxoid	O
39	melanoma	O
40	remained	O
41	in	O
42	the	O
43	block	O
44	after	O
45	previous	O
46	sections	O
47	.	O

1	Patients	O
2	with	O
3	types	O
4	I	O
5	and	O
6	III	O
7	MPGN	O
8	did	O
9	not	O
10	differ	O
11	in	O
12	age	O
13	at	O
14	apparent	O
15	onset	O
16	,	O
17	age	O
18	at	O
19	diagnosis	O
20	,	O
21	or	O
22	interval	O
23	from	O
24	apparent	O
25	onset	O
26	of	O
27	symptoms	O
28	to	O
29	diagnosis	O
30	(	O
31	biopsy	O
32	).	O

1	Residual	O
2	urinary	O
3	abnormalities	O
4	were	O
5	significantly	O
6	more	O
7	frequent	O
8	in	O
9	patients	O
10	with	O
11	type	O
12	III	O
13	than	O
14	type	O
15	I	O
16	MPGN	O
17	.	O

1	Taken	O
2	together	O
3	,	O
4	differences	O
5	in	O
6	signaling	O
7	and	O
8	tissue	O
9	expression	O
10	suggest	O
11	that	O
12	the	O
13	human	B
14	intermediate	I
15	PRLr	I
16	differs	O
17	from	O
18	the	O
19	long	B
20	PRLr	I
21	in	O
22	physiological	O
23	function	O
24	.	O

1	We	O
2	describe	O
3	here	O
4	a	O
5	Drosophila	B
6	melanogaster	I
7	FAK	I
8	homologue	I
9	,	O
10	DFak56	B
11	,	O
12	which	O
13	maps	O
14	to	O
15	band	O
16	56D	O
17	on	O
18	the	O
19	right	O
20	arm	O
21	of	O
22	the	O
23	second	O
24	chromosome	O
25	.	O

1	Because	O
2	the	O
3	Pit	B
4	-	I
5	1	I
6	sites	I
7	in	O
8	the	O
9	hGH	B
10	-	I
11	N	I
12	gene	I
13	promoter	I
14	are	O
15	insufficient	O
16	for	O
17	such	O
18	gene	O
19	activation	O
20	in	O
21	vivo	O
22	,	O
23	these	O
24	data	O
25	suggested	O
26	a	O
27	unique	O
28	chromatin	O
29	-	O
30	mediated	O
31	developmental	O
32	role	O
33	for	O
34	Pit	B
35	-	I
36	1	I
37	in	O
38	the	O
39	hGH	B
40	LCR	I
41	.	O

1	Recombinant	B
2	prenylcysteine	I
3	lyase	I
4	was	O
5	produced	O
6	in	O
7	a	O
8	baculovirus	O
9	-	O
10	Sf9	O
11	expression	O
12	system	O
13	.	O

1	We	O
2	show	O
3	here	O
4	that	O
5	the	O
6	third	O
7	SH3	B
8	domain	I
9	binds	O
10	to	O
11	Sos	B
12	,	O
13	a	O
14	guanine	B
15	nucleotide	I
16	exchange	I
17	factor	I
18	for	O
19	Ras	B
20	and	O
21	Rac	B
22	,	O
23	both	O
24	in	O
25	vitro	O
26	and	O
27	in	O
28	vivo	O
29	.	O

1	Point	O
2	mutations	O
3	in	O
4	the	O
5	third	O
6	SH3	B
7	domain	I
8	abolished	O
9	the	O
10	vinexin	B
11	-	O
12	Sos	B
13	interaction	O
14	.	O

1	In	O
2	gel	O
3	mobility	O
4	shift	O
5	assays	O
6	,	O
7	low	O
8	binding	O
9	activity	O
10	of	O
11	CBF	B
12	to	O
13	the	O
14	wild	B
15	-	I
16	type	I
17	AtpC	I
18	promoter	I
19	sequence	I
20	was	O
21	observed	O
22	with	O
23	nuclear	O
24	extracts	O
25	from	O
26	tissue	O
27	with	O
28	low	O
29	AtpC	B
30	expression	O
31	levels	O
32	,	O
33	i	O
34	.	O
35	e	O
36	.	O
37	extracts	O
38	from	O
39	etiolated	O
40	and	O
41	photobleached	O
42	seedlings	O
43	,	O
44	whereas	O
45	high	O
46	binding	O
47	activity	O
48	was	O
49	detectable	O
50	with	O
51	extracts	O
52	from	O
53	tissues	O
54	with	O
55	high	O
56	AtpC	B
57	expression	O
58	levels	O
59	,	O
60	i	O
61	.	O
62	e	O
63	.	O
64	extracts	O
65	from	O
66	light	O
67	-	O
68	grown	O
69	seedlings	O
70	and	O
71	etiolated	O
72	seedlings	O
73	treated	O
74	with	O
75	cytokinin	B
76	.	O

1	Mycoplasma	O
2	hominis	O
3	infections	O
4	are	O
5	easily	O
6	missed	O
7	because	O
8	conventional	O
9	methods	O
10	for	O
11	bacterial	O
12	detection	O
13	may	O
14	fail	O
15	.	O

1	For	O
2	this	O
3	purpose	O
4	,	O
5	we	O
6	used	O
7	a	O
8	series	O
9	of	O
10	plasmid	O
11	constructs	O
12	encoding	O
13	different	O
14	forms	O
15	of	O
16	the	O
17	envelope	B
18	glycoprotein	I
19	E	I
20	of	I
21	the	I
22	flavivirus	I
23	tick	I
24	-	I
25	borne	I
26	encephalitis	I
27	virus	I
28	.	O

1	They	O
2	are	O
3	subdivided	O
4	into	O
5	two	O
6	types	O
7	that	O
8	activate	O
9	transduction	O
10	pathways	O
11	via	O
12	different	O
13	cell	O
14	surface	O
15	receptors	O
16	.	O

1	We	O
2	report	O
3	here	O
4	that	O
5	out	O
6	of	O
7	the	O
8	major	O
9	pro	O
10	-	O
11	inflammatory	O
12	cytokines	O
13	examined	O
14	,	O
15	IL	B
16	-	I
17	1alpha	I
18	,	O
19	IL	B
20	-	I
21	1beta	I
22	,	O
23	TNF	B
24	-	I
25	alpha	I
26	and	O
27	IL	B
28	-	I
29	6	I
30	,	O
31	only	O
32	IL	B
33	-	I
34	6	I
35	was	O
36	generated	O
37	and	O
38	secreted	O
39	in	O
40	PKCeta	B
41	-	O
42	expressing	O
43	cells	O
44	without	O
45	any	O
46	additional	O
47	inducer	O
48	in	O
49	serum	O
50	-	O
51	supplemented	O
52	cultures	O
53	(	O
54	10	O
55	%	O
56	FCS	O
57	).	O

1	Demyelinating	O
2	diseases	O
3	involving	O
4	the	O
5	grey	O
6	matter	O
7	were	O
8	very	O
9	rare	O
10	,	O
11	but	O
12	we	O
13	must	O
14	consider	O
15	the	O
16	presence	O
17	of	O
18	symmetrical	O
19	thalamic	O
20	involvement	O
21	in	O
22	patients	O
23	with	O
24	ADEM	O
25	.	O

1	To	O
2	define	O
3	the	O
4	minimal	O
5	VDRE	O
6	binding	O
7	domain	O
8	for	O
9	human	B
10	VDR	I
11	(	O
12	hVDR	B
13	),	O
14	a	O
15	series	O
16	of	O
17	C	O
18	-	O
19	terminally	O
20	truncated	O
21	hVDR	B
22	mutants	I
23	(	O
24	Delta134	O
25	,	O
26	Delta113	O
27	,	O
28	Delta102	O
29	,	O
30	Delta90	O
31	,	O
32	Delta84	O
33	,	O
34	Delta80	O
35	,	O
36	and	O
37	Delta60	O
38	)	O
39	was	O
40	generated	O
41	and	O
42	expressed	O
43	in	O
44	bacteria	O
45	.	O

1	By	O
2	an	O
3	induced	O
4	-	O
5	fit	O
6	mechanism	O
7	,	O
8	contacts	O
9	with	O
10	the	O
11	anticodon	O
12	can	O
13	activate	O
14	formation	O
15	of	O
16	a	O
17	robust	O
18	transition	O
19	state	O
20	at	O
21	a	O
22	site	O
23	over	O
24	70	O
25	A	O
26	away	O
27	.	O

1	These	O
2	REPs	O
3	,	O
4	or	O
5	clusters	O
6	of	O
7	paralogous	O
8	loci	O
9	,	O
10	are	O
11	15	O
12	-	O
13	100	O
14	kb	O
15	and	O
16	harbor	O
17	at	O
18	least	O
19	four	O
20	ESTs	O
21	and	O
22	an	O
23	expressed	O
24	SH3GL	B
25	pseudogene	I
26	.	O

1	This	O
2	revealed	O
3	a	O
4	minimum	O
5	of	O
6	six	O
7	novel	O
8	OSBP	B
9	-	I
10	related	I
11	proteins	I
12	,	O
13	designated	O
14	ORP	B
15	-	I
16	1	I
17	to	O
18	ORP	B
19	-	I
20	6	I
21	.	O

1	In	O
2	part	O
3	as	O
4	a	O
5	result	O
6	of	O
7	its	O
8	inability	O
9	to	O
10	sustain	O
11	radiative	O
12	loses	O
13	,	O
14	the	O
15	BB	O
16	resonator	O
17	has	O
18	extremely	O
19	low	O
20	RF	O
21	power	O
22	requirements	O
23	.	O

1	In	O
2	addition	O
3	,	O
4	narZ	B
5	expression	O
6	was	O
7	induced	O
8	approximately	O
9	20	O
10	-	O
11	fold	O
12	intracellularly	O
13	in	O
14	Madin	O
15	-	O
16	Darby	O
17	canine	O
18	kidney	O
19	epithelial	O
20	cells	O
21	and	O
22	16	O
23	-	O
24	fold	O
25	in	O
26	intracellular	O
27	salts	O
28	medium	O
29	,	O
30	which	O
31	is	O
32	believed	O
33	to	O
34	mimic	O
35	the	O
36	intracellular	O
37	milieu	O
38	.	O

1	However	O
2	,	O
3	mechanisms	O
4	underlying	O
5	HIV	O
6	-	O
7	1	O
8	gene	O
9	expression	O
10	in	O
11	the	O
12	CNS	O
13	are	O
14	poorly	O
15	understood	O
16	.	O

1	Is	O
2	radical	O
3	trachelectomy	O
4	a	O
5	safe	O
6	alternative	O
7	to	O
8	radical	O
9	hysterectomy	O
10	for	O
11	patients	O
12	with	O
13	stage	O
14	IA	O
15	-	O
16	B	O
17	carcinoma	O
18	of	O
19	the	O
20	cervix	O
21	?	O
22	BACKGROUND	O
23	:	O
24	The	O
25	prognosis	O
26	associated	O
27	with	O
28	lymph	O
29	node	O
30	negative	O
31	,	O
32	early	O
33	stage	O
34	carcinoma	O
35	of	O
36	the	O
37	cervix	O
38	is	O
39	excellent	O
40	,	O
41	with	O
42	5	O
43	-	O
44	year	O
45	survival	O
46	rates	O
47	greater	O
48	than	O
49	90	O
50	%.	O

1	A	O
2	key	O
3	event	O
4	in	O
5	this	O
6	process	O
7	is	O
8	the	O
9	selective	O
10	recognition	O
11	of	O
12	the	O
13	target	O
14	membrane	O
15	by	O
16	the	O
17	vesicle	O
18	and	O
19	the	O
20	current	O
21	view	O
22	is	O
23	that	O
24	SNARE	B
25	protein	I
26	interactions	O
27	likely	O
28	play	O
29	a	O
30	central	O
31	role	O
32	in	O
33	vesicle	O
34	-	O
35	target	O
36	recognition	O
37	and	O
38	or	O
39	membrane	O
40	fusion	O
41	.	O

1	Scapulae	O
2	with	O
3	a	O
4	Type	O
5	I	O
6	configuration	O
7	were	O
8	found	O
9	to	O
10	have	O
11	low	O
12	values	O
13	for	O
14	the	O
15	coraco	O
16	-	O
17	glenoid	O
18	angle	O
19	and	O
20	coracoid	O
21	overlap	O
22	,	O
23	which	O
24	are	O
25	known	O
26	to	O
27	be	O
28	associated	O
29	with	O
30	a	O
31	short	O
32	coraco	O
33	-	O
34	humeral	O
35	distance	O
36	.	O

1	Measurements	O
2	in	O
3	the	O
4	LWS	O
5	p	O
6	.	O
7	a	O
8	.	O
9	,	O
10	LWS	O
11	lat	O
12	.	O
13	and	O
14	at	O
15	Ward	O
16	'	O
17	s	O
18	triangle	O
19	were	O
20	made	O
21	in	O
22	a	O
23	total	O
24	of	O
25	100	O
26	patients	O
27	.	O

1	A	O
2	group	O
3	of	O
4	66	O
5	DSM	O
6	-	O
7	IV	O
8	paranoid	O
9	schizophrenic	O
10	in	O
11	-	O
12	patients	O
13	were	O
14	assessed	O
15	three	O
16	times	O
17	using	O
18	the	O
19	SAPS	O
20	,	O
21	SANS	O
22	,	O
23	BPRS	O
24	and	O
25	PAS	O
26	.	O

1	In	O
2	conclusion	O
3	:	O
4	(	O
5	i	O
6	)	O
7	TECRA	O
8	kit	O
9	is	O
10	suggested	O
11	to	O
12	be	O
13	used	O
14	for	O
15	screening	O
16	SE	O
17	producing	O
18	strains	O
19	;	O
20	(	O
21	ii	O
22	)	O
23	SET	O
24	-	O
25	RPLA	O
26	and	O
27	RIDASCREEN	O
28	kits	O
29	are	O
30	suitable	O
31	for	O
32	epidemiological	O
33	investigation	O
34	of	O
35	SE	O
36	types	O
37	,	O
38	but	O
39	the	O
40	lack	O
41	of	O
42	ability	O
43	for	O
44	detecting	O
45	SEE	O
46	,	O
47	long	O
48	time	O
49	required	O
50	for	O
51	testing	O
52	with	O
53	SET	O
54	-	O
55	RPLA	O
56	kit	O
57	and	O
58	high	O
59	background	O
60	when	O
61	using	O
62	RIDASCREEN	O
63	kit	O
64	must	O
65	be	O
66	overcome	O
67	;	O
68	and	O
69	(	O
70	iii	O
71	)	O
72	because	O
73	of	O
74	the	O
75	complicated	O
76	test	O
77	procedures	O
78	and	O
79	the	O
80	lack	O
81	of	O
82	ability	O
83	for	O
84	detecting	O
85	SEE	O
86	,	O
87	the	O
88	practicality	O
89	of	O
90	SET	O
91	-	O
92	EIA	O
93	kit	O
94	in	O
95	screening	O
96	and	O
97	epidemiological	O
98	research	O
99	purposes	O
100	is	O
101	low	O
102	.	O

1	Comparison	O
2	of	O
3	immunoassay	O
4	kits	O
5	for	O
6	detection	O
7	of	O
8	staphylococcal	B
9	enterotoxins	I
10	produced	O
11	by	O
12	Staphylococcus	O
13	aureus	O

1	Despite	O
2	the	O
3	high	O
4	frequency	O
5	of	O
6	natural	O
7	infection	O
8	,	O
9	the	O
10	seropositive	O
11	rates	O
12	of	O
13	JEV	O
14	antibody	O
15	still	O
16	correlated	O
17	well	O
18	with	O
19	the	O
20	dose	O
21	of	O
22	vaccine	O
23	received	O
24	,	O
25	i	O
26	.	O
27	e	O
28	.,	O
29	67	O
30	%	O
31	(	O
32	1122	O
33	/	O
34	1664	O
35	),	O
36	66	O
37	%	O
38	(	O
39	65	O
40	/	O
41	97	O
42	),	O
43	33	O
44	%	O
45	(	O
46	4	O
47	/	O
48	12	O
49	)	O
50	and	O
51	40	O
52	%	O
53	(	O
54	19	O
55	/	O
56	47	O
57	)	O
58	for	O
59	children	O
60	receiving	O
61	3	O
62	,	O
63	2	O
64	,	O
65	1	O
66	,	O
67	and	O
68	0	O
69	dose	O
70	of	O
71	JE	O
72	vaccines	O
73	,	O
74	respectively	O
75	(	O
76	P	O
77	<	O
78	0	O
79	.	O
80	0001	O
81	Chi	O
82	-	O
83	square	O
84	for	O
85	trend	O
86	test	O
87	).	O

1	Furthermore	O
2	,	O
3	in	O
4	vivo	O
5	and	O
6	in	O
7	vitro	O
8	protein	O
9	-	O
10	protein	O
11	interaction	O
12	experiments	O
13	have	O
14	shown	O
15	that	O
16	SR33	B
17	protein	I
18	interacts	O
19	with	O
20	itself	O
21	and	O
22	with	O
23	SR45	B
24	protein	I
25	but	O
26	not	O
27	with	O
28	two	O
29	other	O
30	members	O
31	(	O
32	SRZ21	B
33	and	O
34	SRZ22	B
35	)	O
36	of	O
37	the	O
38	SR	B
39	family	I
40	that	O
41	are	O
42	known	O
43	to	O
44	interact	O
45	with	O
46	the	O
47	Arabidopsis	O
48	full	O
49	-	O
50	length	O
51	U	B
52	-	I
53	70K	I
54	only	O
55	.	O

1	In	O
2	summary	O
3	,	O
4	WT1	B
5	is	O
6	enriched	O
7	by	O
8	oligo	O
9	(	O
10	dT	O
11	)	O
12	chromatography	O
13	,	O
14	as	O
15	are	O
16	U2AF65	B
17	,	O
18	the	O
19	U5	B
20	small	I
21	nuclear	I
22	RNP	I
23	-	I
24	associated	I
25	protein	I
26	p116	I
27	and	O
28	hnRNP	O
29	A1	B
30	.	O

1	Six	O
2	out	O
3	of	O
4	ten	O
5	hearts	O
6	from	O
7	macerated	O
8	stillborn	O
9	infants	O
10	showed	O
11	varying	O
12	degrees	O
13	of	O
14	positive	O
15	staining	O
16	.	O

1	Tih1	B
2	maps	O
3	to	O
4	distal	O
5	mouse	O
6	Chr	O
7	1	O
8	and	O
9	human	O
10	Chr	O
11	1q31	O
12	,	O
13	chromosomal	O
14	regions	O
15	that	O
16	have	O
17	not	O
18	shown	O
19	evidence	O
20	for	O
21	imprinting	O
22	and	O
23	,	O
24	in	O
25	contrast	O
26	to	O
27	Ipl	B
28	,	O
29	Tih1	B
30	is	O
31	expressed	O
32	equally	O
33	from	O
34	both	O
35	parental	O
36	alleles	O
37	.	O

1	A	O
2	novel	O
3	pleckstrin	B
4	homology	I
5	-	I
6	related	I
7	gene	I
8	family	I
9	defined	O
10	by	O
11	Ipl	B
12	/	O
13	Tssc3	B
14	,	O
15	TDAG51	B
16	,	O
17	and	O
18	Tih1	B
19	:	O
20	tissue	O
21	-	O
22	specific	O
23	expression	O
24	,	O
25	chromosomal	O
26	location	O
27	,	O
28	and	O
29	parental	O
30	imprinting	O
31	.	O

1	The	O
2	potential	O
3	for	O
4	highly	O
5	reactive	O
6	nanoparticles	O
7	(	O
8	RNP	O
9	)	O
10	to	O
11	absorb	O
12	destructively	O
13	,	O
14	i	O
15	.	O
16	e	O
17	.	O
18	to	O
19	neutralize	O
20	highly	O
21	toxic	O
22	substances	O
23	such	O
24	as	O
25	the	O
26	warfare	O
27	agents	O
28	GA	O
29	,	O
30	GB	O
31	,	O
32	HD	O
33	and	O
34	VX	O
35	,	O
36	has	O
37	been	O
38	demonstrated	O
39	in	O
40	the	O
41	laboratory	O
42	.	O

1	There	O
2	were	O
3	minimal	O
4	negative	O
5	effects	O
6	on	O
7	hematological	O
8	parameters	O
9	,	O
10	acid	O
11	-	O
12	base	O
13	status	O
14	,	O
15	and	O
16	blood	O
17	gases	O
18	.	O

1	Twelve	O
2	out	O
3	of	O
4	43	O
5	renal	O
6	failure	O
7	patients	O
8	had	O
9	troponin	B
10	I	I
11	0	O
12	.	O
13	13	O
14	-	O
15	0	O
16	.	O
17	9	O
18	microg	O
19	/	O
20	l	O
21	using	O
22	Axsym	O
23	method	O
24	and	O
25	4	O
26	had	O
27	levels	O
28	of	O
29	0	O
30	.	O
31	07	O
32	-	O
33	0	O
34	.	O
35	13	O
36	microg	O
37	/	O
38	l	O
39	using	O
40	Immuno	O
41	1	O
42	.	O

1	Therefore	O
2	,	O
3	we	O
4	propose	O
5	that	O
6	p27	B
7	represents	O
8	a	O
9	crucial	O
10	molecule	O
11	in	O
12	HMBA	O
13	signaling	O
14	that	O
15	cannot	O
16	be	O
17	replaced	O
18	by	O
19	p21	B
20	.	O

1	Transient	O
2	,	O
3	high	O
4	-	O
5	level	O
6	Ras	B
7	-	O
8	expression	O
9	induces	O
10	transcriptional	O
11	activation	O
12	of	O
13	p21	B
14	mediated	O
15	by	O
16	a	O
17	GC	O
18	-	O
19	rich	O
20	region	O
21	in	O
22	p21	B
23	promoter	I
24	-	O
25	83	O
26	-	O
27	54	O
28	bp	O
29	relative	O
30	to	O
31	the	O
32	transcription	O
33	initiation	O
34	site	O
35	containing	O
36	binding	O
37	sites	O
38	for	O
39	Sp1	B
40	-	I
41	family	I
42	transcription	I
43	factors	I
44	.	O

1	The	O
2	RET	B
3	/	O
4	PTC3	B
5	rearrangement	O
6	is	O
7	formed	O
8	by	O
9	fusion	O
10	of	O
11	the	O
12	ELE1	B
13	and	O
14	RET	B
15	genes	I
16	,	O
17	and	O
18	is	O
19	highly	O
20	prevalent	O
21	in	O
22	radiation	O
23	-	O
24	induced	O
25	post	O
26	-	O
27	Chernobyl	O
28	papillary	O
29	thyroid	O
30	carcinomas	O
31	.	O

1	Apoptosis	O
2	of	O
3	small	O
4	cells	O
5	is	O
6	still	O
7	observed	O
8	after	O
9	co	O
10	-	O
11	transfection	O
12	of	O
13	JBD	B
14	and	O
15	LMP1	B
16	but	O
17	in	O
18	addition	O
19	a	O
20	few	O
21	apoptotic	O
22	HD	O
23	-	O
24	MyZ	O
25	cells	O
26	with	O
27	large	O
28	fused	O
29	nuclear	O
30	masses	O
31	are	O
32	identified	O
33	suggesting	O
34	that	O
35	specific	O
36	inhibition	O
37	of	O
38	JNK	B
39	leads	O
40	also	O
41	to	O
42	apoptosis	O
43	of	O
44	LMP1	B
45	induced	O
46	RS	O
47	cells	O
48	.	O

1	In	O
2	addition	O
3	to	O
4	the	O
5	bZIP	B
6	protein	I
7	Opaque2	I
8	(	O
9	O2	B
10	),	O
11	there	O
12	are	O
13	other	O
14	maize	O
15	endosperm	O
16	nuclear	O
17	proteins	O
18	that	O
19	recognize	O
20	the	O
21	O2	B
22	box	I
23	in	O
24	22	O
25	kDa	O
26	zein	B
27	gene	O
28	promoters	O
29	.	O

1	The	O
2	mEmBP	B
3	-	I
4	1	I
5	protein	I
6	can	O
7	activate	O
8	transcription	O
9	from	O
10	a	O
11	truncated	O
12	promoter	O
13	containing	O
14	a	O
15	pentamer	O
16	of	O
17	the	O
18	O2	B
19	site	I
20	in	O
21	yeast	O
22	cells	O
23	;	O
24	however	O
25	,	O
26	it	O
27	inhibited	O
28	regulated	O
29	transcription	O
30	of	O
31	a	O
32	22	B
33	kDa	I
34	zein	I
35	promoter	I
36	in	O
37	a	O
38	transient	O
39	expression	O
40	assay	O
41	using	O
42	cultured	O
43	maize	O
44	endosperm	O
45	cells	O
46	.	O

1	GHB	O
2	,	O
3	2	O
4	CB	O
5	,	O
6	HMB	O
7	,	O
8	are	O
9	some	O
10	of	O
11	these	O
12	recent	O
13	substances	O
14	.	O

1	There	O
2	were	O
3	15	O
4	deaths	O
5	,	O
6	seven	O
7	of	O
8	which	O
9	were	O
10	felt	O
11	to	O
12	be	O
13	avoidable	O
14	.	O

1	With	O
2	this	O
3	GH	B
4	and	O
5	estrogen	O
6	treatment	O
7	regimen	O
8	,	O
9	most	O
10	girls	O
11	with	O
12	TS	O
13	can	O
14	grow	O
15	and	O
16	develop	O
17	much	O
18	more	O
19	in	O
20	conformity	O
21	with	O
22	their	O
23	healthy	O
24	peers	O
25	.	O

1	We	O
2	propose	O
3	that	O
4	the	O
5	reduced	O
6	responsiveness	O
7	of	O
8	CYP3A2	B
9	is	O
10	the	O
11	result	O
12	of	O
13	preferential	O
14	binding	O
15	of	O
16	COUP	B
17	-	I
18	TF	I
19	at	O
20	the	O
21	CYP3A2	B
22	DexRE	I
23	-	I
24	1	I
25	site	I
26	.	O

1	Higher	O
2	CYP3A23	B
3	basal	O
4	activity	O
5	appears	O
6	to	O
7	be	O
8	due	O
9	to	O
10	an	O
11	E	O
12	-	O
13	box	O
14	in	O
15	3A23SiteA	B
16	that	O
17	interacts	O
18	with	O
19	USF1	B
20	,	O
21	a	O
22	ubiquitous	O
23	bHLH	B
24	/	I
25	leucine	I
26	zipper	I
27	transcription	I
28	factor	I
29	.	O

1	The	O
2	first	O
3	one	O
4	is	O
5	a	O
6	TPA	O
7	-	O
8	responsive	O
9	element	O
10	that	O
11	controls	O
12	the	O
13	base	O
14	-	O
15	line	O
16	ST3	B
17	promoter	I
18	activity	O
19	but	O
20	is	O
21	not	O
22	required	O
23	for	O
24	its	O
25	activation	O
26	.	O

1	To	O
2	understand	O
3	the	O
4	basis	O
5	for	O
6	the	O
7	increased	O
8	cell	O
9	surface	O
10	stability	O
11	compared	O
12	with	O
13	wild	O
14	-	O
15	type	O
16	peptide	O
17	and	O
18	to	O
19	understand	O
20	the	O
21	differences	O
22	in	O
23	T	O
24	cell	O
25	recognition	O
26	between	O
27	I1Y	B
28	and	O
29	I1F	B
30	,	O
31	we	O
32	determined	O
33	the	O
34	x	O
35	-	O
36	ray	O
37	crystal	O
38	structures	O
39	of	O
40	the	O
41	two	O
42	class	B
43	I	I
44	MHC	I
45	-	I
46	peptide	I
47	complexes	I
48	.	O

1	Redistribution	O
2	of	O
3	mannosidase	B
4	I	I
5	was	O
6	also	O
7	observed	O
8	in	O
9	cells	O
10	incubated	O
11	at	O
12	15	O
13	degrees	O
14	C	O
15	.	O

1	In	O
2	addition	O
3	,	O
4	using	O
5	biochemical	O
6	activity	O
7	assays	O
8	for	O
9	Rho	B
10	-	O
11	like	O
12	GTPases	B
13	,	O
14	we	O
15	show	O
16	that	O
17	the	O
18	expression	O
19	of	O
20	beta1A	B
21	,	O
22	beta1D	B
23	,	O
24	or	O
25	IL2R	B
26	-	O
27	beta1A	B
28	in	O
29	GE11	O
30	or	O
31	GD25	O
32	cells	O
33	triggers	O
34	activation	O
35	of	O
36	both	O
37	RhoA	B
38	and	O
39	Rac1	B
40	,	O
41	but	O
42	not	O
43	of	O
44	Cdc42	B
45	.	O

1	In	O
2	conclusion	O
3	,	O
4	our	O
5	data	O
6	do	O
7	not	O
8	support	O
9	a	O
10	role	O
11	for	O
12	IVIg	B
13	in	O
14	the	O
15	remyelination	O
16	of	O
17	stable	O
18	multiple	O
19	sclerosis	O
20	lesions	O
21	as	O
22	measured	O
23	by	O
24	central	O
25	conduction	O
26	time	O
27	.	O

1	The	O
2	rhabdomyosarcoma	O
3	R1H	O
4	growing	O
5	on	O
6	the	O
7	right	O
8	flank	O
9	of	O
10	male	O
11	WAG	O
12	/	O
13	Rij	O
14	rats	O
15	was	O
16	clamped	O
17	for	O
18	2	O
19	or	O
20	4	O
21	h	O
22	at	O
23	20	O
24	degrees	O
25	C	O
26	or	O
27	37	O
28	degrees	O
29	C	O
30	.	O

1	Relative	O
2	to	O
3	coherent	O
4	control	O
5	words	O
6	(	O
7	e	O
8	.	O
9	g	O
10	.,	O
11	quick	O
12	),	O
13	these	O
14	discourse	O
15	-	O
16	dependent	O
17	semantic	O
18	anomalies	O
19	elicited	O
20	a	O
21	large	O
22	N400	O
23	effect	O
24	that	O
25	began	O
26	at	O
27	about	O
28	200	O
29	to	O
30	250	O
31	msec	O
32	after	O
33	word	O
34	onset	O
35	.	O

1	These	O
2	synergistic	O
3	effects	O
4	were	O
5	strongly	O
6	Jem	B
7	-	I
8	1	I
9	dose	O
10	-	O
11	dependent	O
12	.	O

1	Like	O
2	the	O
3	Tob	B
4	protein	I
5	,	O
6	Tob2	B
7	inhibited	O
8	cell	O
9	cycle	O
10	progression	O
11	from	O
12	the	O
13	G0	O
14	/	O
15	G1	O
16	to	O
17	S	O
18	phases	O
19	.	O

1	The	O
2	coordinate	O
3	increase	O
4	in	O
5	cyclin	B
6	D1	I
7	and	O
8	p21	B
9	had	O
10	the	O
11	effect	O
12	of	O
13	decreasing	O
14	the	O
15	specific	O
16	but	O
17	not	O
18	absolute	O
19	activity	O
20	of	O
21	cyclin	B
22	D1	I
23	/	O
24	cdk4	B
25	.	O
26	p53	B
27	was	O
28	not	O
29	involved	O
30	since	O
31	CSF	B
32	-	I
33	1	I
34	induction	O
35	of	O
36	p21	B
37	was	O
38	unaffected	O
39	by	O
40	dominant	B
41	-	I
42	negative	I
43	p53	I
44	expression	O
45	.	O

1	In	O
2	addition	O
3	,	O
4	SLK	B
5	displays	O
6	high	O
7	homology	O
8	to	O
9	microtubule	B
10	and	I
11	nuclear	I
12	associated	I
13	protein	I
14	(	O
15	M	B
16	-	I
17	NAP	I
18	)	O
19	and	O
20	AT1	B
21	-	I
22	46	I
23	,	O
24	both	O
25	of	O
26	unknown	O
27	function	O
28	.	O

1	In	O
2	this	O
3	study	O
4	26	O
5	patients	O
6	(	O
7	20	O
8	females	O
9	and	O
10	6	O
11	males	O
12	)	O
13	were	O
14	evaluated	O
15	.	O

1	The	O
2	signalling	O
3	molecules	O
4	Wnt1	B
5	and	O
6	Sonic	B
7	hedgehog	I
8	,	O
9	implicated	O
10	in	O
11	the	O
12	activation	O
13	of	O
14	Myf5	B
15	in	O
16	myogenic	O
17	progenitor	O
18	cells	O
19	in	O
20	the	O
21	somite	O
22	,	O
23	are	O
24	also	O
25	produced	O
26	in	O
27	the	O
28	viscinity	O
29	of	O
30	the	O
31	Myf5	B
32	expression	I
33	domain	I
34	in	O
35	the	O
36	mesencephalon	O
37	.	O

1	STUDY	O
2	DESIGN	O
3	AND	O
4	METHODS	O
5	:	O
6	A	O
7	study	O
8	was	O
9	initiated	O
10	to	O
11	compare	O
12	the	O
13	collection	O
14	of	O
15	PBPCs	O
16	with	O
17	the	O
18	new	O
19	device	O
20	,	O
21	the	O
22	AutoPBSC	O
23	(	O
24	version	O
25	[	O
26	V	O
27	]	O
28	6	O
29	.	O
30	0	O
31	with	O
32	AutoPBSC	O
33	tubing	O
34	set	O
35	),	O
36	and	O
37	that	O
38	with	O
39	the	O
40	MNC	O
41	(	O
42	mononuclear	O
43	cell	O
44	)	O
45	procedure	O
46	(	O
47	V4	O
48	.	O
49	7	O
50	with	O
51	white	O
52	cell	O
53	tubing	O
54	set	O
55	),	O
56	for	O
57	patients	O
58	and	O
59	healthy	O
60	donors	O
61	.	O

1	Albumin	B
2	dialysis	O
3	:	O
4	effective	O
5	removal	O
6	of	O
7	copper	O
8	in	O
9	a	O
10	patient	O
11	with	O
12	fulminant	O
13	Wilson	O
14	disease	O
15	and	O
16	successful	O
17	bridging	O
18	to	O
19	liver	O
20	transplantation	O
21	:	O
22	a	O
23	new	O
24	possibility	O
25	for	O
26	the	O
27	elimination	O
28	of	O
29	protein	O
30	-	O
31	bound	O
32	toxins	O
33	.	O

1	Some	O
2	artificial	O
3	promoter	O
4	constructs	O
5	containing	O
6	multiple	O
7	Sp1	B
8	sites	I
9	were	O
10	highly	O
11	responsive	O
12	to	O
13	ethanol	O
14	,	O
15	but	O
16	others	O
17	were	O
18	not	O
19	,	O
20	suggesting	O
21	that	O
22	the	O
23	organization	O
24	of	O
25	the	O
26	proximal	O
27	promoter	O
28	region	O
29	was	O
30	an	O
31	additional	O
32	factor	O
33	that	O
34	affected	O
35	the	O
36	ethanol	O
37	response	O
38	.	O

1	Overexpression	O
2	of	O
3	CDP	B
4	/	O
5	cut	B
6	in	O
7	ROS	O
8	17	O
9	/	O
10	2	O
11	.	O
12	8	O
13	osteosarcoma	O
14	cells	O
15	results	O
16	in	O
17	repression	O
18	of	O
19	OC	B
20	promoter	I
21	activity	O
22	;	O
23	this	O
24	repression	O
25	is	O
26	abrogated	O
27	by	O
28	mutating	O
29	OC	B
30	box	I
31	I	I
32	.	O

1	Injection	O
2	of	O
3	double	O
4	-	O
5	stranded	O
6	RNA	O
7	into	O
8	C	O
9	.	O
10	elegans	O
11	results	O
12	in	O
13	embryonic	O
14	lethality	O
15	;	O
16	thus	O
17	,	O
18	the	O
19	SF1	B
20	gene	I
21	is	O
22	essential	O
23	not	O
24	only	O
25	in	O
26	yeast	O
27	but	O
28	also	O
29	in	O
30	at	O
31	least	O
32	one	O
33	metazoan	O
34	.	O

1	Both	O
2	domains	O
3	were	O
4	required	O
5	for	O
6	specific	O
7	DNA	O
8	binding	O
9	to	O
10	the	O
11	beta	B
12	-	I
13	retinoic	I
14	acid	I
15	receptor	I
16	element	I
17	,	O
18	producing	O
19	a	O
20	DNase	B
21	I	I
22	footprint	O
23	covering	O
24	predominantly	O
25	one	O
26	strand	O
27	.	O

1	Snail	B
2	family	I
3	proteins	I
4	are	O
5	zinc	O
6	finger	O
7	transcriptional	O
8	regulators	O
9	first	O
10	identified	O
11	in	O
12	Drosophila	O
13	which	O
14	play	O
15	critical	O
16	roles	O
17	in	O
18	cell	O
19	fate	O
20	determination	O
21	.	O

1	Consistent	O
2	with	O
3	this	O
4	finding	O
5	,	O
6	beta	B
7	-	I
8	catenin	I
9	interacted	O
10	directly	O
11	with	O
12	the	O
13	RA	B
14	receptor	I
15	(	O
16	RAR	B
17	)	O
18	in	O
19	a	O
20	retinoid	O
21	-	O
22	dependent	O
23	manner	O
24	,	O
25	but	O
26	not	O
27	with	O
28	the	O
29	retinoid	B
30	X	I
31	receptor	I
32	(	O
33	RXR	B
34	),	O
35	and	O
36	RAR	B
37	competed	O
38	with	O
39	TCF	B
40	for	O
41	beta	B
42	-	I
43	catenin	I
44	binding	O
45	.	O

1	Sequence	O
2	analysis	O
3	of	O
4	the	O
5	promoter	O
6	region	O
7	showed	O
8	no	O
9	TATA	O
10	box	O
11	but	O
12	identified	O
13	consensus	O
14	binding	O
15	motifs	O
16	for	O
17	Sp1	B
18	,	O
19	CREB	B
20	,	O
21	and	O
22	half	O
23	sites	O
24	of	O
25	the	O
26	estrogen	B
27	receptor	I
28	binding	I
29	site	I
30	.	O

1	Sak	B
2	kinase	I
3	gene	O
4	structure	O
5	and	O
6	transcriptional	O
7	regulation	O
8	.	O

1	Thrombolysis	O
2	was	O
3	followed	O
4	by	O
5	a	O
6	similar	O
7	increase	O
8	of	O
9	platelet	O
10	activity	O
11	with	O
12	maximal	O
13	values	O
14	reached	O
15	at	O
16	the	O
17	3rd	O
18	hour	O
19	in	O
20	both	O
21	groups	O
22	(	O
23	196	O
24	+/-	O
25	43	O
26	IU	O
27	/	O
28	ml	O
29	in	O
30	Group	O
31	1	O
32	and	O
33	192	O
34	+/-	O
35	39	O
36	in	O
37	Group	O
38	2	O
39	:	O
40	p	O
41	&	O
42	lt	O
43	;	O
44	001versus	O
45	baseline	O
46	and	O
47	p	O
48	NS	O
49	between	O
50	the	O
51	groups	O
52	).	O

1	Similar	O
2	to	O
3	Hp140	B
4	,	O
5	isolated	O
6	Hp55	B
7	binds	O
8	DNA	O
9	with	O
10	moderate	O
11	strength	O
12	and	O
13	was	O
14	a	O
15	specificity	O
16	for	O
17	double	O
18	-	O
19	stranded	O
20	primer	O
21	-	O
22	template	O
23	DNA	O
24	.	O

1	Finally	O
2	,	O
3	three	O
4	new	O
5	missense	O
6	mutations	O
7	,	O
8	E138V	O
9	,	O
10	R254G	O
11	,	O
12	and	O
13	P362R	O
14	,	O
15	were	O
16	identified	O
17	in	O
18	the	O
19	human	B
20	AC	I
21	gene	I
22	from	O
23	FD	O
24	patients	O
25	.	O

1	These	O
2	data	O
3	indicate	O
4	that	O
5	the	O
6	interaction	O
7	of	O
8	eIF4A	B
9	with	O
10	the	O
11	middle	O
12	region	O
13	of	O
14	eIF4GI	B
15	is	O
16	necessary	O
17	for	O
18	translation	O
19	,	O
20	whereas	O
21	the	O
22	interaction	O
23	of	O
24	eIF4A	B
25	with	O
26	the	O
27	C	O
28	-	O
29	terminal	O
30	region	O
31	plays	O
32	a	O
33	modulatory	O
34	role	O
35	.	O

1	The	O
2	DAP5	B
3	/	O
4	p86	B
5	apoptotic	O
6	form	O
7	was	O
8	more	O
9	potent	O
10	than	O
11	DAP5	B
12	/	O
13	p97	B
14	in	O
15	these	O
16	functional	O
17	assays	O
18	.	O

1	12	O
2	:	O
3	2684	O
4	-	O
5	2697	O
6	,	O
7	1998	O
8	):	O
9	a	O
10	key	O
11	step	O
12	of	O
13	this	O
14	model	O
15	is	O
16	the	O
17	activation	O
18	of	O
19	the	O
20	MAPK	B
21	Fus3p	I
22	through	O
23	the	O
24	G	O
25	(	O
26	betagamma	O
27	)-	O
28	dependent	O
29	relocalization	O
30	of	O
31	the	O
32	Ste5p	B
33	-	O
34	MAPK	B
35	cascade	O
36	to	O
37	the	O
38	plasma	O
39	membrane	O
40	.	O

1	Consistent	O
2	with	O
3	this	O
4	finding	O
5	,	O
6	wild	B
7	-	I
8	type	I
9	SAGA	I
10	inhibits	O
11	TBP	B
12	binding	O
13	to	O
14	the	O
15	HIS3	B
16	promoter	I
17	in	O
18	vitro	O
19	,	O
20	while	O
21	SAGA	B
22	lacking	O
23	Spt3	B
24	or	O
25	Spt8	B
26	is	O
27	not	O
28	inhibitory	O
29	.	O

1	Saccharomyces	O
2	cerevisiae	O
3	contains	O
4	a	O
5	genetically	O
6	and	O
7	biochemically	O
8	proven	O
9	CAK	B
10	gene	I
11	,	O
12	CAK1	B
13	,	O
14	that	O
15	encodes	O
16	a	O
17	monomeric	O
18	44	B
19	-	I
20	kDa	I
21	Cak1p	I
22	protein	I
23	unrelated	O
24	to	O
25	Cdk7	B
26	.	O

1	Northern	O
2	blot	O
3	and	O
4	reverse	O
5	transcription	O
6	-	O
7	PCR	O
8	analyses	O
9	of	O
10	human	O
11	mRNA	O
12	samples	O
13	demonstrate	O
14	that	O
15	RNR	B
16	is	O
17	expressed	O
18	exclusively	O
19	in	O
20	the	O
21	retina	O
22	,	O
23	with	O
24	transcripts	O
25	of	O
26	approximately	O
27	7	O
28	.	O
29	5	O
30	kb	O
31	,	O
32	approximately	O
33	3	O
34	.	O
35	0	O
36	kb	O
37	,	O
38	and	O
39	approximately	O
40	2	O
41	.	O
42	3	O
43	kb	O
44	by	O
45	Northern	O
46	blot	O
47	analysis	O
48	.	O

1	Particularly	O
2	striking	O
3	was	O
4	the	O
5	conservation	O
6	of	O
7	an	O
8	AP	B
9	-	I
10	4	I
11	binding	I
12	site	I
13	within	O
14	100	O
15	nucleotides	O
16	upstream	O
17	of	O
18	the	O
19	transcription	O
20	initiation	O
21	site	O
22	in	O
23	both	O
24	Aal	B
25	-	O
26	rpL34	B
27	and	O
28	Aal	B
29	-	O
30	rpL8	B
31	genes	O
32	.	O

1	Based	O
2	on	O
3	a	O
4	type	O
5	I	O
6	error	O
7	of	O
8	0	O
9	.	O
10	05	O
11	,	O
12	our	O
13	study	O
14	had	O
15	a	O
16	power	O
17	greater	O
18	than	O
19	or	O
20	equal	O
21	to	O
22	75	O
23	%	O
24	to	O
25	detect	O
26	group	O
27	differences	O
28	in	O
29	treatment	O
30	effect	O
31	of	O
32	greater	O
33	than	O
34	or	O
35	equal	O
36	to	O
37	15	O
38	%	O
39	to	O
40	20	O
41	%.	O

1	CONCLUSIONS	O
2	:	O
3	Serum	O
4	levels	O
5	of	O
6	S	B
7	-	I
8	100beta	I
9	are	O
10	reliable	O
11	markers	O
12	for	O
13	adverse	O
14	neurologic	O
15	outcomes	O
16	after	O
17	cardiac	O
18	surgery	O
19	.	O

1	However	O
2	,	O
3	no	O
4	genetic	O
5	alteration	O
6	was	O
7	detected	O
8	in	O
9	any	O
10	of	O
11	the	O
12	cancers	O
13	examined	O
14	.	O

1	All	O
2	problems	O
3	were	O
4	associated	O
5	with	O
6	fractured	O
7	or	O
8	lost	O
9	screws	O
10	.	O

1	Statins	B
2	:	O
3	lower	O
4	lipids	O
5	and	O
6	better	O
7	bones	O
8	?	O
9	Although	O
10	statins	O
11	are	O
12	widely	O
13	used	O
14	as	O
15	cholesterol	O
16	-	O
17	lowering	O
18	drugs	O
19	,	O
20	a	O
21	recent	O
22	study	O
23	suggests	O
24	that	O
25	these	O
26	compounds	O
27	have	O
28	anabolic	O
29	effects	O
30	on	O
31	bone	O
32	and	O
33	could	O
34	be	O
35	developed	O
36	into	O
37	new	O
38	treatments	O
39	for	O
40	common	O
41	metabolic	O
42	bone	O
43	diseases	O
44	such	O
45	as	O
46	osteoporosis	O

1	The	O
2	accumulated	O
3	products	O
4	of	O
5	ancient	O
6	duplication	O
7	events	O
8	can	O
9	be	O
10	readily	O
11	observed	O
12	among	O
13	the	O
14	genes	O
15	encoding	O
16	voltage	O
17	-	O
18	dependent	O
19	Ca	O
20	(	O
21	2	O
22	+)	O
23	ion	O
24	channels	O
25	.	O

1	The	O
2	VirR	B
3	response	I
4	regulator	I
5	from	O
6	Clostridium	O
7	perfringens	O
8	binds	O
9	independently	O
10	to	O
11	two	O
12	imperfect	O
13	direct	O
14	repeats	O
15	located	O
16	upstream	O
17	of	O
18	the	O
19	pfoA	B
20	promoter	I
21	.	O

1	Cloning	O
2	and	O
3	sequencing	O
4	of	O
5	the	O
6	upstream	O
7	region	O
8	of	O
9	pepX	B
10	revealed	O
11	the	O
12	presence	O
13	of	O
14	two	O
15	ORFs	O
16	of	O
17	360	O
18	and	O
19	1	O
20	,	O
21	338	O
22	bp	O
23	that	O
24	were	O
25	shown	O
26	to	O
27	be	O
28	able	O
29	to	O
30	encode	O
31	proteins	O
32	with	O
33	high	O
34	homology	O
35	to	O
36	GlnR	B
37	and	O
38	GlnA	B
39	proteins	I
40	,	O
41	respectively	O
42	.	O

1	Objective	O
2	:	O
3	To	O
4	evaluate	O
5	endometrial	O
6	thickness	O
7	and	O
8	the	O
9	incidence	O
10	of	O
11	uterine	O
12	bleeding	O
13	in	O
14	postmenopausal	O
15	women	O
16	using	O
17	either	O
18	tibolone	O
19	2	O
20	.	O
21	5	O
22	mg	O
23	or	O
24	continuous	O
25	combined	O
26	2	O
27	mg	O
28	estradiol	O
29	and	O
30	1	O
31	mg	O
32	norethisterone	O
33	acetate	O
34	(	O
35	E	O
36	+	O
37	NETA	O
38	)	O
39	daily	O
40	as	O
41	hormone	O
42	replacement	O
43	therapy	O
44	.	O

1	Leukocyte	O
2	cultures	O
3	,	O
4	prepared	O
5	from	O
6	blood	O
7	drawn	O
8	from	O
9	these	O
10	18	O
11	children	O
12	at	O
13	6	O
14	months	O
15	of	O
16	age	O
17	,	O
18	produced	O
19	lower	O
20	yields	O
21	of	O
22	IFN	B
23	than	O
24	those	O
25	of	O
26	the	O
27	remaining	O
28	53	O
29	children	O
30	,	O
31	when	O
32	stimulated	O
33	with	O
34	adenovirus	O
35	(	O
36	P	O
37	<	O
38	0	O
39	.	O
40	001	O
41	),	O
42	coronavirus	O
43	(	O
44	P	O
45	<	O
46	0	O
47	.	O
48	001	O
49	)	O
50	or	O
51	rhinovirus	O
52	(	O
53	P	O
54	=	O
55	0	O
56	.	O
57	002	O
58	).	O

1	In	O
2	the	O
3	BF	O
4	ECT	O
5	group	O
6	the	O
7	-	O
8	age	O
9	based	O
10	dose	O
11	would	O
12	have	O
13	been	O
14	similarly	O
15	dependent	O
16	on	O
17	the	O
18	initial	O
19	seizure	O
20	threshold	O
21	level	O
22	.	O

1	Histological	O
2	analysis	O
3	showed	O
4	that	O
5	the	O
6	neuronal	O
7	loss	O
8	in	O
9	the	O
10	DHED	O
11	-	O
12	treated	O
13	group	O
14	was	O
15	notably	O
16	reduced	O
17	in	O
18	the	O
19	hippocampal	O
20	area	O
21	(	O
22	CA1	O
23	)	O
24	of	O
25	ischemic	O
26	rats	O
27	and	O
28	in	O
29	the	O
30	dentate	O
31	gyrus	O
32	and	O
33	hippocampal	O
34	area	O
35	(	O
36	CA1	O
37	and	O
38	CA3	O
39	)	O
40	of	O
41	EC	O
42	-	O
43	lesioned	O
44	rats	O
45	compared	O
46	with	O
47	the	O
48	nontreated	O
49	group	O
50	.	O

1	The	O
2	extents	O
3	of	O
4	phosphorylation	O
5	of	O
6	Ser44	O
7	and	O
8	Ser64	O
9	were	O
10	1	O
11	:	O
12	1	O
13	,	O
14	whereas	O
15	those	O
16	of	O
17	the	O
18	four	O
19	minor	O
20	sites	O
21	all	O
22	together	O
23	were	O
24	<	O
25	30	O
26	%	O
27	of	O
28	the	O
29	major	O
30	one	O
31	.	O

1	Serum	O
2	HBV	O
3	-	O
4	DNA	O
5	,	O
6	viral	O
7	serology	O
8	,	O
9	and	O
10	liver	O
11	enzymes	O
12	were	O
13	measured	O
14	sequentially	O
15	;	O
16	liver	O
17	histology	O
18	was	O
19	taken	O
20	before	O
21	and	O
22	during	O
23	treatment	O
24	in	O
25	12	O
26	patients	O
27	.	O

1	Chem	O
2	.	O

1	Maximum	O
2	induction	O
3	of	O
4	AP	B
5	-	I
6	1	I
7	was	O
8	reached	O
9	at	O
10	a	O
11	concentration	O
12	of	O
13	250	O
14	nmol	O
15	/	O
16	L	O
17	of	O
18	CalC	O
19	.	O

1	Haycocknema	O
2	perplexum	O
3	n	O
4	.	O
5	g	O
6	.,	O
7	n	O
8	.	O
9	sp	O
10	.	O

1	Rams	O
2	were	O
3	weighed	O
4	and	O
5	testis	O
6	size	O
7	was	O
8	estimated	O
9	by	O
10	orchimetry	O
11	at	O
12	each	O
13	time	O
14	period	O
15	.	O

1	Animal	O
2	studies	O
3	showed	O
4	that	O
5	beam	O
6	equalization	O
7	significantly	O
8	improved	O
9	fluoroscopic	O
10	and	O
11	angiographic	O
12	image	O
13	quality	O
14	.	O

1	Role	O
2	of	O
3	estrogen	B
4	receptor	I
5	ligand	O
6	and	O
7	estrogen	O
8	response	O
9	element	O
10	sequence	O
11	on	O
12	interaction	O
13	with	O
14	chicken	B
15	ovalbumin	I
16	upstream	I
17	promoter	I
18	transcription	I
19	factor	I
20	(	O
21	COUP	B
22	-	I
23	TF	I
24	).	O

1	CONCLUSION	O
2	:	O
3	In	O
4	Cdks	B
5	functioning	O
6	throughout	O
7	the	O
8	cell	O
9	cycle	O
10	,	O
11	tyrosine	O
12	phosphorylation	O
13	is	O
14	inhibitory	O
15	to	O
16	the	O
17	activation	O
18	of	O
19	kinase	O
20	,	O
21	whereas	O
22	the	O
23	phosphorylation	O
24	of	O
25	threonine	O
26	in	O
27	the	O
28	T	O
29	-	O
30	loop	O
31	is	O
32	essential	O
33	for	O
34	activation	O
35	.	O

1	We	O
2	also	O
3	report	O
4	that	O
5	AHR	B
6	interacts	O
7	with	O
8	COUP	B
9	-	I
10	TF	I
11	in	O
12	transfected	O
13	CV	O
14	-	O
15	1	O
16	cells	O
17	.	O

1	AB004534	B
2	.	O

1	The	O
2	prevalence	O
3	of	O
4	hepatitis	O
5	C	O
6	virus	O
7	(	O
8	HCV	O
9	)	O
10	infection	O
11	is	O
12	relatively	O
13	low	O
14	in	O
15	childhood	O
16	,	O
17	with	O
18	anti	B
19	-	I
20	HCV	I
21	prevalence	O
22	rates	O
23	of	O
24	0	O
25	.	O
26	1	O
27	-	O
28	0	O
29	.	O
30	4	O
31	%	O
32	in	O
33	the	O
34	Western	O
35	world	O
36	.	O

1	Clear	O
2	and	O
3	evidenced	O
4	-	O
5	based	O
6	information	O
7	should	O
8	be	O
9	provided	O
10	to	O
11	patients	O
12	as	O
13	to	O
14	the	O
15	means	O
16	of	O
17	prevention	O
18	with	O
19	special	O
20	attention	O
21	to	O
22	individual	O
23	risk	O
24	groups	O
25	such	O
26	as	O
27	IV	O
28	drug	O
29	abusers	O
30	.	O

1	During	O
2	latency	O
3	,	O
4	more	O
5	than	O
6	1	O
7	%	O
8	of	O
9	neurons	O
10	in	O
11	ganglia	O
12	that	O
13	innervate	O
14	the	O
15	footpad	O
16	expressed	O
17	beta	B
18	-	I
19	galactosidase	I
20	,	O
21	with	O
22	the	O
23	number	O
24	of	O
25	positive	O
26	cells	O
27	remaining	O
28	constant	O
29	for	O
30	at	O
31	least	O
32	5	O
33	months	O
34	.	O

1	As	O
2	an	O
3	alternative	O
4	approach	O
5	to	O
6	this	O
7	question	O
8	,	O
9	we	O
10	have	O
11	studied	O
12	the	O
13	effects	O
14	of	O
15	ectopically	O
16	expressed	O
17	SHIP	B
18	,	O
19	SHP	B
20	-	I
21	1	I
22	,	O
23	or	O
24	SHP	B
25	-	I
26	2	I
27	SH2	O
28	-	O
29	containing	O
30	decoy	O
31	proteins	O
32	on	O
33	Fc	B
34	gamma	I
35	RIIB1	I
36	signaling	O
37	.	O

1	Compared	O
2	to	O
3	those	O
4	with	O
5	normal	O
6	renal	O
7	functions	O
8	,	O
9	these	O
10	patients	O
11	were	O
12	older	O
13	(	O
14	P	O
15	<	O
16	or	O
17	=	O
18	0	O
19	.	O
20	01	O
21	),	O
22	had	O
23	significantly	O
24	elevated	O
25	blood	O
26	pressures	O
27	(	O
28	P	O
29	<	O
30	0	O
31	.	O
32	01	O
33	or	O
34	P	O
35	=	O
36	0	O
37	.	O
38	0001	O
39	),	O
40	and	O
41	in	O
42	the	O
43	case	O
44	of	O
45	Type	O
46	1	O
47	DM	O
48	,	O
49	with	O
50	a	O
51	higher	O
52	body	O
53	mass	O
54	index	O
55	(	O
56	P	O
57	=	O
58	0	O
59	.	O
60	0001	O
61	)	O
62	and	O
63	waist	O
64	-	O
65	hip	O
66	ratio	O
67	(	O
68	P	O
69	<	O
70	0	O
71	.	O
72	01	O
73	).	O

1	In	O
2	all	O
3	tissues	O
4	examined	O
5	only	O
6	transcripts	O
7	positive	O
8	for	O
9	insert	O
10	3	O
11	,	O
12	an	O
13	18	O
14	bp	O
15	insertion	O
16	in	O
17	repeat	O
18	21	O
19	,	O
20	were	O
21	amplified	O
22	,	O
23	even	O
24	under	O
25	conditions	O
26	in	O
27	which	O
28	a	O
29	30	O
30	%	O
31	level	O
32	of	O
33	insert	O
34	3	O
35	negative	O
36	transcript	O
37	could	O
38	be	O
39	easily	O
40	detected	O
41	in	O
42	artificially	O
43	prepared	O
44	control	O
45	samples	O
46	.	O

1	These	O
2	results	O
3	show	O
4	that	O
5	the	O
6	CAAT	O
7	-	O
8	region	O
9	is	O
10	involved	O
11	in	O
12	upregulating	O
13	the	O
14	MDR1	B
15	promoter	I
16	in	O
17	HL60	O
18	/	O
19	VCR	O
20	cells	O
21	.	O

1	Both	O
2	receptors	O
3	utilize	O
4	protein	B
5	tyrosine	I
6	kinases	I
7	(	O
8	PTKs	B
9	)	O
10	for	O
11	the	O
12	phosphorylation	O
13	of	O
14	various	O
15	signaling	O
16	molecules	O
17	,	O
18	a	O
19	process	O
20	that	O
21	is	O
22	critical	O
23	for	O
24	the	O
25	function	O
26	of	O
27	both	O
28	receptors	O
29	.	O

1	Hypothermia	O
2	After	O
3	Cardiac	O
4	Arrest	O
5	(	O
6	HACA	O
7	)	O
8	Study	O
9	Group	O
10	.	O

1	The	O
2	synergistic	O
3	effect	O
4	due	O
5	to	O
6	the	O
7	5	O
8	'-	O
9	3	O
10	'	O
11	cooperation	O
12	was	O
13	at	O
14	least	O
15	fourfold	O
16	greater	O
17	than	O
18	the	O
19	sum	O
20	of	O
21	the	O
22	contributions	O
23	of	O
24	the	O
25	individual	O
26	UTRs	O
27	.	O

1	We	O
2	demonstrate	O
3	that	O
4	both	O
5	R	B
6	and	O
7	Z	B
8	activate	O
9	the	O
10	cellular	O
11	stress	O
12	mitogen	B
13	-	I
14	activated	I
15	protein	I
16	(	I
17	MAP	I
18	)	I
19	kinases	I
20	,	O
21	p38	B
22	and	O
23	JNK	B
24	,	O
25	resulting	O
26	in	O
27	phosphorylation	O
28	(	O
29	and	O
30	activation	O
31	)	O
32	of	O
33	the	O
34	cellular	B
35	transcription	I
36	factor	I
37	ATF2	I
38	.	O

1	Two	O
2	US	O
3	commercial	O
4	cultivars	O
5	(	O
6	Tehama	O
7	and	O
8	Vina	O
9	),	O
10	three	O
11	European	O
12	commercial	O
13	cultivars	O
14	(	O
15	Esterhazy	O
16	,	O
17	139	O
18	,	O
19	G120	O
20	)	O
21	and	O
22	five	O
23	New	O
24	Zealand	O
25	selections	O
26	(	O
27	Rex	O
28	,	O
29	Dublin	O
30	'	O
31	s	O
32	Glory	O
33	,	O
34	Meyric	O
35	,	O
36	McKinster	O
37	,	O
38	Stanley	O
39	)	O
40	were	O
41	evaluated	O
42	.	O

1	Anatomy	O
2	of	O
3	the	O
4	uterine	O
5	artery	O
6	.	O

1	However	O
2	,	O
3	activation	O
4	of	O
5	the	O
6	cAMP	O
7	pathway	O
8	,	O
9	which	O
10	is	O
11	known	O
12	to	O
13	regulate	O
14	inhibin	B
15	alpha	I
16	expression	O
17	,	O
18	greatly	O
19	enhanced	O
20	the	O
21	actions	O
22	of	O
23	SF	B
24	-	I
25	1	I
26	.	O

1	Deletion	O
2	and	O
3	site	O
4	-	O
5	directed	O
6	mutagenesis	O
7	localized	O
8	a	O
9	novel	O
10	SF	B
11	-	I
12	1	I
13	regulatory	I
14	element	I
15	(	O
16	TCA	O
17	GGGCCA	O
18	;	O
19	-	O
20	137	O
21	to	O
22	-	O
23	129	O
24	)	O
25	adjacent	O
26	to	O
27	a	O
28	variant	O
29	cAMP	O
30	-	O
31	response	O
32	element	O
33	(	O
34	CRE	O
35	;	O
36	-	O
37	120	O
38	to	O
39	-	O
40	114	O
41	).	O

1	Previously	O
2	,	O
3	we	O
4	showed	O
5	that	O
6	the	O
7	APRE	O
8	is	O
9	a	O
10	cytokine	O
11	[	O
12	tumor	B
13	necrosis	I
14	factor	I
15	-	I
16	alpha	I
17	(	O
18	TNFalpha	B
19	)]-	O
20	inducible	O
21	enhancer	O
22	by	O
23	binding	O
24	the	O
25	heterodimeric	B
26	nuclear	I
27	factor	I
28	-	I
29	kappaB	I
30	(	O
31	NF	B
32	-	I
33	kappaB	I
34	)	O
35	complex	O
36	Rel	B
37	A	I
38	x	O
39	NF	B
40	-	I
41	kappaB1	I
42	.	O

1	Angiotensin	B
2	II	I
3	induces	O
4	nuclear	B
5	factor	I
6	(	I
7	NF	I
8	)-	I
9	kappaB1	I
10	isoforms	I
11	to	O
12	bind	O
13	the	O
14	angiotensinogen	B
15	gene	I
16	acute	O
17	-	O
18	phase	O
19	response	O
20	element	O
21	:	O
22	a	O
23	stimulus	O
24	-	O
25	specific	O
26	pathway	O
27	for	O
28	NF	B
29	-	I
30	kappaB	I
31	activation	O
32	.	O

1	Synthetic	O
2	ligands	O
3	have	O
4	been	O
5	identified	O
6	that	O
7	reset	O
8	and	O
9	amplify	O
10	the	O
11	cycle	O
12	of	O
13	pulsatile	O
14	GH	B
15	secretion	O
16	by	O
17	interacting	O
18	with	O
19	the	O
20	orphan	B
21	GH	I
22	-	I
23	secretagogue	I
24	receptor	I
25	(	O
26	GHS	B
27	-	I
28	R	I
29	).	O

1	The	O
2	collection	O
3	of	O
4	mutants	O
5	displaying	O
6	TGN	O
7	sorting	O
8	defects	O
9	includes	O
10	members	O
11	with	O
12	mutations	O
13	in	O
14	previously	O
15	identified	O
16	vacuolar	B
17	protein	I
18	sorting	I
19	genes	I
20	(	O
21	VPS	B
22	),	O
23	including	O
24	the	O
25	dynamin	B
26	family	O
27	member	O
28	VPS1	B
29	.	O

1	Also	O
2	in	O
3	the	O
4	spectrum	O
5	of	O
6	mutants	O
7	with	O
8	TGN	O
9	sorting	O
10	defects	O
11	are	O
12	isolates	O
13	with	O
14	mutations	O
15	in	O
16	the	O
17	following	O
18	:	O
19	RIC1	B
20	,	O
21	encoding	O
22	a	O
23	product	O
24	originally	O
25	proposed	O
26	to	O
27	participate	O
28	in	O
29	ribosome	O
30	biogenesis	O
31	;	O
32	LUV1	B
33	,	O
34	encoding	O
35	a	O
36	product	O
37	potentially	O
38	involved	O
39	in	O
40	vacuole	O
41	and	O
42	microtubule	O
43	organization	O
44	;	O
45	and	O
46	INP53	B
47	,	O
48	encoding	O
49	a	O
50	synaptojanin	B
51	-	I
52	like	I
53	inositol	I
54	polyphosphate	I
55	5	I
56	-	I
57	phosphatase	I
58	.	O

1	The	O
2	single	O
3	strandedness	O
4	is	O
5	manifested	O
6	as	O
7	a	O
8	terminal	O
9	extension	O
10	of	O
11	the	O
12	G	O
13	-	O
14	rich	O
15	strand	O
16	(	O
17	G	O
18	tails	O
19	)	O
20	that	O
21	can	O
22	occur	O
23	independently	O
24	of	O
25	telomerase	B
26	,	O
27	suggesting	O
28	that	O
29	cdc17	B
30	/	O
31	pol1	B
32	mutants	O
33	exhibit	O
34	defects	O
35	in	O
36	telomeric	O
37	lagging	O
38	-	O
39	strand	O
40	synthesis	O
41	.	O

1	In	O
2	addition	O
3	,	O
4	CaMig1	B
5	formed	O
6	specific	O
7	complexes	O
8	with	O
9	the	O
10	URS1	O
11	region	O
12	of	O
13	the	O
14	S	B
15	.	I
16	cerevisiae	I
17	FBP1	I
18	gene	I
19	.	O

1	Furthermore	O
2	,	O
3	the	O
4	wide	O
5	distribution	O
6	of	O
7	the	O
8	GFP	B
9	-	O
10	POLO	B
11	protein	O
12	to	O
13	all	O
14	compartments	O
15	of	O
16	the	O
17	mitotic	O
18	apparatus	O
19	provides	O
20	a	O
21	valuable	O
22	tool	O
23	for	O
24	future	O
25	studies	O
26	on	O
27	cell	O
28	cycle	O
29	during	O
30	development	O
31	.	O

1	An	O
2	ASIC	O
3	-	O
4	chip	O
5	for	O
6	stereoscopic	O
7	depth	O
8	analysis	O
9	in	O
10	video	O
11	-	O
12	real	O
13	-	O
14	time	O
15	based	O
16	on	O
17	visual	O
18	cortical	O
19	cell	O
20	behavior	O
21	.	O

1	However	O
2	,	O
3	calphostin	O
4	C	O
5	,	O
6	a	O
7	specific	O
8	inhibitor	O
9	of	O
10	PKC	B
11	,	O
12	abolished	O
13	the	O
14	TPA	O
15	-	O
16	induced	O
17	increase	O
18	in	O
19	CFI	B
20	mRNA	I
21	levels	O
22	.	O

1	Preimmune	B
2	IgG	I
3	,	O
4	anti	B
5	-	I
6	GalT	I
7	Fab	I
8	fragments	I
9	,	O
10	irrelevant	O
11	polymers	O
12	and	O
13	monomeric	O
14	N	O
15	-	O
16	acetylglucosamine	O
17	had	O
18	no	O
19	effect	O
20	.	O

1	Arhythmacanthus	O
2	Yamaguti	O
3	,	O
4	1935	O
5	is	O
6	maintained	O
7	as	O
8	a	O
9	synonym	O
10	of	O
11	Heterosentis	O
12	because	O
13	the	O
14	distinction	O
15	between	O
16	two	O
17	and	O
18	three	O
19	hook	O
20	types	O
21	is	O
22	made	O
23	equivocal	O
24	when	O
25	the	O
26	transition	O
27	between	O
28	the	O
29	apical	O
30	and	O
31	subapical	O
32	hooks	O
33	is	O
34	gradual	O
35	.	O

1	We	O
2	describe	O
3	a	O
4	case	O
5	of	O
6	acetaminophen	O
7	overdose	O
8	that	O
9	was	O
10	treated	O
11	with	O
12	both	O
13	hemodialysis	O
14	(	O
15	HD	O
16	)	O
17	and	O
18	NAC	O
19	due	O
20	to	O
21	severe	O
22	intoxication	O
23	and	O
24	slow	O
25	drug	O
26	clearance	O
27	.	O

1	Following	O
2	conditioning	O
3	,	O
4	a	O
5	single	O
6	coat	O
7	of	O
8	adhesive	O
9	was	O
10	applied	O
11	and	O
12	light	O
13	-	O
14	cured	O
15	.	O

1	Downstream	O
2	of	O
3	the	O
4	G	O
5	-	O
6	A	O
7	anastomosis	O
8	,	O
9	the	O
10	RD	O
11	,	O
12	CC	O
13	,	O
14	E	O
15	(	O
16	p	O
17	)	O
18	and	O
19	loop	O
20	areas	O
21	were	O
22	significantly	O
23	different	O
24	from	O
25	REF	O
26	,	O
27	but	O
28	significantly	O
29	different	O
30	from	O
31	A	O
32	-	O
33	A	O
34	.	O

1	Induced	O
2	expression	O
3	of	O
4	c	B
5	-	I
6	myc	I
7	is	O
8	likely	O
9	to	O
10	contribute	O
11	to	O
12	the	O
13	proliferation	O
14	of	O
15	Stat1	B
16	-	O
17	null	O
18	cells	O
19	in	O
20	response	O
21	to	O
22	IFNs	B
23	.	O

1	Eastern	O
2	Cooperative	O
3	Oncology	O
4	Group	O
5	trial	O
6	E3186	O
7	was	O
8	initiated	O
9	to	O
10	explore	O
11	this	O
12	question	O
13	.	O

1	We	O
2	determined	O
3	how	O
4	DNA	O
5	repair	O
6	is	O
7	affected	O
8	by	O
9	TFA1	B
10	conditional	O
11	mutations	O
12	.	O

1	These	O
2	articles	O
3	both	O
4	report	O
5	the	O
6	results	O
7	of	O
8	multi	O
9	-	O
10	institutional	O
11	,	O
12	randomized	O
13	,	O
14	phase	O
15	3	O
16	trials	O
17	for	O
18	the	O
19	treatment	O
20	of	O
21	patients	O
22	with	O
23	localized	O
24	(	O
25	T1	O
26	-	O
27	3	O
28	N0	O
29	-	O
30	1	O
31	M0	O
32	)	O
33	esophageal	O
34	squamous	O
35	cell	O
36	carcinoma	O
37	(	O
38	SCC	O
39	)	O
40	or	O
41	esophageal	O
42	adenocarcinoma	O
43	.	O

1	Studies	O
2	of	O
3	MPO	B
4	gene	I
5	regulation	O
6	can	O
7	help	O
8	to	O
9	elucidate	O
10	the	O
11	mechanism	O
12	of	O
13	normal	O
14	and	O
15	abnormal	O
16	myeloid	O
17	differentiation	O
18	.	O

1	NDRF	B
2	/	O
3	NeuroD2	B
4	was	O
5	co	O
6	-	O
7	precipitated	O
8	with	O
9	PKN	B
10	from	O
11	the	O
12	lysate	O
13	of	O
14	COS	O
15	-	O
16	7	O
17	cells	O
18	transfected	O
19	with	O
20	both	O
21	expression	O
22	constructs	O
23	for	O
24	NDRF	B
25	/	O
26	NeuroD2	B
27	and	O
28	PKN	B
29	.	O

1	Transient	O
2	transfection	O
3	assays	O
4	using	O
5	P19	O
6	cells	O
7	revealed	O
8	that	O
9	expression	O
10	of	O
11	NDRF	B
12	/	O
13	NeuroD2	B
14	increased	O
15	the	O
16	transactivation	O
17	of	O
18	the	O
19	rat	B
20	insulin	I
21	promoter	I
22	element	I
23	3	I
24	(	O
25	RIPE3	B
26	)	O
27	enhancer	O
28	up	O
29	to	O
30	approximately	O
31	12	O
32	-	O
33	fold	O
34	and	O
35	that	O
36	co	O
37	-	O
38	expression	O
39	of	O
40	catalytically	O
41	active	O
42	form	O
43	of	O
44	PKN	B
45	,	O
46	but	O
47	not	O
48	kinase	O
49	-	O
50	deficient	O
51	derivative	O
52	,	O
53	resulted	O
54	in	O
55	a	O
56	further	O
57	threefold	O
58	increase	O
59	of	O
60	NDRF	B
61	/	O
62	NeuroD2	B
63	-	O
64	mediated	O
65	transcription	O
66	.	O

1	Two	O
2	Pax2	B
3	/	I
4	5	I
5	/	I
6	8	I
7	-	I
8	binding	I
9	sites	I
10	in	O
11	Engrailed2	B
12	are	O
13	required	O
14	for	O
15	proper	O
16	initiation	O
17	of	O
18	endogenous	O
19	mid	O
20	-	O
21	hindbrain	O
22	expression	O
23	.	O

1	Upon	O
2	tyrosine	O
3	phosphorylation	O
4	at	O
5	the	O
6	ITIMs	O
7	,	O
8	these	O
9	molecules	O
10	recruit	O
11	SH2	B
12	domain	O
13	-	O
14	containing	O
15	phosphatases	O
16	such	O
17	as	O
18	SH2	B
19	-	O
20	containing	O
21	tyrosine	B
22	phosphatase	I
23	-	I
24	1	I
25	and	O
26	negatively	O
27	regulate	O
28	cell	O
29	activity	O
30	.	O

1	AF154055	B
2	.	O

1	Alignment	O
2	of	O
3	the	O
4	cervical	O
5	spine	O
6	,	O
7	vertebral	O
8	abnormalities	O
9	,	O
10	and	O
11	disc	O
12	changes	O
13	also	O
14	were	O
15	evaluated	O
16	.	O

1	The	O
2	concomitant	O
3	interaction	O
4	of	O
5	mSTI1	B
6	with	O
7	hsp70	B
8	and	O
9	hsp90	B
10	at	O
11	its	O
12	N	O
13	-	O
14	and	O
15	C	O
16	-	O
17	termini	O
18	respectively	O
19	is	O
20	mediated	O
21	by	O
22	the	O
23	tetratricopeptide	O
24	repeat	O
25	(	O
26	TPR	O
27	)	O
28	motifs	O
29	in	O
30	these	O
31	regions	O
32	.	O

1	Competition	O
2	experiments	O
3	demonstrate	O
4	a	O
5	negative	O
6	allosteric	O
7	relationship	O
8	between	O
9	these	O
10	RGD	O
11	recognition	O
12	sites	O
13	.	O

1	Sequence	O
2	analysis	O
3	showed	O
4	that	O
5	the	O
6	5	O
7	'-	O
8	flanking	O
9	region	O
10	upstream	O
11	to	O
12	the	O
13	ATG	O
14	codon	O
15	did	O
16	not	O
17	contain	O
18	a	O
19	conventional	O
20	TATA	O
21	box	O
22	.	O

1	After	O
2	i	O
3	.	O
4	v	O
5	.	O
6	administration	O
7	of	O
8	500	O
9	mg	O
10	acetazolamide	O
11	and	O
12	disinfection	O
13	of	O
14	the	O
15	conjunctiva	O
16	,	O
17	50	O
18	micrograms	O
19	rt	B
20	-	I
21	PA	I
22	in	O
23	0	O
24	.	O
25	1	O
26	ml	O
27	(	O
28	BSS	O
29	)	O
30	and	O
31	0	O
32	.	O
33	5	O
34	ml	O
35	SF6	O
36	were	O
37	injected	O
38	intravitreally	O
39	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	VP1	B
6	was	O
7	efficiently	O
8	transported	O
9	to	O
10	the	O
11	nucleus	O
12	and	O
13	localized	O
14	in	O
15	the	O
16	discrete	O
17	subnuclear	O
18	regions	O
19	,	O
20	possibly	O
21	with	O
22	VP2	B
23	and	O
24	VP3	B
25	.	O

1	Differential	O
2	expression	O
3	and	O
4	regulation	O
5	by	O
6	20	O
7	-	O
8	hydroxyecdysone	O
9	of	O
10	mosquito	O
11	ultraspiracle	O
12	isoforms	O
13	.	O

1	The	O
2	three	O
3	isoforms	O
4	purified	O
5	with	O
6	anti	B
7	-	I
8	FLAG	I
9	antibody	I
10	affinity	O
11	column	O
12	transferred	O
13	sulfate	O
14	to	O
15	heparan	O
16	sulfate	O
17	and	O
18	heparin	O
19	but	O
20	not	O
21	to	O
22	other	O
23	glycosaminoglycans	O
24	.	O

1	The	O
2	differentiation	O
3	and	O
4	maintenance	O
5	of	O
6	a	O
7	neurotransmitter	O
8	phenotype	O
9	is	O
10	guided	O
11	by	O
12	the	O
13	interaction	O
14	of	O
15	exogenous	O
16	cues	O
17	with	O
18	intrinsic	O
19	genetic	O
20	machinery	O
21	.	O

1	Analysis	O
2	of	O
3	functional	O
4	domains	O
5	of	O
6	Arix	B
7	reveals	O
8	an	O
9	N	O
10	-	O
11	terminal	O
12	activation	O
13	domain	O
14	and	O
15	a	O
16	C	O
17	-	O
18	terminal	O
19	repression	O
20	domain	O
21	.	O

1	BACKGROUND	O
2	:	O
3	Left	O
4	ventricular	O
5	hypertrophy	O
6	is	O
7	a	O
8	heterogeneous	O
9	disorder	O
10	with	O
11	distinct	O
12	morphologies	O
13	.	O

1	Multivariate	O
2	predictors	O
3	were	O
4	concentric	O
5	remodeling	O
6	(	O
7	P	O
8	<	O
9	0	O
10	.	O
11	0001	O
12	;	O
13	odds	O
14	ratio	O
15	,	O
16	13	O
17	.	O
18	5	O
19	),	O
20	left	O
21	ventricular	O
22	ejection	O
23	fraction	O
24	>	O
25	2	O
26	SD	O
27	above	O
28	normal	O
29	(	O
30	P	O
31	<	O
32	0	O
33	.	O
34	0001	O
35	),	O
36	and	O
37	single	O
38	-	O
39	vessel	O
40	left	O
41	circumflex	O
42	disease	O
43	(	O
44	P	O
45	<	O
46	0	O
47	.	O
48	0007	O
49	;	O
50	odds	O
51	ratio	O
52	,	O
53	7	O
54	.	O
55	6	O
56	).	O

1	The	O
2	case	O
3	for	O
4	completing	O
5	the	O
6	lymphadenectomy	O
7	when	O
8	positive	O
9	lymph	O
10	nodes	O
11	are	O
12	found	O
13	during	O
14	radical	O
15	hysterectomy	O
16	for	O
17	cervical	O
18	carcinoma	O
19	.	O

1	Overexpression	O
2	of	O
3	ICBP90	B
4	in	O
5	COS	O
6	-	O
7	1	O
8	-	O
9	transfected	O
10	cells	O
11	induced	O
12	an	O
13	enhanced	O
14	expression	O
15	of	O
16	endogenous	B
17	topoisomerase	I
18	IIalpha	I
19	.	O

1	The	O
2	RNA	O
3	aptamer	O
4	contains	O
5	three	O
6	stems	O
7	separated	O
8	by	O
9	a	O
10	pair	O
11	of	O
12	two	O
13	-	O
14	base	O
15	bulges	O
16	,	O
17	and	O
18	adopts	O
19	an	O
20	unanticipated	O
21	fold	O
22	in	O
23	which	O
24	both	O
25	junctional	O
26	sites	O
27	are	O
28	anchored	O
29	through	O
30	base	O
31	triple	O
32	formation	O
33	.	O

1	The	O
2	study	O
3	suggests	O
4	the	O
5	presence	O
6	of	O
7	an	O
8	anatomical	O
9	sphincter	O
10	at	O
11	the	O
12	RSJ	O
13	which	O
14	seems	O
15	to	O
16	regulate	O
17	the	O
18	passage	O
19	of	O
20	stools	O
21	from	O
22	the	O
23	sigmoid	O
24	colon	O
25	to	O
26	the	O
27	rectum	O
28	.	O

1	Isolation	O
2	of	O
3	cDNAs	B
4	encoding	I
5	gibbon	I
6	and	I
7	monkey	I
8	platelet	I
9	and	I
10	T	I
11	cell	I
12	activation	I
13	antigen	I
14	1	I
15	(	O
16	PTA1	B
17	).	O

1	To	O
2	quantify	O
3	any	O
4	mechanical	O
5	inhibitory	O
6	effect	O
7	of	O
8	nasal	O
9	intermittent	O
10	positive	O
11	pressure	O
12	ventilation	O
13	(	O
14	IPPV	O
15	)	O
16	on	O
17	inspiratory	O
18	activity	O
19	of	O
20	the	O
21	diaphragm	O
22	we	O
23	ventilated	O
24	five	O
25	conscious	O
26	relaxed	O
27	subjects	O
28	on	O
29	two	O
30	occasions	O
31	at	O
32	respiratory	O
33	rates	O
34	similar	O
35	to	O
36	quiet	O
37	breathing	O
38	(	O
39	QB	O
40	)	O
41	and	O
42	at	O
43	three	O
44	levels	O
45	of	O
46	applied	O
47	pressure	O
48	(	O
49	Pappl	O
50	)--	O
51	6	O
52	,	O
53	9	O
54	and	O
55	12	O
56	cmH2O	O
57	,	O
58	each	O
59	during	O
60	hypocapnia	O
61	(	O
62	P	O
63	(	O
64	CO2	O
65	)	O
66	allowed	O
67	to	O
68	decrease	O
69	)	O
70	and	O
71	eucapnia	O
72	(	O
73	CO2	O
74	added	O
75	to	O
76	inspired	O
77	gas	O
78	).	O

1	METHODS	O
2	:	O
3	Von	B
4	Willebrand	I
5	factor	I
6	(	O
7	vWF	B
8	)	O
9	and	O
10	the	O
11	fibrinolytic	O
12	factors	O
13	tissue	B
14	plasminogen	I
15	activator	I
16	(	O
17	tPA	B
18	),	O
19	measured	O
20	as	O
21	tPA	B
22	capacity	O
23	,	O
24	and	O
25	plasminogen	B
26	activator	I
27	inhibitor	I
28	1	I
29	(	O
30	PAI	B
31	-	I
32	1	I
33	),	O
34	platelets	O
35	,	O
36	fibrinogen	B
37	,	O
38	and	O
39	inflammatory	O
40	markers	O
41	were	O
42	measured	O
43	in	O
44	74	O
45	patients	O
46	with	O
47	active	O
48	seropositive	O
49	RA	O
50	.	O

1	Neuronal	O
2	signaling	O
3	properties	O
4	are	O
5	largely	O
6	determined	O
7	by	O
8	the	O
9	quantity	O
10	and	O
11	combination	O
12	of	O
13	ion	O
14	channels	O
15	expressed	O
16	.	O

1	Treatment	O
2	also	O
3	led	O
4	to	O
5	a	O
6	significant	O
7	dose	O
8	dependent	O
9	reduction	O
10	in	O
11	the	O
12	sum	O
13	of	O
14	ST	O
15	segment	O
16	depression	O
17	at	O
18	both	O
19	trough	O
20	and	O
21	peak	O
22	concentrations	O
23	.	O

1	We	O
2	have	O
3	investigated	O
4	the	O
5	contribution	O
6	of	O
7	specific	O
8	TATA	B
9	-	I
10	binding	I
11	protein	I
12	(	O
13	TBP	B
14	)-	O
15	TATA	O
16	interactions	O
17	to	O
18	the	O
19	promoter	O
20	activity	O
21	of	O
22	a	O
23	constitutively	O
24	expressed	O
25	silkworm	B
26	tRNA	I
27	(	I
28	C	I
29	)(	I
30	Ala	I
31	)	I
32	gene	I
33	and	O
34	have	O
35	also	O
36	asked	O
37	whether	O
38	the	O
39	lack	O
40	of	O
41	similar	O
42	interactions	O
43	accounts	O
44	for	O
45	the	O
46	low	O
47	promoter	O
48	activity	O
49	of	O
50	a	O
51	silk	B
52	gland	I
53	-	I
54	specific	I
55	tRNA	I
56	(	I
57	SG	I
58	)(	I
59	Ala	I
60	)	I
61	gene	I
62	.	O

1	The	O
2	sequences	O
3	showed	O
4	extensive	O
5	homologies	O
6	with	O
7	squalene	B
8	synthase	I
9	genes	I
10	and	O
11	enzymes	O
12	from	O
13	a	O
14	number	O
15	of	O
16	other	O
17	organisms	O
18	and	O
19	extreme	O
20	amino	O
21	acid	O
22	conservation	O
23	within	O
24	the	O
25	binding	O
26	and	O
27	catalytic	O
28	domains	O
29	.	O

1	All	O
2	clones	O
3	and	O
4	strains	O
5	produced	O
6	have	O
7	been	O
8	deposited	O
9	in	O
10	the	O
11	EUROFAN	O
12	genetic	O
13	stock	O
14	centre	O
15	(	O
16	EUROSCARF	O
17	,	O
18	Frankfurt	O
19	).	O

1	Two	O
2	episodes	O
3	of	O
4	peritonitis	O
5	occurred	O
6	while	O
7	the	O
8	patient	O
9	received	O
10	CAPD	O
11	(	O
12	1	O
13	episode	O
14	/	O
15	3	O
16	.	O
17	5	O
18	patient	O
19	-	O
20	months	O
21	).	O

1	Copyright	O
2	2000	O
3	The	O
4	Royal	O
5	College	O
6	of	O
7	Radiologists	O
8	.	O

1	Two	O
2	estrogen	B
3	receptor	I
4	(	O
5	ER	B
6	)	O
7	isoforms	O
8	with	O
9	different	O
10	estrogen	O
11	dependencies	O
12	are	O
13	generated	O
14	from	O
15	the	O
16	trout	B
17	ER	I
18	gene	I
19	.	O

1	Induction	O
2	was	O
3	reversed	O
4	by	O
5	coexpression	O
6	of	O
7	A	B
8	-	I
9	Fos	I
10	,	O
11	a	O
12	dominant	O
13	negative	O
14	to	O
15	AP	B
16	-	I
17	1	I
18	.	O

1	In	O
2	myometrial	O
3	SMC	O
4	,	O
5	both	O
6	isoforms	O
7	of	O
8	the	O
9	progesterone	B
10	receptor	I
11	,	O
12	PR	B
13	-	I
14	B	I
15	and	O
16	PR	B
17	-	I
18	A	I
19	,	O
20	caused	O
21	a	O
22	ligand	O
23	-	O
24	dependent	O
25	activation	O
26	of	O
27	PGDH	B
28	-	I
29	2368	I
30	/	O
31	luc3	B
32	.	O

1	Element	O
2	B	O
3	(-	O
4	249	O
5	/-	O
6	229	O
7	)	O
8	shows	O
9	more	O
10	than	O
11	80	O
12	%	O
13	homology	O
14	to	O
15	a	O
16	consensus	B
17	c	I
18	-	I
19	myb	I
20	element	I
21	,	O
22	but	O
23	formed	O
24	two	O
25	specific	O
26	complexes	O
27	that	O
28	differed	O
29	from	O
30	that	O
31	of	O
32	c	B
33	-	I
34	myb	I
35	in	O
36	the	O
37	electrophoretic	O
38	mobility	O
39	shift	O
40	assay	O
41	.	O

1	High	O
2	resolution	O
3	computed	O
4	tomography	O
5	of	O
6	the	O
7	lungs	O
8	in	O
9	patients	O
10	with	O
11	rheumatoid	O
12	arthritis	O
13	.	O

1	Stable	O
2	transfection	O
3	of	O
4	the	O
5	truncated	O
6	reduced	B
7	folate	I
8	carrier	I
9	cDNA	I
10	into	O
11	mouse	O
12	L1210	O
13	leukemia	O
14	cells	O
15	:	O
16	increased	O
17	folate	O
18	accumulation	O
19	,	O
20	decreased	O
21	their	O
22	leucovorin	O
23	and	O
24	folic	O
25	acid	O
26	growth	O
27	requirements	O
28	,	O
29	and	O
30	increased	O
31	their	O
32	sensitivity	O
33	to	O
34	methotrexate	O
35	.	O

1	Characterization	O
2	of	O
3	a	O
4	human	B
5	alternatively	I
6	spliced	I
7	truncated	I
8	reduced	I
9	folate	I
10	carrier	I
11	increasing	O
12	folate	O
13	accumulation	O
14	in	O
15	parental	O
16	leukemia	O
17	cells	O
18	.	O

1	Electron	O
2	microscopic	O
3	and	O
4	enzymatic	O
5	analyses	O
6	revealed	O
7	that	O
8	the	O
9	A118	O
10	genome	O
11	is	O
12	a	O
13	linear	O
14	,	O
15	circularly	O
16	permuted	O
17	,	O
18	terminally	O
19	redundant	O
20	collection	O
21	of	O
22	double	O
23	-	O
24	stranded	O
25	DNA	O
26	molecules	O
27	.	O

1	Moreover	O
2	,	O
3	increasing	O
4	the	O
5	dosage	O
6	of	O
7	wild	B
8	-	I
9	type	I
10	Fus3	I
11	intensifies	O
12	the	O
13	inhibition	O
14	of	O
15	both	O
16	Ty1	B
17	transposition	O
18	and	O
19	invasive	O
20	growth	O
21	.	O

1	Consistently	O
2	,	O
3	activation	O
4	of	O
5	c	B
6	-	I
7	Jun	I
8	N	I
9	-	I
10	terminal	I
11	kinase	I
12	downstream	O
13	of	O
14	Rho	B
15	family	I
16	GTP	I
17	-	I
18	binding	I
19	proteins	I
20	was	O
21	also	O
22	enhanced	O
23	when	O
24	Dbl	B
25	was	O
26	tyrosine	O
27	-	O
28	phosphorylated	O
29	.	O

1	However	O
2	,	O
3	its	O
4	participation	O
5	in	O
6	collagen	B
7	binding	O
8	has	O
9	not	O
10	been	O
11	shown	O
12	.	O

1	Together	O
2	,	O
3	these	O
4	data	O
5	suggest	O
6	that	O
7	the	O
8	carboxyl	O
9	terminus	O
10	of	O
11	CFTR	B
12	contains	O
13	a	O
14	tyrosine	O
15	-	O
16	based	O
17	internalization	O
18	signal	O
19	that	O
20	interacts	O
21	with	O
22	the	O
23	endocytic	O
24	adaptor	O
25	complex	O
26	AP	B
27	-	I
28	2	I
29	to	O
30	facilitate	O
31	efficient	O
32	entry	O
33	of	O
34	CFTR	B
35	into	O
36	clathrin	B
37	-	O
38	coated	O
39	vesicles	O
40	.	O

1	The	O
2	insulin	B
3	therapy	O
4	regimen	O
5	did	O
6	not	O
7	affect	O
8	the	O
9	evolution	O
10	of	O
11	the	O
12	patients	O
13	and	O
14	no	O
15	significant	O
16	relationship	O
17	existed	O
18	between	O
19	the	O
20	age	O
21	at	O
22	diagnosis	O
23	,	O
24	duration	O
25	of	O
26	diabetes	O
27	,	O
28	daily	O
29	insulin	B
30	dosage	O
31	or	O
32	metabolic	O
33	control	O
34	and	O
35	height	O
36	or	O
37	BMI	O
38	.	O

1	Scmh1	B
2	maps	O
3	to	O
4	4D1	O
5	-	O
6	D2	O
7	.	O
8	1	O
9	in	O
10	mice	O
11	.	O

1	The	O
2	applicability	O
3	of	O
4	laparoscopic	O
5	donor	O
6	nephrectomy	O
7	(	O
8	LDN	O
9	)	O
10	has	O
11	not	O
12	been	O
13	assessed	O
14	in	O
15	the	O
16	obese	O
17	donor	O
18	.	O

1	Hyaluronan	O
2	treatment	O
3	stimulated	O
4	collagen	B
5	remodeling	O
6	in	O
7	the	O
8	peripheral	O
9	region	O
10	and	O
11	inhibited	O
12	swelling	O
13	of	O
14	the	O
15	meniscus	O
16	repaired	O
17	in	O
18	the	O
19	inner	O
20	region	O
21	.	O

1	We	O
2	have	O
3	addressed	O
4	these	O
5	issues	O
6	by	O
7	reconstituting	O
8	and	O
9	characterizing	O
10	the	O
11	KRAB	B
12	:	O
13	KAP	B
14	-	I
15	1	I
16	-	O
17	RBCC	B
18	interaction	O
19	using	O
20	purified	O
21	components	O
22	.	O

1	The	O
2	RING	O
3	finger	O
4	,	O
5	B2	O
6	box	O
7	,	O
8	and	O
9	coiled	O
10	-	O
11	coil	O
12	region	O
13	are	O
14	required	O
15	for	O
16	oligomerization	O
17	of	O
18	KAP	B
19	-	I
20	1	I
21	-	O
22	RBCC	B
23	and	O
24	KRAB	B
25	binding	O
26	,	O
27	as	O
28	mutations	O
29	in	O
30	these	O
31	domains	O
32	concomitantly	O
33	abolished	O
34	these	O
35	functions	O
36	.	O

1	Actins	B
2	show	O
3	two	O
4	different	O
5	forms	O
6	of	O
7	N	O
8	-	O
9	terminal	O
10	processing	O
11	dependent	O
12	on	O
13	their	O
14	N	O
15	-	O
16	terminal	O
17	sequence	O
18	.	O

1	All	O
2	four	O
3	domains	O
4	were	O
5	linked	O
6	via	O
7	proline	O
8	-	O
9	threonine	O
10	-	O
11	rich	O
12	peptides	O
13	.	O

1	JPEG	O
2	53	O
3	,	O
4	resulting	O
5	in	O
6	a	O
7	compression	O
8	ratio	O
9	of	O
10	1	O
11	:	O
12	21	O
13	,	O
14	does	O
15	not	O
16	compromise	O
17	the	O
18	diagnostic	O
19	performance	O
20	in	O
21	general	O
22	.	O

1	We	O
2	critically	O
3	assess	O
4	current	O
5	systematic	O
6	uncertainties	O
7	and	O
8	determine	O
9	the	O
10	primordial	O
11	Li	O
12	abundance	O
13	within	O
14	new	O
15	,	O
16	much	O
17	tighter	O
18	limits	O
19	:	O
20	&	O
21	amp	O
22	;	O
23	parl0	O
24	;	O
25	Li	O
26	&	O
27	amp	O
28	;	O
29	solm0	O
30	;	O
31	H	O
32	&	O
33	amp	O
34	;	O
35	parr0	O
36	;	O
37	p	O
38	=	O
39	1	O
40	.	O
41	23	O
42	+	O
43	0	O
44	.	O
45	68	O
46	-	O
47	0	O
48	.	O
49	32x10	O
50	-	O
51	10	O
52	.	O

1	Like	O
2	their	O
3	yeast	O
4	counterpart	O
5	,	O
6	the	O
7	mouse	O
8	GCN2	B
9	isoforms	O
10	contain	O
11	HisRS	B
12	-	I
13	related	I
14	sequences	I
15	juxtaposed	O
16	to	O
17	the	O
18	kinase	O
19	catalytic	O
20	domain	O
21	.	O

1	Five	O
2	women	O
3	(	O
4	15	O
5	.	O
6	6	O
7	%)	O
8	met	O
9	criteria	O
10	for	O
11	PMS	O
12	.	O

1	MBI	O
2	and	O
3	MMBI	O
4	showed	O
5	similar	O
6	Cmax	O
7	values	O
8	,	O
9	but	O
10	the	O
11	former	O
12	disappeared	O
13	slower	O
14	in	O
15	the	O
16	serum	O
17	than	O
18	the	O
19	latter	O
20	and	O
21	resulted	O
22	in	O
23	its	O
24	larger	O
25	AUC	O
26	values	O
27	.	O

1	Another	O
2	long	O
3	insertion	O
4	in	O
5	the	O
6	cathepsin	B
7	X	I
8	amino	I
9	acid	I
10	sequence	I
11	forms	O
12	a	O
13	beta	O
14	-	O
15	hairpin	O
16	pointing	O
17	away	O
18	from	O
19	the	O
20	active	O
21	site	O
22	.	O

1	Transfection	O
2	experiments	O
3	demonstrated	O
4	that	O
5	the	O
6	5	O
7	'-	O
8	flanking	O
9	region	O
10	(-	O
11	1894	O
12	to	O
13	+	O
14	37	O
15	)	O
16	of	O
17	the	O
18	mStaf	B
19	gene	I
20	drives	O
21	transcription	O
22	in	O
23	mouse	O
24	NMuMG	O
25	cells	O
26	and	O
27	that	O
28	a	O
29	construct	O
30	containing	O
31	a	O
32	fragment	O
33	from	O
34	-	O
35	387	O
36	to	O
37	+	O
38	37	O
39	showed	O
40	the	O
41	highest	O
42	transcriptional	O
43	activity	O
44	.	O

1	Further	O
2	studies	O
3	in	O
4	T	O
5	-	O
6	24	O
7	cells	O
8	demonstrated	O
9	that	O
10	HA	O
11	fragments	O
12	also	O
13	induced	O
14	I	B
15	kappa	I
16	B	I
17	alpha	I
18	phosphorylation	O
19	and	O
20	degradation	O
21	,	O
22	kappa	B
23	B	I
24	-	I
25	linked	I
26	reporter	I
27	gene	I
28	expression	O
29	,	O
30	and	O
31	ICAM	B
32	-	I
33	1	I
34	promoter	I
35	activity	O
36	in	O
37	an	O
38	NF	B
39	-	I
40	kappa	I
41	B	I
42	-	O
43	dependent	O
44	manner	O
45	.	O

1	Pretreatment	O
2	of	O
3	cells	O
4	or	O
5	mouse	O
6	skin	O
7	with	O
8	antisense	O
9	oligonucleotides	O
10	of	O
11	PKCzeta	B
12	impaired	O
13	UV	O
14	-	O
15	induced	O
16	activation	O
17	of	O
18	AP	B
19	-	I
20	1	I
21	in	O
22	JB6	O
23	cells	O
24	as	O
25	well	O
26	as	O
27	in	O
28	AP	B
29	-	I
30	1	I
31	-	O
32	luciferase	B
33	transgenic	O
34	mice	O
35	.	O

1	The	O
2	level	O
3	of	O
4	subclinical	O
5	infection	O
6	was	O
7	75	O
8	%	O
9	among	O
10	seropositive	O
11	dogs	O
12	.	O

1	METHODS	O
2	:	O
3	The	O
4	former	O
5	group	O
6	included	O
7	patients	O
8	who	O
9	had	O
10	been	O
11	treated	O
12	with	O
13	at	O
14	least	O
15	four	O
16	PGE1	O
17	alpha	O
18	-	O
19	ciclodestrina	O
20	,	O
21	short	O
22	-	O
23	term	O
24	treatment	O
25	cycles	O
26	per	O
27	year	O
28	while	O
29	the	O
30	latter	O
31	was	O
32	a	O
33	historical	O
34	reference	O
35	group	O
36	managed	O
37	without	O
38	prostaglandins	O
39	.	O

1	Desmethylferrochloroquine	O
2	1a	O
3	and	O
4	didesmethylferrochloroquine	O
5	2	O
6	would	O
7	be	O
8	more	O
9	potent	O
10	against	O
11	schizontocides	O
12	than	O
13	CQ	O
14	in	O
15	vitro	O
16	against	O
17	two	O
18	strains	O
19	(	O
20	HB3	O
21	and	O
22	Dd2	O
23	)	O
24	of	O
25	Plasmodium	O
26	falciparum	O
27	.	O

1	The	O
2	rrd1	B
3	,	I
4	2delta	I
5	mutant	I
6	was	O
7	partially	O
8	rescued	O
9	by	O
10	inactivation	O
11	of	O
12	HOG1	B
13	or	O
14	PBS2	B
15	,	O
16	suggesting	O
17	an	O
18	interaction	O
19	between	O
20	the	O
21	RRD	B
22	genes	I
23	and	O
24	the	O
25	Hog1p	B
26	signal	I
27	transduction	I
28	pathway	I
29	.	O

1	Members	O
2	of	O
3	the	O
4	JAK	B
5	/	O
6	Tyk	B
7	family	O
8	of	O
9	tyrosine	B
10	kinases	I
11	mediate	O
12	phosphorylation	O
13	of	O
14	STAT3	B
15	at	O
16	Tyr705	O
17	during	O
18	CNTF	B
19	signaling	O
20	;	O
21	however	O
22	,	O
23	the	O
24	kinase	O
25	responsible	O
26	for	O
27	phosphorylation	O
28	at	O
29	STAT3	B
30	Tyr727	O
31	appears	O
32	to	O
33	depend	O
34	on	O
35	both	O
36	the	O
37	extracellular	O
38	stimulus	O
39	and	O
40	the	O
41	cellular	O
42	context	O
43	.	O

1	In	O
2	vivo	O
3	,	O
4	CARbeta	B
5	/	O
6	RXRalpha	B
7	activated	O
8	transcription	O
9	from	O
10	an	O
11	HD	B
12	-	O
13	PPRE	O
14	luciferase	B
15	reporter	I
16	construct	I
17	.	O

1	Zebrafish	O
2	cyclops	B
3	(	O
4	cyc	B
5	)	O
6	encodes	O
7	a	O
8	Transforming	B
9	Growth	I
10	Factor	I
11	beta	I
12	(	O
13	TGFbeta	B
14	)	O
15	signaling	O
16	factor	O
17	closely	O
18	related	O
19	to	O
20	mouse	O
21	Nodal	B
22	.	O

1	Thus	O
2	,	O
3	SOX8	B
4	is	O
5	a	O
6	good	O
7	candidate	O
8	gene	O
9	contributing	O
10	to	O
11	the	O
12	mental	O
13	retardation	O
14	phenotype	O
15	seen	O
16	in	O
17	ATR	O
18	-	O
19	16	O
20	patients	O
21	.	O

1	The	O
2	genome	O
3	organization	O
4	of	O
5	the	O
6	mite	O
7	-	O
8	transmitted	O
9	wheat	O
10	streak	O
11	mosaic	O
12	virus	O
13	(	O
14	WSMV	O
15	)	O
16	appears	O
17	to	O
18	parallel	O
19	that	O
20	of	O
21	members	O
22	of	O
23	the	O
24	Potyviridae	O
25	with	O
26	monopartite	O
27	genomes	O
28	,	O
29	but	O
30	there	O
31	are	O
32	substantial	O
33	amino	O
34	acid	O
35	dissimilarities	O
36	with	O
37	other	O
38	potyviral	O
39	polyproteins	O
40	.	O

1	The	O
2	two	O
3	-	O
4	hybrid	O
5	assay	O
6	was	O
7	then	O
8	performed	O
9	using	O
10	full	O
11	-	O
12	length	O
13	genes	O
14	of	O
15	CI	B
16	,	O
17	HC	B
18	-	I
19	Pro	I
20	,	O
21	P1	B
22	,	O
23	P3	B
24	,	O
25	and	O
26	CP	B
27	,	O
28	but	O
29	no	O
30	heterologous	O
31	interactions	O
32	were	O
33	detected	O
34	.	O

1	Diverse	O
2	endogenous	O
3	light	O
4	chains	O
5	contribute	O
6	to	O
7	basement	O
8	membrane	O
9	reactivity	O
10	in	O
11	nonautoimmune	O
12	mice	O
13	transgenic	O
14	for	O
15	an	O
16	anti	B
17	-	I
18	laminin	I
19	Ig	I
20	heavy	I
21	chain	I
22	.	O

1	Patch	O
2	test	O
3	results	O
4	obtained	O
5	with	O
6	corticosteroid	O
7	allergic	O
8	patients	O
9	tested	O
10	with	O
11	a	O
12	large	O
13	corticosteroid	O
14	series	O
15	validated	O
16	the	O
17	earlier	O
18	classification	O
19	of	O
20	corticosteroid	O
21	molecules	O
22	in	O
23	four	O
24	groups	O
25	of	O
26	cross	O
27	-	O
28	reacting	O
29	molecules	O
30	:	O
31	i	O
32	.	O
33	e	O
34	.,	O
35	group	O
36	A	O
37	(	O
38	hydrocortisone	O
39	type	O
40	),	O
41	group	O
42	B	O
43	(	O
44	acetonides	O
45	),	O
46	group	O
47	C	O
48	(	O
49	betamethasone	O
50	type	O
51	-	O
52	non	O
53	esterified	O
54	)	O
55	and	O
56	group	O
57	D	O
58	(	O
59	esters	O
60	).	O

1	Mechanisms	O
2	of	O
3	tachyphylaxis	O
4	in	O
5	regional	O
6	anesthesia	O
7	of	O
8	long	O
9	duration	O

1	An	O
2	increase	O
3	in	O
4	the	O
5	level	O
6	of	O
7	serum	O
8	enzymes	O
9	,	O
10	such	O
11	as	O
12	aspartate	B
13	transaminase	I
14	,	O
15	alkaline	B
16	phosphatase	I
17	,	O
18	creatine	B
19	phosphokinase	I
20	,	O
21	lactate	B
22	dehydrogenase	I
23	after	O
24	D	O
25	.	O
26	russelli	O
27	venom	O
28	injection	O
29	in	O
30	albino	O
31	rats	O
32	is	O
33	indicative	O
34	of	O
35	cell	O
36	or	O
37	tissue	O
38	damage	O
39	.	O

1	The	O
2	partial	O
3	farm	O
4	budget	O
5	highlighted	O
6	the	O
7	importance	O
8	of	O
9	reducing	O
10	sub	O
11	-	O
12	clinical	O
13	lesions	O
14	in	O
15	a	O
16	feedlot	O
17	.	O

1	Surprisingly	O
2	,	O
3	3	O
4	full	B
5	-	I
6	length	I
7	murine	I
8	survivin	I
9	cDNA	I
10	clones	O
11	were	O
12	isolated	O
13	,	O
14	predicting	O
15	the	O
16	existence	O
17	of	O
18	3	O
19	distinct	O
20	survivin	B
21	proteins	I
22	.	O

1	Thus	O
2	,	O
3	the	O
4	induction	O
5	of	O
6	E2F	B
7	binding	O
8	to	O
9	the	O
10	E2F	B
11	-	I
12	1	I
13	promoter	I
14	by	O
15	the	O
16	E4	B
17	-	I
18	6	I
19	/	I
20	7	I
21	protein	I
22	observed	O
23	in	O
24	vitro	O
25	correlates	O
26	with	O
27	transactivation	O
28	of	O
29	E2F	B
30	-	I
31	1	I
32	promoter	I
33	activity	O
34	in	O
35	vivo	O
36	.	O

1	We	O
2	show	O
3	that	O
4	stabilization	O
5	of	O
6	the	O
7	hairpin	O
8	reduced	O
9	the	O
10	amount	O
11	of	O
12	tRNA	O
13	primer	O
14	that	O
15	is	O
16	annealed	O
17	to	O
18	the	O
19	PBS	O
20	.	O

1	Ischemia	O
2	-	O
3	induced	O
4	biphasic	O
5	arrhythmias	O
6	were	O
7	suppressed	O
8	in	O
9	both	O
10	zatebradine	O
11	and	O
12	propranolol	O
13	groups	O
14	.	O

1	ZK7	B
2	and	O
3	HZF16	B
4	genes	I
5	appear	O
6	to	O
7	be	O
8	the	O
9	splice	O
10	variants	O
11	transcribed	O
12	from	O
13	the	O
14	same	O
15	gene	O
16	.	O

1	CONCLUSION	O
2	:	O
3	Presence	O
4	of	O
5	APOE	B
6	epsilon4	I
7	/*	I
8	seems	O
9	to	O
10	increase	O
11	the	O
12	risk	O
13	for	O
14	dementia	O
15	and	O
16	AD	O
17	independently	O
18	of	O
19	its	O
20	effect	O
21	on	O
22	dyslipidemia	O
23	and	O
24	atherogenesis	O
25	.	O

1	No	O
2	definite	O
3	conclusions	O
4	are	O
5	possible	O
6	because	O
7	of	O
8	the	O
9	small	O
10	number	O
11	of	O
12	patients	O
13	involved	O
14	in	O
15	this	O
16	phase	O
17	II	O
18	trial	O
19	.	O

1	Two	O
2	distinct	O
3	Salmonella	B
4	fimbrins	I
5	,	O
6	AgfA	B
7	and	O
8	SefA	B
9	,	O
10	comprising	O
11	thin	O
12	aggregative	O
13	fimbriae	O
14	SEF17	B
15	and	O
16	SEF14	B
17	,	O
18	respectively	O
19	,	O
20	were	O
21	each	O
22	genetically	O
23	engineered	O
24	to	O
25	carry	O
26	PT3	B
27	,	O
28	an	O
29	alpha	O
30	-	O
31	helical	O
32	16	O
33	-	O
34	amino	O
35	acid	O
36	Leishmania	O
37	T	O
38	-	O
39	cell	O
40	epitope	O
41	derived	O
42	from	O
43	the	O
44	metalloprotease	B
45	gp63	I
46	.	O

1	In	O
2	marked	O
3	contrast	O
4	to	O
5	AgfA	B
6	,	O
7	none	O
8	of	O
9	the	O
10	chimeric	B
11	SefA	I
12	proteins	I
13	were	O
14	expressed	O
15	or	O
16	assembled	O
17	into	O
18	fimbriae	O
19	.	O

1	Productive	O
2	growth	O
3	of	O
4	phage	O
5	P22	O
6	in	O
7	wild	O
8	-	O
9	type	O
10	Salmonella	O
11	typhimurium	O
12	correlates	O
13	with	O
14	the	O
15	presence	O
16	of	O
17	Abc2	B
18	,	O
19	but	O
20	is	O
21	independent	O
22	of	O
23	the	O
24	absolute	O
25	level	O
26	of	O
27	ATP	B
28	-	I
29	dependent	I
30	nuclease	I
31	activity	O
32	,	O
33	suggesting	O
34	a	O
35	qualitative	O
36	change	O
37	in	O
38	the	O
39	nature	O
40	of	O
41	Abc2	B
42	-	O
43	modified	O
44	RecBCD	B
45	nuclease	I
46	activity	O
47	relative	O
48	to	O
49	the	O
50	native	O
51	enzyme	O
52	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	investigated	O
7	the	O
8	molecular	O
9	mechanisms	O
10	underlying	O
11	the	O
12	inducible	O
13	expression	O
14	of	O
15	the	O
16	flt	B
17	-	I
18	1	I
19	gene	I
20	during	O
21	the	O
22	activation	O
23	of	O
24	THP	O
25	-	O
26	1	O
27	cells	O
28	.	O

1	There	O
2	was	O
3	a	O
4	2	O
5	.	O
6	4	O
7	-	O
8	fold	O
9	difference	O
10	in	O
11	CAT	B
12	produced	O
13	from	O
14	these	O
15	transcripts	O
16	in	O
17	HeLa	O
18	cells	O
19	,	O
20	which	O
21	contain	O
22	a	O
23	greater	O
24	natural	O
25	abundance	O
26	of	O
27	PTB	B
28	.	O

1	Multiple	O
2	mitogen	B
3	-	I
4	activated	I
5	protein	I
6	kinase	I
7	signaling	O
8	pathways	O
9	connect	O
10	the	O
11	cot	B
12	oncoprotein	I
13	to	O
14	the	O
15	c	B
16	-	I
17	jun	I
18	promoter	I
19	and	O
20	to	O
21	cellular	O
22	transformation	O
23	.	O

1	Dermatology	O
2	is	O
3	no	O
4	exception	O
5	.	O

1	4	O
2	.	O

1	In	O
2	the	O
3	present	O
4	study	O
5	we	O
6	have	O
7	investigated	O
8	the	O
9	regulatory	O
10	mechanism	O
11	for	O
12	CD95L	B
13	expression	O
14	.	O

1	Protein	O
2	sequence	O
3	analysis	O
4	reveals	O
5	that	O
6	MAN1	B
7	shares	O
8	a	O
9	conserved	O
10	globular	O
11	domain	O
12	of	O
13	approximately	O
14	40	O
15	amino	O
16	acids	O
17	,	O
18	which	O
19	we	O
20	term	O
21	the	O
22	LEM	B
23	module	I
24	,	O
25	with	O
26	inner	O
27	nuclear	O
28	membrane	O
29	proteins	O
30	lamina	B
31	-	I
32	associated	I
33	polypeptide	I
34	2	I
35	and	O
36	emerin	B
37	.	O

1	Molecular	O
2	cloning	O
3	of	O
4	a	O
5	novel	O
6	human	B
7	I	I
8	-	I
9	mfa	I
10	domain	I
11	-	I
12	containing	I
13	protein	I
14	that	O
15	differently	O
16	regulates	O
17	human	O
18	T	O
19	-	O
20	cell	O
21	leukemia	O
22	virus	O
23	type	O
24	I	O
25	and	O
26	HIV	O
27	-	O
28	1	O
29	expression	O
30	.	O

1	The	O
2	encoded	O
3	amino	O
4	acid	O
5	sequences	O
6	in	O
7	the	O
8	full	O
9	-	O
10	length	O
11	bovine	O
12	and	O
13	porcine	O
14	cDNAs	O
15	were	O
16	identical	O
17	,	O
18	consisting	O
19	of	O
20	209	O
21	amino	O
22	acid	O
23	residues	O
24	,	O
25	and	O
26	were	O
27	nearly	O
28	the	O
29	same	O
30	as	O
31	the	O
32	published	O
33	sequence	O
34	determined	O
35	by	O
36	Edman	O
37	degradation	O
38	.	O

1	With	O
2	chemical	O
3	shift	O
4	imaging	O
5	,	O
6	the	O
7	signal	O
8	intensity	O
9	decreased	O
10	on	O
11	the	O
12	out	O
13	-	O
14	of	O
15	-	O
16	phase	O
17	images	O
18	in	O
19	six	O
20	of	O
21	seven	O
22	(	O
23	86	O
24	%)	O
25	patients	O
26	with	O
27	APA	O
28	and	O
29	in	O
30	eight	O
31	of	O
32	nine	O
33	(	O
34	89	O
35	%)	O
36	patients	O
37	with	O
38	BAH	O
39	.	O

1	For	O
2	each	O
3	night	O
4	,	O
5	the	O
6	diary	O
7	allowed	O
8	the	O
9	subjective	O
10	measurement	O
11	of	O
12	bedtime	O
13	,	O
14	wake	O
15	time	O
16	,	O
17	time	O
18	in	O
19	bed	O
20	(	O
21	TIB	O
22	),	O
23	sleep	O
24	efficiency	O
25	,	O
26	number	O
27	of	O
28	minutes	O
29	of	O
30	wake	O
31	after	O
32	sleep	O
33	onset	O
34	(	O
35	WASO	O
36	),	O
37	alertness	O
38	on	O
39	awakening	O
40	,	O
41	and	O
42	percentage	O
43	of	O
44	morning	O
45	needing	O
46	an	O
47	alarm	O
48	(	O
49	or	O
50	a	O
51	person	O
52	functioning	O
53	as	O
54	one	O
55	).	O

1	Acad	O
2	.	O

1	Copyright	O
2	2000	O
3	Academic	O
4	Press	O
5	.	O

1	The	O
2	central	O
3	(	O
4	R	O
5	)	O
6	domain	O
7	is	O
8	responsible	O
9	for	O
10	receptor	O
11	-	O
12	binding	O
13	activity	O
14	whereas	O
15	the	O
16	N	O
17	-	O
18	terminal	O
19	(	O
20	T	O
21	)	O
22	domain	O
23	mediates	O
24	translocation	O
25	,	O
26	the	O
27	process	O
28	by	O
29	which	O
30	the	O
31	C	O
32	-	O
33	terminal	O
34	cytotoxic	O
35	domain	O
36	is	O
37	transported	O
38	from	O
39	the	O
40	receptor	O
41	to	O
42	the	O
43	site	O
44	of	O
45	its	O
46	cytotoxicity	O
47	.	O

1	We	O
2	have	O
3	previously	O
4	demonstrated	O
5	that	O
6	expression	O
7	of	O
8	the	O
9	gene	O
10	for	O
11	the	O
12	reproductive	O
13	neuropeptide	O
14	,	O
15	GnRH	B
16	,	O
17	is	O
18	repressed	O
19	by	O
20	the	O
21	glutamate	O
22	/	O
23	NO	O
24	/	O
25	cyclic	O
26	GMP	O
27	(	O
28	cGMP	O
29	)	O
30	signal	O
31	transduction	O
32	pathway	O
33	through	O
34	cGMP	B
35	-	I
36	dependent	I
37	protein	I
38	kinase	I
39	in	O
40	the	O
41	hypothalamic	O
42	GnRH	B
43	-	O
44	secreting	O
45	neuronal	O
46	cell	O
47	line	O
48	GT1	O
49	-	O
50	7	O
51	.	O

1	These	O
2	data	O
3	suggest	O
4	that	O
5	combined	O
6	lesions	O
7	of	O
8	cholinergic	O
9	and	O
10	serotonergic	O
11	neurons	O
12	in	O
13	the	O
14	rat	O
15	brain	O
16	do	O
17	not	O
18	alter	O
19	olfactory	O
20	perception	O
21	or	O
22	olfactory	O
23	short	O
24	-	O
25	term	O
26	memory	O
27	.	O

1	Extreme	O
2	potency	O
3	of	O
4	botulinum	B
5	toxin	I
6	.	O

1	In	O
2	contrast	O
3	,	O
4	c	B
5	-	I
6	Src	I
7	activated	O
8	by	O
9	isoproterenol	O
10	led	O
11	to	O
12	tyrosine	O
13	phosphorylation	O
14	of	O
15	Shc	B
16	and	O
17	subsequent	O
18	Erk	B
19	activation	O
20	,	O
21	but	O
22	not	O
23	tyrosine	O
24	phosphorylation	O
25	of	O
26	cortactin	B
27	or	O
28	Stat3	B
29	.	O

1	MSSPs	B
2	are	O
3	believed	O
4	to	O
5	regulate	O
6	DNA	O
7	replication	O
8	,	O
9	transcription	O
10	,	O
11	apopotosis	O
12	and	O
13	cell	O
14	cycle	O
15	progression	O
16	by	O
17	interacting	O
18	with	O
19	the	O
20	C	B
21	-	I
22	MYC	I
23	protein	I
24	.	O

1	For	O
2	wild	O
3	type	O
4	MutT	B
5	and	O
6	its	O
7	E53D	B
8	and	O
9	E44D	B
10	mutants	I
11	,	O
12	plots	O
13	of	O
14	log	O
15	(	O
16	k	O
17	(	O
18	cat	O
19	))	O
20	versus	O
21	pH	O
22	exhibited	O
23	a	O
24	limiting	O
25	slope	O
26	of	O
27	1	O
28	on	O
29	the	O
30	ascending	O
31	limb	O
32	and	O
33	then	O
34	a	O
35	hump	O
36	,	O
37	i	O
38	.	O
39	e	O
40	.,	O
41	a	O
42	sharply	O
43	defined	O
44	maximum	O
45	near	O
46	pH	O
47	8	O
48	followed	O
49	by	O
50	a	O
51	plateau	O
52	,	O
53	yielding	O
54	apparent	O
55	pK	O
56	(	O
57	a	O
58	)	O
59	values	O
60	of	O
61	7	O
62	.	O
63	6	O
64	+/-	O
65	0	O
66	.	O
67	3	O
68	and	O
69	8	O
70	.	O
71	4	O
72	+/-	O
73	0	O
74	.	O
75	4	O
76	for	O
77	an	O
78	essential	O
79	base	O
80	and	O
81	a	O
82	nonessential	O
83	acid	O
84	catalyst	O
85	,	O
86	respectively	O
87	,	O
88	in	O
89	the	O
90	active	O
91	quaternary	O
92	MutT	B
93	-	O
94	Mg	O
95	(	O
96	2	O
97	+)-	O
98	dGTP	O
99	-	O
100	Mg	O
101	(	O
102	2	O
103	+)	O
104	complex	O
105	.	O

1	Structural	O
2	changes	O
3	in	O
4	the	O
5	kinetically	O
6	more	O
7	damaged	O
8	E44D	O
9	mutant	O
10	detected	O
11	in	O
12	(	O
13	1	O
14	)	O
15	H	O
16	-(	O
17	15	O
18	)	O
19	N	O
20	HSQC	O
21	spectra	O
22	were	O
23	largely	O
24	limited	O
25	to	O
26	the	O
27	loop	O
28	I	O
29	-	O
30	helix	O
31	I	O
32	motif	O
33	,	O
34	suggesting	O
35	that	O
36	Glu	O
37	-	O
38	44	O
39	stabilizes	O
40	the	O
41	active	O
42	site	O
43	region	O
44	.	O

1	In	O
2	vitro	O
3	expression	O
4	of	O
5	four	O
6	different	O
7	naturally	O
8	occurring	O
9	nonsense	O
10	and	O
11	missense	O
12	mutations	O
13	revealed	O
14	a	O
15	dramatically	O
16	altered	O
17	subcellular	O
18	location	O
19	of	O
20	the	O
21	protein	O
22	in	O
23	cultured	O
24	cells	O
25	.	O

1	After	O
2	i	O
3	.	O
4	v	O
5	.	O

1	Immunity	O
2	acquired	O
3	by	O
4	mice	O
5	during	O
6	I	O
7	.	O
8	scapularis	O
9	nymphal	O
10	activity	O
11	in	O
12	early	O
13	summer	O
14	may	O
15	exclude	O
16	a	O
17	large	O
18	proportion	O
19	of	O
20	the	O
21	mouse	O
22	population	O
23	from	O
24	maintaining	O
25	E	O
26	.	O
27	phagocytophila	O
28	during	O
29	the	O
30	period	O
31	of	O
32	larval	O
33	activity	O
34	later	O
35	in	O
36	the	O
37	season	O
38	.	O

1	The	O
2	emerging	O
3	view	O
4	based	O
5	on	O
6	studies	O
7	in	O
8	yeast	O
9	is	O
10	that	O
11	each	O
12	class	O
13	of	O
14	snoRNPs	O
15	is	O
16	composed	O
17	of	O
18	a	O
19	unique	O
20	set	O
21	of	O
22	proteins	O
23	.	O

1	BCR	B
2	cross	O
3	-	O
4	linking	O
5	also	O
6	led	O
7	to	O
8	increased	O
9	MAPK	B
10	-	O
11	activated	O
12	protein	B
13	kinase	I
14	-	I
15	2	I
16	activity	O
17	,	O
18	an	O
19	enzyme	O
20	that	O
21	lies	O
22	immediately	O
23	downstream	O
24	from	O
25	p38	B
26	MAPK	I
27	;	O
28	MAPK	B
29	-	O
30	activated	O
31	protein	B
32	kinase	I
33	-	I
34	2	I
35	immune	O
36	complexes	O
37	phosphorylated	O
38	a	O
39	peptide	O
40	substrate	O
41	containing	O
42	the	O
43	CREB	B
44	serine	I
45	133	I
46	phosphoacceptor	I
47	motif	I
48	.	O

1	Activation	O
2	of	O
3	a	O
4	CRE	O
5	-	O
6	dependent	O
7	junB	B
8	promoter	I
9	/	O
10	chloramphenicol	B
11	acetyltransferase	I
12	(	O
13	CAT	B
14	)	O
15	reporter	O
16	gene	O
17	by	O
18	the	O
19	BCR	B
20	was	O
21	also	O
22	blocked	O
23	by	O
24	SB203580	O
25	.	O

1	We	O
2	present	O
3	evidence	O
4	that	O
5	the	O
6	upstream	O
7	open	O
8	reading	O
9	frame	O
10	(	O
11	uORF	O
12	)	O
13	represses	O
14	the	O
15	translation	O
16	of	O
17	the	O
18	downstream	O
19	major	O
20	open	O
21	reading	O
22	frame	O
23	(	O
24	mORF	O
25	).	O

1	METHODS	O
2	:	O
3	TBN	O
4	measurements	O
5	were	O
6	performed	O
7	in	O
8	31	O
9	female	O
10	outpatients	O
11	with	O
12	breast	O
13	carcinoma	O
14	who	O
15	were	O
16	undergoing	O
17	standard	O
18	cyclophosphamide	O
19	,	O
20	methotrexate	O
21	,	O
22	and	O
23	5	O
24	-	O
25	fluorouracil	O
26	(	O
27	CMF	O
28	)-	O
29	based	O
30	chemotherapy	O
31	(	O
32	median	O
33	age	O
34	,	O
35	48	O
36	years	O
37	;	O
38	range	O
39	,	O
40	26	O
41	-	O
42	77	O
43	years	O
44	).	O

1	A	O
2	385	O
3	bp	O
4	Glucocorticoid	O
5	Response	O
6	Unit	O
7	(	O
8	GRU	O
9	)	O
10	was	O
11	identified	O
12	whose	O
13	glucocorticoid	O
14	induction	O
15	was	O
16	enhanced	O
17	by	O
18	dibutyryl	O
19	-	O
20	cAMP	O
21	and	O
22	reduced	O
23	by	O
24	phorbol	O
25	esters	O
26	.	O

1	No	O
2	somatic	O
3	mutations	O
4	were	O
5	found	O
6	in	O
7	any	O
8	of	O
9	the	O
10	samples	O
11	,	O
12	suggesting	O
13	that	O
14	ING1	B
15	is	O
16	not	O
17	a	O
18	tumor	O
19	suppressor	O
20	gene	O
21	target	O
22	in	O
23	head	O
24	and	O
25	neck	O
26	cancer	O
27	.	O

1	Ras	B
2	-	O
3	GRF1	B
4	transiently	O
5	expressed	O
6	with	O
7	v	B
8	-	I
9	Src	I
10	was	O
11	tyrosine	O
12	-	O
13	phosphorylated	O
14	and	O
15	showed	O
16	significant	O
17	GEF	B
18	activity	O
19	toward	O
20	Rac	B
21	,	O
22	but	O
23	not	O
24	Rho	B
25	and	O
26	Cdc42	B
27	,	O
28	which	O
29	was	O
30	comparable	O
31	with	O
32	that	O
33	induced	O
34	by	O
35	Gbetagamma	B
36	.	O

1	As	O
2	no	O
3	complete	O
4	PPARgamma	B
5	antagonists	O
6	have	O
7	been	O
8	described	O
9	hitherto	O
10	,	O
11	we	O
12	have	O
13	constructed	O
14	a	O
15	dominant	O
16	-	O
17	negative	O
18	mutant	O
19	receptor	O
20	to	O
21	inhibit	O
22	wild	O
23	-	O
24	type	O
25	PPARgamma	B
26	action	O
27	.	O

1	EMSA	O
2	showed	O
3	that	O
4	nuclear	O
5	proteins	O
6	from	O
7	PC12	O
8	but	O
9	not	O
10	C6	O
11	or	O
12	Rat2	O
13	cells	O
14	bind	O
15	the	O
16	CRE	O
17	as	O
18	a	O
19	complex	O
20	containing	O
21	activating	B
22	transcription	I
23	factor	I
24	(	I
25	ATF	I
26	)-	I
27	4	I
28	and	O
29	CCAAT	B
30	enhancer	I
31	-	I
32	binding	I
33	protein	I
34	beta	I
35	,	O
36	while	O
37	both	O
38	PC12	O
39	and	O
40	C6	O
41	cell	O
42	nuclear	O
43	extracts	O
44	were	O
45	recruited	O
46	by	O
47	the	O
48	CCAAT	O
49	-	O
50	box	O
51	as	O
52	a	O
53	complex	O
54	containing	O
55	nuclear	B
56	factor	I
57	Y	I
58	.	O

1	EMSA	O
2	showed	O
3	that	O
4	nuclear	O
5	proteins	O
6	from	O
7	PC12	O
8	but	O
9	not	O
10	C6	O
11	or	O
12	Rat2	O
13	cells	O
14	bind	O
15	the	O
16	CRE	O
17	as	O
18	a	O
19	complex	O
20	containing	O
21	activating	B
22	transcription	I
23	factor	I
24	(	I
25	ATF	I
26	)-	I
27	4	I
28	and	O
29	CCAAT	B
30	enhancer	I
31	-	I
32	binding	I
33	protein	I
34	beta	I
35	,	O
36	while	O
37	both	O
38	PC12	O
39	and	O
40	C6	O
41	cell	O
42	nuclear	O
43	extracts	O
44	were	O
45	recruited	O
46	by	O
47	the	O
48	CCAAT	O
49	-	O
50	box	O
51	as	O
52	a	O
53	complex	O
54	containing	O
55	nuclear	B
56	factor	I
57	Y	I
58	.	O

1	Despite	O
2	resolution	O
3	of	O
4	the	O
5	solid	O
6	portion	O
7	of	O
8	the	O
9	tumor	O
10	,	O
11	serial	O
12	MRI	O
13	showed	O
14	enlargement	O
15	of	O
16	a	O
17	bilobar	O
18	tumor	O
19	cyst	O
20	3	O
21	years	O
22	after	O
23	the	O
24	original	O
25	diagnosis	O
26	.	O

1	LPO	O
2	and	O
3	SOD	B
4	levels	O
5	were	O
6	measured	O
7	at	O
8	five	O
9	points	O
10	before	O
11	and	O
12	during	O
13	the	O
14	operation	O
15	.	O

1	Sustained	O
2	ventricular	O
3	tachycardia	O
4	and	O
5	its	O
6	successful	O
7	prophylaxis	O
8	during	O
9	high	O
10	-	O
11	dose	O
12	bolus	O
13	interleukin	B
14	-	I
15	2	I
16	therapy	O
17	for	O
18	metastatic	O
19	renal	O
20	cell	O
21	carcinoma	O
22	.	O

1	Second	O
2	,	O
3	when	O
4	the	O
5	NBF1	B
6	+	I
7	R	I
8	protein	I
9	,	O
10	the	O
11	NBF2	B
12	protein	I
13	,	O
14	and	O
15	a	O
16	mixture	O
17	of	O
18	the	O
19	two	O
20	proteins	O
21	were	O
22	folded	O
23	separately	O
24	and	O
25	analyzed	O
26	by	O
27	molecular	O
28	sieve	O
29	chomatography	O
30	,	O
31	the	O
32	mixture	O
33	was	O
34	found	O
35	to	O
36	elute	O
37	prior	O
38	to	O
39	either	O
40	NBF1	B
41	+	I
42	R	I
43	or	O
44	NBF2	B
45	.	O

1	Collectively	O
2	,	O
3	these	O
4	experiments	O
5	demonstrate	O
6	that	O
7	CFTR	B
8	'	I
9	s	I
10	NBF1	I
11	+	I
12	R	I
13	region	I
14	and	O
15	its	O
16	NBF2	B
17	domain	I
18	,	O
19	after	O
20	folding	O
21	separately	O
22	as	O
23	distinct	O
24	units	O
25	,	O
26	have	O
27	a	O
28	strong	O
29	propensity	O
30	to	O
31	interact	O
32	and	O
33	that	O
34	this	O
35	interaction	O
36	is	O
37	stable	O
38	in	O
39	the	O
40	absence	O
41	of	O
42	added	O
43	nucleotides	O
44	or	O
45	exogenously	O
46	induced	O
47	phosphorylation	O
48	.	O

1	Copyright	O
2	2000	O
3	Academic	O
4	Press	O
5	.	O

1	Sulfhydryl	O
2	titration	O
3	with	O
4	iodoacetamide	O
5	,	O
6	monitored	O
7	by	O
8	quantitating	O
9	the	O
10	residual	O
11	thiols	O
12	after	O
13	reaction	O
14	with	O
15	a	O
16	maleimide	O
17	derivative	O
18	of	O
19	biotin	O
20	,	O
21	revealed	O
22	a	O
23	striking	O
24	difference	O
25	in	O
26	the	O
27	apparent	O
28	pK	O
29	(	O
30	a	O
31	)	O
32	values	O
33	of	O
34	the	O
35	cysteines	O
36	at	O
37	the	O
38	two	O
39	splice	O
40	junctions	O
41	.	O

1	After	O
2	nitric	O
3	oxide	O
4	inhalation	O
5	,	O
6	the	O
7	results	O
8	showed	O
9	moderate	O
10	increases	O
11	in	O
12	PaO2	O
13	and	O
14	SaO2	O
15	(	O
16	P	O
17	>	O
18	0	O
19	.	O
20	05	O
21	)	O
22	and	O
23	a	O
24	significant	O
25	decrease	O
26	in	O
27	Qs	O
28	/	O
29	Q	O
30	tau	O
31	ratio	O
32	(	O
33	P	O
34	<	O
35	0	O
36	.	O
37	01	O
38	).	O

1	The	O
2	results	O
3	showed	O
4	that	O
5	MIP	O
6	,	O
7	MMIF	O
8	,	O
9	FIC	O
10	,	O
11	Wimax	O
12	,	O
13	P0	O
14	.	O
15	1	O
16	and	O
17	minute	O
18	ventilation	O
19	(	O
20	Vr	O
21	)	O
22	were	O
23	significantly	O
24	increased	O
25	after	O
26	administration	O
27	of	O
28	methylphenidatum	O
29	and	O
30	aminophylline	O
31	.	O

1	Forty	O
2	4	O
3	-	O
4	month	O
5	old	O
6	SD	O
7	female	O
8	rats	O
9	were	O
10	randomly	O
11	divided	O
12	into	O
13	four	O
14	groups	O
15	,	O
16	namely	O
17	sham	O
18	operation	O
19	,	O
20	bilateral	O
21	ovariectomy	O
22	,	O
23	ovariectomy	O
24	plus	O
25	supplementary	O
26	ethinyl	O
27	estradiol	O
28	(	O
29	0	O
30	.	O
31	2	O
32	microgram	O
33	/	O
34	100	O
35	g	O
36	B	O
37	.	O

1	It	O
2	has	O
3	also	O
4	been	O
5	shown	O
6	that	O
7	a	O
8	variety	O
9	of	O
10	extracellular	O
11	factors	O
12	stimulate	O
13	a	O
14	pair	O
15	of	O
16	MAPK	O
17	p44	B
18	and	O
19	MAPK	O
20	p42	B
21	of	O
22	MAPK	B
23	family	I
24	members	I
25	.	O

1	Covalent	O
2	modification	O
3	of	O
4	the	O
5	transactivator	O
6	protein	O
7	IE2	B
8	-	O
9	p86	B
10	of	O
11	human	O
12	cytomegalovirus	O
13	by	O
14	conjugation	O
15	to	O
16	the	O
17	ubiquitin	B
18	-	I
19	homologous	I
20	proteins	I
21	SUMO	I
22	-	I
23	1	I
24	and	O
25	hSMT3b	B
26	.	O

1	73	O
2	:	O
3	658	O
4	-	O
5	666	O
6	,	O
7	1999	O
8	).	O

1	The	O
2	interaction	O
3	between	O
4	U	O
5	(	O
6	L	O
7	)	O
8	3	O
9	.	O

1	Protamine	B
2	and	O
3	heparin	O
4	doses	O
5	,	O
6	their	O
7	sum	O
8	(	O
9	Sigma	O
10	-	O
11	dose	O
12	)	O
13	and	O
14	differential	O
15	(	O
16	Delta	O
17	-	O
18	dose	O
19	)	O
20	doses	O
21	,	O
22	and	O
23	activated	O
24	clotting	O
25	times	O
26	were	O
27	tabulated	O
28	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	a	O
6	common	O
7	mechanism	O
8	has	O
9	been	O
10	identified	O
11	to	O
12	coordinate	O
13	the	O
14	growth	O
15	-	O
16	and	O
17	FC	O
18	-	O
19	dependent	O
20	expression	O
21	of	O
22	caveolin	B
23	.	O

1	Comparison	O
2	of	O
3	the	O
4	plant	O
5	nuclear	O
6	tRNA	O
7	3	O
8	'	O
9	processing	O
10	enzyme	O
11	with	O
12	the	O
13	plant	O
14	mitochondrial	O
15	one	O
16	suggests	O
17	that	O
18	both	O
19	activities	O
20	are	O
21	different	O
22	enzymes	O
23	.	O

1	The	O
2	requirement	O
3	of	O
4	3	O
5	'	O
6	complementarity	O
7	for	O
8	a	O
9	ligation	O
10	reaction	O
11	is	O
12	reaffirmed	O
13	by	O
14	results	O
15	from	O
16	1	O
17	nt	O
18	insertions	O
19	on	O
20	either	O
21	the	O
22	3	O
23	'-	O
24	or	O
25	5	O
26	'-	O
27	side	O
28	of	O
29	the	O
30	nick	O
31	.	O

1	NKX2	B
2	.	I
3	1	I
4	is	O
5	a	O
6	member	O
7	of	O
8	the	O
9	NK2	B
10	family	I
11	of	O
12	homeodomain	B
13	-	I
14	containing	I
15	transcription	I
16	factors	I
17	whose	O
18	targeted	O
19	disruption	O
20	in	O
21	mouse	O
22	results	O
23	in	O
24	the	O
25	absence	O
26	of	O
27	thyroid	O
28	tissue	O
29	and	O
30	a	O
31	severely	O
32	abnormal	O
33	lung	O
34	phenotype	O
35	.	O

1	National	O
2	abortion	O
3	laws	O
4	usually	O
5	do	O
6	not	O
7	allow	O
8	abortion	O
9	when	O
10	a	O
11	foetus	O
12	is	O
13	independently	O
14	viable	O
15	,	O
16	i	O
17	.	O
18	e	O
19	.	O
20	from	O
21	a	O
22	gestational	O
23	age	O
24	of	O
25	about	O
26	24	O
27	weeks	O
28	.	O

1	Expression	O
2	in	O
3	early	O
4	postnatal	O
5	pituitary	O
6	and	O
7	in	O
8	pre	O
9	-	O
10	somatotrophic	O
11	cells	O
12	suggests	O
13	that	O
14	Zn	B
15	-	I
16	16	I
17	could	O
18	play	O
19	a	O
20	role	O
21	in	O
22	pituitary	O
23	development	O
24	prior	O
25	to	O
26	somatotroph	O
27	differentiation	O
28	.	O

1	Mouse	B
2	growth	I
3	hormone	I
4	transcription	I
5	factor	I
6	Zn	I
7	-	I
8	16	I
9	:	O
10	unique	O
11	bipartite	O
12	structure	O
13	containing	O
14	tandemly	O
15	repeated	O
16	zinc	O
17	finger	O
18	domains	O
19	not	O
20	reported	O
21	in	O
22	rat	B
23	Zn	I
24	-	I
25	15	I
26	.	O

1	The	O
2	CCAAT	O
3	core	O
4	sequence	O
5	mutants	O
6	in	O
7	which	O
8	both	O
9	CIII	O
10	and	O
11	CI	O
12	/	O
13	CII	O
14	were	O
15	abolished	O
16	,	O
17	also	O
18	increased	O
19	the	O
20	promoter	O
21	activity	O
22	.	O

1	Deglutition	O
2	is	O
3	considered	O
4	to	O
5	be	O
6	immature	O
7	in	O
8	infants	O
9	and	O
10	to	O
11	mature	O
12	postnatally	O
13	.	O

1	This	O
2	repression	O
3	does	O
4	not	O
5	require	O
6	the	O
7	PU	B
8	.	I
9	1	I
10	transactivation	O
11	or	O
12	PEST	O
13	domains	O
14	and	O
15	cannot	O
16	be	O
17	reversed	O
18	by	O
19	p300	B
20	expression	O
21	.	O

1	First	O
2	,	O
3	human	O
4	erythroid	O
5	K562	O
6	cells	O
7	stably	O
8	integrated	O
9	with	O
10	various	O
11	HS	B
12	-	I
13	40	I
14	mutants	I
15	cis	O
16	linked	O
17	to	O
18	a	O
19	human	B
20	alpha	I
21	-	I
22	globin	I
23	promoter	I
24	-	O
25	growth	B
26	hormone	I
27	hybrid	O
28	gene	O
29	were	O
30	analyzed	O
31	by	O
32	genomic	O
33	footprinting	O
34	and	O
35	expression	O
36	analysis	O
37	.	O

1	Interestingly	O
2	,	O
3	addition	O
4	of	O
5	purified	O
6	CBP	B
7	to	O
8	the	O
9	nuclear	O
10	extracts	O
11	of	O
12	T47D	O
13	cells	O
14	markedly	O
15	stimulated	O
16	progesterone	O
17	-	O
18	and	O
19	PR	B
20	-	O
21	dependent	O
22	transcription	O
23	from	O
24	a	O
25	nucleosome	O
26	-	O
27	free	O
28	,	O
29	progesterone	O
30	response	O
31	element	O
32	(	O
33	PRE	O
34	)-	O
35	linked	O
36	reporter	O
37	DNA	O
38	template	O
39	.	O

1	Its	O
2	cognate	O
3	binding	O
4	protein	O
5	,	O
6	REST	B
7	/	O
8	NRSF	B
9	,	O
10	is	O
11	an	O
12	essential	O
13	transcription	O
14	factor	O
15	;	O
16	its	O
17	null	O
18	mutations	O
19	result	O
20	in	O
21	embryonic	O
22	lethality	O
23	,	O
24	and	O
25	its	O
26	dominant	O
27	negative	O
28	mutants	O
29	produce	O
30	aberrant	O
31	expression	O
32	of	O
33	neuron	O
34	-	O
35	specific	O
36	genes	O
37	.	O

1	Removal	O
2	of	O
3	all	O
4	core	B
5	histone	I
6	tail	O
7	domains	O
8	by	O
9	limited	O
10	trypsin	B
11	proteolysis	O
12	or	O
13	acetylation	O
14	of	O
15	the	O
16	core	B
17	histone	I
18	tails	O
19	significantly	O
20	relieves	O
21	this	O
22	inhibition	O
23	and	O
24	allows	O
25	TFIIIA	B
26	to	O
27	exhibit	O
28	high	O
29	-	O
30	affinity	O
31	binding	O
32	to	O
33	nucleosomal	O
34	DNA	O
35	.	O

1	Finally	O
2	,	O
3	the	O
4	mechanism	O
5	of	O
6	ASK1	B
7	activation	O
8	involves	O
9	,	O
10	in	O
11	part	O
12	,	O
13	homo	O
14	-	O
15	oligomerization	O
16	.	O

1	OUTCOME	O
2	:	O
3	Acetylcholine	B
4	receptor	I
5	antibodies	I
6	and	O
7	single	O
8	-	O
9	fibre	O
10	electromyogram	O
11	were	O
12	useful	O
13	in	O
14	the	O
15	diagnosis	O
16	of	O
17	myasthenia	O
18	gravis	O
19	.	O

1	Two	O
2	other	O
3	patients	O
4	underwent	O
5	PRFR	O
6	.	O

1	The	O
2	variations	O
3	were	O
4	caused	O
5	by	O
6	opposite	O
7	shifts	O
8	in	O
9	TSH	B
10	frequency	O
11	distribution	O
12	in	O
13	mothers	O
14	and	O
15	neonates	O
16	.	O

1	Characterization	O
2	of	O
3	the	O
4	5	O
5	'-	O
6	flanking	O
7	region	O
8	of	O
9	the	O
10	human	B
11	multidrug	I
12	resistance	I
13	protein	I
14	2	I
15	(	O
16	MRP2	B
17	)	O
18	gene	O
19	and	O
20	its	O
21	regulation	O
22	in	O
23	comparison	O
24	withthe	O
25	multidrug	B
26	resistance	I
27	protein	I
28	3	I
29	(	O
30	MRP3	B
31	)	O
32	gene	O
33	.	O

1	However	O
2	,	O
3	such	O
4	a	O
5	mechanism	O
6	was	O
7	not	O
8	detected	O
9	in	O
10	preliminary	O
11	observations	O
12	on	O
13	M	O
14	.	O
15	synoviae	O
16	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	the	O
6	M	O
7	.	O
8	jannaschii	O
9	as	O
10	well	O
11	as	O
12	related	O
13	archaeal	B
14	20S	I
15	proteasomes	I
16	require	O
17	a	O
18	nucleotidase	O
19	complex	O
20	such	O
21	as	O
22	PAN	B
23	to	O
24	mediate	O
25	the	O
26	energy	O
27	-	O
28	dependent	O
29	hydrolysis	O
30	of	O
31	folded	O
32	-	O
33	substrate	O
34	proteins	O
35	and	O
36	that	O
37	the	O
38	N	O
39	-	O
40	terminal	O
41	73	O
42	amino	O
43	acid	O
44	residues	O
45	of	O
46	PAN	B
47	are	O
48	not	O
49	absolutely	O
50	required	O
51	for	O
52	this	O
53	reaction	O
54	.	O

1	The	O
2	transcription	O
3	factor	O
4	E2F	B
5	plays	O
6	an	O
7	important	O
8	role	O
9	in	O
10	G	O
11	(	O
12	1	O
13	)	O
14	to	O
15	S	O
16	phase	O
17	transition	O
18	in	O
19	the	O
20	higher	O
21	eukaryotic	O
22	cell	O
23	cycle	O
24	.	O

1	In	O
2	two	O
3	-	O
4	field	O
5	nodal	O
6	dissection	O
7	,	O
8	two	O
9	components	O
10	are	O
11	included	O
12	with	O
13	(	O
14	modern	O
15	two	O
16	-	O
17	field	O
18	)	O
19	or	O
20	without	O
21	(	O
22	traditional	O
23	two	O
24	-	O
25	field	O
26	)	O
27	nodal	O
28	dissection	O
29	around	O
30	both	O
31	recurrent	O
32	laryngeal	O
33	nerve	O
34	chains	O
35	in	O
36	the	O
37	upper	O
38	mediastinum	O
39	.	O

1	Of	O
2	the	O
3	153	O
4	patients	O
5	studied	O
6	,	O
7	CK	B
8	-	I
9	MB	I
10	results	O
11	were	O
12	positive	O
13	in	O
14	91	O
15	(	O
16	59	O
17	%)	O
18	patients	O
19	;	O
20	ECG	O
21	revealed	O
22	AMI	O
23	in	O
24	72	O
25	(	O
26	47	O
27	%)	O
28	patients	O
29	.	O

1	The	O
2	effect	O
3	of	O
4	MIB	O
5	on	O
6	the	O
7	dose	O
8	-	O
9	response	O
10	curve	O
11	of	O
12	externally	O
13	applied	O
14	noradrenaline	O
15	was	O
16	also	O
17	studied	O
18	.	O

1	The	O
2	regional	O
3	blockade	O
4	of	O
5	H1R	B
6	was	O
7	observed	O
8	mainly	O
9	in	O
10	the	O
11	frontal	O
12	,	O
13	temporal	O
14	and	O
15	anterior	O
16	cingulate	O
17	cortices	O
18	,	O
19	and	O
20	the	O
21	intravenous	O
22	administration	O
23	of	O
24	d	O
25	-	O
26	chlorpheniramine	O
27	as	O
28	a	O
29	therapeutic	O
30	dose	O
31	(	O
32	2	O
33	mg	O
34	)	O
35	blocked	O
36	over	O
37	60	O
38	%	O
39	of	O
40	H1R	B
41	in	O
42	the	O
43	frontal	O
44	cortices	O
45	.	O

1	The	O
2	expression	O
3	of	O
4	the	O
5	yam8	B
6	(+)	I
7	cDNA	I
8	in	O
9	the	O
10	mid1	B
11	mutant	I
12	cells	O
13	partially	O
14	remediated	O
15	the	O
16	mid	O
17	phenotype	O
18	and	O
19	resulted	O
20	in	O
21	a	O
22	slight	O
23	increase	O
24	in	O
25	Ca	O
26	(	O
27	2	O
28	+)	O
29	uptake	O
30	activity	O
31	.	O

1	Linearized	O
2	overall	O
3	infection	O
4	rates	O
5	(	O
6	events	O
7	/	O
8	100	O
9	patient	O
10	-	O
11	days	O
12	)	O
13	were	O
14	2	O
15	.	O
16	05	O
17	+/-	O
18	0	O
19	.	O
20	33	O
21	(	O
22	heart	O
23	-	O
24	lung	O
25	)	O
26	and	O
27	2	O
28	.	O
29	34	O
30	+/-	O
31	0	O
32	.	O
33	34	O
34	(	O
35	double	O
36	-	O
37	lung	O
38	;	O
39	P	O
40	=	O
41	NS	O
42	)	O
43	at	O
44	3	O
45	months	O
46	.	O

1	Static	O
2	and	O
3	dynamic	O
4	compliance	O
5	was	O
6	measured	O
7	after	O
8	induction	O
9	of	O
10	anesthesia	O
11	,	O
12	before	O
13	and	O
14	immediately	O
15	after	O
16	filtration	O
17	in	O
18	the	O
19	operating	O
20	theater	O
21	,	O
22	1	O
23	hour	O
24	after	O
25	return	O
26	to	O
27	the	O
28	pediatric	O
29	intensive	O
30	care	O
31	unit	O
32	,	O
33	and	O
34	24	O
35	hours	O
36	after	O
37	the	O
38	operation	O
39	.	O

1	Antipyretic	O
2	therapy	O
3	:	O
4	physiologic	O
5	rationale	O
6	,	O
7	diagnostic	O
8	implications	O
9	,	O
10	and	O
11	clinical	O
12	consequences	O
13	.	O

1	There	O
2	is	O
3	no	O
4	correlation	O
5	between	O
6	C2	O
7	-	O
8	C3	O
9	disk	O
10	morphology	O
11	and	O
12	the	O
13	diskographically	O
14	provoked	O
15	response	O
16	.	O

1	KFC	B
2	,	O
3	a	O
4	Ste20	B
5	-	I
6	like	I
7	kinase	I
8	with	O
9	mitogenic	O
10	potential	O
11	and	O
12	capability	O
13	to	O
14	activate	O
15	the	O
16	SAPK	B
17	/	O
18	JNK	B
19	pathway	O
20	.	O

1	TIP30	B
2	has	O
3	an	O
4	intrinsic	O
5	kinase	O
6	activity	O
7	required	O
8	for	O
9	up	O
10	-	O
11	regulation	O
12	of	O
13	a	O
14	subset	O
15	of	O
16	apoptotic	O
17	genes	O
18	.	O

1	We	O
2	have	O
3	mapped	O
4	the	O
5	human	B
6	STAG3	I
7	gene	I
8	to	O
9	the	O
10	7q22	O
11	region	O
12	of	O
13	chromosome	O
14	7	O
15	;	O
16	six	O
17	human	B
18	STAG3	I
19	-	I
20	related	I
21	genes	I
22	have	O
23	also	O
24	been	O
25	mapped	O
26	:	O
27	two	O
28	at	O
29	7q22	O
30	near	O
31	the	O
32	functional	O
33	gene	O
34	,	O
35	one	O
36	at	O
37	7q11	O
38	.	O
39	22	O
40	,	O
41	and	O
42	three	O
43	at	O
44	7q11	O
45	.	O
46	23	O
47	,	O
48	two	O
49	of	O
50	them	O
51	flanking	O
52	the	O
53	breakpoints	O
54	commonly	O
55	associated	O
56	with	O
57	the	O
58	Williams	B
59	-	I
60	Beuren	I
61	syndrome	I
62	(	I
63	WBS	I
64	)	I
65	deletion	I
66	.	O

1	Reaction	O
2	time	O
3	(	O
4	RT	O
5	)	O
6	and	O
7	P300	O
8	were	O
9	collected	O
10	simultaneously	O
11	.	O

1	In	O
2	experiment	O
3	2	O
4	the	O
5	rats	O
6	had	O
7	free	O
8	access	O
9	to	O
10	two	O
11	bottles	O
12	,	O
13	one	O
14	of	O
15	which	O
16	contained	O
17	tap	O
18	water	O
19	,	O
20	and	O
21	the	O
22	other	O
23	contained	O
24	either	O
25	an	O
26	ethanol	O
27	(	O
28	6	O
29	%)	O
30	or	O
31	a	O
32	sucrose	O
33	(	O
34	5	O
35	%)	O
36	solution	O
37	.	O

1	Furthermore	O
2	,	O
3	Zelen	O
4	'	O
5	s	O
6	method	O
7	is	O
8	used	O
9	to	O
10	balance	O
11	the	O
12	number	O
13	of	O
14	patients	O
15	allocated	O
16	to	O
17	the	O
18	two	O
19	groups	O
20	within	O
21	each	O
22	institution	O
23	(	O
24	M	O
25	.	O

1	RESULTS	O
2	:	O
3	In	O
4	this	O
5	group	O
6	of	O
7	patients	O
8	,	O
9	male	O
10	gender	O
11	(	O
12	P	O
13	=	O
14	0	O
15	.	O

1	Selective	O
2	visual	O
3	attention	O
4	involves	O
5	dynamic	O
6	interplay	O
7	between	O
8	attentional	O
9	control	O
10	systems	O
11	and	O
12	sensory	O
13	brain	O
14	structures	O
15	.	O

1	The	O
2	patient	O
3	had	O
4	developed	O
5	left	O
6	-	O
7	sided	O
8	low	O
9	-	O
10	frequency	O
11	tremor	O
12	and	O
13	hemidystonia	O
14	after	O
15	a	O
16	severe	O
17	head	O
18	trauma	O
19	sustained	O
20	at	O
21	15	O
22	years	O
23	of	O
24	age	O
25	.	O

1	However	O
2	,	O
3	the	O
4	a1	O
5	isoform	O
6	is	O
7	expressed	O
8	most	O
9	heavily	O
10	in	O
11	brain	O
12	and	O
13	heart	O
14	,	O
15	a2	O
16	in	O
17	liver	O
18	and	O
19	kidney	O
20	,	O
21	and	O
22	a3	O
23	in	O
24	liver	O
25	,	O
26	lung	O
27	,	O
28	heart	O
29	,	O
30	brain	O
31	,	O
32	spleen	O
33	,	O
34	and	O
35	kidney	O
36	.	O

1	During	O
2	the	O
3	cloning	O
4	by	O
5	reverse	B
6	transcriptase	I
7	-	O
8	polymerase	O
9	chain	O
10	reaction	O
11	of	O
12	the	O
13	human	B
14	HIF	I
15	-	I
16	1alpha	I
17	subunit	I
18	,	O
19	we	O
20	isolated	O
21	two	O
22	cDNA	O
23	clones	O
24	which	O
25	corresponded	O
26	to	O
27	alternative	O
28	splicing	O
29	of	O
30	the	O
31	HIF	B
32	-	I
33	1alpha	I
34	gene	I
35	.	O

1	To	O
2	assess	O
3	the	O
4	relationship	O
5	between	O
6	G	O
7	(	O
8	q	O
9	)/	O
10	G	B
11	(	I
12	11	I
13	)	I
14	function	O
15	with	O
16	the	O
17	phosphatidylinositol	B
18	3	I
19	-	I
20	kinase	I
21	dependent	O
22	pathway	O
23	,	O
24	expression	O
25	of	O
26	a	O
27	dominant	O
28	-	O
29	interfering	O
30	p85	B
31	regulatory	I
32	subunit	I
33	,	O
34	as	O
35	well	O
36	as	O
37	wortmannin	O
38	treatment	O
39	inhibited	O
40	insulin	B
41	-	O
42	stimulated	O
43	but	O
44	not	O
45	G	B
46	(	I
47	q	I
48	)/	I
49	Q209L	I
50	-	O
51	stimulated	O
52	GLUT4	B
53	-	O
54	EGFP	B
55	translocation	O
56	.	O

1	In	O
2	endemic	O
3	BL	O
4	,	O
5	the	O
6	RB2	B
7	/	O
8	p130	B
9	gene	O
10	is	O
11	mutated	O
12	in	O
13	most	O
14	of	O
15	the	O
16	cases	O
17	,	O
18	and	O
19	the	O
20	protein	O
21	is	O
22	restricted	O
23	to	O
24	the	O
25	cytoplasm	O
26	.	O

1	Together	O
2	,	O
3	these	O
4	data	O
5	identify	O
6	ERK2	B
7	as	O
8	a	O
9	specific	O
10	and	O
11	direct	O
12	target	O
13	of	O
14	HePTP	B
15	and	O
16	are	O
17	consistent	O
18	with	O
19	a	O
20	model	O
21	in	O
22	which	O
23	HePTP	B
24	negatively	O
25	regulates	O
26	ERK2	B
27	activity	O
28	as	O
29	part	O
30	of	O
31	a	O
32	feedback	O
33	mechanism	O
34	.	O

1	Cross	O
2	-	O
3	reaction	O
4	between	O
5	a	O
6	monoclonal	O
7	antibody	O
8	and	O
9	two	O
10	alpha	B
11	beta	I
12	T	I
13	cell	I
14	receptors	I
15	.	O

1	Strontium	O
2	nitrate	O
3	mixed	O
4	with	O
5	glycolic	O
6	acid	O
7	,	O
8	in	O
9	comparison	O
10	with	O
11	glycolic	O
12	acid	O
13	alone	O
14	,	O
15	markedly	O
16	(	O
17	p	O
18	<	O
19	0	O
20	.	O
21	01	O
22	)	O
23	shortened	O
24	the	O
25	duration	O
26	of	O
27	the	O
28	irritation	O
29	sensation	O
30	from	O
31	24	O
32	.	O
33	4	O
34	+/-	O
35	4	O
36	.	O
37	1	O
38	(	O
39	mean	O
40	+/-	O
41	SEM	O
42	)	O
43	min	O
44	to	O
45	8	O
46	.	O
47	9	O
48	+/-	O
49	3	O
50	.	O
51	7	O
52	(	O
53	mean	O
54	+/-	O
55	SEM	O
56	)	O
57	min	O
58	,	O
59	and	O
60	significantly	O
61	(	O
62	p	O
63	<	O
64	0	O
65	.	O
66	05	O
67	)	O
68	reduced	O
69	the	O
70	mean	O
71	magnitude	O
72	of	O
73	the	O
74	irritation	O
75	sensation	O
76	at	O
77	all	O
78	time	O
79	points	O
80	(	O
81	overall	O
82	).	O

1	The	O
2	pCMBS	O
3	-	O
4	reactive	O
5	sulfhydryl	O
6	groups	O
7	were	O
8	located	O
9	exclusively	O
10	in	O
11	the	O
12	exofacial	O
13	half	O
14	of	O
15	the	O
16	plasma	O
17	membrane	O
18	and	O
19	,	O
20	when	O
21	presented	O
22	in	O
23	a	O
24	helical	O
25	model	O
26	,	O
27	lie	O
28	along	O
29	one	O
30	side	O
31	of	O
32	the	O
33	helices	O
34	.	O

1	Analysis	O
2	of	O
3	1	O
4	Mb	O
5	of	O
6	published	O
7	sequence	O
8	from	O
9	the	O
10	region	O
11	of	O
12	conserved	O
13	synteny	O
14	on	O
15	human	O
16	chromosome	O
17	5q31	O
18	-	O
19	q33	O
20	identified	O
21	45	O
22	gene	O
23	candidates	O
24	,	O
25	including	O
26	35	O
27	expressed	O
28	genes	O
29	in	O
30	the	O
31	human	B
32	IL	I
33	-	I
34	4	I
35	cytokine	I
36	gene	I
37	cluster	I
38	.	O

1	Human	B
2	AP	I
3	-	I
4	2rep	I
5	repressed	O
6	both	O
7	reporter	O
8	expression	O
9	from	O
10	a	O
11	transiently	O
12	transfected	O
13	AP	B
14	-	I
15	2alpha	I
16	promoter	I
17	and	O
18	the	O
19	endogenous	O
20	AP	B
21	-	I
22	2alpha	I
23	gene	I
24	and	O
25	inversely	O
26	was	O
27	negatively	O
28	regulated	O
29	by	O
30	AP	B
31	-	I
32	2alpha	I
33	.	O

1	In	O
2	order	O
3	to	O
4	gain	O
5	deeper	O
6	insight	O
7	into	O
8	the	O
9	role	O
10	of	O
11	the	O
12	amino	O
13	-	O
14	terminal	O
15	domain	O
16	of	O
17	the	O
18	p24	B
19	(	O
20	CA	B
21	)	O
22	protein	O
23	during	O
24	viral	O
25	replication	O
26	,	O
27	eight	O
28	highly	O
29	conserved	O
30	proline	O
31	residues	O
32	known	O
33	to	O
34	promote	O
35	turns	O
36	and	O
37	to	O
38	terminate	O
39	alpha	O
40	-	O
41	helices	O
42	within	O
43	the	O
44	p24	B
45	tertiary	O
46	structure	O
47	were	O
48	replaced	O
49	by	O
50	a	O
51	leucine	O
52	residue	O
53	(	O
54	P	O
55	-	O
56	position	O
57	-	O
58	L	O
59	).	O

1	Clb	B
2	/	O
3	Cdc28	B
4	kinases	O
5	promote	O
6	nuclear	O
7	export	O
8	of	O
9	the	O
10	replication	B
11	initiator	I
12	proteins	I
13	Mcm2	I
14	-	I
15	7	I
16	.	O

1	Alternatively	O
2	,	O
3	PC12	O
4	-	O
5	E2	O
6	cells	O
7	were	O
8	submitted	O
9	to	O
10	treatment	O
11	with	O
12	antibodies	O
13	to	O
14	the	O
15	fibroblast	B
16	growth	I
17	factor	I
18	(	I
19	FGF	I
20	)	I
21	receptor	I
22	,	O
23	inhibitors	O
24	of	O
25	the	O
26	nonreceptor	B
27	tyrosine	I
28	kinase	I
29	p59	I
30	(	O
31	fyn	B
32	),	O
33	PLC	B
34	,	O
35	PKC	B
36	and	O
37	MEK	B
38	and	O
39	an	O
40	activator	O
41	of	O
42	PKC	B
43	,	O
44	phorbol	O
45	-	O
46	12	O
47	-	O
48	myristate	O
49	-	O
50	13	O
51	-	O
52	acetate	O
53	(	O
54	PMA	O
55	).	O

1	Cooperative	O
2	roles	O
3	of	O
4	Bozozok	B
5	/	O
6	Dharma	B
7	and	O
8	Nodal	B
9	-	I
10	related	I
11	proteins	I
12	in	O
13	the	O
14	formation	O
15	of	O
16	the	O
17	dorsal	O
18	organizer	O
19	in	O
20	zebrafish	O
21	.	O

1	Thiopentone	O
2	sodium	O
3	administered	O
4	at	O
5	30	O
6	and	O
7	10	O
8	min	O
9	before	O
10	or	O
11	5	O
12	,	O
13	10	O
14	and	O
15	15	O
16	min	O
17	after	O
18	exposure	O
19	to	O
20	NOC	O
21	-	O
22	5	O
23	,	O
24	but	O
25	not	O
26	thereafter	O
27	,	O
28	significantly	O
29	attenuated	O
30	NO	O
31	-	O
32	induced	O
33	neurotoxicity	O
34	compared	O
35	with	O
36	controls	O
37	.	O

1	We	O
2	also	O
3	show	O
4	that	O
5	zygotically	O
6	activated	O
7	Xretpos	O
8	transcripts	O
9	are	O
10	restricted	O
11	to	O
12	ventro	O
13	-	O
14	posterior	O
15	specific	O
16	regions	O
17	and	O
18	induced	O
19	by	O
20	UV	O
21	-	O
22	irradiation	O
23	and	O
24	BMP	B
25	-	I
26	4	I
27	overexpression	O
28	in	O
29	cycloheximide	O
30	-	O
31	dependent	O
32	way	O
33	.	O
34	genesis	O
35	26	O
36	:	O
37	198	O
38	-	O
39	207	O
40	,	O
41	2000	O
42	.	O

1	In	O
2	all	O
3	other	O
4	cases	O
5	,	O
6	vestibular	O
7	neurectomy	O
8	or	O
9	chemical	O
10	vestibular	O
11	labyrinthectomy	O
12	,	O
13	by	O
14	means	O
15	of	O
16	intratympanic	O
17	low	O
18	concentration	O
19	gentamicin	O
20	(	O
21	20	O
22	mg	O
23	/	O
24	mL	O
25	),	O
26	are	O
27	indicated	O
28	.	O

1	However	O
2	,	O
3	when	O
4	,	O
5	where	O
6	and	O
7	how	O
8	the	O
9	DSPP	B
10	is	O
11	cleaved	O
12	into	O
13	DSP	B
14	and	O
15	DPP	B
16	is	O
17	not	O
18	clear	O
19	.	O

1	It	O
2	has	O
3	a	O
4	grave	O
5	prognosis	O
6	with	O
7	>	O
8	70	O
9	%	O
10	mortality	O
11	in	O
12	3	O
13	months	O
14	,	O
15	despite	O
16	mechanical	O
17	ventilation	O
18	.	O

1	We	O
2	found	O
3	that	O
4	TCR	B
5	signaling	O
6	induces	O
7	AP	B
8	-	I
9	1	I
10	binding	O
11	to	O
12	this	O
13	site	O
14	and	O
15	regulates	O
16	the	O
17	fasl	B
18	promoter	I
19	function	O
20	in	O
21	a	O
22	fashion	O
23	dependent	O
24	on	O
25	NF	B
26	-	I
27	kappaB	I
28	binding	O
29	.	O

1	Thus	O
2	,	O
3	patients	O
4	with	O
5	metastatic	O
6	melanoma	O
7	are	O
8	not	O
9	tolerant	O
10	to	O
11	gp100	B
12	Ag	I
13	based	O
14	on	O
15	the	O
16	detection	O
17	of	O
18	CD8	B
19	+	I
20	T	O
21	cells	O
22	specific	O
23	for	O
24	multiple	O
25	HLA	B
26	-	I
27	A	I
28	*	I
29	0201	I
30	-	O
31	restricted	O
32	,	O
33	gp100	B
34	-	O
35	derived	O
36	epitopes	O
37	.	O

1	Approximately	O
2	20	O
3	%	O
4	of	O
5	ALCLs	O
6	that	O
7	express	O
8	ALK	B
9	do	O
10	not	O
11	contain	O
12	the	O
13	t	O
14	(	O
15	2	O
16	;	O
17	5	O
18	),	O
19	suggesting	O
20	that	O
21	other	O
22	genetic	O
23	abnormalities	O
24	can	O
25	result	O
26	in	O
27	aberrant	O
28	ALK	B
29	expression	O
30	.	O

1	In	O
2	addition	O
3	,	O
4	expected	O
5	decreases	O
6	in	O
7	ATIC	B
8	enzymatic	O
9	function	O
10	in	O
11	ATIC	B
12	-	O
13	ALK	B
14	-	O
15	containing	O
16	lymphomas	O
17	may	O
18	render	O
19	these	O
20	tumors	O
21	more	O
22	sensitive	O
23	to	O
24	antifolate	O
25	drugs	O
26	such	O
27	as	O
28	methotrexate	O
29	.	O

1	Following	O
2	the	O
3	observation	O
4	that	O
5	non	O
6	-	O
7	organ	O
8	-	O
9	specific	O
10	antibodies	O
11	are	O
12	related	O
13	with	O
14	pregnancy	O
15	loss	O
16	and	O
17	preeclampsia	O
18	,	O
19	the	O
20	role	O
21	of	O
22	organ	O
23	-	O
24	specific	O
25	antibodies	O
26	is	O
27	currently	O
28	being	O
29	extensively	O
30	investigated	O
31	.	O

1	Manganese	O
2	ions	O
3	were	O
4	found	O
5	to	O
6	be	O
7	essential	O
8	for	O
9	autophosphorylation	O
10	of	O
11	BGLF4	B
12	,	O
13	and	O
14	magnesium	O
15	can	O
16	stimulate	O
17	the	O
18	activity	O
19	.	O

1	The	O
2	Mif1	B
3	5	I
4	'	I
5	flanking	I
6	region	I
7	contains	O
8	a	O
9	functional	O
10	ER	O
11	stress	O
12	-	O
13	responsive	O
14	element	O
15	which	O
16	is	O
17	sufficient	O
18	for	O
19	induction	O
20	by	O
21	tunicamycin	O
22	.	O

1	Rigid	O
2	point	O
3	feature	O
4	registration	O
5	using	O
6	mutual	O
7	information	O
8	.	O

1	Methysergide	O
2	is	O
3	a	O
4	serotonin	O
5	antagonist	O
6	and	O
7	has	O
8	been	O
9	demonstrated	O
10	to	O
11	reduce	O
12	wound	O
13	blood	O
14	flow	O
15	and	O
16	edema	O
17	formation	O
18	.	O

1	Serum	O
2	leptin	B
3	concentrations	O
4	in	O
5	women	O
6	during	O
7	gonadotropin	B
8	stimulation	O
9	cycles	O
10	.	O

1	Valuing	O
2	families	O
3	:	O
4	social	O
5	work	O
6	practice	O
7	with	O
8	families	O
9	from	O
10	a	O
11	strengths	O
12	perspective	O
13	.	O

1	PURPOSE	O
2	:	O
3	A	O
4	two	O
5	-	O
6	generation	O
7	consanguineous	O
8	Pakistani	O
9	family	O
10	with	O
11	autosomal	O
12	recessive	O
13	Leber	O
14	congenital	O
15	amaurosis	O
16	(	O
17	LCA	O
18	,	O
19	MIM	O
20	204	O
21	,	O
22	000	O
23	)	O
24	and	O
25	keratoconus	O
26	was	O
27	identified	O
28	.	O

1	Ste18p	B
2	was	O
3	targeted	O
4	to	O
5	the	O
6	plasma	O
7	membrane	O
8	even	O
9	in	O
10	the	O
11	absence	O
12	of	O
13	prenylation	O
14	or	O
15	thioacylation	O
16	.	O

1	Here	O
2	,	O
3	we	O
4	show	O
5	that	O
6	IRF	B
7	-	I
8	1	I
9	is	O
10	degraded	O
11	via	O
12	the	O
13	ubiquitin	B
14	-	O
15	proteasome	O
16	pathway	O
17	.	O

1	An	O
2	amino	O
3	-	O
4	acid	O
5	sequence	O
6	comparison	O
7	revealed	O
8	that	O
9	Bacillus	B
10	YM55	I
11	-	I
12	1	I
13	aspartase	I
14	shared	O
15	71	O
16	%	O
17	homology	O
18	with	O
19	Bacillus	B
20	subtilis	I
21	aspartase	I
22	and	O
23	49	O
24	%	O
25	with	O
26	Escherichia	O
27	coli	O
28	and	O
29	Pseudomonas	B
30	fluorescens	I
31	aspartases	I
32	.	O

1	Unique	O
2	to	O
3	this	O
4	system	O
5	,	O
6	the	O
7	activity	O
8	of	O
9	TraR	B
10	is	O
11	negatively	O
12	modulated	O
13	by	O
14	an	O
15	antiactivator	O
16	called	O
17	TraM	B
18	.	O

1	As	O
2	assessed	O
3	by	O
4	a	O
5	genetic	O
6	assay	O
7	that	O
8	measures	O
9	AAI	O
10	-	O
11	dependent	O
12	DNA	O
13	binding	O
14	,	O
15	TraM	B
16	inhibited	O
17	TraR	B
18	function	O
19	before	O
20	and	O
21	after	O
22	the	O
23	transcription	O
24	factor	O
25	had	O
26	bound	O
27	to	O
28	its	O
29	DNA	O
30	recognition	O
31	site	O
32	.	O

1	Here	O
2	we	O
3	show	O
4	that	O
5	IIIa	O
6	pre	O
7	-	O
8	mRNA	O
9	splicing	O
10	is	O
11	activated	O
12	more	O
13	than	O
14	200	O
15	-	O
16	fold	O
17	in	O
18	nuclear	O
19	extracts	O
20	prepared	O
21	from	O
22	late	O
23	adenovirus	O
24	-	O
25	infected	O
26	cells	O
27	(	O
28	Ad	O
29	-	O
30	NE	O
31	)	O
32	compared	O
33	to	O
34	uninfected	O
35	HeLa	O
36	cell	O
37	nuclear	O
38	extracts	O
39	(	O
40	HeLa	O
41	-	O
42	NE	O
43	).	O

1	Inactivation	O
2	of	O
3	Ulp2	B
4	also	O
5	suppresses	O
6	several	O
7	ulp1	B
8	(	I
9	ts	I
10	)	I
11	defects	O
12	,	O
13	and	O
14	the	O
15	double	O
16	mutant	O
17	accumulates	O
18	far	O
19	fewer	O
20	Smt3	B
21	-	I
22	protein	I
23	conjugates	O
24	than	O
25	either	O
26	single	O
27	mutant	O
28	.	O

1	Collectively	O
2	,	O
3	the	O
4	results	O
5	suggest	O
6	that	O
7	ARF	B
8	binding	O
9	to	O
10	Mdm2	B
11	induces	O
12	a	O
13	conformational	O
14	change	O
15	that	O
16	facilitates	O
17	nucleolar	O
18	import	O
19	of	O
20	the	O
21	ARF	B
22	-	O
23	Mdm2	B
24	complex	O
25	and	O
26	p53	B
27	-	O
28	dependent	O
29	cell	O
30	cycle	O
31	arrest	O
32	.	O

1	Cyclin	B
2	A	I
3	expression	O
4	is	O
5	repressed	O
6	in	O
7	quiescent	O
8	cells	O
9	by	O
10	E2F	B
11	acting	O
12	in	O
13	conjunction	O
14	with	O
15	its	O
16	pocket	O
17	protein	O
18	partners	O
19	Rb	B
20	,	O
21	p107	B
22	,	O
23	and	O
24	p130	B
25	;	O
26	however	O
27	,	O
28	v	B
29	-	I
30	Jun	I
31	overrides	O
32	this	O
33	control	O
34	,	O
35	causing	O
36	phosphorylated	O
37	Rb	B
38	and	O
39	proliferation	O
40	-	O
41	specific	O
42	E2F	B
43	-	O
44	p107	B
45	complexes	O
46	to	O
47	persist	O
48	after	O
49	mitogen	O
50	withdrawal	O
51	.	O

1	D	B
2	-	I
3	cyclin	I
4	-	O
5	cdk	B
6	activity	O
7	is	O
8	required	O
9	for	O
10	Rb	B
11	phosphorylation	O
12	in	O
13	v	B
14	-	I
15	Jun	I
16	-	O
17	transformed	O
18	cells	O
19	,	O
20	since	O
21	ectopic	O
22	expression	O
23	of	O
24	the	O
25	cdk4	B
26	-	O
27	and	O
28	cdk6	B
29	-	O
30	specific	O
31	inhibitor	O
32	p16	B
33	(	O
34	INK4A	B
35	)	O
36	inhibits	O
37	both	O
38	DNA	O
39	synthesis	O
40	and	O
41	cell	O
42	proliferation	O
43	.	O

1	CONCLUSION	O
2	:	O
3	A	O
4	valve	O
5	-	O
6	like	O
7	mechanism	O
8	formed	O
9	by	O
10	the	O
11	capsulorhexis	O
12	rim	O
13	partially	O
14	adhered	O
15	to	O
16	the	O
17	IOL	O
18	optic	O
19	can	O
20	occur	O
21	postoperatively	O
22	.	O

1	The	O
2	protein	O
3	first	O
4	identified	O
5	by	O
6	the	O
7	monoclonal	B
8	antibody	I
9	Q18	I
10	is	O
11	encoded	O
12	by	O
13	a	O
14	gene	O
15	located	O
16	in	O
17	57A	O
18	on	O
19	polytene	O
20	chromosomes	O
21	and	O
22	has	O
23	been	O
24	consequently	O
25	named	O
26	Hrb57A	B
27	.	O

1	3	O
2	'	O
3	RNA	O
4	boundary	O
5	experiments	O
6	indicate	O
7	that	O
8	the	O
9	5	O
10	'	O
11	structure	O
12	reduces	O
13	the	O
14	number	O
15	of	O
16	(	O
17	G	O
18	/	O
19	U	O
20	)	O
21	AG	O
22	repeats	O
23	required	O
24	for	O
25	stable	O
26	TRAP	B
27	-	O
28	trp	B
29	leader	O
30	RNA	O
31	association	O
32	.	O

1	Gene	O
2	silencing	O
3	associated	O
4	with	O
5	repeated	O
6	DNA	O
7	sequences	O
8	has	O
9	been	O
10	reported	O
11	for	O
12	many	O
13	eukaryotes	O
14	,	O
15	including	O
16	plants	O
17	.	O

1	The	O
2	AtERF	B
3	genes	I
4	were	O
5	differentially	O
6	regulated	O
7	by	O
8	ethylene	O
9	and	O
10	by	O
11	abiotic	O
12	stress	O
13	conditions	O
14	,	O
15	such	O
16	as	O
17	wounding	O
18	,	O
19	cold	O
20	,	O
21	high	O
22	salinity	O
23	,	O
24	or	O
25	drought	O
26	,	O
27	via	O
28	ETHYLENE	B
29	-	I
30	INSENSITIVE2	I
31	(	O
32	EIN2	B
33	)-	O
34	dependent	O
35	or	O
36	-	O
37	independent	O
38	pathways	O
39	.	O

1	Animals	O
2	received	O
3	a	O
4	dose	O
5	of	O
6	dexamethasone	O
7	(	O
8	10	O
9	mg	O
10	/	O
11	kg	O
12	i	O
13	.	O
14	p	O
15	.)	O
16	prior	O
17	to	O
18	the	O
19	protein	O
20	-	O
21	free	O
22	surfactant	O
23	preparation	O
24	Exosurf	O
25	(	O
26	pure	O
27	phospholipids	O
28	containing	O
29	surfactant	O
30	,	O
31	Wellcome	O
32	GmbH	O
33	,	O
34	Burgwedel	O
35	,	O
36	Germany	O
37	)	O
38	and	O
39	a	O
40	rSP	O
41	-	O
42	C	O
43	based	O
44	surfactant	O
45	,	O
46	respectively	O
47	.	O

1	BACKGROUND	O
2	:	O
3	The	O
4	aim	O
5	of	O
6	this	O
7	study	O
8	was	O
9	to	O
10	determine	O
11	the	O
12	response	O
13	rates	O
14	and	O
15	toxicity	O
16	of	O
17	two	O
18	regimens	O
19	containing	O
20	granulocyte	B
21	-	I
22	macrophage	I
23	-	I
24	colony	I
25	stimulating	I
26	factor	I
27	(	O
28	GM	B
29	-	I
30	CSF	I
31	)	O
32	in	O
33	combination	O
34	with	O
35	interleukin	B
36	-	I
37	2	I
38	(	O
39	IL	B
40	-	I
41	2	I
42	)	O
43	in	O
44	the	O
45	treatment	O
46	of	O
47	patients	O
48	with	O
49	metastatic	O
50	renal	O
51	cell	O
52	carcinoma	O
53	.	O

1	We	O
2	show	O
3	,	O
4	by	O
5	injection	O
6	of	O
7	synthetic	O
8	mRNAs	O
9	,	O
10	that	O
11	the	O
12	cis	O
13	-	O
14	acting	O
15	sequences	O
16	responsible	O
17	for	O
18	repression	O
19	of	O
20	cyclin	B
21	B1	I
22	mRNA	I
23	reside	O
24	within	O
25	its	O
26	3	O
27	'	O
28	UTR	O
29	.	O

1	These	O
2	data	O
3	indicate	O
4	that	O
5	expansion	O
6	of	O
7	the	O
8	dodecamer	O
9	repeat	O
10	located	O
11	in	O
12	the	O
13	proximal	O
14	promoter	O
15	of	O
16	CSTB	B
17	severely	O
18	disrupts	O
19	the	O
20	function	O
21	of	O
22	the	O
23	promoter	O
24	and	O
25	thereby	O
26	reduces	O
27	transcription	O
28	of	O
29	CSTB	B
30	.	O

1	Thus	O
2	,	O
3	while	O
4	the	O
5	genomic	O
6	organization	O
7	of	O
8	mHuA	B
9	is	O
10	similar	O
11	to	O
12	the	O
13	neural	O
14	-	O
15	restricted	O
16	members	O
17	of	O
18	the	O
19	Elav	B
20	family	I
21	,	O
22	the	O
23	promoter	O
24	element	O
25	differs	O
26	substantially	O
27	both	O
28	by	O
29	sequence	O
30	analysis	O
31	and	O
32	transcriptional	O
33	activity	O
34	in	O
35	non	O
36	-	O
37	neural	O
38	cell	O
39	types	O
40	.	O

1	Analysis	O
2	of	O
3	the	O
4	5	O
5	'	O
6	end	O
7	of	O
8	the	O
9	mouse	B
10	Elavl1	I
11	(	O
12	mHuA	B
13	)	O
14	gene	O
15	reveals	O
16	a	O
17	transcriptional	O
18	regulatory	O
19	element	O
20	and	O
21	evidence	O
22	for	O
23	conserved	O
24	genomic	O
25	organization	O
26	.	O
27	mHuA	B
28	(	O
29	Elavl1	B
30	)	O
31	belongs	O
32	to	O
33	a	O
34	highly	O
35	conserved	O
36	family	O
37	of	O
38	genes	O
39	encoding	O
40	RNA	O
41	-	O
42	binding	O
43	proteins	O
44	and	O
45	has	O
46	been	O
47	linked	O
48	to	O
49	cell	O
50	growth	O
51	and	O
52	proliferation	O
53	through	O
54	its	O
55	regulation	O
56	of	O
57	mRNA	O
58	stability	O
59	.	O

1	Electrophoretic	O
2	mobility	O
3	shift	O
4	assays	O
5	revealed	O
6	that	O
7	Sp1	B
8	binds	O
9	to	O
10	two	O
11	different	O
12	regions	O
13	in	O
14	the	O
15	proximal	O
16	promoter	O
17	,	O
18	a	O
19	typical	O
20	Sp1	B
21	site	I
22	located	O
23	at	O
24	(-	O
25	38	O
26	;	O
27	-	O
28	33	O
29	)	O
30	and	O
31	a	O
32	G	O
33	/	O
34	C	O
35	-	O
36	rich	O
37	region	O
38	between	O
39	(-	O
40	67	O
41	;	O
42	-	O
43	62	O
44	).	O

1	Fgd3	B
2	and	O
3	FGD1	B
4	share	O
5	a	O
6	high	O
7	degree	O
8	of	O
9	sequence	O
10	identity	O
11	that	O
12	spans	O
13	>	O
14	560	O
15	contiguous	O
16	amino	O
17	acid	O
18	residues	O
19	.	O

1	Molecular	O
2	cloning	O
3	of	O
4	mouse	B
5	thioredoxin	I
6	reductases	I
7	.	O

1	The	O
2	HPLC	O
3	method	O
4	involves	O
5	an	O
6	octadecylsilane	O
7	column	O
8	at	O
9	55	O
10	degrees	O
11	C	O
12	,	O
13	a	O
14	mixture	O
15	of	O
16	water	O
17	-	O
18	acetonitrile	O
19	-	O
20	orthophosphoric	O
21	acid	O
22	(	O
23	779	O
24	:	O
25	220	O
26	:	O
27	1	O
28	,	O
29	v	O
30	/	O
31	v	O
32	)	O
33	as	O
34	mobile	O
35	phase	O
36	and	O
37	detection	O
38	at	O
39	226	O
40	nm	O
41	.	O

1	Eight	O
2	patients	O
3	received	O
4	1	O
5	.	O
6	5	O
7	mg	O
8	of	O
9	adefovir	O
10	dipivoxil	O
11	per	O
12	kg	O
13	of	O
14	body	O
15	weight	O
16	,	O
17	and	O
18	six	O
19	patients	O
20	received	O
21	3	O
22	.	O
23	0	O
24	mg	O
25	of	O
26	adefovir	O
27	dipivoxil	O
28	per	O
29	kg	O
30	.	O

1	CYC2	B
2	encodes	O
3	a	O
4	24	O
5	-	O
6	kDa	O
7	protein	O
8	that	O
9	has	O
10	sequence	O
11	identity	O
12	to	O
13	the	O
14	Neurospora	B
15	crassa	I
16	PREG1	I
17	and	O
18	the	O
19	S	B
20	.	I
21	cerevisiae	I
22	PHO80	I
23	cyclin	I
24	.	O

1	To	O
2	determine	O
3	if	O
4	CYC2	B
5	is	O
6	found	O
7	in	O
8	a	O
9	complex	O
10	with	O
11	previously	O
12	identified	O
13	trypanosome	B
14	cdc2	I
15	-	I
16	related	I
17	kinases	I
18	(	O
19	CRKs	B
20	),	O
21	the	O
22	CYC2	B
23	gene	I
24	was	O
25	fused	O
26	to	O
27	the	O
28	TY	B
29	epitope	I
30	tag	O
31	,	O
32	integrated	O
33	into	O
34	the	O
35	trypanosome	O
36	genome	O
37	,	O
38	and	O
39	expressed	O
40	under	O
41	inducible	O
42	control	O
43	.	O

1	These	O
2	findings	O
3	indicate	O
4	the	O
5	involvement	O
6	of	O
7	Sp1	B
8	and	O
9	an	O
10	Inr	O
11	in	O
12	non	O
13	-	O
14	cell	O
15	-	O
16	specific	O
17	regulation	O
18	and	O
19	a	O
20	Kruppel	B
21	-	I
22	like	I
23	transcription	I
24	factor	I
25	and	O
26	Sp1	B
27	in	O
28	the	O
29	cell	O
30	-	O
31	specific	O
32	regulation	O
33	of	O
34	the	O
35	LTC	B
36	(	I
37	4	I
38	)	I
39	S	I
40	gene	I
41	.	O

1	Here	O
2	we	O
3	review	O
4	progress	O
5	to	O
6	date	O
7	in	O
8	this	O
9	area	O
10	.	O

1	Additionally	O
2	,	O
3	the	O
4	mouse	O
5	promoter	O
6	contains	O
7	22	O
8	copies	O
9	of	O
10	a	O
11	CT	O
12	dinucleotide	O
13	repeat	O
14	sequence	O
15	located	O
16	approximately	O
17	155	O
18	bp	O
19	5	O
20	'	O
21	to	O
22	exon	O
23	1	O
24	.	O

1	The	O
2	newly	O
3	defined	O
4	region	O
5	contains	O
6	an	O
7	intron	O
8	that	O
9	may	O
10	be	O
11	alternatively	O
12	spliced	O
13	and	O
14	seven	O
15	polyadenylation	O
16	signal	O
17	sequences	O
18	.	O

1	Depleted	O
2	and	O
3	enriched	O
4	U3O8	O
5	standard	O
6	reference	O
7	materials	O
8	were	O
9	used	O
10	to	O
11	calibrate	O
12	the	O
13	system	O
14	.	O

1	Therefore	O
2	,	O
3	the	O
4	positive	O
5	cAMP	O
6	control	O
7	of	O
8	the	O
9	hypoxic	O
10	SRP1	B
11	and	O
12	HEM13	B
13	genes	I
14	was	O
15	uncoupled	O
16	from	O
17	the	O
18	HOG	B
19	pathway	O
20	.	O

1	Most	O
2	likely	O
3	they	O
4	might	O
5	represent	O
6	regulatory	O
7	RNAs	O
8	or	O
9	transcribed	O
10	transposable	O
11	elements	O
12	.	O

1	This	O
2	paper	O
3	reviews	O
4	the	O
5	middleware	O
6	-	O
7	based	O
8	approach	O
9	adopted	O
10	by	O
11	CEN	O
12	ENV	O
13	12967	O
14	-	O
15	1	O
16	and	O
17	the	O
18	specialisation	O
19	necessary	O
20	for	O
21	the	O
22	healthcare	O
23	record	O
24	based	O
25	on	O
26	CEN	O
27	ENV	O
28	12265	O
29	'	O
30	Electronic	O
31	Healthcare	O
32	Record	O
33	Architecture	O
34	'.	O

1	Sequence	O
2	analyses	O
3	of	O
4	sos2	B
5	mutant	I
6	alleles	I
7	reveal	O
8	that	O
9	both	O
10	the	O
11	N	O
12	-	O
13	terminal	O
14	catalytic	O
15	domain	O
16	and	O
17	the	O
18	C	O
19	-	O
20	terminal	O
21	regulatory	O
22	domain	O
23	of	O
24	SOS2	B
25	are	O
26	functionally	O
27	essential	O
28	.	O

1	A	O
2	mutation	O
3	which	O
4	abrogates	O
5	the	O
6	binding	O
7	of	O
8	these	O
9	factors	O
10	reduces	O
11	Wp	B
12	reporter	I
13	activity	O
14	specifically	O
15	in	O
16	B	O
17	cell	O
18	lines	O
19	,	O
20	whereas	O
21	a	O
22	mutation	O
23	which	O
24	converts	O
25	the	O
26	site	O
27	to	O
28	a	O
29	consensus	O
30	CREB	B
31	-	I
32	binding	I
33	sequence	I
34	maintains	O
35	wild	O
36	-	O
37	type	O
38	promoter	O
39	function	O
40	.	O

1	Here	O
2	we	O
3	describe	O
4	the	O
5	cloning	O
6	,	O
7	tissue	O
8	-	O
9	specific	O
10	expression	O
11	pattern	O
12	,	O
13	and	O
14	functional	O
15	characterization	O
16	of	O
17	two	O
18	novel	O
19	TEF	B
20	-	I
21	1	I
22	isoforms	I
23	,	O
24	TEF	B
25	-	I
26	1beta	I
27	and	O
28	TEF	B
29	-	I
30	1gamma	I
31	.	O

1	Therefore	O
2	the	O
3	binding	O
4	sites	O
5	for	O
6	liver	O
7	-	O
8	enriched	O
9	factors	O
10	,	O
11	present	O
12	in	O
13	the	O
14	hamster	B
15	CYP7A1	I
16	proximal	I
17	promoter	I
18	in	O
19	close	O
20	vicinity	O
21	and	O
22	conserved	O
23	between	O
24	species	O
25	,	O
26	constitute	O
27	a	O
28	regulatory	O
29	unit	O
30	important	O
31	for	O
32	basal	O
33	hepatic	O
34	expression	O
35	and	O
36	tissue	O
37	restriction	O
38	of	O
39	the	O
40	action	O
41	of	O
42	hormones	O
43	such	O
44	as	O
45	insulin	B
46	.	O

1	The	O
2	kinase	O
3	activity	O
4	of	O
5	PfPK6	B
6	is	O
7	sensitive	O
8	to	O
9	CDK	B
10	inhibitors	O
11	such	O
12	as	O
13	olomoucine	O
14	and	O
15	roscovitine	O
16	.	O

1	Although	O
2	MAP	B
3	(	I
4	mitogen	I
5	-	I
6	activated	I
7	protein	I
8	)	I
9	kinases	I
10	are	O
11	implicated	O
12	in	O
13	cell	O
14	proliferation	O
15	and	O
16	differentiation	O
17	in	O
18	many	O
19	cell	O
20	types	O
21	,	O
22	the	O
23	role	O
24	of	O
25	MAP	B
26	kinases	I
27	in	O
28	cardiac	O
29	hypertrophy	O
30	remains	O
31	unclear	O
32	.	O

1	Transfection	O
2	with	O
3	a	O
4	CSF	B
5	-	I
6	1R	I
7	expression	O
8	plasmid	O
9	permitted	O
10	CSF	B
11	-	I
12	1	I
13	-	O
14	dependent	O
15	activation	O
16	of	O
17	the	O
18	signalling	O
19	pathway	O
20	targeting	O
21	an	O
22	Ets	B
23	/	O
24	AP1	B
25	(	O
26	activator	B
27	protein	I
28	1	I
29	)	O
30	element	O
31	in	O
32	the	O
33	uPA	B
34	promoter	I
35	that	O
36	has	O
37	been	O
38	shown	O
39	previously	O
40	to	O
41	be	O
42	a	O
43	target	O
44	of	O
45	oncogenic	B
46	ras	I
47	and	O
48	protein	O
49	kinase	O
50	C	O
51	pathways	O
52	.	O

1	Regulation	O
2	of	O
3	urokinase	B
4	plasminogen	I
5	activator	I
6	gene	I
7	transcription	O
8	in	O
9	the	O
10	RAW264	O
11	murine	O
12	macrophage	O
13	cell	O
14	line	O
15	by	O
16	macrophage	B
17	colony	I
18	-	I
19	stimulating	I
20	factor	I
21	(	O
22	CSF	B
23	-	I
24	1	I
25	)	O
26	is	O
27	dependent	O
28	upon	O
29	the	O
30	level	O
31	of	O
32	cell	O
33	-	O
34	surface	O
35	receptor	O
36	.	O

1	Molecule	O
2	(	O
3	s	O
4	)	O
5	secreted	O
6	by	O
7	neuronal	O
8	cultures	O
9	contribute	O
10	to	O
11	this	O
12	induction	O
13	of	O
14	GLT	B
15	-	I
16	1	I
17	,	O
18	but	O
19	little	O
20	is	O
21	known	O
22	about	O
23	the	O
24	signaling	O
25	pathways	O
26	mediating	O
27	this	O
28	regulation	O
29	.	O

1	Coactivation	O
2	of	O
3	endogenous	O
4	or	O
5	exogenous	O
6	G	B
7	(	I
8	q	I
9	)-	I
10	coupled	I
11	receptors	I
12	with	O
13	the	O
14	delta	B
15	-	I
16	opioid	I
17	receptor	I
18	produced	O
19	strong	O
20	stimulations	O
21	of	O
22	PLCbeta	B
23	and	O
24	such	O
25	responses	O
26	could	O
27	be	O
28	partially	O
29	blocked	O
30	by	O
31	pertussis	B
32	toxin	I
33	.	O

1	Patients	O
2	enrolled	O
3	in	O
4	the	O
5	Integrilin	O
6	to	O
7	Minimize	O
8	Platelet	O
9	Aggregation	O
10	and	O
11	Coronary	O
12	Thrombosis	O
13	-	O
14	II	O
15	(	O
16	IMPACT	O
17	-	O
18	II	O
19	)	O
20	trial	O
21	were	O
22	analyzed	O
23	.	O

1	The	O
2	Wnt	B
3	signaling	O
4	pathway	O
5	functions	O
6	reiteratively	O
7	during	O
8	animal	O
9	development	O
10	to	O
11	control	O
12	cell	O
13	fate	O
14	decisions	O
15	.	O

1	This	O
2	mutation	O
3	no	O
4	longer	O
5	repressed	O
6	the	O
7	HPV	O
8	-	O
9	11	O
10	upstream	O
11	regulatory	O
12	region	O
13	-	O
14	controlled	O
15	reporter	O
16	expression	O
17	.	O

1	In	O
2	the	O
3	icosahaedral	O
4	MVMi	O
5	capsid	O
6	,	O
7	this	O
8	sequence	O
9	forms	O
10	the	O
11	carboxy	O
12	end	O
13	of	O
14	the	O
15	amphipathic	O
16	beta	O
17	-	O
18	strand	O
19	I	O
20	(	O
21	betaI	O
22	),	O
23	and	O
24	all	O
25	its	O
26	basic	O
27	residues	O
28	are	O
29	contiguously	O
30	positioned	O
31	at	O
32	the	O
33	face	O
34	that	O
35	in	O
36	the	O
37	unassembled	O
38	subunit	O
39	would	O
40	be	O
41	exposed	O
42	to	O
43	solvent	O
44	.	O

1	The	O
2	two	O
3	contiguous	O
4	IGF2	B
5	(	O
6	human	B
7	insulin	I
8	-	I
9	like	I
10	growth	I
11	factor	I
12	II	I
13	)	O
14	and	O
15	H19	B
16	genes	I
17	are	O
18	reciprocally	O
19	imprinted	O
20	in	O
21	both	O
22	human	O
23	and	O
24	mouse	O
25	.	O

1	The	O
2	asymmetric	O
3	methylation	O
4	was	O
5	associated	O
6	with	O
7	tissue	O
8	-	O
9	specific	O
10	disruption	O
11	of	O
12	H19	B
13	genomic	O
14	imprinting	O
15	in	O
16	fetal	O
17	brain	O
18	.	O

1	The	O
2	comparison	O
3	of	O
4	the	O
5	expression	O
6	patterns	O
7	of	O
8	the	O
9	known	O
10	Kv4	B
11	family	I
12	members	I
13	shows	O
14	subtype	O
15	specificity	O
16	with	O
17	significant	O
18	overlaps	O
19	.	O

1	Early	O
2	treatment	O
3	mechanics	O
4	of	O
5	the	O
6	Class	O
7	II	O
8	division	O
9	2	O
10	malocclusion	O
11	.	O

1	Preliminary	O
2	use	O
3	of	O
4	the	O
5	Nottingham	O
6	Eczema	O
7	Severity	O
8	Score	O
9	would	O
10	support	O
11	further	O
12	development	O
13	as	O
14	a	O
15	research	O
16	tool	O
17	for	O
18	a	O
19	simple	O
20	assessment	O
21	of	O
22	disease	O
23	severity	O
24	that	O
25	could	O
26	be	O
27	used	O
28	in	O
29	epidemiological	O
30	studies	O
31	.	O

1	The	O
2	consensus	O
3	highlights	O
4	the	O
5	importance	O
6	of	O
7	residues	O
8	other	O
9	than	O
10	the	O
11	eight	O
12	motifs	O
13	that	O
14	are	O
15	often	O
16	associated	O
17	with	O
18	DEAD	B
19	-	I
20	box	I
21	RNA	I
22	helicases	I
23	,	O
24	as	O
25	well	O
26	as	O
27	de	O
28	-	O
29	emphasising	O
30	the	O
31	importance	O
32	of	O
33	the	O
34	"	O
35	A	O
36	"	O
37	residue	O
38	within	O
39	the	O
40	"	O
41	DEAD	O
42	"	O
43	motif	O
44	.	O

1	Advanced	O
2	adenoma	O
3	was	O
4	defined	O
5	as	O
6	an	O
7	adenoma	O
8	larger	O
9	than	O
10	10	O
11	mm	O
12	or	O
13	an	O
14	adenoma	O
15	of	O
16	any	O
17	size	O
18	with	O
19	villous	O
20	component	O
21	,	O
22	high	O
23	-	O
24	grade	O
25	dysplasia	O
26	or	O
27	invasive	O
28	carcinoma	O
29	.	O

1	In	O
2	transient	O
3	assays	O
4	,	O
5	using	O
6	rice	O
7	suspension	O
8	-	O
9	cultured	O
10	cells	O
11	transformed	O
12	by	O
13	particle	O
14	bombardment	O
15	,	O
16	we	O
17	showed	O
18	previously	O
19	that	O
20	Oshox1	B
21	can	O
22	transcriptionally	O
23	repress	O
24	the	O
25	activity	O
26	of	O
27	reporter	O
28	gene	O
29	constructs	O
30	with	O
31	upstream	O
32	HD	B
33	-	I
34	Zip	I
35	binding	O
36	sites	O
37	.	O

1	Results	O
2	of	O
3	two	O
4	-	O
5	hybrid	O
6	assays	O
7	and	O
8	electrophoretic	O
9	mobility	O
10	shift	O
11	assays	O
12	strongly	O
13	suggest	O
14	that	O
15	all	O
16	HD	B
17	-	I
18	Zip	I
19	proteins	I
20	of	O
21	families	O
22	I	O
23	and	O
24	II	O
25	can	O
26	form	O
27	homodimers	O
28	and	O
29	also	O
30	heterodimers	O
31	with	O
32	all	O
33	HD	B
34	-	I
35	Zip	I
36	proteins	I
37	of	O
38	the	O
39	same	O
40	family	O
41	.	O

1	Among	O
2	mammalian	B
3	HSFs	I
4	,	O
5	HSF1	B
6	has	O
7	been	O
8	shown	O
9	to	O
10	be	O
11	important	O
12	for	O
13	regulation	O
14	of	O
15	the	O
16	heat	O
17	-	O
18	induced	O
19	stress	O
20	gene	O
21	expression	O
22	,	O
23	whereas	O
24	the	O
25	function	O
26	of	O
27	HSF2	B
28	in	O
29	stress	O
30	response	O
31	is	O
32	unclear	O
33	.	O

1	Importantly	O
2	,	O
3	concomitant	O
4	expression	O
5	of	O
6	constitutive	O
7	activated	O
8	Raf	B
9	and	O
10	V12N38	B
11	Ras	I
12	results	O
13	in	O
14	almost	O
15	complete	O
16	loss	O
17	of	O
18	TTF	B
19	-	I
20	1	I
21	activity	O
22	.	O

1	They	O
2	share	O
3	many	O
4	downstream	O
5	targets	O
6	,	O
7	including	O
8	remodeling	O
9	of	O
10	the	O
11	actin	B
12	cytoskeleton	O
13	,	O
14	activation	O
15	of	O
16	p70	B
17	(	I
18	S6	I
19	)	I
20	kinase	I
21	and	O
22	c	B
23	-	I
24	jun	I
25	N	I
26	-	I
27	terminal	I
28	kinase	I
29	(	O
30	JNK	B
31	),	O
32	and	O
33	regulation	O
34	of	O
35	transcription	O
36	and	O
37	cell	O
38	proliferation	O
39	.	O

1	Expression	O
2	of	O
3	activated	O
4	Cdc42	B
5	results	O
6	in	O
7	the	O
8	translocation	O
9	of	O
10	PKClambda	B
11	from	O
12	the	O
13	nucleus	O
14	into	O
15	the	O
16	cytosol	O
17	,	O
18	and	O
19	Cdc42	B
20	and	O
21	PKClambda	B
22	colocalize	O
23	at	O
24	the	O
25	plasma	O
26	membrane	O
27	and	O
28	in	O
29	the	O
30	cytoplasm	O
31	.	O

1	Copyright	O
2	2000	O
3	Academic	O
4	Press	O
5	.	O

1	To	O
2	understand	O
3	whether	O
4	Shc	B
5	localization	O
6	in	O
7	membrane	O
8	rafts	O
9	is	O
10	sufficient	O
11	to	O
12	regulate	O
13	Shc	B
14	function	O
15	,	O
16	we	O
17	constructed	O
18	a	O
19	Shc	B
20	chimera	I
21	containing	O
22	the	O
23	Ras	B
24	membrane	I
25	localization	I
26	motif	I
27	at	O
28	the	O
29	C	O
30	-	O
31	terminus	O
32	.	O

1	Southern	O
2	blotting	O
3	and	O
4	single	O
5	strand	O
6	conformation	O
7	polymorphism	O
8	analyses	O
9	did	O
10	not	O
11	show	O
12	tumor	O
13	-	O
14	specific	O
15	alterations	O
16	of	O
17	this	O
18	gene	O
19	in	O
20	gliomas	O
21	and	O
22	RT	O
23	-	O
24	PCR	O
25	studies	O
26	showed	O
27	expression	O
28	in	O
29	glioma	O
30	cell	O
31	lines	O
32	,	O
33	suggesting	O
34	that	O
35	ANOVA	B
36	is	O
37	not	O
38	the	O
39	chromosome	O
40	19q	O
41	glioma	O
42	tumor	O
43	suppressor	O
44	gene	O
45	.	O

1	RegA	B
2	is	O
3	a	O
4	positive	O
5	yet	O
6	nonessential	O
7	regulator	O
8	of	O
9	tol	B
10	-	O
11	oprL	B
12	expression	O
13	.	O

1	Enzyme	B
2	I	I
3	of	O
4	the	O
5	phosphoenolpyruvate	B
6	:	I
7	sugar	I
8	phosphotransferase	I
9	system	O
10	.	O

1	Based	O
2	on	O
3	these	O
4	data	O
5	,	O
6	we	O
7	conclude	O
8	that	O
9	transcription	O
10	of	O
11	prgX	B
12	is	O
13	initiated	O
14	from	O
15	the	O
16	Qa	B
17	promoter	I
18	in	O
19	prgQ	B
20	,	O
21	and	O
22	PrgX	B
23	autoregulates	O
24	its	O
25	transcription	O
26	either	O
27	by	O
28	mediating	O
29	transcriptional	O
30	readthrough	O
31	or	O
32	increasing	O
33	mRNA	O
34	stability	O
35	.	O

1	It	O
2	was	O
3	established	O
4	that	O
5	intrathecal	O
6	or	O
7	intraperitoneal	O
8	PTFL	O
9	,	O
10	elevated	O
11	the	O
12	nociceptive	O
13	threshold	O
14	for	O
15	mechanical	O
16	stimuli	O
17	in	O
18	the	O
19	formalin	O
20	test	O
21	in	O
22	rats	O
23	.	O

1	Molecular	O
2	mimicry	O
3	of	O
4	human	O
5	cytokine	O
6	and	O
7	cytokine	O
8	response	O
9	pathway	O
10	genes	O
11	by	O
12	KSHV	O
13	.	O

1	Family	O
2	environment	O
3	was	O
4	an	O
5	important	O
6	influence	O
7	on	O
8	interpersonal	O
9	relationships	O
10	,	O
11	substance	O
12	use	O
13	,	O
14	and	O
15	social	O
16	support	O
17	.	O

1	By	O
2	electrophoresis	O
3	mobility	O
4	shift	O
5	assays	O
6	using	O
7	probes	O
8	corresponding	O
9	to	O
10	different	O
11	segments	O
12	of	O
13	the	O
14	putative	O
15	human	B
16	c	I
17	-	I
18	myb	I
19	intron	I
20	1	I
21	transcription	I
22	pause	I
23	region	I
24	and	O
25	nuclear	O
26	extracts	O
27	from	O
28	myeloid	O
29	leukemia	O
30	HL	O
31	60	O
32	and	O
33	fibroblast	O
34	WI	O
35	38	O
36	cells	O
37	,	O
38	we	O
39	detected	O
40	a	O
41	HL	O
42	-	O
43	60	O
44	-	O
45	specific	O
46	DNA	O
47	-	O
48	protein	O
49	complex	O
50	with	O
51	a	O
52	123	O
53	-	O
54	bp	O
55	fragment	O
56	containing	O
57	binding	O
58	sites	O
59	for	O
60	the	O
61	interferon	B
62	regulatory	I
63	factors	I
64	(	O
65	IRFs	B
66	)	O
67	nuclear	O
68	proteins	O
69	.	O

1	STUDY	O
2	DESIGN	O
3	:	O
4	Fine	O
5	needle	O
6	aspiration	O
7	cytologic	O
8	smears	O
9	from	O
10	21	O
11	cases	O
12	of	O
13	invasive	O
14	lobular	O
15	carcinoma	O
16	(	O
17	ILC	O
18	)	O
19	of	O
20	breast	O
21	were	O
22	subjected	O
23	to	O
24	detailed	O
25	cytomorphologic	O
26	analysis	O
27	.	O

1	Electrophile	O
2	Response	O
3	Elements	O
4	(	O
5	EpREs	O
6	),	O
7	located	O
8	in	O
9	5	O
10	'-	O
11	flanking	O
12	sequences	O
13	of	O
14	both	O
15	the	O
16	GCSh	B
17	and	O
18	GCSl	B
19	subunit	I
20	genes	I
21	,	O
22	are	O
23	hypothesized	O
24	to	O
25	at	O
26	least	O
27	partially	O
28	mediate	O
29	gene	O
30	induction	O
31	following	O
32	xenobiotic	O
33	exposure	O
34	.	O

1	A	O
2	new	O
3	technique	O
4	to	O
5	create	O
6	an	O
7	artificial	O
8	stenosis	O
9	in	O
10	the	O
11	native	O
12	LAD	O
13	using	O
14	a	O
15	hemoclip	O
16	.	O

1	Dll3	B
2	is	O
3	mutated	O
4	in	O
5	the	O
6	X	O
7	-	O
8	ray	O
9	-	O
10	induced	O
11	mouse	B
12	mutant	I
13	pudgy	I
14	(	O
15	pu	B
16	),	O
17	causing	O
18	a	O
19	variety	O
20	of	O
21	vertebrocostal	O
22	defects	O
23	similar	O
24	to	O
25	SD	O
26	phenotypes	O
27	.	O

1	Schlegel	O
2	,	O
3	J	O
4	.	O

1	TbRAB31	B
2	behaviour	O
3	was	O
4	also	O
5	studied	O
6	during	O
7	the	O
8	cell	O
9	cycle	O
10	;	O
11	TbRAB31	B
12	always	O
13	localised	O
14	to	O
15	a	O
16	discrete	O
17	structure	O
18	that	O
19	duplicated	O
20	very	O
21	early	O
22	in	O
23	mitosis	O
24	and	O
25	relocated	O
26	to	O
27	daughter	O
28	cells	O
29	in	O
30	a	O
31	coordinate	O
32	manner	O
33	with	O
34	the	O
35	basal	O
36	body	O
37	and	O
38	kinetoplast	O
39	,	O
40	suggesting	O
41	the	O
42	involvement	O
43	of	O
44	microtubules	O
45	.	O

1	The	O
2	early	O
3	dg	O
4	.	O
5	of	O
6	rejection	O
7	and	O
8	especially	O
9	acute	O
10	rejection	O
11	,	O
12	it	O
13	'	O
14	s	O
15	adequate	O
16	management	O
17	,	O
18	decreased	O
19	risk	O
20	for	O
21	the	O
22	future	O
23	chronic	O
24	rejection	O
25	nephropathy	O
26	.	O

1	Invertases	B
2	are	O
3	responsible	O
4	for	O
5	the	O
6	breakdown	O
7	of	O
8	sucrose	O
9	to	O
10	fructose	O
11	and	O
12	glucose	O
13	.	O

1	To	O
2	investigate	O
3	the	O
4	molecular	O
5	mechanisms	O
6	of	O
7	this	O
8	Tax	B
9	-	O
10	mediated	O
11	inhibition	O
12	,	O
13	we	O
14	analyzed	O
15	its	O
16	effect	O
17	on	O
18	the	O
19	transcriptional	O
20	activity	O
21	of	O
22	the	O
23	myogenic	O
24	MyoD	B
25	protein	I
26	,	O
27	which	O
28	was	O
29	used	O
30	as	O
31	a	O
32	paradigm	O
33	of	O
34	bHLH	B
35	factors	I
36	.	O

1	The	O
2	human	B
3	T	I
4	cell	I
5	leukemia	I
6	/	I
7	lymphotropic	I
8	virus	I
9	type	I
10	1	I
11	Tax	I
12	protein	I
13	represses	O
14	MyoD	B
15	-	O
16	dependent	O
17	transcription	O
18	by	O
19	inhibiting	O
20	MyoD	B
21	-	O
22	binding	O
23	to	O
24	the	O
25	KIX	B
26	domain	I
27	of	O
28	p300	B
29	.	O

1	Phosphorylation	O
2	and	O
3	spindle	O
4	pole	O
5	body	O
6	localization	O
7	of	O
8	the	O
9	Cdc15p	B
10	mitotic	I
11	regulatory	I
12	protein	I
13	kinase	I
14	in	I
15	budding	I
16	yeast	I
17	.	O

1	Thus	O
2	,	O
3	both	O
4	the	O
5	hyperplasia	O
6	and	O
7	thrombotic	O
8	complications	O
9	which	O
10	often	O
11	follow	O
12	stenting	O
13	might	O
14	be	O
15	minimized	O
16	by	O
17	employing	O
18	gold	O
19	stents	O
20	,	O
21	which	O
22	have	O
23	a	O
24	greater	O
25	capacity	O
26	than	O
27	steel	O
28	in	O
29	supporting	O
30	a	O
31	functional	O
32	neo	O
33	-	O
34	endothelium	O
35	.	O

1	The	O
2	cell	O
3	cycle	O
4	and	O
5	transcriptional	O
6	defects	O
7	caused	O
8	by	O
9	taf17	B
10	(	O
11	slm7	B
12	-	I
13	1	I
14	)	O
15	are	O
16	consistent	O
17	with	O
18	the	O
19	role	O
20	of	O
21	TAF	B
22	(	I
23	II	I
24	)	I
25	s	I
26	as	O
27	modulators	O
28	of	O
29	transcriptional	O
30	activation	O
31	and	O
32	may	O
33	reflect	O
34	a	O
35	role	O
36	for	O
37	TAF17	B
38	in	O
39	regulating	O
40	activation	O
41	by	O
42	SBF	B
43	and	O
44	MBF	B
45	.	O

1	Extracellular	B
2	-	I
3	regulated	I
4	kinase	I
5	(	O
6	ERK	B
7	)	O
8	activation	O
9	and	O
10	molecular	O
11	coupling	O
12	of	O
13	the	O
14	adaptor	O
15	proteins	O
16	p130	B
17	Crk	I
18	-	I
19	associated	I
20	substrate	I
21	(	O
22	CAS	B
23	)	O
24	and	O
25	c	B
26	-	I
27	CrkII	I
28	(	O
29	Crk	B
30	)	O
31	represent	O
32	two	O
33	distinct	O
34	pathways	O
35	that	O
36	induce	O
37	cell	O
38	invasion	O
39	and	O
40	protect	O
41	cells	O
42	from	O
43	apoptosis	O
44	in	O
45	a	O
46	three	O
47	-	O
48	dimensional	O
49	collagen	B
50	matrix	O
51	.	O

1	Proteolysis	O
2	of	O
3	Mbp1	B
4	and	O
5	Swi4	B
6	DNA	I
7	-	I
8	protein	I
9	complexes	I
10	has	O
11	revealed	O
12	the	O
13	extent	O
14	of	O
15	these	O
16	sequences	O
17	,	O
18	and	O
19	C	O
20	-	O
21	terminally	O
22	extended	O
23	molecules	O
24	with	O
25	substantially	O
26	enhanced	O
27	DNA	O
28	binding	O
29	activity	O
30	compared	O
31	to	O
32	the	O
33	core	O
34	domains	O
35	alone	O
36	have	O
37	been	O
38	produced	O
39	.	O

1	The	O
2	evolution	O
3	of	O
4	the	O
5	CCR5	B
6	cis	I
7	-	I
8	regulatory	I
9	region	I
10	versus	O
11	the	O
12	open	O
13	reading	O
14	frame	O
15	as	O
16	well	O
17	as	O
18	among	O
19	different	O
20	domains	O
21	of	O
22	the	O
23	open	O
24	reading	O
25	frame	O
26	differed	O
27	from	O
28	one	O
29	another	O
30	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	residue	O
6	266	O
7	serves	O
8	as	O
9	a	O
10	"	O
11	protein	O
12	sensor	O
13	"	O
14	of	O
15	altered	O
16	minor	O
17	groove	O
18	interactions	O
19	and	O
20	identifies	O
21	which	O
22	base	O
23	pair	O
24	interactions	O
25	are	O
26	altered	O
27	by	O
28	these	O
29	lesions	O
30	.	O

1	The	O
2	recombinant	O
3	enzymes	O
4	exist	O
5	as	O
6	monomers	O
7	.	O

1	A	O
2	pathway	O
3	for	O
4	regulation	O
5	of	O
6	B	B
7	lymphocyte	I
8	antigen	I
9	receptor	I
10	-	O
11	induced	O
12	calcium	O
13	flux	O
14	.	O

1	We	O
2	now	O
3	describe	O
4	a	O
5	second	O
6	RIM	B
7	protein	I
8	,	O
9	called	O
10	RIM2	B
11	,	O
12	that	O
13	is	O
14	highly	O
15	homologous	O
16	to	O
17	RIM1	B
18	and	O
19	also	O
20	expressed	O
21	primarily	O
22	in	O
23	brain	O
24	.	O

1	Inhibitor	B
2	-	I
3	1	I
4	(	O
5	I	B
6	-	I
7	1	I
8	)	O
9	and	O
10	inhibitor	B
11	-	I
12	2	I
13	(	O
14	I	B
15	-	I
16	2	I
17	)	O
18	selectively	O
19	inhibit	O
20	type	B
21	1	I
22	protein	I
23	serine	I
24	/	I
25	threonine	I
26	phosphatases	I
27	(	O
28	PP1	B
29	).	O

1	Scanning	O
2	mutations	O
3	throughout	O
4	the	O
5	AC	O
6	element	O
7	interfered	O
8	with	O
9	induction	O
10	but	O
11	allowed	O
12	us	O
13	to	O
14	define	O
15	five	O
16	overlapping	O
17	sites	O
18	for	O
19	regulatory	O
20	factors	O
21	in	O
22	AC	O
23	and	O
24	to	O
25	design	O
26	probes	O
27	binding	O
28	just	O
29	one	O
30	or	O
31	two	O
32	factors	O
33	.	O

1	The	O
2	substrates	O
3	for	O
4	glycan	O
5	synthesis	O
6	in	O
7	the	O
8	lumen	O
9	of	O
10	the	O
11	Golgi	O
12	are	O
13	nucleotide	O
14	sugars	O
15	that	O
16	must	O
17	be	O
18	transported	O
19	from	O
20	the	O
21	cytosol	O
22	by	O
23	specific	O
24	membrane	O
25	-	O
26	bound	O
27	transporters	O
28	.	O

1	Synaptic	O
2	targeting	O
3	of	O
4	the	O
5	postsynaptic	B
6	density	I
7	protein	I
8	PSD	I
9	-	I
10	95	I
11	mediated	O
12	by	O
13	a	O
14	tyrosine	O
15	-	O
16	based	O
17	trafficking	O
18	signal	O
19	.	O

1	(	O
2	1998	O
3	)	O
4	J	O
5	.	O

1	Bites	O
2	by	O
3	two	O
4	species	O
5	of	O
6	adders	O
7	(	O
8	Vipera	O
9	aspis	O
10	and	O
11	Vipera	O
12	berus	O
13	)	O
14	can	O
15	lead	O
16	to	O
17	extensive	O
18	swelling	O
19	with	O
20	multiorgan	O
21	failure	O
22	.	O

1	Both	O
2	normal	O
3	and	O
4	transforming	O
5	PCPH	B
6	proteins	I
7	have	O
8	guanosine	B
9	diphosphatase	I
10	activity	O
11	but	O
12	only	O
13	the	O
14	oncoprotein	O
15	cooperates	O
16	with	O
17	Ras	B
18	in	O
19	activating	O
20	extracellular	B
21	signal	I
22	-	I
23	regulated	I
24	kinase	I
25	ERK1	I
26	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	virulence	O
6	-	O
7	associated	O
8	genes	O
9	and	O
10	their	O
11	overall	O
12	chromosomal	O
13	arrangement	O
14	are	O
15	relatively	O
16	well	O
17	conserved	O
18	between	O
19	B	O
20	.	O
21	henselae	O
22	and	O
23	other	O
24	gram	O
25	-	O
26	negative	O
27	bacteria	O
28	such	O
29	as	O
30	A	O
31	.	O
32	tumefaciens	O
33	.	O

1	An	O
2	important	O
3	mechanism	O
4	by	O
5	which	O
6	the	O
7	tumor	O
8	suppressor	O
9	p53	B
10	maintains	O
11	genomic	O
12	stability	O
13	is	O
14	to	O
15	induce	O
16	cell	O
17	cycle	O
18	arrest	O
19	through	O
20	activation	O
21	of	O
22	the	O
23	cyclin	B
24	-	I
25	dependent	I
26	kinase	I
27	inhibitor	O
28	p21	B
29	(	O
30	WAF1	B
31	/	O
32	Cip1	B
33	)	O
34	gene	O
35	.	O

1	Paxillin	B
2	acts	O
3	as	O
4	an	O
5	adaptor	O
6	molecule	O
7	in	O
8	integrin	B
9	signaling	O
10	.	O

1	Thus	O
2	,	O
3	growth	O
4	factor	O
5	activation	O
6	of	O
7	ER	B
8	can	O
9	mediate	O
10	transactivation	O
11	vs	O
12	ER	B
13	/	O
14	Sp1	B
15	binding	O
16	to	O
17	GC	O
18	-	O
19	rich	O
20	sites	O
21	and	O
22	represents	O
23	a	O
24	novel	O
25	pathway	O
26	for	O
27	ligand	O
28	-	O
29	independent	O
30	ER	B
31	action	O
32	.	O

1	Furthermore	O
2	,	O
3	analysis	O
4	of	O
5	deletion	O
6	promoter	O
7	-	O
8	reporter	O
9	constructs	O
10	found	O
11	that	O
12	the	O
13	basal	O
14	activity	O
15	of	O
16	P2	O
17	resided	O
18	in	O
19	the	O
20	proximal	O
21	region	O
22	of	O
23	P2	O
24	.	O

1	RESULTS	O
2	:	O
3	Auditory	O
4	thresholds	O
5	collected	O
6	during	O
7	audiometric	O
8	tests	O
9	increased	O
10	gradually	O
11	in	O
12	proportion	O
13	with	O
14	age	O
15	,	O
16	especially	O
17	in	O
18	the	O
19	hypertensive	O
20	group	O
21	(	O
22	p	O
23	<	O
24	0	O
25	.	O
26	05	O
27	).	O

1	In	O
2	addition	O
3	,	O
4	the	O
5	transcription	O
6	of	O
7	c	B
8	-	I
9	IAP2	I
10	promoter	I
11	was	O
12	strongly	O
13	up	O
14	-	O
15	regulated	O
16	when	O
17	CD40	B
18	or	O
19	Epstein	B
20	-	I
21	Barr	I
22	virus	I
23	latent	I
24	membrane	I
25	protein	I
26	1	I
27	was	O
28	overexpressed	O
29	.	O

1	A	O
2	variety	O
3	of	O
4	professional	O
5	and	O
6	self	O
7	-	O
8	applied	O
9	fluoride	O
10	products	O
11	are	O
12	available	O
13	and	O
14	new	O
15	fluoride	O
16	delivery	O
17	systems	O
18	have	O
19	recently	O
20	entered	O
21	the	O
22	market	O
23	.	O

1	These	O
2	studies	O
3	identify	O
4	several	O
5	of	O
6	the	O
7	signal	O
8	-	O
9	transduction	O
10	events	O
11	involved	O
12	in	O
13	the	O
14	apoptosis	O
15	of	O
16	malignant	O
17	B	O
18	cells	O
19	that	O
20	transpire	O
21	following	O
22	ligation	O
23	of	O
24	CD20	B
25	by	O
26	anti	B
27	-	I
28	CD20	I
29	antibodies	I
30	in	O
31	the	O
32	presence	O
33	of	O
34	Fc	B
35	-	I
36	receptor	I
37	-	O
38	expressing	O
39	cells	O
40	or	O
41	secondary	O
42	goat	O
43	anti	B
44	-(	I
45	mouse	I
46	Ig	I
47	)	I
48	antibodies	I
49	and	O
50	which	O
51	may	O
52	contribute	O
53	to	O
54	the	O
55	tumor	O
56	regressions	O
57	observed	O
58	in	O
59	mouse	O
60	models	O
61	and	O
62	clinical	O
63	trials	O
64	.	O

1	CONCLUSION	O
2	:	O
3	Treatment	O
4	of	O
5	sepsis	O
6	with	O
7	the	O
8	platelet	B
9	-	I
10	activating	I
11	factor	I
12	antagonist	O
13	BB	O
14	-	O
15	882	O
16	offers	O
17	no	O
18	advantage	O
19	over	O
20	placebo	O
21	on	O
22	survival	O
23	,	O
24	hemodynamic	O
25	status	O
26	,	O
27	respiratory	O
28	function	O
29	,	O
30	or	O
31	organ	O
32	failure	O
33	scores	O
34	.	O

1	Phenazone	O
2	potentiates	O
3	the	O
4	local	O
5	anaesthetic	O
6	effect	O
7	of	O
8	lidocaine	O
9	in	O
10	mice	O
11	.	O

1	The	O
2	solubility	O
3	of	O
4	all	O
5	the	O
6	mutated	O
7	proteins	O
8	was	O
9	remarkably	O
10	reduced	O
11	.	O

1	Recently	O
2	,	O
3	identical	O
4	RBE	B
5	sequences	I
6	have	O
7	been	O
8	identified	O
9	at	O
10	other	O
11	locations	O
12	in	O
13	the	O
14	human	O
15	genome	O
16	.	O

1	EM	O
2	analysis	O
3	demonstrated	O
4	that	O
5	only	O
6	one	O
7	Rep	B
8	-	I
9	DNA	I
10	complex	I
11	was	O
12	formed	O
13	on	O
14	ch	O
15	-	O
16	19	O
17	target	O
18	DNA	O
19	.	O

1	The	O
2	protein	O
3	was	O
4	associated	O
5	with	O
6	purified	O
7	vaccinia	O
8	virus	O
9	particles	O
10	and	O
11	with	O
12	membranes	O
13	of	O
14	immature	O
15	and	O
16	mature	O
17	virions	O
18	that	O
19	were	O
20	visualized	O
21	by	O
22	electron	O
23	microscopy	O
24	of	O
25	infected	O
26	cells	O
27	.	O

1	In	O
2	vivo	O
3	dimethyl	O
4	sulfate	O
5	footprinting	O
6	of	O
7	the	O
8	cyclin	B
9	E	I
10	promoter	I
11	revealed	O
12	several	O
13	regions	O
14	of	O
15	protection	O
16	and	O
17	hypersensitivity	O
18	that	O
19	were	O
20	unique	O
21	to	O
22	infected	O
23	cells	O
24	.	O

1	A	O
2	total	O
3	of	O
4	194	O
5	STSs	O
6	map	O
7	to	O
8	this	O
9	interval	O
10	of	O
11	3	O
12	Mb	O
13	,	O
14	giving	O
15	an	O
16	average	O
17	marker	O
18	resolution	O
19	of	O
20	approximately	O
21	one	O
22	per	O
23	15	O
24	kb	O
25	.	O

1	Recently	O
2	,	O
3	a	O
4	mutation	O
5	in	O
6	the	O
7	amino	O
8	-	O
9	terminus	O
10	of	O
11	IB1	B
12	was	O
13	associated	O
14	with	O
15	diabetes	O
16	.	O

1	CONCLUSION	O
2	:	O
3	More	O
4	than	O
5	50	O
6	%	O
7	of	O
8	patients	O
9	with	O
10	perennial	O
11	rhinitis	O
12	and	O
13	CRS	O
14	do	O
15	not	O
16	improve	O
17	after	O
18	surgery	O
19	,	O
20	a	O
21	response	O
22	that	O
23	may	O
24	be	O
25	predicted	O
26	by	O
27	more	O
28	cells	O
29	expressing	O
30	IL	B
31	-	I
32	5	I
33	mRNA	I
34	in	O
35	the	O
36	ethmoid	O
37	sinuses	O
38	.	O

1	Biol	O
2	.	O

1	On	O
2	the	O
3	basis	O
4	of	O
5	size	O
6	,	O
7	the	O
8	CRS	O
9	sequence	O
10	to	O
11	which	O
12	it	O
13	binds	O
14	,	O
15	and	O
16	its	O
17	tentative	O
18	identification	O
19	as	O
20	a	O
21	zinc	B
22	finger	I
23	protein	I
24	,	O
25	Adx	B
26	factor	I
27	has	O
28	been	O
29	identified	O
30	as	O
31	a	O
32	Kruppel	B
33	-	I
34	like	I
35	zinc	I
36	finger	I
37	protein	I
38	(	O
39	a	O
40	mouse	B
41	ZBP	I
42	-	I
43	89	I
44	homologue	I
45	).	O

1	METHODS	O
2	:	O
3	The	O
4	most	O
5	distal	O
6	muscle	O
7	fibres	O
8	from	O
9	the	O
10	deep	O
11	and	O
12	superficial	O
13	finger	O
14	flexors	O
15	were	O
16	measured	O
17	relative	O
18	to	O
19	the	O
20	pisiform	O
21	bone	O
22	in	O
23	18	O
24	cadaveric	O
25	specimens	O
26	.	O

1	Here	O
2	we	O
3	report	O
4	on	O
5	the	O
6	isolation	O
7	of	O
8	ICK2	B
9	,	O
10	and	O
11	show	O
12	that	O
13	it	O
14	interacts	O
15	with	O
16	Cdc2aAt	B
17	,	O
18	but	O
19	not	O
20	with	O
21	a	O
22	second	O
23	CDK	B
24	from	I
25	Arabidopsis	I
26	,	O
27	Cdc2bAt	B
28	.	O

1	Systemic	O
2	impact	O
3	of	O
4	risk	O
5	-	O
6	sharing	O
7	arrangements	O
8	.	O

1	METHODS	O
2	:	O
3	We	O
4	determined	O
5	an	O
6	odds	O
7	ratio	O
8	(	O
9	OR	O
10	),	O
11	as	O
12	a	O
13	measure	O
14	of	O
15	the	O
16	relative	O
17	risk	O
18	of	O
19	being	O
20	exposed	O
21	to	O
22	a	O
23	potential	O
24	interaction	O
25	,	O
26	comparing	O
27	the	O
28	use	O
29	of	O
30	the	O
31	H2	B
32	-	I
33	receptor	I
34	antagonist	O
35	,	O
36	cimetidine	O
37	,	O
38	with	O
39	that	O
40	of	O
41	the	O
42	noninteracting	O
43	agents	O
44	ranitidine	O
45	,	O
46	famotidine	O
47	and	O
48	nizatidine	O
49	in	O
50	users	O
51	and	O
52	nonusers	O
53	of	O
54	warfarin	O
55	,	O
56	phenytoin	O
57	and	O
58	theophylline	O
59	.	O

1	The	O
2	prevalence	O
3	of	O
4	malnutrition	O
5	was	O
6	30	O
7	%	O
8	in	O
9	the	O
10	47	O
11	patients	O
12	without	O
13	CVD	O
14	and	O
15	was	O
16	significantly	O
17	higher	O
18	(	O
19	70	O
20	%,	O
21	P	O
22	<	O
23	0	O
24	.	O
25	001	O
26	)	O
27	in	O
28	the	O
29	70	O
30	patients	O
31	with	O
32	CVD	O
33	,	O
34	who	O
35	also	O
36	had	O
37	lower	O
38	tHcy	O
39	,	O
40	SAlb	O
41	,	O
42	plasma	B
43	IGF	I
44	-	I
45	1	I
46	,	O
47	serum	O
48	creatinine	O
49	(	O
50	SCr	O
51	),	O
52	and	O
53	blood	B
54	hemoglobin	I
55	.	O

1	Our	O
2	data	O
3	suggest	O
4	that	O
5	,	O
6	at	O
7	least	O
8	at	O
9	high	O
10	temperature	O
11	,	O
12	a	O
13	critical	O
14	minimal	O
15	level	O
16	of	O
17	Ypt	B
18	protein	I
19	prenylation	O
20	is	O
21	required	O
22	for	O
23	maintaining	O
24	vesicle	O
25	polarization	O
26	.	O

1	The	O
2	second	O
3	functional	O
4	pair	O
5	of	O
6	CreA	B
7	sites	I
8	is	O
9	located	O
10	between	O
11	the	O
12	two	O
13	transcription	O
14	initiation	O
15	sites	O
16	.	O

1	A	O
2	distinct	O
3	staining	O
4	pattern	O
5	for	O
6	the	O
7	N	B
8	-	I
9	utrophin	I
10	was	O
11	not	O
12	detectable	O
13	,	O
14	although	O
15	it	O
16	was	O
17	expected	O
18	to	O
19	localise	O
20	at	O
21	the	O
22	actin	B
23	stress	O
24	fibers	O
25	.	O

1	The	O
2	'	O
3	Newcastle	O
4	'	O
5	model	O
6	,	O
7	which	O
8	is	O
9	based	O
10	on	O
11	Hotelling	O
12	'	O
13	s	O
14	T2	O
15	statistic	O
16	,	O
17	proved	O
18	to	O
19	be	O
20	more	O
21	sensitive	O
22	and	O
23	diagnosed	O
24	a	O
25	systematic	O
26	displacement	O
27	for	O
28	three	O
29	prostate	O
30	patients	O
31	.	O

1	The	O
2	MMA	B
3	,	I
4	DMA	I
5	,	I
6	and	I
7	TMA	I
8	methyltransferases	I
9	are	O
10	not	O
11	homologs	O
12	;	O
13	however	O
14	,	O
15	like	O
16	the	O
17	MMA	B
18	methyltransferase	I
19	gene	I
20	,	O
21	the	O
22	genes	O
23	encoding	O
24	the	O
25	DMA	B
26	and	I
27	TMA	I
28	methyltransferases	I
29	each	O
30	contain	O
31	a	O
32	single	O
33	in	O
34	-	O
35	frame	O
36	amber	O
37	codon	O
38	.	O

1	After	O
2	phosphorylation	O
3	,	O
4	STAT	B
5	proteins	I
6	are	O
7	transported	O
8	into	O
9	the	O
10	nucleus	O
11	and	O
12	exhibit	O
13	transcriptional	O
14	activity	O
15	.	O

1	Overexpression	O
2	of	O
3	mcl	B
4	-	I
5	1	I
6	is	O
7	sufficient	O
8	to	O
9	protect	O
10	against	O
11	apoptosis	O
12	,	O
13	while	O
14	transfection	O
15	of	O
16	a	O
17	mcl	B
18	-	I
19	1	I
20	antisense	O
21	plasmid	O
22	causes	O
23	cell	O
24	death	O
25	.	O

1	Thus	O
2	,	O
3	although	O
4	multiple	O
5	senescence	O
6	pathways	O
7	are	O
8	activated	O
9	in	O
10	response	O
11	to	O
12	a	O
13	ras	B
14	oncogene	I
15	,	O
16	inactivation	O
17	of	O
18	TGFbeta1	B
19	secretion	O
20	or	O
21	response	O
22	is	O
23	sufficient	O
24	to	O
25	block	O
26	the	O
27	senescence	O
28	program	O
29	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	the	O
6	abilities	O
7	of	O
8	constitutive	O
9	and	O
10	conditional	O
11	forms	O
12	of	O
13	the	O
14	three	O
15	Raf	B
16	kinases	I
17	to	O
18	abrogate	O
19	the	O
20	cytokine	O
21	dependency	O
22	of	O
23	FDC	O
24	-	O
25	P1	O
26	cells	O
27	were	O
28	examined	O
29	.	O

1	Application	O
2	of	O
3	the	O
4	method	O
5	to	O
6	a	O
7	representative	O
8	set	O
9	of	O
10	50	O
11	known	O
12	genes	O
13	from	O
14	Arabidopsis	O
15	thaliana	O
16	showed	O
17	significant	O
18	improvement	O
19	in	O
20	prediction	O
21	accuracy	O
22	compared	O
23	to	O
24	previous	O
25	spliced	O
26	alignment	O
27	methods	O
28	.	O

1	The	O
2	complete	O
3	cDNA	O
4	sequence	O
5	of	O
6	human	B
7	betaV	I
8	spectrin	I
9	is	O
10	available	O
11	from	O
12	GenBank	O
13	(	O
14	TM	O
15	)	O
16	as	O
17	accession	O
18	number	O
19	.	O

1	Transactivation	O
2	of	O
3	naturally	O
4	occurring	O
5	HIV	B
6	-	I
7	1	I
8	long	I
9	terminal	I
10	repeats	I
11	by	O
12	the	O
13	JNK	B
14	signaling	O
15	pathway	O
16	.	O

1	These	O
2	data	O
3	show	O
4	that	O
5	the	O
6	alpha	O
7	-	O
8	helix	O
9	domain	O
10	of	O
11	p57	B
12	(	O
13	Kip2	B
14	),	O
15	which	O
16	is	O
17	conserved	O
18	in	O
19	the	O
20	Cip	B
21	/	O
22	Kip	B
23	proteins	O
24	,	O
25	is	O
26	implicated	O
27	in	O
28	protein	O
29	-	O
30	protein	O
31	interaction	O
32	and	O
33	confers	O
34	a	O
35	specific	O
36	regulatory	O
37	mechanism	O
38	,	O
39	outside	O
40	of	O
41	their	O
42	Cdk	B
43	-	O
44	inhibitory	O
45	activity	O
46	,	O
47	by	O
48	which	O
49	the	O
50	p57	B
51	(	O
52	Kip2	B
53	)	O
54	family	O
55	members	O
56	positively	O
57	act	O
58	on	O
59	myogenic	O
60	differentiation	O
61	.	O

1	The	O
2	mode	O
3	of	O
4	resistance	O
5	to	O
6	quinupristin	O
7	/	O
8	dalfopristin	O
9	was	O
10	not	O
11	evident	O
12	(	O
13	sat	O
14	A	O
15	-	O
16	negative	O
17	by	O
18	PCR	O
19	);	O
20	and	O
21	these	O
22	cases	O
23	illustrate	O
24	the	O
25	existence	O
26	of	O
27	streptogramin	O
28	-	O
29	resistant	O
30	isolates	O
31	before	O
32	the	O
33	introduction	O
34	of	O
35	this	O
36	antimicrobial	O
37	class	O
38	into	O
39	human	O
40	clinical	O
41	practice	O
42	.	O

1	This	O
2	study	O
3	was	O
4	carried	O
5	out	O
6	to	O
7	analyze	O
8	PRL	B
9	secretion	O
10	in	O
11	metastatic	O
12	prostate	O
13	cancer	O
14	patients	O
15	both	O
16	at	O
17	basal	O
18	conditions	O
19	and	O
20	in	O
21	response	O
22	to	O
23	L	O
24	-	O
25	Dopa	O
26	and	O
27	metoclopramide	O
28	,	O
29	which	O
30	represents	O
31	the	O
32	most	O
33	classical	O
34	inhibitory	O
35	and	O
36	stimulatory	O
37	tests	O
38	for	O
39	PRL	B
40	secretion	O
41	,	O
42	respectively	O
43	.	O

1	Integrin	B
2	adhesion	I
3	receptors	I
4	transduce	O
5	signals	O
6	that	O
7	control	O
8	complex	O
9	cell	O
10	functions	O
11	which	O
12	require	O
13	the	O
14	regulation	O
15	of	O
16	gene	O
17	expression	O
18	,	O
19	such	O
20	as	O
21	proliferation	O
22	,	O
23	differentiation	O
24	and	O
25	survival	O
26	.	O

1	Recombination	O
2	,	O
3	replication	O
4	,	O
5	repair	O
6	:	O
7	from	O
8	complexity	O
9	to	O
10	harmony	O
11	.	O

1	The	O
2	somatoform	O
3	conundrum	O
4	:	O
5	a	O
6	question	O
7	of	O
8	nosological	O
9	valves	O
10	.	O

1	Intra	O
2	-	O
3	operative	O
4	ultrasound	O
5	(	O
6	IOUS	O
7	)	O
8	has	O
9	been	O
10	widely	O
11	used	O
12	in	O
13	an	O
14	attempt	O
15	to	O
16	overcome	O
17	these	O
18	difficulties	O
19	,	O
20	but	O
21	is	O
22	limited	O
23	by	O
24	its	O
25	two	O
26	-	O
27	dimensional	O
28	nature	O
29	,	O
30	inter	O
31	-	O
32	user	O
33	variability	O
34	,	O
35	and	O
36	image	O
37	obliteration	O
38	with	O
39	ablative	O
40	or	O
41	resectional	O
42	techniques	O
43	.	O

1	CONCLUSIONS	O
2	:	O
3	This	O
4	randomized	O
5	study	O
6	shows	O
7	that	O
8	Vivostat	O
9	fibrin	B
10	sealant	O
11	is	O
12	effective	O
13	in	O
14	preventing	O
15	air	O
16	leakage	O
17	after	O
18	small	O
19	lung	O
20	resections	O
21	in	O
22	pigs	O
23	,	O
24	even	O
25	at	O
26	high	O
27	inspiratory	O
28	pressures	O
29	.	O

1	Hailey	O
2	-	O
3	Hailey	O
4	disease	O
5	is	O
6	caused	O
7	by	O
8	mutations	O
9	in	O
10	ATP2C1	B
11	encoding	O
12	a	O
13	novel	O
14	Ca	O
15	(	O
16	2	O
17	+)	O
18	pump	O
19	.	O

1	Hex	B
2	is	O
3	expressed	O
4	in	O
5	the	O
6	developing	O
7	liver	O
8	coincident	O
9	with	O
10	the	O
11	forkhead	B
12	/	O
13	winged	B
14	helix	I
15	transcription	O
16	factor	O
17	,	O
18	Hepatocyte	B
19	Nuclear	I
20	Factor	I
21	3beta	I
22	(	O
23	HNF3beta	B
24	).	O

1	As	O
2	an	O
3	extension	O
4	of	O
5	our	O
6	structural	O
7	characterization	O
8	of	O
9	the	O
10	exon	O
11	-	O
12	intron	O
13	organization	O
14	of	O
15	the	O
16	mouse	B
17	Pkr	I
18	gene	I
19	,	O
20	we	O
21	now	O
22	have	O
23	isolated	O
24	and	O
25	characterized	O
26	the	O
27	mouse	B
28	Pkr	I
29	promoter	I
30	region	I
31	required	O
32	for	O
33	IFN	B
34	-	O
35	inducible	O
36	transcription	O
37	.	O

1	The	O
2	CRE	O
3	,	O
4	5	O
5	'-	O
6	TGACGTCA	O
7	-	O
8	3	O
9	',	O
10	has	O
11	been	O
12	described	O
13	as	O
14	the	O
15	consensus	O
16	sequence	O
17	for	O
18	the	O
19	cis	O
20	-	O
21	element	O
22	that	O
23	directs	O
24	cAMP	O
25	-	O
26	regulated	O
27	gene	O
28	expression	O
29	.	O

1	Kidney	O
2	length	O
3	did	O
4	not	O
5	significantly	O
6	differ	O
7	between	O
8	right	O
9	and	O
10	left	O
11	,	O
12	however	O
13	,	O
14	kidney	O
15	width	O
16	,	O
17	cortical	O
18	thickness	O
19	and	O
20	size	O
21	did	O
22	(	O
23	p	O
24	<	O
25	0	O
26	.	O
27	05	O
28	).	O

1	The	O
2	clinical	O
3	stage	O
4	was	O
5	I	O
6	(	O
7	T1N0M0	O
8	),	O
9	and	O
10	S2	O
11	sleeve	O
12	segmentectomy	O
13	with	O
14	lymph	O
15	node	O
16	dissection	O
17	(	O
18	R	O
19	2	O
20	b	O
21	)	O
22	was	O
23	performed	O
24	.	O

1	Benztropine	O
2	for	O
3	venlafaxine	O
4	-	O
5	induced	O
6	night	O
7	sweats	O
8	.	O

1	A	O
2	cause	O
3	of	O
4	increase	O
5	of	O
6	alkaline	B
7	phosphatase	I
8	in	O
9	children	O

1	The	O
2	physicians	O
3	in	O
4	charge	O
5	of	O
6	all	O
7	patients	O
8	with	O
9	evidence	O
10	of	O
11	acute	O
12	Q	O
13	fever	O
14	(	O
15	seroconversion	O
16	and	O
17	/	O
18	or	O
19	presence	O
20	of	O
21	IgM	B
22	)	O
23	or	O
24	chronic	O
25	Q	O
26	fever	O
27	(	O
28	prolonged	O
29	disease	O
30	and	O
31	/	O
32	or	O
33	IgG	B
34	antibody	I
35	titer	O
36	to	O
37	phase	O
38	I	O
39	of	O
40	Coxiella	O
41	burnetii	O
42	>	O
43	or	O
44	=	O
45	800	O
46	)	O
47	were	O
48	asked	O
49	to	O
50	complete	O
51	a	O
52	questionnaire	O
53	,	O
54	which	O
55	was	O
56	computerized	O
57	.	O

1	Copyright	O
2	2000	O
3	Academic	O
4	Press	O
5	.	O

1	Viral	O
2	cell	O
3	-	O
4	to	O
5	-	O
6	cell	O
7	movement	O
8	of	O
9	PVX	B
10	CP	I
11	mutant	I
12	was	O
13	complemented	O
14	in	O
15	Nicotiana	O
16	tabacum	O
17	cv	O
18	.	O

1	Induction	O
2	of	O
3	CD86	B
4	expression	O
5	by	O
6	stimulation	O
7	of	O
8	U937	O
9	cells	O
10	with	O
11	IFN	B
12	-	I
13	gamma	I
14	revealed	O
15	the	O
16	presence	O
17	of	O
18	two	O
19	functional	O
20	GAS	B
21	(	O
22	gamma	B
23	-	I
24	interferon	I
25	activation	I
26	site	I
27	)	O
28	elements	O
29	.	O

1	Significantly	O
2	,	O
3	two	O
4	proximal	O
5	GATA	B
6	-	I
7	1	I
8	-	I
9	binding	I
10	sites	I
11	(-	O
12	118	O
13	/-	O
14	113	O
15	and	O
16	-	O
17	98	O
18	/-	O
19	93	O
20	)	O
21	and	O
22	a	O
23	region	O
24	located	O
25	within	O
26	-	O
27	518	O
28	to	O
29	-	O
30	315bp	O
31	of	O
32	the	O
33	mouse	B
34	ALAS2	I
35	promoter	I
36	were	O
37	essential	O
38	for	O
39	transcriptional	O
40	activation	O
41	during	O
42	chemically	O
43	induced	O
44	differentiation	O
45	of	O
46	MEL	O
47	cells	O
48	,	O
49	implying	O
50	their	O
51	importance	O
52	in	O
53	conferring	O
54	erythroid	O
55	specificity	O
56	to	O
57	the	O
58	ALAS2	B
59	transcriptional	O
60	activation	O
61	.	O

1	SNAP	B
2	-	I
3	23	I
4	plays	O
5	an	O
6	important	O
7	role	O
8	in	O
9	the	O
10	regulation	O
11	of	O
12	vesicle	O
13	trafficking	O
14	in	O
15	mammalian	O
16	cells	O
17	.	O

1	The	O
2	HMG	B
3	domain	I
4	of	O
5	both	O
6	HMG20	B
7	proteins	I
8	is	O
9	most	O
10	similar	O
11	to	O
12	that	O
13	of	O
14	yeast	B
15	NHP6A	I
16	(	O
17	38	O
18	%	O
19	to	O
20	42	O
21	%).	O

1	IgM	B
2	and	O
3	IgG	B
4	anti	I
5	A	I
6	and	O
7	anti	B
8	B	I
9	antibody	I
10	status	O
11	of	O
12	100	O
13	antenatal	O
14	O	O
15	group	O
16	mothers	O
17	(	O
18	who	O
19	had	O
20	non	O
21	O	O
22	group	O
23	husbands	O
24	)	O
25	were	O
26	studied	O
27	.	O

1	In	O
2	an	O
3	attempt	O
4	to	O
5	understand	O
6	Wee1	B
7	regulation	O
8	during	O
9	cell	O
10	cycle	O
11	,	O
12	yeast	O
13	two	O
14	-	O
15	hybrid	O
16	screening	O
17	was	O
18	used	O
19	to	O
20	identify	O
21	Wee1	O
22	-	O
23	binding	O
24	protein	O
25	(	O
26	s	O
27	).	O

1	Retroviral	O
2	transduction	O
3	of	O
4	T	B
5	/	I
6	T	I
7	(	I
8	L	I
9	)	I
10	causes	O
11	a	O
12	rapidly	O
13	fatal	O
14	myeloproliferative	O
15	disease	O
16	in	O
17	a	O
18	murine	O
19	bone	O
20	marrow	O
21	transplant	O
22	(	O
23	BMT	O
24	)	O
25	model	O
26	,	O
27	whereas	O
28	T	B
29	/	I
30	T	I
31	(	I
32	F	I
33	)	I
34	causes	O
35	a	O
36	long	O
37	-	O
38	latency	O
39	,	O
40	pre	O
41	-	O
42	B	O
43	-	O
44	cell	O
45	lymphoblastic	O
46	lymphoma	O
47	.	O

1	Ab	O
2	-	O
3	MLV	O
4	strains	O
5	expressing	O
6	P70	B
7	/	O
8	S2	B
9	failed	O
10	to	O
11	transform	O
12	NIH	O
13	3T3	O
14	cells	O
15	and	O
16	demonstrated	O
17	a	O
18	greatly	O
19	reduced	O
20	capacity	O
21	to	O
22	mediate	O
23	signaling	O
24	events	O
25	associated	O
26	with	O
27	the	O
28	Ras	B
29	-	O
30	dependent	O
31	mitogen	B
32	-	I
33	activated	I
34	protein	I
35	(	I
36	MAP	I
37	)	I
38	kinase	I
39	pathway	O
40	.	O

1	The	O
2	codon	O
3	usage	O
4	is	O
5	particularly	O
6	marked	O
7	for	O
8	the	O
9	gag	B
10	,	O
11	pol	B
12	,	O
13	and	O
14	env	B
15	genes	I
16	.	O

1	The	O
2	p53	B
3	-	I
4	homolog	I
5	p73beta	I
6	also	O
7	activated	O
8	the	O
9	PIG3	B
10	promoter	I
11	,	O
12	but	O
13	in	O
14	contrast	O
15	to	O
16	p53	B
17	,	O
18	the	O
19	proline	O
20	-	O
21	rich	O
22	domain	O
23	of	O
24	p73beta	B
25	(	I
26	residues	I
27	81	I
28	-	I
29	113	I
30	)	I
31	was	O
32	dispensable	O
33	to	O
34	induce	O
35	the	O
36	PIG3	B
37	promoter	I
38	.	O

1	Results	O
2	from	O
3	transient	O
4	assays	O
5	using	O
6	these	O
7	mutants	O
8	showed	O
9	that	O
10	the	O
11	DE1	O
12	received	O
13	signals	O
14	from	O
15	phytochromes	B
16	A	I
17	and	I
18	B	I
19	,	O
20	demonstrating	O
21	that	O
22	this	O
23	element	O
24	is	O
25	indeed	O
26	a	O
27	light	O
28	-	O
29	responsive	O
30	element	O
31	.	O

1	Co	O
2	-	O
3	immunoprecipitation	O
4	and	O
5	DNA	O
6	affinity	O
7	chromatography	O
8	prove	O
9	that	O
10	Sp1	B
11	heterodimerizes	O
12	with	O
13	ZBP	B
14	-	I
15	89	I
16	when	O
17	bound	O
18	to	O
19	the	O
20	silencer	O
21	element	O
22	to	O
23	yield	O
24	a	O
25	DNA	O
26	-	O
27	protein	O
28	complex	O
29	whose	O
30	mobility	O
31	is	O
32	indistinguishable	O
33	from	O
34	that	O
35	displayed	O
36	by	O
37	HeLa	O
38	nuclear	O
39	extract	O
40	in	O
41	band	O
42	shift	O
43	assays	O
44	.	O

1	The	O
2	ZNF274	B
3	gene	I
4	is	O
5	mapped	O
6	distal	O
7	to	O
8	marker	O
9	RP	O
10	S28	O
11	1	O
12	in	O
13	the	O
14	human	O
15	chromosome	O
16	19qter	O
17	region	O
18	,	O
19	by	O
20	RH	O
21	mapping	O
22	.	O

1	The	O
2	C	B
3	-	I
4	terminal	I
5	Cdk2	I
6	truncations	O
7	,	O
8	however	O
9	,	O
10	were	O
11	non	O
12	-	O
13	functional	O
14	in	O
15	these	O
16	strains	O
17	and	O
18	thus	O
19	dependent	O
20	for	O
21	activity	O
22	on	O
23	the	O
24	pho85	B
25	coding	I
26	region	I
27	which	O
28	remained	O
29	in	O
30	the	O
31	mutant	B
32	pho85	I
33	::	O
34	HIS3	B
35	chromosomal	I
36	locus	I
37	.	O

1	We	O
2	report	O
3	here	O
4	on	O
5	the	O
6	molecular	O
7	nature	O
8	of	O
9	an	O
10	EMS	O
11	-	O
12	induced	O
13	mutant	O
14	,	O
15	mn1	B
16	-	I
17	89	I
18	,	O
19	a	O
20	leaky	O
21	semidominant	O
22	allele	O
23	of	O
24	the	O
25	Miniature1	B
26	(	O
27	Mn1	B
28	)	O
29	seed	O
30	locus	O
31	that	O
32	encodes	O
33	a	O
34	seed	B
35	-	I
36	specific	I
37	cell	I
38	wall	I
39	invertase	I
40	,	O
41	INCW2	B
42	.	O

1	We	O
2	conclude	O
3	that	O
4	,	O
5	both	O
6	in	O
7	atrial	O
8	myocytes	O
9	and	O
10	in	O
11	Xenopus	O
12	oocytes	O
13	,	O
14	beta	O
15	-	O
16	adrenergic	O
17	stimulation	O
18	potentiates	O
19	the	O
20	ACh	O
21	-	O
22	evoked	O
23	GIRK	B
24	channels	I
25	via	O
26	a	O
27	pathway	O
28	that	O
29	involves	O
30	PKA	B
31	-	O
32	catalyzed	O
33	phosphorylation	O
34	downstream	O
35	from	O
36	beta	B
37	(	I
38	2	I
39	)	I
40	AR	I
41	.	O

1	Slap	B
2	negatively	O
3	regulates	O
4	Src	B
5	mitogenic	O
6	function	O
7	but	O
8	does	O
9	not	O
10	revert	O
11	Src	B
12	-	O
13	induced	O
14	cell	O
15	morphology	O
16	changes	O
17	.	O

1	Identification	O
2	of	O
3	a	O
4	novel	O
5	E2F3	B
6	product	I
7	suggests	O
8	a	O
9	mechanism	O
10	for	O
11	determining	O
12	specificity	O
13	of	O
14	repression	O
15	by	O
16	Rb	B
17	proteins	I
18	.	O

1	In	O
2	DNase	B
3	I	I
4	footprinting	O
5	protection	O
6	analysis	O
7	,	O
8	both	O
9	SFRE	B
10	and	O
11	ERE	O
12	regions	O
13	were	O
14	protected	O
15	by	O
16	glutathione	B
17	S	I
18	-	I
19	transferase	I
20	-	O
21	ERRalpha1	B
22	fusion	O
23	protein	O
24	.	O

1	Overexpressing	O
2	the	O
3	coactivator	O
4	,	O
5	SRC1a	B
6	or	O
7	GRIP1	B
8	,	O
9	further	O
10	enhances	O
11	ERRalpha1	B
12	-	O
13	induced	O
14	transcriptional	O
15	activity	O
16	.	O

1	Estrogen	B
2	receptor	I
3	-	I
4	related	I
5	receptor	I
6	alpha	I
7	1	I
8	interacts	O
9	with	O
10	coactivator	O
11	and	O
12	constitutively	O
13	activates	O
14	the	O
15	estrogen	O
16	response	O
17	elements	O
18	of	O
19	the	O
20	human	B
21	lactoferrin	I
22	gene	I
23	.	O

1	We	O
2	examine	O
3	current	O
4	models	O
5	of	O
6	the	O
7	effects	O
8	of	O
9	aging	O
10	on	O
11	mean	O
12	response	O
13	time	O
14	and	O
15	show	O
16	how	O
17	they	O
18	might	O
19	be	O
20	reinterpreted	O
21	.	O

1	The	O
2	effects	O
3	of	O
4	these	O
5	mutations	O
6	on	O
7	protein	O
8	function	O
9	require	O
10	further	O
11	examination	O
12	.	O

1	The	O
2	median	O
3	levels	O
4	of	O
5	particles	O
6	with	O
7	50	O
8	%	O
9	cut	O
10	-	O
11	off	O
12	aerodynamic	O
13	diameters	O
14	of	O
15	10	O
16	(	O
17	PM10	O
18	)	O
19	and	O
20	2	O
21	.	O
22	5	O
23	microm	O
24	(	O
25	PM2	O
26	.	O
27	5	O
28	)	O
29	were	O
30	170	O
31	(	O
32	range	O
33	103	O
34	-	O
35	613	O
36	)	O
37	and	O
38	95	O
39	(	O
40	range	O
41	61	O
42	-	O
43	218	O
44	)	O
45	micro	O
46	x	O
47	m	O
48	-	O
49	3	O
50	,	O
51	respectively	O
52	.	O

1	Kaposi	O
2	'	O
3	s	O
4	sarcoma	O
5	-	O
6	associated	O
7	herpesvirus	O
8	viral	B
9	interferon	I
10	regulatory	I
11	factor	I
12	confers	O
13	resistance	O
14	to	O
15	the	O
16	antiproliferative	O
17	effect	O
18	of	O
19	interferon	B
20	-	I
21	alpha	I
22	.	O

1	Specific	O
2	and	O
3	heritable	O
4	genetic	O
5	interference	O
6	by	O
7	double	O
8	-	O
9	stranded	O
10	RNA	O
11	in	O
12	Arabidopsis	O
13	thaliana	O
14	.	O

1	Comparison	O
2	of	O
3	sequences	O
4	from	O
5	-	O
6	215	O
7	to	O
8	+	O
9	1	O
10	bp	O
11	identified	O
12	consensus	O
13	binding	O
14	sites	O
15	for	O
16	the	O
17	homeodomain	B
18	transcription	I
19	factor	I
20	thyroid	I
21	transcription	I
22	factor	I
23	-	I
24	1	I
25	(	O
26	TTF	B
27	-	I
28	1	I
29	).	O

1	Two	O
2	additional	O
3	cis	O
4	-	O
5	acting	O
6	sequences	O
7	,	O
8	conserved	O
9	in	O
10	both	O
11	the	O
12	region	O
13	1	O
14	and	O
15	3	O
16	promoters	O
17	,	O
18	were	O
19	identified	O
20	,	O
21	suggesting	O
22	a	O
23	role	O
24	for	O
25	these	O
26	sequences	O
27	in	O
28	the	O
29	coordinate	O
30	regulation	O
31	of	O
32	transcription	O
33	from	O
34	these	O
35	promoters	O
36	.	O

1	Purple	O
2	photosynthetic	O
3	bacteria	O
4	are	O
5	capable	O
6	of	O
7	generating	O
8	cellular	O
9	energy	O
10	from	O
11	several	O
12	sources	O
13	,	O
14	including	O
15	photosynthesis	O
16	,	O
17	respiration	O
18	,	O
19	and	O
20	H	O
21	(	O
22	2	O
23	)	O
24	oxidation	O
25	.	O

1	An	O
2	analysis	O
3	of	O
4	synthetic	O
5	peptides	O
6	revealed	O
7	a	O
8	minimal	O
9	CTD	O
10	sequence	O
11	that	O
12	is	O
13	sufficient	O
14	to	O
15	bind	O
16	to	O
17	the	O
18	second	O
19	Rsp5	B
20	WW	I
21	domain	I
22	(	O
23	Rsp5	B
24	WW2	I
25	)	O
26	in	O
27	vitro	O
28	and	O
29	in	O
30	yeast	O
31	two	O
32	-	O
33	hybrid	O
34	assays	O
35	.	O

1	Furthermore	O
2	,	O
3	bone	O
4	marrow	O
5	-	O
6	derived	O
7	macrophages	O
8	from	O
9	LAT	B
10	-	O
11	deficient	O
12	mice	O
13	displayed	O
14	reduced	O
15	phagocytic	O
16	efficiency	O
17	in	O
18	comparison	O
19	to	O
20	the	O
21	macrophages	O
22	from	O
23	wild	O
24	-	O
25	type	O
26	mice	O
27	.	O

1	T1	O
2	-	O
3	weighted	O
4	MRI	O
5	on	O
6	the	O
7	49th	O
8	postoperative	O
9	day	O
10	demonstrated	O
11	bilateral	O
12	and	O
13	symmetrical	O
14	hyperintense	O
15	lesions	O
16	in	O
17	the	O
18	globus	O
19	pallidus	O
20	.	O

1	The	O
2	method	O
3	is	O
4	applied	O
5	to	O
6	determine	O
7	aberration	O
8	constants	O
9	of	O
10	a	O
11	CM300	O
12	FEG	O
13	/	O
14	UT	O
15	microscope	O
16	with	O
17	correction	O
18	of	O
19	the	O
20	three	O
21	-	O
22	fold	O
23	astigmatism	O
24	.	O

1	The	O
2	interaction	O
3	does	O
4	not	O
5	depend	O
6	on	O
7	the	O
8	presence	O
9	of	O
10	the	O
11	correct	O
12	amino	O
13	-	O
14	terminal	O
15	DNA	O
16	binding	O
17	domain	O
18	or	O
19	the	O
20	amino	O
21	acid	O
22	sequences	O
23	between	O
24	the	O
25	DNA	O
26	binding	O
27	domain	O
28	and	O
29	the	O
30	last	O
31	ten	O
32	amino	O
33	acids	O
34	.	O

1	METHOD	O
2	:	O
3	The	O
4	sample	O
5	of	O
6	subjects	O
7	was	O
8	drawn	O
9	from	O
10	the	O
11	Suffolk	O
12	County	O
13	Mental	O
14	Health	O
15	Project	O
16	,	O
17	a	O
18	longitudinal	O
19	epidemiologic	O
20	study	O
21	of	O
22	first	O
23	-	O
24	hospitalized	O
25	subjects	O
26	with	O
27	psychotic	O
28	disorders	O
29	;	O
30	the	O
31	present	O
32	study	O
33	focused	O
34	on	O
35	patients	O
36	with	O
37	schizophrenic	O
38	disorders	O
39	.	O

1	Marrow	O
2	dysplasia	O
3	is	O
4	a	O
5	major	O
6	characteristic	O
7	of	O
8	patients	O
9	with	O
10	myelodysplastic	O
11	syndrome	O
12	(	O
13	MDS	O
14	),	O
15	along	O
16	with	O
17	marrow	O
18	blastosis	O
19	,	O
20	cytopenia	O
21	and	O
22	cytogenetic	O
23	anomalies	O
24	.	O

1	Eight	O
2	of	O
3	the	O
4	non	O
5	-	O
6	acceptable	O
7	inlays	O
8	/	O
9	onlays	O
10	and	O
11	five	O
12	of	O
13	the	O
14	direct	O
15	restorations	O
16	were	O
17	replaced	O
18	,	O
19	while	O
20	the	O
21	other	O
22	ones	O
23	were	O
24	repaired	O
25	with	O
26	resin	O
27	composite	O
28	.	O

1	How	O
2	plants	O
3	respond	O
4	to	O
5	attack	O
6	by	O
7	the	O
8	range	O
9	of	O
10	herbivores	O
11	and	O
12	pathogens	O
13	that	O
14	confront	O
15	them	O
16	in	O
17	the	O
18	field	O
19	is	O
20	the	O
21	subject	O
22	of	O
23	considerable	O
24	research	O
25	by	O
26	both	O
27	molecular	O
28	biologists	O
29	and	O
30	ecologists	O
31	.	O

1	CONCLUSION	O
2	:	O
3	The	O
4	probability	O
5	of	O
6	cardiopulmonary	O
7	complications	O
8	increases	O
9	significantly	O
10	when	O
11	patients	O
12	develop	O
13	class	O
14	1	O
15	HELLP	O
16	syndrome	O
17	.	O

1	The	O
2	rate	O
3	-	O
4	limiting	O
5	step	O
6	for	O
7	telomerase	B
8	activity	O
9	seems	O
10	to	O
11	be	O
12	the	O
13	expression	O
14	of	O
15	the	O
16	catalytic	O
17	subunit	O
18	of	O
19	the	O
20	enzyme	O
21	,	O
22	encoded	O
23	by	O
24	the	O
25	human	B
26	telomerase	I
27	reverse	I
28	transcriptase	I
29	(	O
30	hTERT	B
31	)	O
32	gene	O
33	.	O

1	In	O
2	the	O
3	control	O
4	group	O
5	,	O
6	platelet	O
7	markers	O
8	increased	O
9	1	O
10	h	O
11	after	O
12	surgery	O
13	.	O

1	However	O
2	,	O
3	the	O
4	element	O
5	proximal	O
6	to	O
7	the	O
8	transcription	O
9	start	O
10	site	O
11	is	O
12	dependent	O
13	on	O
14	the	O
15	SRE	O
16	-	O
17	1	O
18	.	O

1	AMDA	O
2	white	O
3	paper	O
4	identifies	O
5	ways	O
6	to	O
7	improve	O
8	pharmaceutical	O
9	care	O
10	in	O
11	SNFs	O
12	.	O

1	Since	O
2	proteins	O
3	containing	O
4	TPR	O
5	elements	O
6	are	O
7	typically	O
8	involved	O
9	in	O
10	multiple	O
11	protein	O
12	-	O
13	protein	O
14	interactions	O
15	,	O
16	we	O
17	suggest	O
18	that	O
19	the	O
20	102kD	O
21	protein	O
22	interacts	O
23	within	O
24	the	O
25	tri	O
26	-	O
27	snRNP	O
28	with	O
29	both	O
30	the	O
31	U5	B
32	and	O
33	U4	B
34	/	O
35	U6	B
36	snRNPs	O
37	,	O
38	thus	O
39	bridging	O
40	the	O
41	two	O
42	particles	O
43	.	O

1	Antibodies	O
2	raised	O
3	against	O
4	a	O
5	C	O
6	-	O
7	terminal	O
8	portion	O
9	of	O
10	Sec31A	B
11	co	O
12	-	O
13	precipitate	O
14	Sec13	B
15	and	O
16	inhibit	O
17	ER	O
18	-	O
19	Golgi	O
20	transport	O
21	of	O
22	temperature	O
23	-	O
24	arrested	O
25	vesicular	O
26	stomatitis	B
27	G	I
28	protein	I
29	in	O
30	a	O
31	semi	O
32	-	O
33	intact	O
34	cell	O
35	assay	O
36	.	O

1	Regulation	O
2	of	O
3	mitochondrial	O
4	single	O
5	-	O
6	stranded	O
7	DNA	O
8	-	O
9	binding	O
10	protein	O
11	gene	O
12	expression	O
13	links	O
14	nuclear	O
15	and	O
16	mitochondrial	O
17	DNA	O
18	replication	O
19	in	O
20	drosophila	O
21	.	O

1	Genetic	O
2	and	O
3	molecular	O
4	complexity	O
5	of	O
6	the	O
7	position	O
8	effect	O
9	variegation	O
10	modifier	O
11	mod	B
12	(	O
13	mdg4	B
14	)	O
15	in	O
16	Drosophila	O
17	.	O
18	mod	B
19	(	O
20	mdg4	B
21	),	O
22	also	O
23	known	O
24	as	O
25	E	B
26	(	I
27	var	I
28	)	I
29	3	I
30	-	I
31	93D	I
32	,	O
33	is	O
34	involved	O
35	in	O
36	a	O
37	variety	O
38	of	O
39	processes	O
40	,	O
41	such	O
42	as	O
43	gene	O
44	silencing	O
45	in	O
46	position	O
47	effect	O
48	variegation	O
49	(	O
50	PEV	O
51	),	O
52	the	O
53	control	O
54	of	O
55	gypsy	B
56	insulator	I
57	sequences	I
58	,	O
59	regulation	O
60	of	O
61	homeotic	B
62	gene	I
63	expression	O
64	,	O
65	and	O
66	programmed	O
67	cell	O
68	death	O
69	.	O

1	They	O
2	are	O
3	present	O
4	in	O
5	many	O
6	kinds	O
7	of	O
8	living	O
9	things	O
10	,	O
11	but	O
12	their	O
13	functions	O
14	,	O
15	especially	O
16	those	O
17	in	O
18	humans	O
19	,	O
20	are	O
21	unclear	O
22	.	O

1	This	O
2	tendency	O
3	is	O
4	likely	O
5	due	O
6	to	O
7	the	O
8	biased	O
9	nucleotide	O
10	composition	O
11	of	O
12	the	O
13	asparagus	O
14	genome	O
15	,	O
16	rather	O
17	than	O
18	to	O
19	the	O
20	translational	O
21	selection	O
22	for	O
23	specific	O
24	codons	O
25	.	O

1	Transduction	O
2	of	O
3	the	O
4	human	O
5	leukemic	O
6	cell	O
7	line	O
8	K562	O
9	showed	O
10	that	O
11	viral	O
12	MRP1	B
13	-	O
14	PG13	O
15	supernatants	O
16	routinely	O
17	transfer	O
18	the	O
19	MRP1	B
20	gene	I
21	to	O
22	approximately	O
23	35	O
24	%	O
25	of	O
26	target	O
27	K562	O
28	cells	O
29	,	O
30	of	O
31	which	O
32	at	O
33	least	O
34	one	O
35	third	O
36	are	O
37	capable	O
38	of	O
39	proliferating	O
40	in	O
41	the	O
42	presence	O
43	of	O
44	otherwise	O
45	toxic	O
46	concentrations	O
47	of	O
48	etoposide	O
49	.	O

1	Regulation	O
2	of	O
3	pituitary	O
4	vasopressin	B
5	V1b	I
6	receptors	I
7	plays	O
8	a	O
9	critical	O
10	role	O
11	in	O
12	regulating	O
13	pituitary	B
14	adrenocorticotropic	I
15	hormone	I
16	(	O
17	ACTH	B
18	)	O
19	secretion	O
20	during	O
21	adaptation	O
22	to	O
23	stress	O
24	.	O

1	Identification	O
2	of	O
3	an	O
4	AfsA	B
5	homologue	I
6	(	O
7	BarX	B
8	)	O
9	from	O
10	Streptomyces	O
11	virginiae	O
12	as	O
13	a	O
14	pleiotropic	O
15	regulator	O
16	controlling	O
17	autoregulator	O
18	biosynthesis	O
19	,	O
20	virginiamycin	O
21	biosynthesis	O
22	and	O
23	virginiamycin	O
24	M1	O
25	resistance	O
26	.	O

1	Because	O
2	the	O
3	mutant	O
4	defective	O
5	in	O
6	DNA	O
7	binding	O
8	also	O
9	fails	O
10	to	O
11	stimulate	O
12	Abf1	B
13	ARS1	O
14	DNA	O
15	-	O
16	binding	O
17	activity	O
18	,	O
19	our	O
20	results	O
21	suggest	O
22	that	O
23	Cdc6	B
24	DNA	O
25	-	O
26	binding	O
27	activity	O
28	may	O
29	play	O
30	a	O
31	pivotal	O
32	role	O
33	in	O
34	the	O
35	initiation	O
36	of	O
37	DNA	O
38	replication	O
39	.	O

1	Given	O
2	its	O
3	relative	O
4	longevity	O
5	on	O
6	the	O
7	Web	O
8	,	O
9	TIE	O
10	researchers	O
11	have	O
12	been	O
13	in	O
14	a	O
15	unique	O
16	position	O
17	to	O
18	observe	O
19	trends	O
20	in	O
21	telemedicine	O
22	.	O

1	The	O
2	structural	O
3	study	O
4	of	O
5	peptides	O
6	belonging	O
7	to	O
8	the	O
9	terminal	O
10	domains	O
11	of	O
12	histone	B
13	H1	I
14	can	O
15	be	O
16	considered	O
17	as	O
18	a	O
19	step	O
20	toward	O
21	the	O
22	understanding	O
23	of	O
24	the	O
25	function	O
26	of	O
27	H1	B
28	in	O
29	chromatin	O
30	.	O

1	The	O
2	recovery	O
3	rates	O
4	for	O
5	the	O
6	MB	O
7	/	O
8	BacT	O
9	,	O
10	MGIT	O
11	960	O
12	,	O
13	and	O
14	solid	O
15	media	O
16	were	O
17	91	O
18	.	O
19	6	O
20	,	O
21	87	O
22	.	O
23	4	O
24	,	O
25	and	O
26	54	O
27	.	O
28	7	O
29	%,	O
30	respectively	O
31	,	O
32	for	O
33	all	O
34	mycobacteria	O
35	;	O
36	the	O
37	recovery	O
38	rates	O
39	were	O
40	93	O
41	.	O
42	6	O
43	,	O
44	88	O
45	.	O
46	9	O
47	,	O
48	and	O
49	63	O
50	.	O
51	4	O
52	%,	O
53	respectively	O
54	,	O
55	for	O
56	M	O
57	.	O
58	tuberculosis	O
59	complex	O
60	alone	O
61	,	O
62	and	O
63	87	O
64	.	O
65	5	O
66	,	O
67	84	O
68	.	O
69	4	O
70	,	O
71	and	O
72	37	O
73	.	O
74	5	O
75	%,	O
76	respectively	O
77	,	O
78	for	O
79	all	O
80	nontuberculous	O
81	mycobacteria	O
82	.	O

1	Cerebral	O
2	vasculitis	O
3	secondary	O
4	to	O
5	Crohn	O
6	'	O
7	s	O
8	disease	O
9	seems	O
10	to	O
11	be	O
12	a	O
13	very	O
14	rare	O
15	phenomenon	O
16	.	O

1	SELECTION	O
2	CRITERIA	O
3	:	O
4	Randomised	O
5	and	O
6	possibly	O
7	randomised	O
8	trials	O
9	using	O
10	acupuncture	O
11	to	O
12	treat	O
13	asthma	O
14	and	O
15	asthma	O
16	-	O
17	like	O
18	symptoms	O
19	.	O

1	SELECTION	O
2	CRITERIA	O
3	:	O
4	Randomised	O
5	trials	O
6	comparing	O
7	children	O
8	undergoing	O
9	systematic	O
10	therapy	O
11	focusing	O
12	on	O
13	the	O
14	family	O
15	in	O
16	conjunction	O
17	with	O
18	asthma	O
19	medication	O
20	,	O
21	with	O
22	children	O
23	taking	O
24	asthma	O
25	medication	O
26	only	O
27	.	O

1	To	O
2	test	O
3	the	O
4	hypothesis	O
5	that	O
6	progestin	O
7	-	O
8	mediated	O
9	increases	O
10	in	O
11	resting	O
12	core	O
13	temperature	O
14	and	O
15	the	O
16	core	O
17	temperature	O
18	threshold	O
19	for	O
20	sweating	O
21	onset	O
22	are	O
23	counteracted	O
24	by	O
25	estrogen	O
26	,	O
27	we	O
28	studied	O
29	eight	O
30	women	O
31	(	O
32	24	O
33	+/-	O
34	2	O
35	yr	O
36	)	O
37	at	O
38	27	O
39	degrees	O
40	C	O
41	rest	O
42	,	O
43	during	O
44	20	O
45	min	O
46	of	O
47	passive	O
48	heating	O
49	(	O
50	35	O
51	degrees	O
52	C	O
53	),	O
54	and	O
55	during	O
56	40	O
57	min	O
58	of	O
59	exercise	O
60	at	O
61	35	O
62	degrees	O
63	C	O
64	.	O

1	The	O
2	models	O
3	were	O
4	tested	O
5	by	O
6	studying	O
7	their	O
8	response	O
9	to	O
10	disturbances	O
11	of	O
12	the	O
13	afferent	O
14	signal	O
15	from	O
16	the	O
17	bladder	O
18	.	O

1	Our	O
2	data	O
3	show	O
4	also	O
5	that	O
6	phagocytic	O
7	killing	O
8	of	O
9	meningococci	O
10	is	O
11	probably	O
12	a	O
13	more	O
14	consistent	O
15	assay	O
16	than	O
17	antibody	O
18	titer	O
19	levels	O
20	for	O
21	antimeningococcal	O
22	immunity	O
23	,	O
24	especially	O
25	in	O
26	LCC	O
27	-	O
28	deficient	O
29	patients	O
30	.	O

1	These	O
2	studies	O
3	suggest	O
4	an	O
5	additional	O
6	component	O
7	or	O
8	cellular	O
9	environment	O
10	is	O
11	required	O
12	for	O
13	SPRK	B
14	activation	O
15	by	O
16	Cdc42	B
17	.	O

1	M	O
2	.	O

1	Jkappa	B
2	DNA	I
3	-	I
4	binding	I
5	sites	I
6	were	O
7	not	O
8	required	O
9	for	O
10	this	O
11	activation	O
12	,	O
13	and	O
14	a	O
15	mutant	B
16	EBNA	I
17	-	I
18	3C	I
19	protein	I
20	unable	O
21	to	O
22	bind	O
23	Jkappa	B
24	activated	O
25	transcription	O
26	as	O
27	efficiently	O
28	as	O
29	wild	B
30	-	I
31	type	I
32	EBNA	I
33	-	I
34	3C	I
35	,	O
36	indicating	O
37	that	O
38	EBNA	B
39	-	I
40	3C	I
41	can	O
42	regulate	O
43	transcription	O
44	through	O
45	a	O
46	mechanism	O
47	that	O
48	is	O
49	independent	O
50	of	O
51	Jkappa	B
52	.	O

1	Thus	O
2	,	O
3	both	O
4	YY1	B
5	and	O
6	CDP	B
7	appear	O
8	to	O
9	be	O
10	negative	O
11	regulators	O
12	of	O
13	the	O
14	differentiation	O
15	-	O
16	induced	O
17	HPV	B
18	-	I
19	6	I
20	E1	I
21	promoter	I
22	and	O
23	thereby	O
24	the	O
25	HPV	O
26	life	O
27	cycle	O
28	.	O

1	Sequential	O
2	cleavage	O
3	by	O
4	metallopeptidases	B
5	and	O
6	proteasomes	O
7	is	O
8	involved	O
9	in	O
10	processing	O
11	HIV	B
12	-	I
13	1	I
14	ENV	I
15	epitope	I
16	for	O
17	endogenous	O
18	MHC	B
19	class	I
20	I	I
21	antigen	I
22	presentation	O
23	.	O

1	Cloning	O
2	and	O
3	characterization	O
4	of	O
5	human	B
6	Lnk	I
7	,	O
8	an	O
9	adaptor	O
10	protein	O
11	with	O
12	pleckstrin	B
13	homology	O
14	and	O
15	Src	B
16	homology	I
17	2	I
18	domains	I
19	that	O
20	can	O
21	inhibit	O
22	T	O
23	cell	O
24	activation	O
25	.	O

1	Vancomycin	O
2	data	O
3	were	O
4	analyzed	O
5	according	O
6	to	O
7	a	O
8	one	O
9	-	O
10	compartment	O
11	open	O
12	model	O
13	with	O
14	use	O
15	of	O
16	NONMEM	O
17	population	O
18	pharmacokinetic	O
19	software	O
20	.	O

1	Finally	O
2	,	O
3	Cas	B
4	existed	O
5	mainly	O
6	in	O
7	cytosol	O
8	and	O
9	membrane	O
10	cytoskeleton	O
11	fractions	O
12	in	O
13	the	O
14	resting	O
15	state	O
16	,	O
17	and	O
18	remained	O
19	unchanged	O
20	during	O
21	platelet	O
22	aggregation	O
23	,	O
24	when	O
25	FAK	B
26	translocated	O
27	to	O
28	the	O
29	cytoskeletal	O
30	fraction	O
31	.	O

1	We	O
2	also	O
3	show	O
4	that	O
5	p65	B
6	binds	O
7	to	O
8	these	O
9	targets	O
10	with	O
11	almost	O
12	equal	O
13	affinity	O
14	and	O
15	that	O
16	different	O
17	residues	O
18	have	O
19	variable	O
20	roles	O
21	in	O
22	binding	O
23	different	O
24	kappaB	B
25	targets	I
26	.	O

1	Transcriptional	O
2	regulation	O
3	of	O
4	the	O
5	yeast	B
6	PHO8	I
7	promoter	I
8	in	O
9	comparison	O
10	to	O
11	the	O
12	coregulated	O
13	PHO5	B
14	promoter	I
15	.	O

1	The	O
2	Siglecs	B
3	are	O
4	a	O
5	subfamily	O
6	of	O
7	I	B
8	-	I
9	type	I
10	lectins	I
11	(	O
12	immunoglobulin	B
13	superfamily	I
14	proteins	I
15	that	O
16	bind	O
17	sugars	O
18	)	O
19	that	O
20	specifically	O
21	recognize	O
22	sialic	O
23	acids	O
24	.	O

1	Our	O
2	data	O
3	provide	O
4	a	O
5	biochemical	O
6	explanation	O
7	for	O
8	the	O
9	similarity	O
10	in	O
11	phenotype	O
12	between	O
13	A	O
14	-	O
15	T	O
16	and	O
17	NBS	O
18	.	O

1	PATIENTS	O
2	OR	O
3	OTHER	O
4	PARTICIPANTS	O
5	:	O
6	Twenty	O
7	children	O
8	met	O
9	the	O
10	criteria	O
11	for	O
12	being	O
13	learning	O
14	disabled	O
15	.	O

1	Update	O
2	on	O
3	maternal	O
4	-	O
5	fetal	O
6	infections	O
7	by	O
8	hepatitis	O
9	C	O
10	,	O
11	HIV	O
12	and	O
13	cytomegalovirus	O

1	In	O
2	the	O
3	present	O
4	study	O
5	,	O
6	we	O
7	characterized	O
8	cis	O
9	-	O
10	elements	O
11	of	O
12	the	O
13	human	B
14	PCI	I
15	gene	I
16	required	O
17	for	O
18	expression	O
19	in	O
20	the	O
21	hepatoma	O
22	-	O
23	derived	O
24	cell	O
25	line	O
26	,	O
27	HepG2	O
28	cells	O
29	,	O
30	and	O
31	also	O
32	evaluated	O
33	rat	B
34	PCI	I
35	mRNA	I
36	expression	O
37	,	O
38	particularly	O
39	on	O
40	the	O
41	effect	O
42	of	O
43	androgen	O
44	in	O
45	rat	O
46	reproductive	O
47	tissues	O
48	.	O

1	In	O
2	the	O
3	study	O
4	on	O
5	PCI	B
6	mRNA	I
7	expression	O
8	in	O
9	the	O
10	reproductive	O
11	organs	O
12	,	O
13	we	O
14	first	O
15	cloned	O
16	rat	B
17	PCI	I
18	cDNA	I
19	and	O
20	then	O
21	evaluated	O
22	the	O
23	effect	O
24	of	O
25	androgen	O
26	on	O
27	the	O
28	PCI	B
29	mRNA	I
30	expression	O
31	.	O

1	To	O
2	illustrate	O
3	its	O
4	performance	O
5	,	O
6	measurements	O
7	of	O
8	photoluminescence	O
9	in	O
10	GaAs	O
11	/	O
12	AlGaAs	O
13	heterostructures	O
14	are	O
15	presented	O
16	.	O

1	The	O
2	stoichiometry	O
3	of	O
4	the	O
5	complexes	O
6	formed	O
7	with	O
8	the	O
9	dodeca	O
10	-	O
11	satellite	O
12	C	O
13	strand	O
14	suggests	O
15	that	O
16	,	O
17	in	O
18	DDP1	B
19	,	O
20	the	O
21	15	O
22	consecutive	O
23	KH	O
24	domains	O
25	are	O
26	organized	O
27	such	O
28	that	O
29	they	O
30	define	O
31	two	O
32	nucleic	O
33	acid	O
34	binding	O
35	surfaces	O
36	.	O

1	Mutational	O
2	analysis	O
3	of	O
4	mammalian	B
5	translation	I
6	initiation	I
7	factor	I
8	5	I
9	(	O
10	eIF5	B
11	):	O
12	role	O
13	of	O
14	interaction	O
15	between	O
16	the	O
17	beta	O
18	subunit	O
19	of	O
20	eIF2	B
21	and	O
22	eIF5	B
23	in	O
24	eIF5	B
25	function	O
26	in	O
27	vitro	O
28	and	O
29	in	O
30	vivo	O
31	.	O

1	Much	O
2	evidence	O
3	indicates	O
4	that	O
5	p38	B
6	is	O
7	an	O
8	activator	O
9	of	O
10	MyoD	B
11	:	O
12	(	O
13	i	O
14	)	O
15	p38	B
16	kinase	I
17	activity	O
18	is	O
19	required	O
20	for	O
21	the	O
22	expression	O
23	of	O
24	MyoD	B
25	-	O
26	responsive	O
27	genes	O
28	,	O
29	(	O
30	ii	O
31	)	O
32	enforced	O
33	induction	O
34	of	O
35	p38	B
36	stimulates	O
37	the	O
38	transcriptional	O
39	activity	O
40	of	O
41	a	O
42	Gal4	B
43	-	O
44	MyoD	B
45	fusion	O
46	protein	O
47	and	O
48	allows	O
49	efficient	O
50	activation	O
51	of	O
52	chromatin	O
53	-	O
54	integrated	O
55	reporters	O
56	by	O
57	MyoD	B
58	,	O
59	and	O
60	(	O
61	iii	O
62	)	O
63	MyoD	B
64	-	O
65	dependent	O
66	myogenic	O
67	conversion	O
68	is	O
69	reduced	O
70	in	O
71	mouse	O
72	embryonic	O
73	fibroblasts	O
74	derived	O
75	from	O
76	p38alpha	B
77	(-/-)	I
78	embryos	O
79	.	O

1	This	O
2	activity	O
3	is	O
4	stimulated	O
5	by	O
6	complex	O
7	formation	O
8	with	O
9	the	O
10	other	O
11	eIF2B	B
12	subunits	I
13	.	O

1	Our	O
2	analysis	O
3	of	O
4	nonsense	O
5	mutations	O
6	indicates	O
7	that	O
8	the	O
9	C	O
10	terminus	O
11	of	O
12	eIF2Bepsilon	B
13	(	I
14	residues	I
15	518	I
16	to	I
17	712	I
18	)	I
19	is	O
20	required	O
21	for	O
22	both	O
23	catalytic	O
24	activity	O
25	and	O
26	interaction	O
27	with	O
28	eIF2	B
29	.	O

1	In	O
2	contrast	O
3	,	O
4	mutations	O
5	affecting	O
6	the	O
7	other	O
8	two	O
9	Nim1p	B
10	-	I
11	related	I
12	kinases	I
13	in	O
14	S	O
15	.	O
16	cerevisiae	O
17	,	O
18	Hsl1p	B
19	and	O
20	Kcc4p	B
21	,	O
22	produce	O
23	no	O
24	detectable	O
25	effect	O
26	on	O
27	septin	B
28	organization	O
29	.	O

1	CONCLUSIONS	O
2	:	O
3	Physiologic	O
4	pacing	O
5	provides	O
6	little	O
7	benefit	O
8	over	O
9	ventricular	O
10	pacing	O
11	for	O
12	the	O
13	prevention	O
14	of	O
15	stroke	O
16	or	O
17	death	O
18	due	O
19	to	O
20	cardiovascular	O
21	causes	O
22	.	O

1	Among	O
2	non	O
3	-	O
4	cirrhotics	O
5	,	O
6	lack	O
7	of	O
8	portal	O
9	vein	O
10	visualisation	O
11	had	O
12	a	O
13	90	O
14	%	O
15	sensitivity	O
16	,	O
17	88	O
18	%	O
19	specificity	O
20	,	O
21	94	O
22	%	O
23	negative	O
24	predictive	O
25	value	O
26	,	O
27	and	O
28	83	O
29	%	O
30	positive	O
31	predictive	O
32	value	O
33	in	O
34	the	O
35	diagnosis	O
36	of	O
37	pre	O
38	-	O
39	sinusoidal	O
40	portal	O
41	hypertension	O
42	.	O

1	D5	B
2	/	I
3	D1	I
4	(	I
5	CT	I
6	)	I
7	or	O
8	D5	B
9	/	I
10	D1D	I
11	(	I
12	CT	I
13	)	I
14	tail	O
15	substitution	O
16	mutants	O
17	displayed	O
18	a	O
19	rank	O
20	order	O
21	of	O
22	potency	O
23	and	O
24	agonist	O
25	affinities	O
26	virtually	O
27	mimicking	O
28	wild	B
29	-	I
30	type	I
31	(	I
32	wt	I
33	)	I
34	D1	I
35	receptors	I
36	,	O
37	as	O
38	indexed	O
39	by	O
40	both	O
41	ligand	O
42	binding	O
43	and	O
44	dopamine	O
45	-	O
46	stimulated	O
47	cAMP	O
48	accumulation	O
49	assays	O
50	,	O
51	and	O
52	,	O
53	similar	O
54	to	O
55	wt	O
56	D1	B
57	receptors	I
58	,	O
59	did	O
60	not	O
61	exhibit	O
62	receptor	O
63	constitutive	O
64	activity	O
65	or	O
66	responsiveness	O
67	to	O
68	inverse	O
69	agonists	O
70	.	O

1	Modeling	O
2	also	O
3	revealed	O
4	a	O
5	very	O
6	hydrophobic	O
7	surface	O
8	due	O
9	to	O
10	the	O
11	absence	O
12	of	O
13	H12	O
14	,	O
15	exposing	O
16	residues	O
17	from	O
18	H3	O
19	,	O
20	loop	O
21	3	O
22	-	O
23	4	O
24	,	O
25	H4	O
26	,	O
27	and	O
28	H11	O
29	.	O

1	The	O
2	serine	B
3	-	I
4	threonine	I
5	kinase	I
6	gene	I
7	is	O
8	likely	O
9	functional	O
10	,	O
11	whereas	O
12	the	O
13	zinc	O
14	finger	O
15	motif	O
16	is	O
17	likely	O
18	nonfunctional	O
19	.	O

1	Stat	B
2	activation	O
3	in	O
4	response	O
5	to	O
6	GH	B
7	and	O
8	IL	B
9	-	I
10	6	I
11	was	O
12	determined	O
13	by	O
14	reporter	O
15	gene	O
16	induction	O
17	.	O

1	HFA	O
2	134a	O
3	had	O
4	a	O
5	greater	O
6	tendency	O
7	to	O
8	take	O
9	up	O
10	moisture	O
11	from	O
12	the	O
13	environment	O
14	than	O
15	did	O
16	HFA	O
17	227	O
18	.	O

1	RESULTS	O
2	:	O
3	Abnormal	O
4	color	O
5	perception	O
6	was	O
7	found	O
8	in	O
9	32	O
10	%	O
11	of	O
12	the	O
13	epilepsy	O
14	patients	O
15	treated	O
16	with	O
17	vigabatrin	O
18	monotherapy	O
19	and	O
20	28	O
21	%	O
22	of	O
23	the	O
24	epilepsy	O
25	patients	O
26	treated	O
27	with	O
28	carbamazepine	O
29	monotherapy	O
30	.	O

1	In	O
2	the	O
3	SPP2	O
4	screening	O
5	test	O
6	,	O
7	a	O
8	few	O
9	plates	O
10	were	O
11	not	O
12	seen	O
13	in	O
14	both	O
15	groups	O
16	.	O

1	Mitogen	B
2	-	I
3	activated	I
4	protein	I
5	(	I
6	MAP	I
7	)	I
8	kinase	I
9	phosphatase	I
10	-	I
11	3	I
12	(	O
13	MKP	B
14	-	I
15	3	I
16	)	O
17	is	O
18	a	O
19	dual	O
20	specificity	O
21	phosphatase	O
22	that	O
23	inactivates	O
24	extracellular	B
25	signal	I
26	-	I
27	regulated	I
28	kinase	I
29	(	O
30	ERK	B
31	)	O
32	MAP	B
33	kinases	I
34	.	O

1	Consistent	O
2	with	O
3	this	O
4	,	O
5	we	O
6	show	O
7	that	O
8	peptides	O
9	representing	O
10	docking	O
11	sites	O
12	within	O
13	the	O
14	target	O
15	substrates	O
16	Elk	B
17	-	I
18	1	I
19	and	O
20	p90	B
21	(	O
22	rsk	B
23	)	O
24	inhibit	O
25	ERK	B
26	-	O
27	dependent	O
28	activation	O
29	of	O
30	MKP	B
31	-	I
32	3	I
33	.	O

1	HPLC	O
2	phosphopeptide	O
3	mapping	O
4	,	O
5	amino	O
6	acid	O
7	sequencing	O
8	,	O
9	and	O
10	site	O
11	-	O
12	directed	O
13	mutagenesis	O
14	determined	O
15	that	O
16	NCLK	B
17	phosphorylates	O
18	Ser	O
19	(	O
20	67	O
21	)	O
22	of	O
23	I	B
24	-	I
25	1	I
26	.	O

1	When	O
2	the	O
3	entire	O
4	diet	O
5	consisted	O
6	of	O
7	SBF	O
8	,	O
9	voluntary	O
10	feed	O
11	intake	O
12	was	O
13	reduced	O
14	,	O
15	indicating	O
16	that	O
17	SBF	O
18	should	O
19	not	O
20	be	O
21	fed	O
22	to	O
23	ponies	O
24	as	O
25	the	O
26	sole	O
27	dietary	O
28	ingredient	O
29	.	O

1	Hepatitis	O
2	C	O
3	virus	O
4	infection	O
5	and	O
6	lymphoproliferative	O
7	diseases	O
8	in	O
9	France	O
10	:	O
11	a	O
12	national	O
13	study	O
14	.	O

1	The	O
2	immune	O
3	system	O
4	is	O
5	closely	O
6	integrated	O
7	with	O
8	the	O
9	neuroendocrine	O
10	system	O
11	,	O
12	and	O
13	infection	O
14	-	O
15	induced	O
16	increases	O
17	in	O
18	cytokines	O
19	such	O
20	as	O
21	IL	B
22	-	I
23	1	I
24	,	O
25	IL	B
26	-	I
27	6	I
28	and	O
29	TNF	B
30	have	O
31	numerous	O
32	effects	O
33	on	O
34	the	O
35	central	O
36	nervous	O
37	system	O
38	.	O

1	Interestingly	O
2	,	O
3	a	O
4	decreased	O
5	transcription	O
6	from	O
7	the	O
8	endogenous	O
9	c	B
10	-	I
11	Myb	I
12	promoter	I
13	was	O
14	observed	O
15	in	O
16	several	O
17	HTLV	O
18	-	O
19	I	O
20	transformed	O
21	T	O
22	-	O
23	cell	O
24	lines	O
25	.	O

1	H19	B
2	and	O
3	Igf2	B
4	monoallelic	O
5	expression	O
6	is	O
7	regulated	O
8	in	O
9	two	O
10	distinct	O
11	ways	O
12	by	O
13	a	O
14	shared	O
15	cis	O
16	acting	O
17	regulatory	O
18	region	O
19	upstream	O
20	of	O
21	H19	B
22	.	O

1	C	O
2	.	O
3	elegans	O
4	KLP	B
5	-	I
6	11	I
7	/	O
8	OSM	B
9	-	I
10	3	I
11	/	O
12	KAP	B
13	-	I
14	1	I
15	:	O
16	orthologs	O
17	of	O
18	the	O
19	sea	B
20	urchin	I
21	kinesin	I
22	-	I
23	II	I
24	,	O
25	and	O
26	mouse	O
27	KIF3A	B
28	/	O
29	KIFB	B
30	/	O
31	KAP3	B
32	kinesin	I
33	complexes	O
34	.	O

1	Flavonoids	O
2	from	O
3	Brosimum	O
4	acutifolium	O
5	.	O

1	BACKGROUND	O
2	:	O
3	Hepatic	O
4	encephalopathy	O
5	is	O
6	a	O
7	neuropsychiatric	O
8	syndrome	O
9	associated	O
10	with	O
11	acute	O
12	liver	O
13	failure	O
14	,	O
15	chronic	O
16	parenchymal	O
17	liver	O
18	disease	O
19	or	O
20	portal	O
21	systemic	O
22	anastomosis	O
23	.	O

1	These	O
2	natural	O
3	antisense	O
4	S	B
5	transcripts	I
6	co	O
7	-	O
8	exist	O
9	with	O
10	several	O
11	less	O
12	abundant	O
13	sense	O
14	S	B
15	transcripts	I
16	.	O

1	Nor	O
2	is	O
3	such	O
4	adjustment	O
5	possible	O
6	unless	O
7	one	O
8	posits	O
9	a	O
10	model	O
11	that	O
12	relates	O
13	the	O
14	missing	O
15	observations	O
16	to	O
17	other	O
18	observed	O
19	information	O
20	for	O
21	each	O
22	subject	O
23	-	O
24	models	O
25	that	O
26	are	O
27	inherently	O
28	untestable	O
29	.	O

1	However	O
2	,	O
3	the	O
4	presence	O
5	of	O
6	effacement	O
7	seems	O
8	to	O
9	be	O
10	a	O
11	more	O
12	reliable	O
13	and	O
14	practical	O
15	parameter	O
16	that	O
17	will	O
18	be	O
19	preferred	O
20	in	O
21	that	O
22	prediction	O
23	.	O

1	The	O
2	data	O
3	are	O
4	compatible	O
5	with	O
6	the	O
7	idea	O
8	that	O
9	YLL031c	B
10	transfers	O
11	the	O
12	ethanolaminephosphate	O
13	to	O
14	the	O
15	inner	O
16	alpha1	O
17	-	O
18	2	O
19	-	O
20	linked	O
21	mannose	O
22	,	O
23	i	O
24	.	O
25	e	O
26	.	O
27	the	O
28	group	O
29	that	O
30	links	O
31	the	O
32	GPI	O
33	lipid	O
34	anchor	O
35	to	O
36	proteins	O
37	,	O
38	whereas	O
39	Mcd4p	B
40	and	O
41	Gpi7p	B
42	transfer	O
43	ethanolaminephosphate	O
44	onto	O
45	the	O
46	alpha1	O
47	-	O
48	4	O
49	-	O
50	and	O
51	alpha1	O
52	-	O
53	6	O
54	-	O
55	linked	O
56	mannoses	O
57	of	O
58	the	O
59	GPI	O
60	anchor	O
61	,	O
62	respectively	O
63	.	O

1	The	O
2	C	O
3	terminus	O
4	of	O
5	TRBP	B
6	binds	O
7	to	O
8	CBP	B
9	/	O
10	p300	B
11	and	O
12	DRIP130	B
13	,	O
14	a	O
15	component	O
16	of	O
17	the	O
18	DRIP	B
19	/	O
20	TRAP	B
21	/	O
22	ARC	B
23	complex	O
24	,	O
25	which	O
26	suggests	O
27	that	O
28	TRBP	B
29	may	O
30	activate	O
31	transcription	O
32	by	O
33	means	O
34	of	O
35	such	O
36	interactions	O
37	.	O

1	The	O
2	patients	O
3	who	O
4	presented	O
5	with	O
6	mucocutaneous	O
7	disease	O
8	also	O
9	had	O
10	low	O
11	CD4	B
12	+	I
13	T	O
14	lymphocyte	O
15	counts	O
16	,	O
17	and	O
18	most	O
19	of	O
20	them	O
21	had	O
22	AIDS	O
23	defining	O
24	illnesses	O
25	.	O

1	Increased	O
2	dietary	O
3	energy	O
4	decreased	O
5	PAB	O
6	and	O
7	the	O
8	use	O
9	of	O
10	added	O
11	dietary	O
12	CO	O
13	rather	O
14	than	O
15	PF	O
16	decreased	O
17	PSHL	O
18	in	O
19	broiler	O
20	breeders	O
21	between	O
22	26	O
23	and	O
24	47	O
25	wk	O
26	of	O
27	age	O
28	.	O

1	The	O
2	gene	O
3	amplification	O
4	model	O
5	of	O
6	Coquelle	O
7	et	O
8	al	O
9	.	O

1	Hierarchy	O
2	of	O
3	protein	B
4	tyrosine	I
5	kinases	I
6	in	O
7	interleukin	B
8	-	I
9	2	I
10	(	O
11	IL	B
12	-	I
13	2	I
14	)	O
15	signaling	O
16	:	O
17	activation	O
18	of	O
19	syk	B
20	depends	O
21	on	O
22	Jak3	B
23	;	O
24	however	O
25	,	O
26	neither	O
27	Syk	B
28	nor	O
29	Lck	B
30	is	O
31	required	O
32	for	O
33	IL	B
34	-	I
35	2	I
36	-	O
37	mediated	O
38	STAT	B
39	activation	O
40	.	O

1	Immobilized	O
2	dimers	O
3	of	O
4	N	B
5	-	I
6	cadherin	I
7	-	O
8	Fc	B
9	chimera	O
10	mimic	O
11	cadherin	O
12	-	O
13	mediated	O
14	cell	O
15	contact	O
16	formation	O
17	:	O
18	contribution	O
19	of	O
20	both	O
21	outside	O
22	-	O
23	in	O
24	and	O
25	inside	O
26	-	O
27	out	O
28	signals	O
29	.	O

1	Although	O
2	the	O
3	OC	B
4	promoter	I
5	is	O
6	activated	O
7	in	O
8	a	O
9	C	O
10	terminus	O
11	dependent	O
12	manner	O
13	,	O
14	the	O
15	MDR	B
16	,	O
17	LTR	O
18	and	O
19	BSP	B
20	promoters	I
21	are	O
22	repressed	O
23	by	O
24	three	O
25	distinct	O
26	mechanisms	O
27	,	O
28	either	O
29	independent	O
30	of	O
31	or	O
32	involving	O
33	the	O
34	AML	B
35	C	I
36	terminus	I
37	,	O
38	or	O
39	requiring	O
40	only	O
41	the	O
42	conserved	O
43	C	O
44	-	O
45	terminal	O
46	pentapeptide	O
47	VWRPY	O
48	.	O

1	The	O
2	monoclonal	O
3	immunoglobulin	B
4	products	O
5	of	O
6	plasma	O
7	cell	O
8	neoplasm	O
9	can	O
10	give	O
11	rise	O
12	to	O
13	a	O
14	variety	O
15	of	O
16	manifestations	O
17	including	O
18	hyperviscosity	O
19	,	O
20	amyloidosis	O
21	,	O
22	cryoglobulinemia	O
23	,	O
24	neuropathy	O
25	,	O
26	and	O
27	renal	O
28	failure	O
29	.	O

1	Investigation	O
2	of	O
3	the	O
4	structural	O
5	basis	O
6	of	O
7	the	O
8	interaction	O
9	between	O
10	human	B
11	Igs	I
12	and	O
13	gp120	B
14	shows	O
15	that	O
16	the	O
17	viral	B
18	gp120	I
19	SAg	I
20	can	O
21	interact	O
22	only	O
23	with	O
24	a	O
25	subset	O
26	of	O
27	human	B
28	V	I
29	(	I
30	H	I
31	)	I
32	3	I
33	+	I
34	Igs	I
35	.	O

1	Double	O
2	-	O
3	blind	O
4	,	O
5	placebo	O
6	-	O
7	controlled	O
8	trial	O
9	.	O

1	Here	O
2	,	O
3	it	O
4	is	O
5	shown	O
6	that	O
7	TAFII250	B
8	,	O
9	the	O
10	largest	O
11	subunit	O
12	of	O
13	TFIID	B
14	,	O
15	contains	O
16	two	O
17	tandem	O
18	bromodomain	O
19	modules	O
20	that	O
21	bind	O
22	selectively	O
23	to	O
24	multiply	O
25	acetylated	O
26	histone	B
27	H4	I
28	peptides	I
29	.	O

1	Endostatin	O
2	treatment	O
3	for	O
4	10	O
5	minutes	O
6	or	O
7	24	O
8	hours	O
9	induced	O
10	tyrosine	O
11	phosphorylation	O
12	of	O
13	Shb	B
14	and	O
15	formation	O
16	of	O
17	multiprotein	O
18	complexes	O
19	.	O

1	Therefore	O
2	,	O
3	analogs	O
4	of	O
5	vitamin	O
6	D3	O
7	have	O
8	been	O
9	investigated	O
10	in	O
11	a	O
12	number	O
13	of	O
14	trials	O
15	showing	O
16	improvement	O
17	of	O
18	psoriasis	O
19	.	O

1	The	O
2	transcript	O
3	was	O
4	initially	O
5	identified	O
6	as	O
7	a	O
8	partial	O
9	cDNA	O
10	sequence	O
11	in	O
12	the	O
13	course	O
14	of	O
15	constructing	O
16	a	O
17	transcript	O
18	map	O
19	of	O
20	the	O
21	region	O
22	between	O
23	markers	O
24	D11S1765	B
25	and	O
26	uteroglobin	B
27	known	O
28	to	O
29	encompass	O
30	the	O
31	gene	O
32	causing	O
33	Best	O
34	disease	O
35	.	O

1	The	O
2	real	O
3	challenge	O
4	for	O
5	the	O
6	future	O
7	will	O
8	be	O
9	the	O
10	management	O
11	of	O
12	patients	O
13	who	O
14	do	O
15	not	O
16	respond	O
17	to	O
18	first	O
19	-	O
20	line	O
21	treatment	O
22	.	O

1	Iodine	O
2	deficiency	O
3	disorders	O
4	in	O
5	Bangladesh	O
6	.	O

1	The	O
2	network	O
3	evolution	O
4	was	O
5	interpreted	O
6	by	O
7	an	O
8	approach	O
9	based	O
10	on	O
11	the	O
12	Flory	O
13	model	O
14	.	O

1	RESULTS	O
2	:	O
3	Soluble	O
4	CD23	B
5	levels	O
6	were	O
7	significantly	O
8	higher	O
9	in	O
10	women	O
11	with	O
12	endometriosis	O
13	before	O
14	treatment	O
15	than	O
16	in	O
17	ten	O
18	normal	O
19	controls	O
20	.	O

1	CONCLUSION	O
2	:	O
3	Our	O
4	findings	O
5	suggest	O
6	that	O
7	endometriosis	O
8	increases	O
9	soluble	O
10	CD23	B
11	levels	O
12	,	O
13	which	O
14	can	O
15	be	O
16	suppressed	O
17	with	O
18	either	O
19	danazol	O
20	or	O
21	leuprolide	O
22	acetate	O
23	injection	O
24	.	O

1	To	O
2	isolate	O
3	this	O
4	gene	O
5	,	O
6	a	O
7	P	O
8	-	O
9	1	O
10	artificial	O
11	chromosome	O
12	(	O
13	PAC	O
14	)	O
15	library	O
16	was	O
17	screened	O
18	with	O
19	a	O
20	full	B
21	length	I
22	UGT2B7	I
23	probe	O
24	and	O
25	a	O
26	clone	O
27	of	O
28	approximately	O
29	100	O
30	kb	O
31	in	O
32	length	O
33	was	O
34	isolated	O
35	.	O

1	Age	O
2	>/=	O
3	50	O
4	years	O
5	(	O
6	odds	O
7	ratio	O
8	[	O
9	OR	O
10	],	O
11	14	O
12	.	O
13	1	O
14	),	O
15	BMI	O
16	>/=	O
17	28	O
18	kg	O
19	/	O
20	m	O
21	(	O
22	2	O
23	)	O
24	(	O
25	OR	O
26	,	O
27	5	O
28	.	O
29	7	O
30	),	O
31	triglycerides	O
32	>/=	O
33	1	O
34	.	O
35	7	O
36	mmol	O
37	/	O
38	L	O
39	(	O
40	OR	O
41	,	O
42	5	O
43	),	O
44	and	O
45	alanine	B
46	aminotransferase	I
47	(	O
48	ALT	B
49	)	O
50	>/=	O
51	2N	O
52	(	O
53	OR	O
54	,	O
55	4	O
56	.	O
57	6	O
58	)	O
59	were	O
60	independently	O
61	associated	O
62	with	O
63	septal	O
64	fibrosis	O
65	.	O

1	Biologically	O
2	significant	O
3	amounts	O
4	of	O
5	platelet	B
6	activating	I
7	factor	I
8	were	O
9	eluted	O
10	from	O
11	the	O
12	sorbent	O
13	during	O
14	the	O
15	entire	O
16	treatment	O
17	time	O
18	.	O

1	However	O
2	,	O
3	the	O
4	elderly	O
5	group	O
6	showed	O
7	significantly	O
8	longer	O
9	mean	O
10	residence	O
11	times	O
12	(	O
13	MRTs	O
14	)	O
15	and	O
16	lower	O
17	plasma	O
18	clearance	O
19	of	O
20	lidocaine	O
21	during	O
22	the	O
23	period	O
24	compared	O
25	with	O
26	the	O
27	adult	O
28	group	O
29	(	O
30	P	O
31	<	O
32	.	O
33	05	O
34	).	O

1	Here	O
2	,	O
3	we	O
4	show	O
5	that	O
6	the	O
7	zinc	B
8	finger	I
9	protein	I
10	Gis1	I
11	acts	O
12	as	O
13	a	O
14	dosage	O
15	-	O
16	dependent	O
17	suppressor	O
18	of	O
19	the	O
20	rim15Delta	B
21	defect	O
22	in	O
23	nutrient	O
24	limitation	O
25	-	O
26	induced	O
27	transcriptional	O
28	derepression	O
29	of	O
30	SSA3	B
31	.	O

1	The	O
2	so	O
3	-	O
4	called	O
5	"	B
6	SH3	I
7	"	I
8	segment	I
9	of	O
10	the	O
11	linker	O
12	domain	O
13	,	O
14	in	O
15	contrast	O
16	,	O
17	shows	O
18	species	O
19	-	O
20	specific	O
21	sequence	O
22	identity	O
23	in	O
24	all	O
25	but	O
26	one	O
27	amino	O
28	acid	O
29	residues	O
30	in	O
31	both	O
32	factors	O
33	,	O
34	in	O
35	cattle	O
36	,	O
37	human	O
38	,	O
39	and	O
40	mouse	O
41	.	O

1	No	O
2	differences	O
3	in	O
4	total	O
5	cholesterol	O
6	levels	O
7	were	O
8	observed	O
9	between	O
10	mapuches	O
11	and	O
12	aymaras	O
13	.	O

1	Up	O
2	to	O
3	95	O
4	%	O
5	of	O
6	the	O
7	total	O
8	UV	O
9	exposure	O
10	received	O
11	is	O
12	in	O
13	the	O
14	UV	O
15	-	O
16	A	O
17	waveband	O
18	(	O
19	320	O
20	-	O
21	400	O
22	nm	O
23	).	O

1	To	O
2	begin	O
3	to	O
4	characterize	O
5	the	O
6	role	O
7	of	O
8	the	O
9	RNA	O
10	subunits	O
11	in	O
12	enzyme	O
13	function	O
14	and	O
15	substrate	O
16	specificity	O
17	,	O
18	we	O
19	swapped	O
20	two	O
21	hairpin	O
22	structures	O
23	(	O
24	MRP3	O
25	and	O
26	P3	O
27	)	O
28	between	O
29	RNase	B
30	MRP	I
31	RNA	I
32	and	O
33	RNase	B
34	P	I
35	RNA	I
36	of	I
37	S	I
38	.	I
39	cerevisiae	I
40	.	O

1	Among	O
2	genes	O
3	induced	O
4	by	O
5	added	O
6	pMesogenin1	B
7	is	O
8	Xwnt	B
9	-	I
10	8	I
11	,	O
12	a	O
13	signaling	O
14	factor	O
15	that	O
16	induces	O
17	a	O
18	similar	O
19	repertoire	O
20	of	O
21	marker	O
22	genes	O
23	and	O
24	a	O
25	similar	O
26	cellular	O
27	phenotype	O
28	.	O

1	Accordingly	O
2	,	O
3	no	O
4	Ha	B
5	-	I
6	ras	I
7	codon	I
8	12	I
9	mutations	O
10	are	O
11	found	O
12	in	O
13	the	O
14	EtNU	O
15	-	O
16	induced	O
17	mammary	O
18	tumors	O
19	.	O

1	False	O
2	positive	O
3	PET	O
4	FDG	O
5	corresponded	O
6	to	O
7	lung	O
8	infection	O
9	,	O
10	degenerative	O
11	bone	O
12	disease	O
13	,	O
14	and	O
15	reconstruction	O
16	artifact	O
17	.	O

1	Tumor	O
2	stages	O
3	were	O
4	IIB	O
5	(	O
6	T3	O
7	N0	O
8	)	O
9	in	O
10	52	O
11	%,	O
12	IIIA	O
13	in	O
14	15	O
15	%,	O
16	and	O
17	IIIB	O
18	in	O
19	27	O
20	%	O
21	of	O
22	patients	O
23	.	O

1	Similarly	O
2	,	O
3	comparison	O
4	of	O
5	percentage	O
6	reductions	O
7	of	O
8	heart	O
9	rate	O
10	at	O
11	supine	O
12	,	O
13	sitting	O
14	and	O
15	exercise	O
16	by	O
17	repeated	O
18	measure	O
19	analysis	O
20	showed	O
21	the	O
22	Malays	O
23	to	O
24	have	O
25	significantly	O
26	higher	O
27	change	O
28	compared	O
29	to	O
30	the	O
31	Chinese	O
32	(	O
33	p	O
34	=	O
35	0	O
36	.	O
37	040	O
38	).	O

1	Consistent	O
2	with	O
3	our	O
4	model	O
5	,	O
6	CTCF	B
7	binding	O
8	is	O
9	abolished	O
10	by	O
11	DNA	O
12	methylation	O
13	.	O

1	OBJECTIVE	O
2	:	O
3	To	O
4	determine	O
5	the	O
6	efficacy	O
7	and	O
8	safety	O
9	of	O
10	amphotericin	O
11	B	O
12	oral	O
13	suspension	O
14	(	O
15	ABOS	O
16	)	O
17	for	O
18	the	O
19	treatment	O
20	of	O
21	fluconazole	O
22	refractory	O
23	oral	O
24	candidiasis	O
25	in	O
26	persons	O
27	with	O
28	HIV	O
29	infection	O
30	.	O

1	Mucin	B
2	gene	I
3	expression	O
4	has	O
5	been	O
6	shown	O
7	to	O
8	be	O
9	altered	O
10	in	O
11	many	O
12	intestinal	O
13	diseases	O
14	and	O
15	especially	O
16	cancers	O
17	of	O
18	the	O
19	gastrointestinal	O
20	tract	O
21	.	O

1	The	O
2	experimentally	O
3	mapped	O
4	regions	O
5	of	O
6	RPB5	B
7	involved	O
8	in	O
9	these	O
10	interactions	O
11	correspond	O
12	to	O
13	distinct	O
14	and	O
15	surface	O
16	-	O
17	exposed	O
18	alpha	O
19	-	O
20	helical	O
21	structures	O
22	.	O

1	The	O
2	model	O
3	indicates	O
4	that	O
5	a	O
6	0	O
7	.	O
8	076	O
9	%	O
10	reduction	O
11	in	O
12	cigarette	O
13	consumption	O
14	is	O
15	associated	O
16	with	O
17	the	O
18	availability	O
19	of	O
20	nicotine	O
21	patches	O
22	after	O
23	1992	O
24	.	O

1	Paper	O
2	alert	O
3	.	O

1	The	O
2	tryptase	B
3	locus	I
4	also	O
5	contains	O
6	at	O
7	least	O
8	four	O
9	tryptase	B
10	-	I
11	like	I
12	pseudogenes	I
13	,	O
14	including	O
15	mastin	B
16	,	O
17	a	O
18	gene	O
19	expressed	O
20	in	O
21	dogs	O
22	but	O
23	not	O
24	in	O
25	humans	O
26	.	O

1	The	O
2	cellular	O
3	part	O
4	of	O
5	the	O
6	third	O
7	chimeric	O
8	clone	O
9	shows	O
10	significant	O
11	homology	O
12	to	O
13	an	O
14	exon	O
15	of	O
16	the	O
17	human	B
18	tyrosine	I
19	phosphatase	I
20	1	I
21	gene	I
22	,	O
23	although	O
24	oriented	O
25	in	O
26	the	O
27	antisense	O
28	direction	O
29	compared	O
30	to	O
31	the	O
32	adjacent	O
33	LTR	O
34	.	O

1	OBJECTIVE	O
2	:	O
3	This	O
4	study	O
5	was	O
6	conducted	O
7	to	O
8	assess	O
9	the	O
10	relative	O
11	roles	O
12	of	O
13	99mTc	O
14	-	O
15	sestamibi	O
16	scintimammography	O
17	and	O
18	sonography	O
19	in	O
20	the	O
21	evaluation	O
22	of	O
23	breast	O
24	lesions	O
25	that	O
26	are	O
27	indeterminate	O
28	or	O
29	suspicious	O
30	on	O
31	mammography	O
32	or	O
33	clinical	O
34	examination	O
35	.	O

1	Mutational	O
2	analyses	O
3	showed	O
4	that	O
5	in	O
6	-	O
7	frame	O
8	stop	O
9	codons	O
10	introduced	O
11	into	O
12	five	O
13	of	O
14	seven	O
15	RNA	B
16	2	I
17	ORFs	I
18	did	O
19	not	O
20	affect	O
21	accumulation	O
22	of	O
23	progeny	O
24	LIYV	B
25	RNA	I
26	1	I
27	or	O
28	RNA	B
29	2	I
30	,	O
31	confirming	O
32	that	O
33	RNA	B
34	2	I
35	does	O
36	not	O
37	encode	O
38	proteins	O
39	necessary	O
40	for	O
41	LIYV	O
42	RNA	O
43	replication	O
44	.	O

1	Role	O
2	of	O
3	NH	O
4	(	O
5	2	O
6	)-	O
7	and	O
8	COOH	O
9	-	O
10	terminal	O
11	domains	O
12	of	O
13	the	O
14	P	B
15	protein	I
16	of	O
17	human	O
18	parainfluenza	O
19	virus	O
20	type	O
21	3	O
22	in	O
23	transcription	O
24	and	O
25	replication	O
26	.	O

1	Phosphorylation	O
2	of	O
3	tyrosine	O
4	residues	O
5	in	O
6	the	O
7	kinase	O
8	domain	O
9	and	O
10	juxtamembrane	O
11	region	O
12	regulates	O
13	the	O
14	biological	O
15	and	O
16	catalytic	O
17	activities	O
18	of	O
19	Eph	B
20	receptors	I
21	.	O

1	RESULTS	O
2	:	O
3	Fournier	O
4	'	O
5	s	O
6	gangrene	O
7	occurs	O
8	worldwide	O
9	.	O

1	Genomic	O
2	DNA	O
3	sequencing	O
4	in	O
5	the	O
6	vicinity	O
7	of	O
8	methylmalonyl	B
9	-	I
10	CoA	I
11	mutase	I
12	gene	I
13	(	O
14	mutAB	B
15	)	O
16	from	O
17	a	O
18	rifamycin	O
19	SV	O
20	-	O
21	producing	O
22	Amycolatopsis	O
23	mediterranei	O
24	U32	O
25	allowed	O
26	us	O
27	to	O
28	clone	O
29	,	O
30	sequence	O
31	,	O
32	and	O
33	identify	O
34	a	O
35	gene	O
36	encoding	O
37	a	O
38	novel	O
39	serine	B
40	/	I
41	threonine	I
42	protein	I
43	kinase	I
44	(	O
45	amk	B
46	).	O

1	IL	B
2	-	I
3	2	I
4	is	O
5	accepted	O
6	as	O
7	a	O
8	standard	O
9	treatment	O
10	used	O
11	alone	O
12	,	O
13	or	O
14	in	O
15	combination	O
16	with	O
17	chemotherapy	O
18	or	O
19	biotherapy	O
20	in	O
21	the	O
22	management	O
23	of	O
24	metastatic	O
25	melanoma	O
26	and	O
27	metastatic	O
28	renal	O
29	cell	O
30	carcinoma	O
31	.	O

1	Moreover	O
2	,	O
3	expression	O
4	of	O
5	antisense	B
6	Ha	I
7	-	I
8	Ras	I
9	or	O
10	dominant	B
11	negative	I
12	Raf	I
13	-	I
14	1	I
15	abrogated	O
16	the	O
17	mitogenic	O
18	effect	O
19	of	O
20	TGF	B
21	-	I
22	beta1	I
23	in	O
24	TSU	O
25	-	O
26	Pr1	O
27	,	O
28	and	O
29	the	O
30	TGF	B
31	-	I
32	beta1	I
33	inhibition	O
34	of	O
35	DU145	O
36	was	O
37	switched	O
38	to	O
39	stimulation	O
40	by	O
41	V12Ha	B
42	-	I
43	Ras	I
44	transfection	O
45	.	O

1	Taken	O
2	together	O
3	,	O
4	our	O
5	data	O
6	suggest	O
7	that	O
8	prostate	O
9	carcinomas	O
10	with	O
11	the	O
12	Ras	B
13	/	O
14	MAPK	B
15	pathway	O
16	activation	O
17	might	O
18	have	O
19	a	O
20	selective	O
21	growth	O
22	advantage	O
23	by	O
24	autocrine	O
25	TGF	B
26	-	I
27	beta1	I
28	production	O
29	.	O

1	Vbeta	B
2	segments	O
3	are	O
4	appended	O
5	to	O
6	DJbeta	B
7	rearrangements	O
8	,	O
9	with	O
10	little	O
11	or	O
12	no	O
13	direct	O
14	Vbeta	B
15	to	O
16	Jbeta	B
17	joining	O
18	,	O
19	despite	O
20	12	O
21	/	O
22	23	O
23	compatibility	O
24	of	O
25	Vbeta	B
26	23	I
27	-	I
28	RSSs	I
29	and	O
30	Jbeta12	B
31	-	I
32	RSSs	I
33	.	O

1	For	O
2	oral	O
3	administration	O
4	,	O
5	AUC0	O
6	-	O
7	infinity	O
8	was	O
9	58	O
10	.	O
11	47	O
12	+/-	O
13	16	O
14	.	O
15	37	O
16	microg	O
17	x	O
18	h	O
19	/	O
20	ml	O
21	,	O
22	t1	O
23	/	O
24	2beta	O
25	was	O
26	18	O
27	.	O
28	39	O
29	+/-	O
30	0	O
31	.	O
32	06	O
33	hours	O
34	,	O
35	maximum	O
36	concentration	O
37	(	O
38	Cmax	O
39	)	O
40	was	O
41	2	O
42	.	O
43	12	O
44	+/-	O
45	00	O
46	.	O
47	51	O
48	microg	O
49	/	O
50	ml	O
51	,	O
52	time	O
53	to	O
54	Cmax	O
55	was	O
56	2	O
57	.	O
58	20	O
59	+/-	O
60	2	O
61	.	O
62	17	O
63	hours	O
64	,	O
65	mean	O
66	absorption	O
67	time	O
68	was	O
69	2	O
70	.	O
71	09	O
72	+/-	O
73	0	O
74	.	O
75	51	O
76	hours	O
77	,	O
78	and	O
79	bioavailability	O
80	was	O
81	42	O
82	+/-	O
83	0	O
84	.	O
85	42	O
86	%.	O

1	In	O
2	experiment	O
3	2	O
4	,	O
5	no	O
6	difference	O
7	in	O
8	gastric	O
9	emptying	O
10	of	O
11	40	O
12	%	O
13	peptone	O
14	or	O
15	25	O
16	%	O
17	glucose	O
18	was	O
19	found	O
20	between	O
21	rats	O
22	receiving	O
23	TPN	O
24	and	O
25	those	O
26	receiving	O
27	intragastric	O
28	nutrition	O
29	for	O
30	10	O
31	to	O
32	12	O
33	days	O
34	.	O

1	In	O
2	contrast	O
3	,	O
4	H	B
5	-	I
6	NS	I
7	negative	O
8	regulation	O
9	operated	O
10	only	O
11	in	O
12	the	O
13	absence	O
14	of	O
15	Fur	B
16	.	O

1	Thus	O
2	,	O
3	SAG	B
4	appears	O
5	to	O
6	control	O
7	cell	O
8	cycle	O
9	progression	O
10	in	O
11	yeast	O
12	by	O
13	promoting	O
14	ubiquitination	O
15	and	O
16	degradation	O
17	of	O
18	cell	O
19	cycle	O
20	regulatory	O
21	proteins	O
22	.	O

1	E2F	B
2	-	I
3	1	I
4	is	O
5	a	O
6	transcription	O
7	factor	O
8	that	O
9	regulates	O
10	cell	O
11	cycle	O
12	progression	O
13	into	O
14	S	O
15	-	O
16	phase	O
17	.	O

1	It	O
2	brings	O
3	about	O
4	fatigue	O
5	,	O
6	negative	O
7	moods	O
8	,	O
9	and	O
10	impaired	O
11	health	O
12	,	O
13	sleep	O
14	,	O
15	safety	O
16	,	O
17	and	O
18	working	O
19	capacity	O
20	.	O

1	This	O
2	demonstrates	O
3	that	O
4	treatment	O
5	of	O
6	the	O
7	graft	O
8	recipient	O
9	for	O
10	a	O
11	relatively	O
12	short	O
13	period	O
14	during	O
15	and	O
16	after	O
17	surgery	O
18	has	O
19	a	O
20	favorable	O
21	effect	O
22	on	O
23	the	O
24	survival	O
25	of	O
26	grafted	O
27	dopaminergic	O
28	neurons	O
29	.	O

1	The	O
2	relationships	O
3	among	O
4	blood	O
5	concentrations	O
6	of	O
7	thyroid	O
8	hormones	O
9	and	O
10	selenium	O
11	,	O
12	zinc	O
13	,	O
14	retinol	O
15	,	O
16	and	O
17	alpha	O
18	-	O
19	tocopherol	O
20	were	O
21	studied	O
22	in	O
23	44	O
24	healthy	O
25	Northern	O
26	Italian	O
27	oldest	O
28	-	O
29	old	O
30	subjects	O
31	(	O
32	age	O
33	range	O
34	,	O
35	90	O
36	-	O
37	107	O
38	yr	O
39	),	O
40	selected	O
41	by	O
42	the	O
43	criteria	O
44	of	O
45	the	O
46	SENIEUR	O
47	protocol	O
48	.	O

1	Chinese	O
2	Spring	O
3	(	O
4	CS	O
5	)	O
6	carrying	O
7	the	O
8	Q	B
9	gene	I
10	to	O
11	those	O
12	of	O
13	a	O
14	chromosome	O
15	deletion	O
16	line	O
17	of	O
18	CS	O
19	,	O
20	namely	O
21	,	O
22	q5	O
23	,	O
24	which	O
25	lacks	O
26	15	O
27	%	O
28	of	O
29	5AL	O
30	including	O
31	the	O
32	Q	B
33	gene	I
34	.	O

1	Investigations	O
2	using	O
3	hippocampal	O
4	slices	O
5	maintained	O
6	in	O
7	vitro	O
8	have	O
9	demonstrated	O
10	that	O
11	bursts	O
12	of	O
13	oscillatory	O
14	field	O
15	potentials	O
16	in	O
17	the	O
18	gamma	O
19	frequency	O
20	range	O
21	(	O
22	30	O
23	-	O
24	80	O
25	Hz	O
26	)	O
27	are	O
28	followed	O
29	by	O
30	a	O
31	slower	O
32	oscillation	O
33	in	O
34	the	O
35	beta	O
36	1	O
37	range	O
38	(	O
39	12	O
40	-	O
41	20	O
42	Hz	O
43	).	O

1	Karger	O
2	AG	O
3	,	O
4	Basel	O

1	During	O
2	surgery	O
3	bone	O
4	cysts	O
5	were	O
6	excised	O
7	and	O
8	filled	O
9	by	O
10	bone	O
11	grafts	O
12	.	O

1	Urinary	O
2	LTE4	O
3	increased	O
4	after	O
5	both	O
6	challenges	O
7	the	O
8	rise	O
9	being	O
10	higher	O
11	following	O
12	oral	O
13	as	O
14	compared	O
15	to	O
16	inhalation	O
17	provocation	O
18	(	O
19	p	O
20	=	O
21	0	O
22	.	O
23	0001	O
24	).	O

1	Basal	O
2	FVR	O
3	was	O
4	reduced	O
5	by	O
6	approximately	O
7	18	O
8	%	O
9	by	O
10	ERT	O
11	and	O
12	HRT	O
13	,	O
14	but	O
15	FVR	O
16	responses	O
17	to	O
18	noradrenaline	O
19	,	O
20	angiotensin	B
21	II	I
22	,	O
23	acetylcholine	O
24	and	O
25	nitroprusside	O
26	were	O
27	unaffected	O
28	.	O

1	Three	O
2	FGF	B
3	-	I
4	AS	I
5	cDNAs	I
6	were	O
7	isolated	O
8	;	O
9	the	O
10	full	B
11	-	I
12	length	I
13	FGF	I
14	-	I
15	AS	I
16	mRNA	I
17	and	O
18	two	O
19	alternative	O
20	splice	O
21	variants	O
22	lacking	O
23	exon	O
24	2	O
25	or	O
26	exons	O
27	2	O
28	and	O
29	3	O
30	of	O
31	the	O
32	FGF	B
33	-	I
34	AS	I
35	sequence	I
36	.	O

1	Taken	O
2	together	O
3	,	O
4	these	O
5	results	O
6	indicate	O
7	that	O
8	MAP	B
9	kinase	I
10	stimulates	O
11	the	O
12	hPL	B
13	-	I
14	B	I
15	enhancer	I
16	by	O
17	an	O
18	NF	B
19	-	I
20	IL	I
21	-	I
22	6	I
23	-	O
24	dependent	O
25	pathway	O
26	.	O

1	Characterization	O
2	of	O
3	polymorphic	O
4	TNRs	O
5	in	O
6	novel	O
7	and	O
8	even	O
9	known	O
10	genes	O
11	expressed	O
12	in	O
13	human	O
14	spinal	O
15	cord	O
16	is	O
17	likely	O
18	to	O
19	help	O
20	in	O
21	the	O
22	identification	O
23	of	O
24	new	O
25	candidates	O
26	for	O
27	genes	O
28	involved	O
29	in	O
30	neurodegenerative	O
31	disorders	O
32	.	O

1	Finally	O
2	,	O
3	in	O
4	situ	O
5	RNA	O
6	hybridization	O
7	studies	O
8	revealed	O
9	a	O
10	very	O
11	specific	O
12	pattern	O
13	of	O
14	EphA8	B
15	gene	I
16	expression	O
17	restricted	O
18	to	O
19	the	O
20	rostral	O
21	region	O
22	of	O
23	midbrain	O
24	tectum	O
25	during	O
26	embryonic	O
27	development	O
28	.	O

1	Transfection	O
2	of	O
3	cDNAs	O
4	for	O
5	three	O
6	mutant	O
7	enzymes	O
8	into	O
9	FPGS	B
10	-	O
11	null	O
12	Chinese	O
13	hamster	O
14	ovary	O
15	cells	O
16	restored	O
17	a	O
18	reduced	O
19	level	O
20	of	O
21	clonal	O
22	growth	O
23	,	O
24	whereas	O
25	a	O
26	T339I	O
27	mutant	O
28	supported	O
29	growth	O
30	at	O
31	a	O
32	level	O
33	comparable	O
34	to	O
35	that	O
36	of	O
37	the	O
38	wild	O
39	-	O
40	type	O
41	enzyme	O
42	.	O

1	SETTING	O
2	:	O
3	University	O
4	of	O
5	Paris	O
6	VII	O
7	hospital	O
8	.	O
9	Patient	O
10	(	O
11	s	O
12	):	O
13	Nine	O
14	women	O
15	had	O
16	embolization	O
17	for	O
18	symptomatic	O
19	myoma	O
20	,	O
21	with	O
22	12	O
23	pregnancies	O
24	observed	O
25	.	O

1	Improving	O
2	fissure	O
3	sealant	O
4	quality	O
5	:	O
6	mechanical	O
7	preparation	O
8	and	O
9	filling	O
10	level	O
11	.	O

1	The	O
2	Menopause	O
3	-	O
4	Rating	O
5	-	O
6	Scale	O
7	(	O
8	MRS	O
9	I	O
10	)	O
11	was	O
12	used	O
13	in	O
14	clinical	O
15	practice	O
16	since	O
17	1992	O
18	.	O

1	The	O
2	MRS	O
3	II	O
4	meets	O
5	a	O
6	high	O
7	methodological	O
8	standard	O
9	as	O
10	an	O
11	instrument	O
12	standardized	O
13	in	O
14	the	O
15	population	O
16	.	O

1	The	O
2	protein	O
3	encoded	O
4	by	O
5	the	O
6	fruA	B
7	transcript	I
8	is	O
9	well	O
10	conserved	O
11	with	O
12	the	O
13	D	B
14	.	I
15	melanogaster	I
16	type	I
17	A	I
18	protein	I
19	,	O
20	particularly	O
21	the	O
22	BTB	B
23	protein	I
24	-	O
25	protein	O
26	-	O
27	binding	O
28	domain	O
29	,	O
30	which	O
31	is	O
32	encoded	O
33	by	O
34	exons	O
35	I	O
36	and	O
37	II	O
38	and	O
39	is	O
40	100	O
41	%	O
42	conserved	O
43	.	O

1	In	O
2	addition	O
3	,	O
4	the	O
5	mouse	O
6	ortholog	O
7	(	O
8	Mharp	B
9	/	O
10	Smarcal1	B
11	)	O
12	was	O
13	cloned	O
14	,	O
15	and	O
16	the	O
17	Caenorhabditis	O
18	elegans	O
19	ortholog	O
20	(	O
21	CEHARP	B
22	)	O
23	was	O
24	identified	O
25	in	O
26	the	O
27	GenBank	O
28	database	O
29	.	O

1	Sparfloxacin	O
2	and	O
3	clinafloxacin	O
4	were	O
5	evaluated	O
6	against	O
7	Enterococcus	O
8	faecium	O
9	SF2149	O
10	and	O
11	Enterococcus	O
12	faecalis	O
13	WH245	O
14	,	O
15	respectively	O
16	.	O

1	ECP	B
2	and	O
3	tryptase	B
4	levels	O
5	in	O
6	serum	O
7	were	O
8	measured	O
9	before	O
10	and	O
11	after	O
12	the	O
13	last	O
14	oral	O
15	challenge	O
16	.	O

1	Tolterodine	O
2	users	O
3	were	O
4	7	O
5	.	O
6	5	O
7	times	O
8	more	O
9	likely	O
10	to	O
11	have	O
12	received	O
13	another	O
14	spasmolytic	O
15	drug	O
16	(	O
17	RR	O
18	7	O
19	.	O
20	5	O
21	,	O
22	95	O
23	%	O
24	CI	O
25	4	O
26	.	O
27	8	O
28	to	O
29	11	O
30	.	O
31	9	O
32	).	O

1	For	O
2	an	O
3	unsupervised	O
4	program	O
5	,	O
6	the	O
7	costs	O
8	were	O
9	estimated	O
10	at	O
11	$	O
12	311	O
13	for	O
14	the	O
15	first	O
16	year	O
17	and	O
18	$	O
19	73	O
20	for	O
21	all	O
22	additional	O
23	years	O
24	.	O

1	The	O
2	presence	O
3	of	O
4	such	O
5	a	O
6	putative	O
7	RNA	O
8	-	O
9	binding	O
10	domain	O
11	suggests	O
12	a	O
13	mechanism	O
14	for	O
15	the	O
16	observed	O
17	autoregulation	O
18	of	O
19	bacteriophage	O
20	T4	B
21	DNA	I
22	polymerase	I
23	synthesis	O
24	by	O
25	binding	O
26	to	O
27	its	O
28	own	O
29	mRNA	O
30	.	O

1	Deletion	O
2	and	O
3	mutational	O
4	analyses	O
5	revealed	O
6	two	O
7	positive	O
8	cis	O
9	-	O
10	regulatory	O
11	elements	O
12	in	O
13	this	O
14	region	O
15	that	O
16	are	O
17	essential	O
18	for	O
19	CSX1	B
20	expression	O
21	in	O
22	cardiomyocytes	O
23	.	O

1	Functional	O
2	studies	O
3	which	O
4	introduced	O
5	a	O
6	mutation	O
7	in	O
8	the	O
9	AP2	B
10	core	I
11	binding	I
12	region	I
13	as	O
14	well	O
15	as	O
16	cotransfection	O
17	experiments	O
18	using	O
19	an	O
20	AP2	B
21	expression	O
22	vector	O
23	revealed	O
24	that	O
25	AP2	B
26	exerts	O
27	a	O
28	repressive	O
29	role	O
30	on	O
31	the	O
32	HGF	B
33	gene	I
34	promoter	I
35	activity	O
36	.	O

1	Using	O
2	adenoviral	O
3	transfer	O
4	of	O
5	IkappaBalpha	B
6	(	O
7	IkappaBalpha	B
8	overexpression	O
9	),	O
10	the	O
11	production	O
12	of	O
13	TNF	B
14	-	I
15	alpha	I
16	induced	O
17	by	O
18	whole	O
19	GBS	O
20	was	O
21	inhibited	O
22	by	O
23	only	O
24	20	O
25	%.	O

1	In	O
2	reconstitution	O
3	experiments	O
4	,	O
5	we	O
6	first	O
7	showed	O
8	that	O
9	expression	O
10	in	O
11	the	O
12	RAW	O
13	264	O
14	.	O
15	7	O
16	cell	O
17	line	O
18	of	O
19	C	B
20	-	I
21	terminal	I
22	Src	I
23	kinase	I
24	(	O
25	Csk	B
26	)	O
27	inhibited	O
28	and	O
29	that	O
30	of	O
31	a	O
32	membrane	O
33	-	O
34	anchored	O
35	,	O
36	gain	O
37	-	O
38	of	O
39	-	O
40	function	O
41	Csk	B
42	abolished	O
43	the	O
44	Fc	B
45	gamma	I
46	R	I
47	-	O
48	mediated	O
49	signaling	O
50	that	O
51	leads	O
52	to	O
53	phagocytosis	O
54	in	O
55	a	O
56	kinase	O
57	-	O
58	dependent	O
59	manner	O
60	.	O

1	In	O
2	contrast	O
3	,	O
4	c	B
5	-	I
6	Src	I
7	-	I
8	derived	I
9	construct	I
10	(	O
11	a	B
12	-	I
13	Src	I
14	),	O
15	that	O
16	was	O
17	excluded	O
18	from	O
19	detergent	O
20	-	O
21	resistant	O
22	membranes	O
23	,	O
24	could	O
25	not	O
26	restore	O
27	the	O
28	series	O
29	of	O
30	phagocytosis	O
31	signaling	O
32	.	O

1	The	O
2	delta	B
3	srb10	I
4	mutation	I
5	also	O
6	influenced	O
7	on	O
8	the	O
9	transcript	O
10	levels	O
11	of	O
12	meiosis	O
13	-	O
14	inducing	O
15	genes	O
16	called	O
17	IME1	B
18	and	O
19	IME2	B
20	:	O
21	the	O
22	mutation	O
23	elevated	O
24	the	O
25	transcript	O
26	level	O
27	of	O
28	IME1	B
29	but	O
30	reduced	O
31	that	O
32	of	O
33	IME2	B
34	,	O
35	resulting	O
36	in	O
37	partial	O
38	defects	O
39	in	O
40	premeiotic	O
41	DNA	O
42	synthesis	O
43	and	O
44	meiosis	O
45	.	O

1	We	O
2	also	O
3	found	O
4	that	O
5	environmental	O
6	conditions	O
7	for	O
8	meiosis	O
9	finely	O
10	regulate	O
11	the	O
12	transcript	O
13	levels	O
14	of	O
15	KIN28	B
16	and	O
17	CCL1	B
18	,	O
19	such	O
20	that	O
21	nitrogen	O
22	starvation	O
23	first	O
24	elevates	O
25	them	O
26	but	O
27	subsequent	O
28	alkalization	O
29	of	O
30	medium	O
31	decreases	O
32	them	O
33	.	O

1	The	O
2	pJR	O
3	vectors	O
4	differ	O
5	among	O
6	them	O
7	in	O
8	:	O
9	(	O
10	a	O
11	)	O
12	the	O
13	selectable	O
14	marker	O
15	(	O
16	Saccharomyces	O
17	cerevisiae	O
18	LEU	B
19	2	I
20	gene	I
21	,	O
22	which	O
23	complements	O
24	S	B
25	.	I
26	pombe	I
27	leu1	I
28	-	I
29	gene	I
30	and	O
31	S	O
32	.	O
33	pombe	O
34	ura4	B
35	+	I
36	and	O
37	his3	B
38	+	I
39	genes	I
40	);	O
41	(	O
42	b	O
43	)	O
44	the	O
45	thiamine	O
46	-	O
47	repressible	O
48	nmt1	B
49	promoter	I
50	(	O
51	3X	O
52	,	O
53	41X	O
54	and	O
55	81X	O
56	with	O
57	extremely	O
58	high	O
59	,	O
60	moderate	O
61	or	O
62	low	O
63	transcription	O
64	efficiency	O
65	,	O
66	respectively	O
67	);	O
68	and	O
69	(	O
70	c	O
71	)	O
72	the	O
73	multiple	O
74	cloning	O
75	site	O
76	(	O
77	two	O
78	multiple	O
79	cloning	O
80	sites	O
81	,	O
82	with	O
83	12	O
84	restriction	O
85	sites	O
86	each	O
87	).	O

1	(	O
2	GUT	O
3	)	O
4	Sera	O
5	of	O
6	30	O
7	montoux	O
8	negative	O
9	healthy	O
10	adults	O
11	(	O
12	age	O
13	/	O
14	sex	O
15	matched	O
16	)	O
17	were	O
18	taken	O
19	as	O
20	control	O
21	by	O
22	detecting	O
23	IgG	B
24	anti	I
25	bodies	I
26	to	O
27	A60	B
28	antigen	I
29	.	O

1	The	O
2	effect	O
3	of	O
4	acute	O
5	,	O
6	mid	O
7	-	O
8	cervical	O
9	spinal	O
10	cord	O
11	lesions	O
12	on	O
13	neuronal	O
14	and	O
15	reflex	O
16	activity	O
17	evoked	O
18	by	O
19	the	O
20	noxious	O
21	visceral	O
22	stimulus	O
23	,	O
24	colorectal	O
25	distension	O
26	(	O
27	CRD	O
28	;	O
29	80	O
30	mmHg	O
31	,	O
32	20	O
33	s	O
34	),	O
35	was	O
36	determined	O
37	in	O
38	halothane	O
39	-	O
40	anesthetized	O
41	rats	O
42	.	O

1	Franz	O
2	Schubert	O
3	--	O
4	his	O
5	life	O
6	,	O
7	music	O
8	and	O
9	diseases	O

1	The	O
2	results	O
3	suggest	O
4	that	O
5	the	O
6	role	O
7	of	O
8	S	O
9	.	O
10	argyrostoma	O
11	in	O
12	the	O
13	dissemination	O
14	of	O
15	Trichinella	O
16	larvae	O
17	in	O
18	nature	O
19	is	O
20	limited	O
21	in	O
22	comparison	O
23	to	O
24	the	O
25	role	O
26	played	O
27	by	O
28	mammals	O
29	with	O
30	scavenger	O
31	and	O
32	cannibalistic	O
33	behavior	O
34	.	O

1	The	O
2	equilibrium	O
3	dissociation	O
4	binding	O
5	constant	O
6	for	O
7	the	O
8	interaction	O
9	of	O
10	TnrA	B
11	with	O
12	the	O
13	nrgAB	B
14	promoter	I
15	fragment	I
16	was	O
17	7	O
18	.	O
19	7	O
20	nM	O
21	under	O
22	the	O
23	conditions	O
24	used	O
25	here	O
26	.	O

1	These	O
2	results	O
3	demonstrate	O
4	that	O
5	N	O
6	-	O
7	glycans	O
8	flanking	O
9	the	O
10	receptor	O
11	-	O
12	binding	O
13	site	O
14	of	O
15	the	O
16	HA	B
17	molecule	I
18	are	O
19	potent	O
20	regulators	O
21	of	O
22	influenza	O
23	virus	O
24	growth	O
25	,	O
26	with	O
27	the	O
28	glycan	O
29	at	O
30	Asn149	O
31	being	O
32	dominant	O
33	and	O
34	that	O
35	at	O
36	Asn123	O
37	being	O
38	less	O
39	effective	O
40	.	O

1	RESULTS	O
2	:	O
3	The	O
4	introduction	O
5	of	O
6	the	O
7	PAIP	O
8	resulted	O
9	in	O
10	a	O
11	significant	O
12	(	O
13	p	O
14	<	O
15	0	O
16	.	O
17	001	O
18	)	O
19	reduction	O
20	in	O
21	contaminating	O
22	WBCs	O
23	(	O
24	median	O
25	,	O
26	30	O
27	,	O
28	000	O
29	)	O
30	from	O
31	the	O
32	numbers	O
33	seen	O
34	with	O
35	FIP	O
36	(	O
37	median	O
38	,	O
39	2	O
40	,	O
41	300	O
42	,	O
43	000	O
44	)	O
45	while	O
46	maintaining	O
47	the	O
48	separation	O
49	efficacy	O
50	(	O
51	47	O
52	%)	O
53	and	O
54	separation	O
55	time	O
56	.	O

1	All	O
2	were	O
3	tested	O
4	for	O
5	serum	O
6	ferritin	B
7	(	O
8	SF	B
9	),	O
10	hemoglobin	B
11	(	O
12	Hb	B
13	)	O
14	level	O
15	and	O
16	asked	O
17	for	O
18	detailed	O
19	histories	O
20	of	O
21	donations	O
22	and	O
23	iron	O
24	supplementation	O
25	.	O

1	Vascular	B
2	endothelial	I
3	growth	I
4	factor	I
5	(	O
6	VEGF	B
7	),	O
8	a	O
9	potent	O
10	agonist	O
11	secreted	O
12	by	O
13	virtually	O
14	all	O
15	cells	O
16	,	O
17	controls	O
18	migration	O
19	and	O
20	division	O
21	of	O
22	vascular	O
23	endothelial	O
24	cells	O
25	.	O

1	The	O
2	antioxidant	O
3	agent	O
4	pyrrolidine	O
5	dithiocarbamate	O
6	(	O
7	PDTC	O
8	)	O
9	has	O
10	been	O
11	shown	O
12	to	O
13	protect	O
14	endothelial	O
15	cells	O
16	(	O
17	EC	O
18	)	O
19	from	O
20	pro	O
21	-	O
22	inflammatory	O
23	-	O
24	induced	O
25	and	O
26	pro	O
27	-	O
28	oxidant	O
29	-	O
30	induced	O
31	NF	B
32	-	I
33	kappaB	I
34	activation	O
35	.	O

1	We	O
2	further	O
3	studied	O
4	the	O
5	effects	O
6	of	O
7	SIE	B
8	-	I
9	1	I
10	hypermethylation	O
11	on	O
12	p21WAF1	B
13	induction	O
14	by	O
15	STAT	B
16	activation	O
17	.	O

1	Phd	B
2	antibody	O
3	-	O
4	immunoreactive	O
5	peptides	O
6	are	O
7	seen	O
8	in	O
9	light	O
10	-	O
11	adapted	O
12	mouse	O
13	retinal	O
14	cytosolic	O
15	and	O
16	nuclear	O
17	extracts	O
18	.	O

1	In	O
2	the	O
3	pRb	B
4	(-)	I
5	SAOS	O
6	-	O
7	2	O
8	cell	O
9	line	O
10	transiently	O
11	transfected	O
12	with	O
13	a	O
14	reporter	O
15	plasmid	O
16	containing	O
17	six	O
18	tal	B
19	-	I
20	1	I
21	binding	I
22	site	I
23	,	O
24	pRb	B
25	enhances	O
26	the	O
27	transcriptional	O
28	activity	O
29	of	O
30	tal	B
31	-	I
32	1	I
33	-	O
34	E12	B
35	-	O
36	Lmo2	B
37	and	O
38	tal	B
39	-	I
40	1	I
41	-	O
42	E12	B
43	-	O
44	Lmo2	B
45	-	O
46	Ldb1	B
47	complexes	O
48	but	O
49	not	O
50	that	O
51	of	O
52	a	O
53	tal	B
54	-	I
55	1	I
56	-	O
57	E12	B
58	heterodimer	O
59	.	O

1	This	O
2	effect	O
3	was	O
4	not	O
5	seen	O
6	in	O
7	conjunction	O
8	with	O
9	oxycodone	O
10	,	O
11	a	O
12	morphine	B
13	-	I
14	like	I
15	mu	I
16	-	I
17	receptor	I
18	agonist	O
19	.	O

1	In	O
2	contrast	O
3	to	O
4	the	O
5	morphological	O
6	criteria	O
7	,	O
8	the	O
9	few	O
10	data	O
11	available	O
12	from	O
13	recent	O
14	studies	O
15	at	O
16	the	O
17	genetic	O
18	level	O
19	have	O
20	suggested	O
21	that	O
22	EPVs	O
23	infecting	O
24	different	O
25	insect	O
26	orders	O
27	are	O
28	phylogenetically	O
29	distant	O
30	.	O

1	Neurofibromatosis	O
2	of	O
3	the	O
4	breast	O
5	in	O
6	a	O
7	patient	O
8	with	O
9	Morbus	O
10	von	O
11	Recklinghausen	O

1	In	O
2	the	O
3	premating	O
4	period	O
5	male	O
6	rate	O
7	of	O
8	aggression	O
9	was	O
10	not	O
11	significantly	O
12	correlated	O
13	with	O
14	testosterone	O
15	level	O
16	.	O

1	These	O
2	results	O
3	support	O
4	the	O
5	hypothesis	O
6	that	O
7	in	O
8	the	O
9	presence	O
10	of	O
11	tryptophan	O
12	the	O
13	ribosome	O
14	translating	O
15	tnaC	B
16	blocks	O
17	Rho	B
18	'	O
19	s	O
20	access	O
21	to	O
22	the	O
23	boxA	B
24	and	O
25	rut	B
26	sites	I
27	,	O
28	thereby	O
29	preventing	O
30	transcription	O
31	termination	O
32	.	O

1	In	O
2	situ	O
3	hybridization	O
4	with	O
5	the	O
6	antisense	O
7	RNA	O
8	probes	O
9	further	O
10	supported	O
11	the	O
12	expression	O
13	changes	O
14	of	O
15	these	O
16	six	O
17	clones	O
18	and	O
19	localized	O
20	the	O
21	changes	O
22	in	O
23	multiple	O
24	germ	O
25	cell	O
26	stages	O
27	as	O
28	well	O
29	as	O
30	other	O
31	cell	O
32	types	O
33	(	O
34	Sertoli	O
35	,	O
36	interstitial	O
37	and	O
38	peritubular	O
39	cells	O
40	).	O

1	The	O
2	administration	O
3	of	O
4	the	O
5	GnRH	B
6	agonist	O
7	reduced	O
8	the	O
9	bone	O
10	mineral	O
11	density	O
12	in	O
13	the	O
14	whole	O
15	femur	O
16	to	O
17	91	O
18	.	O
19	0	O
20	%	O
21	of	O
22	that	O
23	in	O
24	the	O
25	control	O
26	group	O
27	.	O

1	Prevention	O
2	,	O
3	differential	O
4	diagnosis	O
5	and	O
6	therapy	O
7	of	O
8	travel	O
9	diarrhea	O

1	This	O
2	study	O
3	shows	O
4	that	O
5	C	B
6	/	I
7	EBPbeta	I
8	is	O
9	the	O
10	predominant	O
11	C	B
12	/	I
13	EBP	I
14	isoform	I
15	found	O
16	in	O
17	activated	O
18	stellate	O
19	cells	O
20	and	O
21	that	O
22	increased	O
23	C	B
24	/	I
25	EBPbeta	I
26	protein	I
27	and	O
28	C	B
29	/	I
30	EBPbeta	I
31	binding	O
32	to	O
33	a	O
34	proximal	O
35	C	B
36	/	I
37	EBP	I
38	binding	I
39	site	I
40	in	O
41	the	O
42	promoter	O
43	mediates	O
44	the	O
45	activating	O
46	effect	O
47	of	O
48	acetaldehyde	O
49	.	O

1	Mutation	O
2	analysis	O
3	demonstrates	O
4	that	O
5	the	O
6	motif	O
7	TCCCCT	O
8	is	O
9	critical	O
10	for	O
11	PyRo1	B
12	interaction	O
13	.	O

1	As	O
2	with	O
3	VP16	B
4	,	O
5	the	O
6	transactivation	O
7	function	O
8	of	O
9	Luman	B
10	is	O
11	also	O
12	regulated	O
13	by	O
14	HCF	B
15	.	O

1	After	O
2	two	O
3	successive	O
4	rounds	O
5	of	O
6	selection	O
7	by	O
8	focus	O
9	formation	O
10	assay	O
11	,	O
12	a	O
13	transforming	O
14	ribozyme	O
15	(	O
16	Rz007	B
17	)	O
18	was	O
19	identified	O
20	.	O

1	G	O
2	.,	O
3	and	O
4	Hyde	O
5	,	O
6	C	O
7	.	O

1	Our	O
2	results	O
3	suggest	O
4	that	O
5	proteasome	O
6	inhibition	O
7	leads	O
8	to	O
9	upregulation	O
10	of	O
11	specific	O
12	members	O
13	of	O
14	transcription	O
15	factor	O
16	families	O
17	controlling	O
18	cellular	O
19	stress	O
20	response	O
21	and	O
22	proliferation	O
23	.	O

1	The	O
2	ATR	O
3	-	O
4	X	O
5	syndrome	O
6	results	O
7	from	O
8	mutations	O
9	of	O
10	the	O
11	XH2	B
12	gene	I
13	,	O
14	located	O
15	on	O
16	the	O
17	X	O
18	chromosome	O
19	(	O
20	Xq13	O
21	.	O
22	3	O
23	)	O
24	and	O
25	coding	O
26	for	O
27	a	O
28	transacting	O
29	factor	O
30	which	O
31	regulates	O
32	gene	O
33	expression	O
34	.	O

1	AIMS	O
2	:	O
3	To	O
4	evaluate	O
5	the	O
6	role	O
7	of	O
8	environmental	O
9	intra	O
10	-	O
11	uterine	O
12	factors	O
13	in	O
14	determining	O
15	the	O
16	birthweights	O
17	of	O
18	twins	O
19	with	O
20	increased	O
21	susceptibility	O
22	to	O
23	diabetes	O
24	and	O
25	discordant	O
26	for	O
27	abnormal	O
28	responses	O
29	to	O
30	the	O
31	oral	O
32	glucose	O
33	tolerance	O
34	test	O
35	(	O
36	OGTT	O
37	)	O
38	and	O
39	verify	O
40	the	O
41	possible	O
42	association	O
43	of	O
44	within	O
45	-	O
46	pair	O
47	birthweight	O
48	differences	O
49	and	O
50	metabolic	O
51	abnormalities	O
52	in	O
53	adult	O
54	life	O
55	.	O

1	In	O
2	NASCIS	O
3	III	O
4	,	O
5	a	O
6	randomization	O
7	imbalance	O
8	occurred	O
9	that	O
10	allocated	O
11	a	O
12	disproportionate	O
13	number	O
14	of	O
15	patients	O
16	with	O
17	no	O
18	motor	O
19	deficit	O
20	(	O
21	and	O
22	therefore	O
23	no	O
24	chance	O
25	for	O
26	recovery	O
27	)	O
28	to	O
29	the	O
30	lower	O
31	dose	O
32	control	O
33	group	O
34	.	O

1	Penicillin	B
2	acylase	I
3	(	O
4	PA	B
5	)	O
6	from	O
7	Escherichia	O
8	coli	O
9	ATCC11105	O
10	is	O
11	a	O
12	periplasmic	O
13	heterodimer	O
14	consisting	O
15	of	O
16	a	O
17	24	O
18	kDa	O
19	small	O
20	subunit	O
21	and	O
22	a	O
23	65	O
24	kDa	O
25	large	O
26	subunit	O
27	.	O

1	A	O
2	murine	O
3	expressed	O
4	sequence	O
5	tag	O
6	(	O
7	EST	O
8	)	O
9	showing	O
10	homology	O
11	with	O
12	erythropoietin	B
13	receptor	I
14	(	O
15	EPOR	B
16	)	O
17	was	O
18	identified	O
19	in	O
20	the	O
21	EST	O
22	database	O
23	.	O

1	When	O
2	the	O
3	LCx	O
4	was	O
5	partially	O
6	occluded	O
7	,	O
8	mild	O
9	PM	O
10	-	O
11	induced	O
12	tachycardia	O
13	resulted	O
14	in	O
15	decreased	O
16	AoP	O
17	(	O
18	P	O
19	=	O
20	0	O
21	.	O
22	045	O
23	)	O
24	as	O
25	well	O
26	as	O
27	in	O
28	decreased	O
29	SV	O
30	(	O
31	P	O
32	=	O
33	0	O
34	.	O
35	048	O
36	);	O
37	the	O
38	LVEDP	O
39	remained	O
40	high	O
41	(	O
42	P	O
43	=	O
44	0	O
45	.	O
46	002	O
47	).	O

1	Activation	O
2	of	O
3	nuclear	B
4	factor	I
5	(	I
6	NF	I
7	)-	I
8	kappaB	I
9	and	O
10	subsequent	O
11	proinflammatory	O
12	gene	O
13	expression	O
14	in	O
15	human	O
16	airway	O
17	epithelial	O
18	cells	O
19	can	O
20	be	O
21	evoked	O
22	by	O
23	oxidative	O
24	stress	O
25	.	O

1	GAP	O
2	JUNCTIONS	O
3	IN	O
4	THE	O
5	BRAIN	O
6	:	O
7	PREFACE	O
8	.	O

1	We	O
2	have	O
3	isolated	O
4	and	O
5	functionally	O
6	characterized	O
7	the	O
8	mouse	O
9	gene	O
10	for	O
11	the	O
12	C2	O
13	subunit	O
14	of	O
15	the	O
16	20S	B
17	proteasome	I
18	.	O

1	Furthermore	O
2	,	O
3	as	O
4	in	O
5	the	O
6	human	O
7	gene	O
8	,	O
9	the	O
10	3	O
11	'	O
12	end	O
13	of	O
14	the	O
15	Cacna1f	B
16	gene	I
17	maps	O
18	within	O
19	5	O
20	kb	O
21	of	O
22	the	O
23	5	O
24	'	O
25	end	O
26	of	O
27	the	O
28	mouse	B
29	synaptophysin	I
30	gene	I
31	in	O
32	a	O
33	region	O
34	orthologous	O
35	to	O
36	Xp11	O
37	.	O
38	23	O
39	.	O

1	With	O
2	the	O
3	human	B
4	Rhotekin	I
5	cDNA	I
6	as	O
7	a	O
8	probe	O
9	,	O
10	Northern	O
11	hybridization	O
12	revealed	O
13	that	O
14	a	O
15	4	O
16	.	O
17	0	O
18	-	O
19	kb	O
20	transcript	O
21	was	O
22	expressed	O
23	at	O
24	a	O
25	high	O
26	level	O
27	in	O
28	prostate	O
29	and	O
30	at	O
31	a	O
32	middle	O
33	level	O
34	in	O
35	13	O
36	of	O
37	16	O
38	tissues	O
39	examined	O
40	,	O
41	but	O
42	it	O
43	cannot	O
44	be	O
45	detected	O
46	in	O
47	liver	O
48	and	O
49	lung	O
50	tissues	O
51	.	O

1	Similarly	O
2	,	O
3	co	O
4	-	O
5	expression	O
6	of	O
7	a	O
8	dominant	O
9	-	O
10	negative	O
11	mutant	O
12	of	O
13	p38alpha	B
14	,	O
15	but	O
16	not	O
17	of	O
18	ERK1	B
19	,	O
20	ERK2	B
21	,	O
22	JNK1	B
23	,	O
24	or	O
25	JNK2	B
26	,	O
27	reduces	O
28	basal	O
29	and	O
30	cadmium	O
31	-	O
32	induced	O
33	pE1	B
34	-	I
35	luc	I
36	activity	O
37	.	O

1	BACKGROUND	O
2	:	O
3	Gamma	O
4	knife	O
5	radiosurgery	O
6	(	O
7	GKR	O
8	)	O
9	is	O
10	a	O
11	safe	O
12	and	O
13	effective	O
14	alternative	O
15	to	O
16	surgery	O
17	for	O
18	intracranial	O
19	lesions	O
20	.	O

1	In	O
2	hemodialyzed	O
3	patients	O
4	(	O
5	Epo	B
6	and	O
7	Non	O
8	-	O
9	Epo	B
10	group	O
11	)	O
12	leptin	B
13	levels	O
14	were	O
15	significantly	O
16	higher	O
17	when	O
18	compared	O
19	to	O
20	CAPD	O
21	patients	O
22	(	O
23	Epo	B
24	and	O
25	Non	O
26	-	O
27	Epo	B
28	group	O
29	,	O
30	respectively	O
31	).	O

1	It	O
2	is	O
3	mainly	O
4	transcribed	O
5	in	O
6	neural	O
7	structures	O
8	and	O
9	in	O
10	developing	O
11	organs	O
12	characterized	O
13	by	O
14	epithelial	O
15	-	O
16	mesenchymal	O
17	interactions	O
18	.	O

1	CONCLUSION	O
2	:	O
3	The	O
4	alpha2	O
5	-	O
6	adrenergic	O
7	antagonist	O
8	idazoxan	O
9	increases	O
10	glucose	O
11	-	O
12	induced	O
13	sympathetic	O
14	activity	O
15	but	O
16	not	O
17	energy	O
18	expenditure	O
19	in	O
20	obese	O
21	subjects	O
22	.	O

1	ID	O
2	-	O
3	PaGIA	O
4	diphtheria	B
5	toxin	I
6	polymer	O
7	particle	O
8	diagnostic	O
9	agent	O
10	manufactured	O
11	by	O
12	DiaMed	O
13	AG	O
14	,	O
15	Switzerland	O
16	,	O
17	was	O
18	tried	O
19	at	O
20	bacteriological	O
21	laboratory	O
22	of	O
23	Institute	O
24	of	O
25	Childhood	O
26	Infections	O
27	in	O
28	St	O
29	.	O

1	Next	O
2	,	O
3	we	O
4	show	O
5	that	O
6	two	O
7	EMS	O
8	-	O
9	induced	O
10	mutations	O
11	,	O
12	previously	O
13	shown	O
14	to	O
15	interact	O
16	genetically	O
17	with	O
18	zipper	O
19	(	O
20	Ebr	B
21	),	O
22	disrupt	O
23	the	O
24	RhoA	B
25	locus	I
26	.	O

1	Therefore	O
2	,	O
3	the	O
4	results	O
5	indicate	O
6	that	O
7	repeated	O
8	exposure	O
9	to	O
10	amphetamine	O
11	or	O
12	apomorphine	O
13	overcomes	O
14	the	O
15	context	O
16	-	O
17	dependent	O
18	component	O
19	of	O
20	sensitization	O
21	of	O
22	amphetamine	O
23	-	O
24	or	O
25	apomorphine	O
26	-	O
27	induced	O
28	stereotyped	O
29	behavior	O
30	.	O

1	Testing	O
2	for	O
3	serum	B
4	IgM	I
5	binding	O
6	to	O
7	GM1	O
8	ganglioside	O
9	in	O
10	clinical	O
11	practice	O
12	.	O

1	Objective	O
2	responses	O
3	also	O
4	occurred	O
5	in	O
6	studies	O
7	that	O
8	explored	O
9	sequential	O
10	use	O
11	of	O
12	exemestane	O
13	after	O
14	failure	O
15	of	O
16	aminoglutethimide	O
17	(	O
18	26	O
19	%	O
20	with	O
21	exemestane	O
22	200	O
23	mg	O
24	/	O
25	day	O
26	)	O
27	or	O
28	other	O
29	nonsteroidal	O
30	aromatase	B
31	inhibitors	O
32	(	O
33	6	O
34	.	O
35	6	O
36	%	O
37	with	O
38	exemestane	O
39	25	O
40	mg	O
41	/	O
42	day	O
43	).	O

1	Topics	O
2	reviewed	O
3	here	O
4	include	O
5	:	O
6	data	O
7	supporting	O
8	the	O
9	association	O
10	of	O
11	myositis	O
12	with	O
13	cancer	O
14	and	O
15	the	O
16	appropriate	O
17	evaluations	O
18	for	O
19	malignancy	O
20	in	O
21	a	O
22	myositis	O
23	patient	O
24	;	O
25	an	O
26	approach	O
27	to	O
28	the	O
29	assessment	O
30	of	O
31	patients	O
32	with	O
33	dermatomyositis	O
34	sine	O
35	myositis	O
36	;	O
37	the	O
38	usefulness	O
39	of	O
40	the	O
41	clinicopathological	O
42	and	O
43	serological	O
44	classifications	O
45	;	O
46	a	O
47	discussion	O
48	of	O
49	whether	O
50	childhood	O
51	and	O
52	adult	O
53	myositis	O
54	are	O
55	the	O
56	same	O
57	or	O
58	different	O
59	entities	O
60	;	O
61	a	O
62	review	O
63	of	O
64	those	O
65	prognostic	O
66	factors	O
67	to	O
68	consider	O
69	in	O
70	the	O
71	clinical	O
72	management	O
73	of	O
74	myositis	O
75	patients	O
76	;	O
77	current	O
78	approaches	O
79	and	O
80	their	O
81	limitations	O
82	for	O
83	assessing	O
84	disease	O
85	activity	O
86	and	O
87	damage	O
88	.	O

1	The	O
2	science	O
3	of	O
4	tissue	O
5	engineering	O
6	.	O

1	Endonuclease	B
2	III	I
3	(	O
4	Nth	B
5	)	O
6	of	O
7	Escherichia	O
8	coli	O
9	is	O
10	a	O
11	DNA	B
12	glycosylase	I
13	essential	O
14	for	O
15	the	O
16	removal	O
17	of	O
18	oxidised	O
19	pyrimidine	O
20	base	O
21	residues	O
22	from	O
23	DNA	O
24	.	O

1	The	O
2	duration	O
3	of	O
4	reactive	O
5	hyperemia	O
6	decreased	O
7	with	O
8	aging	O
9	,	O
10	but	O
11	the	O
12	difference	O
13	between	O
14	males	O
15	and	O
16	females	O
17	was	O
18	not	O
19	significant	O
20	at	O
21	any	O
22	age	O
23	.	O

1	Acquired	O
2	bile	O
3	duct	O
4	blockage	O
5	:	O
6	entry	O
7	of	O
8	hepatobiliary	O
9	agent	O
10	into	O
11	an	O
12	intrahepatic	O
13	abscess	O
14	.	O

1	Furthermore	O
2	,	O
3	this	O
4	study	O
5	looks	O
6	at	O
7	the	O
8	impact	O
9	of	O
10	synthesis	O
11	conditions	O
12	on	O
13	block	O
14	length	O
15	and	O
16	crystallinity	O
17	,	O
18	and	O
19	the	O
20	impact	O
21	of	O
22	the	O
23	blocking	O
24	on	O
25	both	O
26	,	O
27	crystallinity	O
28	and	O
29	solubility	O
30	of	O
31	the	O
32	polymers	O
33	.	O

1	However	O
2	,	O
3	little	O
4	was	O
5	understood	O
6	about	O
7	the	O
8	normal	O
9	function	O
10	of	O
11	CREB	B
12	-	I
13	2	I
14	in	O
15	mammalian	O
16	development	O
17	or	O
18	organ	O
19	physiology	O
20	.	O

1	The	O
2	outer	O
3	diameter	O
4	and	O
5	the	O
6	thickness	O
7	of	O
8	the	O
9	rotor	O
10	are	O
11	60	O
12	mm	O
13	and	O
14	8	O
15	mm	O
16	,	O
17	respectively	O
18	.	O

1	Both	O
2	the	O
3	MVBF	O
4	and	O
5	the	O
6	maximum	O
7	EMG	O
8	activity	O
9	in	O
10	the	O
11	right	O
12	masseter	O
13	and	O
14	the	O
15	left	O
16	anterior	O
17	temporalis	O
18	muscles	O
19	were	O
20	significantly	O
21	decreased	O
22	during	O
23	muscle	O
24	pain	O
25	when	O
26	the	O
27	subjects	O
28	bit	O
29	on	O
30	the	O
31	painful	O
32	side	O
33	.	O

1	CONCLUSIONS	O
2	:	O
3	There	O
4	is	O
5	a	O
6	relation	O
7	in	O
8	the	O
9	topography	O
10	of	O
11	some	O
12	visual	O
13	field	O
14	areas	O
15	assessed	O
16	by	O
17	SWAP	O
18	and	O
19	the	O
20	inferotemporal	O
21	neuroretinal	O
22	rim	O
23	area	O
24	,	O
25	which	O
26	may	O
27	play	O
28	a	O
29	role	O
30	in	O
31	the	O
32	diagnosis	O
33	and	O
34	follow	O
35	-	O
36	up	O
37	of	O
38	suspected	O
39	glaucoma	O
40	.	O

1	The	O
2	total	O
3	alkaloids	O
4	contained	O
5	in	O
6	the	O
7	peel	O
8	of	O
9	Atzimba	O
10	,	O
11	Lopez	O
12	,	O
13	Marciana	O
14	,	O
15	Montsama	O
16	,	O
17	Murca	O
18	,	O
19	and	O
20	Puebla	O
21	was	O
22	lower	O
23	than	O
24	the	O
25	limits	O
26	recommended	O
27	for	O
28	food	O
29	safety	O
30	.	O

1	The	O
2	detection	O
3	success	O
4	rate	O
5	was	O
6	determined	O
7	for	O
8	different	O
9	markers	O
10	using	O
11	this	O
12	MEK	B
13	.	O

1	Herein	O
2	,	O
3	we	O
4	show	O
5	that	O
6	Smad3	B
7	physically	O
8	interacts	O
9	with	O
10	the	O
11	HMG	B
12	box	O
13	domain	O
14	of	O
15	LEF1	B
16	and	O
17	that	O
18	TGFbeta	B
19	and	O
20	Wnt	B
21	pathways	O
22	synergize	O
23	to	O
24	activate	O
25	transcription	O
26	of	O
27	the	O
28	Xenopus	O
29	homeobox	O
30	gene	O
31	twin	B
32	(	O
33	Xtwn	B
34	).	O

1	The	O
2	transmembrane	O
3	topology	O
4	of	O
5	Na	O
6	(+)/	O
7	H	O
8	(+)	O
9	exchanger	O
10	NHE3	B
11	has	O
12	been	O
13	studied	O
14	using	O
15	in	O
16	vitro	O
17	transcription	O
18	/	O
19	translation	O
20	of	O
21	two	O
22	types	O
23	of	O
24	fusion	O
25	vectors	O
26	designed	O
27	to	O
28	test	O
29	membrane	O
30	insertion	O
31	properties	O
32	of	O
33	cDNA	O
34	sequences	O
35	encoding	O
36	putative	O
37	NHE3	B
38	membrane	O
39	spanning	O
40	domains	O
41	(	O
42	msds	O
43	).	O

1	ACE	B
2	-	I
3	2	I
4	has	O
5	a	O
6	hydrophobic	O
7	C	O
8	terminus	O
9	of	O
10	H	O
11	type	O
12	.	O

1	Members	O
2	of	O
3	the	O
4	titin	B
5	/	O
6	myosin	B
7	light	I
8	chain	I
9	kinase	I
10	family	O
11	play	O
12	an	O
13	essential	O
14	role	O
15	in	O
16	the	O
17	organization	O
18	of	O
19	the	O
20	actin	B
21	/	O
22	myosin	B
23	cytoskeleton	O
24	,	O
25	especially	O
26	in	O
27	sarcomere	O
28	assembly	O
29	and	O
30	function	O
31	.	O

1	We	O
2	concluded	O
3	that	O
4	activation	O
5	of	O
6	c	B
7	-	I
8	fosER	I
9	mediated	O
10	transcriptional	O
11	inhibition	O
12	of	O
13	p21	B
14	(	O
15	Cip1	B
16	/	O
17	WAF1	B
18	)	O
19	through	O
20	a	O
21	previously	O
22	uncharacterized	O
23	AP	B
24	-	I
25	1	I
26	site	I
27	,	O
28	revealing	O
29	an	O
30	important	O
31	role	O
32	for	O
33	c	B
34	-	I
35	fos	I
36	in	O
37	negative	O
38	control	O
39	of	O
40	cell	O
41	cycle	O
42	regulatory	O
43	genes	O
44	.	O

1	Furthermore	O
2	,	O
3	a	O
4	pTyr317	B
5	Shc	I
6	phosphopeptide	I
7	selectively	O
8	recognized	O
9	Grb2	B
10	,	O
11	Sos1	B
12	,	O
13	SHIP	B
14	,	O
15	and	O
16	the	O
17	p85	B
18	subunit	I
19	of	O
20	phosphatidylinositol	B
21	3	I
22	'	I
23	kinase	I
24	from	O
25	mast	O
26	cells	O
27	,	O
28	as	O
29	characterized	O
30	by	O
31	mass	O
32	spectrometry	O
33	.	O

1	Although	O
2	increased	O
3	expression	O
4	of	O
5	the	O
6	HMG	B
7	-	I
8	I	I
9	/	I
10	Y	I
11	proteins	I
12	is	O
13	associated	O
14	with	O
15	cellular	O
16	proliferation	O
17	,	O
18	neoplastic	O
19	transformation	O
20	,	O
21	and	O
22	several	O
23	human	O
24	cancers	O
25	,	O
26	the	O
27	role	O
28	of	O
29	these	O
30	proteins	O
31	in	O
32	the	O
33	pathogenesis	O
34	of	O
35	malignancy	O
36	remains	O
37	unclear	O
38	.	O

1	The	O
2	naltrexone	O
3	/	O
4	lofexidine	O
5	combination	O
6	was	O
7	associated	O
8	with	O
9	a	O
10	more	O
11	rapid	O
12	resolution	O
13	of	O
14	the	O
15	opiate	O
16	withdrawal	O
17	syndrome	O
18	than	O
19	a	O
20	7	O
21	-	O
22	day	O
23	lofexidine	O
24	-	O
25	only	O
26	treatment	O
27	schedule	O
28	,	O
29	without	O
30	substantial	O
31	increases	O
32	in	O
33	withdrawal	O
34	symptoms	O
35	or	O
36	hypotensive	O
37	side	O
38	-	O
39	effects	O
40	.	O

1	The	O
2	first	O
3	symptoms	O
4	of	O
5	enzootic	O
6	calcinosis	O
7	were	O
8	noted	O
9	in	O
10	March	O
11	1998	O
12	,	O
13	when	O
14	some	O
15	of	O
16	the	O
17	cows	O
18	developed	O
19	locomotor	O
20	abnormalities	O
21	.	O

1	Screening	O
2	,	O
3	counseling	O
4	,	O
5	and	O
6	treatment	O
7	for	O
8	alcohol	O
9	and	O
10	illicit	O
11	drug	O
12	use	O
13	should	O
14	be	O
15	essential	O
16	components	O
17	in	O
18	comprehensive	O
19	HBP	O
20	care	O
21	.	O

1	Transcriptional	O
2	regulation	O
3	of	O
4	the	O
5	mouse	B
6	cytosolic	I
7	chaperonin	I
8	subunit	I
9	gene	I
10	Ccta	I
11	/	I
12	t	I
13	-	I
14	complex	I
15	polypeptide	I
16	1	I
17	by	O
18	selenocysteine	B
19	tRNA	I
20	gene	I
21	transcription	I
22	activating	I
23	factor	I
24	family	I
25	zinc	I
26	finger	I
27	proteins	I
28	.	O

1	The	O
2	unfolded	O
3	protein	O
4	response	O
5	regulates	O
6	multiple	O
7	aspects	O
8	of	O
9	secretory	O
10	and	O
11	membrane	O
12	protein	O
13	biogenesis	O
14	and	O
15	endoplasmic	O
16	reticulum	O
17	quality	O
18	control	O
19	.	O

1	PNRC	B
2	:	O
3	a	O
4	proline	O
5	-	O
6	rich	O
7	nuclear	O
8	receptor	O
9	coregulatory	O
10	protein	O
11	that	O
12	modulates	O
13	transcriptional	O
14	activation	O
15	of	O
16	multiple	O
17	nuclear	O
18	receptors	O
19	including	O
20	orphan	O
21	receptors	O
22	SF1	B
23	(	O
24	steroidogenic	B
25	factor	I
26	1	I
27	)	O
28	and	O
29	ERRalpha1	B
30	(	O
31	estrogen	B
32	related	I
33	receptor	I
34	alpha	I
35	-	I
36	1	I
37	).	O

1	Studies	O
2	using	O
3	a	O
4	reporter	O
5	plasmid	O
6	with	O
7	a	O
8	functionally	O
9	disrupted	O
10	sterol	O
11	-	O
12	responsive	O
13	element	O
14	(	O
15	SRE	O
16	)-	O
17	1	O
18	revealed	O
19	a	O
20	reduced	O
21	stimulatory	O
22	response	O
23	to	O
24	IL	B
25	-	I
26	6	I
27	.	O

1	However	O
2	,	O
3	there	O
4	is	O
5	still	O
6	a	O
7	subset	O
8	of	O
9	tumors	O
10	that	O
11	displayed	O
12	no	O
13	changes	O
14	in	O
15	these	O
16	genes	O
17	.	O

1	We	O
2	have	O
3	shown	O
4	that	O
5	the	O
6	epidural	O
7	(	O
8	EPI	O
9	)	O
10	delivery	O
11	of	O
12	morphine	O
13	encapsulated	O
14	in	O
15	multivesicular	O
16	liposomes	O
17	(	O
18	DepoFoam	O
19	drug	O
20	delivery	O
21	system	O
22	)	O
23	produces	O
24	a	O
25	sustained	O
26	clearance	O
27	of	O
28	morphine	O
29	and	O
30	a	O
31	prolonged	O
32	analgesia	O
33	.	O

1	Following	O
2	EPI	O
3	-	O
4	C0401	O
5	,	O
6	but	O
7	not	O
8	saline	O
9	or	O
10	DepoFoam	O
11	vehicle	O
12	,	O
13	there	O
14	were	O
15	transient	O
16	(<	O
17	72	O
18	hr	O
19	)	O
20	decreases	O
21	in	O
22	food	O
23	consumption	O
24	,	O
25	arousal	O
26	,	O
27	hindlimb	O
28	muscle	O
29	tone	O
30	,	O
31	and	O
32	body	O
33	temperature	O
34	.	O

1	Bailey	O
2	Instruments	O
3	and	O
4	Owen	O
5	Mumford	O
6	filaments	O
7	were	O
8	the	O
9	most	O
10	accurate	O
11	with	O
12	100	O
13	%	O
14	buckling	O
15	within	O
16	+/-	O
17	1	O
18	.	O
19	0	O
20	g	O
21	of	O
22	10	O
23	g	O
24	.	O

1	PARTICIPANTS	O
2	:	O
3	Convenience	O
4	sample	O
5	of	O
6	ambulatory	O
7	outpatients	O
8	with	O
9	hereditary	O
10	motor	O
11	and	O
12	sensory	O
13	neuropathy	O
14	,	O
15	type	O
16	I	O
17	(	O
18	n	O
19	=	O
20	9	O
21	),	O
22	myotonic	O
23	muscular	O
24	dystrophy	O
25	(	O
26	n	O
27	=	O
28	10	O
29	),	O
30	and	O
31	able	O
32	-	O
33	bodied	O
34	controls	O
35	(	O
36	n	O
37	=	O
38	11	O
39	).	O

1	The	O
2	effect	O
3	of	O
4	water	O
5	deprivation	O
6	for	O
7	19	O
8	h	O
9	on	O
10	renal	O
11	Na	O
12	excretion	O
13	of	O
14	conscious	O
15	adrenalectomized	O
16	(	O
17	ADX	O
18	)	O
19	sheep	O
20	maintained	O
21	on	O
22	a	O
23	constant	O
24	intravenous	O
25	infusion	O
26	of	O
27	aldosterone	O
28	and	O
29	cortisol	O
30	(	O
31	ADX	O
32	-	O
33	constant	O
34	steroid	O
35	sheep	O
36	)	O
37	was	O
38	investigated	O
39	.	O

1	Neither	O
2	is	O
3	it	O
4	a	O
5	major	O
6	cause	O
7	of	O
8	rehydration	O
9	-	O
10	induced	O
11	renal	O
12	Na	O
13	retention	O
14	.	O

1	CONCLUSION	O
2	:	O
3	Rheumatic	O
4	fever	O
5	in	O
6	the	O
7	Nazareth	O
8	area	O
9	is	O
10	still	O
11	manifest	O
12	.	O

1	Antithrombin	B
2	III	I
3	deficiency	O
4	:	O
5	when	O
6	substitute	O
7	,	O
8	when	O
9	heparin	O
10	?	O
11	Thrombosis	O
12	ABC	O
13	,	O
14	3	O
15	:	O
16	The	O
17	role	O
18	of	O
19	antithrombin	B
20	III	I

1	Specific	O
2	class	B
3	I	I
4	and	I
5	II	I
6	histone	I
7	deacetylases	I
8	(	O
9	HDACs	B
10	)	O
11	interact	O
12	in	O
13	vivo	O
14	with	O
15	BCoR	B
16	,	O
17	suggesting	O
18	that	O
19	BCoR	B
20	may	O
21	functionally	O
22	link	O
23	these	O
24	two	O
25	classes	O
26	of	O
27	HDACs	B
28	.	O

1	This	O
2	is	O
3	the	O
4	first	O
5	example	O
6	of	O
7	a	O
8	eukaryotic	O
9	transcription	O
10	factor	O
11	complex	O
12	containing	O
13	both	O
14	a	O
15	MADS	B
16	-	I
17	box	I
18	and	O
19	a	O
20	forkhead	B
21	protein	I
22	,	O
23	and	O
24	it	O
25	has	O
26	important	O
27	implications	O
28	for	O
29	the	O
30	regulation	O
31	of	O
32	mammalian	O
33	gene	O
34	expression	O
35	.	O

1	After	O
2	screening	O
3	the	O
4	Berkeley	O
5	Drosophila	O
6	Genome	O
7	Project	O
8	database	O
9	with	O
10	sequences	O
11	from	O
12	a	O
13	recently	O
14	characterized	O
15	Leu	B
16	-	I
17	rich	I
18	repeats	I
19	-	I
20	containing	I
21	G	I
22	protein	I
23	-	I
24	coupled	I
25	receptor	I
26	(	O
27	LGR	B
28	)	O
29	from	O
30	Drosophila	O
31	(	O
32	DLGR	B
33	-	I
34	1	I
35	),	O
36	we	O
37	identified	O
38	a	O
39	second	O
40	gene	O
41	for	O
42	a	O
43	different	O
44	LGR	B
45	(	O
46	DLGR	B
47	-	I
48	2	I
49	)	O
50	and	O
51	cloned	O
52	its	O
53	cDNA	O
54	.	O

1	Degenerate	O
2	primers	O
3	homologous	O
4	to	O
5	highly	O
6	conserved	O
7	regions	O
8	of	O
9	known	O
10	CYP3A	B
11	sequences	I
12	were	O
13	used	O
14	for	O
15	initial	O
16	RT	O
17	-	O
18	PCRs	O
19	.	O

1	When	O
2	cells	O
3	were	O
4	microinjected	O
5	with	O
6	TFOs	O
7	designed	O
8	to	O
9	bind	O
10	to	O
11	a	O
12	30	O
13	-	O
14	bp	O
15	polypurine	O
16	site	O
17	situated	O
18	between	O
19	the	O
20	two	O
21	TK	B
22	genes	I
23	,	O
24	recombination	O
25	was	O
26	observed	O
27	at	O
28	frequencies	O
29	in	O
30	the	O
31	range	O
32	of	O
33	1	O
34	%,	O
35	2	O
36	,	O
37	500	O
38	-	O
39	fold	O
40	above	O
41	the	O
42	background	O
43	.	O

1	Methyllevamisole	O
2	was	O
3	used	O
4	as	O
5	the	O
6	internal	O
7	standard	O
8	.	O

1	Resistance	O
2	ratios	O
3	for	O
4	the	O
5	other	O
6	field	O
7	strains	O
8	obtained	O
9	by	O
10	comparison	O
11	with	O
12	the	O
13	R5	O
14	strain	O
15	ranged	O
16	from	O
17	24	O
18	.	O
19	5	O
20	to	O
21	239	O
22	for	O
23	topical	O
24	application	O
25	and	O
26	from	O
27	1	O
28	.	O
29	2	O
30	to	O
31	9	O
32	.	O
33	8	O
34	for	O
35	the	O
36	glass	O
37	jar	O
38	method	O
39	.	O

1	Only	O
2	transcripts	O
3	specific	O
4	for	O
5	TSGF	B
6	-	I
7	2	I
8	are	O
9	detected	O
10	in	O
11	ovary	O
12	and	O
13	testes	O
14	tissues	O
15	of	O
16	adults	O
17	as	O
18	well	O
19	as	O
20	in	O
21	puparia	O
22	,	O
23	while	O
24	neither	O
25	gene	O
26	is	O
27	expressed	O
28	during	O
29	the	O
30	larval	O
31	developmental	O
32	stages	O
33	.	O

1	In	O
2	a	O
3	gel	O
4	retardation	O
5	assay	O
6	using	O
7	HepG2	O
8	nuclear	O
9	extracts	O
10	,	O
11	the	O
12	5	O
13	'	O
14	flanking	O
15	sequence	O
16	from	O
17	-	O
18	74	O
19	to	O
20	-	O
21	46	O
22	showed	O
23	a	O
24	shifted	O
25	band	O
26	.	O

1	Reliability	O
2	of	O
3	cervical	O
4	range	O
5	of	O
6	motion	O
7	using	O
8	the	O
9	OSI	O
10	CA	O
11	6000	O
12	spine	O
13	motion	O
14	analyser	O
15	on	O
16	asymptomatic	O
17	and	O
18	symptomatic	O
19	subjects	O
20	.	O

1	Coimmunoprecipitation	O
2	experiments	O
3	performed	O
4	in	O
5	transfected	O
6	cells	O
7	showed	O
8	that	O
9	BCMA	B
10	associates	O
11	with	O
12	TNFR	B
13	-	I
14	associated	I
15	factor	I
16	(	I
17	TRAF	I
18	)	I
19	1	I
20	,	O
21	TRAF2	B
22	,	O
23	and	O
24	TRAF3	B
25	adaptor	I
26	proteins	I
27	.	O

1	Since	O
2	the	O
3	RINX	B
4	gene	I
5	is	O
6	likely	O
7	an	O
8	ortholog	O
9	of	O
10	the	O
11	goldfish	B
12	Vsx1	I
13	gene	I
14	,	O
15	it	O
16	has	O
17	been	O
18	named	O
19	VSX1	B
20	by	O
21	the	O
22	Human	O
23	Gene	O
24	Nomenclature	O
25	Committee	O
26	.	O

1	The	O
2	chromosomal	O
3	localization	O
4	on	O
5	distal	O
6	chromosome	O
7	7	O
8	places	O
9	it	O
10	in	O
11	a	O
12	cluster	O
13	of	O
14	imprinted	O
15	genes	O
16	,	O
17	flanked	O
18	by	O
19	the	O
20	previously	O
21	described	O
22	Tapa1	B
23	and	O
24	Kcnq1	B
25	genes	I
26	.	O

1	Activation	O
2	of	O
3	PKA	B
4	by	O
5	8	O
6	-	O
7	bromo	O
8	-	O
9	cyclic	O
10	AMP	O
11	or	O
12	forskolin	O
13	,	O
14	and	O
15	inhibition	O
16	of	O
17	PKC	B
18	by	O
19	calphostin	O
20	C	O
21	,	O
22	resulted	O
23	in	O
24	a	O
25	significant	O
26	decrease	O
27	in	O
28	3TP	B
29	activity	O
30	as	O
31	well	O
32	as	O
33	in	O
34	vitro	O
35	ERK	B
36	kinase	I
37	activity	O
38	in	O
39	CRAC	O
40	.	O

1	The	O
2	present	O
3	study	O
4	was	O
5	designed	O
6	to	O
7	evaluate	O
8	the	O
9	sensitivity	O
10	and	O
11	specificity	O
12	of	O
13	AMP	O
14	CT	O
15	(	O
16	Gen	O
17	-	O
18	Probe	O
19	Incorporated	O
20	,	O
21	San	O
22	Diego	O
23	,	O
24	CA	O
25	,	O
26	USA	O
27	)	O
28	on	O
29	urogenital	O
30	specimens	O
31	taken	O
32	from	O
33	symptomatic	O
34	patients	O
35	and	O
36	on	O
37	first	O
38	void	O
39	urine	O
40	(	O
41	FVU	O
42	)	O
43	specimens	O
44	from	O
45	asymptomatic	O
46	patients	O
47	.	O

1	Mus81p	B
2	also	O
3	shares	O
4	homology	O
5	with	O
6	motifs	O
7	found	O
8	in	O
9	the	O
10	XPF	B
11	endonuclease	I
12	superfamily	I
13	.	O

1	Double	O
2	mutant	O
3	analysis	O
4	suggests	O
5	that	O
6	Rad54p	B
7	and	O
8	Mus81p	B
9	act	O
10	in	O
11	one	O
12	pathway	O
13	for	O
14	the	O
15	repair	O
16	of	O
17	,	O
18	or	O
19	tolerance	O
20	to	O
21	,	O
22	UV	O
23	-	O
24	induced	O
25	DNA	O
26	damage	O
27	.	O

1	The	O
2	linear	O
3	plasmid	O
4	pCLU1	O
5	from	O
6	the	O
7	yeast	O
8	Kluyveromyces	O
9	lactis	O
10	normally	O
11	replicates	O
12	in	O
13	the	O
14	cytoplasm	O
15	,	O
16	with	O
17	the	O
18	aid	O
19	of	O
20	the	O
21	helper	O
22	linear	O
23	plasmid	O
24	pGKL2	O
25	,	O
26	using	O
27	terminal	B
28	protein	I
29	(	O
30	TP	B
31	)	O
32	as	O
33	a	O
34	primer	O
35	.	O

1	The	O
2	repetitive	O
3	ETn	B
4	(	O
5	early	B
6	transposon	I
7	)	O
8	family	O
9	of	O
10	sequences	O
11	represents	O
12	an	O
13	active	O
14	"	O
15	mobile	O
16	mutagen	O
17	"	O
18	in	O
19	the	O
20	mouse	O
21	genome	O
22	.	O

1	The	O
2	two	O
3	main	O
4	experimental	O
5	variables	O
6	were	O
7	the	O
8	attended	O
9	hemifield	O
10	(	O
11	left	O
12	or	O
13	right	O
14	)	O
15	and	O
16	the	O
17	proportion	O
18	of	O
19	trials	O
20	requiring	O
21	a	O
22	shift	O
23	within	O
24	that	O
25	hemifield	O
26	(	O
27	20	O
28	%	O
29	or	O
30	80	O
31	%).	O

1	The	O
2	measurement	O
3	of	O
4	NO	O
5	in	O
6	biological	O
7	systems	O
8	using	O
9	chemiluminescence	O
10	.	O

1	Biochemical	O
2	examinations	O
3	of	O
4	calcium	O
5	-	O
6	phosphorus	O
7	metabolism	O
8	included	O
9	ions	O
10	and	O
11	PTH	B
12	concentrations	O
13	in	O
14	blood	O
15	serum	O
16	,	O
17	and	O
18	the	O
19	activity	O
20	of	O
21	bone	O
22	isoenzyme	O
23	of	O
24	AP	B
25	.	O

1	Atorvastatin	O
2	was	O
3	the	O
4	most	O
5	cost	O
6	-	O
7	effective	O
8	HMG	B
9	-	I
10	CoA	I
11	reductase	I
12	inhibitor	O
13	.	O

1	Pharmacoeconomic	O
2	assessment	O
3	of	O
4	HMG	B
5	-	I
6	CoA	I
7	reductase	I
8	inhibitor	O
9	therapy	O
10	:	O
11	an	O
12	analysis	O
13	based	O
14	on	O
15	the	O
16	CURVES	O
17	study	O
18	.	O

1	Interestingly	O
2	,	O
3	although	O
4	E	O
5	domains	O
6	of	O
7	these	O
8	two	O
9	receptors	O
10	are	O
11	much	O
12	less	O
13	conserved	O
14	,	O
15	replacement	O
16	of	O
17	this	O
18	domain	O
19	in	O
20	rtER	B
21	by	O
22	its	O
23	human	O
24	counterpart	O
25	resulted	O
26	in	O
27	higher	O
28	estradiol	O
29	sensitivity	O
30	but	O
31	no	O
32	increase	O
33	in	O
34	the	O
35	magnitude	O
36	of	O
37	transactivation	O
38	.	O

1	G	O
2	-	O
3	DNA	O
4	is	O
5	a	O
6	four	O
7	-	O
8	stranded	O
9	DNA	O
10	structure	O
11	with	O
12	diverse	O
13	putative	O
14	biological	O
15	roles	O
16	.	O

1	The	O
2	effectiveness	O
3	of	O
4	NRT	O
5	appears	O
6	to	O
7	be	O
8	largely	O
9	independent	O
10	of	O
11	the	O
12	intensity	O
13	of	O
14	additional	O
15	support	O
16	provided	O
17	to	O
18	the	O
19	smoker	O
20	.	O

1	SELECTION	O
2	CRITERIA	O
3	:	O
4	All	O
5	controlled	O
6	trials	O
7	where	O
8	adults	O
9	with	O
10	schizophrenia	O
11	or	O
12	similar	O
13	illnesses	O
14	were	O
15	randomised	O
16	to	O
17	quetiapine	O
18	,	O
19	placebo	O
20	or	O
21	other	O
22	neuroleptic	O
23	drugs	O
24	and	O
25	where	O
26	clinically	O
27	relevant	O
28	outcomes	O
29	were	O
30	reported	O
31	.	O

1	8	O
2	%	O
3	(	O
4	95	O
5	%	O
6	CI	O
7	,	O
8	21	O
9	.	O
10	3	O
11	-	O
12	44	O
13	.	O
14	3	O
15	%).	O

1	In	O
2	contrast	O
3	,	O
4	the	O
5	action	O
6	of	O
7	GLP	B
8	-	I
9	1	I
10	at	O
11	the	O
12	CRE	O
13	was	O
14	not	O
15	blocked	O
16	by	O
17	cotransfection	O
18	with	O
19	M1	B
20	-	I
21	CREB	I
22	,	O
23	an	O
24	isoform	O
25	that	O
26	lacks	O
27	a	O
28	consensus	O
29	serine	O
30	residue	O
31	serving	O
32	as	O
33	substrate	O
34	for	O
35	PKA	B
36	-	O
37	mediated	O
38	phosphorylation	O
39	.	O

1	Because	O
2	all	O
3	PDGFbetaR	B
4	fusions	I
5	described	O
6	thus	O
7	far	O
8	result	O
9	in	O
10	splicing	O
11	to	O
12	a	O
13	common	O
14	exon	O
15	of	O
16	this	O
17	gene	O
18	,	O
19	we	O
20	performed	O
21	5	O
22	'-	O
23	rapid	O
24	amplification	O
25	of	O
26	cDNA	O
27	ends	O
28	PCR	O
29	on	O
30	patient	O
31	RNA	O
32	.	O

1	CONCLUSIONS	O
2	:	O
3	In	O
4	essential	O
5	hypertension	O
6	an	O
7	acute	O
8	protein	O
9	load	O
10	induces	O
11	a	O
12	decrease	O
13	in	O
14	GFR	O
15	that	O
16	may	O
17	normalize	O
18	under	O
19	antihypertensive	O
20	treatment	O
21	.	O

1	This	O
2	finding	O
3	suggested	O
4	that	O
5	the	O
6	PI3K	B
7	-	O
8	Akt	B
9	activation	O
10	pathway	O
11	plays	O
12	some	O
13	role	O
14	in	O
15	the	O
16	antiapoptotic	O
17	effect	O
18	of	O
19	EPO	B
20	.	O

1	Nine	O
2	DNA	O
3	fragments	O
4	that	O
5	were	O
6	specifically	O
7	recognized	O
8	and	O
9	bound	O
10	by	O
11	histidine	O
12	-	O
13	tagged	O
14	AdpA	B
15	were	O
16	isolated	O
17	by	O
18	cycles	O
19	of	O
20	a	O
21	gel	O
22	mobility	O
23	shift	O
24	-	O
25	PCR	O
26	method	O
27	.	O

1	To	O
2	determine	O
3	whether	O
4	the	O
5	NTP	O
6	-	O
7	binding	O
8	motif	O
9	is	O
10	important	O
11	for	O
12	Rad24	B
13	function	O
14	,	O
15	we	O
16	mutated	O
17	the	O
18	conserved	O
19	lysine	O
20	(	O
21	115	O
22	)	O
23	residue	O
24	in	O
25	this	O
26	motif	O
27	.	O

1	The	O
2	carboxyl	O
3	-	O
4	terminal	O
5	proline	O
6	-	O
7	rich	O
8	domain	O
9	of	O
10	SOS1	B
11	is	O
12	involved	O
13	in	O
14	the	O
15	interaction	O
16	with	O
17	the	O
18	PLC	B
19	-	I
20	gamma1	I
21	SH3	I
22	domain	I
23	.	O

1	From	O
2	transient	O
3	expression	O
4	studies	O
5	,	O
6	we	O
7	could	O
8	demonstrate	O
9	that	O
10	the	O
11	SH3	B
12	domain	I
13	of	O
14	PLC	B
15	-	I
16	gamma1	I
17	is	O
18	necessary	O
19	for	O
20	the	O
21	association	O
22	with	O
23	SOS1	B
24	in	O
25	vivo	O
26	.	O

1	Six	O
2	distinct	O
3	Ets	B
4	mRNAs	I
5	were	O
6	identified	O
7	:	O
8	Ets2	B
9	,	O
10	Fli1	B
11	,	O
12	GABPalpha	B
13	,	O
14	SAP1	B
15	,	O
16	Elk1	B
17	,	O
18	and	O
19	PE1	B
20	.	O

1	A	O
2	2	O
3	kb	O
4	transcript	O
5	was	O
6	isolated	O
7	from	O
8	brain	O
9	that	O
10	encodes	O
11	a	O
12	approximately	O
13	57	O
14	kDa	O
15	protein	O
16	;	O
17	the	O
18	predicted	O
19	protein	O
20	contains	O
21	the	O
22	known	O
23	N	B
24	-	I
25	terminal	I
26	Ets	I
27	domain	I
28	of	O
29	PE1	B
30	and	O
31	a	O
32	novel	O
33	C	O
34	-	O
35	terminal	O
36	domain	O
37	with	O
38	signficant	O
39	homology	O
40	to	O
41	murine	B
42	ERF	I
43	.	O

1	Twenty	O
2	eligible	O
3	patients	O
4	with	O
5	cirrhosis	O
6	were	O
7	randomized	O
8	into	O
9	two	O
10	groups	O
11	:	O
12	10	O
13	patients	O
14	treated	O
15	with	O
16	6	O
17	million	O
18	units	O
19	of	O
20	natural	O
21	IFN	B
22	-	I
23	beta	I
24	twice	O
25	a	O
26	week	O
27	for	O
28	36	O
29	months	O
30	and	O
31	10	O
32	patients	O
33	without	O
34	IFN	B
35	therapy	O
36	.	O

1	Wnt	B
2	-	I
3	1	I
4	overexpression	O
5	in	O
6	mammary	O
7	epithelial	O
8	cells	O
9	induced	O
10	cyclin	B
11	D1	I
12	mRNA	I
13	and	O
14	targeted	O
15	overexpression	O
16	of	O
17	Wnt	B
18	-	I
19	1	I
20	in	O
21	the	O
22	mammary	O
23	gland	O
24	of	O
25	transgenic	O
26	mice	O
27	increased	O
28	both	O
29	ILK	B
30	activity	O
31	and	O
32	cyclin	B
33	D1	I
34	levels	O
35	.	O

1	Intravenous	O
2	versus	O
3	oral	O
4	administration	O
5	of	O
6	amitriptyline	O
7	in	O
8	patients	O
9	with	O
10	major	O
11	depression	O
12	.	O

1	Deletion	O
2	of	O
3	the	O
4	RVH	B
5	domain	I
6	resulted	O
7	in	O
8	loss	O
9	of	O
10	Ca	O
11	(	O
12	2	O
13	+)-	O
14	dependent	O
15	activation	O
16	.	O

1	Logistic	O
2	regression	O
3	analysis	O
4	revealed	O
5	that	O
6	physicians	O
7	were	O
8	3	O
9	.	O
10	6	O
11	times	O
12	more	O
13	likely	O
14	to	O
15	detect	O
16	thin	O
17	lesions	O
18	(</=	O
19	0	O
20	.	O
21	75	O
22	mm	O
23	)	O
24	compared	O
25	with	O
26	nonphysician	O
27	detectors	O
28	(	O
29	95	O
30	%	O
31	confidence	O
32	interval	O
33	[	O
34	95	O
35	%	O
36	CI	O
37	],	O
38	2	O
39	.	O
40	1	O
41	,	O
42	6	O
43	.	O
44	5	O
45	;	O
46	P	O
47	=	O
48	0	O
49	.	O
50	0001	O
51	).	O

1	Erythema	O
2	exsudativum	O
3	multiforme	O
4	induced	O
5	by	O
6	granulocyte	B
7	colony	I
8	-	I
9	stimulating	I
10	factor	I
11	in	O
12	an	O
13	allogeneic	O
14	peripheral	O
15	blood	O
16	stem	O
17	cell	O
18	donor	O
19	.	O

1	VaI	O
2	and	O
3	VaII	O
4	co	O
5	-	O
6	immunoprecipitated	O
7	with	O
8	ErbB2	B
9	,	O
10	but	O
11	not	O
12	with	O
13	ErbB1	B
14	,	O
15	ErbB3	B
16	,	O
17	or	O
18	ErbB4	B
19	.	O

1	While	O
2	interactions	O
3	of	O
4	WT	O
5	and	O
6	variant	O
7	TGF	B
8	-	I
9	alpha	I
10	with	O
11	the	O
12	ErbBs	B
13	all	O
14	result	O
15	in	O
16	ErbB2	B
17	activation	O
18	,	O
19	they	O
20	produce	O
21	different	O
22	biological	O
23	consequences	O
24	,	O
25	suggesting	O
26	that	O
27	the	O
28	various	O
29	TGF	B
30	-	I
31	alpha	I
32	precursors	I
33	differentially	O
34	modulate	O
35	ErbB	B
36	signaling	O
37	.	O

1	It	O
2	is	O
3	now	O
4	well	O
5	accepted	O
6	that	O
7	the	O
8	p53	B
9	C	I
10	-	I
11	terminus	I
12	plays	O
13	a	O
14	central	O
15	role	O
16	in	O
17	controlling	O
18	the	O
19	activity	O
20	of	O
21	the	O
22	wild	O
23	-	O
24	type	O
25	molecule	O
26	.	O

1	In	O
2	contrast	O
3	to	O
4	full	B
5	-	I
6	length	I
7	E2F	I
8	-	I
9	3	I
10	,	O
11	which	O
12	is	O
13	expressed	O
14	only	O
15	at	O
16	the	O
17	G1	O
18	/	O
19	S	O
20	boundary	O
21	,	O
22	E2F	B
23	-	I
24	3B	I
25	is	O
26	detected	O
27	throughout	O
28	the	O
29	cell	O
30	cycle	O
31	with	O
32	peak	O
33	levels	O
34	in	O
35	GO	O
36	where	O
37	it	O
38	is	O
39	associated	O
40	with	O
41	Rb	B
42	.	O

1	The	O
2	transcription	O
3	factor	O
4	Jun	B
5	(	O
6	c	B
7	-	I
8	Jun	I
9	)	O
10	functions	O
11	as	O
12	a	O
13	recipient	O
14	of	O
15	extracellular	O
16	growth	O
17	signals	O
18	and	O
19	converts	O
20	them	O
21	into	O
22	patterns	O
23	of	O
24	gene	O
25	expression	O
26	.	O

1	Developmental	O
2	toxicity	O
3	of	O
4	the	O
5	class	O
6	III	O
7	antiarrhythmic	O
8	agent	O
9	almokalant	O
10	in	O
11	mice	O
12	.	O

1	This	O
2	compound	O
3	is	O
4	the	O
5	main	O
6	bioactive	O
7	metabolite	O
8	of	O
9	trimebutine	O
10	II	O
11	(	O
12	Debridat	O
13	,	O
14	CAS	O
15	39133	O
16	-	O
17	31	O
18	-	O
19	8	O
20	),	O
21	an	O
22	antispasmodic	O
23	widely	O
24	used	O
25	for	O
26	intestinal	O
27	diseases	O
28	since	O
29	1969	O
30	.	O

1	In	O
2	addition	O
3	to	O
4	its	O
5	effect	O
6	in	O
7	augmenting	O
8	the	O
9	neutrophil	O
10	response	O
11	to	O
12	eccentric	O
13	exercise	O
14	,	O
15	vitamin	O
16	E	O
17	causes	O
18	a	O
19	greater	O
20	increase	O
21	in	O
22	circulating	O
23	creatine	B
24	kinase	I
25	activity	O
26	,	O
27	perhaps	O
28	indicating	O
29	increased	O
30	skeletal	O
31	muscle	O
32	repair	O
33	.	O

1	This	O
2	enabled	O
3	the	O
4	formation	O
5	of	O
6	stem	O
7	-	O
8	loop	O
9	templates	O
10	with	O
11	the	O
12	fusion	O
13	point	O
14	of	O
15	the	O
16	chimeric	O
17	transcript	O
18	in	O
19	the	O
20	loop	O
21	and	O
22	the	O
23	use	O
24	of	O
25	MLL	B
26	primers	O
27	in	O
28	two	O
29	-	O
30	sided	O
31	PCR	O
32	.	O

1	CONCLUSION	O
2	:	O
3	The	O
4	authors	O
5	emphasize	O
6	that	O
7	the	O
8	initial	O
9	management	O
10	of	O
11	primary	O
12	STS	O
13	should	O
14	be	O
15	adequate	O
16	and	O
17	suggest	O
18	that	O
19	safty	O
20	margin	O
21	of	O
22	>	O
23	or	O
24	=	O
25	2	O
26	cm	O
27	should	O
28	be	O
29	adhered	O
30	to	O
31	.	O

1	Measurements	O
2	were	O
3	compared	O
4	with	O
5	two	O
6	computerised	O
7	treatment	O
8	planning	O
9	systems	O
10	--	O
11	Theraplan	O
12	VO5B	O
13	and	O
14	ADAC	O
15	Pinnacle3	O
16	V4	O
17	.	O
18	0b	O
19	.	O

1	Activation	O
2	was	O
3	biphasic	O
4	;	O
5	peaking	O
6	at	O
7	5	O
8	-	O
9	10	O
10	min	O
11	and	O
12	24	O
13	h	O
14	after	O
15	treatment	O
16	.	O

1	Whereas	O
2	MARTA1	B
3	is	O
4	clearly	O
5	detectable	O
6	in	O
7	crude	O
8	lysates	O
9	,	O
10	cytosolic	O
11	and	O
12	ribosomal	O
13	salt	O
14	-	O
15	wash	O
16	fractions	O
17	,	O
18	and	O
19	in	O
20	nuclear	O
21	extracts	O
22	,	O
23	MARTA2	B
24	is	O
25	preferentially	O
26	found	O
27	in	O
28	the	O
29	ribosomal	O
30	salt	O
31	-	O
32	wash	O
33	preparation	O
34	.	O

1	It	O
2	contains	O
3	25	O
4	exons	O
5	coding	O
6	for	O
7	a	O
8	4	O
9	.	O
10	7kb	O
11	transcript	O
12	including	O
13	large	O
14	5	O
15	'-	O
16	and	O
17	3	O
18	'-	O
19	(	O
20	1218bp	O
21	and	O
22	701bp	O
23	,	O
24	respectively	O
25	)	O
26	untranslated	O
27	regions	O
28	(	O
29	UTRs	O
30	).	O

1	Five	O
2	of	O
3	the	O
4	PDP1	B
5	isoforms	I
6	differ	O
7	by	O
8	the	O
9	substitution	O
10	or	O
11	insertion	O
12	of	O
13	amino	O
14	acids	O
15	at	O
16	or	O
17	near	O
18	the	O
19	N	O
20	-	O
21	terminal	O
22	of	O
23	the	O
24	protein	O
25	.	O

1	The	O
2	optimum	O
3	technique	O
4	for	O
5	the	O
6	pathological	O
7	examination	O
8	of	O
9	sentinel	O
10	lymph	O
11	nodes	O
12	(	O
13	SLNs	O
14	)	O
15	is	O
16	still	O
17	under	O
18	debate	O
19	.	O

1	Partial	O
2	correction	O
3	of	O
4	anemia	O
5	with	O
6	recombinant	B
7	human	I
8	erythropoietin	I
9	likely	O
10	reduces	O
11	left	O
12	ventricular	O
13	mass	O
14	and	O
15	volume	O
16	.	O

1	This	O
2	study	O
3	demonstrated	O
4	that	O
5	the	O
6	PFA	O
7	-	O
8	100	O
9	analyzer	O
10	can	O
11	accurately	O
12	assess	O
13	vWF	B
14	-	O
15	dependent	O
16	platelet	O
17	function	O
18	and	O
19	detect	O
20	other	O
21	platelet	O
22	defects	O
23	under	O
24	high	O
25	shear	O
26	stress	O
27	in	O
28	complex	O
29	patient	O
30	populations	O
31	.	O

1	We	O
2	recently	O
3	reported	O
4	the	O
5	molecular	O
6	cloning	O
7	of	O
8	a	O
9	PL	B
10	scramblase	I
11	of	O
12	human	O
13	(	O
14	HuPLSCR1	B
15	)	O
16	and	O
17	mouse	O
18	origin	O
19	,	O
20	respectively	O
21	.	O

1	To	O
2	analyze	O
3	the	O
4	regulatory	O
5	activity	O
6	of	O
7	Gtx	B
8	,	O
9	we	O
10	first	O
11	identified	O
12	the	O
13	optimal	O
14	Gtx	B
15	-	I
16	binding	I
17	sequence	I
18	using	O
19	an	O
20	in	O
21	vitro	O
22	DNA	O
23	-	O
24	binding	O
25	assay	O
26	.	O

1	Using	O
2	an	O
3	oligomer	O
4	duplex	O
5	5	O
6	'-	O
7	A	O
8	(	O
9	GGGTTA	O
10	)(	O
11	5	O
12	)-	O
13	3	O
14	'/	O
15	5	O
16	'-(	O
17	TAACCC	O
18	)(	O
19	5	O
20	)	O
21	T	O
22	-	O
23	3	O
24	'	O
25	as	O
26	a	O
27	template	O
28	-	O
29	primer	O
30	,	O
31	we	O
32	show	O
33	that	O
34	both	O
35	the	O
36	Klenow	B
37	fragment	I
38	of	I
39	Escherichia	I
40	coli	I
41	DNA	I
42	polymerase	I
43	I	I
44	and	O
45	HIV	B
46	reverse	I
47	transcriptase	I
48	could	O
49	expand	O
50	telomere	O
51	DNA	O
52	sequences	O
53	as	O
54	well	O
55	,	O
56	giving	O
57	products	O
58	greater	O
59	than	O
60	the	O
61	size	O
62	of	O
63	the	O
64	template	O
65	DNA	O
66	.	O

1	Cdk2	B
2	and	O
3	MAPK	B
4	precipitates	O
5	from	O
6	untreated	O
7	tumor	O
8	lysates	O
9	phosphorylated	O
10	recombinant	B
11	wild	I
12	-	I
13	type	I
14	p27	I
15	but	O
16	not	O
17	the	O
18	T187A	O
19	mutant	O
20	in	O
21	vitro	O
22	.	O

1	The	O
2	loss	O
3	of	O
4	avirulence	O
5	activity	O
6	because	O
7	of	O
8	mutations	O
9	in	O
10	the	O
11	acidic	O
12	transcriptional	O
13	activation	O
14	domain	O
15	was	O
16	restored	O
17	by	O
18	addition	O
19	of	O
20	the	O
21	activation	O
22	domain	O
23	from	O
24	the	O
25	herpes	B
26	simplex	I
27	viral	I
28	protein	I
29	VP16	I
30	.	O

1	Mutations	O
2	in	O
3	the	O
4	RP2	B
5	locus	I
6	at	I
7	Xp11	I
8	.	I
9	3	I
10	were	O
11	found	O
12	in	O
13	a	O
14	further	O
15	10	O
16	-	O
17	20	O
18	%	O
19	of	O
20	XLRP	O
21	patients	O
22	,	O
23	as	O
24	predicted	O
25	from	O
26	linkage	O
27	studies	O
28	.	O

1	The	O
2	limit	O
3	between	O
4	the	O
5	cecum	O
6	and	O
7	the	O
8	ascending	O
9	colon	O
10	was	O
11	externally	O
12	marked	O
13	by	O
14	the	O
15	sulcus	O
16	cecocolicus	O
17	dorsalis	O
18	and	O
19	ventralis	O
20	.	O

1	Subsequently	O
2	,	O
3	HD	O
4	inhibited	O
5	healing	O
6	because	O
7	it	O
8	significantly	O
9	delayed	O
10	epithelialization	O
11	and	O
12	caused	O
13	protracted	O
14	inflammation	O
15	.	O

1	The	O
2	effectiveness	O
3	of	O
4	the	O
5	haemodialysate	O
6	Solcoseryl	O
7	for	O
8	second	O
9	-	O
10	intention	O
11	wound	O
12	healing	O
13	in	O
14	horses	O
15	and	O
16	ponies	O
17	.	O

1	Although	O
2	there	O
3	is	O
4	little	O
5	evidence	O
6	that	O
7	diet	O
8	composition	O
9	plays	O
10	a	O
11	clinically	O
12	important	O
13	role	O
14	in	O
15	the	O
16	absorption	O
17	or	O
18	expenditure	O
19	of	O
20	energy	O
21	,	O
22	it	O
23	does	O
24	appear	O
25	to	O
26	play	O
27	a	O
28	role	O
29	in	O
30	food	O
31	intake	O
32	.	O

1	These	O
2	findings	O
3	were	O
4	reinforced	O
5	by	O
6	an	O
7	analysis	O
8	that	O
9	was	O
10	restricted	O
11	to	O
12	living	O
13	donor	O
14	transplants	O
15	without	O
16	acute	O
17	rejection	O
18	.	O

1	These	O
2	results	O
3	further	O
4	support	O
5	an	O
6	important	O
7	role	O
8	for	O
9	CBF2	B
10	in	O
11	mediating	O
12	EBNA2	B
13	transactivation	O
14	;	O
15	they	O
16	identify	O
17	the	O
18	hnRNP	B
19	protein	I
20	AUF1	I
21	as	O
22	a	O
23	major	O
24	component	O
25	of	O
26	CBF2	B
27	and	O
28	are	O
29	also	O
30	the	O
31	first	O
32	evidence	O
33	of	O
34	a	O
35	cis	O
36	-	O
37	acting	O
38	sequence	O
39	other	O
40	than	O
41	a	O
42	CBF1	B
43	binding	I
44	element	I
45	that	O
46	is	O
47	able	O
48	to	O
49	confer	O
50	responsiveness	O
51	to	O
52	EBNA2	B
53	.	O

1	The	O
2	genome	O
3	of	O
4	the	O
5	human	O
6	herpesvirus	O
7	8	O
8	(	O
9	HHV	O
10	-	O
11	8	O
12	)	O
13	contains	O
14	a	O
15	cluster	O
16	of	O
17	open	O
18	reading	O
19	frames	O
20	(	O
21	ORFs	O
22	)	O
23	encoding	O
24	proteins	O
25	with	O
26	homology	O
27	to	O
28	the	O
29	cellular	O
30	transcription	O
31	factors	O
32	of	O
33	the	O
34	interferon	B
35	regulatory	I
36	factor	I
37	(	O
38	IRF	B
39	)	O
40	family	O
41	.	O

1	Despite	O
2	these	O
3	limitations	O
4	the	O
5	CHIME	O
6	monitor	O
7	provides	O
8	an	O
9	opportunity	O
10	to	O
11	record	O
12	physiological	O
13	data	O
14	previously	O
15	unavailable	O
16	in	O
17	the	O
18	home	O
19	.	O

1	DATA	O
2	SYNTHESIS	O
3	:	O
4	Intracoronary	O
5	ultrasound	O
6	has	O
7	been	O
8	shown	O
9	to	O
10	improve	O
11	upon	O
12	demonstrated	O
13	weaknesses	O
14	of	O
15	coronary	O
16	angiography	O
17	.	O

1	TB	O
2	bone	O
3	area	O
4	(	O
5	p	O
6	<	O
7	0	O
8	.	O
9	001	O
10	),	O
11	height	O
12	(	O
13	p	O
14	<	O
15	0	O
16	.	O
17	01	O
18	),	O
19	years	O
20	in	O
21	present	O
22	colony	O
23	(	O
24	p	O
25	=	O
26	0	O
27	.	O
28	03	O
29	),	O
30	and	O
31	menses	O
32	(	O
33	p	O
34	<	O
35	0	O
36	.	O
37	01	O
38	)	O
39	predicted	O
40	TB	O
41	BMC	O
42	.	O

1	CREST	O
2	syndrome	O
3	;	O
4	a	O
5	changing	O
6	clinical	O
7	significance	O

1	Troglitazone	O
2	also	O
3	induced	O
4	an	O
5	endogenous	B
6	PPARgamma	I
7	target	I
8	gene	I
9	in	O
10	T24	O
11	cells	O
12	,	O
13	adipocyte	B
14	-	I
15	type	I
16	fatty	I
17	acid	I
18	binding	I
19	protein	I
20	(	O
21	A	B
22	-	I
23	FABP	I
24	),	O
25	the	O
26	expression	O
27	of	O
28	which	O
29	correlates	O
30	with	O
31	bladder	O
32	cancer	O
33	differentiation	O
34	.	O

1	Viruses	O
2	were	O
3	isolated	O
4	from	O
5	9	O
6	lungs	O
7	:	O
8	7	O
9	with	O
10	PI	O
11	-	O
12	3V	O
13	,	O
14	1	O
15	with	O
16	NCP	O
17	BVDV	O
18	type	O
19	1	O
20	,	O
21	and	O
22	1	O
23	with	O
24	both	O
25	BVHV	O
26	-	O
27	1	O
28	and	O
29	BVDV	O
30	.	O

1	The	O
2	RS447	B
3	human	I
4	megasatellite	I
5	tandem	I
6	repetitive	I
7	sequence	I
8	encodes	O
9	a	O
10	novel	O
11	deubiquitinating	O
12	enzyme	O
13	with	O
14	a	O
15	functional	O
16	promoter	O
17	.	O

1	Previous	O
2	experience	O
3	and	O
4	contextual	O
5	cues	O
6	are	O
7	essential	O
8	elements	O
9	in	O
10	the	O
11	generation	O
12	of	O
13	a	O
14	subjective	O
15	prediction	O
16	.	O

1	To	O
2	characterize	O
3	this	O
4	effect	O
5	,	O
6	we	O
7	looked	O
8	for	O
9	targets	O
10	of	O
11	NS1	B
12	influenza	I
13	virus	I
14	protein	I
15	among	O
16	cellular	O
17	translation	O
18	factors	O
19	.	O

1	Collectively	O
2	,	O
3	these	O
4	and	O
5	previously	O
6	published	O
7	data	O
8	suggest	O
9	a	O
10	model	O
11	where	O
12	NS1	B
13	recruits	O
14	eIF4GI	B
15	specifically	O
16	to	O
17	the	O
18	5	O
19	'	O
20	untranslated	O
21	region	O
22	(	O
23	5	O
24	'	O
25	UTR	O
26	)	O
27	of	O
28	the	O
29	viral	O
30	mRNA	O
31	,	O
32	allowing	O
33	for	O
34	the	O
35	preferential	O
36	translation	O
37	of	O
38	the	O
39	influenza	O
40	virus	O
41	messengers	O
42	.	O

1	Eukaryotic	B
2	translation	I
3	initiation	I
4	factor	I
5	4GI	I
6	is	O
7	a	O
8	cellular	O
9	target	O
10	for	O
11	NS1	B
12	protein	I
13	,	O
14	a	O
15	translational	O
16	activator	O
17	of	O
18	influenza	O
19	virus	O
20	.	O

1	Splicing	O
2	of	O
3	the	O
4	K	B
5	-	I
6	SAM	I
7	alternative	O
8	exon	O
9	of	O
10	the	O
11	fibroblast	B
12	growth	I
13	factor	I
14	receptor	I
15	2	I
16	gene	I
17	is	O
18	heavily	O
19	dependent	O
20	on	O
21	the	O
22	U	O
23	-	O
24	rich	O
25	sequence	O
26	IAS1	B
27	lying	O
28	immediately	O
29	downstream	O
30	from	O
31	its	O
32	5	O
33	'	O
34	splice	O
35	site	O
36	.	O

1	(	O
2	iii	O
3	)	O
4	In	O
5	these	O
6	cells	O
7	,	O
8	PKCbeta	B
9	plays	O
10	a	O
11	unique	O
12	Ras	B
13	-	O
14	independent	O
15	role	O
16	in	O
17	mediating	O
18	insulin	B
19	but	O
20	not	O
21	EGF	B
22	or	O
23	other	O
24	growth	O
25	factor	O
26	mitogenic	O
27	signals	O
28	.	O

1	However	O
2	,	O
3	it	O
4	is	O
5	not	O
6	known	O
7	whether	O
8	the	O
9	recently	O
10	identified	O
11	isoforms	O
12	Vav2	B
13	and	O
14	Vav3	B
15	,	O
16	which	O
17	are	O
18	broadly	O
19	expressed	O
20	,	O
21	can	O
22	couple	O
23	with	O
24	similar	O
25	classes	O
26	of	O
27	receptors	O
28	,	O
29	nor	O
30	is	O
31	it	O
32	known	O
33	whether	O
34	all	O
35	Vav	B
36	isoforms	I
37	possess	O
38	identical	O
39	functional	O
40	activities	O
41	.	O

1	Transcriptional	O
2	regulation	O
3	of	O
4	fbp1	B
5	promoter	I
6	constructs	I
7	containing	O
8	only	O
9	UAS1	O
10	or	O
11	UAS2	O
12	confirms	O
13	that	O
14	the	O
15	PKA	B
16	and	O
17	MAPK	B
18	regulation	O
19	is	O
20	targeted	O
21	to	O
22	both	O
23	sites	O
24	.	O

1	X	O
2	-	O
3	ray	O
4	crystallographic	O
5	data	O
6	show	O
7	that	O
8	the	O
9	PLZF	B
10	BTB	I
11	/	O
12	POZ	O
13	domain	O
14	forms	O
15	an	O
16	obligate	O
17	homodimer	O
18	via	O
19	an	O
20	extensive	O
21	interface	O
22	.	O

1	The	O
2	ability	O
3	of	O
4	SMRT	B
5	to	O
6	associate	O
7	with	O
8	these	O
9	transcription	O
10	factors	O
11	and	O
12	thereby	O
13	to	O
14	mediate	O
15	repression	O
16	is	O
17	strongly	O
18	inhibited	O
19	by	O
20	activation	O
21	of	O
22	tyrosine	B
23	kinase	I
24	signaling	O
25	pathways	O
26	,	O
27	such	O
28	as	O
29	that	O
30	represented	O
31	by	O
32	the	O
33	epidermal	B
34	growth	I
35	factor	I
36	receptor	I
37	.	O

1	In	O
2	addition	O
3	,	O
4	the	O
5	ketamine	O
6	-	O
7	treated	O
8	rats	O
9	had	O
10	more	O
11	neurons	O
12	and	O
13	glial	O
14	cells	O
15	surrounding	O
16	the	O
17	ventricles	O
18	.	O

1	The	O
2	differences	O
3	were	O
4	as	O
5	follows	O
6	:	O
7	for	O
8	overall	O
9	response	O
10	rate	O
11	p	O
12	=	O
13	0	O
14	.	O
15	004	O
16	;	O
17	power	O
18	(	O
19	for	O
20	p	O
21	=	O
22	0	O
23	.	O
24	05	O
25	)	O
26	85	O
27	%;	O
28	for	O
29	survival	O
30	p	O
31	=	O
32	0	O
33	.	O
34	09	O
35	;	O
36	for	O
37	grade	O
38	IV	O
39	granulocytopenia	O
40	p	O
41	=	O
42	0	O
43	.	O
44	3	O
45	;	O
46	and	O
47	for	O
48	febrile	O
49	neutropenia	O
50	p	O
51	=	O
52	0	O
53	.	O
54	61	O
55	.	O

1	Patients	O
2	were	O
3	randomly	O
4	assigned	O
5	to	O
6	treatment	O
7	with	O
8	the	O
9	ACE	B
10	inhibitor	O
11	perindopril	O
12	(	O
13	and	O
14	the	O
15	diuretic	O
16	indapamide	O
17	for	O
18	those	O
19	with	O
20	no	O
21	definite	O
22	indication	O
23	for	O
24	or	O
25	contraindication	O
26	to	O
27	treatment	O
28	with	O
29	a	O
30	diuretic	O
31	)	O
32	or	O
33	matching	O
34	placebo	O
35	(	O
36	s	O
37	).	O

1	The	O
2	results	O
3	indicate	O
4	that	O
5	the	O
6	open	O
7	-	O
8	section	O
9	effect	O
10	decreases	O
11	the	O
12	torsional	O
13	stiffness	O
14	and	O
15	stress	O
16	concentration	O
17	effects	O
18	decrease	O
19	the	O
20	torsional	O
21	strength	O
22	of	O
23	a	O
24	long	O
25	bone	O
26	with	O
27	a	O
28	longitudinal	O
29	defect	O
30	.	O

1	These	O
2	regions	O
3	may	O
4	be	O
5	differentially	O
6	involved	O
7	in	O
8	tissue	O
9	-	O
10	specificity	O
11	,	O
12	and	O
13	/	O
14	or	O
15	circadian	O
16	regulation	O
17	,	O
18	of	O
19	the	O
20	human	B
21	hPer1	I
22	gene	I
23	transcription	O
24	.	O

1	Additionally	O
2	,	O
3	putative	O
4	CF1	B
5	/	O
6	USP	B
7	and	O
8	Broad	B
9	Complex	I
10	Z2	I
11	transcription	O
12	factor	O
13	elements	O
14	were	O
15	found	O
16	in	O
17	the	O
18	upstream	O
19	regions	O
20	of	O
21	MIH	B
22	and	O
23	MO	B
24	-	I
25	IH	I
26	genes	O
27	respectively	O
28	.	O

1	Sequence	O
2	analysis	O
3	reveals	O
4	that	O
5	the	O
6	newly	O
7	discovered	O
8	oasA2	B
9	gene	I
10	represents	O
11	a	O
12	pseudogene	O
13	that	O
14	is	O
15	still	O
16	transcribed	O
17	,	O
18	but	O
19	is	O
20	not	O
21	functionally	O
22	translated	O
23	.	O

1	Genomic	O
2	and	O
3	functional	O
4	characterization	O
5	of	O
6	the	O
7	oas	B
8	gene	I
9	family	I
10	encoding	O
11	O	B
12	-	I
13	acetylserine	I
14	(	I
15	thiol	I
16	)	I
17	lyases	I
18	,	O
19	enzymes	O
20	catalyzing	O
21	the	O
22	final	O
23	step	O
24	in	O
25	cysteine	O
26	biosynthesis	O
27	in	O
28	Arabidopsis	O
29	thaliana	O
30	.	O

1	Two	O
2	distinct	O
3	recessive	O
4	susceptibility	O
5	loci	O
6	for	O
7	vasculitis	O
8	were	O
9	mapped	O
10	on	O
11	chromosome	O
12	(	O
13	Chr	O
14	)	O
15	4	O
16	at	O
17	D4Mit89	B
18	and	O
19	D4Mit147	B
20	in	O
21	both	O
22	progenies	O
23	.	O

1	During	O
2	treatment	O
3	,	O
4	the	O
5	phosphorylation	O
6	state	O
7	of	O
8	Rb	B
9	shifted	O
10	to	O
11	a	O
12	hypophosphorylated	O
13	form	O
14	.	O
15	mRNA	O
16	for	O
17	the	O
18	HPV	O
19	E6	B
20	/	O
21	E7	B
22	genes	O
23	decreased	O
24	;	O
25	however	O
26	,	O
27	significant	O
28	changes	O
29	in	O
30	the	O
31	E7	B
32	protein	I
33	were	O
34	not	O
35	observed	O
36	,	O
37	while	O
38	increased	O
39	levels	O
40	of	O
41	Rb	B
42	immunoprecipitated	O
43	with	O
44	anti	B
45	-	I
46	E7	I
47	antibodies	I
48	were	O
49	observed	O
50	.	O

1	Further	O
2	characterization	O
3	of	O
4	these	O
5	putative	O
6	Hoxa	B
7	-	I
8	1	I
9	target	I
10	genes	I
11	will	O
12	aid	O
13	in	O
14	delineating	O
15	the	O
16	functions	O
17	of	O
18	the	O
19	Hoxa	B
20	-	I
21	1	I
22	protein	I
23	in	O
24	the	O
25	differentiation	O
26	processes	O
27	which	O
28	occur	O
29	during	O
30	embryogenesis	O
31	.	O

1	The	O
2	ability	O
3	of	O
4	U6	B
5	-	O
6	U57	B
7	mutants	O
8	to	O
9	influence	O
10	the	O
11	fidelity	O
12	of	O
13	both	O
14	branch	O
15	site	O
16	and	O
17	3	O
18	'	O
19	splice	O
20	site	O
21	recognition	O
22	suggests	O
23	that	O
24	this	O
25	nucleotide	O
26	may	O
27	participate	O
28	in	O
29	the	O
30	formation	O
31	of	O
32	the	O
33	active	O
34	site	O
35	(	O
36	s	O
37	)	O
38	of	O
39	the	O
40	spliceosome	O
41	.	O

1	We	O
2	have	O
3	determined	O
4	the	O
5	structure	O
6	of	O
7	the	O
8	WNT	B
9	-	I
10	2B	I
11	gene	I
12	.	O

1	The	O
2	role	O
3	of	O
4	daunorubicin	O
5	in	O
6	induction	O
7	therapy	O
8	for	O
9	adult	O
10	acute	O
11	myeloid	O
12	leukemia	O

1	Five	O
2	of	O
3	the	O
4	Aeromonas	O
5	strains	O
6	and	O
7	one	O
8	of	O
9	V	O
10	cholerae	O
11	non	O
12	-	O
13	O1	O
14	were	O
15	positive	O
16	for	O
17	enterotoxin	O
18	activity	O
19	.	O

1	TNF	B
2	-	I
3	alpha	I
4	induced	O
5	a	O
6	dose	O
7	-	O
8	and	O
9	time	O
10	-	O
11	dependent	O
12	increase	O
13	in	O
14	cyclooxygenase	B
15	-	I
16	2	I
17	(	O
18	COX	B
19	-	I
20	2	I
21	)	O
22	expression	O
23	and	O
24	PGE2	O
25	formation	O
26	in	O
27	human	O
28	NCI	O
29	-	O
30	H292	O
31	epithelial	O
32	cells	O
33	.	O

1	The	O
2	therapy	O
3	time	O
4	to	O
5	deliver	O
6	the	O
7	NCS	O
8	therapeutic	O
9	dose	O
10	of	O
11	10000	O
12	RBE	O
13	-	O
14	cGy	O
15	,	O
16	is	O
17	27	O
18	times	O
19	longer	O
20	when	O
21	157Gd	O
22	is	O
23	used	O
24	instead	O
25	of	O
26	10B	O
27	.	O

1	Mis3	B
2	is	O
3	needed	O
4	for	O
5	the	O
6	formation	O
7	of	O
8	18S	B
9	ribosome	I
10	RNA	I
11	,	O
12	and	O
13	may	O
14	hence	O
15	direct	O
16	the	O
17	level	O
18	of	O
19	proteins	O
20	required	O
21	for	O
22	the	O
23	coupling	O
24	.	O

1	Losartan	O
2	Intervention	O
3	For	O
4	Endpoint	O
5	.	O

1	CONCLUSION	O
2	:	O
3	Vitrectomy	O
4	for	O
5	vitreous	O
6	hemorrhage	O
7	in	O
8	Terson	O
9	syndrome	O
10	is	O
11	a	O
12	safe	O
13	and	O
14	effective	O
15	procedure	O
16	,	O
17	offering	O
18	a	O
19	rapid	O
20	and	O
21	prolonged	O
22	improvement	O
23	in	O
24	vision	O
25	.	O

1	RNA	O
2	in	O
3	situ	O
4	hybridization	O
5	on	O
6	brain	O
7	sections	O
8	of	O
9	normal	O
10	human	O
11	embryos	O
12	revealed	O
13	a	O
14	strong	O
15	labeling	O
16	in	O
17	restricted	O
18	areas	O
19	of	O
20	the	O
21	cerebral	O
22	cortex	O
23	.	O

1	To	O
2	facilitate	O
3	manipulation	O
4	of	O
5	large	O
6	genomic	O
7	sequences	O
8	,	O
9	we	O
10	developed	O
11	a	O
12	method	O
13	of	O
14	converting	O
15	Escherichia	O
16	coli	O
17	P1	O
18	artificial	O
19	chromosomes	O
20	(	O
21	PACs	O
22	)	O
23	into	O
24	yeast	O
25	artificial	O
26	chromosomes	O
27	(	O
28	YACs	O
29	).	O

1	After	O
2	gamma	O
3	-	O
4	irradiation	O
5	,	O
6	the	O
7	majority	O
8	of	O
9	F9	O
10	cells	O
11	undergo	O
12	apoptosis	O
13	implying	O
14	that	O
15	wt	B
16	-	I
17	p53	I
18	likely	O
19	triggers	O
20	pro	O
21	-	O
22	apoptotic	O
23	gene	O
24	expression	O
25	in	O
26	DNA	O
27	damaged	O
28	cells	O
29	.	O

1	Mobilization	O
2	with	O
3	cyclophosphamide	O
4	and	O
5	granulocyte	B
6	-	I
7	colony	I
8	stimulating	I
9	factor	I
10	was	O
11	effective	O
12	in	O
13	terms	O
14	of	O
15	CD34	B
16	+	I
17	cell	O
18	shift	O
19	to	O
20	peripheral	O
21	blood	O
22	and	O
23	the	O
24	good	O
25	quality	O
26	autograft	O
27	reliably	O
28	led	O
29	to	O
30	haematopoetic	O
31	recovery	O
32	after	O
33	megachemotherapy	O
34	.	O

1	This	O
2	suggests	O
3	that	O
4	cardiovascular	O
5	magnetic	O
6	resonance	O
7	is	O
8	the	O
9	preferred	O
10	technique	O
11	for	O
12	volume	O
13	and	O
14	ejection	O
15	fraction	O
16	estimation	O
17	in	O
18	heart	O
19	failure	O
20	patients	O
21	,	O
22	because	O
23	of	O
24	its	O
25	3D	O
26	approach	O
27	for	O
28	non	O
29	-	O
30	symmetric	O
31	ventricles	O
32	and	O
33	superior	O
34	image	O
35	quality	O
36	.	O

1	A	O
2	degenerate	O
3	DNA	O
4	transposon	O
5	,	O
6	Pat	B
7	,	O
8	was	O
9	identified	O
10	in	O
11	the	O
12	genomes	O
13	of	O
14	various	O
15	wild	O
16	-	O
17	type	O
18	strains	O
19	of	O
20	the	O
21	filamentous	O
22	fungus	O
23	Podospora	O
24	anserina	O
25	.	O

1	However	O
2	,	O
3	the	O
4	presence	O
5	of	O
6	Tax	B
7	I	I
8	increased	O
9	the	O
10	extent	O
11	and	O
12	altered	O
13	the	O
14	profile	O
15	of	O
16	proteins	O
17	binding	O
18	TRE	B
19	-	I
20	2	I
21	in	O
22	vivo	O
23	.	O

1	We	O
2	have	O
3	also	O
4	identified	O
5	a	O
6	functional	O
7	domain	O
8	in	O
9	the	O
10	ORF	O
11	50	O
12	protein	O
13	,	O
14	an	O
15	immediate	B
16	-	I
17	early	I
18	gene	I
19	product	I
20	that	O
21	is	O
22	mainly	O
23	encoded	O
24	by	O
25	ORF	O
26	50	O
27	.	O

1	A	O
2	2	O
3	.	O
4	3	O
5	-	O
6	kb	O
7	full	O
8	-	O
9	length	O
10	cDNA	O
11	clone	O
12	of	O
13	an	O
14	Atlantic	B
15	halibut	I
16	Mx	I
17	gene	I
18	was	O
19	isolated	O
20	from	O
21	a	O
22	liver	O
23	cDNA	O
24	library	O
25	.	O

1	PLUS	O
2	-	O
3	3	O
4	is	O
5	a	O
6	new	O
7	Swedish	O
8	protocol	O
9	of	O
10	natural	O
11	speech	O
12	in	O
13	3	O
14	-	O
15	year	O
16	-	O
17	old	O
18	children	O
19	.	O

1	Once	O
2	HIT	O
3	II	O
4	is	O
5	suspected	O
6	,	O
7	heparin	O
8	(	O
9	and	O
10	low	O
11	-	O
12	molecular	O
13	-	O
14	weight	O
15	heparins	O
16	)	O
17	should	O
18	be	O
19	stopped	O
20	immediately	O
21	.	O

1	The	O
2	reduced	O
3	efficiency	O
4	in	O
5	the	O
6	glycosylase	B
7	activity	O
8	is	O
9	also	O
10	reflected	O
11	in	O
12	a	O
13	reduced	O
14	ability	O
15	of	O
16	S120K	B
17	MutY	I
18	to	O
19	prevent	O
20	DNA	O
21	mutations	O
22	in	O
23	vivo	O
24	.	O

1	METHODS	O
2	AND	O
3	RESULTS	O
4	:	O
5	We	O
6	prospectively	O
7	compared	O
8	the	O
9	automated	O
10	measurements	O
11	of	O
12	left	O
13	ventricular	O
14	ejection	O
15	fraction	O
16	(	O
17	LVEF	O
18	)	O
19	and	O
20	volumes	O
21	from	O
22	rest	O
23	-	O
24	injected	O
25	gated	O
26	Technetium	O
27	99m	O
28	(	O
29	Tc99m	O
30	)	O
31	perfusion	O
32	SPECT	O
33	with	O
34	equilibrium	O
35	radionuclide	O
36	angiocardiography	O
37	(	O
38	ERNA	O
39	)	O
40	in	O
41	62	O
42	patients	O
43	and	O
44	the	O
45	assessment	O
46	of	O
47	regional	O
48	function	O
49	with	O
50	echocardiography	O
51	in	O
52	22	O
53	patients	O
54	.	O

1	The	O
2	2	O
3	cDNAs	O
4	differed	O
5	in	O
6	the	O
7	length	O
8	of	O
9	their	O
10	respective	O
11	3	O
12	'	O
13	untranslated	O
14	regions	O
15	,	O
16	of	O
17	577	O
18	bp	O
19	in	O
20	Cp	B
21	.	I
22	F6	I
23	and	O
24	72	O
25	bp	O
26	in	O
27	Cp	B
28	.	I
29	F10	I
30	,	O
31	in	O
32	both	O
33	of	O
34	which	O
35	a	O
36	putative	O
37	polyadenylation	O
38	signal	O
39	was	O
40	identified	O
41	.	O

1	This	O
2	intracellular	O
3	signaling	O
4	,	O
5	known	O
6	as	O
7	the	O
8	unfolded	O
9	protein	O
10	response	O
11	(	O
12	UPR	O
13	),	O
14	is	O
15	mediated	O
16	by	O
17	the	O
18	cis	O
19	-	O
20	acting	O
21	ER	O
22	stress	O
23	response	O
24	element	O
25	(	O
26	ERSE	O
27	)	O
28	in	O
29	mammals	O
30	.	O

1	A	O
2	Y	B
3	.	I
4	lipolytica	I
5	Kar2p	I
6	mutant	I
7	was	O
8	isolated	O
9	that	O
10	restored	O
11	interaction	O
12	with	O
13	an	O
14	Sls1p	B
15	mutant	I
16	,	O
17	suggesting	O
18	that	O
19	the	O
20	interaction	O
21	with	O
22	Sls1p	B
23	could	O
24	be	O
25	nucleotide	O
26	and	O
27	/	O
28	or	O
29	conformation	O
30	dependent	O
31	.	O

1	We	O
2	have	O
3	carried	O
4	out	O
5	a	O
6	comprehensive	O
7	and	O
8	systematic	O
9	mutagenesis	O
10	of	O
11	the	O
12	Cse4p	B
13	N	I
14	terminus	I
15	to	O
16	analyze	O
17	its	O
18	function	O
19	.	O

1	The	O
2	spacing	O
3	of	O
4	the	O
5	essential	O
6	N	O
7	-	O
8	terminal	O
9	domain	O
10	(	O
11	END	O
12	)	O
13	relative	O
14	to	O
15	the	O
16	HFD	B
17	can	O
18	be	O
19	changed	O
20	significantly	O
21	without	O
22	an	O
23	apparent	O
24	effect	O
25	on	O
26	Cse4p	B
27	function	O
28	.	O

1	The	O
2	bases	O
3	of	O
4	this	O
5	comparison	O
6	are	O
7	reviewed	O
8	and	O
9	discussed	O
10	.	O

1	In	O
2	invertebrates	O
3	,	O
4	Fhit	B
5	is	O
6	encoded	O
7	as	O
8	a	O
9	fusion	O
10	protein	O
11	with	O
12	Nit	B
13	,	O
14	a	O
15	member	O
16	of	O
17	the	O
18	nitrilase	B
19	superfamily	I
20	.	O

1	Platelet	O
2	counts	O
3	and	O
4	function	O
5	as	O
6	well	O
7	as	O
8	fibrinogen	B
9	and	O
10	von	B
11	Willebrand	I
12	factor	I
13	(	O
14	vWF	B
15	)	O
16	levels	O
17	were	O
18	determined	O
19	in	O
20	each	O
21	sample	O
22	.	O

1	The	O
2	manifestations	O
3	often	O
4	include	O
5	a	O
6	moderate	O
7	thrombocytopenia	O
8	and	O
9	,	O
10	less	O
11	commonly	O
12	,	O
13	hemolysis	O
14	.	O

1	A	O
2	beta2	B
3	RARE	I
4	reporter	I
5	construct	I
6	in	O
7	which	O
8	the	O
9	methylation	O
10	-	O
11	susceptible	O
12	cytosines	O
13	in	O
14	the	O
15	sense	O
16	strand	O
17	were	O
18	replaced	O
19	by	O
20	thymine	O
21	displayed	O
22	marked	O
23	loss	O
24	of	O
25	activity	O
26	in	O
27	a	O
28	replicated	O
29	chromatin	O
30	-	O
31	dependent	O
32	manner	O
33	.	O

1	Non	O
2	-	O
3	poliomyelitis	O
4	AFP	O
5	rate	O
6	had	O
7	increased	O
8	from	O
9	0	O
10	.	O
11	9	O
12	in	O
13	1997	O
14	to	O
15	2	O
16	.	O
17	8	O
18	in	O
19	1998	O
20	.	O

1	Consciousness	O
2	is	O
3	connected	O
4	with	O
5	attention	O
6	,	O
7	working	O
8	memory	O
9	and	O
10	perception	O
11	.	O

1	Multiparity	O
2	had	O
3	a	O
4	protective	O
5	effect	O
6	with	O
7	0	O
8	.	O
9	66	O
10	less	O
11	risk	O
12	(	O
13	95	O
14	%	O
15	CI	O
16	0	O
17	.	O
18	44	O
19	-	O
20	0	O
21	.	O
22	99	O
23	).	O

1	Picture	O
2	the	O
3	smell	O
4	.	O

1	The	O
2	aim	O
3	of	O
4	our	O
5	study	O
6	was	O
7	to	O
8	evaluate	O
9	the	O
10	level	O
11	of	O
12	oxidative	O
13	stress	O
14	in	O
15	healthy	O
16	controls	O
17	(	O
18	CTL	O
19	)	O
20	compared	O
21	with	O
22	CRF	O
23	and	O
24	HD	O
25	patients	O
26	before	O
27	(	O
28	pre	O
29	-	O
30	HD	O
31	)	O
32	and	O
33	after	O
34	(	O
35	post	O
36	-	O
37	HD	O
38	)	O
39	the	O
40	dialysis	O
41	session	O
42	,	O
43	carried	O
44	out	O
45	on	O
46	a	O
47	high	O
48	biocompatible	O
49	polyacrylonitrile	O
50	membrane	O
51	AN69	O
52	.	O

1	Indirect	O
2	plasma	O
3	parameters	O
4	such	O
5	as	O
6	vitamin	O
7	E	O
8	,	O
9	thiol	O
10	and	O
11	uric	O
12	acid	O
13	levels	O
14	were	O
15	also	O
16	quantified	O
17	.	O

1	Only	O
2	two	O
3	of	O
4	27	O
5	participants	O
6	(	O
7	7	O
8	.	O
9	4	O
10	%)	O
11	with	O
12	definite	O
13	POAG	O
14	had	O
15	been	O
16	previously	O
17	diagnosed	O
18	and	O
19	treated	O
20	,	O
21	and	O
22	66	O
23	.	O
24	7	O
25	%	O
26	of	O
27	the	O
28	previously	O
29	undiagnosed	O
30	had	O
31	IOP	O
32	less	O
33	than	O
34	22	O
35	mmHg	O
36	.	O

1	Taken	O
2	together	O
3	,	O
4	they	O
5	uphold	O
6	the	O
7	emerging	O
8	concern	O
9	that	O
10	women	O
11	with	O
12	ER	B
13	(+)	I
14	cancers	O
15	may	O
16	not	O
17	benefit	O
18	significantly	O
19	from	O
20	endocrine	O
21	treatment	O
22	if	O
23	the	O
24	tumors	O
25	also	O
26	overexpress	O
27	HER	B
28	-	I
29	2	I
30	.	O

1	Promoter	O
2	activity	O
3	was	O
4	dose	O
5	-	O
6	dependently	O
7	inhibited	O
8	by	O
9	cotransfection	O
10	with	O
11	either	O
12	ras	B
13	or	O
14	mos	B
15	oncogenes	I
16	,	O
17	but	O
18	oncogene	O
19	inhibition	O
20	was	O
21	reversed	O
22	and	O
23	the	O
24	overall	O
25	activity	O
26	increased	O
27	when	O
28	cells	O
29	were	O
30	treated	O
31	with	O
32	the	O
33	MAP	B
34	kinase	I
35	kinase	I
36	(	O
37	MKK	B
38	)	O
39	inhibitor	O
40	PD98059	O
41	.	O

1	Our	O
2	results	O
3	indicate	O
4	that	O
5	the	O
6	expression	O
7	of	O
8	Cktsf1b1	B
9	,	O
10	a	O
11	gene	O
12	associated	O
13	with	O
14	early	O
15	development	O
16	and	O
17	cell	O
18	transformation	O
19	,	O
20	is	O
21	sensitive	O
22	to	O
23	MKK	B
24	levels	O
25	and	O
26	may	O
27	be	O
28	regulated	O
29	via	O
30	multiple	O
31	transcription	O
32	factor	O
33	complexes	O
34	.	O

1	INTERVENTIONS	O
2	:	O
3	Subcutaneous	O
4	tissue	O
5	PO2	O
6	and	O
7	PCO2	O
8	tensions	O
9	were	O
10	measured	O
11	directly	O
12	in	O
13	patients	O
14	with	O
15	necrotising	O
16	fasciitis	O
17	and	O
18	in	O
19	healthy	O
20	volunteers	O
21	during	O
22	normobaric	O
23	and	O
24	hyperbaric	O
25	conditions	O
26	.	O

1	Because	O
2	GH	B
3	-	O
4	induced	O
5	Akt	B
6	activation	O
7	was	O
8	completely	O
9	inhibited	O
10	in	O
11	both	O
12	cells	O
13	by	O
14	the	O
15	same	O
16	concentration	O
17	of	O
18	LY294002	O
19	,	O
20	these	O
21	findings	O
22	indicate	O
23	that	O
24	the	O
25	wortmannin	O
26	sensitivity	O
27	of	O
28	both	O
29	the	O
30	IRS	B
31	-	I
32	1	I
33	-	O
34	independent	O
35	and	O
36	-	O
37	dependent	O
38	GH	B
39	-	O
40	induced	O
41	MAP	B
42	kinase	I
43	activation	O
44	may	O
45	reflect	O
46	the	O
47	activity	O
48	of	O
49	another	O
50	wortmannin	O
51	-	O
52	sensitive	O
53	target	O
54	(	O
55	s	O
56	)	O
57	in	O
58	addition	O
59	to	O
60	PI3K	B
61	in	O
62	mediation	O
63	of	O
64	GH	B
65	-	O
66	induced	O
67	MAP	B
68	kinase	I
69	activation	O
70	in	O
71	these	O
72	cells	O
73	.	O

1	Insulin	B
2	receptor	I
3	substrate	I
4	-	I
5	1	I
6	-	O
7	mediated	O
8	enhancement	O
9	of	O
10	growth	B
11	hormone	I
12	-	O
13	induced	O
14	mitogen	B
15	-	I
16	activated	I
17	protein	I
18	kinase	I
19	activation	O
20	.	O

1	Functional	O
2	magnetic	O
3	resonance	O
4	imaging	O
5	(	O
6	fMRI	O
7	)	O
8	has	O
9	been	O
10	increasingly	O
11	used	O
12	in	O
13	studying	O
14	human	O
15	brain	O
16	function	O
17	given	O
18	its	O
19	non	O
20	-	O
21	invasive	O
22	feature	O
23	and	O
24	good	O
25	spatial	O
26	resolution	O
27	.	O

1	After	O
2	declamping	O
3	of	O
4	the	O
5	aorta	O
6	,	O
7	there	O
8	were	O
9	also	O
10	severe	O
11	edema	O
12	,	O
13	local	O
14	fibre	O
15	necrosis	O
16	,	O
17	and	O
18	adhesion	O
19	of	O
20	leucocytes	O
21	,	O
22	whereas	O
23	muscle	O
24	fibre	O
25	areas	O
26	became	O
27	3	O
28	,	O
29	935	O
30	.	O
31	18	O
32	micro	O
33	531	O
34	microm	O
35	(	O
36	2	O
37	)	O
38	for	O
39	type	O
40	I	O
41	and	O
42	5	O
43	,	O
44	804	O
45	+/-	O
46	1	O
47	,	O
48	075	O
49	microm	O
50	(	O
51	2	O
52	)	O
53	for	O
54	type	O
55	II	O
56	.	O

1	The	O
2	results	O
3	indicate	O
4	that	O
5	the	O
6	relationship	O
7	between	O
8	comprehension	O
9	and	O
10	production	O
11	is	O
12	different	O
13	at	O
14	different	O
15	stages	O
16	in	O
17	development	O
18	.	O

1	It	O
2	was	O
3	found	O
4	that	O
5	increase	O
6	in	O
7	the	O
8	RH	O
9	level	O
10	boosts	O
11	the	O
12	current	O
13	values	O
14	by	O
15	2	O
16	-	O
17	3	O
18	orders	O
19	of	O
20	magnitude	O
21	;	O
22	contrariwise	O
23	,	O
24	the	O
25	voltage	O
26	values	O
27	rise	O
28	by	O
29	about	O
30	three	O
31	times	O
32	with	O
33	drop	O
34	in	O
35	the	O
36	RH	O
37	.	O

1	On	O
2	long	O
3	-	O
4	term	O
5	follow	O
6	-	O
7	up	O
8	,	O
9	there	O
10	was	O
11	no	O
12	significant	O
13	difference	O
14	in	O
15	the	O
16	incidence	O
17	of	O
18	hospitalizations	O
19	(	O
20	1	O
21	per	O
22	2	O
23	.	O
24	1	O
25	vs	O
26	.	O

1	Genomic	O
2	libraries	O
3	were	O
4	stored	O
5	as	O
6	frozen	O
7	cultures	O
8	in	O
9	a	O
10	96	O
11	-	O
12	well	O
13	format	O
14	,	O
15	each	O
16	well	O
17	containing	O
18	approximately	O
19	300	O
20	-	O
21	600	O
22	colonies	O
23	(	O
24	12	O
25	plates	O
26	for	O
27	small	O
28	library	O
29	,	O
30	four	O
31	for	O
32	medium	O
33	-	O
34	size	O
35	library	O
36	and	O
37	four	O
38	for	O
39	large	O
40	library	O
41	).	O

1	In	O
2	several	O
3	cell	O
4	lines	O
5	,	O
6	mTOR	B
7	or	O
8	its	O
9	downstream	O
10	targets	O
11	can	O
12	be	O
13	regulated	O
14	by	O
15	phosphatidylinositol	B
16	(	I
17	PI	I
18	)	I
19	3	I
20	-	I
21	kinase	I
22	;	O
23	protein	B
24	kinases	I
25	A	I
26	,	I
27	B	I
28	,	I
29	and	I
30	C	I
31	;	O
32	heterotrimeric	B
33	G	I
34	-	I
35	proteins	I
36	;	O
37	a	O
38	PD98059	O
39	-	O
40	sensitive	O
41	kinase	O
42	or	O
43	calcium	O
44	;	O
45	as	O
46	well	O
47	as	O
48	by	O
49	amino	O
50	acids	O
51	.	O

1	The	O
2	tumor	B
3	-	I
4	suppressor	I
5	protein	I
6	p53	I
7	is	O
8	involved	O
9	in	O
10	maintaining	O
11	genomic	O
12	stability	O
13	.	O

1	Abrogation	O
2	of	O
3	p53	B
4	function	O
5	by	O
6	E6	B
7	resulted	O
8	in	O
9	an	O
10	increase	O
11	in	O
12	the	O
13	spontaneous	O
14	mutation	O
15	frequencies	O
16	at	O
17	the	O
18	heterozygous	O
19	thymidine	B
20	kinase	I
21	(	O
22	TK	B
23	)	O
24	locus	O
25	but	O
26	not	O
27	at	O
28	the	O
29	hemizygous	O
30	hypoxanthine	B
31	phosphoribosyl	I
32	transferase	I
33	(	O
34	HPRT	B
35	)	O
36	locus	O
37	.	O

1	Cytogenetic	O
2	analysis	O
3	of	O
4	LOH	O
5	mutants	O
6	by	O
7	chromosome	O
8	painting	O
9	indicated	O
10	a	O
11	mosaic	O
12	of	O
13	chromosomal	O
14	aberrations	O
15	involving	O
16	chromosome	O
17	17	O
18	,	O
19	in	O
20	which	O
21	partial	O
22	chromosome	O
23	deletions	O
24	,	O
25	amplifications	O
26	,	O
27	and	O
28	multiple	O
29	translocations	O
30	appeared	O
31	heterogeneously	O
32	in	O
33	a	O
34	single	O
35	mutant	O
36	.	O

1	These	O
2	results	O
3	support	O
4	a	O
5	model	O
6	in	O
7	which	O
8	p53	B
9	protein	I
10	contributes	O
11	to	O
12	the	O
13	maintenance	O
14	of	O
15	genomic	O
16	integrity	O
17	through	O
18	recombinational	O
19	repair	O
20	.	O

1	The	O
2	importance	O
3	of	O
4	this	O
5	new	O
6	epidemiological	O
7	profile	O
8	of	O
9	schistosomiasis	O
10	in	O
11	the	O
12	State	O
13	of	O
14	Pernambuco	O
15	relies	O
16	on	O
17	the	O
18	fact	O
19	that	O
20	it	O
21	can	O
22	be	O
23	related	O
24	with	O
25	the	O
26	drastic	O
27	human	O
28	interference	O
29	on	O
30	the	O
31	environment	O
32	.	O

1	In	O
2	patients	O
3	with	O
4	type	O
5	II	O
6	tumors	O
7	,	O
8	the	O
9	pattern	O
10	of	O
11	lymphatic	O
12	spread	O
13	was	O
14	primarily	O
15	directed	O
16	toward	O
17	the	O
18	paracardial	O
19	,	O
20	lesser	O
21	curvature	O
22	,	O
23	and	O
24	left	O
25	gastric	O
26	artery	O
27	nodes	O
28	;	O
29	esophagectomy	O
30	offered	O
31	no	O
32	survival	O
33	benefit	O
34	over	O
35	extended	O
36	gastrectomy	O
37	in	O
38	these	O
39	patients	O
40	.	O

1	RESULTS	O
2	:	O
3	No	O
4	significant	O
5	deformation	O
6	in	O
7	vertebral	O
8	artery	O
9	flow	O
10	was	O
11	noted	O
12	in	O
13	the	O
14	flexion	O
15	-	O
16	distraction	O
17	Stage	O
18	I	O
19	injuries	O
20	within	O
21	the	O
22	physiologic	O
23	range	O
24	of	O
25	cervical	O
26	flexion	O
27	.	O

1	We	O
2	screened	O
3	a	O
4	K562	O
5	cDNA	O
6	library	O
7	and	O
8	identified	O
9	novel	O
10	transcripts	O
11	,	O
12	MZF1B	B
13	and	O
14	MZF1C	B
15	.	O

1	The	O
2	human	O
3	cDNA	O
4	clone	O
5	NFBD1	O
6	(	O
7	previously	O
8	designated	O
9	KIAA0170	O
10	)	O
11	encodes	O
12	a	O
13	novel	O
14	protein	O
15	(	O
16	2089	O
17	amino	O
18	acids	O
19	in	O
20	length	O
21	;	O
22	calculated	O
23	molecular	O
24	mass	O
25	226	O
26	,	O
27	440	O
28	D	O
29	)	O
30	with	O
31	possible	O
32	BRCT	B
33	domains	I
34	at	O
35	its	O
36	carboxy	O
37	terminus	O
38	(	O
39	amino	O
40	acid	O
41	residues	O
42	1894	O
43	-	O
44	2089	O
45	).	O

1	RESULTS	O
2	:	O
3	Neither	O
4	basal	O
5	FSH	B
6	level	O
7	nor	O
8	stimulated	O
9	FSH	B
10	level	O
11	alone	O
12	were	O
13	statistically	O
14	significant	O
15	predictors	O
16	of	O
17	IVF	O
18	success	O
19	;	O
20	however	O
21	,	O
22	no	O
23	patient	O
24	with	O
25	a	O
26	day	O
27	3	O
28	FSH	B
29	level	O
30	>	O
31	11	O
32	.	O
33	1	O
34	mIU	O
35	/	O
36	ml	O
37	or	O
38	a	O
39	stimulated	O
40	day	O
41	10	O
42	FSH	B
43	level	O
44	>	O
45	13	O
46	.	O
47	5	O
48	mIU	O
49	/	O
50	ml	O
51	conceived	O
52	and	O
53	carried	O
54	a	O
55	pregnancy	O
56	.	O

1	Parathyroid	B
2	hormone	I
3	regulation	O
4	of	O
5	bone	B
6	sialoprotein	I
7	(	O
8	BSP	B
9	)	O
10	gene	O
11	transcription	O
12	is	O
13	mediated	O
14	through	O
15	a	O
16	pituitary	B
17	-	I
18	specific	I
19	transcription	I
20	factor	I
21	-	I
22	1	I
23	(	O
24	Pit	B
25	-	I
26	1	I
27	)	O
28	motif	O
29	in	O
30	the	O
31	rat	B
32	BSP	I
33	gene	I
34	promoter	I
35	.	O

1	Recent	O
2	target	O
3	BP	O
4	goals	O
5	promulgated	O
6	by	O
7	the	O
8	Sixth	O
9	Report	O
10	from	O
11	the	O
12	Joint	O
13	National	O
14	Committee	O
15	(	O
16	JNC	O
17	VI	O
18	)	O
19	are	O
20	based	O
21	on	O
22	the	O
23	premise	O
24	that	O
25	the	O
26	intensity	O
27	of	O
28	treatment	O
29	directly	O
30	corresponds	O
31	to	O
32	the	O
33	magnitude	O
34	of	O
35	pretreatment	O
36	risk	O
37	.	O

1	Linking	O
2	continuous	O
3	community	O
4	-	O
5	based	O
6	morbidity	O
7	recording	O
8	of	O
9	influenza	O
10	-	O
11	like	O
12	illness	O
13	(	O
14	ILI	O
15	)	O
16	with	O
17	virological	O
18	sampling	O
19	has	O
20	consistently	O
21	proved	O
22	its	O
23	value	O
24	as	O
25	one	O
26	of	O
27	the	O
28	earliest	O
29	indicators	O
30	of	O
31	circulating	O
32	influenza	O
33	activity	O
34	.	O

1	The	O
2	muskox	O
3	is	O
4	a	O
5	new	O
6	host	O
7	record	O
8	for	O
9	T	O
10	.	O
11	gondii	O
12	.	O

1	These	O
2	include	O
3	NPF	O
4	repeats	O
5	,	O
6	a	O
7	leucine	O
8	heptad	O
9	repeat	O
10	enriched	O
11	in	O
12	charged	O
13	residues	O
14	,	O
15	and	O
16	a	O
17	proline	O
18	-	O
19	rich	O
20	SH3	B
21	-	I
22	like	I
23	and	O
24	/	O
25	or	O
26	WW	O
27	domain	O
28	-	O
29	binding	O
30	site	O
31	in	O
32	the	O
33	N	O
34	-	O
35	terminal	O
36	domain	O
37	,	O
38	which	O
39	is	O
40	followed	O
41	by	O
42	a	O
43	membrane	O
44	core	O
45	containing	O
46	four	O
47	putative	O
48	transmembrane	O
49	spans	O
50	and	O
51	three	O
52	amphiphilic	O
53	segments	O
54	that	O
55	are	O
56	the	O
57	most	O
58	highly	O
59	conserved	O
60	structural	O
61	elements	O
62	.	O

1	We	O
2	show	O
3	here	O
4	that	O
5	this	O
6	difference	O
7	is	O
8	due	O
9	to	O
10	the	O
11	presence	O
12	of	O
13	a	O
14	Mot3	B
15	binding	I
16	site	I
17	in	O
18	OpA	B
19	.	O

1	The	O
2	article	O
3	deals	O
4	with	O
5	the	O
6	diagnosing	O
7	and	O
8	correction	O
9	of	O
10	reversible	O
11	ischemia	O
12	of	O
13	the	O
14	intestine	O
15	.	O

1	Mucosal	O
2	application	O
3	of	O
4	NCX	O
5	-	O
6	4016	O
7	,	O
8	however	O
9	,	O
10	did	O
11	not	O
12	cause	O
13	PD	O
14	reduction	O
15	and	O
16	luminal	O
17	H	O
18	+	O
19	loss	O
20	,	O
21	but	O
22	produced	O
23	a	O
24	marked	O
25	hyperemia	O
26	,	O
27	resulting	O
28	in	O
29	no	O
30	damage	O
31	in	O
32	the	O
33	stomach	O
34	of	O
35	both	O
36	normal	O
37	and	O
38	STZ	O
39	-	O
40	diabetic	O
41	rats	O
42	.	O

1	Functional	O
2	recognition	O
3	of	O
4	5	O
5	'	O
6	splice	O
7	site	O
8	by	O
9	U4	B
10	/	O
11	U6	B
12	.	O
13	U5	B
14	tri	O
15	-	O
16	snRNP	O
17	defines	O
18	a	O
19	novel	O
20	ATP	O
21	-	O
22	dependent	O
23	step	O
24	in	O
25	early	O
26	spliceosome	O
27	assembly	O
28	.	O

1	As	O
2	control	O
3	,	O
4	the	O
5	cells	O
6	were	O
7	transfected	O
8	with	O
9	DNA	O
10	mixtures	O
11	containing	O
12	vector	O
13	mU6	O
14	-	O
15	C1	O
16	or	O
17	mU6	O
18	-	O
19	C2	O
20	.	O

1	The	O
2	amino	O
3	acid	O
4	sequence	O
5	of	O
6	matrilysin	B
7	-	I
8	2	I
9	also	O
10	contains	O
11	a	O
12	threonine	O
13	residue	O
14	adjacent	O
15	to	O
16	the	O
17	Zn	O
18	-	O
19	binding	O
20	site	O
21	that	O
22	has	O
23	been	O
24	defined	O
25	as	O
26	a	O
27	specific	O
28	feature	O
29	of	O
30	matrilysin	B
31	.	O

1	In	O
2	this	O
3	regard	O
4	,	O
5	we	O
6	have	O
7	recently	O
8	observed	O
9	that	O
10	a	O
11	constitutively	O
12	active	O
13	G	B
14	protein	I
15	-	I
16	coupled	I
17	receptor	I
18	(	O
19	GPCR	B
20	)	O
21	encoded	O
22	by	O
23	the	O
24	Kaposi	O
25	'	O
26	s	O
27	sarcoma	O
28	-	O
29	associated	O
30	herpes	O
31	virus	O
32	(	O
33	KSHV	O
34	)/	O
35	human	O
36	herpes	O
37	virus	O
38	8	O
39	is	O
40	oncogenic	O
41	and	O
42	stimulates	O
43	angiogenesis	O
44	by	O
45	increasing	O
46	the	O
47	secretion	O
48	of	O
49	vascular	B
50	endothelial	I
51	growth	I
52	factor	I
53	(	O
54	VEGF	B
55	),	O
56	which	O
57	is	O
58	a	O
59	key	O
60	angiogenic	O
61	stimulator	O
62	and	O
63	a	O
64	critical	O
65	mitogen	O
66	for	O
67	the	O
68	development	O
69	of	O
70	Kaposi	O
71	'	O
72	s	O
73	sarcoma	O
74	.	O

1	No	O
2	specific	O
3	subgroup	O
4	of	O
5	clients	O
6	benefited	O
7	more	O
8	from	O
9	URD	O
10	,	O
11	although	O
12	a	O
13	prospective	O
14	study	O
15	employing	O
16	random	O
17	assignment	O
18	might	O
19	be	O
20	more	O
21	successful	O
22	in	O
23	identifying	O
24	such	O
25	a	O
26	group	O
27	.	O

1	In	O
2	the	O
3	lattice	O
4	,	O
5	23	O
6	%	O
7	of	O
8	the	O
9	sites	O
10	are	O
11	occupied	O
12	,	O
13	95	O
14	%	O
15	of	O
16	the	O
17	atoms	O
18	are	O
19	in	O
20	the	O
21	lowest	O
22	energy	O
23	magnetic	O
24	sublevel	O
25	,	O
26	and	O
27	37	O
28	%	O
29	are	O
30	in	O
31	the	O
32	lowest	O
33	3D	O
34	vibrational	O
35	state	O
36	.	O

1	Coexisting	O
2	vertical	O
3	and	O
4	horizontal	O
5	one	O
6	and	O
7	a	O
8	half	O
9	syndromes	O
10	.	O

1	As	O
2	in	O
3	the	O
4	other	O
5	three	O
6	members	O
7	whose	O
8	gene	O
9	expression	O
10	is	O
11	altered	O
12	during	O
13	tumorigenesis	O
14	,	O
15	PI12	B
16	expression	O
17	was	O
18	found	O
19	to	O
20	be	O
21	down	O
22	-	O
23	regulated	O
24	in	O
25	tumor	O
26	brain	O
27	tissues	O
28	and	O
29	in	O
30	two	O
31	brain	O
32	cancer	O
33	cell	O
34	lines	O
35	:	O
36	U	O
37	-	O
38	87	O
39	MG	O
40	and	O
41	H4	O
42	.	O

1	Regarding	O
2	"	O
3	the	O
4	relation	O
5	between	O
6	sexual	O
7	orientation	O
8	and	O
9	penile	O
10	size	O
11	,"	O
12	by	O
13	A	O
14	.	O

1	This	O
2	slope	O
3	was	O
4	further	O
5	significantly	O
6	decreased	O
7	at	O
8	5	O
9	min	O
10	ischemia	O
11	(-	O
12	26	O
13	.	O
14	5	O
15	+/-	O
16	8	O
17	.	O
18	8	O
19	microm	O
20	/	O
21	mmHg	O
22	)	O
23	but	O
24	returned	O
25	toward	O
26	control	O
27	values	O
28	in	O
29	short	O
30	-	O
31	term	O
32	hibernating	O
33	myocardium	O
34	at	O
35	90	O
36	min	O
37	ischemia	O
38	(-	O
39	17	O
40	.	O
41	2	O
42	+/-	O
43	6	O
44	.	O
45	6	O
46	microm	O
47	/	O
48	mmHg	O
49	).	O

1	Whereas	O
2	both	O
3	MAP	O
4	and	O
5	MSNA	O
6	increase	O
7	during	O
8	SHG	O
9	,	O
10	the	O
11	transition	O
12	from	O
13	SHG	O
14	to	O
15	PHI	O
16	is	O
17	characterized	O
18	by	O
19	a	O
20	transient	O
21	reduction	O
22	in	O
23	MAP	O
24	but	O
25	sustained	O
26	elevation	O
27	in	O
28	MSNA	O
29	,	O
30	facilitating	O
31	separation	O
32	of	O
33	these	O
34	factors	O
35	in	O
36	vivo	O
37	.	O

1	Analysis	O
2	of	O
3	Standard	O
4	Reference	O
5	Material	O
6	1846	O
7	,	O
8	Infant	O
9	Formula	O
10	,	O
11	gave	O
12	a	O
13	mean	O
14	value	O
15	of	O
16	0	O
17	.	O
18	95	O
19	+/-	O
20	0	O
21	.	O
22	088	O
23	mg	O
24	vitamin	O
25	K	O
26	/	O
27	kg	O
28	(	O
29	K	O
30	or	O
31	K1	O
32	?)	O
33	(	O
34	n	O
35	=	O
36	31	O
37	)	O
38	with	O
39	a	O
40	coefficient	O
41	of	O
42	variation	O
43	of	O
44	9	O
45	.	O
46	26	O
47	.	O

1	We	O
2	have	O
3	recently	O
4	discovered	O
5	that	O
6	CCAAAT	B
7	/	I
8	enhancer	I
9	-	I
10	binding	I
11	protein	I
12	-	I
13	beta	I
14	(	O
15	C	B
16	/	I
17	EBP	I
18	-	I
19	beta	I
20	)	O
21	induces	O
22	gene	O
23	transcription	O
24	through	O
25	a	O
26	novel	O
27	IFN	B
28	response	I
29	element	I
30	called	O
31	the	O
32	gamma	B
33	-	I
34	IFN	I
35	-	I
36	activated	I
37	transcriptional	I
38	element	I

1	Northern	O
2	blot	O
3	analysis	O
4	demonstrated	O
5	that	O
6	the	O
7	STORP	B
8	gene	I
9	has	O
10	a	O
11	ubiquitous	O
12	pattern	O
13	of	O
14	expression	O
15	similar	O
16	to	O
17	that	O
18	of	O
19	the	O
20	PML	B
21	gene	I
22	.	O

1	In	O
2	the	O
3	TLE	O
4	patients	O
5	the	O
6	NAA	O
7	:	O
8	Cr	O
9	ratios	O
10	were	O
11	reduced	O
12	in	O
13	the	O
14	seizure	O
15	focus	O
16	,	O
17	while	O
18	in	O
19	the	O
20	FLE	O
21	patients	O
22	they	O
23	were	O
24	not	O
25	always	O
26	reduced	O
27	in	O
28	the	O
29	seizure	O
30	focus	O
31	.	O

1	The	O
2	Spo0F	B
3	residues	I
4	making	O
5	up	O
6	the	O
7	hydrophobic	O
8	patch	O
9	are	O
10	very	O
11	similar	O
12	in	O
13	all	O
14	response	O
15	regulators	O
16	suggesting	O
17	that	O
18	the	O
19	binding	O
20	is	O
21	initiated	O
22	through	O
23	the	O
24	same	O
25	residues	O
26	in	O
27	all	O
28	interacting	O
29	response	O
30	regulator	O
31	-	O
32	kinase	O
33	pairs	O
34	.	O

1	The	O
2	psychologic	O
3	factors	O
4	associated	O
5	wth	O
6	serious	O
7	illness	O
8	,	O
9	terminal	O
10	prognoses	O
11	,	O
12	and	O
13	dying	O
14	complicate	O
15	the	O
16	scenario	O
17	even	O
18	more	O
19	as	O
20	compared	O
21	with	O
22	that	O
23	of	O
24	nonmalignant	O
25	pain	O
26	.	O

1	However	O
2	,	O
3	if	O
4	the	O
5	spatial	O
6	resolution	O
7	is	O
8	not	O
9	critical	O
10	and	O
11	interest	O
12	is	O
13	to	O
14	compare	O
15	a	O
16	pathologic	O
17	area	O
18	with	O
19	a	O
20	contralateral	O
21	VOI	O
22	,	O
23	then	O
24	the	O
25	acquisition	O
26	of	O
27	two	O
28	single	O
29	-	O
30	voxel	O
31	spectra	O
32	may	O
33	be	O
34	preferred	O
35	.	O

1	Quantitative	O
2	evaluation	O
3	of	O
4	magneto	O
5	-	O
6	optical	O
7	parameters	O
8	is	O
9	necessary	O
10	in	O
11	order	O
12	to	O
13	apply	O
14	scanning	O
15	near	O
16	-	O
17	field	O
18	optical	O
19	microscope	O
20	(	O
21	SNOM	O
22	)	O
23	technology	O
24	to	O
25	the	O
26	study	O
27	of	O
28	magnetism	O
29	on	O
30	the	O
31	mesoscopic	O
32	scale	O
33	.	O

1	We	O
2	found	O
3	that	O
4	the	O
5	amplitude	O
6	of	O
7	the	O
8	cortical	O
9	evoked	O
10	potentials	O
11	(	O
12	amplitude	O
13	of	O
14	the	O
15	N2	O
16	/	O
17	P2	O
18	peak	O
19	)	O
20	increased	O
21	from	O
22	5	O
23	.	O
24	1	O
25	+/-	O
26	0	O
27	.	O
28	7	O
29	microV	O
30	at	O
31	5	O
32	mA	O
33	to	O
34	16	O
35	.	O
36	3	O
37	+/-	O
38	1	O
39	.	O
40	1	O
41	microV	O
42	at	O
43	20	O
44	mA	O
45	.	O

1	While	O
2	mutations	O
3	in	O
4	K	B
5	-	I
6	Rev	I
7	that	O
8	inactivate	O
9	any	O
10	one	O
11	of	O
12	these	O
13	properties	O
14	also	O
15	blocked	O
16	K	B
17	-	I
18	Rev	I
19	-	O
20	dependent	O
21	nuclear	O
22	RNA	O
23	export	O
24	,	O
25	several	O
26	K	B
27	-	I
28	Rev	I
29	mutants	I
30	were	O
31	comparable	O
32	to	O
33	wild	O
34	type	O
35	when	O
36	assayed	O
37	for	O
38	any	O
39	of	O
40	these	O
41	individual	O
42	activities	O
43	yet	O
44	nevertheless	O
45	defective	O
46	for	O
47	RNA	O
48	export	O
49	.	O

1	LMP	B
2	-	I
3	1	I
4	is	O
5	targeted	O
6	to	O
7	the	O
8	plasma	O
9	membrane	O
10	,	O
11	where	O
12	it	O
13	binds	O
14	TRAF	B
15	,	O
16	TRADD	B
17	,	O
18	and	O
19	JAK	B
20	molecules	I
21	to	O
22	activate	O
23	NF	B
24	-	I
25	kappaB	I
26	-,	O
27	AP	B
28	-	I
29	1	I
30	-,	O
31	and	O
32	STAT	B
33	-	O
34	dependent	O
35	pathways	O
36	as	O
37	does	O
38	CD40	B
39	.	O

1	Identification	O
2	of	O
3	an	O
4	enhancer	O
5	and	O
6	an	O
7	alternative	O
8	promoter	O
9	in	O
10	the	O
11	first	O
12	intron	O
13	of	O
14	the	O
15	alpha	B
16	-	I
17	fetoprotein	I
18	gene	I
19	.	O

1	Studying	O
2	intracellular	O
3	signaling	O
4	pathways	O
5	,	O
6	which	O
7	may	O
8	be	O
9	involved	O
10	in	O
11	malignant	O
12	transformation	O
13	of	O
14	Ret	B
15	-	I
16	9bp	I
17	expressing	O
18	NIH3T3	O
19	cells	O
20	,	O
21	we	O
22	could	O
23	demonstrate	O
24	Ret	B
25	-	I
26	9bp	I
27	dependent	O
28	phosphorylation	O
29	of	O
30	insulin	B
31	receptor	I
32	substrate	I
33	-	I
34	2	I
35	(	O
36	IRS	B
37	-	I
38	2	I
39	)	O
40	with	O
41	consecutive	O
42	activation	O
43	of	O
44	phosphatidylinositol	B
45	3	I
46	-	I
47	kinase	I
48	(	O
49	PI	B
50	3	I
51	-	I
52	kinase	I
53	)	O
54	and	O
55	protein	B
56	kinase	I
57	B	I
58	(	O
59	PKB	B
60	/	O
61	AKT	B
62	).	O

1	METHODS	O
2	:	O
3	In	O
4	the	O
5	current	O
6	study	O
7	the	O
8	authors	O
9	reported	O
10	on	O
11	PPB	O
12	cases	O
13	from	O
14	a	O
15	national	O
16	retrospective	O
17	search	O
18	performed	O
19	in	O
20	18	O
21	Italian	O
22	Associations	O
23	for	O
24	Pediatric	O
25	Hematology	O
26	and	O
27	Oncology	O
28	centers	O
29	.	O

1	Phylogenetic	O
2	analysis	O
3	showed	O
4	that	O
5	the	O
6	ToLCV	O
7	isolates	O
8	from	O
9	Bangalore	O
10	constitute	O
11	a	O
12	group	O
13	of	O
14	viruses	O
15	separated	O
16	from	O
17	those	O
18	of	O
19	Northern	O
20	India	O
21	.	O

1	Mutating	O
2	the	O
3	Fcp1p	B
4	-	O
5	binding	O
6	motif	O
7	KEFGK	O
8	in	O
9	the	O
10	RAP74	B
11	(	O
12	Tfg1p	B
13	)	O
14	subunit	O
15	of	O
16	TFIIF	B
17	to	O
18	EEFGE	O
19	led	O
20	to	O
21	both	O
22	synthetic	O
23	phenotypes	O
24	in	O
25	certain	O
26	fcp1	B
27	tfg1	I
28	double	O
29	mutants	O
30	and	O
31	a	O
32	reduced	O
33	ability	O
34	of	O
35	Fcp1p	B
36	to	O
37	activate	O
38	transcription	O
39	when	O
40	it	O
41	is	O
42	artificially	O
43	tethered	O
44	to	O
45	a	O
46	promoter	O
47	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	Cdc42p	B
6	is	O
7	in	O
8	fact	O
9	required	O
10	for	O
11	pheromone	O
12	response	O
13	and	O
14	that	O
15	interaction	O
16	with	O
17	the	O
18	PAK	B
19	Ste20p	I
20	is	O
21	critical	O
22	for	O
23	that	O
24	role	O
25	.	O

1	Deletion	O
2	of	O
3	an	O
4	intergenic	O
5	DNA	O
6	-	O
7	binding	O
8	site	O
9	for	O
10	this	O
11	complex	O
12	from	O
13	a	O
14	human	B
15	beta	I
16	-	I
17	globin	I
18	locus	I
19	construct	I
20	results	O
21	in	O
22	delayed	O
23	human	B
24	gamma	I
25	-	I
26	to	I
27	beta	I
28	-	I
29	globin	I
30	switching	O
31	in	O
32	transgenic	O
33	mice	O
34	,	O
35	suggesting	O
36	that	O
37	the	O
38	PYR	B
39	complex	I
40	acts	O
41	to	O
42	facilitate	O
43	the	O
44	switch	O
45	.	O

1	The	O
2	product	O
3	of	O
4	rat	B
5	gene	I
6	33	I
7	was	O
8	identified	O
9	as	O
10	an	O
11	ErbB	B
12	-	I
13	2	I
14	-	I
15	interacting	I
16	protein	I
17	in	O
18	a	O
19	two	O
20	-	O
21	hybrid	O
22	screen	O
23	employing	O
24	the	O
25	ErbB	B
26	-	I
27	2	I
28	juxtamembrane	I
29	and	I
30	kinase	I
31	domains	I
32	as	O
33	bait	O
34	.	O

1	Studies	O
2	suggest	O
3	that	O
4	the	O
5	DGOR	O
6	without	O
7	acid	O
8	reflux	O
9	may	O
10	result	O
11	in	O
12	symptoms	O
13	but	O
14	unless	O
15	acid	O
16	reflux	O
17	is	O
18	present	O
19	simultaneously	O
20	,	O
21	it	O
22	does	O
23	not	O
24	cause	O
25	oesophagitis	O
26	.	O

1	Symptoms	O
2	,	O
3	however	O
4	,	O
5	appear	O
6	to	O
7	correlate	O
8	poorly	O
9	with	O
10	oesophagitis	O
11	;	O
12	hence	O
13	,	O
14	severe	O
15	symptoms	O
16	do	O
17	not	O
18	indicate	O
19	there	O
20	is	O
21	greater	O
22	oesophageal	O
23	damage	O
24	.	O

1	OBJECTIVE	O
2	:	O
3	To	O
4	evaluate	O
5	the	O
6	relationship	O
7	between	O
8	blood	O
9	flow	O
10	in	O
11	the	O
12	tumor	O
13	assessed	O
14	by	O
15	color	O
16	Doppler	O
17	ultrasound	O
18	,	O
19	microvessel	O
20	density	O
21	,	O
22	and	O
23	vascular	B
24	endothelial	I
25	growth	I
26	factor	I
27	levels	O
28	in	O
29	endometrial	O
30	carcinoma	O
31	.	O

1	These	O
2	results	O
3	demonstrate	O
4	Ras	B
5	-	O
6	and	O
7	Raf	B
8	-	O
9	independent	O
10	ERK	B
11	MAPK	O
12	activation	O
13	maintains	O
14	cell	O
15	viability	O
16	following	O
17	heat	O
18	shock	O
19	.	O

1	Three	O
2	cDNAs	O
3	encoding	O
4	basic	B
5	leucine	I
6	zipper	I
7	(	I
8	bZIP	I
9	)-	I
10	type	I
11	ABRE	I
12	-	I
13	binding	I
14	proteins	I
15	were	O
16	isolated	O
17	by	O
18	using	O
19	the	O
20	yeast	O
21	one	O
22	-	O
23	hybrid	O
24	system	O
25	and	O
26	were	O
27	designated	O
28	AREB1	B
29	,	O
30	AREB2	B
31	,	O
32	and	O
33	AREB3	B
34	(	O
35	ABA	B
36	-	I
37	responsive	I
38	element	I
39	binding	I
40	protein	I
41	).	O

1	Recombinant	O
2	AROM	B
3	-	O
4	p64	B
5	displayed	O
6	high	O
7	binding	O
8	to	O
9	single	O
10	-	O
11	stranded	O
12	DNA	O
13	and	O
14	poly	O
15	(	O
16	A	O
17	)	O
18	homopolymers	O
19	suggesting	O
20	that	O
21	this	O
22	protein	O
23	could	O
24	play	O
25	a	O
26	role	O
27	in	O
28	mRNA	O
29	maturation	O
30	/	O
31	metabolism	O
32	.	O

1	The	O
2	protein	B
3	-	I
4	tyrosine	I
5	kinase	I
6	fer	I
7	associates	O
8	with	O
9	signaling	O
10	complexes	O
11	containing	O
12	insulin	B
13	receptor	I
14	substrate	I
15	-	I
16	1	I
17	and	O
18	phosphatidylinositol	B
19	3	I
20	-	I
21	kinase	I
22	.	O

1	The	O
2	variable	O
3	phenotype	O
4	of	O
5	the	O
6	allotetraploids	O
7	could	O
8	not	O
9	be	O
10	explained	O
11	by	O
12	cytological	O
13	abnormalities	O
14	.	O

1	In	O
2	the	O
3	PMR	O
4	target	O
5	area	O
6	but	O
7	not	O
8	in	O
9	the	O
10	nontreated	O
11	area	O
12	an	O
13	improvement	O
14	in	O
15	regional	O
16	myocardial	O
17	flow	O
18	reserve	O
19	occurs	O
20	in	O
21	wall	O
22	segments	O
23	with	O
24	initially	O
25	severely	O
26	or	O
27	moderately	O
28	reduced	O
29	stress	O
30	perfusion	O
31	.	O

1	Analysis	O
2	of	O
3	intron	O
4	/	O
5	exon	O
6	boundaries	O
7	of	O
8	the	O
9	genomic	O
10	BAC	O
11	clones	O
12	demonstrate	O
13	that	O
14	junctin	B
15	,	O
16	junctate	B
17	,	O
18	and	O
19	aspartyl	B
20	beta	I
21	-	I
22	hydroxylase	I
23	result	O
24	from	O
25	alternative	O
26	splicing	O
27	of	O
28	the	O
29	same	O
30	gene	O
31	.	O

1	It	O
2	is	O
3	now	O
4	estimated	O
5	that	O
6	inactivation	O
7	mutants	O
8	of	O
9	PTEN	B
10	exist	O
11	in	O
12	60	O
13	%	O
14	of	O
15	all	O
16	forms	O
17	of	O
18	solid	O
19	tumors	O
20	.	O

1	We	O
2	have	O
3	demonstrated	O
4	that	O
5	the	O
6	activity	O
7	of	O
8	ILK	B
9	is	O
10	constitutively	O
11	elevated	O
12	in	O
13	PTEN	B
14	mutant	I
15	cells	O
16	.	O

1	The	O
2	growth	B
3	factor	I
4	receptor	I
5	-	I
6	bound	I
7	protein	I
8	2	I
9	(	O
10	Grb2	B
11	)	O
12	adaptor	O
13	when	O
14	complexed	O
15	with	O
16	Sos	B
17	(	O
18	Son	B
19	of	I
20	sevenless	I
21	),	O
22	the	O
23	exchange	O
24	factor	O
25	of	O
26	Ras	B
27	,	O
28	conveys	O
29	the	O
30	signal	O
31	induced	O
32	by	O
33	tyrosine	B
34	kinase	I
35	-	I
36	activated	I
37	receptor	I
38	to	O
39	Ras	B
40	by	O
41	recruiting	O
42	Sos	B
43	to	O
44	the	O
45	membrane	O
46	,	O
47	allowing	O
48	activation	O
49	of	O
50	Ras	B
51	.	O

1	Mutations	O
2	in	O
3	genes	O
4	encoding	O
5	PR65	B
6	/	I
7	A	I
8	subunits	I
9	have	O
10	been	O
11	identified	O
12	in	O
13	several	O
14	different	O
15	human	O
16	cancers	O
17	and	O
18	the	O
19	PP2A	B
20	inhibitor	O
21	,	O
22	termed	O
23	fostriecin	O
24	,	O
25	is	O
26	being	O
27	tested	O
28	as	O
29	an	O
30	anticancer	O
31	drug	O
32	.	O

1	For	O
2	this	O
3	purpose	O
4	,	O
5	a	O
6	segment	O
7	of	O
8	dxr	B
9	was	O
10	amplified	O
11	from	O
12	Synechococcus	O
13	leopoliensis	O
14	SAUG	O
15	1402	O
16	-	O
17	1	O
18	DNA	O
19	via	O
20	PCR	O
21	using	O
22	oligonucleotides	O
23	for	O
24	conserved	O
25	regions	O
26	.	O

1	Perceptual	O
2	learning	O
3	for	O
4	a	O
5	pattern	O
6	discrimination	O
7	task	O
8	.	O

1	The	O
2	detector	O
3	has	O
4	the	O
5	advantage	O
6	of	O
7	finding	O
8	both	O
9	ST	O
10	segment	O
11	deviations	O
12	and	O
13	entire	O
14	ST	O
15	-	O
16	T	O
17	complex	O
18	changes	O
19	thereby	O
20	providing	O
21	a	O
22	wider	O
23	characterization	O
24	of	O
25	the	O
26	potential	O
27	ischemic	O
28	events	O
29	.	O

1	While	O
2	this	O
3	Saccharomyces	O
4	cerevisiae	O
5	SIN4	B
6	gene	I
7	product	I
8	is	O
9	a	O
10	component	O
11	of	O
12	a	O
13	mediator	O
14	complex	O
15	associated	O
16	with	O
17	RNA	B
18	polymerase	I
19	II	I
20	,	O
21	various	O
22	studies	O
23	suggest	O
24	the	O
25	involvement	O
26	of	O
27	Sin4	B
28	in	O
29	the	O
30	alteration	O
31	of	O
32	higher	O
33	-	O
34	order	O
35	chromatin	O
36	structure	O
37	.	O

1	Primary	O
2	adrenal	O
3	hypersensitivity	O
4	to	O
5	ACTH	B
6	drive	O
7	in	O
8	obesity	O
9	has	O
10	also	O
11	been	O
12	suggested	O
13	.	O

1	In	O
2	addition	O
3	,	O
4	a	O
5	noncanonical	O
6	C	B
7	/	I
8	EBP	I
9	-	I
10	binding	I
11	site	I
12	within	O
13	the	O
14	Gadd45gamma	B
15	promoter	I
16	where	O
17	C	B
18	/	I
19	EBPbeta	I
20	and	O
21	C	B
22	/	I
23	EBPdelta	I
24	could	O
25	bind	O
26	,	O
27	was	O
28	identified	O
29	by	O
30	electrophoretic	O
31	mobility	O
32	shift	O
33	assay	O
34	(	O
35	EMSA	O
36	)	O
37	and	O
38	reporter	O
39	gene	O
40	analysis	O
41	.	O

1	Src	B
2	activation	O
3	induced	O
4	by	O
5	FGF1	B
6	was	O
7	blocked	O
8	by	O
9	the	O
10	SH2	B
11	domain	I
12	of	O
13	Src	B
14	and	O
15	PP2	B
16	,	O
17	a	O
18	specific	O
19	inhibitor	O
20	of	O
21	Src	B
22	.	O

1	The	O
2	use	O
3	of	O
4	the	O
5	PLCgamma	B
6	inhibitory	I
7	peptide	I
8	,	O
9	neomycin	O
10	and	O
11	the	O
12	calcium	O
13	chelator	O
14	BAPTA	O
15	-	O
16	AM	O
17	on	O
18	oocytes	O
19	expressing	O
20	FGFR1	B
21	or	O
22	the	O
23	stimulation	O
24	by	O
25	PDGF	B
26	-	I
27	BB	I
28	of	O
29	oocytes	O
30	expressing	O
31	PDGFR	B
32	-	O
33	FGFR1	B
34	mutated	O
35	on	O
36	the	O
37	PLCgamma	B
38	binding	I
39	site	I
40	,	O
41	prevented	O
42	GVBD	O
43	and	O
44	ERK2	B
45	phosphorylation	O
46	.	O

1	Multiple	O
2	transcription	O
3	start	O
4	sites	O
5	were	O
6	revealed	O
7	by	O
8	primer	O
9	extension	O
10	analysis	O
11	of	O
12	the	O
13	mouse	O
14	gene	O
15	,	O
16	and	O
17	transfection	O
18	constructs	O
19	containing	O
20	the	O
21	prospective	O
22	promoter	O
23	generated	O
24	transcriptional	O
25	activity	O
26	comparable	O
27	to	O
28	that	O
29	of	O
30	the	O
31	SV40	B
32	promoter	I
33	.	O

1	From	O
2	two	O
3	inhibitor	O
4	scaffolds	O
5	,	O
6	we	O
7	have	O
8	identified	O
9	potent	O
10	and	O
11	selective	O
12	inhibitors	O
13	for	O
14	sensitized	O
15	kinases	O
16	from	O
17	five	O
18	distinct	O
19	subfamilies	O
20	.	O

1	To	O
2	determine	O
3	whether	O
4	interaction	O
5	of	O
6	arsenite	O
7	with	O
8	the	O
9	hormone	O
10	-	O
11	binding	O
12	domain	O
13	results	O
14	in	O
15	receptor	O
16	activation	O
17	,	O
18	COS	O
19	-	O
20	1	O
21	cells	O
22	were	O
23	transiently	O
24	cotransfected	O
25	with	O
26	the	O
27	chimeric	B
28	receptors	I
29	GAL	I
30	-	I
31	ER	I
32	,	O
33	which	O
34	contains	O
35	the	O
36	hormone	O
37	-	O
38	binding	O
39	domain	O
40	of	O
41	ERalpha	B
42	and	O
43	the	O
44	DNA	O
45	-	O
46	binding	O
47	domain	O
48	of	O
49	the	O
50	transcription	O
51	factor	O
52	GAL4	B
53	,	O
54	and	O
55	a	O
56	GAL4	B
57	-	O
58	responsive	O
59	CAT	B
60	reporter	I
61	gene	I
62	.	O

1	By	O
2	progressive	O
3	5	O
4	'-	O
5	deletion	O
6	studies	O
7	,	O
8	we	O
9	have	O
10	identified	O
11	a	O
12	248	O
13	-	O
14	bp	O
15	DNA	O
16	fragment	O
17	(-	O
18	1018	O
19	to	O
20	-	O
21	771	O
22	,	O
23	relative	O
24	to	O
25	the	O
26	translation	O
27	start	O
28	site	O
29	)	O
30	at	O
31	the	O
32	5	O
33	'-	O
34	flanking	O
35	region	O
36	of	O
37	the	O
38	human	B
39	GnRHR	I
40	gene	I
41	that	O
42	is	O
43	responsible	O
44	for	O
45	the	O
46	GnRHa	O
47	-	O
48	mediated	O
49	down	O
50	-	O
51	regulation	O
52	of	O
53	human	B
54	GnRHR	I
55	promoter	I
56	activity	O
57	.	O

1	The	O
2	mean	O
3	day	O
4	of	O
5	diagnosis	O
6	of	O
7	periventricular	O
8	echodensities	O
9	was	O
10	3	O
11	+/-	O
12	2	O
13	days	O
14	(	O
15	range	O
16	1	O
17	-	O
18	11	O
19	days	O
20	),	O
21	and	O
22	of	O
23	cystic	O
24	PVL	O
25	21	O
26	+/-	O
27	8	O
28	days	O
29	(	O
30	range	O
31	2	O
32	-	O
33	47	O
34	days	O
35	).	O

1	The	O
2	LAMMER	B
3	protein	O
4	kinase	O
5	encoded	O
6	by	O
7	the	O
8	Doa	B
9	locus	I
10	of	O
11	Drosophila	O
12	is	O
13	required	O
14	in	O
15	both	O
16	somatic	O
17	and	O
18	germline	O
19	cells	O
20	and	O
21	is	O
22	expressed	O
23	as	O
24	both	O
25	nuclear	O
26	and	O
27	cytoplasmic	O
28	isoforms	O
29	throughout	O
30	development	O
31	.	O

1	We	O
2	have	O
3	mutated	O
4	to	O
5	cysteine	O
6	,	O
7	one	O
8	at	O
9	a	O
10	time	O
11	,	O
12	21	O
13	consecutive	O
14	residues	O
15	in	O
16	the	O
17	fourth	O
18	TMS	O
19	(	O
20	TM4	O
21	).	O

1	(	O
2	1995	O
3	)	O
4	J	O
5	.	O

1	HYPOTHESIS	O
2	:	O
3	The	O
4	aim	O
5	of	O
6	this	O
7	study	O
8	was	O
9	to	O
10	investigate	O
11	the	O
12	oxidative	O
13	susceptibility	O
14	of	O
15	apolipoprotein	B
16	B	I
17	-	I
18	containing	I
19	lipoproteins	I
20	and	O
21	antioxidant	O
22	status	O
23	in	O
24	patients	O
25	with	O
26	acute	O
27	coronary	O
28	syndromes	O
29	and	O
30	chronic	O
31	stable	O
32	angina	O
33	pectoris	O
34	.	O

1	In	O
2	group	O
3	B	O
4	37	O
5	MBq	O
6	in	O
7	150	O
8	microL	O
9	of	O
10	99mTc	O
11	-	O
12	HSA	O
13	nanocolloid	O
14	was	O
15	additionally	O
16	injected	O
17	intradermally	O
18	18	O
19	h	O
20	before	O
21	surgery	O
22	(	O
23	3	O
24	-	O
25	6	O
26	aliquots	O
27	injected	O
28	perilesionally	O
29	).	O

1	Post	O
2	-	O
3	operative	O
4	functional	O
5	outcome	O
6	is	O
7	related	O
8	to	O
9	pre	O
10	-	O
11	operative	O
12	functional	O
13	status	O
14	.	O

1	We	O
2	cloned	O
3	a	O
4	DNA	O
5	fragment	O
6	encoding	O
7	the	O
8	N	O
9	-	O
10	terminal	O
11	part	O
12	of	O
13	a	O
14	protein	O
15	with	O
16	significant	O
17	similarity	O
18	to	O
19	members	O
20	of	O
21	the	O
22	LysR	B
23	family	I
24	of	I
25	transcriptional	I
26	regulators	I
27	(	O
28	LTTRs	B
29	).	O

1	AGO1	B
2	is	O
3	similar	O
4	to	O
5	QDE	B
6	-	I
7	2	I
8	required	O
9	for	O
10	quelling	O
11	and	O
12	RDE	B
13	-	I
14	1	I
15	required	O
16	for	O
17	RNAi	O
18	.	O

1	Intracellular	O
2	localization	O
3	studies	O
4	using	O
5	the	O
6	mDAP	B
7	-	I
8	3	I
9	/	O
10	EGFP	B
11	fusion	O
12	protein	O
13	,	O
14	cell	O
15	fractionation	O
16	and	O
17	protease	O
18	protection	O
19	experiments	O
20	localized	O
21	mDAP	B
22	-	I
23	3	I
24	to	O
25	the	O
26	mitochondrial	O
27	matrix	O
28	.	O

1	We	O
2	could	O
3	demonstrate	O
4	the	O
5	involvement	O
6	of	O
7	cAMP	B
8	-	I
9	dependent	I
10	protein	I
11	kinase	I
12	(	O
13	PKA	B
14	)	O
15	in	O
16	the	O
17	phosphorylation	O
18	of	O
19	CDC25Mm	B
20	in	O
21	fibroblasts	O
22	overexpressing	O
23	this	O
24	RasGEF	B
25	as	O
26	well	O
27	as	O
28	in	O
29	mouse	O
30	brain	O
31	synaptosomal	O
32	membranes	O
33	.	O

1	Reporter	O
2	gene	O
3	expression	O
4	analyses	O
5	indicate	O
6	that	O
7	both	O
8	WASP	B
9	promoters	I
10	show	O
11	high	O
12	levels	O
13	of	O
14	expression	O
15	in	O
16	different	O
17	hematopoietic	O
18	cell	O
19	lines	O
20	.	O

1	We	O
2	find	O
3	that	O
4	3T1	O
5	-	O
6	3T2	O
7	mixing	O
8	has	O
9	a	O
10	pronounced	O
11	effect	O
12	on	O
13	the	O
14	line	O
15	shape	O
16	and	O
17	radiative	O
18	decay	O
19	rate	O
20	of	O
21	emission	O
22	from	O
23	the	O
24	3T2	O
25	state	O
26	and	O
27	that	O
28	the	O
29	extent	O
30	of	O
31	mixing	O
32	depends	O
33	critically	O
34	on	O
35	the	O
36	magnitude	O
37	of	O
38	nontetrahedral	O
39	distortions	O
40	.	O

1	A	O
2	total	O
3	of	O
4	576	O
5	1	O
6	-	O
7	day	O
8	-	O
9	old	O
10	Ross	O
11	broiler	O
12	chicks	O
13	were	O
14	housed	O
15	in	O
16	six	O
17	treatment	O
18	groups	O
19	[	O
20	six	O
21	replicates	O
22	of	O
23	16	O
24	each	O
25	;	O
26	control	O
27	,	O
28	CLI	O
29	(	O
30	15	O
31	g	O
32	kg	O
33	(-	O
34	1	O
35	)	O
36	diet	O
37	),	O
38	50	O
39	parts	O
40	per	O
41	billion	O
42	(	O
43	ppb	O
44	)	O
45	AF	B
46	,	O
47	50	O
48	ppb	O
49	AF	B
50	plus	O
51	CLI	O
52	,	O
53	100	O
54	ppb	O
55	AF	B
56	,	O
57	100	O
58	ppb	O
59	AF	B
60	plus	O
61	CLI	O
62	]	O
63	for	O
64	42	O
65	days	O
66	.	O

1	The	O
2	cost	O
3	per	O
4	test	O
5	is	O
6	less	O
7	than	O
8	those	O
9	for	O
10	CC	O
11	,	O
12	kEIA	O
13	and	O
14	PACE2	O
15	.	O

1	Altogether	O
2	these	O
3	results	O
4	suggest	O
5	that	O
6	,	O
7	in	O
8	KG1a	O
9	cells	O
10	,	O
11	TNFalpha	B
12	can	O
13	stimulate	O
14	in	O
15	parallel	O
16	PC	B
17	-	I
18	PLC	I
19	and	O
20	PLD	B
21	,	O
22	whose	O
23	lipid	O
24	products	O
25	activate	O
26	in	O
27	turn	O
28	mitogen	B
29	-	I
30	activated	I
31	protein	I
32	kinase	I
33	(	O
34	MAP	B
35	kinase	I
36	)	O
37	and	O
38	NF	B
39	-	I
40	kappaB	I
41	signalling	O
42	respectively	O
43	.	O

1	Concurrently	O
2	,	O
3	we	O
4	monitored	O
5	weather	O
6	conditions	O
7	and	O
8	used	O
9	time	O
10	-	O
11	activity	O
12	budget	O
13	data	O
14	of	O
15	free	O
16	-	O
17	living	O
18	birds	O
19	and	O
20	laboratory	O
21	data	O
22	on	O
23	resting	O
24	metabolic	O
25	rate	O
26	to	O
27	construct	O
28	time	O
29	-	O
30	activity	O
31	laboratory	O
32	(	O
33	TAL	O
34	)	O
35	estimates	O
36	of	O
37	daily	O
38	energy	O
39	expenditure	O
40	(	O
41	DEE	O
42	)	O
43	and	O
44	to	O
45	partition	O
46	the	O
47	verdins	O
48	'	O
49	energy	O
50	budget	O
51	into	O
52	thermoregulatory	O
53	,	O
54	activity	O
55	and	O
56	basal	O
57	components	O
58	.	O

1	L	O
2	/	O
3	H	O
4	>	O
5	0	O
6	.	O
7	61	O
8	(	O
9	chi	O
10	(	O
11	2	O
12	)=	O
13	10	O
14	.	O
15	8	O
16	;	O
17	P	O
18	:<	O
19	0	O
20	.	O
21	001	O
22	)	O
23	and	O
24	a	O
25	restrictive	O
26	filling	O
27	pattern	O
28	(	O
29	chi	O
30	(	O
31	2	O
32	)=	O
33	3	O
34	.	O
35	6	O
36	;	O
37	P	O
38	:<	O
39	0	O
40	.	O
41	05	O
42	)	O
43	were	O
44	independent	O
45	predictors	O
46	of	O
47	events	O
48	.	O

1	The	O
2	high	O
3	selectivity	O
4	of	O
5	arrestins	B
6	for	O
7	this	O
8	particular	O
9	functional	O
10	form	O
11	of	O
12	receptor	O
13	ensures	O
14	their	O
15	timely	O
16	binding	O
17	and	O
18	dissociation	O
19	.	O

1	When	O
2	cotransfected	O
3	in	O
4	fibroblasts	O
5	with	O
6	a	O
7	C	B
8	/	I
9	EBP	I
10	alpha	I
11	expression	O
12	vector	O
13	,	O
14	reporter	O
15	gene	O
16	expression	O
17	increased	O
18	3	O
19	-	O
20	fold	O
21	only	O
22	in	O
23	the	O
24	wild	O
25	-	O
26	type	O
27	constructs	O
28	.	O

1	Expression	O
2	of	O
3	a	O
4	dominant	B
5	negative	I
6	Smad2	I
7	significantly	O
8	reduces	O
9	the	O
10	level	O
11	of	O
12	luciferase	B
13	reporter	I
14	activity	O
15	induced	O
16	by	O
17	nodal	O
18	treatment	O
19	.	O

1	Normal	O
2	alpha1	B
3	(	I
4	I	I
5	)	I
6	collagen	I
7	mRNA	I
8	showed	O
9	no	O
10	significant	O
11	reduction	O
12	when	O
13	AR	O
14	or	O
15	IR	O
16	was	O
17	expressed	O
18	from	O
19	the	O
20	pHbetaAPr	O
21	-	O
22	1	O
23	-	O
24	neo	O
25	vector	O
26	and	O
27	a	O
28	small	O
29	(	O
30	10	O
31	-	O
32	20	O
33	%)	O
34	but	O
35	significant	O
36	reduction	O
37	when	O
38	either	O
39	ribozyme	O
40	was	O
41	expressed	O
42	from	O
43	the	O
44	pCI	O
45	.	O
46	neo	O
47	vector	O
48	.	O

1	Nature	O
2	398	O
3	,	O
4	828	O
5	-	O
6	830	O
7	)	O
8	that	O
9	the	O
10	amino	O
11	acid	O
12	sequences	O
13	of	O
14	peptide	O
15	fragments	O
16	obtained	O
17	from	O
18	a	O
19	polypeptide	O
20	found	O
21	in	O
22	a	O
23	complex	O
24	of	O
25	proteins	O
26	that	O
27	alters	O
28	chromatin	O
29	structure	O
30	(	O
31	ARC	B
32	)	O
33	are	O
34	identical	O
35	to	O
36	portions	O
37	of	O
38	the	O
39	deduced	O
40	open	O
41	reading	O
42	frame	O
43	of	O
44	TIG	B
45	-	I
46	1	I
47	mRNA	I
48	.	O

1	Abnormalities	O
2	of	O
3	plasma	B
4	cholecystokinin	I
5	were	O
6	observed	O
7	only	O
8	in	O
9	patients	O
10	with	O
11	delayed	O
12	gastric	O
13	emptying	O
14	.	O

1	5	O
2	(	O
3	Sunset	O
4	Yellow	O
5	FCF	O
6	)	O
7	were	O
8	determined	O
9	using	O
10	liquid	O
11	chromatography	O
12	/	O
13	mass	O
14	spectrometry	O
15	(	O
16	LC	O
17	/	O
18	MS	O
19	)	O
20	with	O
21	electrospray	O
22	ionization	O
23	.	O

1	Polysome	O
2	and	O
3	40S	B
4	ribosome	I
5	fractions	O
6	were	O
7	severely	O
8	decreased	O
9	in	O
10	the	O
11	krr1	B
12	mutant	I
13	and	O
14	Kri1p	B
15	-	O
16	depleted	O
17	cells	O
18	.	O

1	They	O
2	also	O
3	negatively	O
4	modulate	O
5	the	O
6	PI	B
7	3	I
8	-	I
9	kinase	I
10	catalytic	O
11	activity	O
12	but	O
13	to	O
14	different	O
15	extents	O
16	,	O
17	dependent	O
18	on	O
19	the	O
20	unique	O
21	N	O
22	-	O
23	terminal	O
24	structure	O
25	of	O
26	each	O
27	isoform	O
28	.	O

1	Cam	B
2	kinase	I
3	II	I
4	induces	O
5	in	O
6	vivo	O
7	phosphorylation	O
8	of	O
9	Smad2	B
10	and	O
11	Smad4	B
12	and	O
13	,	O
14	to	O
15	a	O
16	lesser	O
17	extent	O
18	,	O
19	Smad3	B
20	.	O

1	The	O
2	Drosophila	B
3	melanogaster	I
4	suppressor	I
5	of	I
6	sable	I
7	gene	I
8	,	O
9	su	O
10	(	O
11	s	O
12	),	O
13	encodes	O
14	a	O
15	novel	O
16	,	O
17	150	O
18	-	O
19	kDa	O
20	nuclear	O
21	RNA	O
22	binding	O
23	protein	O
24	,	O
25	SU	O
26	(	O
27	S	O
28	),	O
29	that	O
30	negatively	O
31	regulates	O
32	RNA	O
33	accumulation	O
34	from	O
35	mutant	O
36	alleles	O
37	of	O
38	other	O
39	genes	O
40	that	O
41	have	O
42	transposon	O
43	insertions	O
44	in	O
45	the	O
46	5	O
47	'	O
48	transcribed	O
49	region	O
50	.	O

1	As	O
2	a	O
3	result	O
4	,	O
5	we	O
6	have	O
7	defined	O
8	two	O
9	arginine	O
10	-	O
11	rich	O
12	motifs	O
13	(	O
14	ARM1	O
15	and	O
16	ARM2	O
17	)	O
18	that	O
19	mediate	O
20	the	O
21	RNA	O
22	binding	O
23	activity	O
24	of	O
25	SU	O
26	(	O
27	S	O
28	).	O

1	This	O
2	interaction	O
3	inhibits	O
4	the	O
5	histone	B
6	acetyltransferase	I
7	activity	O
8	of	O
9	p300	B
10	,	O
11	resulting	O
12	in	O
13	drastic	O
14	reduction	O
15	of	O
16	nucleosomal	O
17	histone	B
18	acetylation	O
19	and	O
20	alteration	O
21	of	O
22	chromatin	O
23	structure	O
24	.	O

1	Recombinant	B
2	BRI1	I
3	-	I
4	KD	I
5	autophosphorylated	O
6	on	O
7	serine	O
8	(	O
9	Ser	O
10	)	O
11	and	O
12	threonine	O
13	(	O
14	Thr	O
15	)	O
16	residues	O
17	with	O
18	p	O
19	-	O
20	Ser	O
21	predominating	O
22	.	O

1	Flow	O
2	cytomery	O
3	was	O
4	used	O
5	for	O
6	cell	O
7	cycle	O
8	analysis	O
9	.	O

1	Further	O
2	research	O
3	is	O
4	required	O
5	to	O
6	better	O
7	measure	O
8	treatment	O
9	effects	O
10	,	O
11	modification	O
12	of	O
13	MS	O
14	natural	O
15	history	O
16	,	O
17	and	O
18	net	O
19	societal	O
20	costs	O
21	of	O
22	IFN	B
23	beta	I
24	-	I
25	1b	I
26	in	O
27	RRMS	O
28	.	O

1	Cost	O
2	-	O
3	effectiveness	O
4	of	O
5	interferon	B
6	beta	I
7	-	I
8	1b	I
9	in	O
10	slowing	O
11	multiple	O
12	sclerosis	O
13	disability	O
14	progression	O
15	.	O

1	Both	O
2	the	O
3	Cmax	O
4	and	O
5	AUC	O
6	values	O
7	were	O
8	almost	O
9	doubled	O
10	with	O
11	doubling	O
12	the	O
13	dose	O
14	.	O

1	Hyperactivation	O
2	of	O
3	Cdc2	B
4	in	O
5	fission	O
6	yeast	O
7	causes	O
8	cells	O
9	to	O
10	undergo	O
11	a	O
12	lethal	O
13	premature	O
14	mitosis	O
15	called	O
16	mitotic	O
17	catastrophe	O
18	.	O

1	Diary	O
2	.	O

1	Cells	O
2	differentiate	O
3	in	O
4	response	O
5	to	O
6	various	O
7	extracellular	O
8	stimuli	O
9	.	O

1	Transforming	B
2	growth	I
3	factor	I
4	-	I
5	beta1	I
6	(	O
7	TGF	B
8	-	I
9	beta1	I
10	)	O
11	can	O
12	act	O
13	as	O
14	a	O
15	tumor	O
16	suppressor	O
17	or	O
18	a	O
19	tumor	O
20	promoter	O
21	depending	O
22	on	O
23	the	O
24	characteristics	O
25	of	O
26	the	O
27	malignant	O
28	cell	O
29	.	O

1	Vasoactive	B
2	intestinal	I
3	peptide	I
4	and	O
5	pituitary	B
6	adenylate	I
7	cyclase	I
8	-	I
9	activating	I
10	polypeptide	I
11	inhibit	O
12	nuclear	B
13	factor	I
14	-	I
15	kappa	I
16	B	I
17	-	I
18	dependent	I
19	gene	I
20	activation	O
21	at	O
22	multiple	O
23	levels	O
24	in	O
25	the	O
26	human	O
27	monocytic	O
28	cell	O
29	line	O
30	THP	O
31	-	O
32	1	O
33	.	O

1	Mn2	O
2	+	O
3	increased	O
4	both	O
5	the	O
6	junction	O
7	binding	O
8	and	O
9	cleaving	O
10	activities	O
11	of	O
12	the	O
13	mutant	O
14	proteins	O
15	.	O

1	While	O
2	Pt	B
3	;	I
4	cycH	I
5	;	I
6	1	I
7	and	O
8	Os	B
9	;	I
10	cycH	I
11	;	I
12	1	I
13	were	O
14	expressed	O
15	in	O
16	all	O
17	tissues	O
18	examined	O
19	,	O
20	the	O
21	transcripts	O
22	accumulated	O
23	abundantly	O
24	in	O
25	dividing	O
26	cells	O
27	.	O

1	Moreover	O
2	,	O
3	an	O
4	in	O
5	vitro	O
6	pull	O
7	-	O
8	down	O
9	assay	O
10	showed	O
11	that	O
12	Os	B
13	;	I
14	CycH	I
15	;	I
16	1	I
17	specifically	O
18	bound	O
19	to	O
20	R2	B
21	but	O
22	not	O
23	to	O
24	other	O
25	rice	B
26	CDKs	I
27	.	O

1	In	O
2	transient	O
3	analysis	O
4	using	O
5	particle	O
6	bombardment	O
7	of	O
8	tobacco	O
9	leaf	O
10	sections	O
11	,	O
12	a	O
13	tetramer	O
14	of	O
15	the	O
16	distB	O
17	ABRE	O
18	(	O
19	abscisic	O
20	acid	O
21	-	O
22	responsive	O
23	element	O
24	)	O
25	mediated	O
26	transactivation	O
27	by	O
28	ABI3	B
29	and	O
30	ABI3	B
31	-	O
32	dependent	O
33	response	O
34	to	O
35	ABA	O
36	,	O
37	whereas	O
38	a	O
39	tetramer	O
40	of	O
41	the	O
42	composite	O
43	RY	O
44	/	O
45	G	O
46	complex	O
47	,	O
48	containing	O
49	RY	O
50	repeats	O
51	and	O
52	a	O
53	G	O
54	-	O
55	box	O
56	,	O
57	mediated	O
58	only	O
59	ABA	O
60	-	O
61	independent	O
62	transactivation	O
63	by	O
64	ABI3	B
65	.	O

1	The	O
2	major	O
3	neurological	O
4	manifestations	O
5	of	O
6	brain	O
7	injury	O
8	in	O
9	these	O
10	babies	O
11	are	O
12	spastic	O
13	motor	O
14	deficits	O
15	.	O

1	Spores	O
2	from	O
3	Rhizopus	O
4	stolonifer	O
5	were	O
6	suspended	O
7	in	O
8	distilled	O
9	water	O
10	(	O
11	1	O
12	x	O
13	10	O
14	(	O
15	6	O
16	)	O
17	spores	O
18	/	O
19	mL	O
20	)	O
21	and	O
22	used	O
23	as	O
24	starter	O
25	.	O

1	Overexpression	O
2	of	O
3	Trdpm1	B
4	in	O
5	a	O
6	dpm1	O
7	(+)::	O
8	his7	B
9	/	I
10	dpm1	I
11	(+)	I
12	S	O
13	.	O
14	pombe	O
15	diploid	O
16	resulted	O
17	in	O
18	a	O
19	4	O
20	-	O
21	fold	O
22	increase	O
23	in	O
24	specific	O
25	DPM	B
26	synthase	I
27	activity	O
28	.	O

1	The	O
2	LMW	B
3	FGF	I
4	-	I
5	2	I
6	up	O
7	-	O
8	regulated	O
9	the	O
10	PKC	B
11	epsilon	I
12	levels	O
13	by	O
14	1	O
15	.	O
16	6	O
17	-	O
18	fold	O
19	;	O
20	by	O
21	contrast	O
22	the	O
23	HMW	B
24	isoform	I
25	down	O
26	-	O
27	regulated	O
28	the	O
29	level	O
30	of	O
31	this	O
32	PKC	B
33	isotype	I
34	by	O
35	about	O
36	3	O
37	-	O
38	fold	O
39	and	O
40	increased	O
41	the	O
42	amount	O
43	of	O
44	PKC	B
45	delta	I
46	by	O
47	1	O
48	.	O
49	7	O
50	-	O
51	fold	O
52	.	O

1	Helicobacter	O
2	pylori	O
3	and	O
4	stomach	O
5	diseases	O
6	:	O
7	from	O
8	clinical	O
9	point	O
10	of	O
11	view	O

1	For	O
2	this	O
3	purpose	O
4	,	O
5	the	O
6	writhing	O
7	test	O
8	,	O
9	capsaicin	O
10	and	O
11	formalin	O
12	induced	O
13	-	O
14	pain	O
15	in	O
16	mice	O
17	were	O
18	used	O
19	.	O

1	2000	O
2	update	O
3	of	O
4	recommendations	O
5	for	O
6	the	O
7	use	O
8	of	O
9	hematopoietic	B
10	colony	I
11	-	I
12	stimulating	I
13	factors	I
14	:	O
15	evidence	O
16	-	O
17	based	O
18	,	O
19	clinical	O
20	practice	O
21	guidelines	O
22	.	O

1	Prominent	O
2	findings	O
3	were	O
4	chronic	O
5	pancreatitis	O
6	with	O
7	acinar	O
8	and	O
9	ductal	O
10	plugs	O
11	,	O
12	granulomatous	O
13	and	O
14	necrotizing	O
15	peripancreatic	O
16	steatitis	O
17	,	O
18	degenerative	O
19	myopathy	O
20	,	O
21	testicular	O
22	atrophy	O
23	,	O
24	candidiasis	O
25	and	O
26	bacterial	O
27	necrotizing	O
28	glossitis	O
29	.	O

1	Taken	O
2	together	O
3	,	O
4	our	O
5	data	O
6	indicate	O
7	that	O
8	multiple	O
9	survival	O
10	pathways	O
11	are	O
12	triggered	O
13	via	O
14	this	O
15	receptor	O
16	,	O
17	whereas	O
18	NF	B
19	-	I
20	kappaB	I
21	/	O
22	Rel	B
23	and	O
24	PI	B
25	-	I
26	3K	I
27	are	O
28	crucial	O
29	for	O
30	CD40	B
31	-	O
32	induced	O
33	proliferation	O
34	.	O

1	In	O
2	vitro	O
3	,	O
4	Arix	B
5	and	O
6	NBPhox	B
7	form	O
8	DNA	O
9	-	O
10	independent	O
11	multimers	O
12	and	O
13	exhibit	O
14	cooperative	O
15	binding	O
16	to	O
17	the	O
18	DB1	B
19	regulatory	I
20	element	I
21	,	O
22	which	O
23	contains	O
24	two	O
25	homeodomain	B
26	recognition	I
27	sites	I
28	.	O

1	We	O
2	conclude	O
3	from	O
4	this	O
5	study	O
6	that	O
7	Arix	B
8	and	O
9	NBPhox	B
10	exhibit	O
11	indistinguishable	O
12	and	O
13	independent	O
14	transcriptional	O
15	regulatory	O
16	properties	O
17	on	O
18	the	O
19	DBH	B
20	promoter	I
21	.	O

1	METHODS	O
2	AND	O
3	RESULTS	O
4	:	O
5	Studies	O
6	were	O
7	undertaken	O
8	in	O
9	9	O
10	isolated	O
11	guinea	O
12	pig	O
13	hearts	O
14	,	O
15	which	O
16	demonstrated	O
17	reverse	O
18	use	O
19	-	O
20	dependent	O
21	prolongation	O
22	of	O
23	cardiac	O
24	repolarization	O
25	by	O
26	100	O
27	nmol	O
28	/	O
29	L	O
30	domperidone	O
31	.	O

1	The	O
2	N	O
3	-	O
4	terminal	O
5	small	O
6	segment	O
7	of	O
8	yeast	B
9	TAF145	I
10	(	O
11	yTAF145	B
12	)	O
13	binds	O
14	to	O
15	TBP	B
16	and	O
17	thereby	O
18	inhibits	O
19	TBP	B
20	function	O
21	.	O

1	OBJECTIVE	O
2	:	O
3	To	O
4	evaluate	O
5	the	O
6	overall	O
7	performance	O
8	of	O
9	a	O
10	new	O
11	oscillometric	O
12	wrist	O
13	blood	O
14	pressure	O
15	monitor	O
16	(	O
17	Braun	O
18	PrecisionSensor	O
19	,	O
20	Braun	O
21	GmbH	O
22	,	O
23	Kronberg	O
24	,	O
25	Germany	O
26	)	O
27	as	O
28	defined	O
29	by	O
30	the	O
31	ANSI	O
32	/	O
33	AAMI	O
34	SP10	O
35	-	O
36	1992	O
37	guidelines	O
38	,	O
39	and	O
40	to	O
41	analyze	O
42	the	O
43	data	O
44	for	O
45	the	O
46	optimized	O
47	selection	O
48	of	O
49	the	O
50	algorithm	O
51	that	O
52	derives	O
53	the	O
54	blood	O
55	pressure	O
56	values	O
57	from	O
58	the	O
59	oscillometric	O
60	blood	O
61	pressure	O
62	curves	O
63	.	O

1	Following	O
2	the	O
3	results	O
4	of	O
5	toxicological	O
6	experiments	O
7	in	O
8	the	O
9	target	O
10	animals	O
11	"	O
12	Toxicological	O
13	Drinking	O
14	Water	O
15	Standards	O
16	for	O
17	Animals	O
18	"	O
19	can	O
20	be	O
21	established	O
22	.	O

1	An	O
2	increase	O
3	in	O
4	hypothalamic	O
5	expression	O
6	of	O
7	at	O
8	least	O
9	two	O
10	of	O
11	the	O
12	erbB	B
13	receptors	I
14	is	O
15	initiated	O
16	before	O
17	the	O
18	pubertal	O
19	augmentation	O
20	of	O
21	gonadal	O
22	steroid	O
23	secretion	O
24	and	O
25	is	O
26	completed	O
27	on	O
28	the	O
29	day	O
30	of	O
31	the	O
32	first	O
33	preovulatory	O
34	surge	O
35	of	O
36	gonadotropins	B
37	.	O

1	Dsh	B
2	is	O
3	required	O
4	for	O
5	two	O
6	different	O
7	pathways	O
8	,	O
9	the	O
10	Wnt	B
11	pathway	O
12	and	O
13	planar	O
14	polarity	O
15	pathway	O
16	in	O
17	Drosophila	O
18	.	O

1	Catch	O
2	-	O
3	up	O
4	growth	O
5	and	O
6	craniofacial	O
7	dimensions	O
8	following	O
9	administration	O
10	of	O
11	the	O
12	antineoplastic	O
13	agent	O
14	vincristine	O
15	to	O
16	young	O
17	rats	O
18	.	O

1	CONCLUSIONS	O
2	:	O
3	LSCC	O
4	malformation	O
5	,	O
6	like	O
7	other	O
8	inner	O
9	ear	O
10	malformations	O
11	such	O
12	as	O
13	large	O
14	vestibular	O
15	aqueduct	O
16	and	O
17	X	O
18	-	O
19	linked	O
20	mixed	O
21	deafness	O
22	with	O
23	perilymph	O
24	gusher	O
25	,	O
26	can	O
27	be	O
28	associated	O
29	with	O
30	CHL	O
31	,	O
32	SNHL	O
33	,	O
34	or	O
35	normal	O
36	hearing	O
37	.	O

1	Escalation	O
2	to	O
3	180	O
4	mg	O
5	/	O
6	m2	O
7	was	O
8	to	O
9	be	O
10	carried	O
11	out	O
12	if	O
13	white	O
14	blood	O
15	cell	O
16	nadir	O
17	count	O
18	was	O
19	>	O
20	2	O
21	.	O
22	0	O
23	x	O
24	10	O
25	(	O
26	9	O
27	)/	O
28	l	O
29	and	O
30	platelet	O
31	nadir	O
32	count	O
33	was	O
34	>	O
35	75	O
36	x	O
37	10	O
38	(	O
39	9	O
40	)/	O
41	l	O
42	.	O

1	Methyl	O
2	formate	O
3	was	O
4	used	O
5	as	O
6	the	O
7	solvent	O
8	of	O
9	biodegradable	O
10	oligoesters	O
11	for	O
12	the	O
13	fabrication	O
14	of	O
15	microspheres	O
16	with	O
17	encapsulated	O
18	bovine	B
19	serum	I
20	albumin	I
21	(	O
22	BSA	B
23	).	O

1	The	O
2	small	B
3	monomeric	I
4	GTP	I
5	-	I
6	binding	I
7	proteins	I
8	of	O
9	the	O
10	RAB	B
11	subfamily	I
12	are	O
13	key	O
14	regulatory	O
15	elements	O
16	of	O
17	the	O
18	machinery	O
19	that	O
20	controls	O
21	membrane	O
22	traffic	O
23	in	O
24	eukaryotic	O
25	cells	O
26	.	O

1	Furthermore	O
2	,	O
3	loss	O
4	of	O
5	methylation	O
6	also	O
7	greatly	O
8	reduced	O
9	the	O
10	association	O
11	of	O
12	another	O
13	yeast	O
14	B	O
15	-	O
16	type	O
17	subunit	O
18	,	O
19	Rts1p	B
20	.	O

1	Thus	O
2	,	O
3	methylation	O
4	of	O
5	Pph21p	B
6	is	O
7	important	O
8	for	O
9	formation	O
10	of	O
11	PP2A	B
12	trimeric	I
13	and	I
14	dimeric	I
15	complexes	I
16	,	O
17	and	O
18	consequently	O
19	,	O
20	for	O
21	PP2A	B
22	function	O
23	.	O

1	The	O
2	purpose	O
3	of	O
4	this	O
5	study	O
6	was	O
7	to	O
8	analyze	O
9	the	O
10	temporal	O
11	characteristics	O
12	and	O
13	the	O
14	spatial	O
15	mapping	O
16	of	O
17	the	O
18	independent	O
19	components	O
20	identified	O
21	by	O
22	ICA	O
23	when	O
24	the	O
25	subject	O
26	performs	O
27	a	O
28	finger	O
29	-	O
30	tapping	O
31	task	O
32	.	O

1	The	O
2	authors	O
3	present	O
4	the	O
5	only	O
6	two	O
7	studies	O
8	that	O
9	have	O
10	proved	O
11	successful	O
12	in	O
13	treating	O
14	animal	O
15	models	O
16	of	O
17	osteoarthritis	O
18	using	O
19	gene	O
20	therapy	O
21	,	O
22	and	O
23	propose	O
24	an	O
25	overview	O
26	of	O
27	several	O
28	strategies	O
29	for	O
30	the	O
31	development	O
32	of	O
33	gene	O
34	therapy	O
35	in	O
36	osteoarthritis	O
37	treatment	O
38	in	O
39	the	O
40	future	O
41	.	O

1	Together	O
2	,	O
3	these	O
4	results	O
5	indicate	O
6	that	O
7	IL	B
8	-	I
9	1	I
10	beta	I
11	induces	O
12	VEGF	B
13	gene	I
14	expression	O
15	at	O
16	both	O
17	transcriptional	O
18	and	O
19	post	O
20	-	O
21	transcriptional	O
22	levels	O
23	,	O
24	and	O
25	IL	B
26	-	I
27	1	I
28	beta	I
29	evokes	O
30	p38	B
31	MAPK	O
32	and	O
33	JNK	B
34	signalings	O
35	,	O
36	which	O
37	in	O
38	turn	O
39	stimulate	O
40	the	O
41	transcription	O
42	of	O
43	the	O
44	VEGF	B
45	gene	I
46	through	O
47	Sp1	B
48	-	I
49	binding	I
50	sites	I
51	.	O

1	Binding	O
2	of	O
3	NusA	B
4	to	O
5	RNA	O
6	in	O
7	the	O
8	presence	O
9	of	O
10	alpha	O
11	or	O
12	N	O
13	involves	O
14	an	O
15	amino	B
16	-	I
17	terminal	I
18	S1	I
19	homology	I
20	region	I
21	that	O
22	is	O
23	otherwise	O
24	inactive	O
25	in	O
26	full	B
27	-	I
28	length	I
29	NusA	I
30	.	O

1	The	O
2	subjects	O
3	were	O
4	diagnosed	O
5	on	O
6	the	O
7	basis	O
8	of	O
9	DSM	O
10	-	O
11	IV	O
12	pathological	O
13	gambling	O
14	criteria	O
15	and	O
16	completed	O
17	the	O
18	Turkish	O
19	Version	O
20	of	O
21	South	O
22	Oaks	O
23	Gambling	O
24	Screen	O
25	(	O
26	SOGS	O
27	).	O

1	Lys	O
2	(	O
3	193	O
4	)	O
5	and	O
6	Arg	O
7	(	O
8	194	O
9	),	O
10	located	O
11	at	O
12	the	O
13	COOH	O
14	-	O
15	terminal	O
16	end	O
17	of	O
18	HD	B
19	,	O
20	are	O
21	essential	O
22	for	O
23	dimerization	O
24	.	O

1	Elevation	O
2	of	O
3	intracellular	O
4	Ca	O
5	(	O
6	2	O
7	+)	O
8	levels	O
9	are	O
10	also	O
11	involved	O
12	because	O
13	treatment	O
14	with	O
15	receptor	O
16	-	O
17	associated	O
18	protein	O
19	,	O
20	nifedipine	O
21	,	O
22	MK801	O
23	,	O
24	removal	O
25	of	O
26	Ca	O
27	(	O
28	2	O
29	+)	O
30	from	O
31	the	O
32	medium	O
33	and	O
34	dantrolene	O
35	all	O
36	served	O
37	to	O
38	inhibit	O
39	calcium	O
40	elevation	O
41	and	O
42	attenuate	O
43	the	O
44	activation	O
45	of	O
46	CREB	B
47	.	O

1	The	O
2	present	O
3	study	O
4	shows	O
5	that	O
6	phosphatidylinositol	B
7	3	I
8	-	I
9	kinase	I
10	-	O
11	dependent	O
12	p38	B
13	kinase	I
14	activation	O
15	regulates	O
16	Akt	B
17	phosphorylation	O
18	and	O
19	activity	O
20	in	O
21	human	O
22	neutrophils	O
23	.	O

1	When	O
2	BFDS	O
3	was	O
4	taken	O
5	as	O
6	the	O
7	reference	O
8	,	O
9	W	O
10	/	O
11	A	O
12	Z	O
13	scores	O
14	showed	O
15	consistent	O
16	positive	O
17	increments	O
18	,	O
19	from	O
20	birth	O
21	in	O
22	girls	O
23	and	O
24	1	O
25	mo	O
26	in	O
27	boys	O
28	.	O

1	These	O
2	probable	O
3	border	O
4	sequences	O
5	are	O
6	closely	O
7	related	O
8	to	O
9	those	O
10	of	O
11	other	O
12	known	O
13	T	O
14	-	O
15	regions	O
16	and	O
17	define	O
18	a	O
19	second	O
20	T	O
21	-	O
22	region	O
23	of	O
24	pTiChry5	O
25	,	O
26	called	O
27	T	O
28	-	O
29	right	O
30	(	O
31	TR	O
32	),	O
33	that	O
34	confers	O
35	production	O
36	of	O
37	the	O
38	Amadoriopines	O
39	.	O

1	Using	O
2	purified	O
3	recombinant	B
4	HMG	I
5	I	I
6	,	O
7	we	O
8	have	O
9	identified	O
10	several	O
11	high	O
12	-	O
13	affinity	O
14	binding	O
15	sites	O
16	which	O
17	overlap	O
18	important	O
19	transcription	O
20	factor	O
21	binding	O
22	sites	O
23	.	O

1	High	B
2	-	I
3	mobility	I
4	-	I
5	group	I
6	protein	I
7	I	I
8	can	O
9	modulate	O
10	binding	O
11	of	O
12	transcription	O
13	factors	O
14	to	O
15	the	O
16	U5	B
17	region	I
18	of	O
19	the	O
20	human	B
21	immunodeficiency	I
22	virus	I
23	type	I
24	1	I
25	proviral	I
26	promoter	I
27	.	O

1	Another	O
2	cis	O
3	-	O
4	acting	O
5	element	O
6	,	O
7	exonic	O
8	splicing	O
9	suppressor	O
10	1	O
11	(	O
12	ESS1	O
13	),	O
14	represses	O
15	use	O
16	of	O
17	the	O
18	nt	O
19	3225	O
20	3	O
21	'	O
22	splice	O
23	site	O
24	.	O

1	Leptinaemia	O
2	does	O
3	not	O
4	correlate	O
5	with	O
6	the	O
7	actual	O
8	or	O
9	mean	O
10	blood	O
11	pressure	O
12	reading	O
13	nor	O
14	with	O
15	stage	O
16	of	O
17	hypertension	O
18	according	O
19	to	O
20	the	O
21	WHO	O
22	classification	O
23	.	O

1	5	O
2	'-	O
3	RACE	O
4	analysis	O
5	suggested	O
6	a	O
7	single	O
8	transcription	O
9	initiation	O
10	site	O
11	187	O
12	bp	O
13	upstream	O
14	from	O
15	the	O
16	translational	O
17	start	O
18	site	O
19	.	O

1	Thus	O
2	,	O
3	diamide	O
4	treatment	O
5	of	O
6	nuclear	O
7	extracts	O
8	strongly	O
9	reduces	O
10	the	O
11	binding	O
12	of	O
13	NFI	B
14	proteins	I
15	,	O
16	and	O
17	the	O
18	addition	O
19	of	O
20	higher	O
21	concentrations	O
22	of	O
23	dithiothreitol	O
24	to	O
25	nuclear	O
26	extracts	O
27	from	O
28	TG	B
29	-	O
30	treated	O
31	cells	O
32	restores	O
33	NFI	B
34	-	I
35	DNA	I
36	binding	O
37	to	O
38	levels	O
39	in	O
40	extracts	O
41	from	O
42	untreated	O
43	cells	O
44	.	O

1	LMP2A	B
2	enhances	O
3	Lyn	B
4	and	O
5	Syk	B
6	ubiquitination	O
7	in	O
8	vivo	O
9	in	O
10	a	O
11	fashion	O
12	that	O
13	depends	O
14	on	O
15	the	O
16	activity	O
17	of	O
18	Nedd4	B
19	family	O
20	members	O
21	and	O
22	correlates	O
23	with	O
24	destabilization	O
25	of	O
26	the	O
27	Lyn	B
28	tyrosine	I
29	kinase	I
30	.	O

1	Further	O
2	,	O
3	Tax	B
4	-	O
5	mediated	O
6	apoptosis	O
7	was	O
8	effectively	O
9	prevented	O
10	by	O
11	ectopic	O
12	expression	O
13	of	O
14	the	O
15	p300	B
16	coactivator	I
17	.	O

1	Our	O
2	results	O
3	,	O
4	however	O
5	,	O
6	were	O
7	obtained	O
8	for	O
9	Z	O
10	itself	O
11	and	O
12	not	O
13	for	O
14	[	O
15	Z	O
16	].	O

1	Fisher	O
2	'	O
3	s	O
4	exact	O
5	test	O
6	or	O
7	Pearson	O
8	'	O
9	s	O
10	chi2	O
11	test	O
12	were	O
13	used	O
14	for	O
15	statistical	O
16	analysis	O
17	.	O

1	RESULTS	O
2	:	O
3	In	O
4	the	O
5	pregnant	O
6	group	O
7	,	O
8	serum	O
9	PP14	B
10	concentrations	O
11	were	O
12	markedly	O
13	increased	O
14	after	O
15	ET	O
16	,	O
17	and	O
18	a	O
19	significant	O
20	difference	O
21	between	O
22	the	O
23	pregnant	O
24	group	O
25	and	O
26	the	O
27	nonpregnant	O
28	group	O
29	was	O
30	observed	O
31	8	O
32	days	O
33	following	O
34	ET	O
35	(	O
36	p	O
37	<	O
38	0	O
39	.	O
40	01	O
41	).	O

1	Thromboelastography	O
2	is	O
3	a	O
4	test	O
5	that	O
6	could	O
7	potentially	O
8	correlate	O
9	with	O
10	the	O
11	degree	O
12	of	O
13	anticoagulation	O
14	produced	O
15	by	O
16	low	O
17	molecular	O
18	weight	O
19	heparin	O
20	.	O

1	High	O
2	expression	O
3	of	O
4	the	O
5	peroxisome	B
6	proliferator	I
7	-	I
8	activated	I
9	receptor	I
10	alpha	I
11	(	O
12	PPARalpha	B
13	)	O
14	differentiates	O
15	brown	O
16	fat	O
17	from	O
18	white	O
19	,	O
20	and	O
21	is	O
22	related	O
23	to	O
24	its	O
25	high	O
26	capacity	O
27	of	O
28	lipid	O
29	oxidation	O
30	.	O

1	This	O
2	-	O
3	2485	O
4	/-	O
5	2458	O
6	element	O
7	bound	O
8	PPARalpha	B
9	and	O
10	PPARgamma	B
11	from	O
12	brown	O
13	fat	O
14	nuclei	O
15	.	O

1	These	O
2	results	O
3	provide	O
4	direct	O
5	evidence	O
6	for	O
7	differential	O
8	susceptibility	O
9	to	O
10	endonuclease	O
11	-	O
12	mediated	O
13	mRNA	O
14	decay	O
15	resulting	O
16	from	O
17	the	O
18	differential	O
19	affinity	O
20	of	O
21	a	O
22	RNA	O
23	-	O
24	binding	O
25	protein	O
26	for	O
27	cis	O
28	-	O
29	acting	O
30	stability	O
31	determinants	O
32	.	O

1	RESULTS	O
2	:	O
3	Twenty	O
4	-	O
5	two	O
6	(	O
7	26	O
8	%)	O
9	patients	O
10	had	O
11	PHG	O
12	before	O
13	(	O
14	group	O
15	A	O
16	)	O
17	and	O
18	64	O
19	(	O
20	74	O
21	%)	O
22	developed	O
23	PHG	O
24	after	O
25	variceal	O
26	eradication	O
27	(	O
28	group	O
29	B	O
30	).	O

1	Response	O
2	was	O
3	extremely	O
4	poor	O
5	in	O
6	African	O
7	Americans	O
8	and	O
9	those	O
10	with	O
11	HCV	O
12	genotype	O
13	1	O
14	.	O

1	Aspirin	O
2	causes	O
3	peptic	O
4	ulcers	O
5	predominately	O
6	by	O
7	reducing	O
8	gastric	B
9	mucosal	I
10	cyclooxygenase	I
11	(	O
12	COX	B
13	)	O
14	activity	O
15	and	O
16	prostaglandin	O
17	synthesis	O
18	.	O

1	A	O
2	total	O
3	of	O
4	1060	O
5	clones	O
6	were	O
7	randomly	O
8	selected	O
9	for	O
10	sequencing	O
11	of	O
12	one	O
13	end	O
14	.	O

1	Expression	O
2	of	O
3	a	O
4	hybrid	O
5	protein	O
6	containing	O
7	the	O
8	cytoplasmic	O
9	C	O
10	-	O
11	terminal	O
12	half	O
13	of	O
14	UhpB	B
15	fused	O
16	to	O
17	glutathione	B
18	S	I
19	-	I
20	transferase	I
21	(	O
22	GST	B
23	)	O
24	also	O
25	interfered	O
26	with	O
27	Uhp	B
28	signaling	O
29	.	O

1	CONCLUSIONS	O
2	:	O
3	The	O
4	surgical	O
5	or	O
6	multimodality	O
7	treatment	O
8	of	O
9	MSGT	O
10	has	O
11	provided	O
12	a	O
13	good	O
14	locoregional	O
15	control	O
16	(	O
17	78	O
18	%)	O
19	and	O
20	68	O
21	%	O
22	10	O
23	-	O
24	year	O
25	survival	O
26	in	O
27	a	O
28	series	O
29	of	O
30	patients	O
31	treated	O
32	at	O
33	the	O
34	oncology	O
35	department	O
36	of	O
37	a	O
38	general	O
39	hospital	O
40	in	O
41	Quito	O
42	,	O
43	Ecuador	O
44	.	O

1	RESULTS	O
2	:	O
3	Glaucoma	O
4	suspects	O
5	were	O
6	divided	O
7	into	O
8	two	O
9	groups	O
10	according	O
11	to	O
12	their	O
13	SWAP	O
14	results	O
15	:	O
16	high	O
17	risk	O
18	(	O
19	with	O
20	SWAP	O
21	abnormalities	O
22	)	O
23	and	O
24	low	O
25	risk	O
26	(	O
27	with	O
28	normal	O
29	SWAP	O
30	result	O
31	).	O

1	The	O
2	gene	O
3	is	O
4	separated	O
5	into	O
6	four	O
7	exons	O
8	by	O
9	three	O
10	short	O
11	introns	O
12	,	O
13	and	O
14	the	O
15	open	O
16	reading	O
17	frame	O
18	consists	O
19	of	O
20	6660	O
21	base	O
22	pairs	O
23	(	O
24	bp	O
25	)	O
26	capable	O
27	of	O
28	encoding	O
29	a	O
30	polypeptide	O
31	of	O
32	2220	O
33	amino	O
34	acid	O
35	residues	O
36	.	O

1	Like	O
2	the	O
3	p190	B
4	-	I
5	B	I
6	exon	O
7	,	O
8	the	O
9	first	O
10	exon	O
11	of	O
12	p190	B
13	-	I
14	A	I
15	is	O
16	extremely	O
17	large	O
18	(	O
19	3	O
20	.	O
21	7	O
22	kb	O
23	in	O
24	length	O
25	),	O
26	encoding	O
27	both	O
28	the	O
29	GTPase	B
30	and	O
31	middle	O
32	domains	O
33	(	O
34	residues	O
35	1	O
36	-	O
37	1228	O
38	),	O
39	but	O
40	not	O
41	the	O
42	remaining	O
43	GAP	B
44	domain	I
45	,	O
46	suggesting	O
47	a	O
48	high	O
49	conservation	O
50	of	O
51	genomic	O
52	structure	O
53	between	O
54	two	O
55	p190	B
56	genes	I
57	.	O

1	The	O
2	entire	O
3	human	B
4	teneurin	I
5	-	I
6	1	I
7	(	O
8	TEN1	B
9	)	O
10	gene	O
11	is	O
12	contained	O
13	in	O
14	eight	O
15	PAC	O
16	clones	O
17	representing	O
18	part	O
19	of	O
20	the	O
21	chromosomal	O
22	locus	O
23	Xq25	O
24	.	O

1	The	O
2	plexiform	O
3	neurofibroma	O
4	and	O
5	multiple	O
6	localized	O
7	neurofibromas	O
8	are	O
9	characteristic	O
10	of	O
11	NF1	B
12	.	O

1	In	O
2	general	O
3	lookback	O
4	,	O
5	all	O
6	patients	O
7	who	O
8	received	O
9	blood	O
10	before	O
11	being	O
12	tested	O
13	for	O
14	hepatitis	O
15	C	O
16	are	O
17	advised	O
18	to	O
19	undergo	O
20	testing	O
21	.	O

1	The	O
2	proposed	O
3	algorithm	O
4	consists	O
5	of	O
6	several	O
7	steps	O
8	.	O

1	It	O
2	contained	O
3	seven	O
4	extra	O
5	amino	O
6	acids	O
7	of	O
8	FVVLNLQ	O
9	;	O
10	this	O
11	short	O
12	stretch	O
13	of	O
14	extra	O
15	sequence	O
16	was	O
17	found	O
18	between	O
19	Gln	O
20	(	O
21	421	O
22	)	O
23	and	O
24	Phe	O
25	(	O
26	422	O
27	)	O
28	within	O
29	the	O
30	SET	B
31	(	O
32	Suvar3	B
33	-	I
34	9	I
35	,	O
36	Enhancer	B
37	-	I
38	of	I
39	-	I
40	zeste	I
41	,	O
42	Trithorax	B
43	)	O
44	interacting	O
45	domain	O
46	(	O
47	SID	O
48	)	O
49	of	O
50	rMTM	B
51	.	O

1	MED1	B
2	has	O
3	a	O
4	weak	O
5	glycosylase	B
6	activity	O
7	on	O
8	the	O
9	mutagenic	O
10	adduct	O
11	3	O
12	,	O
13	N	O
14	(	O
15	4	O
16	)-	O
17	ethenocytosine	O
18	,	O
19	a	O
20	metabolite	O
21	of	O
22	vinyl	O
23	chloride	O
24	and	O
25	ethyl	O
26	carbamate	O
27	.	O

1	There	O
2	were	O
3	no	O
4	instances	O
5	of	O
6	major	O
7	flap	O
8	necrosis	O
9	although	O
10	two	O
11	flaps	O
12	showed	O
13	tip	O
14	ischaemia	O
15	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	XAB1	B
6	is	O
7	a	O
8	novel	O
9	cytoplasmic	B
10	GTPase	I
11	involved	O
12	in	O
13	nuclear	O
14	localization	O
15	of	O
16	XPA	B
17	.	O

1	One	O
2	of	O
3	these	O
4	factors	O
5	,	O
6	IRF	B
7	-	I
8	2	I
9	,	O
10	was	O
11	initially	O
12	cloned	O
13	as	O
14	an	O
15	antagonistic	O
16	counterpart	O
17	to	O
18	IRF	B
19	-	I
20	1	I
21	with	O
22	oncogenic	O
23	potential	O
24	.	O

1	Among	O
2	the	O
3	total	O
4	CDSs	O
5	,	O
6	8	O
7	.	O
8	8	O
9	%	O
10	match	O
11	sequences	O
12	of	O
13	proteins	O
14	found	O
15	only	O
16	in	O
17	Bacillus	O
18	subtilis	O
19	and	O
20	66	O
21	.	O
22	7	O
23	%	O
24	are	O
25	widely	O
26	conserved	O
27	in	O
28	comparison	O
29	with	O
30	the	O
31	proteins	O
32	of	O
33	various	O
34	organisms	O
35	,	O
36	including	O
37	B	O
38	.	O
39	subtilis	O
40	.	O

1	Tobramycin	O
2	-	O
3	loaded	O
4	SLN	O
5	administered	O
6	i	O
7	.	O
8	v	O
9	.	O
10	showed	O
11	a	O
12	prolonged	O
13	circulation	O
14	time	O
15	compared	O
16	to	O
17	the	O
18	i	O
19	.	O
20	v	O
21	.	O
22	administered	O
23	tobramycin	O
24	solution	O
25	.	O

1	Bacteriol	O
2	.	O

1	Terminal	B
2	deoxynucleotidyl	I
3	transferase	I
4	-	O
5	mediated	O
6	nick	O
7	end	O
8	labeling	O
9	assays	O
10	revealed	O
11	that	O
12	hormonal	O
13	activation	O
14	of	O
15	the	O
16	PAX3	B
17	repressors	I
18	induced	O
19	extensive	O
20	apoptosis	O
21	that	O
22	correlated	O
23	with	O
24	down	O
25	-	O
26	regulation	O
27	of	O
28	BCL	B
29	-	I
30	X	I
31	(	I
32	L	I
33	)	I
34	expression	O
35	.	O

1	VEGF	B
2	promoter	I
3	activity	O
4	in	O
5	transient	O
6	transfections	O
7	was	O
8	decreased	O
9	by	O
10	either	O
11	pharmacological	O
12	or	O
13	genetic	O
14	inhibition	O
15	of	O
16	EGFR	B
17	,	O
18	Ras	B
19	,	O
20	or	O
21	phosphatidylinositol	B
22	3	I
23	'-	I
24	kinase	I
25	[	O
26	PI	O
27	(	O
28	3	O
29	)	O
30	kinase	O
31	].	O

1	Epidermal	B
2	growth	I
3	factor	I
4	receptor	I
5	transcriptionally	O
6	up	O
7	-	O
8	regulates	O
9	vascular	B
10	endothelial	I
11	growth	I
12	factor	I
13	expression	O
14	in	O
15	human	O
16	glioblastoma	O
17	cells	O
18	via	O
19	a	O
20	pathway	O
21	involving	O
22	phosphatidylinositol	B
23	3	I
24	'-	I
25	kinase	I
26	and	O
27	distinct	O
28	from	O
29	that	O
30	induced	O
31	by	O
32	hypoxia	O
33	.	O

1	Thus	O
2	,	O
3	IHHNV	O
4	is	O
5	closely	O
6	related	O
7	to	O
8	densoviruses	O
9	of	O
10	the	O
11	genus	O
12	Brevidensovirus	O
13	in	O
14	the	O
15	family	O
16	Parvoviridae	O
17	,	O
18	and	O
19	we	O
20	therefore	O
21	propose	O
22	to	O
23	rename	O
24	this	O
25	virus	O
26	Penaeus	O
27	stylirostris	O
28	densovirus	O
29	(	O
30	PstDNV	O
31	).	O

1	Stress	B
2	-	I
3	activated	I
4	protein	I
5	kinase	I
6	1	I
7	(	O
8	SAPK1	B
9	),	O
10	also	O
11	called	O
12	c	B
13	-	I
14	Jun	I
15	N	I
16	-	I
17	terminal	I
18	kinase	I
19	(	O
20	JNK	B
21	),	O
22	becomes	O
23	activated	O
24	in	O
25	vivo	O
26	in	O
27	response	O
28	to	O
29	pro	O
30	-	O
31	inflammatory	O
32	cytokines	O
33	or	O
34	cellular	O
35	stresses	O
36	.	O

1	Catalytic	O
2	activation	O
3	of	O
4	mitogen	B
5	-	I
6	activated	I
7	protein	I
8	(	I
9	MAP	I
10	)	I
11	kinase	I
12	phosphatase	I
13	-	I
14	1	I
15	by	O
16	binding	O
17	to	O
18	p38	B
19	MAP	I
20	kinase	I
21	:	O
22	critical	O
23	role	O
24	of	O
25	the	O
26	p38	B
27	C	I
28	-	I
29	terminal	I
30	domain	I
31	in	O
32	its	O
33	negative	O
34	regulation	O
35	.	O

1	Thus	O
2	,	O
3	the	O
4	class	B
5	C	I
6	-	O
7	Vps	B
8	complex	O
9	directs	O
10	multiple	O
11	reactions	O
12	during	O
13	the	O
14	docking	O
15	and	O
16	fusion	O
17	of	O
18	vesicles	O
19	with	O
20	the	O
21	vacuole	O
22	,	O
23	each	O
24	of	O
25	which	O
26	contributes	O
27	to	O
28	the	O
29	overall	O
30	specificity	O
31	and	O
32	efficiency	O
33	of	O
34	this	O
35	transport	O
36	process	O
37	.	O

1	Combined	O
2	intravenous	O
3	and	O
4	intra	O
5	-	O
6	arterial	O
7	recombinant	O
8	tissue	B
9	plasminogen	I
10	activator	I
11	in	O
12	acute	O
13	ischemic	O
14	stroke	O
15	.	O

1	To	O
2	begin	O
3	to	O
4	understand	O
5	this	O
6	role	O
7	,	O
8	we	O
9	overexpressed	O
10	ATF	B
11	-	I
12	2	I
13	in	O
14	a	O
15	human	O
16	cancer	O
17	cell	O
18	line	O
19	.	O

1	Signal	O
2	transduction	O
3	via	O
4	modulation	O
5	of	O
6	phosphorylation	O
7	after	O
8	selective	O
9	inhibition	O
10	of	O
11	protein	B
12	phosphatase	I
13	(	I
14	PP	I
15	)	I
16	1	I
17	and	O
18	/	O
19	or	O
20	PP2A	B
21	appears	O
22	to	O
23	play	O
24	a	O
25	role	O
26	in	O
27	okadaic	O
28	acid	O
29	(	O
30	OA	O
31	)-	O
32	mediated	O
33	effects	O
34	.	O

1	Botulinum	B
2	toxin	I
3	A	I
4	in	O
5	the	O
6	treatment	O
7	of	O
8	hemiplegic	O
9	spastic	O
10	foot	O
11	drop	O
12	--	O
13	clinical	O
14	and	O
15	functional	O
16	outcomes	O
17	.	O

1	Exon	O
2	A	O
3	is	O
4	located	O
5	approximately	O
6	7	O
7	kb	O
8	5	O
9	'	O
10	to	O
11	the	O
12	HSL	B
13	translation	I
14	start	I
15	site	I
16	.	O

1	NF	B
2	-	I
3	kappaB	I
4	is	O
5	a	O
6	redox	O
7	-	O
8	sensitive	O
9	transcription	O
10	factor	O
11	known	O
12	to	O
13	be	O
14	activated	O
15	by	O
16	oxidative	O
17	stress	O
18	as	O
19	well	O
20	as	O
21	chemical	O
22	and	O
23	biological	O
24	reductants	O
25	.	O

1	Cardiovascular	O
2	risk	O
3	factors	O
4	and	O
5	antihypertensive	O
6	treatment	O
7	.	O

1	What	O
2	to	O
3	look	O
4	for	O
5	during	O
6	a	O
7	compliance	O
8	review	O
9	:	O
10	10	O
11	common	O
12	mistakes	O
13	made	O
14	by	O
15	SNFs	O
16	.	O

1	CONCLUSIONS	O
2	:	O
3	EBCT	O
4	technology	O
5	allows	O
6	minimally	O
7	invasive	O
8	evaluation	O
9	of	O
10	intramyocardial	O
11	microcirculatory	O
12	function	O
13	and	O
14	permits	O
15	assessment	O
16	of	O
17	microvascular	O
18	BV	O
19	distribution	O
20	in	O
21	different	O
22	functional	O
23	components	O
24	.	O

1	These	O
2	two	O
3	mAbs	O
4	used	O
5	the	O
6	same	O
7	V	O
8	(	O
9	H	O
10	)	O
11	and	O
12	J	O
13	(	O
14	H	O
15	)	O
16	gene	O
17	segments	O
18	,	O
19	but	O
20	different	O
21	D	O
22	,	O
23	Vkappa	O
24	,	O
25	and	O
26	Jkappa	O
27	genes	O
28	.	O

1	SSF	O
2	experiments	O
3	were	O
4	carried	O
5	out	O
6	in	O
7	bench	O
8	-	O
9	scale	O
10	bioreactors	O
11	(	O
12	equipped	O
13	with	O
14	CO2	O
15	and	O
16	volatile	O
17	organic	O
18	traps	O
19	)	O
20	containing	O
21	a	O
22	mixture	O
23	of	O
24	lignocellulosic	O
25	materials	O
26	and	O
27	a	O
28	radiolabeled	O
29	pesticide	O
30	.	O

1	Characterization	O
2	of	O
3	a	O
4	Xenopus	B
5	laevis	I
6	CXC	I
7	chemokine	I
8	receptor	I
9	4	I
10	:	O
11	implications	O
12	for	O
13	hematopoietic	O
14	cell	O
15	development	O
16	in	O
17	the	O
18	vertebrate	O
19	embryo	O
20	.	O

1	Patients	O
2	had	O
3	to	O
4	have	O
5	adequate	O
6	liver	O
7	,	O
8	renal	O
9	,	O
10	and	O
11	marrow	O
12	functions	O
13	.	O

1	Inhibition	O
2	of	O
3	RNA2	B
4	translation	O
5	was	O
6	selective	O
7	,	O
8	with	O
9	no	O
10	effect	O
11	on	O
12	general	O
13	cellular	O
14	translation	O
15	or	O
16	translation	O
17	of	O
18	BMV	O
19	RNA1	B
20	-	O
21	encoded	O
22	replication	B
23	factor	I
24	1a	I
25	,	O
26	and	O
27	was	O
28	independent	O
29	of	O
30	p20	B
31	,	O
32	a	O
33	cellular	O
34	antagonist	O
35	of	O
36	DED1	B
37	function	O
38	in	O
39	translation	O
40	.	O

1	Abbreviations	O
2	:	O
3	CAS	B
4	,	O
5	CRK	B
6	-	I
7	associated	I
8	substrate	I
9	;	O
10	CH	B
11	,	O
12	calponin	B
13	-	I
14	homology	I
15	domain	I
16	;	O
17	CSK	B
18	,	O
19	C	B
20	-	I
21	terminal	I
22	SRC	I
23	kinase	I
24	;	O
25	E6	B
26	,	O
27	Papillomavirus	B
28	E6	I
29	protein	I
30	;	O
31	FAK	B
32	,	O
33	focal	B
34	adhesion	I
35	kinase	I
36	;	O
37	GIT	B
38	,	O
39	GRK	B
40	interacter	I
41	;	O
42	GPCR	B
43	,	O
44	heterotrimeric	B
45	-	I
46	G	I
47	-	I
48	protein	I
49	-	I
50	coupled	I
51	receptor	I
52	;	O
53	GRK	B
54	,	O
55	G	B
56	-	I
57	protein	I
58	-	I
59	coupled	I
60	-	I
61	receptor	I
62	kinase	I
63	;	O
64	MAPK	B
65	,	O
66	mitogen	B
67	-	I
68	activated	I
69	protein	I
70	kinase	I
71	(	O
72	ERK	B
73	,	O
74	p38	B
75	,	O
76	JNK	B
77	);	O
78	PAK	B
79	,	O
80	p21	B
81	-	I
82	activated	I
83	kinase	I
84	;	O
85	PBS	B
86	,	O
87	paxillin	B
88	-	I
89	binding	I
90	subdomain	I
91	;	O
92	PIX	B
93	,	O
94	PAK	B
95	-	I
96	interacting	I
97	exchange	I
98	factor	I
99	;	O
100	PKL	B
101	,	O
102	paxillin	B
103	kinase	I
104	linker	I
105	;	O
106	POR1	B
107	,	O
108	partner	B
109	of	I
110	Rac	I
111	;	O
112	PS	O
113	,	O
114	phosphoserine	O
115	;	O
116	PT	O
117	,	O
118	phosphothreonine	O
119	;	O
120	PY	O
121	,	O
122	phosphotyrosine	O
123	;	O
124	RTK	B
125	,	O
126	growth	B
127	factor	I
128	receptor	I
129	tyrosine	I
130	kinase	I
131	;	O
132	SH	B
133	,	O
134	SRC	B
135	-	I
136	homology	I
137	domain	I
138	.	O

1	In	O
2	15	O
3	ventilator	O
4	-	O
5	dependent	O
6	,	O
7	SB	O
8	,	O
9	and	O
10	actively	O
11	expiring	O
12	patients	O
13	,	O
14	we	O
15	found	O
16	that	O
17	the	O
18	difference	O
19	PEEP	O
20	(	O
21	i	O
22	),	O
23	dyn	O
24	-	O
25	Pga	O
26	,	O
27	total	O
28	decay	O
29	(	O
30	mean	O
31	+/-	O
32	SD	O
33	,	O
34	5	O
35	.	O
36	7	O
37	+/-	O
38	1	O
39	.	O
40	9	O
41	cm	O
42	H	O
43	(	O
44	2	O
45	)	O
46	O	O
47	)	O
48	was	O
49	quite	O
50	similar	O
51	to	O
52	PEEP	O
53	(	O
54	i	O
55	),	O
56	dyn	O
57	ref	O
58	(	O
59	5	O
60	.	O
61	3	O
62	+/-	O
63	1	O
64	.	O
65	9	O
66	cm	O
67	H	O
68	(	O
69	2	O
70	)	O
71	O	O
72	).	O

1	Of	O
2	208	O
3	eligible	O
4	subjects	O
5	,	O
6	82	O
7	received	O
8	supervised	O
9	IPT	O
10	at	O
11	a	O
12	dose	O
13	of	O
14	900	O
15	mg	O
16	twice	O
17	weekly	O
18	for	O
19	6	O
20	mo	O
21	(	O
22	Regimen	O
23	A	O
24	),	O
25	73	O
26	received	O
27	unsupervised	O
28	IPT	O
29	900	O
30	mg	O
31	twice	O
32	weekly	O
33	for	O
34	6	O
35	mo	O
36	(	O
37	Regimen	O
38	B	O
39	),	O
40	and	O
41	53	O
42	received	O
43	unsupervised	O
44	IPT	O
45	300	O
46	mg	O
47	daily	O
48	for	O
49	6	O
50	mo	O
51	(	O
52	Regimen	O
53	C	O
54	).	O

1	There	O
2	were	O
3	122	O
4	cases	O
5	of	O
6	tuberculosis	O
7	over	O
8	an	O
9	average	O
10	10	O
11	.	O
12	3	O
13	yr	O
14	of	O
15	follow	O
16	-	O
17	up	O
18	(	O
19	crude	O
20	annual	O
21	incidence	O
22	,	O
23	76	O
24	.	O
25	2	O
26	/	O
27	100	O
28	,	O
29	000	O
30	).	O

1	These	O
2	results	O
3	suggested	O
4	that	O
5	BACH1t	B
6	recruits	O
7	BACH1	B
8	to	O
9	the	O
10	nucleus	O
11	through	O
12	BTB	B
13	domain	O
14	-	O
15	mediated	O
16	interaction	O
17	.	O

1	The	O
2	U17	B
3	/	O
4	U16	B
5	and	O
6	the	O
7	U16	B
8	+	I
9	gene	I
10	products	I
11	transactivated	O
12	the	O
13	HIV	B
14	LTR	I
15	.	O

1	Transcription	O
2	of	O
3	the	O
4	six	O
5	EBNA	B
6	genes	I
7	,	O
8	which	O
9	are	O
10	expressed	O
11	in	O
12	EBV	O
13	-	O
14	immortalized	O
15	primary	O
16	B	O
17	cells	O
18	,	O
19	arises	O
20	from	O
21	one	O
22	of	O
23	two	O
24	promoters	O
25	,	O
26	Cp	B
27	and	O
28	Wp	B
29	,	O
30	located	O
31	near	O
32	the	O
33	left	O
34	end	O
35	of	O
36	the	O
37	viral	O
38	genome	O
39	.	O

1	The	O
2	Cili	B
3	-	I
4	2	I
5	sequences	I
6	possess	O
7	similarity	O
8	to	O
9	the	O
10	RNaseH	B
11	domain	I
12	of	O
13	Lian	B
14	-	O
15	Aa1	B
16	,	O
17	a	O
18	mosquito	B
19	non	I
20	-	I
21	LTR	I
22	retrotransposon	I
23	.	O

1	This	O
2	dynamic	O
3	response	O
4	strongly	O
5	suggests	O
6	that	O
7	the	O
8	p53	B
9	and	O
10	Rb	B
11	tumor	O
12	suppressor	O
13	pathways	O
14	are	O
15	intact	O
16	in	O
17	HeLa	O
18	cells	O
19	and	O
20	that	O
21	repression	O
22	of	O
23	HPV	B
24	E6	I
25	and	O
26	E7	B
27	mobilizes	O
28	these	O
29	pathways	O
30	in	O
31	an	O
32	orderly	O
33	fashion	O
34	to	O
35	deliver	O
36	growth	O
37	inhibitory	O
38	signals	O
39	to	O
40	the	O
41	cells	O
42	.	O

1	Thus	O
2	,	O
3	blocks	O
4	in	O
5	the	O
6	RARalpha	B
7	-	O
8	specific	O
9	pathway	O
10	of	O
11	retinoid	O
12	-	O
13	induced	O
14	differentiation	O
15	may	O
16	be	O
17	bypassed	O
18	during	O
19	retinoid	O
20	induction	O
21	of	O
22	FR	B
23	-	I
24	beta	I
25	expression	O
26	.	O

1	Is	O
2	more	O
3	better	O
4	?	O
5	About	O
6	dose	O
7	levels	O
8	of	O
9	ACE	B
10	inhibitors	O
11	in	O
12	chronic	O
13	heart	O
14	failure	O
15	.	O

1	To	O
2	test	O
3	whether	O
4	or	O
5	not	O
6	SOCS	B
7	-	I
8	3	I
9	also	O
10	binds	O
11	to	O
12	the	O
13	IGFIR	B
14	,	O
15	we	O
16	cloned	O
17	human	B
18	SOCS	I
19	-	I
20	3	I
21	by	O
22	reverse	O
23	transcription	O
24	-	O
25	polymerase	O
26	chain	O
27	reaction	O
28	from	O
29	human	O
30	skeletal	O
31	muscle	O
32	mRNA	O
33	.	O

1	A	O
2	protein	O
3	lacking	O
4	the	O
5	SH2	B
6	and	O
7	RING	O
8	finger	O
9	domains	O
10	has	O
11	no	O
12	activity	O
13	,	O
14	but	O
15	a	O
16	chimeric	O
17	protein	O
18	with	O
19	the	O
20	SH2	B
21	and	O
22	RING	O
23	finger	O
24	domains	O
25	of	O
26	SLI	B
27	-	I
28	1	I
29	replaced	O
30	by	O
31	the	O
32	equivalent	O
33	domains	O
34	of	O
35	c	B
36	-	I
37	Cbl	I
38	has	O
39	activity	O
40	.	O

1	To	O
2	evaluate	O
3	the	O
4	effects	O
5	of	O
6	HRT	O
7	on	O
8	those	O
9	factors	O
10	in	O
11	end	O
12	-	O
13	stage	O
14	renal	O
15	disease	O
16	(	O
17	ESRD	O
18	)	O
19	patients	O
20	,	O
21	we	O
22	evaluated	O
23	the	O
24	changes	O
25	of	O
26	lipid	O
27	profile	O
28	,	O
29	coagulation	O
30	and	O
31	fibrinolysis	O
32	markers	O
33	,	O
34	and	O
35	plasma	O
36	homocysteine	O
37	levels	O
38	after	O
39	treatment	O
40	.	O

1	There	O
2	was	O
3	a	O
4	weak	O
5	significant	O
6	correlation	O
7	between	O
8	TGF	B
9	beta	I
10	1	I
11	levels	O
12	and	O
13	normal	O
14	cell	O
15	radiosensitivity	O
16	(	O
17	lymphocyte	O
18	SF2	O
19	).	O

1	Acute	O
2	feasibility	O
3	and	O
4	safety	O
5	of	O
6	a	O
7	smoking	O
8	reduction	O
9	strategy	O
10	for	O
11	smokers	O
12	with	O
13	schizophrenia	O
14	.	O

1	Tightly	O
2	ordered	O
3	proteasomal	O
4	degradation	O
5	of	O
6	proteins	O
7	critical	O
8	for	O
9	cell	O
10	cycle	O
11	control	O
12	implies	O
13	a	O
14	role	O
15	of	O
16	the	O
17	proteasome	O
18	in	O
19	maintaining	O
20	cell	O
21	proliferation	O
22	and	O
23	cell	O
24	survival	O
25	.	O

1	The	O
2	sixth	O
3	nucleotide	O
4	was	O
5	bulged	O
6	out	O
7	to	O
8	allow	O
9	stacking	O
10	of	O
11	this	O
12	U	O
13	.	O
14	G	O
15	pair	O
16	on	O
17	the	O
18	adjacent	O
19	helical	O
20	region	O
21	.	O

1	Functional	O
2	analysis	O
3	of	O
4	the	O
5	mutant	B
6	desmin	I
7	in	O
8	SW13	O
9	(	O
10	vim	B
11	-)	O
12	cells	O
13	showed	O
14	aggregation	O
15	of	O
16	abnormal	O
17	coarse	O
18	clumps	O
19	of	O
20	desmin	B
21	positive	O
22	material	O
23	dispersed	O
24	throughout	O
25	the	O
26	cytoplasm	O
27	.	O

1	Patients	O
2	with	O
3	lesions	O
4	affecting	O
5	the	O
6	PRC	O
7	but	O
8	sparing	O
9	the	O
10	PHC	O
11	,	O
12	and	O
13	patients	O
14	with	O
15	lesions	O
16	affecting	O
17	both	O
18	PRC	O
19	and	O
20	PHC	O
21	,	O
22	performed	O
23	an	O
24	oculomotor	O
25	delayed	O
26	response	O
27	task	O
28	with	O
29	unpredictably	O
30	varied	O
31	memory	O
32	delays	O
33	of	O
34	up	O
35	to	O
36	30	O
37	s	O
38	.	O

1	In	O
2	addition	O
3	,	O
4	26	O
5	amino	O
6	acid	O
7	residues	O
8	,	O
9	K69	O
10	,	O
11	D88	O
12	,	O
13	E94	O
14	,	O
15	D134	O
16	,	O
17	R154	O
18	,	O
19	K169	O
20	,	O
21	H197	O
22	,	O
23	D233	O
24	,	O
25	G235	O
26	,	O
27	G236	O
28	,	O
29	G237	O
30	,	O
31	F238	O
32	,	O
33	E274	O
34	,	O
35	G276	O
36	,	O
37	R277	O
38	,	O
39	Y278	O
40	,	O
41	K294	O
42	,	O
43	Y323	O
44	,	O
45	Y331	O
46	,	O
47	D332	O
48	,	O
49	C360	O
50	,	O
51	D361	O
52	,	O
53	D364	O
54	,	O
55	G387	O
56	,	O
57	Y389	O
58	,	O
59	and	O
60	F397	O
61	(	O
62	mouse	O
63	ODC	B
64	numbering	O
65	),	O
66	all	O
67	of	O
68	which	O
69	are	O
70	implicated	O
71	in	O
72	the	O
73	formation	O
74	of	O
75	the	O
76	pyridoxal	O
77	phosphate	O
78	-	O
79	binding	O
80	domain	O
81	and	O
82	the	O
83	substrate	O
84	-	O
85	binding	O
86	domain	O
87	and	O
88	in	O
89	dimer	O
90	stabilization	O
91	with	O
92	the	O
93	eukaryotic	O
94	ODCs	B
95	,	O
96	were	O
97	also	O
98	conserved	O
99	in	O
100	S	O
101	.	O
102	ruminantium	O
103	LDC	B
104	.	O

1	The	O
2	Psc2	B
3	cDNA	I
4	contained	O
5	an	O
6	open	O
7	reading	O
8	frame	O
9	homologous	O
10	to	O
11	CP2	B
12	family	I
13	proteins	I
14	.	O

1	Our	O
2	results	O
3	indicate	O
4	that	O
5	Shh	B
6	can	O
7	drive	O
8	continued	O
9	cycling	O
10	in	O
11	immature	O
12	,	O
13	proliferating	O
14	CGNPs	O
15	.	O

1	The	O
2	QT	O
3	interval	O
4	was	O
5	related	O
6	to	O
7	various	O
8	components	O
9	of	O
10	the	O
11	insulin	B
12	resistance	O
13	syndrome	O
14	,	O
15	including	O
16	BP	O
17	and	O
18	insulin	B
19	sensitivity	O
20	.	O

1	The	O
2	wavenumbers	O
3	corresponding	O
4	to	O
5	the	O
6	normal	O
7	modes	O
8	of	O
9	vibration	O
10	were	O
11	calculated	O
12	using	O
13	the	O
14	DFT	O
15	(	O
16	B3LYP	O
17	/	O
18	6	O
19	-	O
20	31G	O
21	**)	O
22	approximation	O
23	and	O
24	their	O
25	agreement	O
26	with	O
27	the	O
28	measured	O
29	values	O
30	improved	O
31	after	O
32	scaling	O
33	of	O
34	the	O
35	associated	O
36	force	O
37	field	O
38	.	O

1	The	O
2	data	O
3	provide	O
4	strong	O
5	evidence	O
6	that	O
7	ThlA	B
8	is	O
9	involved	O
10	in	O
11	the	O
12	metabolism	O
13	of	O
14	both	O
15	acid	O
16	and	O
17	solvent	O
18	formation	O
19	,	O
20	whereas	O
21	the	O
22	physiological	O
23	function	O
24	of	O
25	ThlB	B
26	has	O
27	yet	O
28	to	O
29	be	O
30	elucidated	O
31	.	O

1	In	O
2	addition	O
3	,	O
4	npm3	B
5	,	O
6	which	O
7	is	O
8	usually	O
9	coactivated	O
10	with	O
11	fgf8	B
12	by	O
13	MMTV	O
14	insertion	O
15	,	O
16	was	O
17	not	O
18	up	O
19	-	O
20	regulated	O
21	by	O
22	androgens	O
23	in	O
24	SC	O
25	-	O
26	3	O
27	cells	O
28	.	O

1	Experiments	O
2	with	O
3	epitope	O
4	-	O
5	tagged	O
6	proteins	O
7	show	O
8	that	O
9	UEV1A	B
10	is	O
11	a	O
12	nuclear	O
13	protein	O
14	,	O
15	whereas	O
16	both	O
17	Kua	B
18	and	O
19	Kua	B
20	-	O
21	UEV	B
22	localize	O
23	to	O
24	cytoplasmic	O
25	structures	O
26	,	O
27	indicating	O
28	that	O
29	the	O
30	Kua	B
31	domain	I
32	determines	O
33	the	O
34	cytoplasmic	O
35	localization	O
36	of	O
37	Kua	B
38	-	O
39	UEV	B
40	.	O

1	Stoichiometric	O
2	phosphorylation	O
3	of	O
4	human	B
5	p53	I
6	at	O
7	Ser315	O
8	stimulates	O
9	p53	B
10	-	O
11	dependent	O
12	transcription	O
13	.	O
14	p53	B
15	protein	I
16	activity	O
17	as	O
18	a	O
19	transcription	O
20	factor	O
21	can	O
22	be	O
23	activated	O
24	in	O
25	vivo	O
26	by	O
27	antibodies	O
28	that	O
29	target	O
30	its	O
31	C	O
32	-	O
33	terminal	O
34	negative	O
35	regulatory	O
36	domain	O
37	suggesting	O
38	that	O
39	cellular	O
40	enzymes	O
41	that	O
42	target	O
43	this	O
44	domain	O
45	may	O
46	play	O
47	a	O
48	role	O
49	in	O
50	stimulating	O
51	p53	B
52	-	O
53	dependent	O
54	gene	O
55	expression	O
56	.	O

1	Interestingly	O
2	,	O
3	this	O
4	mutant	O
5	cell	O
6	line	O
7	lacks	O
8	expression	O
9	of	O
10	the	O
11	IKK	B
12	regulatory	I
13	protein	I
14	,	O
15	IKKgamma	B
16	.	O

1	The	O
2	Tax	B
3	/	O
4	IKKgamma	B
5	interaction	O
6	serves	O
7	to	O
8	recruit	O
9	Tax	B
10	to	O
11	the	O
12	IKK	B
13	catalytic	I
14	subunits	I
15	,	O
16	IKKalpha	B
17	and	O
18	IKKbeta	B
19	,	O
20	and	O
21	this	O
22	recruitment	O
23	appears	O
24	to	O
25	be	O
26	an	O
27	essential	O
28	mechanism	O
29	by	O
30	which	O
31	Tax	B
32	stimulates	O
33	the	O
34	activity	O
35	of	O
36	IKK	B
37	.	O

1	An	O
2	anchored	O
3	AFLP	O
4	-	O
5	and	O
6	retrotransposon	O
7	-	O
8	based	O
9	map	O
10	of	O
11	diploid	O
12	Avena	O
13	.	O

1	In	O
2	addition	O
3	,	O
4	we	O
5	identified	O
6	a	O
7	novel	O
8	type	O
9	of	O
10	inhibitory	O
11	domain	O
12	in	O
13	the	O
14	N	O
15	-	O
16	terminal	O
17	60	O
18	amino	O
19	acids	O
20	of	O
21	IRF	B
22	-	I
23	1	I
24	which	O
25	strongly	O
26	inhibits	O
27	its	O
28	transcriptional	O
29	activity	O
30	.	O

1	Effects	O
2	of	O
3	spatial	O
4	and	O
5	temporal	O
6	smoothing	O
7	on	O
8	stimulated	O
9	brillouin	O
10	scattering	O
11	in	O
12	the	O
13	independent	O
14	-	O
15	hot	O
16	-	O
17	spot	O
18	model	O
19	limit	O
20	The	O
21	influence	O
22	of	O
23	laser	O
24	beam	O
25	smoothing	O
26	on	O
27	stimulated	O
28	Brillouin	O
29	backscattering	O
30	(	O
31	SBBS	O
32	)	O
33	is	O
34	studied	O
35	analytically	O
36	in	O
37	the	O
38	limit	O
39	of	O
40	the	O
41	independent	O
42	hot	O
43	spot	O
44	model	O
45	.	O

1	Simultaneous	O
2	determination	O
3	of	O
4	theophylline	O
5	and	O
6	its	O
7	metabolites	O
8	by	O
9	HPLC	O
10	]	O
11	A	O
12	high	O
13	performance	O
14	liquid	O
15	chromatography	O
16	(	O
17	HPLC	O
18	)	O
19	method	O
20	has	O
21	been	O
22	developed	O
23	for	O
24	the	O
25	simultaneous	O
26	determination	O
27	of	O
28	theophylline	O
29	and	O
30	its	O
31	metabolites	O
32	,	O
33	with	O
34	caffeine	O
35	and	O
36	its	O
37	metabolites	O
38	.	O

1	Ten	O
2	males	O
3	performed	O
4	both	O
5	test	O
6	conditions	O
7	and	O
8	oxygen	O
9	uptake	O
10	VO2	O
11	,	O
12	heart	O
13	rate	O
14	,	O
15	minute	O
16	ventilation	O
17	VE	O
18	,	O
19	perceived	O
20	exertion	O
21	and	O
22	spinal	O
23	shrinkage	O
24	were	O
25	recorded	O
26	.	O

1	CONCLUSION	O
2	:	O
3	SPT	O
4	is	O
5	more	O
6	useful	O
7	than	O
8	WST	O
9	in	O
10	differentiating	O
11	patients	O
12	predisposed	O
13	to	O
14	aspiration	O
15	.	O

1	Studied	O
2	groups	O
3	were	O
4	(	O
5	1	O
6	)	O
7	untreated	O
8	control	O
9	,	O
10	n	O
11	=	O
12	12	O
13	;	O
14	(	O
15	2	O
16	)	O
17	FK	O
18	-	O
19	1	O
20	,	O
21	n	O
22	=	O
23	8	O
24	;	O
25	(	O
26	3	O
27	)	O
28	FK	O
29	-	O
30	3	O
31	,	O
32	n	O
33	=	O
34	8	O
35	.	O

1	DNA	O
2	binding	O
3	and	O
4	glutathione	B
5	S	I
6	-	I
7	transferase	I
8	pull	O
9	-	O
10	down	O
11	assays	O
12	demonstrate	O
13	that	O
14	binding	O
15	requires	O
16	Elk	B
17	-	I
18	1	I
19	(	I
20	1	I
21	-	I
22	212	I
23	)	I
24	but	O
25	not	O
26	the	O
27	C	O
28	-	O
29	terminal	O
30	transactivation	O
31	domain	O
32	.	O

1	Unexpectedly	O
2	,	O
3	ALK7	B
4	signaling	O
5	produced	O
6	a	O
7	remarkable	O
8	change	O
9	in	O
10	cell	O
11	morphology	O
12	characterized	O
13	by	O
14	cell	O
15	flattening	O
16	and	O
17	elaboration	O
18	of	O
19	blunt	O
20	,	O
21	short	O
22	cell	O
23	processes	O
24	.	O

1	The	O
2	swa2	B
3	-	I
4	1	I
5	allele	I
6	recovered	O
7	from	O
8	the	O
9	original	O
10	screen	O
11	carries	O
12	a	O
13	point	O
14	mutation	O
15	in	O
16	its	O
17	tetratricopeptide	O
18	repeat	O
19	(	O
20	TPR	O
21	)	O
22	domain	O
23	,	O
24	a	O
25	motif	O
26	not	O
27	found	O
28	in	O
29	auxilin	B
30	but	O
31	known	O
32	in	O
33	other	O
34	proteins	O
35	to	O
36	mediate	O
37	interaction	O
38	with	O
39	heat	B
40	-	I
41	shock	I
42	proteins	I
43	.	O

1	Association	O
2	of	O
3	stress	O
4	during	O
5	delivery	O
6	with	O
7	increased	O
8	numbers	O
9	of	O
10	nucleated	O
11	cells	O
12	and	O
13	hematopoietic	O
14	progenitor	O
15	cells	O
16	in	O
17	umbilical	O
18	cord	O
19	blood	O
20	.	O

1	In	O
2	slightly	O
3	older	O
4	embryos	O
5	,	O
6	the	O
7	expression	O
8	was	O
9	skewed	O
10	to	O
11	one	O
12	side	O
13	of	O
14	the	O
15	embryo	O
16	and	O
17	by	O
18	E6	O
19	.	O
20	5	O
21	,	O
22	at	O
23	the	O
24	onset	O
25	of	O
26	gastrulation	O
27	,	O
28	expression	O
29	was	O
30	seen	O
31	in	O
32	the	O
33	epiblast	O
34	,	O
35	visceral	O
36	endoderm	O
37	,	O
38	nascent	O
39	mesoderm	O
40	,	O
41	and	O
42	the	O
43	primitive	O
44	streak	O
45	.	O

1	Transformation	O
2	of	O
3	the	O
4	sconC3	B
5	mutant	I
6	with	O
7	sconB	B
8	+	I
9	restores	O
10	the	O
11	wild	O
12	-	O
13	type	O
14	phenotype	O
15	.	O

1	The	O
2	authors	O
3	proposed	O
4	that	O
5	the	O
6	highly	O
7	convergent	O
8	inputs	O
9	to	O
10	the	O
11	entorhinal	O
12	cortex	O
13	indicate	O
14	this	O
15	region	O
16	may	O
17	be	O
18	particularly	O
19	important	O
20	for	O
21	selecting	O
22	or	O
23	compressing	O
24	information	O
25	.	O

1	Influence	O
2	of	O
3	oil	O
4	emulsions	O
5	and	O
6	diphenyl	O
7	on	O
8	post	O
9	-	O
10	harvest	O
11	physiconutritional	O
12	changes	O
13	in	O
14	Kagzi	O
15	limes	O
16	(	O
17	Citrus	O
18	aurantifolia	O
19	)	O
20	was	O
21	studied	O
22	.	O

1	Detailed	O
2	analysis	O
3	of	O
4	alpha1	B
5	,	I
6	3GT	I
7	transcripts	I
8	revealed	O
9	two	O
10	major	O
11	alternative	O
12	splicing	O
13	patterns	O
14	in	O
15	the	O
16	5	O
17	'-	O
18	untranslated	O
19	region	O
20	(	O
21	5	O
22	'-	O
23	UTR	O
24	)	O
25	and	O
26	evidence	O
27	for	O
28	minor	O
29	splicing	O
30	activity	O
31	that	O
32	occurs	O
33	in	O
34	a	O
35	tissue	O
36	-	O
37	specific	O
38	manner	O
39	.	O

1	A	O
2	thermal	O
3	Kubo	O
4	-	O
5	Martin	O
6	-	O
7	Schwinger	O
8	condition	O
9	arises	O
10	due	O
11	to	O
12	the	O
13	coupling	O
14	of	O
15	a	O
16	computer	O
17	to	O
18	a	O
19	strong	O
20	periodic	O
21	source	O
22	,	O
23	namely	O
24	,	O
25	the	O
26	daily	O
27	and	O
28	weekly	O
29	usage	O
30	patterns	O
31	of	O
32	the	O
33	system	O
34	.	O

1	The	O
2	non	O
3	-	O
4	homologous	O
5	sequences	O
6	in	O
7	the	O
8	5	O
9	'	O
10	untranslated	O
11	regions	O
12	might	O
13	be	O
14	acquired	O
15	at	O
16	or	O
17	after	O
18	transcription	O
19	during	O
20	retrotransposition	O
21	of	O
22	the	O
23	ATLN	O
24	elements	O
25	.	O

1	The	O
2	time	O
3	course	O
4	of	O
5	RNA1	B
6	replication	O
7	and	O
8	RNA3	B
9	synthesis	O
10	in	O
11	induced	O
12	yeast	O
13	paralleled	O
14	that	O
15	in	O
16	yeast	O
17	transfected	O
18	with	O
19	natural	O
20	FHV	O
21	virion	O
22	RNA	O
23	.	O

1	The	O
2	transcription	O
3	and	O
4	alternative	O
5	splicing	O
6	of	O
7	human	B
8	ORL1	I
9	and	O
10	GAIP	B
11	are	O
12	cell	O
13	-	O
14	type	O
15	specific	O
16	.	O

1	RESULTS	O
2	:	O
3	The	O
4	main	O
5	effect	O
6	of	O
7	muscle	O
8	pain	O
9	,	O
10	compared	O
11	to	O
12	non	O
13	-	O
14	painful	O
15	stimulation	O
16	,	O
17	was	O
18	a	O
19	significant	O
20	and	O
21	long	O
22	-	O
23	lasting	O
24	increase	O
25	of	O
26	delta	O
27	(	O
28	1	O
29	-	O
30	3	O
31	Hz	O
32	)	O
33	power	O
34	and	O
35	an	O
36	alpha	O
37	-	O
38	1	O
39	(	O
40	9	O
41	-	O
42	11	O
43	Hz	O
44	)	O
45	power	O
46	increase	O
47	over	O
48	the	O
49	contralateral	O
50	parietal	O
51	locus	O
52	.	O

1	The	O
2	extraction	O
3	was	O
4	subsequently	O
5	rated	O
6	as	O
7	'	O
8	easy	O
9	'	O
10	or	O
11	'	O
12	difficult	O
13	'.	O
14	Taking	O
15	Pell	O
16	-	O
17	Gregory	O
18	class	O
19	C	O
20	as	O
21	a	O
22	predictor	O
23	of	O
24	a	O
25	'	O
26	difficult	O
27	'	O
28	extraction	O
29	,	O
30	specificity	O
31	was	O
32	88	O
33	%	O
34	but	O
35	sensitivity	O
36	was	O
37	low	O
38	at	O
39	15	O
40	%.	O

1	In	O
2	addition	O
3	,	O
4	our	O
5	results	O
6	show	O
7	that	O
8	ERKs	B
9	and	O
10	PI3Ks	B
11	can	O
12	synergise	O
13	to	O
14	convert	O
15	ectoderm	O
16	into	O
17	mesoderm	O
18	.	O

1	Based	O
2	on	O
3	16S	B
4	rRNA	I
5	gene	I
6	sequence	I
7	analysis	O
8	,	O
9	the	O
10	11	O
11	species	O
12	having	O
13	two	O
14	tuf	B
15	genes	I
16	all	O
17	have	O
18	a	O
19	common	O
20	ancestor	O
21	,	O
22	while	O
23	the	O
24	six	O
25	species	O
26	having	O
27	only	O
28	one	O
29	copy	O
30	diverged	O
31	from	O
32	the	O
33	enterococcal	O
34	lineage	O
35	before	O
36	that	O
37	common	O
38	ancestor	O
39	.	O

1	Nevertheless	O
2	,	O
3	protein	B
4	kinase	I
5	A	I
6	stimulation	O
7	induces	O
8	CREMalpha	B
9	to	O
10	activate	O
11	the	O
12	complex	O
13	native	O
14	promoter	O
15	in	O
16	the	O
17	phosphoenolpyruvate	B
18	carboxykinase	I
19	(	O
20	PEPCK	B
21	)	O
22	gene	O
23	.	O

1	Another	O
2	putative	O
3	HNF3	B
4	site	I
5	in	O
6	close	O
7	apposition	O
8	to	O
9	a	O
10	NF1	B
11	/	O
12	CTF	B
13	site	O
14	was	O
15	localized	O
16	upstream	O
17	of	O
18	the	O
19	silencer	O
20	-	O
21	like	O
22	element	O
23	.	O

1	This	O
2	transcriptional	O
3	regulation	O
4	occurs	O
5	through	O
6	modulation	O
7	of	O
8	the	O
9	forkhead	B
10	transcription	I
11	factor	I
12	FKHR	I
13	-	I
14	L1	I
15	,	O
16	and	O
17	IL	B
18	-	I
19	3	I
20	inhibited	O
21	FKHR	B
22	-	I
23	L1	I
24	activity	O
25	in	O
26	a	O
27	PI3K	B
28	-	O
29	dependent	O
30	manner	O
31	.	O

1	Taken	O
2	together	O
3	,	O
4	these	O
5	observations	O
6	indicate	O
7	that	O
8	inhibition	O
9	of	O
10	p27	B
11	(	O
12	KIP1	B
13	)	O
14	transcription	O
15	through	O
16	PI3K	B
17	-	O
18	induced	O
19	FKHR	B
20	-	I
21	L1	I
22	phosphorylation	O
23	provides	O
24	a	O
25	novel	O
26	mechanism	O
27	of	O
28	regulating	O
29	cytokine	O
30	-	O
31	mediated	O
32	survival	O
33	and	O
34	proliferation	O
35	.	O

1	DNase	B
2	I	I
3	genomic	O
4	footprinting	O
5	revealed	O
6	that	O
7	the	O
8	c	B
9	-	I
10	Myb	I
11	site	I
12	is	O
13	occupied	O
14	in	O
15	a	O
16	tissue	O
17	-	O
18	specific	O
19	fashion	O
20	in	O
21	vivo	O
22	.	O

1	We	O
2	conclude	O
3	that	O
4	c	B
5	-	I
6	Myb	I
7	regulates	O
8	the	O
9	RAG	B
10	-	I
11	2	I
12	promoter	I
13	in	O
14	T	O
15	cells	O
16	by	O
17	binding	O
18	to	O
19	this	O
20	consensus	B
21	c	I
22	-	I
23	Myb	I
24	binding	I
25	site	I
26	.	O

1	A	O
2	recently	O
3	reported	O
4	new	O
5	member	O
6	of	O
7	the	O
8	Vav	B
9	family	I
10	proteins	I
11	,	O
12	Vav3	B
13	has	O
14	been	O
15	identified	O
16	as	O
17	a	O
18	Ros	B
19	receptor	I
20	protein	I
21	tyrosine	I
22	kinase	I
23	(	O
24	RPTK	B
25	)	O
26	interacting	O
27	protein	O
28	by	O
29	yeast	O
30	two	O
31	-	O
32	hybrid	O
33	screening	O
34	.	O

1	Subsequently	O
2	,	O
3	we	O
4	show	O
5	that	O
6	the	O
7	reexpression	O
8	of	O
9	the	O
10	r	B
11	-	I
12	PTPeta	I
13	gene	I
14	in	O
15	highly	O
16	malignant	O
17	rat	O
18	thyroid	O
19	cells	O
20	transformed	O
21	by	O
22	retroviruses	O
23	carrying	O
24	the	O
25	v	B
26	-	I
27	mos	I
28	and	O
29	v	B
30	-	I
31	ras	I
32	-	I
33	Ki	I
34	oncogenes	I
35	suppresses	O
36	their	O
37	malignant	O
38	phenotype	O
39	.	O

1	Induced	O
2	expression	O
3	of	O
4	Rnd3	B
5	is	O
6	associated	O
7	with	O
8	transformation	O
9	of	O
10	polarized	O
11	epithelial	O
12	cells	O
13	by	O
14	the	O
15	Raf	B
16	-	O
17	MEK	B
18	-	O
19	extracellular	O
20	signal	O
21	-	O
22	regulated	O
23	kinase	O
24	pathway	O
25	.	O

1	The	O
2	activity	O
3	of	O
4	the	O
5	transcription	B
6	factor	I
7	CREB	I
8	is	O
9	regulated	O
10	by	O
11	extracellular	O
12	stimuli	O
13	that	O
14	result	O
15	in	O
16	its	O
17	phosphorylation	O
18	at	O
19	a	O
20	critical	O
21	serine	O
22	residue	O
23	,	O
24	Ser133	O
25	.	O

1	RESULTS	O
2	:	O
3	Average	O
4	age	O
5	at	O
6	symptom	O
7	onset	O
8	was	O
9	41	O
10	.	O
11	2	O
12	years	O
13	.	O

1	When	O
2	10	O
3	fields	O
4	were	O
5	analysed	O
6	,	O
7	a	O
8	strong	O
9	relationship	O
10	was	O
11	found	O
12	between	O
13	the	O
14	presence	O
15	of	O
16	bacteria	O
17	on	O
18	Gram	O
19	staining	O
20	and	O
21	the	O
22	final	O
23	diagnosis	O
24	of	O
25	VAP	O
26	(	O
27	for	O
28	PSB	O
29	and	O
30	PTC	O
31	respectively	O
32	:	O
33	sensitivity	O
34	74	O
35	and	O
36	81	O
37	%,	O
38	specificity	O
39	94	O
40	and	O
41	100	O
42	%,	O
43	positive	O
44	predictive	O
45	value	O
46	91	O
47	and	O
48	100	O
49	%,	O
50	negative	O
51	predictive	O
52	value	O
53	82	O
54	and	O
55	88	O
56	%).	O

1	Unlike	O
2	the	O
3	mammalian	O
4	proteins	O
5	,	O
6	XFGF3	B
7	is	O
8	efficiently	O
9	secreted	O
10	as	O
11	a	O
12	Mr	O
13	31	O
14	,	O
15	000	O
16	glycoprotein	O
17	,	O
18	gp31	B
19	,	O
20	which	O
21	undergoes	O
22	proteolytic	O
23	cleavage	O
24	to	O
25	produce	O
26	an	O
27	NH2	O
28	-	O
29	terminally	O
30	truncated	O
31	product	O
32	,	O
33	gp27	B
34	.	O

1	NH2	O
2	-	O
3	terminal	O
4	trimming	O
5	of	O
6	Xenopus	O
7	and	O
8	mammalian	B
9	FGF3s	I
10	may	O
11	therefore	O
12	be	O
13	a	O
14	prerequisite	O
15	of	O
16	optimal	O
17	biological	O
18	activity	O
19	.	O

1	Here	O
2	,	O
3	we	O
4	identified	O
5	three	O
6	cis	O
7	-	O
8	elements	O
9	required	O
10	for	O
11	replication	O
12	within	O
13	the	O
14	200	O
15	bp	O
16	promoter	O
17	,	O
18	using	O
19	autonomously	O
20	replicating	O
21	plasmids	O
22	carrying	O
23	various	O
24	mutations	O
25	and	O
26	deletions	O
27	.	O

1	Tranilast	O
2	in	O
3	the	O
4	Therapy	O
5	of	O
6	Coronary	O
7	Artery	O
8	Disease	O
9	.	O

1	The	O
2	objectives	O
3	of	O
4	the	O
5	present	O
6	study	O
7	were	O
8	to	O
9	evaluate	O
10	the	O
11	effects	O
12	of	O
13	adding	O
14	Equex	O
15	to	O
16	a	O
17	TRIS	O
18	-	O
19	extender	O
20	,	O
21	diluting	O
22	the	O
23	semen	O
24	in	O
25	1	O
26	or	O
27	2	O
28	steps	O
29	,	O
30	freezing	O
31	according	O
32	to	O
33	2	O
34	methods	O
35	,	O
36	thawing	O
37	at	O
38	2	O
39	rates	O
40	,	O
41	and	O
42	the	O
43	interactions	O
44	between	O
45	these	O
46	treatments	O
47	,	O
48	on	O
49	the	O
50	post	O
51	-	O
52	thaw	O
53	survival	O
54	of	O
55	dog	O
56	spermatozoa	O
57	at	O
58	38	O
59	degrees	O
60	C	O
61	.	O

1	This	O
2	study	O
3	is	O
4	a	O
5	further	O
6	and	O
7	more	O
8	extensive	O
9	validation	O
10	of	O
11	the	O
12	clinician	O
13	rated	O
14	NIMH	O
15	-	O
16	LCM	O
17	-	O
18	p	O
19	.	O

1	The	O
2	Aie1	B
3	locus	I
4	was	O
5	mapped	O
6	to	O
7	mouse	O
8	chromosome	O
9	7A2	O
10	-	O
11	A3	O
12	by	O
13	fluorescent	O
14	in	O
15	situ	O
16	hybridization	O
17	.	O

1	Psychiatric	O
2	disorders	O
3	in	O
4	children	O
5	and	O
6	adolescents	O
7	carry	O
8	considerable	O
9	morbidity	O
10	,	O
11	impede	O
12	development	O
13	,	O
14	and	O
15	carry	O
16	a	O
17	significant	O
18	mortality	O
19	by	O
20	suicide	O
21	.	O

1	Molecular	O
2	cloning	O
3	and	O
4	expression	O
5	of	O
6	human	B
7	UDP	I
8	-	I
9	d	I
10	-	I
11	Xylose	I
12	:	I
13	proteoglycan	I
14	core	I
15	protein	I
16	beta	I
17	-	I
18	d	I
19	-	I
20	xylosyltransferase	I
21	and	O
22	its	O
23	first	O
24	isoform	B
25	XT	I
26	-	I
27	II	I
28	.	O

1	Thyrotoxicosis	O
2	due	O
3	to	O
4	amiodarone	O
5	is	O
6	difficult	O
7	to	O
8	treat	O
9	and	O
10	is	O
11	further	O
12	complicated	O
13	by	O
14	the	O
15	pro	O
16	-	O
17	arrhythmic	O
18	potential	O
19	of	O
20	thyrotoxicosis	O
21	and	O
22	the	O
23	fading	O
24	antiarrhythmic	O
25	effect	O
26	after	O
27	amiodarone	O
28	withdrawal	O
29	.	O

1	Chaperones	O
2	/	O
3	HSPs	B
4	thus	O
5	play	O
6	important	O
7	roles	O
8	within	O
9	cell	O
10	cycle	O
11	processes	O
12	.	O

1	Oncogenic	O
2	signalling	O
3	by	O
4	E2F1	B
5	has	O
6	recently	O
7	been	O
8	linked	O
9	to	O
10	stabilization	O
11	and	O
12	activation	O
13	of	O
14	the	O
15	tumour	O
16	suppressor	O
17	p53	B
18	(	O
19	refs	O
20	1	O
21	,	O
22	3	O
23	,	O
24	4	O
25	).	O

1	This	O
2	study	O
3	allows	O
4	us	O
5	to	O
6	draw	O
7	conclusions	O
8	about	O
9	the	O
10	identity	O
11	of	O
12	proteins	O
13	required	O
14	for	O
15	the	O
16	development	O
17	of	O
18	the	O
19	nervous	O
20	system	O
21	in	O
22	Drosophila	O
23	and	O
24	provides	O
25	an	O
26	example	O
27	of	O
28	a	O
29	molecular	O
30	approach	O
31	to	O
32	characterize	O
33	en	O
34	masse	O
35	transposon	O
36	-	O
37	tagged	O
38	mutations	O
39	identified	O
40	in	O
41	genetic	O
42	screens	O
43	.	O

1	We	O
2	describe	O
3	the	O
4	identification	O
5	and	O
6	initial	O
7	characterization	O
8	of	O
9	neurobeachin	B
10	,	O
11	a	O
12	neuron	O
13	-	O
14	specific	O
15	multidomain	O
16	protein	O
17	of	O
18	327	O
19	kDa	O
20	with	O
21	a	O
22	high	O
23	-	O
24	affinity	O
25	binding	O
26	site	O
27	(	O
28	K	O
29	(	O
30	d	O
31	),	O
32	10	O
33	nm	O
34	)	O
35	for	O
36	the	O
37	type	B
38	II	I
39	regulatory	I
40	subunit	I
41	of	I
42	protein	I
43	kinase	I
44	A	I
45	(	O
46	PKA	B
47	RII	I
48	).	O

1	Children	O
2	with	O
3	ADD	O
4	showed	O
5	an	O
6	attenuated	O
7	frontal	O
8	CNV	O
9	-	O
10	1	O
11	amplitude	O
12	and	O
13	a	O
14	trend	O
15	towards	O
16	increased	O
17	CNV	O
18	-	O
19	1	O
20	and	O
21	CNV	O
22	-	O
23	2	O
24	occipital	O
25	amplitudes	O
26	.	O

1	Where	O
2	UMDNJ	O
3	is	O
4	headed	O
5	.	O

1	Overexpression	O
2	of	O
3	c	B
4	-	I
5	Myc	I
6	in	O
7	serum	O
8	-	O
9	starved	O
10	human	O
11	or	O
12	mouse	O
13	embryonic	O
14	cells	O
15	leads	O
16	to	O
17	apoptosis	O
18	which	O
19	is	O
20	significantly	O
21	reduced	O
22	in	O
23	the	O
24	presence	O
25	of	O
26	growth	O
27	factor	O
28	-	O
29	containing	O
30	serum	O
31	.	O
32	c	B
33	-	I
34	Myc	I
35	-	O
36	induced	O
37	apoptosis	O
38	appears	O
39	to	O
40	be	O
41	deficient	O
42	in	O
43	bax	B
44	-	O
45	null	O
46	as	O
47	compared	O
48	with	O
49	bax	B
50	-	O
51	wild	O
52	-	O
53	type	O
54	mouse	O
55	embryonic	O
56	fibroblasts	O
57	.	O

1	Antimicrobial	O
2	Susceptibility	O
3	of	O
4	Klebsiella	O
5	pneumoniae	O
6	Producing	O
7	Extended	B
8	-	I
9	Spectrum	I
10	beta	I
11	-	I
12	lactamase	I
13	(	O
14	ESBL	B
15	)	O
16	Isolated	O
17	in	O
18	Hospitals	O
19	in	O
20	Brazil	O
21	.	O

1	CONCLUSION	O
2	:	O
3	Our	O
4	results	O
5	suggest	O
6	that	O
7	AIF	O
8	peak	O
9	saturation	O
10	leads	O
11	to	O
12	a	O
13	significant	O
14	systematic	O
15	error	O
16	in	O
17	the	O
18	determination	O
19	of	O
20	CBV	O
21	and	O
22	CBF	O
23	values	O
24	and	O
25	has	O
26	necessarily	O
27	to	O
28	be	O
29	taken	O
30	into	O
31	account	O
32	for	O
33	dynamic	O
34	contrast	O
35	-	O
36	enhanced	O
37	MR	O
38	perfusion	O
39	studies	O
40	.	O

1	METHODS	O
2	:	O
3	T2	O
4	*-	O
5	weighted	O
6	,	O
7	three	O
8	-	O
9	dimensional	O
10	gradient	O
11	-	O
12	echo	O
13	images	O
14	were	O
15	acquired	O
16	by	O
17	exploiting	O
18	the	O
19	magnetic	O
20	susceptibility	O
21	difference	O
22	between	O
23	oxygenated	O
24	and	O
25	deoxygenated	O
26	hemoglobin	B
27	in	O
28	the	O
29	vasculature	O
30	and	O
31	microvasculature	O
32	.	O

1	In	O
2	the	O
3	COPD	O
4	patients	O
5	,	O
6	the	O
7	variability	O
8	of	O
9	Delta	O
10	-	O
11	inst	O
12	Rrs	O
13	(	O
14	30	O
15	%)	O
16	was	O
17	greater	O
18	than	O
19	that	O
20	of	O
21	FOT	O
22	Rrs	O
23	(	O
24	21	O
25	%).	O

1	Toward	O
2	this	O
3	end	O
4	,	O
5	we	O
6	prepared	O
7	synthetic	O
8	proteins	O
9	with	O
10	either	O
11	the	O
12	catalytic	O
13	domain	O
14	of	O
15	FAP	B
16	-	I
17	1	I
18	(	I
19	C	I
20	-	I
21	terminal	I
22	399	I
23	amino	I
24	acids	I
25	)	I
26	or	O
27	its	O
28	inactive	O
29	form	O
30	(	O
31	Cys2408	O
32	-->	O
33	Ser	O
34	)	O
35	fused	O
36	to	O
37	glutathione	B
38	-	I
39	S	I
40	-	I
41	transferase	I
42	(	O
43	GST	B
44	).	O

1	Thus	O
2	,	O
3	Pet111p	B
4	could	O
5	play	O
6	dual	O
7	roles	O
8	in	O
9	both	O
10	membrane	O
11	localization	O
12	and	O
13	regulation	O
14	of	O
15	Cox2p	B
16	synthesis	O
17	within	O
18	mitochondria	O
19	.	O

1	Furthermore	O
2	,	O
3	transfection	O
4	of	O
5	cells	O
6	with	O
7	the	O
8	spacer	O
9	-	O
10	RING	O
11	domain	O
12	alone	O
13	suppressed	O
14	the	O
15	antiapoptotic	O
16	function	O
17	of	O
18	the	O
19	N	O
20	-	O
21	terminal	O
22	BIR	B
23	domain	O
24	of	O
25	c	B
26	-	I
27	IAP1	I
28	and	O
29	induced	O
30	apoptosis	O
31	.	O

1	The	O
2	determination	O
3	of	O
4	the	O
5	double	O
6	bounds	O
7	in	O
8	blood	O
9	serum	O
10	lipids	O
11	by	O
12	titration	O
13	with	O
14	ozone	O
15	:	O
16	the	O
17	pathophysiology	O
18	and	O
19	diagnostic	O
20	significance	O
21	]	O
22	In	O
23	this	O
24	article	O
25	the	O
26	method	O
27	of	O
28	definition	O
29	of	O
30	double	O
31	binders	O
32	in	O
33	lipids	O
34	of	O
35	blood	O
36	serum	O
37	in	O
38	patients	O
39	with	O
40	different	O
41	diseases	O
42	basically	O
43	atherosclerosis	O
44	and	O
45	ischemic	O
46	heart	O
47	disease	O
48	,	O
49	with	O
50	use	O
51	titration	O
52	by	O
53	ozone	O
54	is	O
55	given	O
56	.	O

1	Ang	B
2	II	I
3	-	O
4	induced	O
5	fibronectin	B
6	mRNA	O
7	was	O
8	not	O
9	affected	O
10	by	O
11	PKC	B
12	inhibitors	O
13	or	O
14	PKC	B
15	depletion	O
16	,	O
17	whereas	O
18	specific	O
19	inhibition	O
20	of	O
21	EGF	B
22	-	I
23	R	I
24	function	O
25	by	O
26	a	O
27	dominant	B
28	negative	I
29	EGF	I
30	-	I
31	R	I
32	mutant	I
33	and	O
34	tyrphostin	O
35	AG1478	O
36	abolished	O
37	induction	O
38	of	O
39	fibronectin	B
40	mRNA	I
41	.	O

1	Acoust	O
2	.	O

1	Video	O
2	images	O
3	of	O
4	the	O
5	nostrils	O
6	were	O
7	captured	O
8	and	O
9	then	O
10	analyzed	O
11	for	O
12	area	O
13	,	O
14	perimeter	O
15	,	O
16	centroid	O
17	,	O
18	principal	O
19	axis	O
20	,	O
21	moments	O
22	about	O
23	the	O
24	major	O
25	and	O
26	minor	O
27	axes	O
28	(	O
29	I11	O
30	,	O
31	I22	O
32	),	O
33	anisometry	O
34	,	O
35	bulkiness	O
36	,	O
37	lateral	O
38	offset	O
39	,	O
40	internostril	O
41	angle	O
42	,	O
43	and	O
44	rotational	O
45	angle	O
46	.	O

1	MS	O
2	characteristics	O
3	of	O
4	coumarins	O
5	,	O
6	psoralens	O
7	and	O
8	polymethoxylated	O
9	flavones	O
10	with	O
11	different	O
12	substitution	O
13	patterns	O
14	were	O
15	determined	O
16	on	O
17	the	O
18	basis	O
19	of	O
20	the	O
21	response	O
22	obtained	O
23	with	O
24	the	O
25	APcI	O
26	interface	O
27	.	O

1	Young	O
2	fish	O
3	(	O
4	Oreochromis	O
5	mossambicus	O
6	)	O
7	were	O
8	exposed	O
9	to	O
10	microgravity	O
11	(	O
12	micro	O
13	g	O
14	)	O
15	for	O
16	9	O
17	to	O
18	10	O
19	days	O
20	during	O
21	space	O
22	missions	O
23	STS	O
24	-	O
25	55	O
26	and	O
27	STS	O
28	-	O
29	84	O
30	,	O
31	or	O
32	to	O
33	hypergravity	O
34	(	O
35	hg	O
36	)	O
37	for	O
38	9	O
39	days	O
40	.	O

1	S6K2	B
2	is	O
3	highly	O
4	homologous	O
5	to	O
6	S6K1	B
7	in	O
8	the	O
9	core	O
10	kinase	O
11	and	O
12	linker	O
13	regulatory	O
14	domains	O
15	but	O
16	differs	O
17	from	O
18	S6K1	B
19	in	O
20	the	O
21	N	O
22	-	O
23	and	O
24	C	O
25	-	O
26	terminal	O
27	regions	O
28	and	O
29	is	O
30	differently	O
31	localized	O
32	primarily	O
33	to	O
34	the	O
35	nucleus	O
36	because	O
37	of	O
38	a	O
39	C	O
40	-	O
41	terminal	O
42	nuclear	O
43	localization	O
44	signal	O
45	unique	O
46	to	O
47	S6K2	B
48	.	O

1	Pretreatment	O
2	of	O
3	cells	O
4	with	O
5	the	O
6	mitogen	B
7	-	I
8	activated	I
9	protein	I
10	-	I
11	extracellular	I
12	signal	I
13	-	I
14	regulated	I
15	kinase	I
16	kinase	I
17	(	O
18	MEK	B
19	)	O
20	inhibitor	O
21	U0126	O
22	inhibited	O
23	S6K2	B
24	activation	O
25	to	O
26	a	O
27	greater	O
28	extent	O
29	than	O
30	S6K1	B
31	.	O

1	T	O
2	cells	O
3	express	O
4	two	O
5	isoforms	O
6	of	O
7	S6k1	B
8	:	O
9	a	O
10	70	O
11	kDa	O
12	cytoplasmic	O
13	kinase	O
14	and	O
15	an	O
16	85	O
17	kDa	O
18	isoform	O
19	that	O
20	has	O
21	a	O
22	classic	O
23	nuclear	O
24	localisation	O
25	.	O

1	Ketanserin	O
2	,	O
3	a	O
4	hypotensive	O
5	drug	O
6	with	O
7	5	B
8	-	I
9	HT2	I
10	receptor	I
11	antagonism	O
12	,	O
13	when	O
14	administered	O
15	by	O
16	topical	O
17	infusion	O
18	of	O
19	a	O
20	0	O
21	.	O
22	25	O
23	%	O
24	w	O
25	/	O
26	v	O
27	solution	O
28	by	O
29	corneal	O
30	and	O
31	scleral	O
32	applications	O
33	,	O
34	was	O
35	found	O
36	to	O
37	lower	O
38	intraocular	O
39	pressure	O
40	with	O
41	four	O
42	times	O
43	more	O
44	activity	O
45	than	O
46	its	O
47	metabolite	O
48	,	O
49	ketanserinol	O
50	.	O

1	A	O
2	prospectively	O
3	gated	O
4	2D	O
5	axial	O
6	sequence	O
7	with	O
8	velocity	O
9	encoding	O
10	in	O
11	the	O
12	craniocaudal	O
13	direction	O
14	in	O
15	the	O
16	cervical	O
17	region	O
18	was	O
19	set	O
20	at	O
21	a	O
22	velocity	O
23	of	O
24	+/-	O
25	10	O
26	cm	O
27	/	O
28	s	O
29	.	O

1	It	O
2	was	O
3	subsequently	O
4	shown	O
5	that	O
6	Tip60	B
7	had	O
8	histone	B
9	acetyltransferase	I
10	(	O
11	HAT	B
12	)	O
13	activity	O
14	.	O

1	Our	O
2	data	O
3	show	O
4	that	O
5	multiple	O
6	MLSN1	B
7	transcripts	I
8	,	O
9	both	O
10	constitutively	O
11	expressed	O
12	and	O
13	inducible	O
14	,	O
15	are	O
16	present	O
17	in	O
18	cultured	O
19	pigmented	O
20	melanoma	O
21	cells	O
22	,	O
23	and	O
24	suggest	O
25	that	O
26	MLSN1	B
27	expression	O
28	can	O
29	be	O
30	regulated	O
31	at	O
32	the	O
33	level	O
34	of	O
35	both	O
36	transcription	O
37	and	O
38	mRNA	O
39	processing	O
40	.	O

1	Copyright	O
2	2000	O
3	Academic	O
4	Press	O
5	.	O

1	Plectin	B
2	and	O
3	desmoplakin	B
4	have	O
5	GSR	O
6	-	O
7	containing	O
8	domains	O
9	at	O
10	their	O
11	C	O
12	-	O
13	termini	O
14	and	O
15	we	O
16	further	O
17	demonstrate	O
18	that	O
19	the	O
20	GSR	O
21	-	O
22	containing	O
23	domain	O
24	of	O
25	plectin	B
26	,	O
27	but	O
28	not	O
29	desmoplakin	B
30	,	O
31	can	O
32	bind	O
33	to	O
34	MTs	O
35	in	O
36	vivo	O
37	.	O

1	Characterization	O
2	of	O
3	the	O
4	microtubule	O
5	binding	O
6	domain	O
7	of	O
8	microtubule	B
9	actin	I
10	crosslinking	I
11	factor	I
12	(	O
13	MACF	B
14	):	O
15	identification	O
16	of	O
17	a	O
18	novel	O
19	group	O
20	of	O
21	microtubule	B
22	associated	I
23	proteins	I
24	.	O

1	These	O
2	results	O
3	also	O
4	suggest	O
5	the	O
6	involvement	O
7	of	O
8	additional	O
9	elements	O
10	in	O
11	the	O
12	UPR	O
13	.	O

1	We	O
2	show	O
3	that	O
4	in	O
5	contrast	O
6	to	O
7	SRC1	B
8	,	O
9	direct	O
10	binding	O
11	of	O
12	CBP	B
13	to	O
14	the	O
15	estrogen	B
16	receptor	I
17	is	O
18	weak	O
19	,	O
20	suggesting	O
21	that	O
22	SRC1	B
23	functions	O
24	primarily	O
25	as	O
26	an	O
27	adaptor	O
28	to	O
29	recruit	O
30	CBP	B
31	and	O
32	p300	B
33	.	O

1	Remarkably	O
2	,	O
3	a	O
4	construct	O
5	corresponding	O
6	to	O
7	residues	O
8	631	O
9	to	O
10	970	O
11	,	O
12	which	O
13	contains	O
14	only	O
15	the	O
16	LXXLL	O
17	motifs	O
18	and	O
19	the	O
20	AD1	O
21	region	O
22	of	O
23	SRC1	B
24	,	O
25	retained	O
26	strong	O
27	coactivator	O
28	activity	O
29	in	O
30	our	O
31	assays	O
32	.	O

1	Since	O
2	MEK	B
3	acts	O
4	as	O
5	a	O
6	cytoplasmic	O
7	anchor	O
8	for	O
9	the	O
10	ERKs	B
11	,	O
12	the	O
13	lack	O
14	of	O
15	a	O
16	MEK	B
17	interaction	O
18	resulted	O
19	in	O
20	the	O
21	aberrant	O
22	nuclear	O
23	localization	O
24	of	O
25	ERK2	B
26	-	O
27	Delta19	B
28	-	I
29	25	I
30	mutants	O
31	in	O
32	serum	O
33	-	O
34	starved	O
35	cells	O
36	.	O

1	Pmt2	B
2	is	O
3	a	O
4	member	O
5	of	O
6	a	O
7	six	O
8	-	O
9	protein	O
10	family	O
11	in	O
12	yeast	O
13	that	O
14	catalyzes	O
15	the	O
16	first	O
17	step	O
18	in	O
19	O	O
20	mannosylation	O
21	of	O
22	target	O
23	proteins	O
24	.	O

1	Fecal	O
2	samples	O
3	were	O
4	collected	O
5	at	O
6	the	O
7	beginning	O
8	and	O
9	end	O
10	of	O
11	each	O
12	trial	O
13	period	O
14	and	O
15	were	O
16	analyzed	O
17	for	O
18	gastrointestinal	O
19	nematode	O
20	eggs	O
21	and	O
22	Giardia	O
23	cyst	O
24	.	O

1	The	O
2	aim	O
3	of	O
4	this	O
5	study	O
6	was	O
7	to	O
8	determine	O
9	the	O
10	risk	O
11	factors	O
12	for	O
13	background	O
14	diabetic	O
15	retinopathy	O
16	(	O
17	BDR	O
18	)	O
19	and	O
20	PDR	O
21	by	O
22	following	O
23	394	O
24	Japanese	O
25	patients	O
26	with	O
27	early	O
28	-	O
29	onset	O
30	type	O
31	2	O
32	diabetes	O
33	diagnosed	O
34	before	O
35	30	O
36	years	O
37	of	O
38	age	O
39	(	O
40	mean	O
41	age	O
42	27	O
43	,	O
44	mean	O
45	blood	O
46	pressure	O
47	at	O
48	entry	O
49	116	O
50	/	O
51	73	O
52	mm	O
53	Hg	O
54	).	O

1	Of	O
2	the	O
3	21	O
4	quadrants	O
5	positive	O
6	in	O
7	the	O
8	controls	O
9	,	O
10	17	O
11	were	O
12	correlated	O
13	with	O
14	previously	O
15	detected	O
16	jaw	O
17	pathoses	O
18	.	O

1	Four	O
2	cases	O
3	of	O
4	synovial	O
5	chondromatosis	O
6	are	O
7	presented	O
8	.	O

1	Previous	O
2	studies	O
3	have	O
4	shown	O
5	that	O
6	the	O
7	pro	O
8	-	O
9	inflammatory	O
10	cytokines	O
11	tumor	B
12	necrosis	I
13	factor	I
14	alpha	I
15	and	O
16	interferon	B
17	gamma	I
18	reduce	O
19	the	O
20	expression	O
21	of	O
22	the	O
23	cystic	B
24	fibrosis	I
25	transmembrane	I
26	conductance	I
27	regulator	I
28	(	O
29	CFTR	B
30	)	O
31	gene	O
32	(	O
33	CFTR	B
34	)	O
35	in	O
36	HT	O
37	-	O
38	29	O
39	and	O
40	T84	O
41	cells	O
42	by	O
43	acting	O
44	post	O
45	-	O
46	transcriptionally	O
47	.	O

1	Regulation	O
2	of	O
3	RhoA	B
4	is	O
5	required	O
6	to	O
7	maintain	O
8	adhesion	O
9	in	O
10	stationary	O
11	cells	O
12	,	O
13	but	O
14	is	O
15	also	O
16	critical	O
17	for	O
18	cell	O
19	spreading	O
20	and	O
21	migration	O
22	[	O
23	3	O
24	].	O

1	Here	O
2	we	O
3	show	O
4	in	O
5	mouse	O
6	fibroblasts	O
7	stably	O
8	transformed	O
9	by	O
10	v	B
11	-	I
12	Src	I
13	that	O
14	mRNA	O
15	and	O
16	protein	O
17	levels	O
18	of	O
19	p21	B
20	(	O
21	WAF1	B
22	/	O
23	CIP1	B
24	),	O
25	cyclin	B
26	D1	I
27	,	O
28	and	O
29	cyclin	B
30	E	I
31	are	O
32	elevated	O
33	.	O

1	ORFA	O
2	and	O
3	ccdA	B
4	were	O
5	constitutively	O
6	cotranscribed	O
7	as	O
8	determined	O
9	by	O
10	primer	O
11	extension	O
12	analysis	O
13	.	O

1	Mouse	B
2	Impact	I
3	is	O
4	a	O
5	paternally	O
6	expressed	O
7	gene	O
8	encoding	O
9	an	O
10	evolutionarily	O
11	conserved	O
12	protein	O
13	of	O
14	unknown	O
15	function	O
16	.	O

1	These	O
2	cells	O
3	produced	O
4	P2Y	B
5	(	I
6	11	I
7	)	I
8	mRNA	I
9	during	O
10	culture	O
11	.	O

1	Coexpression	O
2	studies	O
3	indicate	O
4	that	O
5	insulin	B
6	and	O
7	PKB	B
8	suppress	O
9	transactivation	O
10	by	O
11	C	B
12	/	I
13	EBPbeta	I
14	,	O
15	but	O
16	not	O
17	C	B
18	/	I
19	EBPalpha	I
20	,	O
21	and	O
22	that	O
23	N	O
24	-	O
25	terminal	O
26	transactivation	O
27	domains	O
28	in	O
29	C	B
30	/	I
31	EBPbeta	I
32	are	O
33	required	O
34	.	O

1	Among	O
2	eight	O
3	graminaceous	O
4	species	O
5	tested	O
6	,	O
7	Ids3	B
8	expression	O
9	was	O
10	observed	O
11	only	O
12	in	O
13	Fe	O
14	-	O
15	deficient	O
16	roots	O
17	of	O
18	H	O
19	.	O
20	vulgare	O
21	and	O
22	Secale	O
23	cereale	O
24	.	O
25	which	O
26	not	O
27	only	O
28	secrete	O
29	2	O
30	'-	O
31	deoxymugineic	O
32	acid	O
33	(	O
34	DMA	O
35	),	O
36	but	O
37	also	O
38	mugineic	O
39	acid	O
40	(	O
41	MA	O
42	)	O
43	and	O
44	3	O
45	-	O
46	epihydroxymugineic	O
47	acid	O
48	(	O
49	epiHMA	O
50	,	O
51	H	O
52	.	O
53	vulgare	O
54	),	O
55	and	O
56	3	O
57	-	O
58	hydroxymugineic	O
59	acid	O
60	(	O
61	HMA	O
62	,	O
63	S	O
64	.	O
65	cereale	O
66	).	O

1	In	O
2	contrast	O
3	,	O
4	high	O
5	COUP	B
6	-	I
7	TFI	I
8	expression	O
9	impeded	O
10	the	O
11	neuronal	O
12	differentiation	O
13	of	O
14	P19	O
15	cells	O
16	induced	O
17	with	O
18	RA	O
19	,	O
20	resulting	O
21	in	O
22	cell	O
23	cultures	O
24	lacking	O
25	neurons	O
26	.	O

1	Because	O
2	PET	O
3	is	O
4	also	O
5	useful	O
6	for	O
7	the	O
8	pretreatment	O
9	and	O
10	follow	O
11	-	O
12	up	O
13	evaluation	O
14	,	O
15	the	O
16	use	O
17	of	O
18	stereotactic	O
19	PET	O
20	in	O
21	these	O
22	patients	O
23	can	O
24	enable	O
25	an	O
26	accurate	O
27	comparison	O
28	of	O
29	PET	O
30	-	O
31	based	O
32	metabolic	O
33	data	O
34	with	O
35	MR	O
36	-	O
37	based	O
38	anatomical	O
39	data	O
40	.	O

1	Therefore	O
2	,	O
3	in	O
4	our	O
5	in	O
6	vitro	O
7	model	O
8	,	O
9	the	O
10	localization	O
11	of	O
12	the	O
13	mutation	O
14	in	O
15	the	O
16	K	B
17	-	I
18	ras	I
19	gene	I
20	predisposes	O
21	to	O
22	a	O
23	different	O
24	level	O
25	of	O
26	aggressiveness	O
27	in	O
28	the	O
29	transforming	O
30	phenotype	O
31	.	O

1	Here	O
2	,	O
3	we	O
4	describe	O
5	the	O
6	isolation	O
7	of	O
8	MdPin1	B
9	,	O
10	a	O
11	Pin1	B
12	homologue	O
13	from	O
14	the	O
15	plant	O
16	species	O
17	apple	O
18	(	O
19	Malus	O
20	domestica	O
21	)	O
22	and	O
23	show	O
24	that	O
25	it	O
26	has	O
27	the	O
28	same	O
29	phosphorylation	O
30	-	O
31	specific	O
32	substrate	O
33	specificity	O
34	and	O
35	can	O
36	be	O
37	inhibited	O
38	by	O
39	juglone	O
40	in	O
41	vitro	O
42	,	O
43	as	O
44	is	O
45	the	O
46	case	O
47	for	O
48	Pin1	B
49	.	O

1	Differential	O
2	association	O
3	of	O
4	products	O
5	of	O
6	alternative	O
7	transcripts	O
8	of	O
9	the	O
10	candidate	O
11	tumor	B
12	suppressor	I
13	ING1	I
14	with	O
15	the	O
16	mSin3	B
17	/	O
18	HDAC1	B
19	transcriptional	O
20	corepressor	O
21	complex	O
22	.	O

1	These	O
2	and	O
3	other	O
4	data	O
5	presented	O
6	suggest	O
7	that	O
8	TAg	B
9	'	O
10	re	O
11	-	O
12	models	O
13	'	O
14	host	O
15	cell	O
16	transcription	O
17	factors	O
18	that	O
19	are	O
20	used	O
21	early	O
22	in	O
23	viral	O
24	infection	O
25	,	O
26	and	O
27	thereby	O
28	mimics	O
29	an	O
30	event	O
31	that	O
32	naturally	O
33	occurs	O
34	during	O
35	transformation	O
36	.	O

1	This	O
2	sensitivity	O
3	analysis	O
4	showed	O
5	that	O
6	the	O
7	practical	O
8	limits	O
9	of	O
10	the	O
11	accuracy	O
12	of	O
13	the	O
14	used	O
15	screening	O
16	test	O
17	jeopardize	O
18	the	O
19	estimation	O
20	of	O
21	the	O
22	true	O
23	herd	O
24	prevalence	O
25	within	O
26	reasonable	O
27	confidence	O
28	limits	O
29	,	O
30	because	O
31	the	O
32	within	O
33	-	O
34	herd	O
35	PTB	O
36	true	O
37	prevalence	O
38	was	O
39	low	O
40	.	O
41	For	O
42	this	O
43	reason	O
44	we	O
45	augmented	O
46	the	O
47	herd	O
48	specificity	O
49	for	O
50	herds	O
51	with	O
52	larger	O
53	adult	O
54	herd	O
55	size	O
56	(>	O
57	5	O
58	).	O

1	ORFK10	B
2	.	I
3	5	I
4	encodes	O
5	a	O
6	protein	O
7	,	O
8	latency	B
9	-	I
10	associated	I
11	nuclear	I
12	antigen	I
13	2	I
14	(	O
15	LANA2	B
16	),	O
17	which	O
18	is	O
19	expressed	O
20	in	O
21	KSHV	O
22	-	O
23	infected	O
24	hematopoietic	O
25	tissues	O
26	,	O
27	including	O
28	PEL	O
29	and	O
30	CD	O
31	but	O
32	not	O
33	KS	O
34	lesions	O
35	.	O

1	As	O
2	hypothesized	O
3	,	O
4	believers	O
5	showed	O
6	relatively	O
7	higher	O
8	right	O
9	hemispheric	O
10	activation	O
11	and	O
12	reduced	O
13	hemispheric	O
14	asymmetry	O
15	of	O
16	functional	O
17	complexity	O
18	.	O

1	In	O
2	Xenopus	O
3	,	O
4	BMPs	B
5	act	O
6	as	O
7	epidermal	O
8	inducers	O
9	and	O
10	also	O
11	as	O
12	negative	O
13	regulators	O
14	of	O
15	neurogenesis	O
16	.	O

1	Presently	O
2	four	O
3	unique	O
4	variants	O
5	carrying	O
6	distinct	O
7	GAF	B
8	sequences	I
9	in	O
10	the	O
11	N	O
12	-	O
13	terminal	O
14	region	O
15	have	O
16	been	O
17	identified	O
18	.	O

1	Genomic	O
2	organization	O
3	of	O
4	the	O
5	human	O
6	phosphodiesterase	B
7	PDE11A	I
8	gene	I
9	.	O

1	The	O
2	present	O
3	findings	O
4	revealed	O
5	that	O
6	the	O
7	rib	B
8	-	I
9	2	I
10	protein	I
11	was	O
12	a	O
13	unique	O
14	alpha1	B
15	,	I
16	4	I
17	-	I
18	N	I
19	-	I
20	acetylglucosaminyltransferase	I
21	involved	O
22	in	O
23	the	O
24	biosynthetic	O
25	initiation	O
26	and	O
27	elongation	O
28	of	O
29	heparan	O
30	sulfate	O
31	.	O

1	Inhibition	O
2	of	O
3	the	O
4	Mek	B
5	/	O
6	Erk	B
7	pathway	O
8	in	O
9	Rat1	O
10	/	O
11	ras	B
12	cells	O
13	,	O
14	using	O
15	the	O
16	Mek	B
17	inhibitor	O
18	,	O
19	PD98059	O
20	,	O
21	resulted	O
22	in	O
23	complete	O
24	cytoskeletal	O
25	recovery	O
26	,	O
27	indistinguishable	O
28	from	O
29	that	O
30	induced	O
31	by	O
32	HR12	O
33	.	O

1	The	O
2	transcription	O
3	factor	O
4	CHOP	B
5	/	O
6	GADD153	B
7	gene	O
8	is	O
9	induced	O
10	by	O
11	cellular	O
12	stress	O
13	and	O
14	is	O
15	involved	O
16	in	O
17	mediating	O
18	apoptosis	O
19	.	O

1	Addition	O
2	of	O
3	synthetic	O
4	tyrosine	O
5	-	O
6	phosphorylated	O
7	peptides	O
8	derived	O
9	from	O
10	betac	O
11	cytoplasmic	O
12	tyrosines	O
13	prior	O
14	to	O
15	GM	B
16	-	I
17	CSF	I
18	stimulation	O
19	inhibited	O
20	the	O
21	in	O
22	vitro	O
23	activation	O
24	of	O
25	STAT5	B
26	.	O

1	MAIN	O
2	OUTCOME	O
3	MEASURES	O
4	:	O
5	Percentage	O
6	change	O
7	in	O
8	the	O
9	apnea	O
10	-	O
11	hypopnea	O
12	index	O
13	(	O
14	AHI	O
15	;	O
16	apnea	O
17	events	O
18	+	O
19	hypopnea	O
20	events	O
21	per	O
22	hour	O
23	of	O
24	sleep	O
25	)	O
26	and	O
27	odds	O
28	of	O
29	developing	O
30	moderate	O
31	-	O
32	to	O
33	-	O
34	severe	O
35	SDB	O
36	(	O
37	defined	O
38	by	O
39	an	O
40	AHI	O
41	>	O
42	or	O
43	=	O
44	15	O
45	events	O
46	per	O
47	hour	O
48	of	O
49	sleep	O
50	),	O
51	with	O
52	respect	O
53	to	O
54	change	O
55	in	O
56	weight	O
57	.	O

1	Paraneoplastic	O
2	rheumatic	O
3	syndromes	O
4	.	O

1	This	O
2	article	O
3	reviews	O
4	recent	O
5	information	O
6	on	O
7	the	O
8	frequency	O
9	,	O
10	characteristics	O
11	,	O
12	and	O
13	possible	O
14	pathogenic	O
15	mechanisms	O
16	of	O
17	the	O
18	vasculitides	O
19	occurring	O
20	in	O
21	patients	O
22	with	O
23	the	O
24	main	O
25	connective	O
26	tissue	O
27	diseases	O
28	.	O

1	Tec	B
2	kinase	I
3	signaling	O
4	in	O
5	T	O
6	cells	O
7	is	O
8	regulated	O
9	by	O
10	phosphatidylinositol	B
11	3	I
12	-	I
13	kinase	I
14	and	O
15	the	O
16	Tec	B
17	pleckstrin	I
18	homology	I
19	domain	I
20	.	O

1	Current	O
2	evidence	O
3	for	O
4	this	O
5	type	O
6	of	O
7	DNA	O
8	supercoiling	O
9	-	O
10	dependent	O
11	transcriptional	O
12	coupling	O
13	,	O
14	based	O
15	largely	O
16	on	O
17	the	O
18	in	O
19	vivo	O
20	activities	O
21	of	O
22	promoters	O
23	contained	O
24	in	O
25	engineered	O
26	DNA	O
27	constructs	O
28	,	O
29	suggests	O
30	that	O
31	the	O
32	transcription	O
33	complex	O
34	must	O
35	be	O
36	physically	O
37	hindered	O
38	to	O
39	generate	O
40	DNA	O
41	supercoils	O
42	and	O
43	to	O
44	prevent	O
45	their	O
46	diffusion	O
47	throughout	O
48	the	O
49	DNA	O
50	duplex	O
51	.	O

1	The	O
2	structure	O
3	of	O
4	the	O
5	free	O
6	SH2	B
7	domain	I
8	has	O
9	been	O
10	compared	O
11	to	O
12	that	O
13	of	O
14	the	O
15	SH2	B
16	complexed	O
17	with	O
18	a	O
19	doubly	O
20	phosphorylated	O
21	peptide	O
22	derived	O
23	from	O
24	polyomavirus	B
25	middle	I
26	T	I
27	antigen	I
28	(	O
29	MT	B
30	).	O

1	We	O
2	have	O
3	identified	O
4	three	O
5	binding	O
6	sites	O
7	for	O
8	protein	O
9	complexes	O
10	:	O
11	a	O
12	palindrome	O
13	,	O
14	a	O
15	direct	O
16	repeat	O
17	,	O
18	and	O
19	a	O
20	C	O
21	+	O
22	T	O
23	sequence	O
24	that	O
25	corresponds	O
26	to	O
27	seven	O
28	GAGA	O
29	motifs	O
30	on	O
31	the	O
32	transcribed	O
33	strand	O
34	.	O

1	Copyright	O
2	2000	O
3	Academic	O
4	Press	O
5	.	O

1	Nucleotide	O
2	sequence	O
3	,	O
4	genome	O
5	organization	O
6	and	O
7	phylogenetic	O
8	analysis	O
9	of	O
10	pineapple	O
11	mealybug	O
12	wilt	O
13	-	O
14	associated	O
15	virus	O
16	-	O
17	2	O
18	.	O

1	Patients	O
2	underwent	O
3	pretreatment	O
4	cystoscopy	O
5	and	O
6	detailed	O
7	tumor	O
8	mapping	O
9	,	O
10	and	O
11	were	O
12	treated	O
13	with	O
14	75	O
15	mg	O
16	.	O
17	/	O
18	m	O
19	.	O
20	2	O
21	cisplatin	O
22	on	O
23	day	O
24	1	O
25	and	O
26	1	O
27	gm	O
28	./	O
29	m	O
30	.	O
31	2	O
32	daily	O
33	,	O
34	5	O
35	-	O
36	fluorouracil	O
37	on	O
38	days	O
39	1	O
40	to	O
41	4	O
42	and	O
43	definitive	O
44	radiotherapy	O
45	.	O

1	All	O
2	9	O
3	untreated	O
4	patients	O
5	underwent	O
6	laparoscopy	O
7	,	O
8	which	O
9	identified	O
10	3	O
11	intra	O
12	-	O
13	abdominal	O
14	,	O
15	3	O
16	vanished	O
17	and	O
18	2	O
19	peeping	O
20	testes	O
21	,	O
22	and	O
23	1	O
24	atrophic	O
25	testis	O
26	in	O
27	the	O
28	inguinal	O
29	canal	O
30	.	O

1	This	O
2	philosophy	O
3	was	O
4	instituted	O
5	for	O
6	the	O
7	compound	O
8	RP	O
9	73401	O
10	,	O
11	a	O
12	specific	O
13	phosphodiesterase	B
14	IV	I
15	inhibitor	O
16	,	O
17	that	O
18	was	O
19	being	O
20	developed	O
21	simultaneously	O
22	for	O
23	delivery	O
24	by	O
25	both	O
26	oral	O
27	and	O
28	pulmonary	O
29	routes	O
30	of	O
31	administration	O
32	.	O

1	Increased	O
2	levels	O
3	of	O
4	anticardiolipin	B
5	immunoglobulin	I
6	G	I
7	may	O
8	also	O
9	cause	O
10	bleeding	O
11	.	O

1	RESULTS	O
2	:	O
3	Prevalence	O
4	of	O
5	obesity	O
6	(	O
7	BMI	O
8	SDS	O
9	>	O
10	2	O
11	.	O
12	0	O
13	)	O
14	was	O
15	<	O
16	2	O
17	%	O
18	at	O
19	diagnosis	O
20	,	O
21	but	O
22	increased	O
23	to	O
24	16	O
25	%	O
26	at	O
27	3y	O
28	.	O

1	One	O
2	of	O
3	the	O
4	sequelae	O
5	of	O
6	the	O
7	antiphospholipid	O
8	-	O
9	antibodies	O
10	is	O
11	an	O
12	impaired	O
13	uteroplacental	O
14	circulation	O
15	.	O

1	Bupropion	O
2	to	O
3	aid	O
4	smoking	O
5	cessation	O
6	.	O

1	Using	O
2	a	O
3	natural	O
4	dominant	O
5	negative	O
6	for	O
7	AP	B
8	-	I
9	1	I
10	transcriptional	O
11	activity	O
12	in	O
13	ROS	O
14	17	O
15	/	O
16	2	O
17	.	O
18	8	O
19	cells	O
20	,	O
21	we	O
22	then	O
23	showed	O
24	that	O
25	AP	B
26	-	I
27	1	I
28	transcription	I
29	factors	I
30	mediated	O
31	TGF	B
32	-	I
33	beta1	I
34	-	O
35	and	O
36	BMP	B
37	-	I
38	2	I
39	-	O
40	regulated	O
41	expression	O
42	of	O
43	the	O
44	(	B
45	alpha1	I
46	)	I
47	collagen	I
48	I	I
49	gene	I
50	as	O
51	well	O
52	as	O
53	TGF	B
54	-	I
55	beta1	I
56	-	O
57	regulated	O
58	expression	O
59	of	O
60	the	O
61	parathyroid	B
62	hormone	I
63	(	O
64	PTH	B
65	)/	O
66	PTH	B
67	-	I
68	related	I
69	peptide	I
70	(	I
71	PTHrP	I
72	)	I
73	receptor	I
74	.	O

1	PM	O
2	12	O
3	or	O
4	18	O
5	mg	O
6	/	O
7	kg	O
8	daily	O
9	plus	O
10	a	O
11	standard	O
12	dose	O
13	of	O
14	SB	O
15	for	O
16	21	O
17	days	O
18	was	O
19	statistically	O
20	more	O
21	effective	O
22	than	O
23	SB	O
24	in	O
25	producing	O
26	a	O
27	final	O
28	cure	O
29	for	O
30	patients	O
31	with	O
32	VL	O
33	in	O
34	Bihar	O
35	,	O
36	India	O
37	.	O

1	Adjuvant	O
2	therapy	O
3	for	O
4	colon	O
5	cancer	O
6	]	O
7	Surgery	O
8	alone	O
9	may	O
10	fail	O
11	to	O
12	cure	O
13	a	O
14	considerable	O
15	number	O
16	of	O
17	locally	O
18	advanced	O
19	colon	O
20	cancers	O
21	.	O

1	There	O
2	were	O
3	significant	O
4	differences	O
5	(	O
6	p	O
7	<	O
8	0	O
9	.	O
10	05	O
11	)	O
12	between	O
13	the	O
14	fracture	O
15	and	O
16	nonfracture	O
17	groups	O
18	in	O
19	the	O
20	total	O
21	femur	O
22	BMD	O
23	(	O
24	13	O
25	%),	O
26	trabecular	O
27	BMD	O
28	in	O
29	the	O
30	distal	O
31	radius	O
32	(	O
33	4	O
34	%),	O
35	and	O
36	the	O
37	fractal	O
38	dimension	O
39	in	O
40	the	O
41	radiographs	O
42	(	O
43	FD2	O
44	)	O
45	(	O
46	3	O
47	%).	O

1	BACKGROUND	O
2	:	O
3	The	O
4	aim	O
5	of	O
6	this	O
7	study	O
8	was	O
9	to	O
10	determine	O
11	and	O
12	compare	O
13	interleukin	B
14	-	I
15	6	I
16	(	O
17	IL	B
18	-	I
19	6	I
20	)	O
21	levels	O
22	in	O
23	gingival	O
24	crevicular	O
25	fluid	O
26	(	O
27	GCF	O
28	)	O
29	and	O
30	clinical	O
31	periodontal	O
32	findings	O
33	in	O
34	patients	O
35	with	O
36	rheumatoid	O
37	arthritis	O
38	(	O
39	RA	O
40	)	O
41	and	O
42	adult	O
43	periodontitis	O
44	(	O
45	AP	O
46	).	O

1	In	O
2	a	O
3	prospective	O
4	,	O
5	multicentre	O
6	trial	O
7	the	O
8	efficacy	O
9	of	O
10	an	O
11	Vitex	O
12	agnus	O
13	castus	O
14	L	O
15	extract	O
16	Ze	O
17	440	O
18	was	O
19	investigated	O
20	in	O
21	50	O
22	patients	O
23	with	O
24	pre	O
25	-	O
26	menstrual	O
27	syndrome	O
28	(	O
29	PMS	O
30	).	O

1	Studies	O
2	are	O
3	necessary	O
4	to	O
5	assess	O
6	the	O
7	source	O
8	of	O
9	contamination	O
10	and	O
11	potential	O
12	role	O
13	of	O
14	MRSA	O
15	-	O
16	contaminated	O
17	milk	O
18	in	O
19	the	O
20	transmission	O
21	of	O
22	MRSA	O
23	to	O
24	neonates	O
25	.	O

1	Effects	O
2	of	O
3	Trypanosoma	O
4	vivax	O
5	on	O
6	pregnancy	O
7	of	O
8	Yankasa	O
9	sheep	O
10	and	O
11	the	O
12	results	O
13	of	O
14	homidum	O
15	chloride	O
16	chemotherapy	O
17	.	O

1	NF	B
2	kappa	I
3	B	I
4	was	O
5	activated	O
6	to	O
7	a	O
8	much	O
9	greater	O
10	extent	O
11	by	O
12	roscovitine	O
13	in	O
14	the	O
15	WT	O
16	cells	O
17	than	O
18	in	O
19	Y8	O
20	cells	O
21	.	O

1	Depending	O
2	on	O
3	treatment	O
4	exposures	O
5	,	O
6	this	O
7	at	O
8	-	O
9	risk	O
10	population	O
11	may	O
12	experience	O
13	life	O
14	-	O
15	threatening	O
16	late	O
17	effects	O
18	,	O
19	such	O
20	as	O
21	cirrhosis	O
22	secondary	O
23	to	O
24	hepatitis	O
25	C	O
26	or	O
27	late	O
28	-	O
29	onset	O
30	anthracycline	O
31	-	O
32	induced	O
33	cardiomyopathy	O
34	,	O
35	or	O
36	life	O
37	-	O
38	changing	O
39	late	O
40	effects	O
41	,	O
42	such	O
43	as	O
44	cognitive	O
45	dysfunction	O
46	.	O

1	The	O
2	presence	O
3	of	O
4	locus	O
5	-	O
6	specific	O
7	residues	O
8	throughout	O
9	the	O
10	entire	O
11	promoter	O
12	region	O
13	strongly	O
14	suggests	O
15	that	O
16	the	O
17	various	O
18	HLA	B
19	class	I
20	I	I
21	loci	I
22	are	O
23	differentially	O
24	regulated	O
25	.	O

1	Because	O
2	the	O
3	number	O
4	of	O
5	parameters	O
6	required	O
7	by	O
8	a	O
9	Volterra	O
10	series	O
11	grows	O
12	rapidly	O
13	with	O
14	both	O
15	the	O
16	length	O
17	of	O
18	its	O
19	memory	O
20	and	O
21	the	O
22	order	O
23	of	O
24	its	O
25	nonlinearity	O
26	,	O
27	methods	O
28	for	O
29	identifying	O
30	these	O
31	models	O
32	from	O
33	measurements	O
34	of	O
35	input	O
36	/	O
37	output	O
38	data	O
39	are	O
40	limited	O
41	to	O
42	low	O
43	-	O
44	order	O
45	systems	O
46	with	O
47	relatively	O
48	short	O
49	memories	O
50	.	O

1	The	O
2	standard	O
3	method	O
4	for	O
5	calculating	O
6	the	O
7	composite	O
8	score	O
9	on	O
10	the	O
11	S	O
12	-	O
13	B	O
14	IV	O
15	excludes	O
16	subtests	O
17	with	O
18	a	O
19	raw	O
20	score	O
21	of	O
22	0	O
23	,	O
24	which	O
25	overestimates	O
26	cognitive	O
27	functioning	O
28	in	O
29	young	O
30	biologically	O
31	high	O
32	risk	O
33	children	O
34	.	O

1	NiCl	O
2	(	O
3	2	O
4	)-	O
5	induced	O
6	MCP	B
7	-	I
8	1	I
9	synthesis	O
10	required	O
11	activation	O
12	of	O
13	NF	B
14	-	I
15	kappaB	I
16	since	O
17	mutation	O
18	of	O
19	NF	B
20	-	I
21	kappaB	I
22	-	I
23	binding	I
24	sites	I
25	in	O
26	the	O
27	promoter	O
28	resulted	O
29	in	O
30	complete	O
31	loss	O
32	of	O
33	inducible	O
34	promoter	O
35	activity	O
36	.	O

1	Engagement	O
2	of	O
3	human	B
4	CD2	I
5	by	O
6	mitogenic	O
7	pairs	O
8	of	O
9	anti	B
10	-	I
11	CD2	I
12	mAb	I
13	induces	O
14	tyrosine	O
15	phosphorylation	O
16	of	O
17	a	O
18	number	O
19	of	O
20	intracellular	O
21	proteins	O
22	including	O
23	a	O
24	120	O
25	kDa	O
26	phosphoprotein	O
27	that	O
28	we	O
29	identify	O
30	as	O
31	the	O
32	proto	B
33	-	I
34	oncogene	I
35	c	I
36	-	I
37	Cbl	I
38	.	O

1	Validity	O
2	of	O
3	NIR	O
4	spectroscopy	O
5	for	O
6	quantitatively	O
7	measuring	O
8	muscle	O
9	oxidative	O
10	metabolic	O
11	rate	O
12	in	O
13	exercise	O
14	.	O

1	Previous	O
2	studies	O
3	have	O
4	demonstrated	O
5	that	O
6	tissue	O
7	-	O
8	restricted	O
9	transcription	O
10	factors	O
11	including	O
12	PU	B
13	.	I
14	1	I
15	and	O
16	PU	B
17	.	I
18	1	I
19	interaction	I
20	partner	I
21	(	O
22	PIP	B
23	)	O
24	function	O
25	synergistically	O
26	with	O
27	c	B
28	-	I
29	Fos	I
30	plus	O
31	c	B
32	-	I
33	Jun	I
34	to	O
35	stimulate	O
36	the	O
37	kappaE3	B
38	'-	I
39	enhancer	I
40	in	O
41	3T3	O
42	cells	O
43	.	O

1	The	O
2	murine	B
3	int	I
4	-	I
5	6	I
6	locus	I
7	,	O
8	identified	O
9	as	O
10	a	O
11	frequent	O
12	integration	O
13	site	O
14	of	O
15	mouse	O
16	mammary	O
17	tumor	O
18	viruses	O
19	,	O
20	encodes	O
21	the	O
22	48	B
23	-	I
24	kDa	I
25	eIF3e	I
26	subunit	I
27	of	I
28	translation	I
29	initiation	I
30	factor	I
31	eIF3	I
32	.	O

1	An	O
2	int6	B
3	deletion	I
4	(	O
5	int6Delta	B
6	)	O
7	mutant	O
8	was	O
9	viable	O
10	but	O
11	grew	O
12	slowly	O
13	in	O
14	minimal	O
15	medium	O
16	.	O

1	Additionally	O
2	,	O
3	MIP	B
4	-	I
5	2A	I
6	antagonizes	O
7	cell	O
8	growth	O
9	regulatory	O
10	role	O
11	of	O
12	MBP	B
13	-	I
14	1	I
15	.	O

1	We	O
2	produced	O
3	transgenic	O
4	plants	O
5	expressing	O
6	the	O
7	antisense	B
8	Arabidopsis	I
9	HD	I
10	(	O
11	AtHD1	B
12	)	O
13	gene	O
14	.	O

1	3	O
2	.	O
3	04	O
4	+/-	O
5	1	O
6	.	O
7	2	O
8	,	O
9	P	O
10	<	O
11	0	O
12	.	O
13	0001	O
14	),	O
15	large	O
16	accelerations	O
17	/	O
18	30	O
19	min	O
20	(	O
21	1	O
22	.	O
23	46	O
24	+/-	O
25	1	O
26	.	O
27	96	O
28	vs	O
29	.	O

1	Four	O
2	transcription	O
3	initiation	O
4	sites	O
5	have	O
6	been	O
7	identified	O
8	by	O
9	full	O
10	-	O
11	length	O
12	RNA	B
13	ligase	I
14	-	O
15	mediated	O
16	rapid	O
17	amplification	O
18	of	O
19	cDNA	O
20	ends	O
21	(	O
22	RLM	O
23	-	O
24	RACE	O
25	)	O
26	between	O
27	-	O
28	61	O
29	and	O
30	-	O
31	32	O
32	bp	O
33	from	O
34	the	O
35	translation	O
36	initiation	O
37	codon	O
38	.	O
39	Reverse	O
40	transcription	O
41	-	O
42	PCR	O
43	analysis	O
44	revealed	O
45	that	O
46	PFK	B
47	-	I
48	A	I
49	,	O
50	PFK	B
51	-	I
52	B	I
53	and	O
54	PFK	B
55	-	I
56	C	I
57	genes	I
58	were	O
59	expressed	O
60	,	O
61	in	O
62	all	O
63	mouse	O
64	tissues	O
65	tested	O
66	,	O
67	at	O
68	varying	O
69	levels	O
70	.	O

1	PFK	B
2	-	I
3	A	I
4	mRNA	O
5	was	O
6	more	O
7	abundantly	O
8	expressed	O
9	in	O
10	all	O
11	tissues	O
12	than	O
13	were	O
14	the	O
15	PFK	B
16	-	I
17	B	I
18	and	O
19	PFK	B
20	-	I
21	C	I
22	genes	I
23	.	O

1	We	O
2	used	O
3	the	O
4	Toshiba	O
5	IIDR	O
6	system	O
7	,	O
8	which	O
9	is	O
10	composed	O
11	of	O
12	an	O
13	X	O
14	-	O
15	ray	O
16	TV	O
17	system	O
18	and	O
19	a	O
20	digital	O
21	image	O
22	managing	O
23	circuit	O
24	.	O

1	In	O
2	whole	O
3	sardine	O
4	,	O
5	domoic	O
6	acid	O
7	was	O
8	detected	O
9	in	O
10	levels	O
11	exceeding	O
12	sometimes	O
13	the	O
14	regulatory	O
15	limit	O
16	.	O

1	In	O
2	addition	O
3	,	O
4	we	O
5	identified	O
6	two	O
7	mutations	O
8	,	O
9	Delta	O
10	M1281	O
11	and	O
12	IVS51	O
13	+	O
14	5G	O
15	-->	O
16	A	O
17	,	O
18	in	O
19	a	O
20	German	O
21	USH1	B
22	patient	O
23	.	O

1	Closeup	O
2	:	O
3	a	O
4	resource	O
5	for	O
6	nurses	O
7	who	O
8	smoke	O
9	.	O

1	[	O
2	18F	O
3	](+)-	O
4	4	O
5	-	O
6	fluorobenzyltrozamicol	O
7	(	O
8	FBT	O
9	),	O
10	which	O
11	selectively	O
12	binds	O
13	to	O
14	the	O
15	vesicular	O
16	acetylcholine	B
17	transporter	I
18	in	O
19	the	O
20	presynaptic	O
21	cholinergic	O
22	neuron	O
23	,	O
24	has	O
25	previously	O
26	been	O
27	shown	O
28	to	O
29	be	O
30	a	O
31	useful	O
32	ligand	O
33	for	O
34	the	O
35	study	O
36	of	O
37	cholinergic	O
38	terminal	O
39	density	O
40	in	O
41	the	O
42	basal	O
43	ganglia	O
44	with	O
45	PET	O
46	.	O

1	We	O
2	demonstrate	O
3	that	O
4	the	O
5	protein	O
6	is	O
7	a	O
8	murine	B
9	homologue	I
10	of	I
11	SAF	I
12	-	I
13	A	I
14	which	O
15	has	O
16	been	O
17	shown	O
18	to	O
19	bind	O
20	selectively	O
21	to	O
22	MARs	O
23	and	O
24	is	O
25	responsible	O
26	for	O
27	the	O
28	satMa	B
29	-	O
30	binding	O
31	activity	O
32	in	O
33	the	O
34	chromatographic	O
35	fractions	O
36	.	O

1	The	O
2	molecular	O
3	associations	O
4	dictating	O
5	INCENP	B
6	behavior	O
7	during	O
8	mitosis	O
9	are	O
10	currently	O
11	unknown	O
12	.	O

1	Ang	B
2	II	I
3	significantly	O
4	induced	O
5	Ang2	B
6	mRNA	I
7	accumulations	O
8	without	O
9	affecting	O
10	Ang1	B
11	or	O
12	Tie2	B
13	expression	O
14	,	O
15	which	O
16	was	O
17	inhibited	O
18	by	O
19	protein	B
20	kinase	I
21	C	I
22	inhibitors	O
23	and	O
24	by	O
25	intracellular	O
26	Ca	O
27	(	O
28	2	O
29	+)	O
30	chelating	O
31	agents	O
32	.	O

1	Promoter	O
2	analysis	O
3	demonstrated	O
4	that	O
5	the	O
6	sequence	O
7	identical	O
8	to	O
9	consensus	O
10	cAMP	O
11	-	O
12	responsive	O
13	element	O
14	(	O
15	CRE	O
16	)	O
17	located	O
18	at	O
19	-	O
20	481	O
21	of	O
22	the	O
23	SMemb	B
24	promoter	I
25	was	O
26	critical	O
27	for	O
28	Hex	B
29	responsiveness	O
30	.	O

1	LH	B
2	/	I
3	CG	I
4	receptor	I
5	activation	O
6	of	O
7	ARNO	B
8	is	O
9	not	O
10	mediated	O
11	by	O
12	activation	O
13	of	O
14	phosphatidylinositol	B
15	3	I
16	-	I
17	kinase	I
18	(	O
19	PI	B
20	3	I
21	-	I
22	kinase	I
23	)	O
24	or	O
25	by	O
26	G	B
27	protein	I
28	beta	I
29	gamma	I
30	subunits	I
31	.	O

1	Deletion	O
2	analysis	O
3	showed	O
4	that	O
5	the	O
6	-	O
7	321	O
8	/+	O
9	41	O
10	sequence	O
11	was	O
12	sufficient	O
13	for	O
14	both	O
15	the	O
16	constitutive	O
17	promoter	O
18	activity	O
19	and	O
20	auto	O
21	-	O
22	activation	O
23	and	O
24	electrophoretic	O
25	mobility	O
26	shift	O
27	assays	O
28	identified	O
29	the	O
30	interaction	O
31	of	O
32	C	B
33	/	I
34	EBPs	I
35	and	O
36	Sp1	B
37	to	O
38	this	O
39	region	O
40	.	O

1	Termination	O
2	of	O
3	induced	O
4	VT	O
5	on	O
6	the	O
7	first	O
8	attempt	O
9	was	O
10	comparable	O
11	with	O
12	BV	O
13	pacing	O
14	(	O
15	87	O
16	.	O
17	4	O
18	%)	O
19	versus	O
20	RV	O
21	pacing	O
22	(	O
23	89	O
24	.	O
25	6	O
26	%).	O

1	We	O
2	compare	O
3	the	O
4	results	O
5	of	O
6	this	O
7	algorithm	O
8	with	O
9	the	O
10	results	O
11	obtained	O
12	with	O
13	two	O
14	other	O
15	algorithms	O
16	,	O
17	the	O
18	optimal	O
19	algorithm	O
20	for	O
21	monochannel	O
22	nonoverlapping	O
23	noise	O
24	and	O
25	the	O
26	optimal	O
27	algorithm	O
28	for	O
29	multichannel	O
30	additive	O
31	noise	O
32	,	O
33	and	O
34	we	O
35	show	O
36	that	O
37	in	O
38	both	O
39	cases	O
40	improvement	O
41	can	O
42	be	O
43	obtained	O
44	.	O

1	Changes	O
2	in	O
3	stimulation	O
4	levels	O
5	over	O
6	time	O
7	in	O
8	nucleus	O
9	22	O
10	cochlear	O
11	implant	O
12	users	O
13	.	O

1	Nuclease	O
2	probing	O
3	and	O
4	structure	O
5	-	O
6	directed	O
7	mutagenesis	O
8	revealed	O
9	that	O
10	the	O
11	105	O
12	-	O
13	nt	O
14	TE	O
15	(	O
16	TE105	O
17	)	O
18	forms	O
19	a	O
20	cruciform	O
21	secondary	O
22	structure	O
23	containing	O
24	four	O
25	helices	O
26	connected	O
27	by	O
28	single	O
29	-	O
30	stranded	O
31	regions	O
32	.	O

1	Tele	O
2	-	O
3	Talk	O
4	has	O
5	the	O
6	extra	O
7	capability	O
8	of	O
9	operating	O
10	in	O
11	live	O
12	conference	O
13	situations	O
14	using	O
15	microphone	O
16	input	O
17	.	O

1	A	O
2	marked	O
3	decrease	O
4	in	O
5	the	O
6	type	B
7	1	I
8	insulin	I
9	-	I
10	like	I
11	growth	I
12	factor	I
13	(	I
14	IGF	I
15	)	I
16	receptor	I
17	(	O
18	IGF	B
19	-	I
20	IR	I
21	)	O
22	occurs	O
23	in	O
24	prostate	O
25	epithelial	O
26	cells	O
27	during	O
28	transformation	O
29	from	O
30	the	O
31	benign	O
32	to	O
33	the	O
34	metastatic	O
35	state	O
36	.	O

1	The	O
2	P69	O
3	cell	O
4	line	O
5	was	O
6	derived	O
7	by	O
8	immortalization	O
9	of	O
10	human	O
11	primary	O
12	prostate	O
13	epithelial	O
14	cells	O
15	with	O
16	simian	B
17	virus	I
18	-	I
19	40	I
20	T	I
21	antigen	I
22	and	O
23	is	O
24	rarely	O
25	tumorigenic	O
26	.	O

1	We	O
2	determined	O
3	whether	O
4	the	O
5	human	B
6	StAR	I
7	promoter	I
8	is	O
9	responsive	O
10	to	O
11	sterol	B
12	regulatory	I
13	element	I
14	-	I
15	binding	I
16	proteins	I
17	(	O
18	SREBPs	B
19	).	O

1	Expression	O
2	of	O
3	SREBP	B
4	-	I
5	1a	I
6	stimulated	O
7	StAR	B
8	promoter	I
9	activity	O
10	in	O
11	the	O
12	context	O
13	of	O
14	COS	O
15	-	O
16	1	O
17	cells	O
18	and	O
19	human	O
20	granulosa	O
21	-	O
22	lutein	O
23	cells	O
24	.	O

1	Because	O
2	the	O
3	high	B
4	-	I
5	density	I
6	lipoprotein	I
7	receptor	I
8	(	O
9	HDL	B
10	-	I
11	R	I
12	)	O
13	is	O
14	a	O
15	key	O
16	element	O
17	in	O
18	cholesterol	O
19	homeostasis	O
20	and	O
21	a	O
22	potential	O
23	therapeutic	O
24	target	O
25	for	O
26	hypercholesterolemic	O
27	drugs	O
28	,	O
29	an	O
30	understanding	O
31	of	O
32	HDL	B
33	-	I
34	R	I
35	regulation	O
36	is	O
37	essential	O
38	.	O

1	IFN	B
2	-	I
3	stimulated	I
4	gene	I
5	factor	I
6	-	I
7	3	I
8	and	O
9	STAT1	B
10	homodimers	I
11	formed	O
12	and	O
13	bound	O
14	an	O
15	IFN	B
16	-	I
17	stimulated	I
18	response	I
19	element	I
20	(	O
21	ISRE	B
22	)	O
23	and	O
24	gamma	B
25	-	I
26	activated	I
27	sequence	I
28	(	O
29	GAS	B
30	)	O
31	element	O
32	,	O
33	respectively	O
34	.	O

1	We	O
2	have	O
3	therefore	O
4	studied	O
5	the	O
6	molecular	O
7	mechanisms	O
8	of	O
9	TGF	B
10	-	I
11	beta1	I
12	action	O
13	on	O
14	thyroglobulin	B
15	(	O
16	TG	B
17	)	O
18	gene	O
19	expression	O
20	by	O
21	focusing	O
22	our	O
23	attention	O
24	on	O
25	TGF	B
26	-	I
27	beta1	I
28	regulation	O
29	of	O
30	thyroid	O
31	-	O
32	specific	O
33	transcription	O
34	factors	O
35	.	O

1	The	O
2	epitope	O
3	-	O
4	protected	O
5	lysine	O
6	(	O
7	K	O
8	)	O
9	was	O
10	present	O
11	in	O
12	a	O
13	30	B
14	-	I
15	aa	I
16	TPO	I
17	fragment	I
18	that	O
19	,	O
20	by	O
21	N	O
22	-	O
23	terminal	O
24	sequencing	O
25	,	O
26	was	O
27	found	O
28	to	O
29	be	O
30	K713	O
31	.	O

1	To	O
2	understand	O
3	the	O
4	molecular	O
5	regulation	O
6	of	O
7	these	O
8	genes	O
9	in	O
10	thyroid	O
11	cells	O
12	,	O
13	the	O
14	effect	O
15	of	O
16	thyroid	B
17	transcription	I
18	factor	I
19	1	I
20	(	O
21	TTF	B
22	-	I
23	1	I
24	)	O
25	and	O
26	the	O
27	paired	B
28	domain	I
29	-	I
30	containing	I
31	protein	I
32	8	I
33	(	O
34	Pax	B
35	-	I
36	8	I
37	)	O
38	on	O
39	the	O
40	transcriptional	O
41	activity	O
42	of	O
43	the	O
44	deiodinase	B
45	promoters	I
46	were	O
47	studied	O
48	.	O
